<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd"><PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36763930</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Pathway analysis of microarray data from corpora cavernosal tissue of patients with a prostatectomy or Peyronie disease in comparison with a cavernous nerve-injured rat model of erectile dysfunction.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>151</EndPage><MedlinePgn>139-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jsxmed/qdac019</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with a prostatectomy are at high risk of developing erectile dysfunction (ED) that is refractory to phosphodiesterase type 5 inhibitors. The cavernous nerve (CN) is frequently damaged during prostatectomy, causing loss of innervation to the penis. This initiates corpora cavernosal remodeling (apoptosis and fibrosis) and results in ED.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To aid in the development of novel ED therapies, the current aim was to obtain a global understanding of how signaling mechanisms alter in the corpora cavernosa with loss of CN innervation that results in ED.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Microarray and pathway analysis were performed on the corpora cavernosal tissue of patients with a prostatectomy (n&#x2009;=&#x2009;3) or Peyronie disease (control, n&#x2009;=&#x2009;3). Results were compared with an analysis of a Sprague-Dawley rat CN injury model (n&#x2009;=&#x2009;10). RNA was extracted by TRIzol, DNase treated, and purified by a Qiagen Mini Kit. Microarray was performed with the Human Gene 2.0 ST Array and the RU34 rat array. Differentially expressed genes were identified through several analytic tools (ShinyGO, Ingenuity, WebGestalt) and databases (GO, Reactome). A 2-fold change was used as the threshold for differential expression.</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Pathways that were altered (up- or downregulated) in response to CN injury in the prostatectomy patients and a rat CN injury model were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Microarray identified 197 differentially expressed protein-coding genes in the corpora cavernosa from the prostatectomy cohort, with 100 genes upregulated and 97 genes downregulated. Altered signaling pathways that were identified that affect tissue morphology included the following: neurologic disease, cell death and survival, tissue and cellular development, skeletal and muscle development and disorders, connective tissue development and function, tissue morphology, embryonic development, growth and proliferation, cell-to-cell signaling, and cell function and maintenance. These human pathways have high similarity to those observed in the CN-injured rat ED model.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS" NlmCategory="CONCLUSIONS">Significant penile remodeling continues in patients long after the acute surgical injury to the CN takes place, offering the opportunity for clinical intervention to reverse penile remodeling and improve erectile function.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS" NlmCategory="UNASSIGNED">Understanding how signaling pathways change in response to CN injury and how these changes translate to altered morphology of the corpora cavernosa and ensuing ED is critical to identify strategic targets for therapy development.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Altered signaling in pathways that regulate tissue homeostasis, morphogenesis, and development was identified in penes of patients with a prostatectomy, and competitive forces of apoptosis and proliferation/regeneration were found to compete to establish dominance after CN injury. How these pathways interact to regulate penis tissue homeostasis is a complex process that requires further investigation.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Searl</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL 60612, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohlander</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL 60612, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVary</LastName><ForeName>Kevin T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Urology, Loyola University Stritch School of Medicine, Maywood, IL 60153, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podlasek</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Departments of Urology, Physiology, Bioengineering, and Biochemistry, University of Illinois at Chicago, Chicago, IL 60612, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020196" MajorTopicYN="Y">Trauma, Nervous System</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Peyronie</Keyword><Keyword MajorTopicYN="N">corpora cavernosa</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">penis</Keyword><Keyword MajorTopicYN="N">prostatectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36763930</ArticleId><ArticleId IdType="doi">10.1093/jsxmed/qdac019</ArticleId><ArticleId IdType="pii">6986026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36762774</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2927</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Andrology</Title><ISOAbbreviation>Andrology</ISOAbbreviation></Journal><ArticleTitle>Low-intensity pulsed ultrasound ameliorates erectile dysfunction induced by bilateral cavernous nerve injury through enhancing Schwann cell-mediated cavernous nerve regeneration.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/andr.13406</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cavernous nerve injury-induced erectile dysfunction caused by pelvic surgery or trauma is refractory to conventional medications and required an alternative treatment. Low-intensity pulsed ultrasound is a noninvasive mechanical therapy that promotes nerve regeneration.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the therapeutic effect and potential mechanism of low-intensity pulsed ultrasound in the treatment of neurogenic erectile dysfunction.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Thirty rats were randomly divided into the sham-operated group, bilateral cavernous nerve injury group, and bilateral cavernous nerve injury + low-intensity pulsed ultrasound group. The erectile function was assessed 3&#xa0;weeks after daily low-intensity pulsed ultrasound treatment. The penile tissues and cavernous nerve tissues were harvested and subjected to histologic analysis. Primary Schwann cells and explants were extracted from adult rats. The effects of low-intensity pulsed ultrasound on proliferation, migration, and nerve growth factor expression of Schwann cells and axonal elongation were examined in vitro. RNA sequencing and western blot assay were applied to predict and verify the molecular mechanism of low-intensity pulsed ultrasound-induced Schwann cell activation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study showed that low-intensity pulsed ultrasound promoted Schwann cells proliferation, migration, and neurotrophic factor nerve growth factor expression. Meanwhile, low-intensity pulsed ultrasound exhibits a stronger ability to enhance Schwann cells-mediated neurite outgrowth of major pelvic ganglion neurons and major pelvic ganglion/cavernous nerve explants in vitro. In vivo experiments demonstrated that the erectile function of the rats in the bilateral cavernous nerve injury + low-intensity pulsed ultrasound group was significantly higher than those in the bilateral cavernous nerve injury groups. Moreover, the expression levels of smooth muscle and cavernous endothelium also increased significantly in the bilateral cavernous nerve injury + low-intensity pulsed ultrasound group. In addition, we observed the higher density and number of cavernous nerve regenerating axons in the bilateral cavernous nerve injury + low-intensity pulsed ultrasound group, indicating that low-intensity pulsed ultrasound promotes axonal regeneration following cavernous nerve injury in vivo. RNA sequencing analysis and bioinformatic analysis suggested that low-intensity pulsed ultrasound might trigger the activation of the PI3K/Akt pathway. Western blot assay confirmed that low-intensity pulsed ultrasound activated Schwann cells through TrkB/Akt/CREB signaling.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low-intensity pulsed ultrasound promoted nerve regeneration and ameliorated erectile function by enhancing Schwann cells proliferation, migration, and neurotrophic factor nerve growth factor expression. The TrkB/Akt/CREB axis is the possible mechanism of low-intensity pulsed ultrasound-mediated Schwann cell activation. Low-intensity pulsed ultrasound-based therapy could be a novel potential treatment strategy for cavernous nerve injury-induced neurogenic erectile dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2023 American Society of Andrology and European Academy of Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zitaiyu</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-0805-8816</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Yinghao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dongjie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Dongyi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Liangyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yihong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7717-993X</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yingbo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Andrology</MedlineTA><NlmUniqueID>101585129</NlmUniqueID><ISSNLinking>2047-2919</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Schwann cell</Keyword><Keyword MajorTopicYN="N">cavernous nerve</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">low-intensity pulsed ultrasound</Keyword><Keyword MajorTopicYN="N">regeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>7</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36762774</ArticleId><ArticleId IdType="doi">10.1111/andr.13406</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Shamloul R, Ghanem H. Erectile dysfunction. Lancet North Am Ed. 2013;381(9861):153-165.</Citation></Reference><Reference><Citation>Tsertsvadze A, Fink HA, Yazdi F, et&#xa0;al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650-661.</Citation></Reference><Reference><Citation>User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003;169(3):1175-1179.</Citation></Reference><Reference><Citation>Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: A meta-analysis. J Sex Med. 2009;6(9):2538-2546.</Citation></Reference><Reference><Citation>Raina R, Lakin MM, Agarwal A, et&#xa0;al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology. 2004;63(5):960-966.</Citation></Reference><Reference><Citation>Cattin A-L, Burden JJ, Van Emmenis L, et&#xa0;al. Macrophage-induced blood vessels guide Schwann cell-mediated regeneration of peripheral nerves. Cell. 2015;162(5):1127-1139.</Citation></Reference><Reference><Citation>Li R, Li D, Wu C, et&#xa0;al. Nerve growth factor activates autophagy in Schwann cells to enhance myelin debris clearance and to expedite nerve regeneration. Theranostics. 2020;10(4):1649.</Citation></Reference><Reference><Citation>Jessen KR, Mirsky R. The success and failure of the Schwann cell response to nerve injury. Front Cell Neurosci. 2019;13:33.</Citation></Reference><Reference><Citation>Caillaud M, Richard L, Vallat J-M, Desmouli&#xe8;re A, Billet F. Peripheral nerve regeneration and intraneural revascularization. Neural Regen Res. 2019;14(1):24.</Citation></Reference><Reference><Citation>Daeschler SC, Harhaus L, Schoenle P, Boecker A, Kneser U, Bergmeister KD. Ultrasound and shock-wave stimulation to promote axonal regeneration following nerve surgery: a systematic review and meta-analysis of preclinical studies. Sci Rep. 2018;8(1):1-11.</Citation></Reference><Reference><Citation>Acheta J, Stephens SB, Belin S, Poitelon Y. Therapeutic low-intensity ultrasound for peripheral nerve regeneration-a Schwann cell perspective. Front Cell Neurosci. 2021;15:812588.</Citation></Reference><Reference><Citation>Ying Z-m, Lin T, Yan S-g. Low-intensity pulsed ultrasound therapy: A potential strategy to stimulate tendon-bone junction healing. J Zhejiang Univ Sci B. 2012;13(12):955-963.</Citation></Reference><Reference><Citation>Khanna A, Nelmes RT, Gougoulias N, Maffulli N, Gray J. The effects of LIPUS on soft-tissue healing: A review of literature. Br Med Bull. 2009;89(1):169-182.</Citation></Reference><Reference><Citation>Kumagai K, Takeuchi R, Ishikawa H, et&#xa0;al. Low-intensity pulsed ultrasound accelerates fracture healing by stimulation of recruitment of both local and circulating osteogenic progenitors. J Orthop Res. 2012;30(9):1516-1521.</Citation></Reference><Reference><Citation>Jiang W, Wang Y, Tang J, et&#xa0;al. Low-intensity pulsed ultrasound treatment improved the rate of autograft peripheral nerve regeneration in rat. Sci Rep. 2016;6(1):1-13.</Citation></Reference><Reference><Citation>Park SC, Oh SH, Seo TB, Namgung U, Kim JM, Lee JH. Ultrasound-stimulated peripheral nerve regeneration within asymmetrically porous PLGA/Pluronic F127 nerve guide conduit. J Biomed Mater Res B Appl Biomater. 2010;94(2):359-366.</Citation></Reference><Reference><Citation>Gupta VK, You Y, Gupta VB, Klistorner A, Graham SL. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int J Mol Sci. 2013;14(5):10122-10142.</Citation></Reference><Reference><Citation>Richner M, Ulrichsen M, Elmegaard SL, Dieu R, Pallesen LT, Vaegter CB. Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol Neurobiol. 2014;50(3):945-970.</Citation></Reference><Reference><Citation>Read DE, Gorman AM. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci. 2009;66(18):2975-2984.</Citation></Reference><Reference><Citation>Wu X, Liang Y, Jing X, et&#xa0;al. Rifampicin prevents SH-SY5Y cells from rotenone-induced apoptosis via the PI3K/Akt/GSK-3&#x3b2;/CREB signaling pathway. Neurochem Res. 2018;43(4):886-893.</Citation></Reference><Reference><Citation>Su W-S, Wu C-H, Chen S-F, Yang F-Y. Transcranial ultrasound stimulation promotes brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury. Brain Stimul. 2017;10(6):1032-1041.</Citation></Reference><Reference><Citation>Liu S-H, Lai Y-L, Chen B-L, Yang F-Y. Ultrasound enhances the expression of brain-derived neurotrophic factor in astrocyte through activation of TrkB-Akt and calcium-CaMK signaling pathways. Cereb Cortex. 2017;27(6):3152-3160.</Citation></Reference><Reference><Citation>Li Z, Yin Y, He K, et&#xa0;al. Intracavernous pressure recording in a cavernous nerve injury rat model. J Vis Exp. 2021;(175):e63024.</Citation></Reference><Reference><Citation>Peng D, Reed-Maldonado AB, Zhou F, et&#xa0;al. Exosome released from schwann cells may be involved in microenergy acoustic pulse-associated cavernous nerve regeneration. J Sex Med. 2020;17(9):1618-1628.</Citation></Reference><Reference><Citation>Jiang N, Wu C, Zhou X, Zhai G, Wu J. Cavernous nerve injury resulted erectile dysfunction and regeneration. J Immunol Res. 2021;2021:5353785.</Citation></Reference><Reference><Citation>Sivarajan G, Prabhu V, Taksler GB, Laze J, Lepor H. Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. Eur Urol. 2014;65(1):58-65.</Citation></Reference><Reference><Citation>Stember DS, Nelson CJ, Mulhall JP. Preoperative erectile function is an independent predictor for decision to spare cavernous nerves during radical prostatectomy. J Sex Med. 2013;10(8):2101-2107.</Citation></Reference><Reference><Citation>Philippou YA, Jung JH, Steggall MJ, et&#xa0;al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018;10(10):CD012414.</Citation></Reference><Reference><Citation>Zhang D-L, Chen Z, Wang F-X, et&#xa0;al. Adding a vacuum erection device to regular use of Tadalafil improves penile rehabilitation after posterior urethroplasty. Asian J Androl. 2019;21(6):582.</Citation></Reference><Reference><Citation>Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009;55(2):334-347.</Citation></Reference><Reference><Citation>Lv Y, Nan P, Chen G, Sha Y, Xia B, Yang L. In vivo repair of rat transected sciatic nerve by low-intensity pulsed ultrasound and induced pluripotent stem cells-derived neural crest stem cells. Biotechnol Lett. 2015;37(12):2497-2506.</Citation></Reference><Reference><Citation>Wang T, Ito A, Xu S, Kawai H, Kuroki H, Aoyama T. Low-intensity pulsed ultrasound prompts both functional and histologic improvements while upregulating the brain-derived neurotrophic factor expression after sciatic crush injury in rats. Ultrasound Med Biol. 2021;47(6):1586-1595.</Citation></Reference><Reference><Citation>Peng D-Y, Reed-Maldonado AB, Lin G-T, Xia S-J, Lue TF. Low-intensity pulsed ultrasound for regenerating peripheral nerves: Potential for penile nerve. Asian J Androl. 2020;22(4):335.</Citation></Reference><Reference><Citation>Belin S, Zuloaga KL, Poitelon Y. Influence of mechanical stimuli on Schwann cell biology. Front Cell Neurosci. 2017;11:347.</Citation></Reference><Reference><Citation>Gupta R, Nassiri N, Hazel A, Bathen M, Mozaffar T. Chronic nerve compression alters Schwann cell myelin architecture in a murine model. Muscle Nerve. 2012;45(2):231-241.</Citation></Reference><Reference><Citation>Gupta R, Steward O. Chronic nerve compression induces concurrent apoptosis and proliferation of Schwann cells. J Comp Neurol. 2003;461(2):174-186.</Citation></Reference><Reference><Citation>Qin J, Wang L, Sun Y, et&#xa0;al. Concentrated growth factor increases Schwann cell proliferation and neurotrophic factor secretion and promotes functional nerve recovery in vivo. Int J Mol Med. 2016;37(2):493-500.</Citation></Reference><Reference><Citation>Li R, Wu J, Lin Z, et&#xa0;al. Single injection of a novel nerve growth factor coacervate improves structural and functional regeneration after sciatic nerve injury in adult rats. Exp Neurol. 2017;288:1-10.</Citation></Reference><Reference><Citation>Ito A, Wang T, Nakahara R, et&#xa0;al. Ultrasound therapy with optimal intensity facilitates peripheral nerve regeneration in rats through suppression of pro-inflammatory and nerve growth inhibitor gene expression. PLoS One. 2020;15(6):e0234691.</Citation></Reference><Reference><Citation>Ni X-J, Wang X-D, Zhao Y-H, et&#xa0;al. The effect of low-intensity ultrasound on brain-derived neurotropic factor expression in a rat sciatic nerve crushed injury model. Ultrasound Med Biol. 2017;43(2):461-468.</Citation></Reference><Reference><Citation>Oliveira FB, Pereira VMD, APNTd Trindade, Shimano AC, Gabriel RECD, Borges APO. Action of therapeutic laser and ultrasound in peripheral nerve regeneration. Acta Ortop Bras. 2012;20:98-103.</Citation></Reference><Reference><Citation>Chen W-Z, Qiao H, Zhou W, Wu J, Wang Z-B. Upgraded nerve growth factor expression induced by low-intensity continuous-wave ultrasound accelerates regeneration of neurotometicly injured sciatic nerve in rats. Ultrasound Med Biol. 2010;36(7):1109-1117.</Citation></Reference><Reference><Citation>Zhang W, Song J-k, Yan R, et&#xa0;al. Diterpene ginkgolides protect against cerebral ischemia/reperfusion damage in rats by activating Nrf2 and CREB through PI3K/Akt signaling. Acta Pharmacol Sin. 2018;39(8):1259-1272.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36736911</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Bilateral Cavernosal Artery Ligation to Treat Ischemic Priapism following Inflatable Penile Prosthesis Implantation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(23)00067-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2022.12.041</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the first known case of recurrent acute priapism after penile prosthesis implantation.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A 60 year old gentleman with a history of recurrent ischemic priapism without hemoglobinopathy presented with refractory erectile dysfunction and underwent uncomplicated penile prosthesis placement. His course was complicated by early acute ischemic priapism confirmed via ultrasound. Due to his pain, attempts to relieve the priapism using ultrasound-guided phenylephrine injections were attempted but were unsuccessful.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">He subsequently underwent exploration with confirmation of distal ischemic priapism followed by brisk bright red blood from the proximal corpora upon device externalization. A perineal exploration was performed and the bilateral cavernosal arteries were suture ligated with immediate relief. The device was reimplanted and the patient recovered uneventfully.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We report the first known case of ischemic priapism following inflatable penile prosthesis implantation. The details of this case challenge the dogma that priapism is a binary event and instead support an imbalance between unopposed cavernosal artery inflow possibly due to vascular calcifications and compromised venous outflow due to the presence of the device. Prosthetic urologists should be aware of this rare phenomenon and consider all available approaches on an individualized case-by-case basis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fascelli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundy</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angermeier</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajic</LastName><ForeName>Petar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: bajicp@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cavernosal artery</Keyword><Keyword MajorTopicYN="N">Inflatable penile prosthesis</Keyword><Keyword MajorTopicYN="N">Stuttering priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36736911</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2022.12.041</ArticleId><ArticleId IdType="pii">S0090-4295(23)00067-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36396558</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-4569</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European urology focus</Title><ISOAbbreviation>Eur Urol Focus</ISOAbbreviation></Journal><ArticleTitle>Insertion of Penile Implants in Patients with Priapism: When Is the Right Time?</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>50</EndPage><MedlinePgn>49-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euf.2022.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2405-4569(22)00245-0</ELocationID><Abstract><AbstractText>Acute ischaemic priapism is a urological emergency that requires prompt intervention. Refractory cases result in the development of fibrosis in the corpus cavernosum, which results in erectile dysfunction. Early insertion of a penile prosthesis in refractory cases allows easier dilatation and maintains the penile length and girth.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Andrology and NIHR Biomedical Research Centre, University College London Hospital, London, UK. Electronic address: asif.muneer@nhs.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Urol Focus</MedlineTA><NlmUniqueID>101665661</NlmUniqueID><ISSNLinking>2405-4569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="Y">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>22</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36396558</ArticleId><ArticleId IdType="doi">10.1016/j.euf.2022.11.005</ArticleId><ArticleId IdType="pii">S2405-4569(22)00245-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36303674</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2673-3153</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in reproductive health</Title><ISOAbbreviation>Front Reprod Health</ISOAbbreviation></Journal><ArticleTitle>Global Perspective on the Management of Peyronie's Disease.</ArticleTitle><Pagination><StartPage>863844</StartPage><MedlinePgn>863844</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">863844</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/frph.2022.863844</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Peyronie's disease is the disease that results in an alteration in the curvature of the penis, which can lead to a shortening of length, pain in erection, or difficulties in penetration, thus leading the patient to psychological alterations due to loss of functionality such as aesthetic alteration. That is why there are several studies to define the best form of treatment, which currently continues to be the first choice surgical treatment.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">We present the most recommended therapies for Peyronie's disease and suggest an algorithm as a guide to direct therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used the PubMed platform to review the literature related to Peyronie's disease. Various editorials were reviewed as well as original articles and reviews focusing on the various treatments as well as their indications and results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Peyronie's disease in which conservative or drug treatment does not have a response, surgical treatment with corporoplasty, penile prosthesis implantation or both may be indicated. Corporoplasty refers to both the plication of the tunica albuginea as well as the incision of the tunica with the placement of a graft. An accurate history should always be carried out to identify erectile dysfunction as well as to be able to guide you on the repercussions of the treatment. If refractory erectile dysfunction is present, placement of a penile prosthesis with or without further adjunctive straightening maneuvers is recommended. We reviewed the indications, advantages, disadvantages, and results of the available techniques, and proposed a surgical treatment algorithm.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Penile shortening procedures are usually indicated in curvatures &lt;60&#xb0;, in penises with adequate length. Partial excision/incision and grafting are indicated for curvatures &gt;60&#xb0;, hourglass or hinge deformities, and short penises, if the patient's erectile function is adequate. The presence of "borderline" erectile function and/or ventral curvature tilts the choice toward shortening procedures, and refractory erectile dysfunction is an indication for penile prosthesis placement. An accurate risk/benefit assessment of the individual patient as well as meticulous patient counseling are critically important.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Mois&#xe9;s da Silva, D&#xe1;vila, Rosito and Martins.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mois&#xe9;s da Silva</LastName><ForeName>Gabriel Veber</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital de Cl&#xed;nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe1;vila</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital de Cl&#xed;nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosito</LastName><ForeName>Tiago Elias</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital de Cl&#xed;nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Francisco E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Lisbon, School of Medicine, Centro Hospitalar Universitario Lisboa Norte (CHULN), Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Reprod Health</MedlineTA><NlmUniqueID>9918230899006676</NlmUniqueID><ISSNLinking>2673-3153</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Peyronie's disease</Keyword><Keyword MajorTopicYN="N">curvature</Keyword><Keyword MajorTopicYN="N">deformity</Keyword><Keyword MajorTopicYN="N">grafting</Keyword><Keyword MajorTopicYN="N">penile</Keyword><Keyword MajorTopicYN="N">penile reconstruction</Keyword><Keyword MajorTopicYN="N">plaque</Keyword><Keyword MajorTopicYN="N">prosthesis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>2</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36303674</ArticleId><ArticleId IdType="pmc">PMC9580779</ArticleId><ArticleId IdType="doi">10.3389/frph.2022.863844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. . Evidence-based management on Peyronie's disease. J Sex Med. (2016) 13:905&#x2013;23. 10.1016/j.jsxm.2016.04.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.04.062</ArticleId><ArticleId IdType="pubmed">27215686</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S. Herati Alexander W. Pastuszak the genetic basis of peyronie disease: a review. Sexual Med Rev. (2016) 4:85&#x2013;94. 10.1016/j.sxmr.2015.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2015.10.002</ArticleId><ArticleId IdType="pmc">PMC4778255</ArticleId><ArticleId IdType="pubmed">27872008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielsen JS. Peyronie's disease: is it genetic or not? Transl Androl Urol. (2020) 9:S262&#x2013;8. 10.21037/tau.2019.10.21</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2019.10.21</ArticleId><ArticleId IdType="pmc">PMC7108984</ArticleId><ArticleId IdType="pubmed">32257867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bias WB, Nyberg LM, Hochberg MC, Walsh PC. Peyronie's disease: a newly recognized autosomal-dominant trait. Am J Med Genet. (1982) 12:227. 10.1002/ajmg.1320120213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320120213</ArticleId><ArticleId IdType="pubmed">6213155</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology. (2004) 64:399. 10.1016/j.urology.2004.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2004.04.006</ArticleId><ArticleId IdType="pubmed">15302515</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. (1997) 157:285&#x2013;290. 10.1016/S0022-5347(01)65361-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)65361-8</ArticleId><ArticleId IdType="pubmed">8976281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol. (1997) 158:1388&#x2013;90. 10.1016/S0022-5347(01)64222-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)64222-8</ArticleId><ArticleId IdType="pubmed">9302127</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden EL, Teloken C, Ting HY, Lucas ML, Teod&#xf3;sio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50-y-old from southern Brazil. Int J Impot Res. (2001) 13:291&#x2013;3. 10.1038/sj.ijir.3900727</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900727</ArticleId><ArticleId IdType="pubmed">11890516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, et al. . Epidemiology of Peyronie's disease. Int J Impot Res. (2002) 14:379&#x2013;83. 10.1038/sj.ijir.3900863</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900863</ArticleId><ArticleId IdType="pubmed">12454689</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie's disease in the United States: a population-based study. PLoS ONE. (2016) 11:e0150157. 10.1371/journal.pone.0150157</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150157</ArticleId><ArticleId IdType="pmc">PMC4764365</ArticleId><ArticleId IdType="pubmed">26907743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. . Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care. (2010) 33:562&#x2013;568. 10.2337/dc09-1524</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-1524</ArticleId><ArticleId IdType="pmc">PMC2827508</ArticleId><ArticleId IdType="pubmed">20067953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int. (2006) 97:570&#x2013;4. 10.1111/j.1464-410X.2006.05969.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2006.05969.x</ArticleId><ArticleId IdType="pubmed">16469028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. (2006) 175:2115&#x2013;8. 10.1016/S0022-5347(06)00270-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(06)00270-9</ArticleId><ArticleId IdType="pubmed">16697815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol. (2013) 190:627&#x2013;34. 10.1016/j.juro.2013.01.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2013.01.090</ArticleId><ArticleId IdType="pubmed">23376705</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res. (2003) 15:S103&#x2013;12. 10.1038/sj.ijir.3901083</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901083</ArticleId><ArticleId IdType="pubmed">14551586</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zmez A, Ortac M, Cevik G, Akdere H, Bakir B, Kadioglu A. The effectiveness of 3-D computed tomography in the evaluation of penile deformities in patients with Peyronie's disease: a pilot study. Sexual Med. (2019) 7:311&#x2013;7. 10.1016/j.esxm.2019.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2019.06.009</ArticleId><ArticleId IdType="pmc">PMC6728762</ArticleId><ArticleId IdType="pubmed">31324507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauck EW, HJackstein N, Vosshenrich R, Diemer T, Schmelz HU, Bschleipfer T, et al. . Diagnostic value of magnetic resonance imaging in Peryronie's disease &#x2013; a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol. (2003) 43:293&#x2013;300. 10.1016/S0302-2838(03)00003-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0302-2838(03)00003-4</ArticleId><ArticleId IdType="pubmed">12600434</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang KK, Bennett N. Peryronie's disease and injectable collagenase Clostridium Histolyticum: safety efficacy and improvements in subjective symptoms. Urology. (2016) 94:143&#x2013;7. 10.1016/j.urology.2016.04.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.04.049</ArticleId><ArticleId IdType="pubmed">27211926</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, et al. . Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Res Rep Urol. (2016) 8:1&#x2013;10. 10.2147/RRU.S97194</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RRU.S97194</ArticleId><ArticleId IdType="pmc">PMC4706125</ArticleId><ArticleId IdType="pubmed">26770906</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie's disease compared with pentoxifylline. Glob J Health Sci. (2014) 6:23&#x2013;30. 10.5539/gjhs.v6n7p23</Citation><ArticleIdList><ArticleId IdType="doi">10.5539/gjhs.v6n7p23</ArticleId><ArticleId IdType="pmc">PMC4796342</ArticleId><ArticleId IdType="pubmed">25363175</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner W, Hauck EW, Schnitker K. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective placebo-controlled randomized study. Eur Urol. (2005) 47:530. 10.1016/j.eururo.2004.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2004.12.022</ArticleId><ArticleId IdType="pubmed">15774254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. . The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med. (2010) 7:2359&#x2013;74. 10.1111/j.1743-6109.2010.01850.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01850.x</ArticleId><ArticleId IdType="pubmed">20497306</ArticleId></ArticleIdList></Reference><Reference><Citation>Teloken C, Rhoden RL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. (1999) 162:2003. 10.1016/S0022-5347(05)68087-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)68087-1</ArticleId><ArticleId IdType="pubmed">10569556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. (2011) 8:1472&#x2013;1477. 10.1111/j.1743-6109.2011.02217.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02217.x</ArticleId><ArticleId IdType="pubmed">21324095</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012 35:190&#x2013;195. 10.1111/j.1365-2605.2011.01226.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2605.2011.01226.x</ArticleId><ArticleId IdType="pubmed">22085227</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller A, Mulhall JP. Peyronie's disease intervention trials: methodological challenges and issues. J Sex Med. (2009) 6:848&#x2013;61. 10.1111/j.1743-6109.2008.01081.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01081.x</ArticleId><ArticleId IdType="pubmed">19138374</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol. (2007) 51:640&#x2013;647. 10.1016/j.eururo.2006.10.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.10.042</ArticleId><ArticleId IdType="pubmed">17092631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. . Clinical efficacy safety and tolerability of collagenase clostridium histolyticum in the treatment of Peyronie's disease from 2 large double-blind randomized placebo-controlled phase 3 studies. J Urol. (2013) 190:199&#x2013;207. 10.1016/j.juro.2013.01.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2013.01.087</ArticleId><ArticleId IdType="pubmed">23376148</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie's disease. J Sex Med. (2017) 14:1220e1225. 10.1016/j.jsxm.2017.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.08.008</ArticleId><ArticleId IdType="pubmed">28874331</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG. Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease. Urology. (2016) 100:125&#x2013;30. 10.1016/j.urology.2016.09.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.09.050</ArticleId><ArticleId IdType="pubmed">27816605</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. . Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int. (2017) 120:717&#x2013;23. 10.1111/bju.13932</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13932</ArticleId><ArticleId IdType="pubmed">28612401</ArticleId></ArticleIdList></Reference><Reference><Citation>Capece M, Cocci A, Russo G, Cito G, Gibilei G, Cacciamani G, et al. . Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. Andrology. (2018) 6:84. 10.1111/andr.12497</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12497</ArticleId><ArticleId IdType="pubmed">29733116</ArticleId></ArticleIdList></Reference><Reference><Citation>Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature. World J Urol. (2019) 38:279&#x2013;85. 10.1007/s00345-019-02850-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-019-02850-3</ArticleId><ArticleId IdType="pubmed">31250098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitch WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl topical trifluoperazine and topical magnesium sulfate for the treatment of Peyronie's disease&#x2013;a placebo-controlled pilot study. J Sex Med. (2007) 4:477. 10.1111/j.1743-6109.2006.00417.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00417.x</ArticleId><ArticleId IdType="pubmed">17367443</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. (2002) 168:2483. 10.1016/S0022-5347(05)64173-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)64173-0</ArticleId><ArticleId IdType="pubmed">12441945</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl CR, Sternig P, Gall&#xe9; G, Langmann F, Vcelar B, Vorauer K, et al. . Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. (2005) 48:656. 10.1016/j.eururo.2005.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2005.04.011</ArticleId><ArticleId IdType="pubmed">15982798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: a review. J Urol. (2003) 169:1234&#x2013;41. 10.1097/01.ju.0000053800.62741.fe</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000053800.62741.fe</ArticleId><ArticleId IdType="pubmed">12629334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled prospective randomized single-blind study. J Sex Med. (2013) 10:2815&#x2013;21. 10.1111/jsm.12275</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12275</ArticleId><ArticleId IdType="pubmed">23898925</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med. (2008) 5:1468&#x2013;1473. 10.1111/j.1743-6109.2008.00814.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00814.x</ArticleId><ArticleId IdType="pubmed">18373527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L, et al. . Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. (2014) 11:506&#x2013;15. 10.1111/jsm.12400</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12400</ArticleId><ArticleId IdType="pubmed">24261900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, Trost L. Outcome of a novel penile traction device in men with Peyronie's disease: a randomized single-blind controlled trial. J Urol. (2019) 202:599&#x2013;610. 10.1097/JU.0000000000000245</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JU.0000000000000245</ArticleId><ArticleId IdType="pubmed">30916626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol. (2002) 167:1187&#x2013;8. 10.1016/S0022-5347(02)80380-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(02)80380-9</ArticleId><ArticleId IdType="pubmed">11905897</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gomez B, Ralph D, Levine L, Moncada-Iribarren I, Djinovic R, Albersen M, et al. . Grafts for Peyronie's disease: a comprehensive review. Andrology. (2017) 6:117&#x2013;26. 10.1111/andr.12421</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12421</ArticleId><ArticleId IdType="pubmed">29266877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. (1990) 143:80&#x2013;2. 10.1016/S0022-5347(17)39871-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)39871-3</ArticleId><ArticleId IdType="pubmed">2294269</ArticleId></ArticleIdList></Reference><Reference><Citation>Essed E, Schroeder FH. New surgical treatment for Peyronie disease. Urology. (1985) 25:582&#x2013;587. 10.1016/0090-4295(85)90285-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(85)90285-7</ArticleId><ArticleId IdType="pubmed">4012950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. (2020) 167:2066&#x2013;2069. 10.1016/S0022-5347(05)65085-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)65085-9</ArticleId><ArticleId IdType="pubmed">11956440</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine CJ, Horton CE. Surgical treatment of Peyronie's disease with a dermal graft. J Urol. (1974) 111:44&#x2013;9. 10.1016/S0022-5347(17)59886-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)59886-9</ArticleId><ArticleId IdType="pubmed">4273261</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman NU, Carrion RE, Bochinski D, Lue TF. Combined penile plication surgery and insertion of penile prosthesis for severe penile curvature and erectile dysfunction. J Urol. (2004) 171:2346&#x2013;9. 10.1097/01.ju.0000124042.74905.70</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000124042.74905.70</ArticleId><ArticleId IdType="pubmed">15126818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR. A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J Urol. (1994) 152:1121&#x2013;3. 10.1016/S0022-5347(17)32519-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)32519-3</ArticleId><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, James R. Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sexual Med. (2011) 8:2112&#x2013;2117. 10.1111/j.1743-6109.2011.02285.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02285.x</ArticleId><ArticleId IdType="pubmed">21492409</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie' disease. BJU Int. (2011) 108:1152&#x2013;6. 10.1111/j.1464-410X.2010.10023.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2010.10023.x</ArticleId><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med. (2005) 2:132&#x2013;8. 10.1111/j.1743-6109.2005.20113.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.20113.x</ArticleId><ArticleId IdType="pubmed">16422916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. . EAU guidelines on penile curvature. Eur Urol. (2012) 62:543&#x2013;51. 10.1016/j.eururo.2012.05.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2012.05.040</ArticleId><ArticleId IdType="pubmed">22658761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nature. (2005) 2:291&#x2013;7. 10.1038/ncpuro0201</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpuro0201</ArticleId><ArticleId IdType="pubmed">16474811</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36238423</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Three-Piece Inflatable Penile Prosthesis Implantation for the Treatment of Severe Erectile Dysfunction Following a Complex Pelvic Fracture: A Case Report.</ArticleTitle><Pagination><StartPage>e30151</StartPage><MedlinePgn>e30151</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30151</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.30151</ELocationID><Abstract><AbstractText>Pelvic fracture is one of the common causes of erectile dysfunction (ED). The pathophysiology of ED following pelvic injury is quite complicated and comprises vascular, neurogenic, corporal, as well as psychogenic causes. Penile prosthesis implantation is the third-line treatment of ED due to any reason including pelvic trauma that poorly responds to other standard treatments. In this study, we reported a case of a 33-year-old man with severe erectile dysfunction and urethral stricture following a complex pelvic fracture due to a traffic accident who was successfully implanted with a three-piece inflatable penile prosthesis at People's Hospital 115. At the sixth month of follow-up, this device has been working effectively, the patient had the ability to attain full erection for sexual intercourse. Both the patient and the partner are satisfied with their sexual lives. ED is a long-term consequence of pelvic fracture. The high proportion of young patients with a demand for erection rehabilitation and complex pathophysiology make the treatments even more challenging. Penile implant surgery is a potential treatment for refractory ED patients suffering from pelvic trauma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Truong et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Minh H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, People's Hospital 115, Ho Chi Minh, VNM.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephro-Urology and Andrology, Pham Ngoc Thach University of Medicine, Ho Chi Minh, VNM.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Trung Q</ForeName><Initials>TQ</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal transplantation, People's Hospital 115, Ho Chi Minh, VNM.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">impotence</Keyword><Keyword MajorTopicYN="N">pelvic fracture</Keyword><Keyword MajorTopicYN="N">penile prosthesis implantation</Keyword><Keyword MajorTopicYN="N">urethral injury</Keyword></KeywordList><CoiStatement>All authors contributed equally to this article as co-first authors. All authors read and approved the final manuscript</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>3</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36238423</ArticleId><ArticleId IdType="pmc">PMC9550429</ArticleId><ArticleId IdType="doi">10.7759/cureus.30151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pelvic trauma: WSES classification and guidelines. Coccolini F, Stahel PF, Montori G, et al. World J Emerg Surg. 2017;12:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241998</ArticleId><ArticleId IdType="pubmed">28115984</ArticleId></ArticleIdList></Reference><Reference><Citation>The outcome of complex pelvic fracture after internal fixation surgery. Ismail HD, Lubis MF, Djaja YP. Malays Orthop J. 2016;10:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333698</ArticleId><ArticleId IdType="pubmed">28435542</ArticleId></ArticleIdList></Reference><Reference><Citation>Erectile dysfunction after fracture of the pelvis. Harwood PJ, Grotz M, Eardley I, Giannoudis PV. https://doi.org/10.1302/0301-620X.87B3.15662. J Bone Joint Surg Br. 2005;87:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">15773631</ArticleId></ArticleIdList></Reference><Reference><Citation>Impotence after fractures of the pelvis. King J. https://pubmed.ncbi.nlm.nih.gov/1201996/ J Bone Joint Surg Am. 1975;57:1107&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">1201996</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association of Urology Guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Salonia A, Bettocchi C, Boeri L, et al. Eur Urol. 2021;80:333&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">34183196</ArticleId></ArticleIdList></Reference><Reference><Citation>Erectile dysfunction: AUA guideline. Burnett AL, Nehra A, Breau RH, et al. J Urol. 2018;200:633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes. Sangkum P, Levy J, Yafi FA, Hellstrom WJ. https://doi.org/10.1111/andr.12015. Andrology. 2015;3:443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">25784590</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk stratification for erectile dysfunction after pelvic fracture urethral injuries. Chung PH, Gehring C, Firoozabadi R, Voelzke BB. Urology. 2018;115:174&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">29432870</ArticleId></ArticleIdList></Reference><Reference><Citation>Blunt trauma: the pathophysiology of hemodynamic injury leading to erectile dysfunction. Munarriz RM, Yan QR, Nehra A, Udelson D, Goldstein I. J Urol. 1995;153:1831&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pubmed">7752329</ArticleId></ArticleIdList></Reference><Reference><Citation>The incidence and causes of erectile dysfunction after pelvic fractures associated with posterior urethral disruption. Shenfeld OZ, Kiselgorf D, Gofrit ON, et al. J Urol. 2003;169:2173&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771742</ArticleId></ArticleIdList></Reference><Reference><Citation>An assessment of the efficacy and safety of sildenafil administered to patients with erectile dysfunction referred for posterior urethroplasty: a single-center experience. Fu Q, Sun X, Tang C, Cui R, Chen L. J Sex Med. 2012;9:282&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">21933349</ArticleId></ArticleIdList></Reference><Reference><Citation>Erectile dysfunction after urethroplasty: is the risk overstated? Baumgarten AS, Hudak SJ, Morey AF. J Sex Med. 2020;17:171&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">31680005</ArticleId></ArticleIdList></Reference><Reference><Citation>The relationship between erectile dysfunction and open urethroplasty: a systematic review and meta-analysis. Feng C, Xu YM, Barbagli G, Lazzeri M, Tang CY, Fu Q, Sa YL. J Sex Med. 2013;10:2060&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656595</ArticleId></ArticleIdList></Reference><Reference><Citation>De novo erectile dysfunction after anterior urethroplasty: a systematic review and meta-analysis. Blaschko SD, Sanford MT, Cinman NM, McAninch JW, Breyer BN. BJU Int. 2013;112:655&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740455</ArticleId><ArticleId IdType="pubmed">23924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Urology. 2006;68:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904479</ArticleId></ArticleIdList></Reference><Reference><Citation>Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Padma-Nathan H, McCullough AR, Levine LA, et al. Int J Impot Res. 2008;20:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650827</ArticleId></ArticleIdList></Reference><Reference><Citation>Erectile dysfunction following pelvic fracture urethral injury. Johnsen NV, Kaufman MR, Dmochowski RR, Milam DF. Sex Med Rev. 2018;6:114&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">28757357</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term follow-up after penile prosthesis implantation&#x2014;survival and quality of life outcomes. Chierigo F, Capogrosso P, Deh&#xf2; F, et al. J Sex Med. 2019;16:1827&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501062</ArticleId></ArticleIdList></Reference><Reference><Citation>An unusual complication of penile prosthesis following urethroplasty. Kardar AH, Aslam M, Lindstedt E. Scand J Urol Nephrol. 2002;36:89&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12002368</ArticleId></ArticleIdList></Reference><Reference><Citation>An unusual success with simultaneous urethral repair and reimplantation of penile prosthesis in a patient with urethral stricture induced by rotated tubing. Cui WS, Kim SD, Choi KS, Zhao C, Park JK. J Sex Med. 2009;6:1783&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">19473469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36210629</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy after mRNA COVID19 vaccination.</ArticleTitle><Pagination><StartPage>103201</StartPage><MedlinePgn>103201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2022.103201</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(22)00171-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 vaccine-associated peripheral and central neuroimmunological disorders have been well described. We present the case of a 56&#xa0;year old male who developed &#x3b1;3-ganglionic AChR antibody positive Autoimmune Autonomic Ganglionopathy (AAG) after completion of a two-dose course of mRNA (Comirnaty) vaccination for COVID19.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A previously hypertensive 56&#xa0;year old male presented with the subacute onset of severe constipation, urinary retention, erectile dysfunction, sudomotor failure, sicca symptoms, non-reactive pupils and severe orthostatic hypotension shortly after receiving the second dose of an mRNA vaccine against COVID19. Autonomic testing revealed severe cardiovagal, adrenergic and sudomotor impairment, and tonic 'half-mast' pupils with evidence of sympathetic and parasympathetic denervation. Pathological &#x3b1;3-ganglionic ACHR antibodies were positive in serum as detected by a new flow cytometric immunomodulation assay. Malignancy was excluded. The patient was diagnosed with severe, treatment-refractory acute AAG.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While autonomic dysfunction has been previously reported post-COVID19 vaccination, to our knowledge this is the first reported case of antibody-positive AAG in this setting. The severity of this case is in marked contrast to the existing literature on idiopathic antibody-positive autoimmune pandysautonomia.</AbstractText><CopyrightInformation>Crown Copyright &#xa9; 2022. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Liverpool Hospital, Sydney, NSW, Australia. Electronic address: simon.rowe@health.nsw.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spies</LastName><ForeName>Judith M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urriola</LastName><ForeName>Nicol&#xe1;s</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005725" MajorTopicYN="N">Ganglia, Autonomic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="Y">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054969" MajorTopicYN="Y">Primary Dysautonomias</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010523" MajorTopicYN="Y">Peripheral Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020274" MajorTopicYN="Y">Autoimmune Diseases of the Nervous System</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune autonomic ganglionopathy</Keyword><Keyword MajorTopicYN="N">COVID19 vaccination</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Comirnaty</Keyword><Keyword MajorTopicYN="N">Pandysautonomia</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>2</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36210629</ArticleId><ArticleId IdType="pmc">PMC9484853</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2022.103201</ArticleId><ArticleId IdType="pii">S1568-9972(22)00171-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koay S., Vichayanrat E., Bremner F., et al. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Ann Neurol. 2021;89:753&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">33438240</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernino S., Low P.A., Fealey R.D., Stewart J.D., Farrugia G., Lennon V.A. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343:847&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995864</ArticleId></ArticleIdList></Reference><Reference><Citation>Urriola N., Spies J.M., Blazek K., Lang B., Adelstein S. A flow cytometric assay to detect functional ganglionic acetylcholine receptor antibodies by immunomodulation in autoimmune autonomic ganglionopathy. Front Immunol [online serial] 2021;12 https://www.frontiersin.org/article/10.3389/fimmu.2021.705292 Accessed at:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.705292</ArticleId><ArticleId IdType="pmc">PMC8261233</ArticleId><ArticleId IdType="pubmed">34249013</ArticleId></ArticleIdList></Reference><Reference><Citation>Urriola N., Adelstein S. Autoimmune autonomic ganglionopathy: ganglionic acetylcholine receptor autoantibodies. Autoimmun Rev. 2021;21</Citation><ArticleIdList><ArticleId IdType="pubmed">34728435</ArticleId></ArticleIdList></Reference><Reference><Citation>Shouman K., Vanichkachorn G., Cheshire W.P., et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31:385&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050227</ArticleId><ArticleId IdType="pubmed">33860871</ArticleId></ArticleIdList></Reference><Reference><Citation>Iodice V., Kimpinski K., Vernino S., Sandroni P., Fealey R., Low P. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology. 2009;72:2002&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837591</ArticleId><ArticleId IdType="pubmed">19506222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36209303</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>New findings regarding the influence of assistants on surgical outcomes in penile prosthesis implantation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-022-00624-x</ELocationID><Abstract><AbstractText>Penile prosthesis implantation is the definitive treatment for refractory erectile dysfunction, yet exposure to this procedure during training of urology residents is often limited. To assess the effects of resident participation in penile prosthesis surgery, we compared surgical outcomes in a retrospective case series of 253 penile prosthesis surgeries by a single surgeon at the same institution between 2017 and 2020 with the assistance of either a registered nurse first assistant (RNFA) or a resident. Pertinent patient characteristics and surgical complications including device complications, surgical site infection, postoperative bleeding, iatrogenic injury, cardiovascular events, pulmonary events, and urinary retention were documented. Measured outcomes included operative time, Emergency Room (ER) visits, unplanned postoperative visits, pain medication refills, and surgical&#xa0;complications. Compared to RFNAs, resident-assisted penile prosthesis surgery was associated with significant increase in mean operative time (71.4&#x2009;min vs. 87.9&#x2009;min, p&#x2009;&lt;&#x2009;0.01) and postoperative ER visits (3.0% vs. 10.6%, p&#x2009;=&#x2009;0.03) but not surgical complications (19.7% vs. 20.8%, OR 1.03, 95% CI [0.46 -2.30]) or other measured outcomes. Compared to a dedicated RFNA, Resident assistance increased operative time by approximately 17&#x2009;min, but did not increase post-operative surgical complications, supporting the notion that resident assistance in these procedures may be appropriate as an integral part of training.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shuo-Chieh</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanton</LastName><ForeName>Amanda R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>James M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-1413-2536</Identifier><AffiliationInfo><Affiliation>Geisel School of Medicine at Dartmouth, Hanover, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-2716-8642</Identifier><AffiliationInfo><Affiliation>Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. Martin.S.Gross@hitchcock.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>8</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36209303</ArticleId><ArticleId IdType="doi">10.1038/s41443-022-00624-x</ArticleId><ArticleId IdType="pii">10.1038/s41443-022-00624-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.281.6.537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DJ, Najari BB, Davison WL, Al Hussein Al Awamlh B, Zhao F, Paduch DA, et al. Trends in the utilization of penile prostheses in the treatment of erectile dysfunction in the United States. J Sex Med. 2015;12:1638&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169:1429&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000056047.74268.9c</ArticleId></ArticleIdList></Reference><Reference><Citation>Saavedra-Belaunde JA, Clavell-Hernandez J, Wang R. Epidemiology regarding penile prosthetic surgery. Asian J Androl. 2020;22:2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aja.aja_124_19</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi C, Fortier &#xc9;, Faix A, Mart&#xed;nez-Salamanca JI. Penile implant surgery satisfaction assessment. J Sex Med. 2021;18:868&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2021.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac JR. Centers of excellence for penile prosthetics are a novel concept that will likely prove difficult to implement. Transl Androl Urol. 2017;6:S898&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.11.21</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberlin DT, Matulewicz RS, Bachrach L, Hofer MD, Brannigan RE, Flury SC. National practice patterns of treatment of erectile dysfunction with penile prosthesis implantation. J Urol. 2015;193:2040&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.11.095</ArticleId></ArticleIdList></Reference><Reference><Citation>Damadi A, Davis AT, Saxe A, Apelgren K. ACGME duty-hour restrictions decrease resident operative volume: a 5-year comparison at an ACGME-accredited university general surgery residency. J Surg Educ. 2007;64:256&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsurg.2007.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>McAbee KE, Pearlman AM, Terlecki RP. Infection following penile prosthesis placement at an academic training center remains low despite involvement of surgeons-in-training. Investig Clin Urol. 2018;59:342.</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/icu.2018.59.5.342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahan ME, Parker DM, Fluck M, Gabrielsen JD, Petrick AT, Horsley RD. First assistant impact on early morbidity and mortality in bariatric surgery. Surg Obes Relat Dis. 2019;15:1541&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soard.2019.06.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuce TK, Holmstrom A, Soper NJ, Nagle AP, Hungness ES, Merkow RP, et al. Complications and readmissions associated with first assistant training level following elective bariatric surgery. J Gastrointest Surg. 2021;25:1948&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-020-04787-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Archie JP. Influence of the first assistant on abdominal aortic aneurysm surgery. Tex Heart Inst J. 1992;19:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15227463</ArticleId><ArticleId IdType="pmc">325010</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000133083.54934.ae</ArticleId></ArticleIdList></Reference><Reference><Citation>Matulewicz RS, Pilecki M, Rambachan A, Kim JYS, Kundu SD. Impact of resident involvement on urological surgery outcomes: an analysis of 40,000 patients from the ACS NSQIP database. J Urol. 2014;192:885&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.03.096</ArticleId></ArticleIdList></Reference><Reference><Citation>Priv&#xe9; B, Kortleve M, van Basten JP. Evaluating the impact of resident involvement during the laparoscopic nephrectomy. Cent European J Urol. 2019;72. https://doi.org/10.5173/ceju.2019.0021 .</Citation></Reference><Reference><Citation>McMillan DT, Viera AJ, Matthews J, Raynor MC, Woods ME, Pruthi RS, et al. Resident involvement and experience do not affect perioperative complications following robotic prostatectomy. World J Urol. 2015;33:793&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-014-1356-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Baber J, Staff I, McLaughlin T, Tortora J, Champagne A, Gangakhedkar A, et al. Impact of urology resident involvement on intraoperative, long-term oncologic and functional outcomes of robotic assisted laparoscopic radical prostatectomy. Urology. 2019;132:43&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2019.05.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhotina N, Dagenais J, Gandaglia G, Sood A, Abdollah F, Chang SL, et al. The impact of resident involvement in minimally-invasive urologic oncology procedures. CUAJ. 2014;8:334.</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.2170</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer CP, Hanske J, Friedlander DF, Schmid M, Dahlem R, Trinh VQ, et al. The impact of resident involvement in male one-stage anterior urethroplasties. Urology. 2015;85:937&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2015.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Caras RJ, Lustik MB, Kern SQ, Sterbis JR, McMann LP. Laparoscopic radical prostatectomy demonstrates less morbidity than open radical prostatectomy: an analysis of the American College of Surgeons-National Surgical Quality Improvement Program database with a focus on surgical trainee involvement. J Endourol. 2014;28:298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/end.2013.0475</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard CB, Meyer CP, Gandaglia G, Chang SL, Chun FKH, Gelpi-Hammerschmidt F, et al. The effect of resident involvement on perioperative outcomes in transurethral urologic surgeries. J Surg Educ. 2015;72:1018&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsurg.2015.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy JM, Walker J, Gupta S, Davenport DL, Preston DM. Risk factors for removal or revision of penile prostheses in the veteran population. Urology. 2016;98:189&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.06.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Bennett NE. Comparing risk factors for adverse outcomes in virgin inflatable penile prosthesis implantations and revisions: a retrospective cohort study. Sex Med. 2020;8:388&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2020.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185:614&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.09.094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Carson CC. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol. 2011;60:167&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.01.046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36058552</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>217</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Urological Society of Australia and New Zealand (USANZ) and Australasian Chapter of Sexual Health Medicine (AChSHM) for the Royal Australasian College of Physicians (RACP) clinical guidelines on the management of erectile dysfunction.</ArticleTitle><Pagination><StartPage>318</StartPage><EndPage>324</EndPage><MedlinePgn>318-324</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.51694</ELocationID><Abstract><AbstractText Label="INTRODUCTION">These clinical practice recommendations by the Urological Society of Australia and New Zealand (USANZ) and the Australasian Chapter of Sexual Health Medicine (AChSHM) for the Royal Australasian College of Physicians (RACP) provide evidence-based clinical guidelines on the management of erectile dysfunction (ED) in Australia.</AbstractText><AbstractText Label="MAIN RECOMMENDATIONS">A comprehensive clinical history and a tailored physical examination are essential (Level of evidence [LoE] 3; GRADE B). Laboratory testing should include fasting glucose, lipid profile and total testosterone level (LoE 3; GRADE A). Specialised diagnostic tests are recommended in selected cases and the patient should be counselled accordingly (LoE 4; GRADE B). Lifestyle changes and optimisation of existing medical conditions should accompany all ED treatment regimens (LoE 1; GRADE A). Oral phosphodiesterase type 5 inhibitor (PDE5i) is an effective first line medical therapy (LoE 1; GRADE A). Intracavernosal injections and vacuum erection devices are recommended as second line therapy (LoE 1; GRADE B). A penile prosthesis implant can be considered in men who are medically refractory or unable to tolerate the side effects of medical therapy (LoE 4; GRADE B). Pro-erectile regenerative therapy remains largely experimental (LoE 3; GRADE B).</AbstractText><AbstractText Label="CHANGES IN MANAGEMENT AS A RESULT OF THESE GUIDELINES">Modification of lifestyle behaviour, management of reversible risk factors and optimisation of existing medical conditions remain pivotal, and existing standard ED therapies are often effective and safe following cardiovascular risk stratification. Caution should be exercised on the use of regenerative technology in ED due to unknown long term outcomes.</AbstractText><CopyrightInformation>&#xa9; 2022 AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3373-3668</Identifier><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, QLD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, Brisbane, QLD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AndroUrology Centre, Brisbane, QLD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowy</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Male Clinic, Sydney, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Men's Health Doctor, Brisbane, QLD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Urology South, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Darren</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0861-5643</Identifier><AffiliationInfo><Affiliation>Men's Health Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neilsen</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stonewall Medical Centre, Brisbane, QLD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Med J Aust. 2022 Nov 21;217(10):525</RefSource><PMID Version="1">36207013</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N" Type="Geographic">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="Y">Physicians</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074384" MajorTopicYN="Y">Sexual Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sexual dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>4</Day><Hour>19</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36058552</ArticleId><ArticleId IdType="doi">10.5694/mja2.51694</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010; 7: 3572-3588.</Citation></Reference><Reference><Citation>Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004; 1: 35-39.</Citation></Reference><Reference><Citation>Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99-109.</Citation></Reference><Reference><Citation>Nehra A, Jackson G, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87: 766-778.</Citation></Reference><Reference><Citation>Jackson G, Nehra A, Miner M, et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract 2013; 67: 1163-1172.</Citation></Reference><Reference><Citation>Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-825.</Citation></Reference><Reference><Citation>McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust 2019; 210: 469-476. https://www.mja.com.au/journal/2019/210/10/current-diagnosis-and-management-erectile-dysfunction</Citation></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-814.</Citation></Reference><Reference><Citation>Bella AJ, Lee JC, Carrier S, et al. 2015 CUA Practice guidelines for erectile dysfunction. Can Urol Assoc J 2015; 9: 23-29.</Citation></Reference><Reference><Citation>Ryu JK, Cho KS, Kim SJ, et al. Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction. World J Mens Health 2013; 31: 83-102.</Citation></Reference><Reference><Citation>American Urological Association. Erectile dysfunction: AUA guidelines (2018) [website]. https://www.auanet.org/guidelines/erectile-dysfunction-(ed)-guideline (viewed Jan 2020).</Citation></Reference><Reference><Citation>Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J&#xa0;Sex Med 2016; 13: 465-488.</Citation></Reference><Reference><Citation>Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men. J&#xa0;Sex Med 2018; 15: 430-457.</Citation></Reference><Reference><Citation>Kimoto Y, Nagao K, Sasaki H, et al. JSSM guidelines for erectile dysfunction. Int J Urol 2008; 15: 564-576.</Citation></Reference><Reference><Citation>Mulhall JP, Giraldi A, Hackett, G et al. The 2018 revision to the process of care model for evaluation of erectile dysfunction. J Sex Med 2018; 15: 1280-1292.</Citation></Reference><Reference><Citation>Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM Evidence Levels of Evidence (introductory document). Oxford Centre for Evidence-Based Medicine, 2011. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/levels-of-evidence-introductory-document (viewed Aug 2022).</Citation></Reference><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.</Citation></Reference><Reference><Citation>Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005; 17: 307-319.</Citation></Reference><Reference><Citation>Ghanem HM, Salonia A, Martin-Morales A. SOP: Physical examination and laboratory testing for men with erectile dysfunction. J Sex Med 2013; 10: 108-110.</Citation></Reference><Reference><Citation>Meuleman EJH, Hatzichristou D, Rosen RC, Sadovsky R. Diagnostic tests for male erectile dysfunction revisited. Committee Consensus Report of the International Consultation in Sexual Medicine. J Sex Med 2010; 7: 2375-2381.</Citation></Reference><Reference><Citation>Bu BY, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 2016; 205: 173-178. https://www.mja.com.au/journal/2016/205/4/endocrine-society-australia-position-statement-male-hypogonadism-part-1</Citation></Reference><Reference><Citation>Schmidt HM, Munder T, Gerger H, et al. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J Sex Med 2014; 11: 1376-1391.</Citation></Reference><Reference><Citation>Chung E, Yan H, De Young L, Brock GB. Penile Doppler sonographic and clinical characteristics in Peyronie&#x2019;s disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int 2012; 110: 1201-1205.</Citation></Reference><Reference><Citation>Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: Standard operating procedures for duplex ultrasound. J Sex Med 2013; 10: 120-129.</Citation></Reference><Reference><Citation>Glina S, Ghanem H. SOP: corpus cavernosum assessment (cavernosography/cavernosometry). J Sex Med 2013; 10: 111-114.</Citation></Reference><Reference><Citation>Elhanbly S, Elkholy A. Nocturnal penile erections: the role of RigiScan in the diagnosis of vascular erectile dysfunction. J Sex Med 2012; 9: 3219-3226.</Citation></Reference><Reference><Citation>Jannini EA, Granata AM, Hatzimouratidis K, Goldstein I. Use and abuse of RigiScan in the diagnosis of erectile dysfunction. J Sex Med 2009; 6: 1820-1829.</Citation></Reference><Reference><Citation>Giuliano F, Rowland DL. Standard operating procedures for neurophysiologic assessment of male sexual dysfunction. J Sex Med 2013; 10: 1205-1211.</Citation></Reference><Reference><Citation>Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63: 902-912.</Citation></Reference><Reference><Citation>Jannini EA, DeRogatis LR, Chung E, Brock GB. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 2012; 9: 26-33.</Citation></Reference><Reference><Citation>Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med 2013; 10 (Suppl): 102-111.</Citation></Reference><Reference><Citation>Chung E, Gillman M. Prostate cancer survivorship: a review of current literature in erectile dysfunction and the concept of penile rehabilitation following prostate cancer therapy. Med J Aust 2014; 200: 582-585. https://www.mja.com.au/journal/2014/200/10/prostate-cancer-survivorship-review-erectile-dysfunction-and-penile</Citation></Reference><Reference><Citation>Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 2013; 10: 130-171.</Citation></Reference><Reference><Citation>Levine LA, Becher E, Bella A, et al. Penile prosthesis surgery: current recommendations from the International Consultation on Sexual Medicine. J Sex Med 2016; 13: 489-518.</Citation></Reference><Reference><Citation>Chung E. Penile prosthesis implant: Scientific advances and technological innovations over the last four decades. Transl Androl Urol 2017; 6: 37-45.</Citation></Reference><Reference><Citation>Chung E, Lee J, Liu CC, et al. Clinical practice guideline recommendation on the use of low intensity extracorporeal shock wave therapy and low intensity pulsed ultrasound shock wave therapy to treat erectile dysfunction: the Asia-Pacific Society for Sexual Medicine position statement. World J Mens Health 2021; 39: 1-8.</Citation></Reference><Reference><Citation>Chung E, Wang J. A state-of-art review of low intensity extracorporeal shock wave therapy and lithotripter machines for the treatment of erectile dysfunction. Expert Rev Med Device 2017; 14: 929-934.</Citation></Reference><Reference><Citation>Chung E. Stem-cell-based therapy in the file of urology: A review of stem cell basic science, clinical applications and future directions in the treatment of various sexual and urinary conditions. Expert Opin Biol Ther 2015; 15: 1623-1632.</Citation></Reference><Reference><Citation>Scott S, Roberts M, Chung E. Platelet-rich plasma and treatment of erectile dysfunction: Critical review of literature and global trends in platelet-rich plasma clinics. Sex Med Rev 2019; 7: 306-312.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36047071</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2287-4208</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2022</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>The world journal of men's health</Title><ISOAbbreviation>World J Mens Health</ISOAbbreviation></Journal><ArticleTitle>Relaxin-2 Prevents Erectile Dysfunction by Cavernous Nerve, Endothelial and Histopathological Protection Effects in Rats with Bilateral Cavernous Nerve Injury.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.5534/wjmh.220003</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cavernous nerve injury induced erectile dysfunction (ED) is a refractory complication with high incidence in person under radical prostatectomy. Studies have shown that relaxin-2 (RLX-2) plays a vital role of endothelial protection, vasodilation, anti-fibrosis and neuroprotection in a variety of diseases. However, whether penile cavernous erection can benefit from RLX-2 remains unknown. The purpose of the experiment was to explore the effects of RLX-2 on ED in the rat suffering with bilateral cavernous nerve injury (BCNI).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The rats were divided into three groups: Sham group was underwent sham operation, BCNI+RLX group or BCNI group was underwent bilateral cavernous nerve crush and then randomly treated with RLX-2 (0.4 mg/kg/d) or saline by continuous administration using a subcutaneously implanted micro pump for 4 weeks respectively. Then, erectile function was evaluated by electrical stimulation of cavernous nerves. Cavernous nerves and penile tissues and were collected for histological evaluation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Erectile function of rats with BCNI was partially improved after RLX-2 treatment. The BCNI group had lower expression of relaxin family peptide receptor (RXFP) 1, p-AKT/AKT, p-eNOS/eNOS ratios than sham operation rats, but RLX-2 could partially reversed these changes. Histologically, the BCNI+RLX group had a significant effect on preservation of neurofilament, neuronal glial antigen 2 of penile tissue and nNOS of cavernous nerves when compared with BCNI group. RLX-2 could inhibited the lever of BCNI induced corporal fibrosis and apoptosis <i>via</i> regulating TGF&#x3b2;1-Smad2/3-CTGF pathway and the expression of Bax/Bcl-2 ratio, caspase3.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RLX-2 could improve erectile function of BCNI rats by protecting cavernous nerve and endothelial function and suppressing corporal fibrosis and apoptosis <i>via</i> RXFP1 and AKT/eNOS pathway. Our findings may provide a promising treatment for refractory BCNI induced ED.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Korean Society for Sexual Medicine and Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kang</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5234-3342</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Taotao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2889-4419</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenchao</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-6947-427X</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jingyu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6715-2813</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinwei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5364-2299</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7767-7309</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9886-1874</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6566-679X</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8775-7326</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6138-5229</Identifier><AffiliationInfo><Affiliation>Male Reproductive and Sexual Medicine, Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jiancheng</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7703-7667</Identifier><AffiliationInfo><Affiliation>Male Reproductive and Sexual Medicine, Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Enli</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3079-3059</Identifier><AffiliationInfo><Affiliation>Male Reproductive and Sexual Medicine, Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Zhongcheng</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-0361-2737</Identifier><AffiliationInfo><Affiliation>Male Reproductive and Sexual Medicine, Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2952-8397</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shaogang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3206-1495</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jihong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9711-2428</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luan</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7153-3814</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. yangluan@tjh.tjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81801439</GrantID><Agency>National Natural Science Foundation of China</Agency><Country>China</Country></Grant><Grant><GrantID>81873831</GrantID><Agency>National Natural Science Foundation of China</Agency><Country>China</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>World J Mens Health</MedlineTA><NlmUniqueID>101596899</NlmUniqueID><ISSNLinking>2287-4208</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Nerve</Keyword><Keyword MajorTopicYN="N">Penis</Keyword><Keyword MajorTopicYN="N">Relaxin</Keyword></KeywordList><CoiStatement>The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>3</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36047071</ArticleId><ArticleId IdType="doi">10.5534/wjmh.220003</ArticleId><ArticleId IdType="pii">40.e50</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35929992</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2927</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Andrology</Title><ISOAbbreviation>Andrology</ISOAbbreviation></Journal><ArticleTitle>The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>269</EndPage><MedlinePgn>257-269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/andr.13257</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Erectile dysfunction is associated with diabetes mellitus with an estimated prevalence of 52.5% in the diabetic population. The first-line therapy for erectile dysfunction is phosphodiesterase type 5 inhibitors, but data suggest that diabetic men may be less responsive than non-diabetic men. Thus, other treatments, including intracavernosal injections, intraurethral prostaglandin, vacuum erection devices and penile prosthetic surgery, should be considered in management of diabetic men with erectile dysfunction refractory to phosphodiesterase type 5 inhibitors. Furthermore, combination therapy of phosphodiesterase type 5 inhibitors and other oral treatments such as arginine or l-carnitine may have synergistic effects resulting in better outcomes. In addition, there are novel therapies such as low-intensity shockwave therapy and stem-cell therapy, which may also be effective in targeted treatment modalities. Furthermore, studies suggest that erectile dysfunction can be improved by targeting concurrent comorbidities or metabolic diseases such as depression, hypertension, hypogonadism, and dyslipidaemia. We present an evidence-based narrative review focusing on the management of erectile dysfunction in diabetic men who have not responded to phosphodiesterase type 5 inhibitors.</AbstractText><AbstractText Label="CONCLUSIONS">Both clinicians and patients should be aware of the different management options in diabetic patients who have not responded to phosphodiesterase type 5 inhibitors.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cayetano-Alcaraz</LastName><ForeName>Axel Alberto</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-7041-0564</Identifier><AffiliationInfo><Affiliation>Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tharakan</LastName><ForeName>Tharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Runzhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofikitis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Ioannina School of Medicine, Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Suks</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Andrology</MedlineTA><NlmUniqueID>101585129</NlmUniqueID><ISSNLinking>2047-2919</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidants</Keyword><Keyword MajorTopicYN="N">combination</Keyword><Keyword MajorTopicYN="N">diabetes complications/complications</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">drug therapy</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">hypogonadism</Keyword><Keyword MajorTopicYN="N">intracavernosal injection therapy</Keyword><Keyword MajorTopicYN="N">low-intensity extracorporeal shockwave therapy</Keyword><Keyword MajorTopicYN="N">non-responders to PDE5i</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">phosphodiesterase 5 inhibitors</Keyword><Keyword MajorTopicYN="N">stem-cell therapy</Keyword><Keyword MajorTopicYN="N">vacuum pump</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>11</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35929992</ArticleId><ArticleId IdType="doi">10.1111/andr.13257</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kouidrat Y, Pizzol D, Cosco T, et&#xa0;al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabetes Med. 2017;34(9):1185-1192.</Citation></Reference><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61.</Citation></Reference><Reference><Citation>Angulo J, Gonzalez-Corrochano R, Cuevas P, et&#xa0;al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med. 2010;7(2 pt 1):758-768.</Citation></Reference><Reference><Citation>Gerbild H, Larsen CM, Graugaard C, Josefsson KA. Physical activity to improve erectile function: a systematic review of intervention studies. Sex Med. 2018;6(2):75-89.</Citation></Reference><Reference><Citation>Raheem OA, Su JJ, Wilson JR, Hsieh TC. The association of erectile dysfunction and cardiovascular disease: a systematic critical review. Am J Mens Health. 2017;11(3):552-563.</Citation></Reference><Reference><Citation>Besiroglu H, Otunctemur A, Ozbek E. The relationship between metabolic syndrome, its components, and erectile dysfunction: a systematic review and a meta-analysis of observational studies. J Sex Med. 2015;12(6):1309-1318.</Citation></Reference><Reference><Citation>Pizzol D, Smith L, Fontana L, et&#xa0;al. Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis. Rev Endocr Metab Disord. 2020;21(4):657-666.</Citation></Reference><Reference><Citation>Defeudis G, Mazzilli R, Tenuta M, et&#xa0;al. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2021:e3494.</Citation></Reference><Reference><Citation>Kamenov ZA. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes. 2015;123(3):141-158.</Citation></Reference><Reference><Citation>Shah AD, Langenberg C, Rapsomaniki E, et&#xa0;al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113.</Citation></Reference><Reference><Citation>La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol. 2019;26(2):15-24.</Citation></Reference><Reference><Citation>Montorsi P, Ravagnani PM, Galli S, et&#xa0;al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M-23M.</Citation></Reference><Reference><Citation>Yamada T, Hara K, Umematsu H, Suzuki R, Kadowaki T. Erectile dysfunction and cardiovascular events in diabetic men: a meta-analysis of observational studies. PLoS One. 2012;7(9):e43673.</Citation></Reference><Reference><Citation>Corona G, Rastrelli G, Isidori AM, et&#xa0;al. Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc Ther. 2020;18(3):155-164.</Citation></Reference><Reference><Citation>Pegge NC, Twomey AM, Vaughton K, Gravenor MB, Ramsey MW, Price DE. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabetes Med. 2006;23(8):873-878.</Citation></Reference><Reference><Citation>De Angelis L, Marfella MA, Siniscalchi M, et&#xa0;al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia. 2001;44(9):1155-1160.</Citation></Reference><Reference><Citation>Azmi S, Ferdousi M, Alam U, et&#xa0;al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia. 2017;60(6):1094-1101.</Citation></Reference><Reference><Citation>Pop-Busui R, Hotaling J, Braffett BH, et&#xa0;al. Cardiovascular autonomic neuropathy, erectile dysfunction and lower urinary tract symptoms in men with type 1 diabetes: findings from the DCCT/EDIC. J Urol. 2015;193(6):2045-2051.</Citation></Reference><Reference><Citation>Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol. 2003;31(3):401-418.</Citation></Reference><Reference><Citation>Newsholme P, Haber EP, Hirabara SM, et&#xa0;al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007;583(pt 1):9-24.</Citation></Reference><Reference><Citation>Morano S, Gatti A, Mandosi E, et&#xa0;al. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. J Urol. 2007;177(2):655-659.</Citation></Reference><Reference><Citation>Tagliabue M, Pinach S, Di Bisceglie C, et&#xa0;al. Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. Int J Androl. 2005;28(3):156-162.</Citation></Reference><Reference><Citation>Al-Hunayan A, Thalib L, Kehinde EO, Asfar S. Hyperhomocysteinemia is a risk factor for erectile dysfunction in men with adult-onset diabetes mellitus. Urology. 2008;71(5):897-900.</Citation></Reference><Reference><Citation>Mokdad AH, Ford ES, Bowman BA, et&#xa0;al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-79.</Citation></Reference><Reference><Citation>Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):25.</Citation></Reference><Reference><Citation>Fillo J, Levcikova M, Ondrusova M, Breza J, Labas P. Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence. Am J Mens Health. 2017;11(2):240-245.</Citation></Reference><Reference><Citation>Han TS, Tajar A, O'Neill TW, et&#xa0;al. Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. Eur J Endocrinol. 2011;164(6):1003-1011.</Citation></Reference><Reference><Citation>Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014;16(4):581-591.</Citation></Reference><Reference><Citation>Garc&#xed;a-Cruz E, Leibar-Tamayo A, Romero J, et&#xa0;al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med. 2013;10(10):2529-2538.</Citation></Reference><Reference><Citation>Hajhashemy Z, Shahdadian F, Moslemi E, Mirenayat FS, Saneei P. Serum vitamin D levels in relation to metabolic syndrome: a systematic review and dose-response meta-analysis of epidemiologic studies. Obes Rev. 2021;22(7):e13223.</Citation></Reference><Reference><Citation>Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-2029.</Citation></Reference><Reference><Citation>Crafa A, Cannarella R, Condorelli RA, La Vignera S, Calogero AE. Is there an association between vitamin D deficiency and erectile dysfunction? A systematic review and meta-analysis. Nutrients. 2020;12(5).</Citation></Reference><Reference><Citation>D'Andrea S, Martorella A, Coccia F, et&#xa0;al. Relationship of vitamin D status with testosterone levels: a systematic review and meta-analysis. Endocrine. 2021;72(1):49-61.</Citation></Reference><Reference><Citation>Lazarte J, Hegele RA. Dyslipidemia management in adults with diabetes. Can J Diabetes. 2020;44(1):53-60.</Citation></Reference><Reference><Citation>Verges B. Dyslipidemia in type 1 diabetes: a masked danger. Trends Endocrinol Metab. 2020;31(6):422-434.</Citation></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, et&#xa0;al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082-e1143.</Citation></Reference><Reference><Citation>American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S37-S47.</Citation></Reference><Reference><Citation>Corona G, Mannucci E, Petrone L, et&#xa0;al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18(2):190-197.</Citation></Reference><Reference><Citation>Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462-5468.</Citation></Reference><Reference><Citation>Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000-1011.</Citation></Reference><Reference><Citation>Hackett G, Kirby M, Wylie K, et&#xa0;al. British society for sexual medicine guidelines on the management of erectile dysfunction in men-2017. J Sex Med. 2018;15(4):430-457.</Citation></Reference><Reference><Citation>Corona G, Isidori AM, Buvat J, et&#xa0;al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11(6):1577-1592.</Citation></Reference><Reference><Citation>Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10(6):1612-1627.</Citation></Reference><Reference><Citation>Hackett G, Cole N, Bhartia M, et&#xa0;al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014;68(2):203-215.</Citation></Reference><Reference><Citation>Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943-947.</Citation></Reference><Reference><Citation>Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and diabetes mellitus: coprediction and time trajectories. Hypertension. 2018;71(3):422-428.</Citation></Reference><Reference><Citation>de Oliveira AA, Nunes KP. Hypertension and erectile dysfunction: breaking down the challenges. Am J Hypertens. 2021;34(2):134-142.</Citation></Reference><Reference><Citation>Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Bohm M. Cardiovascular risk, drugs and erectile function-a systematic analysis. Int J Clin Pract. 2011;65(3):289-298.</Citation></Reference><Reference><Citation>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351-357.</Citation></Reference><Reference><Citation>Cordero A, Bertomeu-Martinez V, Mazon P, et&#xa0;al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther. 2010;28(1):15-22.</Citation></Reference><Reference><Citation>Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069-1078.</Citation></Reference><Reference><Citation>Wang X, Yang X, Cai Y, Wang S, Weng W. High prevalence of erectile dysfunction in diabetic men with depressive symptoms: a meta-analysis. J Sex Med. 2018;15(7):935-941.</Citation></Reference><Reference><Citation>Makhlouf A, Kparker A, Niederberger CS. Depression and erectile dysfunction. Urol Clin North Am. 2007;34(4):565-574, vii.</Citation></Reference><Reference><Citation>McCullough AR, Carson CC, Hatzichristou D. A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. Urology. 2006;68(3):38-46.</Citation></Reference><Reference><Citation>McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2 suppl 2):28-38.</Citation></Reference><Reference><Citation>Hackett G. Should all men with type 2 diabetes be routinely prescribed a phosphodiesterase type 5 inhibitor? World J Mens Health. 2020;38(3):271-284.</Citation></Reference><Reference><Citation>McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1(3):292-300.</Citation></Reference><Reference><Citation>Antinozzi C, Sgro P, Di Luigi L. Advantages of phosphodiesterase type 5 inhibitors in the management of glucose metabolism disorders: a clinical and translational issue. Int J Endocrinol. 2020;2020:7078108.</Citation></Reference><Reference><Citation>Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16):1264-1270.</Citation></Reference><Reference><Citation>Anderson SG, Hutchings DC, Woodward M, et&#xa0;al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750-1756.</Citation></Reference><Reference><Citation>Walsh TJ, Hotaling JM, Smith A, Saigal C, Wessells H. Men with diabetes may require more aggressive treatment for erectile dysfunction. Int J Impot Res. 2014;26(3):112-115.</Citation></Reference><Reference><Citation>Salonia A, Bettocchi C, Boeri L, et&#xa0;al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333-357.</Citation></Reference><Reference><Citation>Mykoniatis I, Pyrgidis N, Sokolakis I, et&#xa0;al. Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(2):e2036337.</Citation></Reference><Reference><Citation>Tharakan T, Salonia A, Minhas S. European Association of Urology Working Group on Male Sexual and Reproductive Health. Male life expectancy is still inferior to that of women: urologists must refine and develop the concept of men's health. Eur Urol. 2019;76(6):712-713.</Citation></Reference><Reference><Citation>Wessells H, Penson DF, Cleary P, et&#xa0;al. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol. 2011;185(5):1828-1834.</Citation></Reference><Reference><Citation>Wing RR, Rosen RC, Fava JL, et&#xa0;al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010;7(1 pt 1):156-165.</Citation></Reference><Reference><Citation>Menafra D, de Angelis C, Garifalos F, et&#xa0;al. Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2022.</Citation></Reference><Reference><Citation>Gentile V, Antonini G, Antonella Bertozzi M, et&#xa0;al. Effect of propionyl-l-carnitine, l-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin. 2009;25(9):2223-2228.</Citation></Reference><Reference><Citation>Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-l-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004;20(9):1377-1384.</Citation></Reference><Reference><Citation>Rhim HC, Kim MS, Park YJ, et&#xa0;al. The potential role of arginine supplements on erectile dysfunction: a systemic review and meta-analysis. J Sex Med. 2019;16(2):223-234.</Citation></Reference><Reference><Citation>Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res. 2004;16(1):S15-S19.</Citation></Reference><Reference><Citation>Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004;15(6):659-665.</Citation></Reference><Reference><Citation>Ng CF, Lee CP, Ho AL, Lee VW. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. J Sex Med. 2011;8(10):2883-2893.</Citation></Reference><Reference><Citation>Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, de Sotomayor MA. Pharmacological effects and clinical applications of propionyl-l-carnitine. Nutr Rev. 2011;69(5):279-290.</Citation></Reference><Reference><Citation>El Taieb M, Hegazy E, Ibrahim A. Daily oral l-arginine plus tadalafil in diabetic patients with erectile dysfunction: a double-blinded, randomized, controlled clinical trial. J Sex Med. 2019;16(9):1390-1397.</Citation></Reference><Reference><Citation>Vicari E, La Vignera S, Condorelli R, Calogero AE. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med. 2010;7(3):1247-1253.</Citation></Reference><Reference><Citation>Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. Sex Med Rev. 2015;3(1):11-23.</Citation></Reference><Reference><Citation>Bearelly P, Phillips EA, Pan S, et&#xa0;al. Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. Int J Impot Res. 2020;32(3):345-351.</Citation></Reference><Reference><Citation>Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110(11):1787-1791.</Citation></Reference><Reference><Citation>Sung HH, Ahn JS, Kim JJ, Choo SH, Han DH, Lee SW. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology. 2014;2(1):45-50.</Citation></Reference><Reference><Citation>Hsiao W, Bennett N, Guhring P, Narus J, Mulhall JP. Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med. 2011;8(2):512-517.</Citation></Reference><Reference><Citation>Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res. 2005;17(4):354-358.</Citation></Reference><Reference><Citation>Costa P, Potempa AJ. Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012;72(17):2243-2254.</Citation></Reference><Reference><Citation>Hellstrom WJ, Bennett AH, Gesundheit N, et&#xa0;al. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology. 1996;48(6):851-856.</Citation></Reference><Reference><Citation>Padma-Nathan H, Hellstrom WJ, Kaiser FE, et&#xa0;al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1-7.</Citation></Reference><Reference><Citation>Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impot Res. 1997;9(4):187-192.</Citation></Reference><Reference><Citation>Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55(1):109-113.</Citation></Reference><Reference><Citation>Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int. 1999;83(7):812-815.</Citation></Reference><Reference><Citation>Williams P, McBain H, Amirova A, Newman S, Mulligan K. Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review. Int J Impot Res. 2021;33(1):16-42.</Citation></Reference><Reference><Citation>Garrido Abad P, Sinues Ojas B, Martinez Blazquez L, Conde Caturla P, Fernandez Arjona M. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. Actas Urol Esp. 2015;39(10):635-640.</Citation></Reference><Reference><Citation>Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol. 2000;38(1):30-34.</Citation></Reference><Reference><Citation>Garrido-Abad P, Senra-Bravo I, Manfredi C, et&#xa0;al. Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. Int J Impot Res. 2021;34(2):164-171.</Citation></Reference><Reference><Citation>Beaudreau SA, Van Moorleghem K, Dodd SM, Liou-Johnson V, Suresh M, Gould CE. Satisfaction with a vacuum constriction device for erectile dysfunction among middle-aged and older veterans. Clin Gerontol. 2021;44(3):307-315.</Citation></Reference><Reference><Citation>Yuan J, Hoang AN, Romero CA, Lin H, Dai Y, Wang R. Vacuum therapy in erectile dysfunction-science and clinical evidence. Int J Impot Res. 2010;22(4):211-219.</Citation></Reference><Reference><Citation>Brison D, Seftel A, Sadeghi-Nejad H. The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med. 2013;10(4):1124-1135.</Citation></Reference><Reference><Citation>Sun L, Peng FL, Yu ZL, Liu CL, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol. 2014;21(12):1263-1267.</Citation></Reference><Reference><Citation>Kramer AC, Schweber A. Patient expectations prior to coloplast titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med. 2010;7(6):2261-2266.</Citation></Reference><Reference><Citation>Habous M, Tal R, Tealab A, et&#xa0;al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int. 2018;121(2):293-300.</Citation></Reference><Reference><Citation>Dick BP, Yousif A, Raheem O, Hellstrom WJG. Does lowering hemoglobin a1c reduce penile prosthesis infection: a systematic review. Sex Med Rev. 2021;9(4):628-635.</Citation></Reference><Reference><Citation>Gon LM, de Campos CCC, Voris BRI, Passeri LA, Fregonesi A, Riccetto CLZ. A systematic review of penile prosthesis infection and meta-analysis of diabetes mellitus role. BMC Urol. 2021;21(1):35.</Citation></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MJ, et&#xa0;al. Impact of surgeon case volume on reoperation rates after inflatable penile prosthesis surgery. J Urol. 2017;197(1):223-229.</Citation></Reference><Reference><Citation>Donnelly H, Salmeron-Sanchez M, Dalby MJ. Designing stem cell niches for differentiation and self-renewal. J R Soc Interface. 2018;15(145).</Citation></Reference><Reference><Citation>Pakpahan C, Ibrahim R, William W, et&#xa0;al. Stem cell therapy and diabetic erectile dysfunction: a critical review. World J Stem Cells. 2021;13(10):1549-1563.</Citation></Reference><Reference><Citation>Mirzaei M, Bagherinasabsarab M, Pakmanesh H, et&#xa0;al. The effect of intracavernosal injection of stem cell in the treatment of erectile dysfunction in diabetic patients: a randomized Single-blinded clinical trial. Urol J. 2021;18(6):675-681.</Citation></Reference><Reference><Citation>Al Demour S, Jafar H, Adwan S, et&#xa0;al. Safety and potential therapeutic effect of two intracavernous autologous bone marrow derived mesenchymal stem cells injections in diabetic patients with erectile dysfunction: an open label phase I clinical trial. Urol Int. 2018;101(3):358-365.</Citation></Reference><Reference><Citation>Bahk JY, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8(2):150-160.</Citation></Reference><Reference><Citation>Protogerou V, Michalopoulos E, Mallis P, et&#xa0;al. Administration of adipose derived mesenchymal stem cells and platelet lysate in erectile dysfunction: a single center pilot study. Bioengineering. 2019;6(1):21.</Citation></Reference><Reference><Citation>Levy JA, Marchand M, Iorio L, Cassini W, Zahalsky MP. Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc. 2016;116(1):e1-e5.</Citation></Reference><Reference><Citation>Sokolakis I, Dimitriadis F, Psalla D, Karakiulakis G, Kalyvianakis D, Hatzichristou D. Effects of low-intensity shock wave therapy (LiST) on the erectile tissue of naturally aged rats. Int J Impot Res. 2019;31(3):162-169.</Citation></Reference><Reference><Citation>Assaly R, Giuliano F, Clement P, et&#xa0;al. Extracorporeal shock waves therapy delivered by aries improves erectile dysfunction in spontaneously hypertensive rats through penile tissue remodeling and neovascularization. Sex Med. 2019;7(4):441-450.</Citation></Reference><Reference><Citation>Man L, Li G. Low-intensity extracorporeal shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Urology. 2018;119:97-103.</Citation></Reference><Reference><Citation>Spivak L, Shultz T, Appel B, Verze P, Yagudaev D, Vinarov A. Low-intensity extracorporeal shockwave therapy for erectile dysfunction in diabetic patients. Sex Med Rev. 2021;9(4):619-627.</Citation></Reference><Reference><Citation>Heaton JP, Lording D, Liu SN, et&#xa0;al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13(6):317-321.</Citation></Reference><Reference><Citation>Tsai YS, Lin JS, Lin YM. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol. 2000;38(2):177-183.</Citation></Reference><Reference><Citation>Gasser TC, Roach RM, Larsen EH, Madsen PO, Bruskewitz RC. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence. J Urol. 1987;137(4):678-680.</Citation></Reference><Reference><Citation>Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008;102(8):933-937.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35898433</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2214-4420</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Urology case reports</Title><ISOAbbreviation>Urol Case Rep</ISOAbbreviation></Journal><ArticleTitle>A case report of right cardiac ventricle perforation by uncontrolled embolization coil inserted for treating penile veno-occlusive dysfunction.</ArticleTitle><Pagination><StartPage>102166</StartPage><MedlinePgn>102166</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102166</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eucr.2022.102166</ELocationID><Abstract><AbstractText>Coil embolization (CE) is believed effective-safe for treating penile veno-occlusive dysfunction (VOD). From 2012 to 2016, refractory impotence prompted four men to seek further treatment, although they underwent six CEs elsewhere. Uncontrolled coils scattered along penile drainage veins including the deep dorsal veins (n&#xa0;=&#xa0;3), periprostatic plexus (n&#xa0;=&#xa0;1), iliac vein (n&#xa0;=&#xa0;1), right pulmonary artery (n&#xa0;=&#xa0;2), left pulmonary artery (n&#xa0;=&#xa0;1), and right ventricle (n&#xa0;=&#xa0;1). The last one occurred in a 40-year-old house builder, and the coil perforated the right ventricle wall and diaphragm 18 months later. Given no sustainable improvement, CE's safety and efficacy are unreliable for treating patients with VOD.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Geng-Long</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology, Shu-Tien Urology Ophthalmology Clinic and Chung Shan Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yi-Kai</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Urology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, 10002, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>I-Ni</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Department of Urology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, 10002, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chih-Yuan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology, Shu-Tien Urology Ophthalmology Clinic and Chung Shan Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hong-Chiang</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Urology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, 10002, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chueh</LastName><ForeName>Shih Chieh Jeff</ForeName><Initials>SCJ</Initials><AffiliationInfo><Affiliation>Department of Urology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, 10002, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urol Case Rep</MedlineTA><NlmUniqueID>101626357</NlmUniqueID><ISSNLinking>2214-4420</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CE, Coil embolization</Keyword><Keyword MajorTopicYN="N">ED, erectile dysfunction</Keyword><Keyword MajorTopicYN="N">PDE-5, phosphodiesterase type 5</Keyword><Keyword MajorTopicYN="N">VOD, veno-occlusive dysfunction</Keyword></KeywordList><CoiStatement>None of the contributing authors have any conflict of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>2</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35898433</ArticleId><ArticleId IdType="pmc">PMC9310111</ArticleId><ArticleId IdType="doi">10.1016/j.eucr.2022.102166</ArticleId><ArticleId IdType="pii">S2214-4420(22)00178-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anonymous FDA approves oral therapy for erectile dysfunction. Am J Health Syst Pharm. 1998;55:981&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">9606444</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhanbly S., Abdel-Gaber S., Fathy H., et al. Erectile dysfunction in smoker: a penile dynamic and vascular study. J Androl. 2004;25:991&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477374</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague D.K. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin. 2011;38:217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621088</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtheoux P., Maize D., Henriet J.P., et al. Erectile dysfunction caused by venous leakage: treatment with detachable balloons and coils. Radiology. 1986;161:807&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">3786738</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi G. History of the genesis of detachable coils. J Neurosurg. 2009;111:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19284239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35677998</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2233-4521</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of preventive medicine and public health = Yebang Uihakhoe chi</Title><ISOAbbreviation>J Prev Med Public Health</ISOAbbreviation></Journal><ArticleTitle>Estimation of Utility Weights for Prostate-related Health States in Korea.</ArticleTitle><Pagination><StartPage>243</StartPage><EndPage>252</EndPage><MedlinePgn>243-252</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3961/jpmph.21.426</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Very limited previous research has investigated the utility weights of prostate-related diseases in the general population in Korea. The purpose of this study was to calculate the utility of prostate-related health states in the Korean general public using the standard gamble (SG) method.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Seven health states for hypothetical prostate cancers, 1 for benign prostate hyperplasia, and 1 for erectile dysfunction were developed based on patient education material and previous publications. In total, 460 responses from the Korean general population were used to analyze the utility of prostate-related health states. Computer-assisted personal interviews were conducted, and utility values were measured using a visual analogue scale (VAS) and SG. Mean utility values were calculated for each prostate-related health state.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean utility values of prostate cancer derived from SG ranged from 0.281 (metastatic castration-refractory prostate cancer) to 0.779 (localized prostate cancer requiring prostatectomy). The utility value of benign prostate hyperplasia was 0.871, and that of erectile dysfunction was 0.812. The utility values obtained using the SG method in all conditions were higher than the values obtained by VAS. There were no significant demographic variables affecting utility values in multivariate analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings might be useful for economic evaluation and utility calculation of screening and interventions for prostate-related conditions in the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seon-Ha</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Nursing, Dankook University, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ock</LastName><ForeName>Minsu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Min-Woo</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sungchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Prev Med Public Health</MedlineTA><NlmUniqueID>101242972</NlmUniqueID><ISSNLinking>1975-8375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006965" MajorTopicYN="N">Hyperplasia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Korea</Keyword><Keyword MajorTopicYN="N">Prostatic hyperplasia</Keyword><Keyword MajorTopicYN="N">Prostatic neoplasms</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Quality-adjusted life years</Keyword></KeywordList><CoiStatement><b>CONFLICT OF INTEREST</b>. The authors have no conflicts of interest associated with the material presented in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>2</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35677998</ArticleId><ArticleId IdType="pmc">PMC9201095</ArticleId><ArticleId IdType="doi">10.3961/jpmph.21.426</ArticleId><ArticleId IdType="pii">jpmph.21.426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer 1975 2014 featuring survival. J Natl Cancer Inst. 2017;109(9):djx030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409140</ArticleId><ArticleId IdType="pubmed">28376154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474385</ArticleId></ArticleIdList></Reference><Reference><Citation>Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424666</ArticleId></ArticleIdList></Reference><Reference><Citation>Won YJ, Jung KW, Oh CM, Park EH, Kong HJ, Lee DH, et al. Geographical variations and trends in major cancer incidences throughout Korea during 1999&#x2013;2013. Cancer Res Treat. 2018;50(4):1281&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192921</ArticleId><ArticleId IdType="pubmed">29334607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">29740894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785&#x2013;2800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033186</ArticleId><ArticleId IdType="pubmed">29786848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung KW, Won YJ, Kong HJ, Lee ES, Community of Population-Based Regional Cancer Registries Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50(2):303&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5912151</ArticleId><ArticleId IdType="pubmed">29566481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000&#x2013;2010. Cancer Res Treat. 2015;47(3):387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506103</ArticleId><ArticleId IdType="pubmed">25672582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YJ, Lee JW, Park J, Seo SI, Chung JI, Yoo TK, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016;57(6):424&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109794</ArticleId><ArticleId IdType="pubmed">27847916</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert G, De La Taille A, Descazeaud A. Epidemiology of benign prostatic hyperplasia. Prog Urol. 2018;28(15):803&#x2013;812. (French)</Citation><ArticleIdList><ArticleId IdType="pubmed">30266373</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013;31(3):193&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888888</ArticleId><ArticleId IdType="pubmed">24459652</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int. 2016;118(1):153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">26765325</ArticleId></ArticleIdList></Reference><Reference><Citation>Glina S, Santana AW, Azank F, Mello LF, Moreira ED., Jr Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int. 2006;97(4):763&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">16536769</ArticleId></ArticleIdList></Reference><Reference><Citation>Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med. 2009;6(4):1103&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73(3):562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">19167031</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ. 1996;15(2):209&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10159110</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21037243</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond MF, Sculpher MJ, Torrance GW, O&#x2019;Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. pp. 147&#x2013;173.</Citation></Reference><Reference><Citation>Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci. 1976;10(3):129&#x2013;136.</Citation></Reference><Reference><Citation>Wee HL, Li SC, Xie F, Zhang XH, Luo N, Feeny D, et al. Validity, feasibility and acceptability of time trade-off and standard gamble assessments in health valuation studies: a study in a multiethnic Asian population in Singapore. Value Health. 2008;11(Suppl 1):S3&#x2013;S10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Lee SI, Jo MW. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population. Qual Life Res. 2017;26(12):3387&#x2013;3397.</Citation><ArticleIdList><ArticleId IdType="pubmed">28801862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ. 1997;16(2):155&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10169092</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10311607</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21(4):329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11475389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making. 2007;27(3):288&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502448</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health. 2009;12(8):1194&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">19695009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenberg E, Halpern E, Divi N, Prosser LA, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. Qual Life Res. 2006;15(4):645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">16688497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Hwang JS, Ahn J, Lee SM, Lee YJ, Shin S. Utilities for prostate cancer by cancer stage and treatment step in Korea. Korean J Health Econ Policy. 2013;19(2):1&#x2013;20. (Korean)</Citation></Reference><Reference><Citation>Kim SH, Jo MW, Ock M, Lee HJ, Lee JW. Estimation of health state utilities in breast cancer. Patient Prefer Adherence. 2017;11:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359127</ArticleId><ArticleId IdType="pubmed">28352159</ArticleId></ArticleIdList></Reference><Reference><Citation>Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. 2010.  [cited 2021 Jul 1]. Available from:  https://www.york.ac.uk/media/che/documents/papers/researchpapers/rp54_appropriate_perspectives_for_health_care_decisions.pdf.</Citation></Reference><Reference><Citation>Jo MW, Kwon DS, Kim SH, Kil SR, Lee SI. Validity and reliability of Korean EQ-5D valuation study using a computer-assisted standard gamble method. Korean J Health Promot. 2010;10(3):105&#x2013;112. (Korean)</Citation></Reference><Reference><Citation>Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41(1):153&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gries KS, Regier DA, Ramsey SD, Patrick DL. Utility estimates of disease-specific health states in prostate cancer from three different perspectives. Appl Health Econ Health Policy. 2017;15(3):375&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">27704390</ArticleId></ArticleIdList></Reference><Reference><Citation>Torvinen S, F&#xe4;rkkil&#xe4; N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol. 2013;52(6):1094&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">23368678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol. 2017;51(1):13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">27809631</ArticleId></ArticleIdList></Reference><Reference><Citation>Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer Prostatic Dis. 2009;12(4):361&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">19901935</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KJ, Roberts MS. Quality-of-life utility values for erectile function and sildenafil treatment. Clin Drug Investig. 2005;25(2):99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17523759</ArticleId></ArticleIdList></Reference><Reference><Citation>Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making. 2000;20(2):186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">10772356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007;45(3):259&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">17304084</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol. 2002;12(2):160&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12033527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35625828</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10051091</ELocationID><Abstract><AbstractText>About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonanni</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8069-592X</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Athena Biomedical Innovations, 50126 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massaro</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3007-5313</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedetto</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8831-6178</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology San Filippo Neri Hospital, 00135 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esperto</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0108-1864</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Biocampus, 00128 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Federici</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauriello</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7351-5676</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangiorgi</LastName><ForeName>Giuseppe Massimo</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0001-5862-1967</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, Institute of Cardiology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell therapy</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">immune centric revolution</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword><Keyword MajorTopicYN="N">peripheral blood mononuclear cells</Keyword><Keyword MajorTopicYN="N">stem cell</Keyword></KeywordList><CoiStatement>Giuseppe Sangiorgi has received Research Grant and Consultancy Honoraria from Concept Medical. All the other authors declared that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35625828</ArticleId><ArticleId IdType="pmc">PMC9138496</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10051091</ArticleId><ArticleId IdType="pii">biomedicines10051091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brotons F.B., Campos J.C., Gonzalez-Correales R., Mart&#xed;n-Morales A., Moncada I., Pomerol J.M. Core document on erectile dysfunction: Key aspects in the care of a patient with erectile dysfunction. Int. J. Impot Res. 2004;16((Suppl. 2)):S26&#x2013;S39. doi: 10.1038/sj.ijir.3901240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901240</ArticleId><ArticleId IdType="pubmed">15496854</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A., Bettocchi C., Boeri L., Capogrosso P., Carvalho J., Cilesiz N.C., Cocci A., Corona G., Dimitropolous K., G&#xfc;l M., et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur. Urol. 2021;25:333&#x2013;357. doi: 10.1016/j.eururo.2021.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2021.06.007</ArticleId><ArticleId IdType="pubmed">34183196</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett A.L., Nehra A., Breau R.H., Culkin D.J., Faraday M.M., Hakim L.S., Heidelbaugh J., Khera M., McVary K.T., Miner M.M., et al. Erectile Dysfunction: AUA Guideline. J. Urol. 2018;200:633&#x2013;641. doi: 10.1016/j.juro.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C.N., Smith C.J., Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332:589&#x2013;592. doi: 10.1136/bmj.332.7541.589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.332.7541.589</ArticleId><ArticleId IdType="pmc">PMC1397768</ArticleId><ArticleId IdType="pubmed">16528082</ArticleId></ArticleIdList></Reference><Reference><Citation>Penson D.F., Latini D.M., Lubeck D.P., Wallace K.L., Henning J.M., Lue T.F. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care. 2003;26:1093&#x2013;1099. doi: 10.2337/diacare.26.4.1093.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.26.4.1093</ArticleId><ArticleId IdType="pubmed">12663579</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis L., Marfella M.A., Siniscalchi M., Marino L., Nappo F., Giugliano F., De Lucia D., Giugliano D. Erectile and endothelial dysfunction in Type II diabetes: A possible link. Diabetologia. 2001;44:1155&#x2013;1160. doi: 10.1007/s001250100616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250100616</ArticleId><ArticleId IdType="pubmed">11596671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitaley K. Type 1 and Type 2 diabetic-erectile dysfunction: Same diagnosis (ICD-9), different disease? J. Sex. Med. 2009;6((Suppl. 3)):262&#x2013;268. doi: 10.1111/j.1743-6109.2008.01183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01183.x</ArticleId><ArticleId IdType="pubmed">19267848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitaley K., Kupelian V., Subak L., Wessells H. Diabetes, obesity and erectile dysfunction: Field overview and research priorities. J. Urol. 2009;182((Suppl. 6)):S45&#x2013;S50. doi: 10.1016/j.juro.2009.07.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2009.07.089</ArticleId><ArticleId IdType="pmc">PMC2864637</ArticleId><ArticleId IdType="pubmed">19846136</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol. 1994;151:54&#x2013;61. doi: 10.1016/S0022-5347(17)34871-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)34871-1</ArticleId><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman T.P., Jacobs J.A. Etiology of diabetic impotence. J. Urol. 1983;129:291&#x2013;294. doi: 10.1016/S0022-5347(17)52057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)52057-1</ArticleId><ArticleId IdType="pubmed">6834492</ArticleId></ArticleIdList></Reference><Reference><Citation>Koncz L., Balodimos M.C. Impotence in diabetes mellitus. Med. Times. 1970;98:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">5454743</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead E.D., Klyde B.J. Diabetes-related impotence in the elderly. Clin. Geriatr. Med. 1990;6:771&#x2013;795. doi: 10.1016/S0749-0690(18)30580-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0690(18)30580-9</ArticleId><ArticleId IdType="pubmed">2224746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz P., Vita J.A. Testing endothelial vasomotor function: Nitric oxide, a multipotent molecule. Circulation. 2003;108:2049&#x2013;2053. doi: 10.1161/01.CIR.0000089507.19675.F9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000089507.19675.F9</ArticleId><ArticleId IdType="pubmed">14581383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N., Azadzoi K.M., Goldstein I., Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Investig. 1991;88:112&#x2013;118. doi: 10.1172/JCI115266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115266</ArticleId><ArticleId IdType="pmc">PMC296010</ArticleId><ArticleId IdType="pubmed">1647413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellek S., Rodrigo J., Lobos E., Fern&#xe1;ndez P., Serrano J., Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus&#x2014;A nitric oxide-dependent phenomenon. Br. J. Pharmacol. 1999;128:1804&#x2013;1812. doi: 10.1038/sj.bjp.0702981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0702981</ArticleId><ArticleId IdType="pmc">PMC1571816</ArticleId><ArticleId IdType="pubmed">10588937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988;318:1315&#x2013;1321. doi: 10.1056/NEJM198805193182007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198805193182007</ArticleId><ArticleId IdType="pubmed">3283558</ArticleId></ArticleIdList></Reference><Reference><Citation>Melis M.R., Argiolas A. Role of central nitric oxide in the control of penile erection and yawning. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1997;21:899&#x2013;922. doi: 10.1016/S0278-5846(97)00088-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0278-5846(97)00088-2</ArticleId><ArticleId IdType="pubmed">9380788</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartledge J.J., Eardley I., Morrison J.F. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int. 2001;87:394&#x2013;401. doi: 10.1046/j.1464-410x.2001.00065.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.2001.00065.x</ArticleId><ArticleId IdType="pubmed">11251538</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz de Tejada I., Goldstein I., Azadzoi K., Krane R.J., Cohen R.A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. 1989;320:1025&#x2013;1030. doi: 10.1056/NEJM198904203201601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198904203201601</ArticleId><ArticleId IdType="pubmed">2927481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua T.J., Champion H.C., Usta M.F., Cellek S., Chitaley K., Webb R.C., Lewis R.L., Mills T.M., Hellstrom W.J., Kadowitz P.J. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. USA. 2004;101:9121&#x2013;9126. doi: 10.1073/pnas.0400520101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400520101</ArticleId><ArticleId IdType="pmc">PMC428483</ArticleId><ArticleId IdType="pubmed">15184671</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita J.A., Keaney J.F., Jr. Endothelial function: A barometer for cardiovascular risk? Circulation. 2002;106:640&#x2013;642. doi: 10.1161/01.CIR.0000028581.07992.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000028581.07992.56</ArticleId><ArticleId IdType="pubmed">12163419</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsholme P., Haber E.P., Hirabara S.M., Rebelato E.L., Procopio J., Morgan D., Oliveira-Emilio H.C., Carpinelli A.R., Curi R. Diabetes associated cell stress and dysfunction: Role of mitochondrial and non-mitochondrial ROS production and activity. Pt 1J. Physiol. 2007;583:9&#x2013;24. doi: 10.1113/jphysiol.2007.135871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.135871</ArticleId><ArticleId IdType="pmc">PMC2277225</ArticleId><ArticleId IdType="pubmed">17584843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 2008;4:285&#x2013;293. doi: 10.1038/ncpendmet0786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpendmet0786</ArticleId><ArticleId IdType="pubmed">18332897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignarelli A., Genchi V.A., D&#x2019;Oria R., Giordano F., Caruso I., Perrini S., Natalicchio A., Laviola L., Giorgino F. Role of Glucose-Lowering Medications in Erectile Dysfunction. J. Clin. Med. 2021;10:2501. doi: 10.3390/jcm10112501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112501</ArticleId><ArticleId IdType="pmc">PMC8201035</ArticleId><ArticleId IdType="pubmed">34198786</ArticleId></ArticleIdList></Reference><Reference><Citation>Morano S., Gatti A., Mandosi E., Tiberti C., Fallarino M., Cipriani R., Buchetti B., Gandini L., Sgr&#xf2; P., Jannini E.A., et al. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. J. Urol. 2007;177:655&#x2013;659. doi: 10.1016/j.juro.2006.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.09.046</ArticleId><ArticleId IdType="pubmed">17222652</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C.G. Current diagnosis and management of erectile dysfunction. Med. J. Aust. 2019;210:469&#x2013;476. doi: 10.5694/mja2.50167.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50167</ArticleId><ArticleId IdType="pubmed">31099420</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh T.J., Hotaling J.M., Smith A., Saigal C., Wessells H. Men with diabetes may require more aggressive treatment for erectile dysfunction. Int. J. Impot. Res. 2014;26:112&#x2013;115. doi: 10.1038/ijir.2013.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2013.46</ArticleId><ArticleId IdType="pubmed">24352244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K., Hatzichristou D.G. Phosphodiesterase type 5 inhibitors: Unmet needs. Curr. Pharm. Des. 2009;15:3476&#x2013;3485. doi: 10.2174/138161209789207042.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161209789207042</ArticleId><ArticleId IdType="pubmed">19860693</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehm N., Marggi S., Ueki Y., Schumacher D., Keo H.H., Regli C., Do D.D., Moeltgen T., Grimsehl P., Wyler S., et al. Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. J. Endovasc. Ther. 2019;26:181&#x2013;190. doi: 10.1177/1526602819829903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1526602819829903</ArticleId><ArticleId IdType="pubmed">30741067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan H., Chen F., Zhang T., He S., Xu L., Wei A. Stem cell therapy for erectile dysfunction of cavernous nerve injury rats: A systematic review and meta-analysis. PLoS ONE. 2015;10:e0121428. doi: 10.1371/journal.pone.0121428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0121428</ArticleId><ArticleId IdType="pmc">PMC4393097</ArticleId><ArticleId IdType="pubmed">25860455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D.Z., Abelson B., Babbar P., Damaser M.S. Harnessing the mesenchymal stem cell secretome for regenerative urology. Nat. Rev. Urol. 2019;16:363&#x2013;375. doi: 10.1038/s41585-019-0169-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41585-019-0169-3</ArticleId><ArticleId IdType="pmc">PMC7027199</ArticleId><ArticleId IdType="pubmed">30923338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C., Lin H., Yu W., Li X., Chen Y., Qiu X., Wang R., Dai Y. Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats. Int. J. Androl. 2012;35:601&#x2013;607. doi: 10.1111/j.1365-2605.2012.01250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2605.2012.01250.x</ArticleId><ArticleId IdType="pubmed">22428616</ArticleId></ArticleIdList></Reference><Reference><Citation>Korf-Klingebiel M., Kempf T., Sauer T., Brinkmann E., Fischer P., Meyer G.P., Ganser A., Drexler H., Wollert K.C. Bone marrow cells are a rich source of growth factors and cytokines: Implications for cell therapy trials after myocardial infarction. Eur. Heart J. 2008;29:2851&#x2013;2858. doi: 10.1093/eurheartj/ehn456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehn456</ArticleId><ArticleId IdType="pubmed">18953051</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L., Mildner M., Gy&#xf6;ngy&#xf6;si M., Ankersmit H.J. Peripheral blood mononuclear cell secretome for tissue repair. Apoptosis. 2016;21:1336&#x2013;1353. doi: 10.1007/s10495-016-1292-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-016-1292-8</ArticleId><ArticleId IdType="pmc">PMC5082595</ArticleId><ArticleId IdType="pubmed">27696124</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M.M., Fandel T.M., Lin G., Shindel A.W., Banie L., Lin C.S., Lue T.F. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. Pt 1J. Sex. Med. 2010;7:89&#x2013;98. doi: 10.1111/j.1743-6109.2009.01541.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01541.x</ArticleId><ArticleId IdType="pmc">PMC2904063</ArticleId><ArticleId IdType="pubmed">20104670</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Li H., Ruan Y., Wang T., Liu J. Stem Cell Therapy for Diabetic Erectile Dysfunction in Rats: A Meta-Analysis. PLoS ONE. 2016;11:e0154341. doi: 10.1371/journal.pone.0154341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154341</ArticleId><ArticleId IdType="pmc">PMC4844188</ArticleId><ArticleId IdType="pubmed">27111659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahk J.Y., Jung J.H., Han H., Min S.K., Lee Y.S. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: Preliminary report of 7 cases. Exp. Clin. Transpl. 2010;8:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565373</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy J.A., Marchand M., Iorio L., Cassini W., Zahalsky M.P. Determining the Feasibility of Managing Erectile Dysfunction in Humans With Placental-Derived Stem Cells. J. Am. Osteopath. Assoc. 2016;116:e1&#x2013;e5. doi: 10.7556/jaoa.2016.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.7556/jaoa.2016.007</ArticleId><ArticleId IdType="pubmed">26745574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiou R., Hamidou L., Birebent B., Bitari D., Lecorvoisier P., Contremoulins I., Khodari M., Rodriguez A.M., Augustin D., Roudot-Thoraval F., et al. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study. Eur. Urol. 2016;69:988&#x2013;991. doi: 10.1016/j.eururo.2015.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.09.026</ArticleId><ArticleId IdType="pubmed">26439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiou R., Hamidou L., Birebent B., Bitari D., Le Corvoisier P., Contremoulins I., Rodriguez A.M., Augustin D., Roudot-Thoraval F., de la Taille A., et al. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur. Urol. Focus. 2017;3:643&#x2013;645. doi: 10.1016/j.euf.2017.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2017.06.009</ArticleId><ArticleId IdType="pubmed">28753830</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Demour S., Jafar H., Adwan S., AlSharif A., Alhawari H., Alrabadi A., Zayed A., Jaradat A., Awidi A. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. Urol. Int. 2018;101:358&#x2013;365. doi: 10.1159/000492120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492120</ArticleId><ArticleId IdType="pubmed">30173210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieri M., Said E., Antonini G., Dickerson D., Tuma J., Bartlett C.E., Patel A.N., Gershman A. Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction. J. Transl. Med. 2020;18:24. doi: 10.1186/s12967-019-02195-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02195-w</ArticleId><ArticleId IdType="pmc">PMC6958721</ArticleId><ArticleId IdType="pubmed">31937310</ArticleId></ArticleIdList></Reference><Reference><Citation>Haahr M.K., Harken Jensen C., Toyserkani N.M., Andersen D.C., Damkier P., S&#xf8;rensen J.A., Sheikh S.P., Lund L. A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. Urology. 2018;121:203.e6&#x2013;203.e13. doi: 10.1016/j.urology.2018.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2018.06.018</ArticleId><ArticleId IdType="pubmed">29958973</ArticleId></ArticleIdList></Reference><Reference><Citation>Protogerou V., Michalopoulos E., Mallis P., Gontika I., Dimou Z., Liakouras C., Stavropoulos-Giokas C., Kostakopoulos N., Chrisofos M., Deliveliotis C. Administration of Adipose Derived Mesenchymal Stem Cells and Platelet Lysate in Erectile Dysfunction: A Single Center Pilot Study. Bioengineering. 2019;6:21. doi: 10.3390/bioengineering6010021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering6010021</ArticleId><ArticleId IdType="pmc">PMC6466012</ArticleId><ArticleId IdType="pubmed">30841525</ArticleId></ArticleIdList></Reference><Reference><Citation>Protogerou V., Beshari S.E., Michalopoulos E., Mallis P., Chrysikos D., Samolis A.A., Stavropoulos-Giokas C., Troupis T. The Combined Use of Stem Cells and Platelet Lysate Plasma for the Treatment of Erectile Dysfunction: A Pilot Study-6 Months Results. Medicines. 2020;7:14. doi: 10.3390/medicines7030014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines7030014</ArticleId><ArticleId IdType="pmc">PMC7151592</ArticleId><ArticleId IdType="pubmed">32197323</ArticleId></ArticleIdList></Reference><Reference><Citation>Magenta A., Florio M.C., Ruggeri M., Furgiuele S. Autologous cell therapy in diabetes-associated critical limb ischemia: From basic studies to clinical outcomes (Review) Int. J. Mol. Med. 2021;48:173. doi: 10.3892/ijmm.2021.5006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.5006</ArticleId><ArticleId IdType="pmc">PMC8285046</ArticleId><ArticleId IdType="pubmed">34278463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini G.P., Spinetti G., Santopaolo M., Madeddu P. Impaired Regeneration Contributes to Poor Outcomes in Diabetic Peripheral Artery Disease. Arterioscler. Thromb. Vasc. Biol. 2020;40:34&#x2013;44. doi: 10.1161/ATVBAHA.119.312863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.119.312863</ArticleId><ArticleId IdType="pubmed">31510789</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarajapu Y.P., Hazra S., Segal M., Li Calzi S., Jadhao C., Qian K., Mitter S.K., Raizada M.K., Boulton M.E., Grant M.B. Vasoreparative dysfunction of CD34+ cells in diabetic individuals involves hypoxic desensitization and impaired autocrine/paracrine mechanisms. PLoS ONE. 2014;9:e93965. doi: 10.1371/journal.pone.0093965. Erratum in: PLoS ONE 2014, 9, e103913. LiCalzi, Sergio [corrected to Li Calzi, Sergio]; Jhadao, Chandra [corrected to Jadhao, Chandra].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093965</ArticleId><ArticleId IdType="pmc">PMC3979711</ArticleId><ArticleId IdType="pubmed">24713821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.K., Green L.A., Motaganahalli R.L., Wilson M.G., Fajardo A., Murphy M.P. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia. J. Vasc. Surg. 2017;65:1850&#x2013;1857.e2. doi: 10.1016/j.jvs.2017.01.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2017.01.054</ArticleId><ArticleId IdType="pubmed">28390770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D., Jiang Y., Deng W., Zhang Y., Liang Z., Wu Q., Jiang X., Zhang L., Gao F., Cao Y., et al. Long-Term Outcomes of BMMSC Compared with BMMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes. Cell Transplant. 2019;28:645&#x2013;652. doi: 10.1177/0963689719835177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689719835177</ArticleId><ArticleId IdType="pmc">PMC7103602</ArticleId><ArticleId IdType="pubmed">30917698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianfarani F., Toietta G., Di Rocco G., Cesareo E., Zambruno G., Odorisio T. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen. 2013;21:545&#x2013;553. doi: 10.1111/wrr.12051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/wrr.12051</ArticleId><ArticleId IdType="pubmed">23627689</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue O., Usui S., Takashima S.I., Nomura A., Yamaguchi K., Takeda Y., Goten C., Hamaoka T., Ootsuji H., Murai H., et al. Diabetes impairs the angiogenic capacity of human adipose-derived stem cells by reducing the CD271+ subpopulation in adipose tissue. Biochem. Biophys. Res. Commun. 2019;517:369&#x2013;375. doi: 10.1016/j.bbrc.2019.07.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.07.081</ArticleId><ArticleId IdType="pubmed">31362891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennert R.C., Sorkin M., Januszyk M., Duscher D., Kosaraju R., Chung M.T., Lennon J., Radiya-Dixit A., Raghvendra S., Maan Z.N., et al. Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem Cell Res. Ther. 2014;5:79. doi: 10.1186/scrt468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt468</ArticleId><ArticleId IdType="pmc">PMC4097831</ArticleId><ArticleId IdType="pubmed">24943716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehl D., Generali M., Mallone A., Heller M., Uldry A.C., Cheng P., Gantenbein B., Hoerstrup S.P., Weber B. Proteomic analysis of human mesenchymal stromal cell secretomes: A systematic comparison of the angiogenic potential. NPJ Regen. Med. 2019;4:8. doi: 10.1038/s41536-019-0070-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41536-019-0070-y</ArticleId><ArticleId IdType="pmc">PMC6467904</ArticleId><ArticleId IdType="pubmed">31016031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornicka K., Houston J., Marycz K. Dysfunction of Mesenchymal Stem Cells Isolated from Metabolic Syndrome and Type 2 Diabetic Patients as Result of Oxidative Stress and Autophagy may Limit Their Potential Therapeutic Use. Stem Cell Rev. Rep. 2018;14:337&#x2013;345. doi: 10.1007/s12015-018-9809-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-018-9809-x</ArticleId><ArticleId IdType="pmc">PMC5960487</ArticleId><ArticleId IdType="pubmed">29611042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X.G., Li S.W., Zheng X.M., Hu L.Q., Hu W.L., Luo Y. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J. Androl. 2009;11:215&#x2013;221. doi: 10.1038/aja.2008.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aja.2008.37</ArticleId><ArticleId IdType="pmc">PMC3735030</ArticleId><ArticleId IdType="pubmed">19151738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Wu Y.N., Ho H.O., Chen K.C., Sheu M.T., Chiang H.S. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J. Sex. Med. 2012;9:2838&#x2013;2848. doi: 10.1111/j.1743-6109.2012.02881.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02881.x</ArticleId><ArticleId IdType="pubmed">22906160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.N., Wu C.C., Sheu M.T., Chen K.C., Ho H.O., Chiang H.S. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J. Tissue Eng. Regen. Med. 2016;10:E294&#x2013;E304. doi: 10.1002/term.1806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/term.1806</ArticleId><ArticleId IdType="pubmed">23950105</ArticleId></ArticleIdList></Reference><Reference><Citation>Epifanova M.V., Chalyi M.E., Krasnov A.O. Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction. Urologiia. 2017;1:46&#x2013;48. doi: 10.18565/urology.2017.4.46-48. (In Russian)</Citation><ArticleIdList><ArticleId IdType="doi">10.18565/urology.2017.4.46-48</ArticleId><ArticleId IdType="pubmed">28952692</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz E.L., Pearlman A.M., Terlecki R.P. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig. Clin. Urol. 2018;59:61&#x2013;65. doi: 10.4111/icu.2018.59.1.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/icu.2018.59.1.61</ArticleId><ArticleId IdType="pmc">PMC5754585</ArticleId><ArticleId IdType="pubmed">29333517</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanley L.C., Mahon O.R., Kelly D.J., Dunne A. Harnessing the innate and adaptive immune system for tissue repair and regeneration: Considering more than macrophages. Acta Biomater. 2021;133:208&#x2013;221. doi: 10.1016/j.actbio.2021.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.02.023</ArticleId><ArticleId IdType="pubmed">33657453</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein J.A. A Time to Press Reset and Regenerate Cardiac Stem Cell Biology. JAMA Cardiol. 2019;4:95&#x2013;96. doi: 10.1001/jamacardio.2018.4435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2018.4435</ArticleId><ArticleId IdType="pubmed">30480702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompkins B.A., Balkan W., Winkler J., Gy&#xf6;ngy&#xf6;si M., Goliasch G., Fern&#xe1;ndez-Avil&#xe9;s F., Hare J.M. Pre-clinical Studies of Stem Cell Therapy for Heart Disease. Circ. Res. 2018;122:1006&#x2013;1020. doi: 10.1161/CIRCRESAHA.117.312486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.312486</ArticleId><ArticleId IdType="pmc">PMC7340290</ArticleId><ArticleId IdType="pubmed">29599277</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi R.J., Maillet M., Sargent M.A., Khalil H., Johansen A.K.Z., Schwanekamp J.A., York A.J., Huang V., Nahrendorf M., Sadayappan S., et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577:405&#x2013;409. doi: 10.1038/s41586-019-1802-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1802-2</ArticleId><ArticleId IdType="pmc">PMC6962570</ArticleId><ArticleId IdType="pubmed">31775156</ArticleId></ArticleIdList></Reference><Reference><Citation>Godwin J.W., Pinto A.R., Rosenthal N.A. Chasing the recipe for a pro-regenerative immune system. Semin. Cell Dev. Biol. 2017;61:71&#x2013;79. doi: 10.1016/j.semcdb.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2016.08.008</ArticleId><ArticleId IdType="pmc">PMC5338634</ArticleId><ArticleId IdType="pubmed">27521522</ArticleId></ArticleIdList></Reference><Reference><Citation>Godwin J.W., Debuque R., Salimova E., Rosenthal N.A. Heart regeneration in the salamander relies on macrophage-mediated control of fibroblast activation and the extracellular landscape. NPJ Regen. Med. 2017;2:22. doi: 10.1038/s41536-017-0027-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41536-017-0027-y</ArticleId><ArticleId IdType="pmc">PMC5677961</ArticleId><ArticleId IdType="pubmed">29201433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Mordechai T., Holbova R., Landa-Rouben N., Harel-Adar T., Feinberg M.S., Abd Elrahman I., Blum G., Epstein F.H., Silman Z., Cohen S., et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J. Am. Coll. Cardiol. 2013;62:1890&#x2013;1901. doi: 10.1016/j.jacc.2013.07.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.07.057</ArticleId><ArticleId IdType="pubmed">23973704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto A.R., Godwin J.W., Rosenthal N.A. Macrophages in cardiac homeostasis, injury responses and progenitor cell mobilisation. Pt 3Stem Cell Res. 2014;13:705&#x2013;714. doi: 10.1016/j.scr.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2014.06.004</ArticleId><ArticleId IdType="pubmed">25087895</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A., Mar&#xed;n S., Riol N., Carbonell-Uberos F., Mi&#xf1;ana M.D. Human adipose tissue-resident monocytes exhibit an endothelial-like phenotype and display angiogenic properties. Stem Cell Res. Ther. 2014;5:50. doi: 10.1186/scrt438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt438</ArticleId><ArticleId IdType="pmc">PMC4055093</ArticleId><ArticleId IdType="pubmed">24731246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J., Feng J., Liu K., Zhou S., Lu F. Early Macrophage Infiltration Improves Fat Graft Survival by Inducing Angiogenesis and Hematopoietic Stem Cell Recruitment. Plast. Reconstr. Surg. 2018;141:376&#x2013;386. doi: 10.1097/PRS.0000000000004028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0000000000004028</ArticleId><ArticleId IdType="pubmed">29036027</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich D., Seebach C., Verboket R., Schaible A., Marzi I., Bonig H. The osteo-inductive activity of bone-marrow-derived mononuclear cells resides within the CD14+ population and is independent of the CD34+ population. Eur. Cell Mater. 2018;35:165&#x2013;177. doi: 10.22203/eCM.v035a12.</Citation><ArticleIdList><ArticleId IdType="doi">10.22203/eCM.v035a12</ArticleId><ArticleId IdType="pubmed">29509226</ArticleId></ArticleIdList></Reference><Reference><Citation>Centeno C.J., Al-Sayegh H., Bashir J., Goodyear S., Freeman M.D. A dose response analysis of a specific bone marrow concentrate treatment protocol for knee osteoarthritis. BMC Musculoskelet. Disord. 2015;16:258. doi: 10.1186/s12891-015-0714-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-015-0714-z</ArticleId><ArticleId IdType="pmc">PMC4575428</ArticleId><ArticleId IdType="pubmed">26385099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaput C.D., Shar A., Jupiter D., Hubert Z., Clough B., Krause U., Gregory C.A. How stem cell composition in bone marrow aspirate relates to clinical outcomes when used for cervical spine fusion. PLoS ONE. 2018;13:e0203714. doi: 10.1371/journal.pone.0203714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203714</ArticleId><ArticleId IdType="pmc">PMC6152872</ArticleId><ArticleId IdType="pubmed">30248138</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhas M., Abutaleb N., Wang J.T., Ye J., Shaikh Z., Sriworarat C., Qian Y., Bursac N. Incorporation of macrophages into engineered skeletal muscle enables enhanced muscle regeneration. Nat. Biomed. Eng. 2018;2:942&#x2013;954. doi: 10.1038/s41551-018-0290-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-018-0290-2</ArticleId><ArticleId IdType="pmc">PMC6296488</ArticleId><ArticleId IdType="pubmed">30581652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopper N., Wardale J., Howard D., Brooks R., Rushton N., Henson F. Peripheral blood derived mononuclear cells enhance the migration and chondrogenic differentiation of multipotent mesenchymal stromal cells. Stem Cells Int. 2015;2015:323454. doi: 10.1155/2015/323454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/323454</ArticleId><ArticleId IdType="pmc">PMC4309296</ArticleId><ArticleId IdType="pubmed">25663840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopper N., Wardale J., Brooks R., Power J., Rushton N., Henson F. Peripheral Blood Mononuclear Cells Enhance Cartilage Repair in in vivo Osteochondral Defect Model. PLoS ONE. 2015;10:e0133937. doi: 10.1371/journal.pone.0133937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133937</ArticleId><ArticleId IdType="pmc">PMC4529143</ArticleId><ArticleId IdType="pubmed">26252391</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller K.L., Koh T.J. Macrophage-based therapeutic strategies in regenerative medicine. Adv. Drug. Deliv. Rev. 2017;122:74&#x2013;83. doi: 10.1016/j.addr.2017.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2017.05.010</ArticleId><ArticleId IdType="pmc">PMC5690893</ArticleId><ArticleId IdType="pubmed">28526591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogle M.E., Segar C.E., Sridhar S., Botchwey E.A. Monocytes and macrophages in tissue repair: Implications for immunoregenerative biomaterial design. Exp. Biol. Med. 2016;241:1084&#x2013;1097. doi: 10.1177/1535370216650293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370216650293</ArticleId><ArticleId IdType="pmc">PMC4898192</ArticleId><ArticleId IdType="pubmed">27229903</ArticleId></ArticleIdList></Reference><Reference><Citation>Julier Z., Park A.J., Briquez P.S., Martino M.M. Promoting tissue regeneration by modulating the immune system. Acta Biomater. 2017;53:13&#x2013;28. doi: 10.1016/j.actbio.2017.01.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2017.01.056</ArticleId><ArticleId IdType="pubmed">28119112</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes S.J., Rosenthal N. Preparing the ground for tissue regeneration: From mechanism to therapy. Nat. Med. 2014;20:857&#x2013;869. doi: 10.1038/nm.3653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3653</ArticleId><ArticleId IdType="pubmed">25100531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubsky M., Jirkovska A., Bem R., Fejfarova V., Pagacova L., Sixta B., Varga M., Langkramer S., Sykova E., Jude E.B. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab. Res. Rev. 2013;29:369&#x2013;376. doi: 10.1002/dmrr.2399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.2399</ArticleId><ArticleId IdType="pubmed">23390092</ArticleId></ArticleIdList></Reference><Reference><Citation>Persiani F., Paolini A., Camilli D., Mascellari L., Platone A., Magenta A., Furgiuele S. Peripheral Blood Mononuclear Cells Therapy for Treatment of Lower Limb Ischemia in Diabetic Patients: A Single-Center Experience. Ann. Vasc. Surg. 2018;53:190&#x2013;196. doi: 10.1016/j.avsg.2018.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2018.05.036</ArticleId><ArticleId IdType="pubmed">30053546</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis B., Gentile P., Orlandi F., Bocchini I., Di Pasquali C., Agovino A., Gizzi C., Patrizi F., Scioli M.G., Orlandi A., et al. Limb rescue: A new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers. Tissue Eng. Part C Methods. 2015;21:423&#x2013;435. doi: 10.1089/ten.tec.2014.0245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ten.tec.2014.0245</ArticleId><ArticleId IdType="pubmed">25341088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantin A., Vieira J.M., Gestri G., Denti L., Schwarz Q., Prykhozhij S., Peri F., Wilson S.W., Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116:829&#x2013;840. doi: 10.1182/blood-2009-12-257832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-12-257832</ArticleId><ArticleId IdType="pmc">PMC2938310</ArticleId><ArticleId IdType="pubmed">20404134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung E., Helisch A. Macrophages in collateral arteriogenesis. Front. Physiol. 2012;3:353. doi: 10.3389/fphys.2012.00353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00353</ArticleId><ArticleId IdType="pmc">PMC3457069</ArticleId><ArticleId IdType="pubmed">23055975</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett F.H., Rosenfeld M., Wood M., Kiosses W.B., Usui Y., Marchetti V., Aguilar E., Friedlander M. Macrophages form functional vascular mimicry channels in vivo. Sci. Rep. 2016;6:36659. doi: 10.1038/srep36659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36659</ArticleId><ArticleId IdType="pmc">PMC5105153</ArticleId><ArticleId IdType="pubmed">27834402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurevich D.B., Severn C.E., Twomey C., Greenhough A., Cash J., Toye A.M., Mellor H., Martin P. Live imaging of wound angiogenesis reveals macrophage orchestrated vessel sprouting and regression. EMBO J. 2018;37:e97786. doi: 10.15252/embj.201797786.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797786</ArticleId><ArticleId IdType="pmc">PMC6028026</ArticleId><ArticleId IdType="pubmed">29866703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Wu C., Yang Q., Gao J., Li L., Yang D., Luo L. Macrophages Mediate the Repair of Brain Vascular Rupture through Direct Physical Adhesion and Mechanical Traction. Immunity. 2016;44:1162&#x2013;1176. doi: 10.1016/j.immuni.2016.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.03.008</ArticleId><ArticleId IdType="pubmed">27156384</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnasamy K., Limbourg A., Kapanadze T., Gamrekelashvili J., Beger C., H&#xe4;ger C., Lozanovski V.J., Falk C.S., Napp L.C., Bauersachs J., et al. Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. Nat. Commun. 2017;8:952. doi: 10.1038/s41467-017-00953-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00953-2</ArticleId><ArticleId IdType="pmc">PMC5643305</ArticleId><ArticleId IdType="pubmed">29038527</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad O., Dedkov E.I., Jiao C., Bloomer S., Tomanek R.J., Schatteman G.C. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler. Thromb. Vasc. Biol. 2006;26:758&#x2013;764. doi: 10.1161/01.ATV.0000203513.29227.6f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000203513.29227.6f</ArticleId><ArticleId IdType="pubmed">16410458</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre J.S., Mallat Z., Tedgui A., L&#xe9;vy B.I. Post-ischaemic neovascularization and inflammation. Cardiovasc. Res. 2008;78:242&#x2013;249. doi: 10.1093/cvr/cvn027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvn027</ArticleId><ArticleId IdType="pubmed">18252762</ArticleId></ArticleIdList></Reference><Reference><Citation>Stabile E., Kinnaird T., la Sala A., Hanson S.K., Watkins C., Campia U., Shou M., Zbinden S., Fuchs S., Kornfeld H., et al. CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation. 2006;113:118&#x2013;124. doi: 10.1161/CIRCULATIONAHA.105.576702. Erratum in: Circulation 2006, 113, e711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.576702</ArticleId><ArticleId IdType="pubmed">16380545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu&#x17e;nik Z., Anchouche S., Dana R., Yin J. Regulatory T Cells in Angiogenesis. J. Immunol. 2020;205:2557&#x2013;2565. doi: 10.4049/jimmunol.2000574.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000574</ArticleId><ArticleId IdType="pmc">PMC7664842</ArticleId><ArticleId IdType="pubmed">33168598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zouggari Y., Ait-Oufella H., Waeckel L., Vilar J., Loinard C., Cochain C., R&#xe9;calde A., Duriez M., Levy B.I., Lutgens E., et al. Regulatory T cells modulate postischemic neovascularization. Circulation. 2009;120:1415&#x2013;1425. doi: 10.1161/CIRCULATIONAHA.109.875583. Erratum in: Circulation 2010, 121, e31. Lutgens, Ester [corrected to Lutgens, Esther]</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.875583</ArticleId><ArticleId IdType="pubmed">19770391</ArticleId></ArticleIdList></Reference><Reference><Citation>Seraphim P.M., Leal E.C., Moura J., Gon&#xe7;alves P., Gon&#xe7;alves J.P., Carvalho E. Lack of lymphocytes impairs macrophage polarization and angiogenesis in diabetic wound healing. Life Sci. 2020;254:117813. doi: 10.1016/j.lfs.2020.117813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117813</ArticleId><ArticleId IdType="pubmed">32428597</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung O.M., Li J., Li X., Chan V.W., Yang K.Y., Ku M., Ji L., Sun H., Waldmann H., Tian X.Y., et al. Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes. Cell Rep. 2018;24:1610&#x2013;1626. doi: 10.1016/j.celrep.2018.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.07.019</ArticleId><ArticleId IdType="pubmed">30089270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigato M., Monami M., Fadini G.P. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. Circ. Res. 2017;120:1326&#x2013;1340. doi: 10.1161/CIRCRESAHA.116.309045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.309045</ArticleId><ArticleId IdType="pubmed">28096194</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaltro G., Straino S., Gambini E., Bassetti B., Persico L., Zoli S., Zanobini M., Capogrossi M.C., Spirito R., Quarti C., et al. Characterization of the Pall Celeris system as a point-of-care device for therapeutic angiogenesis. Cytotherapy. 2015;17:1302&#x2013;1313. doi: 10.1016/j.jcyt.2015.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2015.04.006</ArticleId><ArticleId IdType="pubmed">26038175</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P.P., Yang X.F., Li S.Z., Wen J.C., Zhang Y., Han Z.C. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb. Haemost. 2007;98:1335&#x2013;1342. doi: 10.1160/TH07-02-0137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH07-02-0137</ArticleId><ArticleId IdType="pubmed">18064333</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubsk&#xfd; M., Jirkovsk&#xe1; A., Bem R., Fejfarov&#xe1; V., Pagacov&#xe1; L., Nemcov&#xe1; A., Sixta B., Chlupac J., Peregrin J.H., Sykov&#xe1; E., et al. Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. Cytotherapy. 2014;16:1733&#x2013;1738. doi: 10.1016/j.jcyt.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2014.08.010</ArticleId><ArticleId IdType="pubmed">25304666</ArticleId></ArticleIdList></Reference><Reference><Citation>Scatena A., Petruzzi P., Maioli F., Lucaroni F., Ambrosone C., Ventoruzzo G., Liistro F., Tacconi D., Di Filippi M., Attempati N., et al. Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients with No-Option Critical Limb Ischemia. J. Clin. Med. 2021;10:2213. doi: 10.3390/jcm10102213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10102213</ArticleId><ArticleId IdType="pmc">PMC8161401</ArticleId><ArticleId IdType="pubmed">34065278</ArticleId></ArticleIdList></Reference><Reference><Citation>Baer C., Squadrito M.L., Iruela-Arispe M.L., De Palma M. Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Exp. Cell Res. 2013;319:1626&#x2013;1634. doi: 10.1016/j.yexcr.2013.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2013.03.026</ArticleId><ArticleId IdType="pmc">PMC8014949</ArticleId><ArticleId IdType="pubmed">23542777</ArticleId></ArticleIdList></Reference><Reference><Citation>Terlizzese G., Stubinski R., Casini A., Clerici G., Sangiorgi G. A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction. Eur. Heart J. Case Rep. 2021;5:ytab244. doi: 10.1093/ehjcr/ytab244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytab244</ArticleId><ArticleId IdType="pmc">PMC8364765</ArticleId><ArticleId IdType="pubmed">34409246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang W.C., Oh P.C., Lee K., Ahn T., Byun K. Increasing injection frequency enhances the survival of injected bone marrow derived mesenchymal stem cells in a critical limb ischemia animal model. Korean J. Physiol. Pharmacol. 2016;20:657&#x2013;667. doi: 10.4196/kjpp.2016.20.6.657.</Citation><ArticleIdList><ArticleId IdType="doi">10.4196/kjpp.2016.20.6.657</ArticleId><ArticleId IdType="pmc">PMC5106400</ArticleId><ArticleId IdType="pubmed">27847443</ArticleId></ArticleIdList></Reference><Reference><Citation>Halim H.I.A.E.l., Elbakary R.H., Okasha E.F., Mousa A.M., Salah E.F. Effect of Peripheral Blood Mononuclear Cells on Induced Ischemia/Reperfusion in Skeletal Muscle of Adult Male Albino Rat: An Immunohistochemical Study. Int. J. Curr. Microbiol. Appl. Sci. 2020;9:2133&#x2013;2144. doi: 10.20546/ijcmas.2020.910.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.20546/ijcmas.2020.910.260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35619683</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2053-8855</ISSN><JournalIssue CitedMedium="Print"><Volume>2022</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Oxford medical case reports</Title><ISOAbbreviation>Oxf Med Case Reports</ISOAbbreviation></Journal><ArticleTitle>Primary myelofibrosis with concurrent paroxysmal nocturnal haemoglobinuria presenting with erectile dysfunction.</ArticleTitle><Pagination><StartPage>omac047</StartPage><MedlinePgn>omac047</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">omac047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/omcr/omac047</ELocationID><Abstract><AbstractText>Primary myelofibrosis and paroxysmal nocturnal haemoglobinuria (PNH) are uncommon clonal blood disorders that are rarely found together. We report a case of primary myelofibrosis (PMF) with concomitant subtle PNH in a 42-year-old man who presented with a 4-week history of fatigue, unexplained chest pain, and new-onset erectile dysfunction. Bone marrow biopsy showed severe fibrosis consistent with PMF. However, smooth muscle dystonia symptoms in the form of new-onset erectile dysfunction and oesophageal spasm were not fully explained by PMF but were clues for PNH, confirmed by flow cytometric assays. Routine PNH testing for patients with new-onset PMF and clinical symptoms suggestive of PNH, as well as those with refractory anaemia despite effective therapy, is crucial since these two conditions can coexist. As a result, a lack of early testing may cause a delay in diagnosis, increasing the patient's transfusion load and the facility's costs.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alsalman</LastName><ForeName>Zaenb</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-1008-7977</Identifier><AffiliationInfo><Affiliation>Departments of Family Medicine, King Faisal University, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsalman</LastName><ForeName>Mortadah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Medicine, King Faisal University, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albesher</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsalman</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saif</LastName><ForeName>Sultan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldandan</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsuliman</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oxf Med Case Reports</MedlineTA><NlmUniqueID>101642070</NlmUniqueID><ISSNLinking>2053-8855</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35619683</ArticleId><ArticleId IdType="pmc">PMC9127941</ArticleId><ArticleId IdType="doi">10.1093/omcr/omac047</ArticleId><ArticleId IdType="pii">omac047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almomen AK, Al Bakistani AG, Alsaeed A, Alolama A, Hejazi A, Awarji Cet al. . Paroxysmal nocturnal hemoglobinuria: Diagnosis and management protocol. J Appl Hematology 2014;5:37&#x2013;44.</Citation></Reference><Reference><Citation>Griffin M, Kulasekararaj A, Gandhi S, Munir T, Richards S, Arnold Let al. . Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: A UK experience. Haematologica 2018;103:345&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068026</ArticleId><ArticleId IdType="pubmed">29545341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Myelofibrosis Treatment Algorithm 2018. Blood Cancer J 2018;8:72.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 &#x2013; clinical utility. Cytometry B Clin Cytom 2018;94:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiman YS, Cuka N, Batista D, Vuica-Ross M, Moliterno AR. Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm. J Blood Med 2016;7:107&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4892839</ArticleId><ArticleId IdType="pubmed">27313483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura JI. Paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki 2012;53:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">22374521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang Let al. . Paroxysmal nocturnal hemoglobinuria and concurrent JAK2 V617F mutation. Blood Cancer J 2012;2:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317526</ArticleId><ArticleId IdType="pubmed">22829258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35543028</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Acute Management of Prolonged, Recalcitrant Priapism in a Pediatric Patient.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2021054941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2021-054941</ELocationID><Abstract><AbstractText>Although rare in pediatrics, ischemic priapism carries significant risk of erectile dysfunction if not treated promptly. We report a case of idiopathic ischemic priapism in a male aged 14 years, refractory to traditional therapies, including aspiration/irrigation, phenylephrine injection, and distal shunt. However, the priapism resolved after intracavernosal injections of tissue plasminogen activator (tPA) with preservation of normal erectile function. To our knowledge, this is the first reported case of intracavernosal tPA for treatment of pediatric priapism. tPA may be a useful management option for recalcitrant ischemic priapism in pediatric patients and may prevent devastating outcomes such as lifelong erectile dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sherrer</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Urology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology, Oncology &amp; Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Sushant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatrics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinde</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Oncology &amp; Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhat</LastName><ForeName>Walid A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Departments of Urology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.68</RegistryNumber><NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="Y">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="Y">Priapism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35543028</ArticleId><ArticleId IdType="doi">10.1542/peds.2021-054941</ArticleId><ArticleId IdType="pii">187011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35439722</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2210-2612</ISSN><JournalIssue CitedMedium="Print"><Volume>94</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of surgery case reports</Title><ISOAbbreviation>Int J Surg Case Rep</ISOAbbreviation></Journal><ArticleTitle>Plaque excision with the Shah Penile Implant&#x2122; and tunica vaginalis graft in Peyronie's disease with erectile dysfunction: A case report.</ArticleTitle><Pagination><StartPage>106976</StartPage><MedlinePgn>106976</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">106976</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijscr.2022.106976</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2210-2612(22)00222-X</ELocationID><Abstract><AbstractText>Peyronie's disease (PD) is a condition characterized by the deposition of scar tissue in the tunica albuginea of the penis. Peyronie's disease often causes pain, worsens the quality of erections, a variable degree of penile deformation and shortening, which can cause severe distress for the patient and the partner and impact negatively on self-esteem and quality of life in general. Surgery still represents the gold standard treatment for PD in the chronic phase, and it aims to guarantee a penis straight and rigid enough to allow the patient to resume penetrative sex with confidence. Penile prosthesis implantation should be reserved for patients with refractory erectile dysfunction or in these patients with complex deformities and impaired erections. Herein is reported the case of a 51-year-old male with a large ossified PD plaque and erectile dysfunction who underwent simultaneous plaque excision and grafting and penile implantation surgery with a semirigid penile prosthesis. This was the first case of penile prosthesis implantation for Peyronie's disease in Indonesia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atmoko</LastName><ForeName>Widi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Pangeran Diponegoro No 71, Jakarta 10310, Indonesia. Electronic address: dr.widiatmoko@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felizio</LastName><ForeName>Jody</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Pangeran Diponegoro No 71, Jakarta 10310, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birowo</LastName><ForeName>Ponco</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Pangeran Diponegoro No 71, Jakarta 10310, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasyid</LastName><ForeName>Nur</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Pangeran Diponegoro No 71, Jakarta 10310, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taher</LastName><ForeName>Akmal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Pangeran Diponegoro No 71, Jakarta 10310, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Andrologia Internazionale Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Surg Case Rep</MedlineTA><NlmUniqueID>101529872</NlmUniqueID><ISSNLinking>2210-2612</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Grafting</Keyword><Keyword MajorTopicYN="N">Penile implantation</Keyword><Keyword MajorTopicYN="N">Peyronie's disease</Keyword><Keyword MajorTopicYN="N">Tunica vaginalis</Keyword></KeywordList><CoiStatement>The authors report no declarations of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35439722</ArticleId><ArticleId IdType="pmc">PMC9026975</ArticleId><ArticleId IdType="doi">10.1016/j.ijscr.2022.106976</ArticleId><ArticleId IdType="pii">S2210-2612(22)00222-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Terrier J.E., Nelson C.J. Psychological aspects of Peyronie&#x2019;s disease. Transl. Androl. Urol. 2016;5(3):290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893509</ArticleId><ArticleId IdType="pubmed">27298775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski K.A., Gannon J.R., Walsh T.J. A review of the epidemiology and treatment of Peyronie&#x2019;s disease. Res. Rep. Urol. 2016;8:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857830</ArticleId><ArticleId IdType="pubmed">27200305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalkut M., Gonzalez-cadavid N., Rajfer J. Peyronie&#x2019;s disease: a review. 2003;5(3):142&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473022</ArticleId><ArticleId IdType="pubmed">16985635</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine C.J.J., Somers K.D., Jordan S.G., Schlossberg S.M. Proposal: trauma as the cause of the Peyronie&#x2019;s lesion. J. Urol. 1997;157(1):285&#x2013;290. (Jan)</Citation><ArticleIdList><ArticleId IdType="pubmed">8976281</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A., Bettoocchi C., Carvalho J., Corona G., Minhas S., Serefoglu E.C. 2020. EAU Guidelines on Sexual and Reproductive Health; pp. 10&#x2013;31.</Citation></Reference><Reference><Citation>Chung E., Ralph D., Kagioglu A., Garaffa G., Shamsodini A., Bivalacqua T., et al. Evidence-based management guidelines on Peyronie&#x2019;s disease. J. Sex. Med. 2016;13(6):905&#x2013;923. (Jun)</Citation><ArticleIdList><ArticleId IdType="pubmed">27215686</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmonov D., Ragheb A., Ward S., Blecher G., Falcone M., Soave A., et al. ESSM position statement on surgical treatment of Peyronie&#x2019;s disease. Sex Med. 2021;10(1) (Nov 22)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847818</ArticleId><ArticleId IdType="pubmed">34823053</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J., Yafi F.A. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie&#x2019;s disease. Transl. Androl. Urol. 2016;5(3):342&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893506</ArticleId><ArticleId IdType="pubmed">27298781</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa P., Tripathi A., Shah R. Surgical outcomes and patient satisfaction with the low-cost, semirigid shah penile prosthesis: a boon to the developing countries. Sex Med. 2021;9(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360909</ArticleId><ArticleId IdType="pubmed">34274823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R. Twenty-five years of the low-cost, noninflatable, Shah Indian penile prosthesis: the history of its evolution. Indian J. Urol. 2021;37:113&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8173931</ArticleId><ArticleId IdType="pubmed">34103792</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha R.A., Franchi T., Sohrabi C., Mathew G., for the SCARE Group The SCARE 2020 guideline: updating consensus surgical CAse REport (SCARE) guidelines. Int. J. Surg. 2020;84:226&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">33181358</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa P., Pascual E.F., Carballido J., Moncada I., Garcia E.L., Salamanca J.I.M. Surgical management of Peyronie&#x2019;s disease with co-existent erectile dysfunction. Sex Med. 2019;7(4):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963125</ArticleId><ArticleId IdType="pubmed">31540882</ArticleId></ArticleIdList></Reference><Reference><Citation>American Urological Association . American Urological Association Education and Research, Inc.; United States of America: 2015. Diagnosis and Treatment of Peyronie&#x2019;s Disease: AUA Guideline.</Citation></Reference><Reference><Citation>Chung E., Solomon M., DeYoung L., Brock G.B. Comparison between AMS 700TM CX and ColoplastTM titan inflatable penile prosthesis for Peyronie&#x2019;s disease treatment and remodeling: clinical outcomes and patient satisfaction. J. Sex. Med. 2013;10(11):2855&#x2013;2860. (Nov)</Citation><ArticleIdList><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Becher E.F., Bella A.J., Brant W.O., Kohler T.S., Martinez-Salamanca J.I., et al. Penile prosthesis surgery: current recommendations from the International Consultation on Sexual Medicine. J. Sex. Med. 2016;13(4):489&#x2013;518. (Apr)</Citation><ArticleIdList><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G., Minervini A., Christopher N.A., Minhas S., Ralph D.J. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011;108(7):1152&#x2013;1156. (Oct)</Citation><ArticleIdList><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gomez B., Ralph D., Levine L., Moncada-Iribarren I., Djinovic R., Albersen M., et al. Grafts for Peyronie&#x2019;s disease: a comprehensive review. Andrology. 2018;6(1):117&#x2013;126. (Jan)</Citation><ArticleIdList><ArticleId IdType="pubmed">29266877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Li Q., Cheng G., Song N., Gu M., Wang Z. Surgical treatment of Peyronie&#x2019;s disease with autologous tunica vaginalis of testis. BMC Urol. 2016;16:1. (Jan 13)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711076</ArticleId><ArticleId IdType="pubmed">26762220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A., Sanli O., Akman T., Ersay A., Guven S., Mammadov F. Graft materials in Peyronie&#x2019;s disease surgery: a comprehensive review. J. Sex. Med. 2007;4(3):581&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17419820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35370101</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>The Efficacy of Suspensory Ligament Release and Pubic Lipectomy Via Penopubic Z Plasty During Penile Prosthesis Implantation in Improving Sexual Satisfaction: A Prospective Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>852</StartPage><EndPage>863</EndPage><MedlinePgn>852-863</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2022.02.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(22)00606-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">The utility of penile suspensory ligament release (SLR) in the setting of penile prosthesis implantation (PPI) has received limited attention in the literature.</AbstractText><AbstractText Label="AIM">To assess the efficacy and safety of penile SLR release, pubic lipectomy (PL), and the utility of penopubic Z-plasty (ZP) during malleable PPI in improving sexual satisfaction compared to that achieved with the conventional method.</AbstractText><AbstractText Label="METHODS">Between August 2018 and April 2020, 61 patients with refractory erectile dysfunction were prospectively randomized into 2 groups; group A included 31 patients who underwent PPI with SLR and PL via ZP, and group B included 30 patients who underwent conventional PPI via a penoscrotal incision.</AbstractText><AbstractText Label="OUTCOMES">Penile length was assessed at 3 months, and sexual satisfaction was assessed up to 1 year after PPI using both validated and non-validated tools.</AbstractText><AbstractText Label="RESULTS">The median operative time was higher in group A than in group B (170 min; interquartile range [IQR] [160-190] vs 97.5 min; IQR [90-110] P &lt; .001).The median pre- to postoperative differences in functional and visible penile lengths for group A were 1.5 cm; IQR [0-2] and 2.5 cm; IQR [1-3.5], respectively, while those in group B were both 0 cm; IQR [-1 to 0] P &lt; .001). Group A patients reported higher scores in the International Index of Erectile Function satisfaction domains than the group B patients did (13; IQR [12-14] and 9; IQR [8-10] vs 11; IQR [9.5-12] and 8; IQR [6.5-8.5], respectively, P &lt; .001). Moreover, the postoperative Erectile Dysfunction Inventory of Treatment Satisfaction score was higher in group A than that in group B (95.40; IQR [91-97.7] vs 85.20; IQR [72.7-91], respectively, P &lt; .001). Common complications in group A were penile edema (77.4%), penile instability (9.7%) and glans numbness (9.7%).</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">The benefit in patient satisfaction following SLR and PL via ZP during PPI may outweigh the incremental increase in complications.</AbstractText><AbstractText Label="STRENGTH &amp; LIMITATIONS">To our knowledge, this is the first prospective randomized controlled study to evaluate the efficacy and safety of SLR, PL, and ZP during PPI. However, because an optimal tool for assessing sexual satisfaction after PPI is lacking at this time, we alternatively adopted the most used assessment tools. Further, our data applies only to malleable penile prosthesis.</AbstractText><AbstractText Label="CONCLUSION">SLR and PL via ZP during PPI resulted in a substantial improvement of the patients' sexual satisfaction without serious complications. Fotouh El Gharably MA, Ghoneima W, Lotfi MR, et&#xa0;al. The Efficacy of Suspensory Ligament Release and Pubic Lipectomy Via Penopubic Z Plasty During Penile Prosthesis Implantation in Improving Sexual Satisfaction: A Prospective Randomized Controlled Trial. J Sex Med 2022;19:852-863.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aboul Fotouh El Gharably</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoneima</LastName><ForeName>Waleed</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotfi</LastName><ForeName>Mohamed Amr</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AbdelWahab</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkady</LastName><ForeName>Amr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Rassoul</LastName><ForeName>Mohammed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Urology Department, Cairo University, Cairo, Egypt. Electronic address: mohammed.abdel_rassoul@kasralainy.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008022" MajorTopicYN="N">Ligaments</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015187" MajorTopicYN="Y">Lipectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Pubic Lipectomy</Keyword><Keyword MajorTopicYN="N">Sexual Satisfaction</Keyword><Keyword MajorTopicYN="N">Suspensory Ligament</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>4</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35370101</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2022.02.024</ArticleId><ArticleId IdType="pii">S1743-6095(22)00606-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35352532</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2282-4197</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</Title><ISOAbbreviation>Arch Ital Urol Androl</ISOAbbreviation></Journal><ArticleTitle>The use of a polyglycolic acid polymer graft in Peyronie's disease - preliminary outcomes.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>90</EndPage><MedlinePgn>87-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4081/aiua.2022.1.87</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Plaque incision and grafting is indicated for patients with Peyronie's Disease [PD] and severe curvature, complex deformities or for patients with significant penile shortening. To date, no graft studied has been considered ideal. The aim of this study is to conduct a descriptive analysis about functional results with the use of a bioabsorbable graft for PD treatment.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A single-center, retrospective evaluation of a cohort of patients who were treated by plaque incision and grafting with a polyglycolic acid polymer graft (Gore&#xae; Bio-A&#xae;) between 2018 and 2021 was conducted. Correction of penile curvature was the main outcome. Loss of penile sensitivity, de novo erectile dysfunction and any other adverse event were the secondary endpoints.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">14 patients were included in this study (mean age 59.5 &#xb1; 7.2 years). The median follow-up time was 12 months (range 3-12). The curvature correction rate was 78.5%. Glans hypoesthesia was present in one of 14 patients (7.1%) and refractory erectile dysfunction was reported in 64.2%. None of the patients presented any major adverse event based on Clavien-Dindo classification.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Curvature correction and changes in penile sensitivity rates were similar to those found in the literature. No major surgical complications, such as graft rejection, infection, and extrusion, occurred in this sample. Although a population with a higher prevalence of erectile dysfunction was included in this sample, higher rates of refractory erectile dysfunction were observed and these findings should be confirmed in further studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edler Zandon&#xe1;</LastName><ForeName>Pedro Caetano</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Urology of Hospital Governador Celso Ramos, Florian&#xf3;polis. uropedrozandona@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Nivio Pascoal</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Urology of Hospital Governador Celso Ramos, Florian&#xf3;polis. nivio@uromed.com.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Henrique Eduardo</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Urology of Hospital Governador Celso Ramos, Florian&#xf3;polis. henriqueoliveira02@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares Garcia</LastName><ForeName>Jorge Hamilton</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology of Hospital Governador Celso Ramos, Florian&#xf3;polis. jorge@anestesiologistas.com.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Arch Ital Urol Androl</MedlineTA><NlmUniqueID>9308247</NlmUniqueID><ISSNLinking>1124-3562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>26009-03-0</RegistryNumber><NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011100" MajorTopicYN="N">Polyglycolic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35352532</ArticleId><ArticleId IdType="doi">10.4081/aiua.2022.1.87</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35059330</PMID><DateRevised><Year>2022</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2253-2447</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Research and reports in urology</Title><ISOAbbreviation>Res Rep Urol</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis Implantation in Refractory Ischaemic Priapism: Patient Selection and Special Considerations.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>6</EndPage><MedlinePgn>1-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/RRU.S278807</ELocationID><Abstract><AbstractText>Ischemic priapism accounts for more than 95% of all priapic episodes. It has to be considered a urological emergency because its time extension may lead to necrosis of smooth muscle cells of the corpora cavernosa, resulting in a complete erectile dysfunction, penile shortening and loss of girth. In the present systematic review, we perform an up-to-date literature search for patients suffering from refractory ischemic priapism who undergo penile prosthesis implantation with particular interests to the patients characteristics. The conservative management of the priapic episode consists of a sympathomimetic agent in the first istance.&#xa0;Failure or recurrence of priapism following these conservative measures is an indication for surgical management. Shunt procedures between the corpora cavernosa and the neighbouring structures are often used first line; however, in refractory ischemic priapism the success rate is minimal. In such cases (&gt;48&#x2009;h) an indication of immediate placement of a penile prosthesis could be the best solution.</AbstractText><CopyrightInformation>&#xa9; 2022 Capece et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1951-404X</Identifier><AffiliationInfo><Affiliation>Department of Urology, AOU Federico II, University Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1101-892X</Identifier><AffiliationInfo><Affiliation>Department of Neurourology, A.O.U. Citt&#xe0; della Salute e della Scienza di Torino - Unit&#xe0; Spinale Unipolare, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ospedale Santa Chiara, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmieri</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, AOU Federico II, University Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Rocca</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, AOU Federico II, University Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Res Rep Urol</MedlineTA><NlmUniqueID>101576971</NlmUniqueID><ISSNLinking>2253-2447</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">priapism</Keyword><Keyword MajorTopicYN="N">refractory ischemic priapism</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35059330</ArticleId><ArticleId IdType="pmc">PMC8765601</ArticleId><ArticleId IdType="doi">10.2147/RRU.S278807</ArticleId><ArticleId IdType="pii">278807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. Eur Urol. 2014;65:480&#x2013;489. doi:10.1016/j.eururo.2013.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2013.11.008</ArticleId><ArticleId IdType="pubmed">24314827</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7(1 Pt 2):476&#x2013;500. doi:10.1111/j.1743-6109.2009.01625.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01625.x</ArticleId><ArticleId IdType="pubmed">20092449</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318&#x2013;1324. doi:10.1097/01.ju.0000087608.07371.ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000087608.07371.ca</ArticleId><ArticleId IdType="pubmed">14501756</ArticleId></ArticleIdList></Reference><Reference><Citation>Capece M, Gillo A, Cocci A, et al. Management of refractory ischemic priapism: current perspectives. Res Rep Urol. 2017;9:175&#x2013;179. doi:10.2147/RRU.S128003</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RRU.S128003</ArticleId><ArticleId IdType="pmc">PMC5587151</ArticleId><ArticleId IdType="pubmed">28920056</ArticleId></ArticleIdList></Reference><Reference><Citation>Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol. 1986;135:142&#x2013;147. doi:10.1016/S0022-5347(17)45549-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)45549-2</ArticleId><ArticleId IdType="pubmed">3941454</ArticleId></ArticleIdList></Reference><Reference><Citation>Capece M, La Rocca R, Mirone V, et al. A systematic review on ischemic priapism and immediate implantation: do we need more data? Sex Med Rev. 2019;7(3):530&#x2013;534. doi:10.1016/j.sxmr.2018.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.10.007</ArticleId><ArticleId IdType="pubmed">30898595</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets. 2015;16:474&#x2013;483. doi:10.2174/1389450115666141111111842</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450115666141111111842</ArticleId><ArticleId IdType="pmc">PMC4430197</ArticleId><ArticleId IdType="pubmed">25392014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56:1033&#x2013;1038. doi:10.1016/j.eururo.2008.09.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2008.09.044</ArticleId><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Y&#xfc;cel &#xd6;B, Pazir Y, Kadioglu A. Penile prosthesis implantation in priapism. Sex Med Rev. 2018;6:310&#x2013;318. doi:10.1016/j.sxmr.2017.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.08.002</ArticleId><ArticleId IdType="pubmed">28916463</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay J, Shekarriz B, Dhabuwala CB. Penile implant for intractable priapism associated with sickle cell disease. Urology. 1998;51(4):638&#x2013;639. doi:10.1016/s0090-4295(97)00704-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(97)00704-8</ArticleId><ArticleId IdType="pubmed">9586621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002;90(9):893&#x2013;897. doi:10.1046/j.1464-410x.2002.03058.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.2002.03058.x</ArticleId><ArticleId IdType="pubmed">12460352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Evans LA, Morey AF. Immediate insertion of a semirigid penile prosthesis for refractory ischemic priapism. Mil Med. 2007;172(11):1211&#x2013;1212. doi:10.7205/milmed.172.11.1211</Citation><ArticleIdList><ArticleId IdType="doi">10.7205/milmed.172.11.1211</ArticleId><ArticleId IdType="pubmed">18062399</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010;183(6):2300&#x2013;2303. doi:10.1016/j.juro.2010.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.02.014</ArticleId><ArticleId IdType="pubmed">20400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedigh O, Rolle L, Negro CL, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011;23(4):158&#x2013;164. doi:10.1038/ijir.2011.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2011.23</ArticleId><ArticleId IdType="pubmed">21654814</ArticleId></ArticleIdList></Reference><Reference><Citation>Faddan AA, Aksenov AV, Naumann CM, J&#xfc;nemann KP, Osmonov DK. Semi-rigid penile prosthesis as a salvage management of idiopathic ischemic stuttering priapism. Res Rep Urol. 2015;7:137&#x2013;141. doi:10.2147/RRU.S83361</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RRU.S83361</ArticleId><ArticleId IdType="pmc">PMC4567212</ArticleId><ArticleId IdType="pubmed">26380229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Zhao LC, Morey AF, et al. Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism. J Sex Med. 2015;12(3):824&#x2013;826. doi:10.1111/jsm.12803</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12803</ArticleId><ArticleId IdType="pubmed">25536880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, De Luca F, Raheem AA, et al. Early insertion of a malleable penile prosthesis in ischaemic priapism allows later upsizing of the cylinders. Scand J Urol. 2015;49(6):468&#x2013;471. doi:10.3109/21681805.2015.1059359</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21681805.2015.1059359</ArticleId><ArticleId IdType="pubmed">26116193</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Bettocchi C, Boeri L, et al.; EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021. doi:10.1016/j.eururo.2021.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2021.06.007</ArticleId><ArticleId IdType="pubmed">34183196</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178&#x2013;189. doi:10.1016/j.jclinepi.2021.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.03.001</ArticleId><ArticleId IdType="pubmed">33789819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34632459</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-432X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Faculty reviews</Title><ISOAbbreviation>Fac Rev</ISOAbbreviation></Journal><ArticleTitle>Penile implant surgery-managing complications.</ArticleTitle><Pagination><StartPage>73</StartPage><MedlinePgn>73</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">73</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12703/r/10-73</ELocationID><Abstract><AbstractText>Penile prosthesis surgery represents the end-stage treatment for erectile dysfunction. It is conventionally used only in cases of erectile dysfunction refractory to pharmacological treatments or vacuum constriction devices. Contemporary literature suggests that penile prothesis surgery is associated with a high satisfaction rate and a low complication profile. However, it must be appreciated that the complications of surgery can have devastating consequences on a patient's quality of life and satisfaction and include infection, prosthesis malfunction, penile corporal perforation and penile length loss. Several factors - such as appropriate patient selection, methodical preoperative assessment and patient optimization, specific intraoperative protocols and postoperative recommendations - can reduce the risk of surgical complications. This narrative review discusses the diagnosis and management of both intraoperative and postoperative complications of penile prosthesis surgery.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Minhas S et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cayetano-Alcaraz</LastName><ForeName>Axel Alberto</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yassin</LastName><ForeName>Musaab</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Ankit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tharakan</LastName><ForeName>Tharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsampoukas</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Urology Department, Princess Alexandria Hospital, Harlow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurli</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Suks</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Andrology Department, Imperial College Healthcare NHS Trust, Charing Cross, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Fac Rev</MedlineTA><NlmUniqueID>101769226</NlmUniqueID><ISSNLinking>2732-432X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile implantation</Keyword><Keyword MajorTopicYN="N">erectile dysfunction surgery</Keyword><Keyword MajorTopicYN="N">glans ischemia</Keyword><Keyword MajorTopicYN="N">glans necrosis</Keyword><Keyword MajorTopicYN="N">inflatable penile prosthesis (IPP)</Keyword><Keyword MajorTopicYN="N">instrumentation</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">preoperative care</Keyword><Keyword MajorTopicYN="N">prosthesis implantation</Keyword><Keyword MajorTopicYN="N">prosthesis-related infections</Keyword><Keyword MajorTopicYN="N">reoperation</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">salvage therapy</Keyword><Keyword MajorTopicYN="N">urethra</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34632459</ArticleId><ArticleId IdType="pmc">PMC8483239</ArticleId><ArticleId IdType="doi">10.12703/r/10-73</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levine LA, Becher EF, Bella AJ, et al. : Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine. J Sex Med. 2016; 13(4): 489&#x2013;518. 10.1016/j.jsxm.2016.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouhan JD, Pearlman AM, Kovell RC, et al. : A Quality Analysis of the Last Decade's Most Heavily Cited Data Relative to Outcomes After Penile Prosthesis Placement. J Sex Med. 2020; 17(5): 861&#x2013;9. 10.1016/j.jsxm.2020.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2020.02.025</ArticleId><ArticleId IdType="pubmed">32273243</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Kansal NS, Callaway M, et al. : Centers of excellence concept and penile prostheses: An outcome analysis. J Urol. 2009; 181(3): 1264&#x2013;8. 10.1016/j.juro.2008.10.157</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.10.157</ArticleId><ArticleId IdType="pubmed">19152945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotan Y, Roehrborn CG, McConnell JD, et al. : Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology. 2003; 62(5): 918&#x2013;21. 10.1016/s0090-4295(03)00665-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(03)00665-4</ArticleId><ArticleId IdType="pubmed">14624920</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MJ, et al. : Impact of Surgeon Case Volume on Reoperation Rates after Inflatable Penile Prosthesis Surgery. J Urol. 2017; 197(1): 223&#x2013;9. 10.1016/j.juro.2016.08.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.08.083</ArticleId><ArticleId IdType="pubmed">27545573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Carson 3rd CC: Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol. 2011; 60(1): 167&#x2013;72. 10.1016/j.eururo.2011.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.01.046</ArticleId><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, et al. : Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int. 2018; 121(2): 293&#x2013;300. 10.1111/bju.14076</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.14076</ArticleId><ArticleId IdType="pmc">PMC7478354</ArticleId><ArticleId IdType="pubmed">29124870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon LM, de Campos CCC, Voris BRI, et al. : A systematic review of penile prosthesis infection and meta-analysis of diabetes mellitus role. BMC Urol. 2021; 21(1): 35. 10.1186/s12894-020-00730-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12894-020-00730-2</ArticleId><ArticleId IdType="pmc">PMC7945372</ArticleId><ArticleId IdType="pubmed">33691670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, 2nd: Inflatable Penile Implant Infection: Predisposing Factors and Treatment Suggestions. J Urol. 1995; 153(3 Pt 1): 659&#x2013;61. 10.1016/S0022-5347(01)67678-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)67678-X</ArticleId><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisasue S, Sato Y, Horita H, et al. : Erosion of a penile prosthesis due to an indwelling urethral catheter as a late complication. Int J Urol. 2002; 9(9): 525&#x2013;7. 10.1046/j.1442-2042.2002.00502.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1442-2042.2002.00502.x</ArticleId><ArticleId IdType="pubmed">12410936</ArticleId></ArticleIdList></Reference><Reference><Citation>Steidle CP, Mulcahy JJ: Erosion of Penile Prostheses: A Complication of Urethral Catheterization. J Urol. 1989; 142(3): 736&#x2013;9. 10.1016/s0022-5347(17)38871-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(17)38871-7</ArticleId><ArticleId IdType="pubmed">2769851</ArticleId></ArticleIdList></Reference><Reference><Citation>Balen A, Gross MS, Phillips EA, et al. : Active Polysubstance Abuse Concurrent With Surgery as a Possible Newly Identified Infection Risk Factor in Inflatable Penile Prosthesis Placement Based on a Retrospective Analysis of Health and Socioeconomic Factors. J Sex Med. 2016; 13(4): 697&#x2013;701. 10.1016/j.jsxm.2016.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.010</ArticleId><ArticleId IdType="pubmed">26928774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, et al. : Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology. 2007; 70(2): 337&#x2013;40. 10.1016/j.urology.2007.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.03.058</ArticleId><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. : Penile prosthesis implantation for the treatment for male erectile dysfunction: Clinical outcomes and lessons learnt after 955 procedures. World J Urol. 2013; 31(3): 591&#x2013;5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>Dick B, Greenberg JW, Polchert M, et al. : A Systematic Review of Penile Prosthesis Surgery in Organ Transplant Recipients. Sex Med Rev. 2020; S2050-0521(20)30049-4. 10.1016/j.sxmr.2020.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2020.05.006</ArticleId><ArticleId IdType="pubmed">32641224</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Brandes ER, Chang SL, et al. : Trends in penile prosthesis implantation and analysis of predictive factors for removal. World J Urol. 2019; 37(4): 639&#x2013;46. 10.1007/s00345-018-2491-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-018-2491-4</ArticleId><ArticleId IdType="pubmed">30251052</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil MI, Bramwell AK, Bhandari NR, et al. : Concurrent Penile Prosthesis and Artificial Urinary Sphincter versus Penile Prosthesis and Male Sling: A National Multi-Institutional Analysis of National Surgical Quality Improvement Program Database Comparing Postoperative Morbidity. World J Mens Health. 2021; 39(1): 75&#x2013;82. 10.5534/wjmh.190172</Citation><ArticleIdList><ArticleId IdType="doi">10.5534/wjmh.190172</ArticleId><ArticleId IdType="pmc">PMC7752517</ArticleId><ArticleId IdType="pubmed">32378369</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheem OA, Hsieh TC: Penile prosthetic surgery for the management of Peyronie&#x2019;s disease. Transl Androl Urol. 2017; 6(Suppl 5): S815&#x2013;S821. 10.21037/tau.2017.03.83</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.03.83</ArticleId><ArticleId IdType="pmc">PMC5715173</ArticleId><ArticleId IdType="pubmed">29238661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AC, Schweber A: Patient expectations prior to coloplast titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med. 2010; 7(6): 2261&#x2013;6. 10.1111/j.1743-6109.2010.01799.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01799.x</ArticleId><ArticleId IdType="pubmed">20367767</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalheira A, Santana R, Pereira NM: Why Are Men Satisfied or Dissatisfied with Penile Implants? A Mixed Method Study on Satisfaction with Penile Prosthesis Implantation. J Sex Med. 2015; 12(12): 2474&#x2013;80. 10.1111/jsm.13054</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13054</ArticleId><ArticleId IdType="pubmed">26639576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ: The Prevention and Management of Noninfectious Complications of Penile Implants. Sex Med Rev. 2015; 3(3): 203&#x2013;13. 10.1002/smrj.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.41</ArticleId><ArticleId IdType="pubmed">27784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, et al. : Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006; 3(4): 743&#x2013;8. 10.1111/j.1743-6109.2006.00278.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00278.x</ArticleId><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen LT: Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: A systematic review and meta-analysis. Arch Surg. 2012; 147(4): 373&#x2013;83. 10.1001/archsurg.2012.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2012.5</ArticleId><ArticleId IdType="pubmed">22508785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dick BP, Yousif A, Raheem O, et al. : Does Lowering Hemoglobin A1c Reduce Penile Prosthesis Infection: A Systematic Review. Sex Med Rev. 2020; S2050-0521(20)30068-8. 10.1016/j.sxmr.2020.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2020.06.004</ArticleId><ArticleId IdType="pubmed">32768358</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh LM, Huang E, El-Khatib FM, et al. : A Systematic Review of Literature Regarding Whether Immediate Preoperative Hemoglobin A1c or Serum Glucose Are Risk Factors for Infection Following Penile Prosthesis Implantation. Urology. 2021; 152: 15&#x2013;24. 10.1016/j.urology.2021.01.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2021.01.066</ArticleId><ArticleId IdType="pubmed">33705821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahon J, Dornbier R, Wegrzyn G, et al. : Infectious Adverse Events Following the Placement of a Penile Prosthesis: A Systematic Review. Sex Med Rev. 2020; 8(2): 348&#x2013;54. 10.1016/j.sxmr.2019.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.07.005</ArticleId><ArticleId IdType="pubmed">31519461</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Carrasquillo RJ, et al. : Multicenter Investigation of the Micro-Organisms Involved in Penile Prosthesis Infection: An Analysis of the Efficacy of the AUA and EAU Guidelines for Penile Prosthesis Prophylaxis. J Sex Med. 2017; 14(3): 455&#x2013;63. 10.1016/j.jsxm.2017.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.01.007</ArticleId><ArticleId IdType="pubmed">28189561</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. : Erectile Dysfunction: AUA Guideline. J Urol. 2018; 200(3): 633&#x2013;41. 10.1016/j.juro.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavoussi NL, Viers BR, Pagilara TJ, et al. : Are Urine Cultures Necessary Prior to Urologic Prosthetic Surgery? Sex Med Rev. 2018; 6(1): 157&#x2013;61. 10.1016/j.sxmr.2017.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.03.007</ArticleId><ArticleId IdType="pubmed">28479079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner J, Norrie P, Melen K: Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev. 2011; (11): CD004122. 10.1002/14651858.CD004122.pub4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004122.pub4</ArticleId><ArticleId IdType="pubmed">22071812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner J, Dumville JC, Norman G, et al. : Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev. 2016; (1): CD004288. 10.1002/14651858.CD004288.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004288.pub3</ArticleId><ArticleId IdType="pubmed">26799160</ArticleId></ArticleIdList></Reference><Reference><Citation>EAU Guidelines: Edn. presented at the EAU Annual Congress Milan Italy 2021. 2021.</Citation></Reference><Reference><Citation>Wolf JS, Bennett CJ, Dmochowski RR, et al. : Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008; 179(4): 1379&#x2013;90. 10.1016/j.juro.2008.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.01.068</ArticleId><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaee ME, Towe M, Osman MM, et al. : A Multicenter Investigation Examining American Urological Association Recommended Antibiotic Prophylaxis vs Nonstandard Prophylaxis in Preventing Device Infections in Penile Prosthesis Surgery in Diabetic Patients. J Urol. 2020; 204(5): 969&#x2013;75. 10.1097/JU.0000000000001158</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JU.0000000000001158</ArticleId><ArticleId IdType="pubmed">32519913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Reinstatler L, Henry GD, et al. : Multicenter Investigation of Fungal Infections of Inflatable Penile Prostheses. J Sex Med. 2019; 16(7): 1100&#x2013;5. 10.1016/j.jsxm.2019.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.05.003</ArticleId><ArticleId IdType="pubmed">31255212</ArticleId></ArticleIdList></Reference><Reference><Citation>Dropkin BM, Chisholm LP, Dallmer JD, et al. : Penile Prosthesis Insertion in the Era of Antibiotic Stewardship-Are Postoperative Antibiotics Necessary? J Urol. 2020; 203(3): 611&#x2013;4. 10.1097/JU.0000000000000578</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JU.0000000000000578</ArticleId><ArticleId IdType="pubmed">31580192</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamsky MA, Boysen WR, Cohen AJ, et al. : Evaluating the Role of Postoperative Oral Antibiotic Administration in Artificial Urinary Sphincter and Inflatable Penile Prosthesis Explantation: A Nationwide Analysis. Urology. 2018; 111: 92&#x2013;8. 10.1016/j.urology.2017.07.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2017.07.064</ArticleId><ArticleId IdType="pmc">PMC5747981</ArticleId><ArticleId IdType="pubmed">28964819</ArticleId></ArticleIdList></Reference><Reference><Citation>Herati AS, Lo EM: Penile prosthesis biofilm formation and emerging therapies against them. Transl Androl Urol. 2018; 7(6): 960&#x2013;7. 10.21037/tau.2018.09.05</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2018.09.05</ArticleId><ArticleId IdType="pmc">PMC6256047</ArticleId><ArticleId IdType="pubmed">30505734</ArticleId></ArticleIdList></Reference><Reference><Citation>Stulberg JJ, Delaney CP, Neuhauser DV, et al. : Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA. 2010; 303(24): 2479&#x2013;85. 10.1001/jama.2010.841</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.841</ArticleId><ArticleId IdType="pubmed">20571014</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz BF, Gaunay GS, Barazani Y, et al. : Use of a preoperative checklist reduces risk of penile prosthesis infection. J Urol. 2014; 192(1): 130&#x2013;5. 10.1016/j.juro.2013.12.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2013.12.044</ArticleId><ArticleId IdType="pubmed">24384159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, et al. : A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: A randomized controlled trial. J Urol. 2013; 189(1): 136&#x2013;40. 10.1016/j.juro.2012.08.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.08.086</ArticleId><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Wall MJ, Itani KMF, et al. : Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010; 362(1): 18&#x2013;26. 10.1056/NEJMoa0810988</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810988</ArticleId><ArticleId IdType="pubmed">20054046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Zhu M, Munro JT, et al. : Glove change to reduce the risk of surgical site infection or prosthetic joint infection in arthroplasty surgeries: A systematic review. ANZ J Surg. 2019; 89(9): 1009&#x2013;15. 10.1111/ans.14936</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.14936</ArticleId><ArticleId IdType="pubmed">30497094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner J, Parkinson H: Double gloving to reduce surgical cross-infection. Cochrane Database Syst Rev. 2006; 2006(3): CD003087. 10.1002/14651858.CD003087.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003087.pub2</ArticleId><ArticleId IdType="pmc">PMC7173754</ArticleId><ArticleId IdType="pubmed">16855997</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipps S, Lim YN, McClinton S, et al. : Short term urinary catheter policies following urogenital surgery in adults. Cochrane Database Syst Rev. 2006; (2): CD004374. 10.1002/14651858.CD004374.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004374.pub2</ArticleId><ArticleId IdType="pubmed">16625600</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, et al. : Coated implants and "no touch" surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology. 2012; 79(6): 1310&#x2013;5. 10.1016/j.urology.2011.11.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2011.11.076</ArticleId><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, et al. : Infection retardant coated inflatable penile prostheses decrease the incidence of infection: A systematic review and meta-analysis. J Urol. 2012; 188(5): 1855&#x2013;60. 10.1016/j.juro.2012.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.07.022</ArticleId><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Ilbeigi P, Wilson SK, et al. : Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res. 2005; 17(6): 535&#x2013;8. 10.1038/sj.ijir.3901354</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901354</ArticleId><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Parker J, Carrion R, et al. : Distortion of the implanted penis: SST and cylinder crossover. Int J Impot Res. 2021; 33(3): 278&#x2013;85. 10.1038/s41443-020-0309-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-020-0309-6</ArticleId><ArticleId IdType="pubmed">32488212</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpman E: Management of Distal &amp; Proximal Penile Prosthesis Crossover. J Sex Med. 2016; 13(6): 1008&#x2013;12. 10.1016/j.jsxm.2016.04.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.04.063</ArticleId><ArticleId IdType="pubmed">27215691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma D, Smith RP: Troubleshooting intraoperative complications of penile prosthesis placement. Transl Androl Urol. 2017; 6(Suppl 5): S892&#x2013;S897. 10.21037/tau.2017.07.13</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.07.13</ArticleId><ArticleId IdType="pmc">PMC5715183</ArticleId><ArticleId IdType="pubmed">29238668</ArticleId></ArticleIdList></Reference><Reference><Citation>Muneer A, Fowler S, Ralph DJ, et al. : UK practice for penile prosthesis surgery: Baseline analysis of the British Association of Urological Surgeons (BAUS) Penile Prosthesis Audit. BJU Int. 2021; 127(3): 326&#x2013;31. 10.1111/bju.15219</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.15219</ArticleId><ArticleId IdType="pubmed">32869902</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Le BV, Burnett AL: Suprapubic cystostomy for the management of urethral injuries during penile prosthesis implantation. Sex Med. 2014; 2(4): 178&#x2013;81. 10.1002/sm2.44</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sm2.44</ArticleId><ArticleId IdType="pmc">PMC4272249</ArticleId><ArticleId IdType="pubmed">25548649</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP: Outcome of penile prosthesis implantation for treating erectile dysfunction: Experience with 504 procedures. BJU Int. 2006; 97(1): 129&#x2013;33. 10.1111/j.1464-410X.2005.05907.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar NB, Angermeier KW, Montague DK: Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol. 2006; 176(6 Pt 1): 2599&#x2013;601; discussion 2601. 10.1016/j.juro.2006.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.08.012</ArticleId><ArticleId IdType="pubmed">17085168</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentes JL, Yi YA, Davenport MT, et al. : Long-term sequelae of inflatable penile prosthesis: Clinical characteristics of patients who develop distal cylinder tip extrusion. Transl Androl Urol. 2020; 9(1): 38&#x2013;42. 10.21037/tau.2019.08.30</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2019.08.30</ArticleId><ArticleId IdType="pmc">PMC6995929</ArticleId><ArticleId IdType="pubmed">32055464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H: Penile prosthesis surgery: A review of prosthetic devices and associated complications. J Sex Med. 2007; 4(2): 296&#x2013;309. 10.1111/j.1743-6109.2007.00434.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00434.x</ArticleId><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas S: Urethral Perforation During Penile Implant Surgery: What to Do? J Sex Med. 2017; 14(7): 867&#x2013;9. 10.1016/j.jsxm.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.05.003</ArticleId><ArticleId IdType="pubmed">28673431</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos EC, Sexton SJ, Lentz AC, et al. : Urethral Injury and the Penile Prosthesis. Sex Med Rev. 2019; 7(2): 360&#x2013;8. 10.1016/j.sxmr.2018.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.06.003</ArticleId><ArticleId IdType="pubmed">30078620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Ditonno P, Palumbo F, et al. : Penile prosthesis: What should we do about complications? Adv Urol. 2008; 2008: 573560. 10.1155/2008/573560</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/573560</ArticleId><ArticleId IdType="pmc">PMC2581729</ArticleId><ArticleId IdType="pubmed">19009029</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito P: Urethral injury during inflatable penile prosthesis: a new repair. Video J Prosthet Urol. 2014; 1: 034.</Citation></Reference><Reference><Citation>Kim YD, Yang SO, Lee JK, et al. : Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol. 2008; 15(10): 919&#x2013;23. 10.1111/j.1442-2042.2008.02115.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02115.x</ArticleId><ArticleId IdType="pubmed">18651861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Mora-Estaves C, Egydio P, et al. : Glans Necrosis Following Penile Prosthesis Implantation: Prevention and Treatment Suggestions. Urology. 2017; 107: 144&#x2013;8. 10.1016/j.urology.2017.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2017.06.020</ArticleId><ArticleId IdType="pubmed">28648967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert KJ, Kohler TS: Glans ischemia following inflatable penile prosthesis surgery. Transl Androl Urol. 2020; 9(2): 824&#x2013;7. 10.21037/tau.2020.01.04</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2020.01.04</ArticleId><ArticleId IdType="pmc">PMC7215035</ArticleId><ArticleId IdType="pubmed">32420191</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio PH, Kuehhas FE: The Multiple-Slit Technique (MUST) for Penile Length and Girth Restoration. J Sex Med. 2018; 15(2): 261&#x2013;9. 10.1016/j.jsxm.2017.11.223</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.11.223</ArticleId><ArticleId IdType="pubmed">29275049</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavell-Hern&#xe1;ndez J, Shah A, Wang R: Non-Infectious Reservoir-Related Complications During and After Penile Prosthesis Placement. Sex Med Rev. 2019; 7(3): 521&#x2013;9. 10.1016/j.sxmr.2018.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.12.005</ArticleId><ArticleId IdType="pubmed">30786958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AC, Chason J, Kusakabe A: Report of two cases of bladder perforation caused by reservoir of inflatable penile prosthesis. J Sex Med. 2009; 6(7): 2064&#x2013;7. 10.1111/j.1743-6109.2009.01277.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01277.x</ArticleId><ArticleId IdType="pubmed">19453911</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB, Morris A: Intravesical penile implant reservoir: Case report, literature review, and strategies for prevention. Int J Impot Res. 2013; 25(2): 41&#x2013;4. 10.1038/ijir.2012.31</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2012.31</ArticleId><ArticleId IdType="pubmed">22931762</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Jang SW, Lee SW, et al. : Rare complication of multiple revision surgeries of penile prosthesis. J Sex Med. 2005; 2(5): 735&#x2013;6. 10.1111/j.1743-6109.2005.00100.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00100.x</ArticleId><ArticleId IdType="pubmed">16422833</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldefrawy A, Kava BR: An unusual complication during inflatable penile prosthesis implantation. Urology. 2010; 76(4): 847. 10.1016/j.urology.2009.11.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2009.11.034</ArticleId><ArticleId IdType="pubmed">20138343</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer ND, Dick B, Gabrielson AT, et al. : Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sex Med Rev. 2019; 7(2): 349&#x2013;59. 10.1016/j.sxmr.2018.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.04.002</ArticleId><ArticleId IdType="pubmed">30033128</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Hoeh MP: Review of penile prosthetic reservoir: Complications and presentation of a modified reservoir placement technique. J Sex Med. 2012; 9(11): 2759&#x2013;69. 10.1111/j.1743-6109.2012.02807.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02807.x</ArticleId><ArticleId IdType="pubmed">22672516</ArticleId></ArticleIdList></Reference><Reference><Citation>Godiwalla SY, Beres J, Jacobs SC: Erosion of an Inflatable Penile Prosthesis Reservoir into an Ileal Conduit. J Urol. 1987; 137(2): 297&#x2013;8. 10.1016/s0022-5347(17)43986-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(17)43986-3</ArticleId><ArticleId IdType="pubmed">3806825</ArticleId></ArticleIdList></Reference><Reference><Citation>Stember DS, Garber BB, Perito PE: Outcomes of abdominal wall reservoir placement in inflatable penile prosthesis implantation: A safe and efficacious alternative to the space of Retzius. J Sex Med. 2014; 11(2): 605&#x2013;12. 10.1111/jsm.12408</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12408</ArticleId><ArticleId IdType="pubmed">24286533</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry G, Hsiao W, Hsaio W, et al. : A guide for inflatable penile prosthesis reservoir placement: Pertinent anatomical measurements of the retropubic space. J Sex Med. 2014; 11(1): 273&#x2013;8. 10.1111/jsm.12361</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12361</ArticleId><ArticleId IdType="pubmed">24274160</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke Jr TK, Erbella A, Zhang Y, et al. : Prevention, identification, and management of post-operative penile implant complications of infection, hematoma, and device malfunction. Transl Androl Urol. 2017; 6(Suppl 5): S832&#x2013;S848. 10.21037/tau.2017.06.07</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.06.07</ArticleId><ArticleId IdType="pmc">PMC5715191</ArticleId><ArticleId IdType="pubmed">29238663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S, Cleves M, Delk J: Hematoma formation following penile prosthesis implantation: to drain or not to drain. J Urol. 1996; 55: 634A.</Citation></Reference><Reference><Citation>Swanton AR, Munarriz RM, Gross MS: Updates in penile prosthesis infections. Asian J Androl. 2020; 22(1): 28&#x2013;33. 10.4103/aja.aja_84_19</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aja.aja_84_19</ArticleId><ArticleId IdType="pmc">PMC6958973</ArticleId><ArticleId IdType="pubmed">31489848</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Farag M, Williamson B, et al. : Conservative Therapy is an Effective Option in Patients With Localized Infection After Penile Implant Surgery. J Sex Med. 2016; 13(6): 972&#x2013;6. 10.1016/j.jsxm.2016.04.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.04.064</ArticleId><ArticleId IdType="pmc">PMC5317031</ArticleId><ArticleId IdType="pubmed">27162191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ: Treatment alternatives for the infected penile implant. Int J Impot Res. 2003; 15 Suppl 5: S147&#x2013;9. 10.1038/sj.ijir.3901092</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901092</ArticleId><ArticleId IdType="pubmed">14551595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Balen A, et al. : The Malleable Implant Salvage Technique: Infection Outcomes after Mulcahy Salvage Procedure and Replacement of Infected Inflatable Penile Prosthesis with Malleable Prosthesis. J Urol. 2016; 195(3): 694&#x2013;7. 10.1016/j.juro.2015.08.091</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.08.091</ArticleId><ArticleId IdType="pubmed">26343986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopategui DM, Balise RR, Bouzoubaa LA, et al. : The Impact of Immediate Salvage Surgery on Corporeal Length Preservation in Patients Presenting with Penile Implant Infections. J Urol. 2018; 200(1): 171&#x2013;7. 10.1016/j.juro.2018.01.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.01.082</ArticleId><ArticleId IdType="pubmed">29408215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisa E, Keskin MZ, Yucel C, et al. : Comparison of penile prosthesis types' complications: A retrospective analysis of single center. Arch Ital Urol Androl. 2020; 92(4). 10.4081/aiua.2020.4.386</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2020.4.386</ArticleId><ArticleId IdType="pubmed">33348970</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorissen C, de Bruyna H, Baten E, et al. : Clinical Outcome: Patient and Partner Satisfaction after Penile Implant Surgery. Curr Urol. 2019; 13(2): 94&#x2013;100. 10.1159/000499286</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000499286</ArticleId><ArticleId IdType="pmc">PMC6872984</ArticleId><ArticleId IdType="pubmed">31768176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan S, Bertolotto M, Shamsodini A, et al. : Comprehensive Multimodality Imaging Review of Complications of Penile Prostheses. AJR Am J Roentgenol. 2018; 210(6): 1200&#x2013;7. 10.2214/AJR.17.18943</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.17.18943</ArticleId><ArticleId IdType="pubmed">29528712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ: Surgical management of penile prosthesis complications. Int J Impot Res. 2000; 12 Suppl 4: S108&#x2013;11. 10.1038/sj.ijir.3900587</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900587</ArticleId><ArticleId IdType="pubmed">11035396</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh-Doyle JC, Lin JS, Doumanian LR, et al. : Outcomes of Alternative Reservoir Placement in the Lateral Retroperitoneum During Inflatable Penile Prosthesis Placement. Urology. 2021; 152: 35&#x2013;41. 10.1016/j.urology.2021.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2021.02.021</ArticleId><ArticleId IdType="pubmed">33647306</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB: Inflatable penile prosthesis: Results of 150 cases. Br J Urol. 1996; 78(6): 933&#x2013;5. 10.1046/j.1464-410x.1996.17622.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.1996.17622.x</ArticleId><ArticleId IdType="pubmed">9014722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman JM, Weldon TE: Cylinder aneurysm of parylene-coated American Medical System (AMS) 700CX penile prosthesis. J Sex Med. 2008; 5(11): 2713&#x2013;5. 10.1111/j.1743-6109.2008.00975.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00975.x</ArticleId><ArticleId IdType="pubmed">18761594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreiro C, Torremad&#xe9; J, Pujol L, et al. : [Adjuvant surgical maneuvers in penile prostheses implant to improve their aesthetic and functional outcomes]. Rev Int Androl. 2019; 17(2): 68&#x2013;77. 10.1016/j.androl.2017.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.androl.2017.12.001</ArticleId><ArticleId IdType="pubmed">31029440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickell M, Manimala N, Parker J, et al. : Floppy Glans Syndrome: Pathogenesis and Treatment. Sex Med Rev. 2016; 4(2): 149&#x2013;56. 10.1016/j.sxmr.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2015.12.001</ArticleId><ArticleId IdType="pubmed">27872024</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncada I, Ascensios J, L&#xf3;pez I, et al. : Intraoperative and postoperative complications of penile implant surgery. Diagnosis and treatment. Actas Urol Esp (Engl Ed). 2020; 44(5): 357&#x2013;66. 10.1016/j.acuro.2020.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acuro.2020.01.014</ArticleId><ArticleId IdType="pubmed">32532509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Kim FJ: Reconstructing penile supersonic transporter (SST) deformity using glanulopexy (glans fixation). Urology. 2001; 57(6): 1160&#x2013;2. 10.1016/s0090-4295(01)00961-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(01)00961-x</ArticleId><ArticleId IdType="pubmed">11377333</ArticleId></ArticleIdList></Reference><Reference><Citation>Morey AF: Reconstructing Penile Supersonic Transporter (SST) Deformity Using Glanulopexy (Glans Fixation). J Urol. 2005; 174(3): 969.</Citation><ArticleIdList><ArticleId IdType="pubmed">16094013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball Jr TP: Surgical repair of penile &#x201c;SST&#x201d; Deformity. Urology. 1980; 15(6): 603&#x2013;4. 10.1016/0090-4295(80)90379-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(80)90379-9</ArticleId><ArticleId IdType="pubmed">7394993</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang A, Wang R: Nondegloving technique for Peyronie's disease with penile prosthesis implantation and double dorsal-ventral patch graft. Asian J Androl. 2018; 20(1): 90&#x2013;2. 10.4103/aja.aja_42_17</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aja.aja_42_17</ArticleId><ArticleId IdType="pmc">PMC5753562</ArticleId><ArticleId IdType="pubmed">28959941</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah T, Wang R: A Review of Factors Affecting Patient Satisfaction With Inflatable Penile Prosthesis. Sex Med Rev. 2021; 9(2): 350&#x2013;7. 10.1016/j.sxmr.2020.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2020.04.001</ArticleId><ArticleId IdType="pubmed">32580912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraile Poblador A, D&#xed;az P&#xe9;rez D, Hevia Palacios M, et al. : Analysis of preoperative and postoperative expectations of penile implant candidates. Actas Urol Esp (Engl Ed). 2020; 44(5): 345&#x2013;50. 10.1016/j.acuro.2020.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acuro.2020.01.007</ArticleId><ArticleId IdType="pubmed">32354643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah BB, Kent M, Valenzuela R: Advanced Penile Length Restoration Techniques to Optimize Penile Prosthesis Placement Outcomes. Sex Med Rev. 2020; S2050-0521(20)30050-0. 10.1016/j.sxmr.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2020.05.007</ArticleId><ArticleId IdType="pubmed">32653404</ArticleId></ArticleIdList></Reference><Reference><Citation>Panuganti S, Kannady C, Wang R: Expanding the Limits-Improving Penile Length With Inflatable Penile Prosthesis Implantation: A Review. Sex Med Rev. 2021; 9(3): 498&#x2013;506. 10.1016/j.sxmr.2020.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2020.06.006</ArticleId><ArticleId IdType="pubmed">32863198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A, Akman T, Sanli O, et al. : Surgical treatment of Peyronie's disease: A critical analysis. Eur Urol. 2006; 50(2): 235&#x2013;48. 10.1016/j.eururo.2006.04.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.04.030</ArticleId><ArticleId IdType="pubmed">16716495</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio PH, Kuehhas FE: Penile lengthening and widening without grafting according to a modified 'sliding' technique. BJU Int. 2015; 116(6): 965&#x2013;72. 10.1111/bju.13065</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13065</ArticleId><ArticleId IdType="pubmed">25644141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L, Ceruti C, Timpano M, et al. : A new A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the "sliding technique". J Sex Med. 2012; 9(9): 2389&#x2013;95. 10.1111/j.1743-6109.2012.02675.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02675.x</ArticleId><ArticleId IdType="pubmed">22429331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34618409</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2927</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Andrology</Title><ISOAbbreviation>Andrology</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of botulinum neurotoxin in the treatment of erectile dysfunction refractory to phosphodiesterase inhibitors: Results of a randomized controlled trial.</ArticleTitle><Pagination><StartPage>254</StartPage><EndPage>261</EndPage><MedlinePgn>254-261</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/andr.13104</ELocationID><Abstract><AbstractText Label="BACKGROUND">There has been recent interest in the use of botulinum neurotoxin (BoNT) in the field of Andrology, whereby it has been investigated in the treatment of penile retraction and premature ejaculation.</AbstractText><AbstractText Label="OBJECTIVES">To evaluate the safety and efficacy of intracavernosal BoNT-A injection in the treatment of patients with erectile dysfunction (ED) refractory to oral phosphodiesterase inhibitors (PDE5Is).</AbstractText><AbstractText Label="PATIENTS AND METHODS">A double-blind randomized placebo-controlled prospective comparative study conducted at one center and involved 70 patients with ED refractory to PDE5Is. At baseline, the following data were collected: erection hardness score (EHS), peak systolic velocity (PSV), end diastolic velocity (EDV), sexual health inventory for men (SHIM), and the sexual encounter profile 2&amp;3 (SEP-2&amp;3) questionnaires. Treatment group (n&#xa0;=&#xa0;35) received a single ICI of 100 units of BoNT-A in 2&#xa0;ml of saline and control group (n&#xa0;=&#xa0;35) received a single ICI of 2&#xa0;ml of saline. EHS, PSV, and EDV were assessed at 2&#xa0;weeks post treatment. SHIM, SEP-2, SEP-3, and global assessment questionnaire (GAQ-Q1&amp;Q2) were completed at 2-, 6-, and 12-weeks post treatment.</AbstractText><AbstractText Label="RESULTS">Two weeks post treatment, the treatment group showed a statistically significant improvement in the mean EHS, PSV, EDV, and GAQ-Q1 positive responders (p&#xa0;&lt;&#xa0;0.001) compared to the control group. At 6- and 12-weeks post treatment, the treatment group showed a statistically significant improvement in the SHIM scores, SEP-2, and GAQ-Q1&amp;Q2 positive responders compared to the control group. At 6&#xa0;weeks, where there was a 5-point improvement in the mean SHIM score of the treatment group (10&#xb1;5.9 from 5.4&#xb1;1.7 at baseline) versus no improvement in the placebo group, 18 patients in the treatment group (53%) were able to have an erection hard enough for vaginal penetration versus only one patient in the control group.</AbstractText><AbstractText Label="CONCLUSION">BoNT-A is safe and effective as a potential treatment for ED refractory to PDE5I therapy.</AbstractText><CopyrightInformation>&#xa9; 2021 American Society of Andrology and European Academy of Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdelrahman</LastName><ForeName>Islam Fathy Soliman</ForeName><Initials>IFS</Initials><Identifier Source="ORCID">0000-0001-6469-5858</Identifier><AffiliationInfo><Affiliation>Andrology Department, Cairo University - Facuty of medicine, Cairo, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Armed Forces College of Medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>Amr Abdel</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Andrology Department, Cairo University - Facuty of medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkhiat</LastName><ForeName>Yaser</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Andrology Department, Cairo University - Facuty of medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aburahma</LastName><ForeName>Abdelrahman A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Andrology Department, Cairo University - Facuty of medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Raheem</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Physiology Department, Cairo University - Faculty of Medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanem</LastName><ForeName>Hussein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Andrology Department, Cairo University - Facuty of medicine, Cairo, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Andrology</MedlineTA><NlmUniqueID>101585129</NlmUniqueID><ISSNLinking>2047-2919</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001905" MajorTopicYN="N">Botulinum Toxins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BOTOX</Keyword><Keyword MajorTopicYN="N">Botulinum Neurotoxin</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase Inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34618409</ArticleId><ArticleId IdType="doi">10.1111/andr.13104</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56.</Citation></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I, et&#xa0;al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804-814.</Citation></Reference><Reference><Citation>Ventimiglia E, Capogrosso P, Montorsi F, Salonia A. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf. 2016;15:141-152.</Citation></Reference><Reference><Citation>Yafi FA, Jenkins L, Albersen M, et&#xa0;al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.</Citation></Reference><Reference><Citation>Evans JD, Hill SR. A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient Prefer Adherence. 2015;9:1159-1164.</Citation></Reference><Reference><Citation>Stuckey BG, Jadzinsky MN, Murphy LJ, et&#xa0;al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26:279-284.</Citation></Reference><Reference><Citation>Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol. 1995;75:786-791.</Citation></Reference><Reference><Citation>Moreland RB, Kim N, Nehra A, Goldstein I, Traish A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res. 2003;15:362-368.</Citation></Reference><Reference><Citation>Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287-292. discussion 92-3.</Citation></Reference><Reference><Citation>Jorissen C, De Bruyna H, Baten E, Van Renterghem K. Clinical outcome: patient and partner satisfaction after penile implant surgery. Curr Urol. 2019;13:94-100.</Citation></Reference><Reference><Citation>Trost LW, McCaslin R, Linder B, Hellstrom WJ. Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Rev Med Devices. 2013;10:353-366.</Citation></Reference><Reference><Citation>Aoki KR. Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol. 2002;30:107-116.</Citation></Reference><Reference><Citation>Chung E. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions. Expert Opin Biol Ther. 2015;15:95-102.</Citation></Reference><Reference><Citation>Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(Suppl 1):3-10.</Citation></Reference><Reference><Citation>Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161-165.</Citation></Reference><Reference><Citation>Smith CP, Franks ME, McNeil BK, et&#xa0;al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003;169:1896-1900.</Citation></Reference><Reference><Citation>Chapple C, Sievert KD, MacDiarmid S, et&#xa0;al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249-256.</Citation></Reference><Reference><Citation>Cruz F, Herschorn S, Aliotta P, et&#xa0;al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742-750.</Citation></Reference><Reference><Citation>Cruz F, Nitti V. Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn. 2014;33(Suppl 3):S26-31.</Citation></Reference><Reference><Citation>Escuder AG, Hunter DG. The role of botulinum toxin in the treatment of strabismus. Semin Ophthalmol. 2019;34:198-204.</Citation></Reference><Reference><Citation>Nitti VW, Dmochowski R, Herschorn S, et&#xa0;al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186-2193.</Citation></Reference><Reference><Citation>Jones DH, Kerscher M, Geister T, Hast MA, Weissenberger P. Efficacy of incobotulinumtoxinA for the treatment of glabellar frown lines in male subjects: post-hoc analyses from randomized, double-blind pivotal studies. Dermatol Surg. 2017;43(Suppl 2):S235-S41.</Citation></Reference><Reference><Citation>Kattimani V, Tiwari RVC, Gufran K, Wasan B, Shilpa PH, Khader AA. Botulinum toxin application in facial esthetics and recent treatment indications (2013-2018). J Int Soc Prev Community Dent. 2019;9:99-105.</Citation></Reference><Reference><Citation>Kim DW, Cundiff J, Toriumi DM. Botulinum toxin A for the treatment of lateral periorbital rhytids. Facial Plast Surg Clin North Am. 2003;11:445-451.</Citation></Reference><Reference><Citation>Matsudo PK. Botulinum toxin for correction of fronto-glabella wrinkles: preliminary evaluation. Aesthetic Plast Surg. 1996;20:439-441.</Citation></Reference><Reference><Citation>Qaqish C. Botulinum toxin use in the upper face. Atlas Oral Maxillofac Surg Clin North Am. 2016;24:95-103.</Citation></Reference><Reference><Citation>Sarrabayrouse MA. Indications and limitations for the use of botulinum toxin for the treatment of facial wrinkles. Aesthetic Plast Surg. 2002;26:233-238.</Citation></Reference><Reference><Citation>Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5:274-279.</Citation></Reference><Reference><Citation>Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55:8-14.</Citation></Reference><Reference><Citation>Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44:165-174.</Citation></Reference><Reference><Citation>MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience. 1982;7:997-1006.</Citation></Reference><Reference><Citation>Gandaglia G, Briganti A, Jackson G, et&#xa0;al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65:968-978.</Citation></Reference><Reference><Citation>Ghanem H, Raheem AA, AbdelRahman IFS, Johnson M, Abdel-Raheem T. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6:135-142.</Citation></Reference><Reference><Citation>Serefoglu EC, Hawley WR, Lasker GF, et&#xa0;al. Effect of botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats. J Sex Med. 2014;11:1657-1663.</Citation></Reference><Reference><Citation>Shaeer O, Shaeer K, Shaeer A. Botulinum toxin a (Botox) for relieving penile retraction. J Sex Med. 2009;6:2788-2794.</Citation></Reference><Reference><Citation>Ghanem H, Fathy I, Raheem AA, Shamloul R, Hamid MA. 024 The effect of botulinum toxin on penile vascular parameters and clinical outcome in patients with severe Ed: a pilot study. J Sex Med. 2017;14(1):S11.</Citation></Reference><Reference><Citation>Ghanem H, Raheem AA, Fathy I. 037 Safety and effectiveness of botulinum toxin in the treatment of severe ED: a pilot study. J Sex Med. 2017;14(2):e18.</Citation></Reference><Reference><Citation>Ghanem H, Soliman I, AbdulHamid M, Shamloul R. PS-08-016 Can intracavernosal botulinum toxin injection salvage vascular erectile dysfunction patients not responding to oral and intracavernous therapy? A pilot study. J Sex Med. 2016;13(5):S116.</Citation></Reference><Reference><Citation>Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med. 2013;10:120-129.</Citation></Reference><Reference><Citation>Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16:452-455.</Citation></Reference><Reference><Citation>Giuliano F, Joussain C, Denys P. Safety and efficacy of intracavernosal injections of abobotulinumtoxinA (Dysport((R))) as add on therapy to phosphosdiesterase type 5 inhibitors or prostaglandin E1 for erectile dysfunction-case studies. Toxins (Basel). 2019:11:283.</Citation></Reference><Reference><Citation>Denys P, Le Normand L, Ghout I, et&#xa0;al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61:520-529.</Citation></Reference><Reference><Citation>Dmochowski R, Chapple C, Nitti VW, et&#xa0;al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416-2422.</Citation></Reference><Reference><Citation>Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231-2236.</Citation></Reference><Reference><Citation>Tincello DG, Kenyon S, Abrams KR, et&#xa0;al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62:507-514.</Citation></Reference><Reference><Citation>De Young L, Campbell J, Radomski S, Alzubaidi R, Brock G. 142 Intracavernosal injection of botulinum toxin to improve erectile function in older rats. J Sex Med. 2017;14(1):S40-1.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34582341</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1911-6470</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Canadian Urological Association journal = Journal de l'Association des urologues du Canada</Title><ISOAbbreviation>Can Urol Assoc J</ISOAbbreviation></Journal><ArticleTitle>Chronic pain associated with penile prostheses may persist despite revision or explantation.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>46</EndPage><MedlinePgn>42-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5489/cuaj.7391</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prosthesis (IPP) implantation is the gold standard treatment for medically refractory erectile dysfunction. New chronic pain after IPP implantation is rarely discussed and the optimal treatment is unclear. We evaluated whether IPP re-operation for a primary indication of chronic pain improves patients' symptoms. Our secondary aim was to explore factors associated with resolution or persistence of pain after IPP reoperation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective analysis of 315 patients who had an IPP revision or explantation at two high-volume prosthetic centers between May 2007 and May 2017. We excluded patients who had device malfunction, pain for &lt;2 months, pain associated with infection or erosion, and patients without long-term followup data. Persistent pain was diagnosed based on patient self-report.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 31 patients met our criteria for having undergone a surgical revision (n=18) or explantation (n=13) for pain relief. Eighteen (58%) patients had persistent pain despite surgical intervention. Only patients who had pain secondary to a device malposition improved after re-operation (n=13). A prior diagnosis of a chronic pain syndrome was associated with persistent pain despite intervention. Pain improvement was not associated with age, comorbid conditions, duration of implant, or the number of surgical revisions performed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Surgical intervention for chronic penile prosthesis pain is unlikely to relieve symptoms, particularly for patients with chronic pain disorders. Patients should be counselled that IPP reoperative procedures as a treatment for pain should be avoided unless the device is identified to be malpositioned, and consideration of alternative therapeutic options may be more beneficial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, the Johns Hopkins School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ernest Pang</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pierdominico</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakus</LastName><ForeName>Serkan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, the Johns Hopkins School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trock</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, the Johns Hopkins School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Gerald B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, the Johns Hopkins School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Urol Assoc J</MedlineTA><NlmUniqueID>101312644</NlmUniqueID><ISSNLinking>1911-6470</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can Urol Assoc J. 16:47.</RefSource><PMID Version="1">35143391</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Competing interests:</b> Dr. Brock has been an advisory board member for and holds investments in Boston Scientific. Dr. Burnett been an advisory board member for UroMissionsWorks Inc.; has received payment for consultant work/article publication/steering committee participation for clinical trials from Astellas, Boston Scientific, and Novartis; has received grants/honoraria from Boston Scientific and Endo Pharmaceuticals; and has participated in clinical trials on urinary incontinence, prostate cancer monitoring, and erectile dysfunction supported by Boston Scientific; Myriad, and Futura Medical, respectively. The remaining authors do not report any competing personal or financial interests related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>17</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34582341</ArticleId><ArticleId IdType="pmc">PMC8932433</ArticleId><ArticleId IdType="doi">10.5489/cuaj.7391</ArticleId><ArticleId IdType="pii">cuaj.7391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;2. doi: 10.1016/0090-4295(73)90224-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: Single surgical group experience with 2384 first-time implants spanning two decades. J Sex Med. 2007;4:1074&#x2013;9. doi: 10.1111/j.1743-6109.2007.00540.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, McCaslin R, Linder B, et al. Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Rev Med Devices. 2013;10:353&#x2013;66. doi: 10.1586/erd.12.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erd.12.92</ArticleId><ArticleId IdType="pubmed">23668707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lled&#xf3;-Garc&#xed;a E, Jara-Rasc&#xf3;n J, Moncada Iribarren I, et al. Penile prosthesis first and replacement surgeries: Analysis of patient and partner satisfaction. J Sex Med. 2015;12:1646&#x2013;53. doi: 10.1111/jsm.12932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12932</ArticleId><ArticleId IdType="pubmed">26193766</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA Guideline. J Urol. 2018;200:633&#x2013;41. doi: 10.1016/j.juro.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncada I, Hern&#xe1;ndez C, Jara J, et al. Buckling of cylinders may cause prolonged penile pain after prosthesis implantation: A case control study using magnetic resonance imaging of the penis. J Urol. 1998;160:67&#x2013;71. doi: 10.1016/S0022-5347(01)63033-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)63033-7</ArticleId><ArticleId IdType="pubmed">9628607</ArticleId></ArticleIdList></Reference><Reference><Citation>Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth. 2008;101:77&#x2013;86. doi: 10.1093/bja/aen099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aen099</ArticleId><ArticleId IdType="pubmed">18434337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez JC, Trost L, Kohler T, et al. Emerging complications following alternative reservoir placement during inflatable penile prosthesis placement: A 5-year multi-institutional experience. J Urol. 2019;201:581&#x2013;6. doi: 10.1016/j.juro.2018.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.10.013</ArticleId><ArticleId IdType="pubmed">30366022</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal V, Rickards D, Ralph DJ. Ejaculatory pain as a result of inflatable penile prosthesis reservoir compressing a seminal vesicle. Urology. 2006;68:888. doi: 10.1016/j.urology.2006.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2006.05.002</ArticleId><ArticleId IdType="pubmed">17070377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagedorn JC, Osbun N, Lundy S, et al. Inflatable penile prosthesis failure and complications: review of a national database. J Urol. 2015;193:4Se43&#x2013;4. doi: 10.1016/j.juro.2015.02.193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.02.193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DS, Yang KM, Chung HJ, et al. AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term followup. J Sex Med. 2010;7:2602&#x2013;27. doi: 10.1111/j.1743-6109.2010.01801.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01801.x</ArticleId><ArticleId IdType="pubmed">20384938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler TS, Moore A, Ring J. A contemporary series of penile implant complications occurring at a training institution. J Urol. 2016;13:S68. doi: 10.1016/j.jsxm.2016.02.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.02.151</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal S, Vetter J, Brandes SB, et al. A population-based analysis of contemporary rates of reoperation for penile prosthesis procedures. Urology. 2014;84:112&#x2013;6. doi: 10.1016/j.urology.2014.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2014.02.028</ArticleId><ArticleId IdType="pmc">PMC4252045</ArticleId><ArticleId IdType="pubmed">24785986</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000;93:1123&#x2013;33. doi: 10.1097/00000542-200010000-00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200010000-00038</ArticleId><ArticleId IdType="pubmed">11020770</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser EJ. Chronic post-surgical pain: Epidemiology and clinical implications for acute pain management. Acute Pain. 2006;8:73&#x2013;81. doi: 10.1016/j.acpain.2006.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acpain.2006.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Searle RD, Simpson KH. Chronic post-surgical pain. Continu Educ Anaesth Crit Care Pain. 2010;10:12&#x2013;4. doi: 10.1093/bjaceaccp/mkp041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjaceaccp/mkp041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong CMC, Lucas J, Shah A, et al. Novel multimodal analgesia protocol significantly decreases opioid requirements in inflatable penile prosthesis patients. J Sex Med. 2018;15:1187&#x2013;94. doi: 10.1016/j.jsxm.2018.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.05.017</ArticleId><ArticleId IdType="pubmed">30017719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas J, Gross M, Yafi F, et al. A multi-institutional assessment of multimodal analgesia in penile implant recipients demonstrates dramatic reduction in pain scores and narcotic usage. J Sex Med. 2019;17:518&#x2013;25. doi: 10.1016/j.jsxm.2019.11.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.11.267</ArticleId><ArticleId IdType="pubmed">31866125</ArticleId></ArticleIdList></Reference><Reference><Citation>Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019;393:1537&#x2013;46. doi: 10.1016/S0140-6736(19)30352-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30352-6</ArticleId><ArticleId IdType="pubmed">30983589</ArticleId></ArticleIdList></Reference><Reference><Citation>McBeth J, Prescott G, Scotland G, et al. Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med. 2012;172:48&#x2013;57. doi: 10.1001/archin-ternmed.2011.555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archin-ternmed.2011.555</ArticleId><ArticleId IdType="pubmed">22082706</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa P, Euasobhon P. Chronic postsurgical pain: current evidence for prevention and management. Korean J Pain. 2018;31:155&#x2013;73. doi: 10.3344/kjp.2018.31.3.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3344/kjp.2018.31.3.155</ArticleId><ArticleId IdType="pmc">PMC6037807</ArticleId><ArticleId IdType="pubmed">30013730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34552785</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>Tips and tricks in the management of inflatable penile prosthesis infection: A review.</ArticleTitle><Pagination><StartPage>346</StartPage><EndPage>352</EndPage><MedlinePgn>346-352</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/2090598X.2021.1946335</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the management of inflatable penile prosthesis (IPP) infection.<b>Methods</b>: The 'gold-standard' treatment for medication-refractory erectile dysfunction is the IPP, wherein the most dreaded complication is infection. To prevent and manage an infected IPP requires a strict protocol during the pre-, intra-, and postoperative course. A variety of techniques and antibiotics are used in conjunction with IPP implantation to prevent contamination. This modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) review of the literature examines the current practices by leading urologists in the management of IPP infection, as well as provides insights for improved patient outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">: Patient selection is important to reduce IPP infections, and those with risk factors need to be optimised prior to surgery. Proper antibiotic prophylaxis includes pre-, intra-, and postoperative administration. As most infections derive from normal skin flora, every measure must be taken to sterilise the skin and avoid direct device skin contact. Up to 3% of virgin IPPs develop infections and this number increases to 18% in revision cases. Antibiotic coverage depends on the presenting microbe, which can vary significantly between patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">: A greater success in IPP implantation can be attributed to appropriate prophylaxis, field sterilisation, and surgical technique. For those implants that do become infected, often erectile function can be preserved by immediate antibiotic coverage combined with salvage procedures.</AbstractText><CopyrightInformation>&#xa9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brimley</LastName><ForeName>Scott C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousif</LastName><ForeName>Ayad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJG</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prosthesis</Keyword><Keyword MajorTopicYN="N">erectile function</Keyword><Keyword MajorTopicYN="N">implant</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">salvage</Keyword></KeywordList><CoiStatement>Dr Wayne Hellstrom is a consultant for Coloplast. No other potential competing interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34552785</ArticleId><ArticleId IdType="pmc">PMC8451622</ArticleId><ArticleId IdType="doi">10.1080/2090598X.2021.1946335</ArticleId><ArticleId IdType="pii">1946335</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, et al. Infection retardant coated inflatable penile prostheses decrease the incidence of infection: a systematic review and meta-analysis. J Urol. 2012;188(5):1855&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4648343</ArticleId><ArticleId IdType="pubmed">24670166</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Wanzek P, Bailey G.. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol. 2016;13(1):33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky MJ, Onyeji I, Golan R, et al. Diabetes is a risk factor for inflatable penile prosthesis infection: analysis of a large statewide database. Sex Med. 2019;7(1):35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377380</ArticleId><ArticleId IdType="pubmed">30674445</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M, Pearce I. Infection of penile prostheses in patients with diabetes mellitus. Surg Infect (Larchmt). 2016;17(1):2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Canguven O, Talib R, El Ansari W, et al. Is Hba1c level of diabetic patients associated with penile prosthesis implantation infections? Aging Male. 2018:1&#x2013;6. DOI:10.1080/13685538.2018.1448059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13685538.2018.1448059</ArticleId><ArticleId IdType="pubmed">29523037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dick BP, Yousif A, Raheem O, et al. Does lowering hemoglobin a1c reduce penile prosthesis infection: a systematic review. Sex Med Rev. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32768358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendi P, Banderet F, Graber P, et al. Periprosthetic joint infection following Staphylococcus aureus bacteremia. J Infect. 2011;63(1):17&#x2013;22. .</Citation><ArticleIdList><ArticleId IdType="pubmed">21663971</ArticleId></ArticleIdList></Reference><Reference><Citation>Balen A, Gross MS, Phillips EA, et al. Active polysubstance abuse concurrent with surgery as a possible newly identified infection risk factor in inflatable penile prosthesis placement based on a retrospective analysis of health and socioeconomic factors. J Sex Med. 2016;13(4):697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">26928774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda M, Burnett AL. Penile prosthesis infections-a review of risk factors, prevention, and treatment. Sex Med Rev. 2016;4(4):389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">27872031</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz DJ, Stember DS, Nelson CJ, et al. Perioperative prevention of penile prosthesis infection: practice patterns among surgeons of SMSNA and ISSM. J Sex Med. 2012;9(6):1705&#x2013;1712. quiz 712-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510324</ArticleId></ArticleIdList></Reference><Reference><Citation>Urologic procedures and antimicrobial prophylaxis. 2019.  [cited 2020 Jan8]. Available from: https://www.auanet.org/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019)</Citation></Reference><Reference><Citation>Southwell-Keely JP, Russo RR, March L, et al. Antibiotic prophylaxis in hip fracture surgery: a metaanalysis. Clin Orthop Relat Res. 2004;419(419):179&#x2013;184. .</Citation><ArticleIdList><ArticleId IdType="pubmed">15021151</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer ND, Dick B, Gabrielson AT, et al. Penile prosthesis complications: planning, prevention, and decision making. Sex Med Rev. 2019;7(2):349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">30033128</ArticleId></ArticleIdList></Reference><Reference><Citation>Masterson TA, Palmer J, Dubin J, et al. Medical pre-operative considerations for patients undergoing penile implantation. Transl Androl Urol. 2017;6(Suppl 5):S824&#x2013;S829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715179</ArticleId><ArticleId IdType="pubmed">29238662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4(4 Pt 1):1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP. Risk factors for penile prosthetic infection. J Urol. 1996;156(2 Pt 1):402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Carson CC 3rd, Chapin AK, et al. Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol. 2012;188(3):899&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">22819402</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC 3rd, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185(2):614&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, et al. Coated implants and &#x201c;no touch&#x201d; surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology. 2012;79(6):1310&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Towe M, Huynh LM, Osman MM, et al. Impact of antimicrobial dipping solutions on postoperative infection rates in patients with diabetes undergoing primary insertion of a coloplast titan inflatable penile prosthesis. J Sex Med. 2020;17(10):2077&#x2013;2083.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807707</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner J, Norrie P, Melen K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev. 2011;(11):CD004122. DOI:10.1002/14651858.CD004122.pub4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004122.pub4</ArticleId><ArticleId IdType="pubmed">22071812</ArticleId></ArticleIdList></Reference><Reference><Citation>SMSNA Position Statement . Razors and preoperative preparation of the male genitalia. [cited2020September29]. Available from: https://www.smsna.org/V1/resources/position-statements</Citation></Reference><Reference><Citation>Best Practices Statements . Urologic procedures and antimicrobial prophylaxis. 2019.  [cited 2020 Sept29]. Available from: https://www.auanet.org/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019)</Citation></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol. 2013;189(1):136&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Carrasquillo RJ, et al. Multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis. J Sex Med. 2017;14(3):455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">28189561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJG, DeLay KJ. Re: multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis. Eur Urol. 2017;72(5):854&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">28651790</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvajal A, Benavides J, Garcia-Perdomo HA, et al. Risk factors associated with penile prosthesis infection: systematic review and meta-analysis. Int J Impot Res. 2020;32(6):587&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">32015525</ArticleId></ArticleIdList></Reference><Reference><Citation>Selph JP, Carson CC 3rd. Penile prosthesis infection: approaches to prevention and treatment. Urol Clin North Am. 2011;38(2):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621089</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res. 2003;15(Suppl 5):S139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Treatment alternatives for the infected penile implant. Int J Impot Res. 2003;15(Suppl 5):S147&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Penile prosthesis infection: progress in prevention and treatment. Curr Urol Rep. 2010;11(6):400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">20821356</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: immediate replacement of the infected penile prosthesis. J Urol. 1996;155(1):155&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. 2000;163(2):481&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD. Penile prosthetic infection: management by delayed and immediate salvage techniques. Urology. 1998;52(2):287&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Balen A, et al. The malleable implant salvage technique: infection outcomes after mulcahy salvage procedure and replacement of infected inflatable penile prosthesis with malleable prosthesis. J Urol. 2016;195(3):694&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">26343986</ArticleId></ArticleIdList></Reference><Reference><Citation>Swords K, Martinez DR, Lockhart JL, et al. A preliminary report on the usage of an intracorporal antibiotic cast with synthetic high purity CaSO4 for the treatment of infected penile implant. J Sex Med. 2013;10(4):1162&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">23347377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman JM, Kaufman JL, Borges FD. Immediate salvage procedure for infected penile prosthesis. J Urol. 1998;159(3):816&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">9474157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosnitzer MS, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med. 2011;8(5):1521&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lightner DJ, Wymer K, Sanchez J, et al. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">31441676</ArticleId></ArticleIdList></Reference><Reference><Citation>EAU guidelines of sexual and reproductive health. 2020.  [cited 2020 Sept29]. Available from: https://uroweb.org/guideline/sexual-and-reproductive-health/#5.</Citation></Reference><Reference><Citation>Adamsky MA, Boysen WR, Cohen AJ, et al. Evaluating the role of postoperative oral antibiotic administration in artificial urinary sphincter and inflatable penile prosthesis explantation: a nationwide analysis. Urology. 2018;111:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747981</ArticleId><ArticleId IdType="pubmed">28964819</ArticleId></ArticleIdList></Reference><Reference><Citation>Dropkin BM, Chisholm LP, Dallmer JD, et al. Penile prosthesis insertion in the era of antibiotic stewardship-are postoperative antibiotics necessary? J Urol. 2020;203(3):611&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">31580192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34538619</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Hematospermia Etiology, Diagnosis, Treatment, and Sexual Ramifications: A Narrative Review.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>680</EndPage><MedlinePgn>669-680</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2021.07.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(21)00064-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Hematospermia (HS) is the presence of blood in ejaculatory fluid. It is a rare condition that is historically idiopathic or associated with sexual behavior. Technological advances have identified many of the etiologies behind HS, improving treatment. Though often benign, HS remains a source of considerable sexual anxiety for patients. Few papers have outlined a diagnostic and therapeutic approach to HS, and none have explicitly addressed its sexual consequences.</AbstractText><AbstractText Label="OBJECTIVES">To provide a comprehensive overview of HS, emphasizing its sexual ramifications.</AbstractText><AbstractText Label="METHODS">A PubMed literature search was performed through May 2021 to identify all relevant publications related to etiology, diagnosis, treatment, and sexual effects of HS. Original research and reviews were analyzed, and pertinent studies were included in this review.</AbstractText><AbstractText Label="RESULTS">Iatrogenic interventions (eg, transrectal ultrasound-guided prostate biopsies) are the most common cause of HS. Infection and/or nonspecific inflammation is the most common non-iatrogenic etiology. Malignancies, including prostate, testicular, and other genitourinary cancers, are rarely the cause of HS. Diagnostic approaches to HS can be organized according to patient age (less than or greater than 40 years old), persistence of bleeding, and the presence/absence of concerning symptoms. Though HS often spontaneously resolves, treatment may require various medications (eg, antibiotics, anti-inflammatories) or surgical interventions. HS has several sexual ramifications, including libido-affecting anxiety, social repercussions from sexual partners and non-sexual affiliates, increased risk of erectile dysfunction or transmission of sexual infections, and compromised fertility, especially when cryopreservation is utilized.</AbstractText><AbstractText Label="CONCLUSION">HS may significantly affect sexual health through several mechanisms, though there is a paucity of formal data on this subject. Further research is needed to fully understand the severity and extent of HS's effect on sexual well-being, especially in those with refractory bleeding. Drury RH, King B, Herzog B, et al. Hematospermia Etiology, Diagnosis, Treatment, and Sexual Ramifications: A Narrative Review. Sex Med Rev. 2022;10:669-680.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drury</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzog</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJG</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA. Electronic address: whellst@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051516" MajorTopicYN="Y">Hemospermia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Hematospermia</Keyword><Keyword MajorTopicYN="N">Infertility</Keyword><Keyword MajorTopicYN="N">Sexual</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>20</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34538619</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2021.07.004</ArticleId><ArticleId IdType="pii">S2050-0521(21)00064-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34520643</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0332-3102</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Irish medical journal</Title><ISOAbbreviation>Ir Med J</ISOAbbreviation></Journal><ArticleTitle>A 10-year Audit of Penile Prosthesis Insertion.</ArticleTitle><Pagination><StartPage>408</StartPage><MedlinePgn>408</MedlinePgn></Pagination><Abstract><AbstractText>Introduction Penile prosthesis (PP) insertion is the gold standard surgical treatment option for men with refractory Erectile Dysfunction (ED). PP insertion is considered effective but has a well-documented array of complications. Our aim was to assess outcomes following single-surgeon insertion of PP for ED within an Irish cohort. Methods Following review of the Hospital In-Patient Enquiry (HIPE) system, a retrospective chart review of all patients who underwent PP insertion over a 10-year period from 2008-2017 inclusive was performed, and an electronic database was analysed for results. Results One-hundred-and-eleven PPs were inserted in 96 patients. The most common aetiology for ED in our cohort was post-prostatectomy, affecting 25 (26%) patients. The most frequently implanted device was a 3-piece inflatable PP (3p-IPP) (AMS 700TM; American Medical Systems Inc., Minnesota, USA) and the peno-scrotal approach was utilised in the majority of patients (86, 77.5%). No intraoperative complications were recorded. Twelve (12.5%) patients developed peri-operative complications. Thirteen (13.5%) patients required device revision, the majority for device failure. Of the 71 patient satisfaction responses, 61 (85.9%) patients were satisfied with their PP. Conclusions This single-surgeon retrospective audit of PP surgery demonstrates complication rates in-line with internationally published data. Patients should be adequately counselled regarding possible complications, including device failure and erosion. PP insertion should be considered for suitable patients with refractory ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Looney</LastName><ForeName>A T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seery</LastName><ForeName>B E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>L C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Ir Med J</MedlineTA><NlmUniqueID>0430275</NlmUniqueID><ISSNLinking>0332-3102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">penis surgery</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34520643</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34452868</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Pathophysiology and Grayscale Ultrasonography of Penile Corporal Fibrosis.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>107</EndPage><MedlinePgn>99-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2021.07.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(21)00065-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Penile corporal fibrosis may occur secondary to explantation of an infected penile prosthesis, severe penile trauma, refractory low-flow priapism, Peyronie's disease, or chronic intra-cavernous injection of vasoactive drugs. Other etiologies of corporal fibrosis, presenting primarily with erectile dysfunction, can develop in chronic smokers, hypertensive patients, alcoholics, diabetics, and after radical prostatectomy. Corporal erectile tissue fibrosis is a significant pathophysiologic component of erectile dysfunction; however, current ultrasound-based penile imaging protocols do not directly assess it.</AbstractText><AbstractText Label="OBJECTIVE">To determine if grayscale ultrasonography (US) is a suitable imaging modality to identify and assess penile corporal erectile tissue fibrosis.</AbstractText><AbstractText Label="METHODS">A PubMed literature review was performed for studies that detailed ultrasonographic methods and findings of pathologies causing penile corporal fibrosis. Our main outcome measure was the ultrasonographic findings of pathologies causing penile corporal fibrosis.</AbstractText><AbstractText Label="RESULTS">Grayscale US demonstrates the capability to detect and localize the fibrotic changes of the corpora cavernosa. Ultrasonographic findings capture penile corporal tissue heterogeneity including diffuse, circumscribed, or localized patterns.</AbstractText><AbstractText Label="CONCLUSION">Overall, grayscale US may be a useful and convenient imaging modality to assess penile corporal fibrosis secondary to explantation of an infected penile prosthesis, priapism, penile trauma, chronic intra-cavernous injection of vasoactive drugs, diabetes, Peyronie's disease, and vascular disease. While limited by the skill and knowledge of the US operator, the combined knowledge of pathophysiology and US may help clinicians identify and manage the underlying etiology of penile corporal fibrosis. Kim J, Drury R, Morenas R et al. Pathophysiology and Grayscale Ultrasonography of Penile Corporal Fibrosis. Sex Med Rev 2022;10:99-107.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drury</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morenas</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>Omer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: oraheem@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Grayscale</Keyword><Keyword MajorTopicYN="N">Imaging</Keyword><Keyword MajorTopicYN="N">Penile Fibrosis</Keyword><Keyword MajorTopicYN="N">Ultrasound</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34452868</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2021.07.005</ArticleId><ArticleId IdType="pii">S2050-0521(21)00065-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34384079</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0399</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>11-12</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Urologia internationalis</Title><ISOAbbreviation>Urol Int</ISOAbbreviation></Journal><ArticleTitle>Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial.</ArticleTitle><Pagination><StartPage>935</StartPage><EndPage>943</EndPage><MedlinePgn>935-943</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000517364</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Stem cell therapy is a novel treatment with regenerative ability that can treat erectile dysfunction (ED). This phase 1/2 clinical trial (NCT02945449) using 2 consecutive intracavernous (IC) injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) was studied for the first time in the treatment of diabetic patients with ED. The primary outcome was to assess the safety and tolerability, and the secondary outcome was to assess the efficacy of 2 consecutive IC injections of allogeneic WJ-MSCs in diabetic ED.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Twenty-two diabetic patients with refractory ED were included. Two consecutive IC injections of allogeneic WJ-MSCs were performed. Tolerability was assessed immediately, and at 24 h, safety was evaluated for 12 months. Efficacy was assessed using International Index of Erectile Function-5 (IIEF-5), Erection Hardness Score (EHS), and Color Duplex Doppler Ultrasound for 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The procedure was well-tolerated. Minimal and transient adverse events were redness and bruising at the site of injections. There were no patient-reported serious adverse effects. There were significant improvements in IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV, all over the follow-up time points in comparison to the baseline.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first human study with proven tolerability, safety, and efficacy of IC injections of allogeneic WJ-MSCs for the treatment of diabetic patients with ED.</AbstractText><CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al Demour</LastName><ForeName>Saddam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adwan</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Histology, School of Medicine, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmeh</LastName><ForeName>Reem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhawari</LastName><ForeName>Hussam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awidi</LastName><ForeName>Abdalla</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Urol Int</MedlineTA><NlmUniqueID>0417373</NlmUniqueID><ISSNLinking>0042-1138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007597" MajorTopicYN="N" Type="Geographic">Jordan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059631" MajorTopicYN="N">Wharton Jelly</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34384079</ArticleId><ArticleId IdType="doi">10.1159/000517364</ArticleId><ArticleId IdType="pii">000517364</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">34304610</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1724-6075</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Urologia</Title><ISOAbbreviation>Urologia</ISOAbbreviation></Journal><ArticleTitle>Radical cystectomy and orthotopic neobladder in a patient with a preexisting three-components inflatable penile prosthesis.</ArticleTitle><Pagination><StartPage>3915603211033165</StartPage><MedlinePgn>3915603211033165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/03915603211033165</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">As erectile dysfunction is more commonly being diagnosed and treated with a preexisting inflatable penile prosthesis (IPP) insertion at younger ages, surgeons will increasingly encounter pre-placed abdominal reservoirs when performing pelvic surgery.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A 69-year-old Caucasian man with BCG refractory carcinoma-in-situ (CIS) and past history of non-invasive high-grade urothelial carcinoma of the bladder was a candidate for a radical cystectomy and an ileal-neobladder diversion. He had a three-components IPP inserted for the treatment of Peyronie disease and organic erectile dysfunction (ED). During the radical cystectomy the reservoir was encapsulated on the left lateral pelvic wall over the external iliac vessels. It was isolated and IPP was inflated to reduce the reservoir size. After accurate disinfection, the reservoir was removed from Retzius space without disconnecting it from the pump. Then, the radical cystectomy was carried out without any intraoperative complications and Studer ileal orthotopic neobladder was performed. At the end of the surgery, the reservoir was disinfected with the Mulcahy protocol and then placed in the same position.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A week after catheter removal the IPP was successfully activated. The patient's postoperative recovery was uneventful and no postoperative complication occurred. Definitive histological examination described a multifocal urothelial carcinoma of the bladder: pG3Tis N0 R0. The patient reports excellent functionality of the penile prosthesis and is currently using it.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sexual functionality preservation in oncologic patients should be pursued when possible. In this report, the functionality of the IPP was preserved, while still performing oncologically radical procedures. A multicenter study is needed to assure more solid recommendations on this rare procedure that is surely burdened by a lot of risks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rebez</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runti</LastName><ForeName>Ottavia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-5032-2863</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trombetta</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liguori</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urologia</MedlineTA><NlmUniqueID>0417372</NlmUniqueID><ISSNLinking>0391-5603</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Implantations</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">orthotopic neobladder</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">radical cystectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34304610</ArticleId><ArticleId IdType="doi">10.1177/03915603211033165</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34274824</PMID><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Sacral Neuromodulation for Lower Urinary Tract Symptoms: Effect of Therapy on Saudi Patient Sexual Function.</ArticleTitle><Pagination><StartPage>100388</StartPage><MedlinePgn>100388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2021.100388</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(21)00068-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sacral neuromodulation (SNM) is FDA-approved therapy for lower urinary tract and bowel dysfunction. It is newly introduced therapy in Saudi Arabia.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the effect of SNM therapy in both male and female Saudi patient's sexual function.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective cohort study was conducted for all patients who underwent SNM implantation from January 2016 till January 2020 at a single center in Jeddah, Saudi Arabia. Sexual function was assessed before and after treatment using International Index of Erectile Function (IIEF-5) for men and the Female Sexual Function Index (FSFI) for women.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Sexual function score changes from the baseline was reported. Correlation analysis was studied between IIEF-5 to assess erectile dysfunction and FSFI assessing desire, arousal, orgasm, pain and sexual satisfaction and other collected data including patient's age, functional diagnosis and post void residual (PVR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 13 total patients (8 female, 5 male) with mean age 47y (33-60). Diagnosis included non-obstructive urine retention (5), refractory overactive bladder (3), combined retention&#xa0;+&#xa0;over active bladder (OAB) (1), pelvic pain syndrome (3) and impotence in 1 patient. All male patients showed significant improvement in their IIEF-5 score from mean pre op 7.8 &#xb1;5.7 to post op sore of 19.8&#xb1;2.3 with significant p value p=0.003. Female patients showed significant improvement in their FSFI total score from baseline of 18.313&#xb1;7.4 to post-operative mean FSFI score 26.7&#xb1;1.8 with p value&#xa0;=&#xa0;0.013. Domains od FSFI which showed significant improvement were desire, arousal, orgasm and sexual satisfaction with p value =0.002, p=00.1,0.012, and p=0.015. Age, functional diagnosis and PVR did not show significant correlation with IIEF-5 and FSFI score.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that SNM might improve male and female sexual dysfunction regardless of patient's age and diagnosis. Banakhar MA, Younos A. Sacral neuromodulation for lower urinary tract symptoms: effect of therapy on Saudi patient sexual function. Sex Med 2021;9:100388.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banakhar</LastName><ForeName>Mai Ahmed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Urology Department, Consultant of Urology, King Abdulaziz University, Faculty of Medicine, Jeddah, Saudi Arabia. Electronic address: drmaibanakher@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youness</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Resident Urology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Female sexual function index (FSFI)</Keyword><Keyword MajorTopicYN="N">International index of Erectile function (IIEF-5)</Keyword><Keyword MajorTopicYN="N">Saudi patients with lower urinary tract symptoms</Keyword><Keyword MajorTopicYN="N">Sexual Function</Keyword><Keyword MajorTopicYN="N">sacral nerve stimulation</Keyword><Keyword MajorTopicYN="N">sacral neuromodulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>18</Day><Hour>20</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34274824</ArticleId><ArticleId IdType="pmc">PMC8360934</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2021.100388</ArticleId><ArticleId IdType="pii">S2050-1161(21)00068-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berman JR, Adhikari SP, Goldstein I. Anatomy and physiology of female sexual function and dysfunction: Classification, evaluation and treatment options. Eur Urol. 2000;38:20&#x2013;29. doi: 10.1159/000020247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000020247</ArticleId><ArticleId IdType="pubmed">10859437</ArticleId></ArticleIdList></Reference><Reference><Citation>23. Meston CM, Frohlich PF. Update on female sexual function. Curr Opin Urol. 2001;11:603&#x2013;609. doi: 10.1097/00042307-200111000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042307-200111000-00008</ArticleId><ArticleId IdType="pubmed">11734697</ArticleId></ArticleIdList></Reference><Reference><Citation>AlMogbel TA. Erectile Dysfunction and Other Sexual Activity Dysfunctions among Saudi Type 2 Diabetic Patients. Int J Health Sci (Qassim) 2014;8:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350889</ArticleId><ArticleId IdType="pubmed">25780354</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nozha M, Al-Maatouq M, Al-Mazrou Y. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">15573186</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EZ, Hofmann P, Niederwieser G. Sexuality in multiple sclerosis. J Neural Transm. 2005;112:1201&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750683</ArticleId></ArticleIdList></Reference><Reference><Citation>Redelman MJ. Sexual difficulties for persons with multiple sclerosis in New South Wales. Australia. Int J Rehabil Res. 2009;32:337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">19440157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronner G, Elran E, Golomb J. Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. Acta Neurol Scand. 2010;121:289&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">20070276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang Motta Guilherme, Quir&#xf3;z Yesica, Llorens Erika. The impact of neurogenic bladder bowel dysfunction in the sexuality of female spina bifida patients. J pediatric Urol. ,2021;19 doi: 10.1016/j.jpurol.2021.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpurol.2021.01.016</ArticleId><ArticleId IdType="pubmed">33546979</ArticleId></ArticleIdList></Reference><Reference><Citation>Banakhar M, Gazwani Y, Kelini ME. Effect of sacral neuromodulation on female sexual function and quality of life: are they correlated? Can Urol Assoc J. 2014;8:E762&#x2013;E767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250238</ArticleId><ArticleId IdType="pubmed">25485001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassouna M, Siegel S, Nyeholt A. Sacral neuromodulation in the treatment of urgency- frequency symptoms: A multicenter study on efficacy and safety. J Urol. 2000;163:1849&#x2013;1854. doi: 10.1016/S0022-5347(05)67558-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67558-1</ArticleId><ArticleId IdType="pubmed">10799197</ArticleId></ArticleIdList></Reference><Reference><Citation>Banakhar M, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder: An emerging tool for an old problem. Ther Adv Urol. 2012;4:179&#x2013;185. doi: 10.1177/1756287212445179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287212445179</ArticleId><ArticleId IdType="pmc">PMC3398598</ArticleId><ArticleId IdType="pubmed">22852028</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul - R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16:452&#x2013;455. doi: 10.1038/sj.ijir.3901248. PMID: 15175638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901248</ArticleId><ArticleId IdType="pubmed">15175638</ArticleId></ArticleIdList></Reference><Reference><Citation>Eduardo P Miranda 1, John P. Mulhall International index of erectile function erectile function domain vs the sexually health inventory for men: methodological challenges in the radical prostatectomy population. BJU Int. 2015;115:355&#x2013;356. doi: 10.1111/bju.12806. Epub 2014 Aug 11.PMID: 24823263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.12806</ArticleId><ArticleId IdType="pubmed">24823263</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis1 Tarek H, Gheit Samah Aboul, Saied Hanan S. Arabic Translation of Female Sexual Function Index and Validation in an Egyptian Population. J Sex Med. 2011;8:3370&#x2013;3378. doi: 10.1111/j.1743-6109.2011.02471. Epub 2011 Oct 13. PMID: 21995610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02471</ArticleId><ArticleId IdType="pubmed">21995610</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LF, Ka-Kit Leung G, Lui WM. Sacral nerve stimulation for neurogenic bladder. World Neurosurg. 2016;90:236&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">26960284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeates W. Ejaculatory disturbances. In: Pryor JP, Lipschultz L, editors. Andrology. Butter-worths; London: 1987. p. 183.</Citation></Reference><Reference><Citation>O'Connell HE, Eizenberg N, Rahman M. The anatomy of the distal vagina: towards unity. J Sex Med. 2008;5:1883&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">18564153</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Jiang X. Clinical autonomic neuro-physiology and the male sexual response: an overview. J Sex Med. 2009;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712633</ArticleId><ArticleId IdType="pubmed">19267845</ArticleId></ArticleIdList></Reference><Reference><Citation>Blok BF, Groen J, Bosch JL. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int. 2006;98:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill BC, Pizarro-Berdichevsky J, Bhattacha-ryya PK. Realtime changes in brain activity during sacral neuromodulation for overactive bladder. J Urol. 2017;198:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">28645869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren K, Egberg K. The sexual experience in younger males with complete spinal cord injury. Scand J Rehabil Med Suppl. 1983;9:189&#x2013;194. PMID: 6585940.</Citation><ArticleIdList><ArticleId IdType="pubmed">6585940</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlifue 1 SW, Gerhart KA, Menter RR. Sexual issues of women with spinal cord injuries. Paraplegia. 1992;30:192&#x2013;199. doi: 10.1038/sc.1992.54. PMID: 1630847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sc.1992.54</ArticleId><ArticleId IdType="pubmed">1630847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi G, Musco S, Kessler TM. Management of sexual dysfunction due to central nervous system disorders: a systematic review. BJU Int. 2015;115:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabihi N, Mourtzinos A, Maher MG. The effects of bilateral caudal epidural S2-4 neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:697&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">18060341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedro Simoes de Oliveira Jos&#xe9; Palma Reis Tiago Ribeiro de Oliveira David Martinho Ricardo Pereira e Silva Joao Marcelino Sandro Gaspar Francisco Martins Tome Lopes The Impact of Sacral Neuromodulation on Sexual Dysfunction. Curr Urol. 2018;12:188&#x2013;194. doi: 10.1159/000499307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000499307</ArticleId><ArticleId IdType="pmc">PMC6738141</ArticleId><ArticleId IdType="pubmed">31602184</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34274823</PMID><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Surgical Outcomes and Patient Satisfaction With the Low-Cost, Semi-Rigid Shah Penile Prosthesis: A boon to the Developing Countries.</ArticleTitle><Pagination><StartPage>100399</StartPage><MedlinePgn>100399</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100399</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2021.100399</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(21)00079-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In developing countries most patients with refractory erectile dysfunction cannot afford a penile prosthesis (PP) due to its cost and non-coverage by insurance companies.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the patient satisfaction outcomes with a novel, low-cost, semi-rigid PP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">52 patients who had received the Shah semi-rigid PP between January 2013 and December 2018 were included in this bidirectional study. Patient demographics including age, etiology, body mass index, length of PP received and post-operative complications were recorded. Patient satisfaction with the PP was evaluated using the modified Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome measures were overall satisfaction, total EDITS and mean EDITS score. The secondary outcome measures were residual penile tumescence, ease of concealment and post-operative complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of the patients was 38.79 years (25-68). Overall satisfaction (EDITS Q-1) of 4 (0-4) was reported by 84.62% (44/52) of patients. There was no significant difference (P &gt; .7) in the total EDITS and overall satisfaction based on various etiological factors. The mean EDITS scores (0-100) were 95.67 &#xb1; 10.76, 95.53 &#xb1; 8.46 and 91.72 &#xb1; 22.42 in 52 patients with BMI &lt;25, 25-29.9 and &gt;30 kg/m2 respectively. During sexual arousal after PP implantation, 26 (50%), 17 (32.7%) and 9 (17.3%) patients noted "good", "some" or "no" residual penile tumescence respectively. 47 (90.4%), 4 (7.7%) and 1 (1.9%) patients reported "good", "fair" and "poor" concealment respectively. In the prospective group, major and minor post-operative complications were seen in 10.7% (3/28) and 21.4% (6/28) of patients respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The semi-rigid Shah PP is a safe, effective and affordable option to treat patients with refractory ED. The ability to remove 1 or both sleeves in the Shah PP helps achieve a good fit with a small inventory. Krishnappa P, Tripathi A, Shah R. Surgical Outcomes and Patient Satisfaction With the Low-Cost, Semi-Rigid Shah Penile Prosthesis: A boon to the Developing Countries. Sex Med 2021;9:100399.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnappa</LastName><ForeName>Pramod</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Andrology, Department of Urology, NU Hospitals, Bangalore, India. Electronic address: Pramod23dr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Rupin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EDITS</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Residual Penile Tumescence</Keyword><Keyword MajorTopicYN="N">Semirigid Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Shah Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>18</Day><Hour>20</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34274823</ArticleId><ArticleId IdType="pmc">PMC8360909</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2021.100399</ArticleId><ArticleId IdType="pii">S2050-1161(21)00079-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bajic P, Mahon J, Faraday M. Etiology of erectile dysfunction and duration of symptoms in patients undergoing penile prosthesis: A systematic review. Sex Med Rev. 2020;8:333&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">31278064</ArticleId></ArticleIdList></Reference><Reference><Citation>Low WY, Ng CJ, Tan NC. Management of erectile dysfunction: Barriers faced by general practitioners. Asian J Androl. 2004;6:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15154082</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R. Twenty-five years of the low-cost, noninflatable, Shah Indian penile prosthesis: The history of its evolution. Indian J Urol. 2021;37:113&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8173931</ArticleId><ArticleId IdType="pubmed">34103792</ArticleId></ArticleIdList></Reference><Reference><Citation>Verze P, Capece M, Califano G, La Rocca R. Two-piece inflatable and semi-rigid penile implants: An effective alternative? Int J Impot Res. 2020;32:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">31685942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Penile prosthesis implant: scientific advances and technological innovations over the last four decades. Transl Androl Urol. 2017;6:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313299</ArticleId><ArticleId IdType="pubmed">28217449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lightner DJ, Wymer K, Sanchez J. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203:351&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">31441676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatem A, Kovac JR. Post-operative antibiotics following placement of a penile prosthesis. Transl Androl Urol. 2017;6(Suppl 5):S774&#x2013;S775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715177</ArticleId><ArticleId IdType="pubmed">29239400</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, Corty EW, Levine SB. EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001;166:932&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera M, Mulcahy J, Wen L. Is there still a place for malleable penile implants in the United States? Wilson's Workshop #18. Int J Impot Res. 2020 doi: 10.1038/s41443-020-00376-6. Epub ahead of print. PMID: 33273715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-020-00376-6</ArticleId><ArticleId IdType="pubmed">33273715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao M, Graydon RJ, Bieniek JM. Salvage penile prosthetic surgery utilizing temporary malleable implants. Transl Androl Urol. 2017;6(Suppl 5):S806&#x2013;S812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715178</ArticleId><ArticleId IdType="pubmed">29238660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chierigo F, Capogrosso P, Deh&#xf2; F. Long-Term follow-up after penile prosthesis implantation-survival and quality of life outcomes. J Sex Med. 2019;16:1827&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501062</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydman V, Pinar U, Abdessater M. Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: A single-centre experience. Basic Clin Androl. 2021;31:4. doi: 10.1186/s12610-021-00123-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12610-021-00123-x</ArticleId><ArticleId IdType="pmc">PMC7931532</ArticleId><ArticleId IdType="pubmed">33658014</ArticleId></ArticleIdList></Reference><Reference><Citation>Natali A, Olianas R, Fisch M. Penile implantation in Europe: Successes and complications with 253 implants in Italy and Germany. J Sex Med. 2008;5:1503&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AI, El-Dakhakhny A, Gabr AH. Post malleable penile prosthesis satisfaction in elderly patients: Serial assessments. Andrologia. 2019;51:e13399.</Citation><ArticleIdList><ArticleId IdType="pubmed">31502262</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tealab A, Farag M. Malleable penile implant is an effective therapeutic option in men with Peyronie's disease and erectile dysfunction. Sex Med. 2018;6:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815935</ArticleId><ArticleId IdType="pubmed">29336942</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;ayan S, A&#x15f;c&#x131; R, Efesoy O. Comparison of long-term results and couples' satisfaction with penile implant types and brands: lessons learned from 883 patients with erectile dysfunction who underwent penile prosthesis implantation. J Sex Med. 2019;16:1092&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">31155387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro MA, Barroso Filho HB, Mesquita FJ. Multiple site fracture of both rods in a malleable penile implant. Case Rep Urol. 2016;2016 doi: 10.1155/2016/9564904. Epub 2016 Mar 15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9564904</ArticleId><ArticleId IdType="pmc">PMC4811081</ArticleId><ArticleId IdType="pubmed">27066289</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrini L. Subrini penile implants: surgical, sexual and psychological results. Eur Urol. 1982;8:222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">7094964</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama N, Kishimoto T, Kanayama HO. Unusual trivial trauma may end with extrusion of a well-functioning penile prosthesis: A case report. J Med Case Rep. 2007;1:34. doi: 10.1186/1752-1947-1-34. PMID: 17594510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-1947-1-34</ArticleId><ArticleId IdType="pmc">PMC1913532</ArticleId><ArticleId IdType="pubmed">17594510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34247953</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Practical Considerations in Inflatable Penile Implant Surgery.</ArticleTitle><Pagination><StartPage>1320</StartPage><EndPage>1327</EndPage><MedlinePgn>1320-1327</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2021.05.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(21)00525-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Penile prosthesis implantation remains an effective solution for men with medical-refractory erectile dysfunction (ED) following radical pelvic surgery. Despite the distortion of pelvic anatomy, a penile implant can be performed with excellent clinical outcomes provided strict patient selection, proper preoperative workup and safe surgical principles are adhered to.</AbstractText><AbstractText Label="AIM">To provide practical recommendations on inflatable penile prosthesis (IPP) implantation in patients with medical-refractory ED, with an emphasis on patient selection and counselling, preoperative workup as well as surgical considerations to minimize intraoperative complications.</AbstractText><AbstractText Label="METHODS">A Medline search on relevant English-only articles on penile prostheses and pelvic surgery was undertaken and the following terms were included in the search for articles of interest: "bladder cancer", "prostate cancer", "rectal cancer", "pelvic surgery" and "inflatable penile implant".</AbstractText><AbstractText Label="OUTCOMES">Clinical key recommendations on patient selection, preoperative workup and surgical principles.</AbstractText><AbstractText Label="RESULTS">Patients should be made aware of the mechanics of IPP and the informed consent process should outline the benefits and disadvantages of IPP surgery, alternative treatment options, cost, potential prosthetic complications and patient's expectations on clinical outcomes. Specialised diagnostic test for workup for ED is often not necessary although preoperative workup should include screening for active infection and optimising pre-existing medical comorbidities. Precautionary measures should be carried out to minimise infective complication. Corporal dilation and reservoir placement can be challenging in this group, and surgeons may require knowledge of advanced reconstructive surgical techniques when dealing with specific cases such as coexisting Peyronie's disease and continence issue.</AbstractText><AbstractText Label="CLINICAL TRANSLATION">Strict patient selection and counselling process coupled with safe surgical principles are important to achieve excellent linical outcomes and patient satisfaction rates.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS">This masterclass paper provides an overview of the practical considerations for men who are undergoing IPP surgery following radical pelvic surgery. Limitations include the lack of highquality data and detailed surgical description on each surgical troubleshooting steps for various prosthetic-related complications.</AbstractText><AbstractText Label="CONCLUSION">The IPP implantation can be performed efficiently and safely in patients following radical pelvic surgery. Chung E, Mulhall J. Practical Considerations in Inflatable Penile Implant Surgery. J Sex Med 2021;18:1320-1327.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AndroUrology Centre, Brisbane QLD, Australia; Princess Alexandra Hospital, University of Queensland, Brisbane QLD, Australia; Macquarie University Hospital, Sydney, NSW, Australia. Electronic address: ericchg@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulhall</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical outcomes</Keyword><Keyword MajorTopicYN="N">Inflatable penile prosthesis</Keyword><Keyword MajorTopicYN="N">Patient selection</Keyword><Keyword MajorTopicYN="N">Radical pelvic surgery</Keyword><Keyword MajorTopicYN="N">Surgical challenges</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>12</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34247953</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2021.05.017</ArticleId><ArticleId IdType="pii">S1743-6095(21)00525-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34237684</PMID><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>A Case Report of Large Bowel Obstruction in a Patient With an Inflatable Penile Prosthesis.</ArticleTitle><Pagination><StartPage>100391</StartPage><MedlinePgn>100391</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100391</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2021.100391</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(21)00071-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prostheses (IPP) consist of 2 cylinders implanted into the corpora cavernosa, a pump placed in the scrotum, and a saline-filled reservoir traditionally placed in the space of Retzius. IPPs are used to treat refractory erectile dysfunction with few rare, but serious, complications. Cases of reservoirs causing erosion into the bladder, small bowel obstructions, vascular compression, and inguinal herniation have been described.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We highlight the importance of keeping a broad differential diagnosis when assessing patients with bowel obstructions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 68-year-old man with a previous IPP placement presented with left lower quadrant abdominal pain, constipation and obstipation for 5 days. On exam, he was afebrile, and noted to have a firm, distended, tympanic abdomen. CT scan showed a distended cecum at 11 cm, narrowing of the proximal sigmoid with adjacent inflammatory changes, and minimal peri-colonic air, suggestive of a localized perforation. The IPP reservoir was seen in the left iliac fossa, coinciding with the lead point of the obstruction, suggesting that the reservoir may have itself caused the obstruction. The patient was taken to the operating room for an emergent exploratory laparotomy, which revealed a mass in the colon abutting the IPP reservoir.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Considerations for IPP component explantation, factors considered for reintervention, and preservation of penile length with avoidance of penile fibrosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A left colectomy with transverse colostomy was successfully performed and the IPP reservoir was explanted. Intraoperative frozen section revealed adenocarcinoma. Upon initial review of the imaging, it was thought that the IPP reservoir may have caused the obstruction, but intraoperatively, the colonic tumor was found to be the culprit.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although complications related to IPPs, including bowel obstructions, have been previously described in the literature, treatment for large bowel obstructions must take into account all possible etiologies, including malignancy. Atri E, Mallory C, Perez A, et&#xa0;al. A Case Report of Large Bowel Obstruction in a Patient With an Inflatable Penile Prosthesis. Sex Med 2021;9:100391.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atri</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallory</LastName><ForeName>Chase</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Columbia University Division of Urology at Mount Sinai Medical Center, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordon</LastName><ForeName>Billy H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Columbia University Division of Urology at Mount Sinai Medical Center, Miami, FL, USA. Electronic address: billy.cordon@msmc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adenocarcinoma</Keyword><Keyword MajorTopicYN="N">Bowel Obstruction</Keyword><Keyword MajorTopicYN="N">Five-Step Technique</Keyword><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Large Bowel Obstruction</Keyword><Keyword MajorTopicYN="N">Reservoir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>20</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34237684</ArticleId><ArticleId IdType="pmc">PMC8360932</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2021.100391</ArticleId><ArticleId IdType="pii">S2050-1161(21)00071-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Markogiannakis H, Messaris E, Dardamanis D. Acute mechanical bowel obstruction: Clinical presentation, etiology, management and outcome. World J Gastroenterol. 2007;13:432&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065900</ArticleId><ArticleId IdType="pubmed">17230614</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe T, Thompson WM. Large-bowel obstruction in the adult: Classic radiographic and CT findings, etiology, and mimics. Radiology. 2015;275:651&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">25997131</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PH, Tee YS, Fu CY. The role of noncontrast CT in the evaluation of surgical abdomen patients. Am Surg. 2018;84:1015&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">29981641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-nejad H, Sharma A, Irwin RJ. Reservoir herniation as a complication of three-piece penile prosthesis insertion. Urology. 2001;57:142&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RP. Small bowel obstruction secondary to migration of an inflatable penile prosthesis reservoir: Recognition and prevention. J Urol. 1988;139:1053&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283378</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther MM, O'brien DP. Re: Small bowel obstruction secondary to migration of an inflatable penile prosthesis reservoir: Recognition and prevention. J Urol. 1989;142:141&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">2733092</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I, Godec CJ. Asynchronous erosion of inflatable penile prosthesis into small and large bowel. J Urol. 1992;147:709&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">1538467</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgarten AS, Kavoussi M, Vandyke ME. Avoiding deep pelvic complications using a 'Five-Step' technique for high submuscular placement of inflatable penile prosthesis reservoirs. BJU Int. 2020;126:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">32400957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34215514</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1166-7087</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie</Title><ISOAbbreviation>Prog Urol</ISOAbbreviation></Journal><ArticleTitle>Penile prosthesis implantation: A single center 25 years of experience.</ArticleTitle><Pagination><StartPage>663</StartPage><EndPage>670</EndPage><MedlinePgn>663-670</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.purol.2021.06.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1166-7087(21)00163-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We analyzed the long-term results of malleable and inflatable penile prosthesis: the rates of complications, revision surgery and patient satisfaction.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Between January 1996 and December 2020, a total of 138 patients underwent implantation of a malleable or inflatable types penile prosthesis. The data of the patients were derived from the patient files and digital recording system. The patients were contacted face-to-face interaction if possible. If it is not possible, phone connection was made.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of patients was 56 (21-83) years. Fourteen (10.2%) 1-piece, 46 (33.3%) 2-piece and 78 (56.5%) 3-piece penile prosthesis were implanted. The mostly used perioperative antibiotic was teicoplanin+amikacin in 107 patients. Total complication rate was 30% (n=42). Prosthesis infection constituted 9% (n=13) of these complications. The total satisfaction rate was 89.1%. There was no correlation between the complications and antibiotic regimen or prosthesis type (P=0.488, P=0.454, respectively). The rate of infection showed a slight increase in 3-piece penile prosthesis without any statistically significance (P=0.633). The patients with complications expressed more dissatisfaction compared to those without complications (P=0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In our series, penile prosthesis implantation seems to be a recommended treatment method with high patient satisfaction in the treatment of refractory erectile dysfunction.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">4.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Topuz</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey. Electronic address: drbtopuz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebilo&#x11f;lu</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zor</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaya</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sar&#x131;kaya</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emrah Co&#x11f;uplugil</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;rdal</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedir</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>G&#xfc;lhane Training and Research Hospital, Department of Urology, 06010 Etlik, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Prog Urol</MedlineTA><NlmUniqueID>9307844</NlmUniqueID><ISSNLinking>1166-7087</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infection de proth&#xe8;se</Keyword><Keyword MajorTopicYN="N">La satisfaction du patient</Keyword><Keyword MajorTopicYN="N">Patient satisfaction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Prosthesis infection</Keyword><Keyword MajorTopicYN="N">Proth&#xe8;se p&#xe9;nienne</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34215514</ArticleId><ArticleId IdType="doi">10.1016/j.purol.2021.06.002</ArticleId><ArticleId IdType="pii">S1166-7087(21)00163-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34213492</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Modified malleable prosthesis with a fixed mesh: case series for the Ghattas technique.</ArticleTitle><Pagination><StartPage>167</StartPage><EndPage>170</EndPage><MedlinePgn>167-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/aja.aja_55_21</ELocationID><Abstract><AbstractText>Penile prosthetic implantation represents a cornerstone for patients with organic erectile dysfunction (ED) that is refractory, unsatisfactory, or contra-indicated for other approved medical or mechanical options. In this study, we introduce the "Ghattas technique," wherein we constructed a polypropylene mesh sheath that surrounds and is fixed to a 13-mm malleable prosthesis cylinder, which can increase the cylinder diameter for cases that need a larger prosthesis. All patients underwent preoperative evaluation and completed the five-item International Index of Erectile Function questionnaire (IIEF-5). Postoperative outcomes were evaluated by IIEF-5 and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaires at final follow-up. The mean age of the 23 included patients was 57.9 (standard deviation [s.d.]: 11.4) years and the mean duration of ED was 8.5 (s.d.: 7.9) years. Erection improvement was determined by comparing mean preoperative and postoperative IIEF-5 scores (8.3 [s.d.: 3.9] vs 24.6 [s.d.: 0.6], P &lt; 0.001). High treatment satisfaction was determined according to a mean EDITS score of 94.9 (s.d.: 9.9). The proposed Ghattas technique was safe and effective in our patients, and provides opportunity for cases that need a diameter larger than 13 mm. Further studies are needed to confirm these results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghattas</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Dar-elzokora Center of Andrology, Alexandria 21500, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doheim</LastName><ForeName>Mohamed Fahmy</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Alexandria Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotb</LastName><ForeName>Hossam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dar-elzokora Center of Andrology, Alexandria 21500, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013526" MajorTopicYN="N">Surgical Mesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">mesh</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">surgical technique</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34213492</ArticleId><ArticleId IdType="pmc">PMC8887114</ArticleId><ArticleId IdType="doi">10.4103/aja.aja_55_21</ArticleId><ArticleId IdType="pii">319894</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans C. The use of penile prostheses in the treatment of impotence. Br J Urol. 1998;81:591&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9598633</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitarelli A, Divenuto L, Fortunato F, Falco A, Pagliarulo V, et al. Long-term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl. 2013;85:133&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24085235</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, Terlecki R, Brant W. The evolution and utility of the Small-Carrion prosthesis, its impact, and progression to the modern-day malleable penile prosthesis. J Sex Med. 2015;12(Suppl 7):423&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26565570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghattas O, Doheim MF, Burnett AL. A letter to the editor on the original article: spontaneous penile tumescence by sparing cavernous tissue in the course of malleable penile prosthesis implantation. J Sex Med. 2020;17:1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">32340918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, Palazzo S, Saracino GA, et al. Penile prostheses. Ther Adv Urol. 2010;2:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126066</ArticleId><ArticleId IdType="pubmed">21789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, Corty EW, Levine SB, Levine F, Burnett AL. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss D, Gabouev AI, Jonas U, Nikolaj A. Bogoraz (1874&#x2013;1952): pioneer of phalloplasty and penile implant surgery. J Sex Med. 2005;2:139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422917</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdemir F, Okulu E, Kay&#x131;gil &#xd6;. Long-term outcomes of AMS Spectra&#xae; penile prosthesis implantation and satisfaction rates. Int J Impot Res. 2017;29:184&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28424506</ArticleId></ArticleIdList></Reference><Reference><Citation>Casab&#xe9; A, Sarotto N, Gutierrez C, Bechara AJ. Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models. Int J Impot Res. 2016;28:228&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27557609</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrianne R, Balde S, De Leval J, Kempeners P, Mormont C. Penile prosthesis in case of impotence: 12 years of clinical experience. Acta Urol Belg. 1995;63:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">7725996</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin ZC, Guo YL, Choi HK. A retrospective study of 548 cases of erectile dysfunction treated by penile prosthesis implantation. Chin J Urol. 2005;21:755&#x2013;7.</Citation></Reference><Reference><Citation>Haney NM, Huang MM, Liu JL, Hawksworth DJ, Burnett AL. Acellular dermal matrix tissues in genitourinary reconstructive surgery: a review of the literature and case discussions. Sex Med Rev. 2020 Doi: 10.1016/j.sxmr.2020.07.003. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">32917558</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">25905326</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK279101</ArticleId></ArticleIdList><Book><Publisher><PublisherName>MDText.com, Inc.</PublisherName><PublisherLocation>South Dartmouth (MA)</PublisherLocation></Publisher><BookTitle book="endotext">Endotext</BookTitle><PubDate><Year>2000</Year></PubDate><BeginningDate><Year>2000</Year></BeginningDate><AuthorList Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Feingold</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Professor of Medicine Emeritus, University of California, San Francisco, CA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anawalt</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine, University of Washington</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackman</LastName><ForeName>Marc R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Sr. Physician Scientist, Washington DC VA Medical Center; Professor of Medicine &amp; Rehabilitation Medicine, Georgetown University; Clinical Professor of Medicine, Biochemistry and Molecular Medicine, George Washington University; and Professor of Medicine (Part-time), Johns Hopkins University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Endocrinologist and Associate Research Physician in the Skeletal Diseases and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrousos</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Professor of Pediatrics and Endocrinology, Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corpas</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>M.D. Ph.D in Gerontology. Honorary Professor of Medicine, Universidad de Alcal&#xe1;, Madrid. Consultant in Endocrinology, Hospital HLA Guadalajara (Spain).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Herder</LastName><ForeName>Wouter W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Professor of Endocrine Oncology, Erasmus MC and Erasmus MC Cancer Center, Rotterdam, the Netherlands</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhatariya</LastName><ForeName>Ketan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Consultant in Diabetes, Endocrinology and General Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust and University of East Anglia, Norwich, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofland</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Consultant Endocrinologist, Erasmus MC and Erasmus MC Cancer Center, Rotterdam, the Netherlands</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dungan</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Ohio State University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofland</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Consultant Endocrinologist, Erasmus MC and Erasmus MC Cancer Center, Rotterdam, the Netherlands</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Consultant Endocrinologist, Department of Endocrinology, Bharti Hospital, Karnal, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaltsas</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Professor of General Medicine-Endocrinology, 1st Department of Propaedeutic Medicine, National and Kapodistrian University of Athens, Athens, Greece</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Professor of Endocrinology, Department of Endocrinology, Diabetes and Metabolism, Christian Medical College &amp; Hospital, Vellore, Tamil Nadu, India, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Professor, The University of Tennessee Health Science Center, Memphis, Tennessee</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Professor of Medicine and Chief of the Division of Endocrinology, Diabetology and Metabolism, University of Lausanne, Switzerland</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korbonits</LastName><ForeName>M&#xe1;rta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Professor of Endocrinology and Metabolism, Centre Lead for Endocrinology and Deputy Institute Director, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, England</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>University Research Professor and Professor of Medicine (Endocrinology and Metabolism), Obstetrics &amp; Gynecology, and BioMedical Sciences, at Memorial University of Newfoundland in St. John&#x2019;s, Newfoundland, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuohung</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Director of the Division of Reproductive Endocrinology at Boston Medical Center and an Associate Professor of Obstetrics and Gynecology at the Boston University School of Medicine</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laferr&#xe8;re</LastName><ForeName>Blandine</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Professor of Medicine, New York Nutrition Obesity Research Center, Division of Endocrinology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Miles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Consultant endocrinologist at University Hospitals of Leicester and Honorary Associate Professor at Leicester University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Professor of Obstetrics and Gynecology at the University of Vermont and Director of the Division of Reproductive Endocrinology and Infertility. Burlington, Vermont</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLachlan</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Director of Clinical Research, Hudson Institute of Medical Research; Consultant Endocrinologist, Monash Medical Centre, Melbourne, Australia</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>New</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Professor of Pediatrics, Professor of Genetics and Genomic Sciences, and Chief of the Adrenal Steroid Disorders Program, Icahn School of Medicine, Mount Sinai School of Medicine, New York, NY</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purnell</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Professor of Medicine, Knight Cardiovascular Institute and the Division of Endocrinology, and Associate Director, Bob and Charlee Moore Institute for Nutrition and Wellness, Oregon Health and Science University, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahay</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Professor and Head of Department of Endocrinology, Osmania Medical College and Osmania General Hospital, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Director of the Endocrine/Bone Disease Program, Saint Johns Cancer Institute at Saint John&#x2019;s Health Center, Santa Monica, CA; Clinical Professor of Medicine, UCLA School of Medicine, Los Angeles, CA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Professorial Lecturer, Division of Pediatric Endocrinology and Diabetes, Icahn School of Medicine at Mount Sinai, New York, NY. Emeritus Professor and Chair, Department of Pediatrics, University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratakis</LastName><ForeName>Constantine A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>CSO, ELPEN, Inc. &amp; Director, Research Institute, Athens, Greece &amp; Senior Investigator, Human Genetics &amp; Precision Medicine, FORTH (ITE), Heraklion, Greece. Emeritus Scientific Director &amp; Senior Investigator, NICHD, NIH, Bethesda, MD, USA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trence</LastName><ForeName>Dace L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Professor of Medicine, Emeritus, University of Washington, Seattle, WA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Don P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Endowed Chair, Cardiovascular Health and Risk Prevention, Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX</Affiliation></AffiliationInfo></Author></AuthorList><Medium>Internet</Medium></Book><ArticleTitle book="endotext" part="sex-dysfunction-diab">Sexual Dysfunction in Diabetes</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Shindel</LastName><ForeName>Alan W.</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Professor, Department of Urology, University of California, San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Tom F.</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Professor, Department of Urology, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Diabetes is an increasingly prevalent problem that has been associated very strongly with sexual problems in both men and women. Diabetes has numerous end organ effects and also exerts a substantial psychological toll which may predispose diabetic people to sexual problems. Erectile Dysfunction (ED) is common in men with diabetes; these men tend to present with more severe and refractory ED compared to non-diabetic peers. While ED is the best-established diabetes-related sexual dysfunction, ejaculatory and sexual desires issues may also occur in men with diabetes. Women with diabetes are also at risk for sexual dysfunction. Sexual health inquiry is an important aspect of diabetes care. Importantly, lifestyle change and close management of diabetes has been associated with improvements in sexual function. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.</AbstractText><CopyrightInformation>Copyright &#xa9; 2000-2023, MDText.com, Inc.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.ABSTRACT">ABSTRACT</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.INTRODUCTION">INTRODUCTION</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.EPIDEMIOLOGY">EPIDEMIOLOGY</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.PATHOGENESIS">PATHOGENESIS</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.TREATMENT_OF_ED_WIT">TREATMENT OF ED WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5I)</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.TREATMENT_OF_ED_WIT_1">TREATMENT OF ED WITH OTHER MODALITIES</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.PENILE_PROSTHETICS">PENILE PROSTHETICS</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.EXPERIMENTAL_THERAP">EXPERIMENTAL THERAPIES FOR ED</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.TREATMENT_OF_LOW_TE">TREATMENT OF LOW TESTOSTERONE LEVELS</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.EJACULATORY_DYSFUNC">EJACULATORY DYSFUNCTION</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.FEMALE_SEXUAL_DYSFU">FEMALE SEXUAL DYSFUNCTION</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.THE_IMPORTANCE_OF_M">THE IMPORTANCE OF MANAGING LIFESTYLE FACTORS IN TREATING SEXUAL PROBLEMS IN DIABETES</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.CONCLUSION">CONCLUSION</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.SUMMARY">SUMMARY</SectionTitle></Section><Section><SectionTitle book="endotext" part="sex-dysfunction-diab" sec="sex-dysfunction-diab.REFERENCES">REFERENCES</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>6</Month><Day>8</Day></ContributionDate><ReferenceList><Reference><Citation>Jacobson A.M., Braffett B.H., Cleary P.A., Dunn R.L., Larkin M.E., Wessells H., et al. Relationship of urologic complications with health-related quality of life and perceived value of health in men and women with type I diabetes: the Diabetes Control and Complications Trial/Epidemiology of Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care. 2015 Oct;38(10):1904&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4580606</ArticleId><ArticleId IdType="pubmed">26203062</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H.A., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouidrat, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34:1185&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">28722225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenov Z.A. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):141&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25502583</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch D.K., et al. The natural history of impotence in diabetic men. Diabetologia. 1984;26(6):437&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">6468793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi J. The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management. CUrr Diabetes Rev. 2017;13:573&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">27875946</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartledge J.J., Eardley I., Morrison J.F. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int. 2001;87(4):402&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11251537</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz de Tejada I., et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989;320(16):1025&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">2927481</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel DP., et al. Serum Biomarkers of Erectile Dysfunction in Diabetes Mellitus: A Systematic Review of Current Literature. Sex Med Rev. 2017;5:339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">28579439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP., et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018 Aug;200(2):423&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">29601923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor D, et al. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl. 2007 Dec;30(6):500&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">18028199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandona P, et al. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male. 2008 Sep;11(3):107&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821286</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy. J Endocrinol Invest. 2007 Nov;30(10):880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhasin S., et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715&#x2013;1744.</Citation><ArticleIdList><ArticleId IdType="pubmed">29562364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, et al. Identification of late-onset hypogonadism, in middle-aged and elderly men. N Engl J Med. 2010 Jul 8;363(2):123&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20554979</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean R, et al. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin NA. 2005 Nov;32(4):379&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351051</ArticleId><ArticleId IdType="pubmed">16291031</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I., et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610037</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz de Tejada I., et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453954</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrend L., Vibe-Petersen J., Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res. 2005;17(3):264&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15674401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008 Feb;25(2):138&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">18290855</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K, et al. Chronic treatment with a type 5 Phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signaling in a rat model of diabetic erectile dysfunction. Eur Urol. 2008;53:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">18243503</ArticleId></ArticleIdList></Reference><Reference><Citation>DeYoung LX, et al. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alteration in cavernous tissue of diabetic rats. Eur Urol. 2008;54:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342431</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, et al. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol. 2009;181:245&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">19013603</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008 Jan;25(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199130</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Brock G, Lee J, Shapiro J, van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640769</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200(3):633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004;23:149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15146094</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton J.P., et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13(6):317&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11918246</ArticleId></ArticleIdList></Reference><Reference><Citation>Perimenis P., et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl. 2006;8(2):219&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16491275</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa A, et al. Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012 Dec 3;72(17):2243&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder R.E., et al. Impotence in diabetes: aetiology, implications for treatment and preferred vacuum device. Diabet Med. 1992;9(10):893&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1478032</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoz T., et al. The use of iliac bone flap as a penile stiffener in a diabetic patient with erectile dysfunction. Plast Reconstr Surg. 1999;103(7):1975&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10359262</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy J.J., et al. The penile implant for erectile dysfunction. J Sex Med. 2004;1(1):98&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422990</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Estrada C.R., Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001;166(3):932&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F., et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000;37(1):50&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop J.R., et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol. 1992;147(2):386&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159(5):1537&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cakan M., et al. Risk factors for penile prosthetic infection. Int Urol Nephrol. 2003;35(2):209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15072498</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JD, et al. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. Ther Adv Urol. 2019 Mar 29;11:1756287219838364. doi: 10.1177/1756287219838364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287219838364</ArticleId><ArticleId IdType="pmc">PMC6444401</ArticleId><ArticleId IdType="pubmed">30956690</ArticleId></ArticleIdList></Reference><Reference><Citation>Spivak et al. Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction in Diabetic Patients. Sex Med Rev. 2019 Aug 1:S2050-0521(19)30072-1. doi: 10.1016/j.sxmr.2019.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Buvat J, et al. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006 Dec;24(6):657&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor D, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006 Jun;154(6):899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">16728551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor D, et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur j Endocrinol. 2007 May;156(5):595&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianatti E.J., Dupuis P., Hoermann R., Zajac J.D., Grossmann M. Effects of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014 Oct;99(10):3821&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24978674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett G., Cole N., Bhartia M., Kennedy D., Raju J., Wilkinson P., et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014 Feb;68(2):203&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355040</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement P, Giuliano F. Physiology and Pharmacology of Ejaculation. Basic Clin Pharmacol Toxicol. 2016 Oct;119 suppl 3:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">26709195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamischke A., Nieschlag E. Update on medical treatment of ejaculatory disorders. Int J Androl. 2002;25(6):333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12406365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasi P.A., Fanciulli G., Delitala G. Successful treatment of retrograde ejaculation with the alpha1-adrenergic agonist methoxamine: case study. Int J Impot Res. 2005;17(3):297&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15674403</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldi A., Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res. 2010;47:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">20358461</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitzer J., Alder J. Diabetes and female sexual health. Women's health. 2009;5:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19863466</ArticleId></ArticleIdList></Reference><Reference><Citation>Parish SJ., et al. The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. Sex Med Rev. 2021;9:36&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">32800563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.C., et al. Sexually responsive vascular tissue of the vulva. BJU Int. 2006;97(4):766&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16536770</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso S., et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16579999</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito K, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006 Jul-Aug;18(4):405&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16395320</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito K, et al. Mediterranean diet improves sexual function in women with the metabolic syndrome. Int J Impot Res. 2007 Sep-Oct;19(5):486&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing R.R., Bond D.S., Gendrano I. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diabetes Care. 2013 Oct;26(10):29. N 3rd, Wadden, T., Bahnson, J., Lewis, C.E., et al.</Citation></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25905326</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34017115</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Topically delivered nitric oxide acts synergistically with an orally administered PDE5 inhibitor in eliciting an erectile response in a rat model of radical prostatectomy.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>580</EndPage><MedlinePgn>573-580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-021-00451-6</ELocationID><Abstract><AbstractText>Patients undergoing radical prostatectomy (RP) have a high incidence of postoperative erectile dysfunction (ED) refractory to treatment by oral phosphodiesterase-5 inhibitors (PDE5i). In the present studies, we investigated if a topically applied, nitric oxide microparticle delivery system (NO-MP) might act synergistically with an oral PDE5i (sildenafil) to improve erectile function outcomes in a rat model of RP. Thirty-five Sprague-Dawley rats underwent bilateral transection of the cavernous nerve (CN) for 1 week. After 1 week, animals were orally administered 0, 0.05, or 0.005&#x2009;mg sildenafil/kg and the erectile response following topical application to the penile shaft of 250 or 100&#x2009;mg NO-MP, or blank-MP, was monitored over a 2-h timeframe by recording the intracorporal pressure normalized to systemic blood pressure (ICP/BP, N&#x2009;=&#x2009;5 animals/treatment group). Oral treatment with sildenafil by itself resulted in no observable erectile response. However, a combination of orally administered 0.05 sildenafil/kg with topical application of 250&#x2009;mg NO-MP, compared to 250&#x2009;mg NO-MP by itself, resulted in significantly more spontaneous erections (4.6 compared to 2 erections per hour, t-test; p value&#x2009;=&#x2009;0.043), with a significantly faster onset for the first erectile response (11 compared to 22&#x2009;min; t-test, p value&#x2009;=&#x2009;0.041). Our results demonstrate a synergistic effect between orally administered PDE5i and topically applied NO-MP in eliciting an erectile response. Furthermore, they suggest a potential novel therapeutic approach to treat men with ED resulting from RP, through combination therapy of a topically applied NO-MP and an orally administered PDE5i.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tar</LastName><ForeName>Moses T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joel M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draganski</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Zylo Therapeutics, Inc, Greenville, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Kelvin P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0002-0201-9210</Identifier><AffiliationInfo><Affiliation>Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA. kelvin.davies@einsteinmed.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY, USA. kelvin.davies@einsteinmed.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 DK123969</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK109314</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 DK121587</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="Y">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34017115</ArticleId><ArticleId IdType="mid">NIHMS1703010</ArticleId><ArticleId IdType="pmc">PMC8842897</ArticleId><ArticleId IdType="doi">10.1038/s41443-021-00451-6</ArticleId><ArticleId IdType="pii">10.1038/s41443-021-00451-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rawla P Epidemiology of Prostate Cancer. World J Oncol 2019; 10(2): 63&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497009</ArticleId><ArticleId IdType="pubmed">31068988</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough AR. Sexual Dysfunction after Radical Prostatectomy. Reviews in Urology 2005; 7(Suppl 2): S3&#x2013;S10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1477599</ArticleId><ArticleId IdType="pubmed">16985895</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Anastasiadis AG. Erectile dysfunction. Annu Rev Med 2003; 54: 153&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">12525671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med 2006; 3(3): 442&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16681469</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin GD, Yaxley JW, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19(8): 1051&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">30017351</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Musicki B. The nitric oxide signaling pathway in the penis. Curr Pharm Des 2005; 11(31): 3987&#x2013;3994.</Citation><ArticleIdList><ArticleId IdType="pubmed">16378505</ArticleId></ArticleIdList></Reference><Reference><Citation>Sezen SF, Lagoda G, Burnett AL. Neuronal nitric oxide signaling regulates erection recovery after cavernous nerve injury. J Urol 2012; 187(2): 757&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4474518</ArticleId><ArticleId IdType="pubmed">22177198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghalayini IF. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. Int J Impot Res 2004; 16(6): 459&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170(2): 843&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">2166511</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T 2013; 38(7): 407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776492</ArticleId><ArticleId IdType="pubmed">24049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol 2018; 175(13): 2554&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003652</ArticleId><ArticleId IdType="pubmed">29667180</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120(2): 151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275456</ArticleId></ArticleIdList></Reference><Reference><Citation>Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20(5): 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650827</ArticleId></ArticleIdList></Reference><Reference><Citation>Tar M, Cabrales P, Navati M, Adler B, Nacharaju P, Friedman AJ et al. Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy. J Sex Med 2014; 11(12): 2903&#x2013;2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257846</ArticleId><ArticleId IdType="pubmed">25302850</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, Tar M, Kuppam DS, Friedman A, Melman A, Friedman J et al. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med 2010; 7(1 Pt 1): 224&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864537</ArticleId><ArticleId IdType="pubmed">19765204</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuzeid WM, Girish VM, Fastenberg JH, Draganski AR, Lee AY, Nosanchuk JD et al. Nitric oxide-releasing microparticles as a potent antimicrobial therapeutic against chronic rhinosinusitis bacterial isolates. Int Forum Allergy Rhinol 2018; 8(10): 1190&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">30044542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Mavelli GV, Nacharaju P, Li K, Cleare LG, Nosanchuk JD et al. Novel nitric oxide-generating platform using manuka honey as an anti-biofilm strategy in chronic rhinosinusitis. Int Forum Allergy Rhinol 2020; 10(2): 223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">31834677</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganski A, Tar MT, Villegas G, Friedman JM, Davies KP. Topically Applied Curcumin-Loaded Nanoparticles Treat Erectile Dysfunction in a Rat Model of Type-2 Diabetes. J Sex Med 2018; 15(5): 645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826927</ArticleId><ArticleId IdType="pubmed">29699754</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur S, Sikka SC, Knight GE, Burnstock G, Hellstrom WJ. Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. Asian J Androl 2010; 12(3): 415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739254</ArticleId><ArticleId IdType="pubmed">20305675</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B, Shao Y, Omerovic E. Influence of anesthetic agent, depth of anesthesia and body temperature on cardiovascular functional parameters in the rat. Lab Anim 2014; 48(1): 6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23985835</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar T, Sharp J, Lawson D. Heart rates of male and female Sprague-Dawley and spontaneously hypertensive rats housed singly or in groups. J Am Assoc Lab Anim Sci 2011; 50(2): 175&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061417</ArticleId><ArticleId IdType="pubmed">21439210</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakus S, Musicki B, Navati MS, Friedman JM, Davies KP, Burnett AL. NO-Releasing Nanoparticles Ameliorate Detrusor Overactivity in Transgenic Sickle Cell Mice via Restored NO/ROCK Signaling. J Pharmacol Exp Ther 2020; 373(2): 214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160861</ArticleId><ArticleId IdType="pubmed">32144123</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19(1): 12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushiyama M, Kuramochi T, Katayama S. Treatment with hypotensive agents affects the impaired relaxation of the penile corpus cavernosum in hypertensive rats. Hypertens Res 2006; 29(7): 523&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17044665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi A, Costantini E, Scroppo FI, Silvani M, Kopa Z, Illiano E et al. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. Andrology 2019; 7(6): 804&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790582</ArticleId><ArticleId IdType="pubmed">31350821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Brock G, Oelke M, Fode M, Probst KA, Henneges C et al. Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy--Results from a Randomized Controlled Trial (REACTT). J Sex Med 2016; 13(4): 679&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33996350</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2186-3644</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Intractable &amp; rare diseases research</Title><ISOAbbreviation>Intractable Rare Dis Res</ISOAbbreviation></Journal><ArticleTitle>Perspectives on urological care in multiple sclerosis patients.</ArticleTitle><Pagination><StartPage>62</StartPage><EndPage>74</EndPage><MedlinePgn>62-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5582/irdr.2021.01029</ELocationID><Abstract><AbstractText>Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. Lower urinary tract dysfunction due to MS includes a dysfunction of the storage phase or dysfunction of the voiding phase or a detrusor-sphincter dyssynergia. Baseline evaluation includes a voiding chart, an ultrasound scan of the urinary tract, urine culture, and an urodynamic study. For storage symptoms, antimuscarinics are the first-line treatment, and clean intermittent catheterization (CIC) is indicated if there is concomitant incomplete bladder emptying. Intradetrusor injections with botulinum toxin A (BTX-A), are recommended for refractory cases. Urinary diversion is rarely indicated. For patients with voiding symptoms, CIC and alpha-blockers are usually offered. Sexual dysfunction in patients with MS is multifactorial. Phosphodiesterase type 5 inhibitors are first-line therapies for MS-associated erectile dysfunction in both male and female patients. This review summarizes the epidemiology, pathogenesis, risk factors, genetic, clinical manifestations, diagnostic tests, and management of MS. Lastly, the urologic outcomes and therapies are reviewed.</AbstractText><CopyrightInformation>2021, International Research and Cooperation Association for Bio &amp; Socio - Sciences Advancement.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chairman of Urology Department, Lebanese University &amp; Al Zahraa Hospital, University Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou Chakra</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Department, Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papatsoris</LastName><ForeName>Athanasios G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabboucy</LastName><ForeName>Baraa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Urology, Children's National Hospital, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, The George Washington University, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dellis</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology/General Surgery, Areteion Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fares</LastName><ForeName>Youssef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intractable Rare Dis Res</MedlineTA><NlmUniqueID>101586847</NlmUniqueID><ISSNLinking>2186-3644</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lower urinary tract dysfunction</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurogenic bladder</Keyword><Keyword MajorTopicYN="N">urology</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33996350</ArticleId><ArticleId IdType="pmc">PMC8122310</ArticleId><ArticleId IdType="doi">10.5582/irdr.2021.01029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017; 19:1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241505</ArticleId><ArticleId IdType="pubmed">28367411</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019; 26:27-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30300457</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WJ, Chen WW, Zhang X. Multiple sclerosis: pathology, diagnosis and treatments. Exp Ther Med. 2017; 13:3163-3166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450788</ArticleId><ArticleId IdType="pubmed">28588671</ArticleId></ArticleIdList></Reference><Reference><Citation>Klocke S, Hahn N. Multiple sclerosis. Ment Health Clin. 2019; 9:349-358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6881109</ArticleId><ArticleId IdType="pubmed">31857931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020; 133:1380-1390.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704606</ArticleId><ArticleId IdType="pubmed">32682869</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg MM. Multiple sclerosis review. P T. 2012; 37:175-184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351877</ArticleId><ArticleId IdType="pubmed">22605909</ArticleId></ArticleIdList></Reference><Reference><Citation>Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019; 32:365-377.</Citation><ArticleIdList><ArticleId IdType="pubmed">30985372</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi M, Rocca MA. Rethinking multiple sclerosis treatment strategies. Lancet Neurol. 2020; 19:281-282.</Citation><ArticleIdList><ArticleId IdType="pubmed">32199086</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999; 161:743-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">10022678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid TM, Hollander JB. Multiple sclerosis and the neurogenic bladder. Phys Med Rehabil Clin N Am. 1998; 9:615-629.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894113</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015; 14:720-732.</Citation><ArticleIdList><ArticleId IdType="pubmed">26067125</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharony SM, Lam O, Corcos J. Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. Can Urol Assoc J. 2017; 11:61-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403674</ArticleId><ArticleId IdType="pubmed">28443147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornic J, Panicker JN. The management of lower urinary tract dysfunction in multiple sclerosis. Curr Neurol Neurosci Rep. 2018; 18:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022518</ArticleId><ArticleId IdType="pubmed">29956001</ArticleId></ArticleIdList></Reference><Reference><Citation>Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016; 172:3-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718593</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V&#xe9;csei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006; 13:700-722.</Citation><ArticleIdList><ArticleId IdType="pubmed">16834700</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18:269-285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372756</ArticleId><ArticleId IdType="pubmed">30679040</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MK. Immunopathogenesis of multiple sclerosis. Ann Indian Acad Neurol. 2009; 12:215-220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824947</ArticleId><ArticleId IdType="pubmed">20182567</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004; 106:246-248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15177777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Br&#xfc;ck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002; 125(Pt 10):2202-2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12244078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikbin B, Bonab MM, Khosravi F, Talebian F. Role of B cells in pathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007; 79:13-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewitt MS, Boyd GW. The role of insulin-like growth factors and insulin-like growth factor-binding proteins in the nervous system. Biochem Insights. 2019; 12:1178626419842176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472167</ArticleId><ArticleId IdType="pubmed">31024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesik D, Wilczak N, De Keyser J. The insulin-like growth factor system in multiple sclerosis. Int Rev Neurobiol. 2007; 79:203-226.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S, Guillen M, Pays L. TGFB1-mediated gliosis in multiple sclerosis spinal cords is favored by the regionalized expression of HOXA5 and the age-dependent decline in androgen receptor ligands. Int J Mol Sci. 2019; 20:5934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6928867</ArticleId><ArticleId IdType="pubmed">31779094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PW, Severin ME, Lovett-Racke AE. TGF-&#x3b2; regulation of encephalitogenic and regulatory T cells in multiple sclerosis. Eur J Immunol. 2017; 47:446-453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5499671</ArticleId><ArticleId IdType="pubmed">28102541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci. 2013; 333:76-87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726569</ArticleId><ArticleId IdType="pubmed">23578791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Br&#xfc;ck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 2000; 123 (Pt 6):1174-1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825356</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets. 2012; 11:545-555.</Citation><ArticleIdList><ArticleId IdType="pubmed">22583442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013; 13(12 Suppl):3-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24289836</ArticleId></ArticleIdList></Reference><Reference><Citation>Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019; 6:1905-1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764632</ArticleId><ArticleId IdType="pubmed">31392849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Li R, Yan JW, Wan YN, Tao JH, Chen B, Huang XL, Yang GJ, Wang J, Ye DQ. The epidemiology of alcohol consumption and multiple sclerosis: a review. Neurol Sci. 2015; 36:189-196.</Citation><ArticleIdList><ArticleId IdType="pubmed">25388777</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004; 3:709-718.</Citation><ArticleIdList><ArticleId IdType="pubmed">15556803</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnell GP, Booth DR. The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities. Front Immunol. 2017; 8:425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394466</ArticleId><ArticleId IdType="pubmed">28458668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cree BA. Multiple sclerosis genetics. Handb Clin Neurol. 2014; 122:193-209.</Citation><ArticleIdList><ArticleId IdType="pubmed">24507519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019; 26:27-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30300457</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch MW, Ilnytskyy Y, Golubov A, Metz LM, Yong VW, Kovalchuk O. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. Eur J Neurol. 2018; 25:651-658.</Citation><ArticleIdList><ArticleId IdType="pubmed">29316044</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018; 391:1622-1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">29576504</ArticleId></ArticleIdList></Reference><Reference><Citation>Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011; 9:409-416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151595</ArticleId><ArticleId IdType="pubmed">22379455</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrower BW. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology. 2007; 68:S12-S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin FD, Reingold SC, Cohen JA, et al. . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83:278-286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117366</ArticleId><ArticleId IdType="pubmed">24871874</ArticleId></ArticleIdList></Reference><Reference><Citation>Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018; 8:a028928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6120692</ArticleId><ArticleId IdType="pubmed">29358317</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshamrani F, Alnajashi H, Freedman M. Radiologically isolated syndrome: watchful waiting vs. active treatment. Expert Rev Neurother. 2017; 17:441-447.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830953</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017; 389:1336-1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">27889190</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;merhoca S, Akka&#x15f; SY, &#x130;&#xe7;en NK. Multiple sclerosis: diagnosis and differential diagnosis. Noro Psikiyatr Ars. 2018; 55:S1-S9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278620</ArticleId><ArticleId IdType="pubmed">30692847</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi M, Preziosa P, Banwell BL, et al. . Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019; 142:1858-1875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598631</ArticleId><ArticleId IdType="pubmed">31209474</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung HP, Graf J, Aktas O, Mares J, Barnett MH. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. Curr Opin Neurol. 2019; 32:327-337.</Citation><ArticleIdList><ArticleId IdType="pubmed">30985371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med (Lond). 2020; 20:380-383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385797</ArticleId><ArticleId IdType="pubmed">32675142</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019; 9:55-78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613013</ArticleId><ArticleId IdType="pubmed">31308790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamout B, Sahraian M, Bohlega S, et al. . Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020; 37:101459.</Citation><ArticleIdList><ArticleId IdType="pubmed">31670208</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassari LE, Fox RJ. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs. 2018; 78:1549-1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">30255442</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2019; 28:1051-1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">31603362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Options Neurol. 2018; 20:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">29627873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sand PK, Sand RI. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis Mon. 2013; 59:261-268.</Citation><ArticleIdList><ArticleId IdType="pubmed">23786660</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews KL, Husmann DA. Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc. 1997; 72:1176-1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413302</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissbart SJ, Pechersky D, Malykhina A, Bavaria T, Parrillo L, Arya LA, Bilello M, Wein AJ, Smith AL. The impact of pontine disease on lower urinary tract symptoms in patients with multiple sclerosis. Neurourol Urodyn. 2017; 36:453-456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505067</ArticleId><ArticleId IdType="pubmed">26741487</ArticleId></ArticleIdList></Reference><Reference><Citation>de S&#xe8;ze M, Ruffion A, Denys P, Joseph PA, Perrouin- Verbe B; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007; 13:915-928.</Citation><ArticleIdList><ArticleId IdType="pubmed">17881401</ArticleId></ArticleIdList></Reference><Reference><Citation>G h e z z i A, C a r o n e R, D e l P o p o l o G, e t a l. Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurol Sci. 2011; 32:1223-1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">21948057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009; 80:470-477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19372287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann A, Kaeder M, Greulich W, Lax H, Priebel J, Kirschner-Hermanns R, F&#xfc;sgen I. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases. World J Urol. 2013; 31:229-233.</Citation><ArticleIdList><ArticleId IdType="pubmed">22227822</ArticleId></ArticleIdList></Reference><Reference><Citation>Averbeck MA, Iacovelli V, Panicker J, Schurch B, Finazzi Agr&#xf2; E. Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group. Neurourol Urodyn. 2020; 39:73-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">31746485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ph&#xe9; V, Pakzad M, Curtis C, Porter B, Haslam C, Chataway J, Panicker JN. Urinary tract infections in multiple sclerosis. Mult Scler. 2016; 22:855-861.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892318</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher SG, Dillon BE, Gilchrist AS, Haverkorn RM, Yan J, Frohman EM, Lemack GE. Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Mult Scler. 2013; 19:1169-1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">23339136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ineichen BV, Schneider MP, Hlavica M, Hagenbuch N, Linnebank M, Kessler TM. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler. 2018; 24:529-534.</Citation><ArticleIdList><ArticleId IdType="pubmed">28367674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan V, Chen WM, Jain R, De S, Monga M. Multiple sclerosis and nephrolithiasis: a matched-case comparative study. BJU Int. 2017; 119:919-925.</Citation><ArticleIdList><ArticleId IdType="pubmed">28220601</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico E, Chisari CG, Arena S, Zangh&#xec; A, Toscano S, Lo Fermo S, Maimone D, Castaing M, Sciacca S, Zappia M, Patti F. Cancer risk and multiple sclerosis: evidence from a large Italian cohort. Front Neurol. 2019; 10:337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469363</ArticleId><ArticleId IdType="pubmed">31024431</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie RA, Maxwell C, Mahar A, Ekuma O, McClintock C, Seitz D, Webber C, Groome PA. Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study. Neurology. 2021; 96:e501-e512.</Citation><ArticleIdList><ArticleId IdType="pubmed">33239364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew-Starowicz M, Gianotten WL. Sexual dysfunction in patients with multiple sclerosis. Handb Clin Neurol. 2015; 130:357-370.</Citation><ArticleIdList><ArticleId IdType="pubmed">26003254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009; 9:341-350.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271943</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsamo R, Arcaniolo D, Stizzo M, Illiano E, Autorino R, Natale F, Costantini E, Damiano R, De Sio M. Increased risk of erectile dysfunction in men with multiple sclerosis: an Italian cross-sectional study. Cent European J Urol. 2017; 70:289-295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656369</ArticleId><ArticleId IdType="pubmed">29104793</ArticleId></ArticleIdList></Reference><Reference><Citation>Marck CH, Jelinek PL, Weiland TJ, Hocking JS, De Livera AM, Taylor KL, Neate SL, Pereira NG, Jelinek GA. Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics: an international cross-sectional study. BMC Neurol. 2016; 16:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097380</ArticleId><ArticleId IdType="pubmed">27814701</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo S, Kinzy T, Thompson N, Gales S, Stone L, Sullivan A. Factors associated with sexual dysfunction in individuals with multiple sclerosis: implications for assessment and treatment. Int J MS Care. 2018; 20:191-197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107343</ArticleId><ArticleId IdType="pubmed">30150904</ArticleId></ArticleIdList></Reference><Reference><Citation>Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006; 56:78-105.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam J, Gross MD, Cheung A, Melville PM, Kim JM, Weissbart SJ. Fluid intake and urinary symptoms in patients with multiple sclerosis. J Urol. 2020; 204:1284-1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">32924823</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyronnet B, Krupp LB, Reynolds WS, Gam&#xe9; X, Amarenco G, Cornu JN, Ryerson LZ, Sammarco CL, Howard JE, Charlson RW, Dmochowski RR, Brucker BM. Nocturia in Patients With Multiple Sclerosis. Rev Urol. 2019; 21:63-73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6864911</ArticleId><ArticleId IdType="pubmed">31768133</ArticleId></ArticleIdList></Reference><Reference><Citation>Block V, Rivera M, Melnick M, Allen DD. Do physical therapy interventions affect urinary incontinence and quality of life in people with multiple sclerosis?: an evidence-based review. Int J MS Care. 2015; 17:172-180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542712</ArticleId><ArticleId IdType="pubmed">26300703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bientinesi R, Gandi C, Bassi P. Managing urological disorders in multiple sclerosis patients: a review of available and emerging therapies. Int Neurourol J. 2020; 24:118-126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332813</ArticleId><ArticleId IdType="pubmed">32615673</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011; 4:139-168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105633</ArticleId><ArticleId IdType="pubmed">21694816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016; 5:51-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739981</ArticleId><ArticleId IdType="pubmed">26904412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergic medication in MS: Adding insult to injury? Mult Scler Relat Disord. 2012; 1:156-161.</Citation><ArticleIdList><ArticleId IdType="pubmed">25877263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas R, Young C, Friede T. Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf. 2010; 9:905-915.</Citation><ArticleIdList><ArticleId IdType="pubmed">20569078</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol. 2016; 5:63-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739988</ArticleId><ArticleId IdType="pubmed">26904413</ArticleId></ArticleIdList></Reference><Reference><Citation>Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011; 37:642-648.</Citation><ArticleIdList><ArticleId IdType="pubmed">22099277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010; 184:1011-1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">20643431</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurch B, Carda S. OnabotulinumtoxinA and multiple sclerosis. Ann Phys Rehabil Med. 2014; 57:302-314.</Citation><ArticleIdList><ArticleId IdType="pubmed">24953702</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, Apostolidis A, Hamid R, Dasgupta P, Kessler TM, Fowler CJ. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011; 185:1344-1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">21334639</ArticleId></ArticleIdList></Reference><Reference><Citation>Averbeck MA, Moreno-Palacios J, Aparicio A. Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction? Int Braz J Urol. 2020; 46:891-901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527110</ArticleId><ArticleId IdType="pubmed">32758301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ph&#xe9; V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016; 13:275-288.</Citation><ArticleIdList><ArticleId IdType="pubmed">27030526</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubaro A, Puccini F, De Nunzio C, Digesu GA, Elneil S, Gobbi C, Khullar V. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. Curr Urol Rep. 2012; 13:335-342.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886612</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth JH, Sahai A, Panicker JN. Lower urinary tract dysfunction in multiple sclerosis. Curr Bladder Dysfunct Rep. 2012; 7:97-104.</Citation></Reference><Reference><Citation>Akakpo W, Chartier-Kastler E, Joussain C, Denys P, Lubetzki C, Ph&#xe9; V. Outcomes of ileal conduit urinary diversion in patients with multiple sclerosis. Neurourol Urodyn. 2020; 39:771-777.</Citation><ArticleIdList><ArticleId IdType="pubmed">31951678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey JM, Stoffel JT. Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms. Investig Clin Urol. 2016; 57:377-383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109793</ArticleId><ArticleId IdType="pubmed">27847911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyndaele JJ. Self-intermittent catheterization in multiple sclerosis. Ann Phys Rehabil Med. 2014; 57:315-320.</Citation><ArticleIdList><ArticleId IdType="pubmed">24951384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde MH, McMahon JM, McDonald MV, Tang W, Wang W, Brasch J, Fairbanks E, Shah S, Zhang F, Chen DG. Self-management intervention for long-term indwelling urinary catheter users: randomized clinical trial. Nurs Res. 2015; 64:24-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4268883</ArticleId><ArticleId IdType="pubmed">25502058</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995; 153:1114-1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7869476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider MP, Tornic J, S&#xfd;kora R, Abo Youssef N, Mordasini L, Krhut J, Chartier-Kastler E, Davies M, Gajewski J, Schurch B, Bachmann LM, Kessler TM. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2019; 38:1482-1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">31099113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahfouz W, Corcos J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur J Phys Rehabil Med. 2011; 47:639-650.</Citation><ArticleIdList><ArticleId IdType="pubmed">22081065</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldred-Evans D, Dasgupta P. Use of botulinum toxin for voiding dysfunction. Transl Androl Urol. 2017; 6:234-251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422676</ArticleId><ArticleId IdType="pubmed">28540231</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo ZN, He SY, Zhang HL, Wu J, Yang Y. Multiple sclerosis and sexual dysfunction. Asian J Androl. 2012; 14:530-535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720075</ArticleId><ArticleId IdType="pubmed">22447199</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf6;ttgen J, Rose A, van de Vis W, Engelbrecht J, Pirard M, Lau S, Heesen C, K&#xf6;pke S; RiMS Special Interest Group Psychology and Neuropsychology. Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review. PLoS One. 2018; 13:e0193381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828449</ArticleId><ArticleId IdType="pubmed">29486006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol D. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol. 2004; 171:1189-1193; discussion 1193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14767298</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33784020</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2927</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Andrology</Title><ISOAbbreviation>Andrology</ISOAbbreviation></Journal><ArticleTitle>Intra-cavernous injection of BOTOX<sup>&#xae;</sup> (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial.</ArticleTitle><Pagination><StartPage>1166</StartPage><EndPage>1175</EndPage><MedlinePgn>1166-1175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/andr.13010</ELocationID><Abstract><AbstractText Label="BACKGROUND">Erectile dysfunction (ED) is a socioeconomic problem.There are several options for its management including intra-cavernosal injection (ICI).</AbstractText><AbstractText Label="OBJECTIVE">To compare the safety, efficacy, and durability of ICI of onabotulinum toxin-A (BTX) in different doses (50 and 100 U) against placebo (saline) in the management of vasculogenic ED non-responding to pharmacological therapy (phosphodiesterase type 5 inhibitors or/and ICI of trimix).</AbstractText><AbstractText Label="MATERIALS AND METHODS">A prospective randomized double-blind placebo-controlled trial was conducted between July 2016 and February 2019. A total of 176 patients were randomly assigned (1:1:1) to one of the treatment sequences: Botox 100 U group (BTX-100; 62 patients), Botox 50 U group (BTX-50; 59 patients), or placebo group (55 patients). All patients were followed up for 6 months.</AbstractText><AbstractText Label="RESULTS">Significant improvement in all parameters, that is, SHIM score &amp; Erection Hardness Score (EHS), Sexual Encounter Profile (SEP), Global Assessment Score (GAS), and Doppler parameters (p&#xa0;&lt;&#xa0;0.001) was observed in patients of BTX-100 and BTX-50 groups with maximum improvement at 3rd month of treatment. Around 40% of patients were responders and were able to engage in sexual intercourse. Patients in placebo group did not experience significant improvement (p&#xa0;=&#xa0;0.264). It was noted that at the 2nd week and 3rd months after treatment, there was no statistically significant difference in the improvement of these parameters in BTX-100 and BTX-50 groups (p&#xa0;&gt;&#xa0;0.05). In the 6th month, there was a statistically significant difference between the aforementioned groups in favor of BTX-100 (p&#xa0;&lt;&#xa0;0.01).</AbstractText><AbstractText Label="CONCLUSIONS">Only one-time ICI of BTX (50 U and 100 U) is effective and safe for the treatment of refractory ED. This agent has a considerable long duration of action, particularly BTX-100U seems to be more durable.</AbstractText><CopyrightInformation>&#xa9; 2021 American Society of Andrology and European Academy of Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Shaer</LastName><ForeName>Waleed</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4337-9375</Identifier><AffiliationInfo><Affiliation>Department of Urology, Banha University Hospital, Banha, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanem</LastName><ForeName>Hussein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Andrology Department, Cairo University Hospitals, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Tamer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Banha University Hospital, Banha, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abo-Taleb</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Banha University Hospital, Banha, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandeel</LastName><ForeName>Wael</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Banha University Hospital, Banha, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Andrology</MedlineTA><NlmUniqueID>101585129</NlmUniqueID><ISSNLinking>2047-2919</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="C000629279">onabotulinum toxin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int Braz J Urol. 2022 Nov-Dec;48(6):990-991</RefSource><PMID Version="1">36173411</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019274" MajorTopicYN="N">Botulinum Toxins, Type A</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ICI</Keyword><Keyword MajorTopicYN="N">PDE5Is</Keyword><Keyword MajorTopicYN="N">SHIM score</Keyword><Keyword MajorTopicYN="N">botox</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33784020</ArticleId><ArticleId IdType="doi">10.1111/andr.13010</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Jannini EA, Sternbach N, Limoncin E, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med. 2014;11(1):40-50.</Citation></Reference><Reference><Citation>Ismail EA, El-Sakka AI. Innovative trends and perspectives for erectile dysfunction treatment: a systematic review. Arab J Urol. 2016;14(2):84-93.</Citation></Reference><Reference><Citation>Capogrosso P, Ventimiglia E, Boeri L, et al. Age at first presentation for erectile dysfunction: analysis of changes over a 12-yr period. Eur Urol Focus. 2018;5:899-905. https://doi.org/10.1016/j.euf.2018.02.006</Citation></Reference><Reference><Citation>Liu Q, Zhang Y, Wang J, et al. Erectile dysfunction and depression: a systematic review and meta-analysis. J Sex Med. 2018;15(8):1073-1082. https://doi.org/10.1016/j.jsxm.2018.05.016</Citation></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.</Citation></Reference><Reference><Citation>Le TV, Tsambarlis P, Hellstrom WJG. Pharmacodynamics of the agents used for the treatment of erectile dysfunction. Expert Opin Drug Metab Toxicol. 2019;15(2):121-131. https://doi.org/10.1080/17425255.2019.1560421</Citation></Reference><Reference><Citation>Engeler D (chairman), Baranowski AP, Elneil S, et al.. European Association of Urology Guidelines. Published online 2012.</Citation></Reference><Reference><Citation>Giuliano F, Brock G. Botox for erectile dysfunction. J Sex Med. 2017;14(2):177-178.</Citation></Reference><Reference><Citation>Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using Tadalafil. Sex Med. 2018;50:3. https://doi.org/10.1016/j.esxm.2018.11.008</Citation></Reference><Reference><Citation>Chung E. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions. Expert Opin Biol Ther. 2015;15(1):95-102.</Citation></Reference><Reference><Citation>Tang Q, Chen C, Wang X, et al. Botulinum toxin A improves adipose tissue engraftment by promoting cell proliferation, adipogenesis and angiogenesis. Int J Mol Med. 2017;40(3):713-720. https://doi.org/10.3892/ijmm.2017.3073</Citation></Reference><Reference><Citation>Zhou Y, Liu Y, Hao Y, et al. The mechanism of botulinum A on Raynaud syndrome. Drug Des Devel Ther. 2018;12:1905-1915. https://doi.org/10.2147/DDDT.S161113</Citation></Reference><Reference><Citation>Ghanem HM. Re: botox for erectile dysfunction. J Sex Med. 2017;14(6):865. https://doi.org/10.1016/j.jsxm.2017.04.662</Citation></Reference><Reference><Citation>Bernie HL, Segal R, Le B, Burnett A, Bivalacqua TJ. An empirical vs risk-based approach algorithm to intracavernosal injection therapy: a prospective study. Sex Med. 2017;5(1):e31-e36. https://doi.org/10.1016/j.esxm.2016.08.001</Citation></Reference><Reference><Citation>Sikka SC, Hellstrom WJG, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction. J Sex Med. 2013;10(1):120-129. https://doi.org/10.1111/j.1743-6109.2012.02825.x</Citation></Reference><Reference><Citation>Wessells H, Lue TF, Mcaninch JW. Penile length in the flaccid and erect states: guidelines for penile augmentation. J Urol. 1996;156(3):995-997. https://doi.org/10.1016/S0022-5347(01)65682-9</Citation></Reference><Reference><Citation>Chen CJ, Kuo TBJ, Tseng Y-J, Yang CCH. Combined cardiac sympathetic excitation and vagal impairment in patients with non-organic erectile dysfunction. Clin Neurophysiol. 2009;120(2):348-352.</Citation></Reference><Reference><Citation>Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7(2):31-39.</Citation></Reference><Reference><Citation>Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the international index of erectile function scale. Eur Urol. 2011;60(5):1010-1016. https://doi.org/10.1016/j.eururo.2011.07.053</Citation></Reference><Reference><Citation>Ghanem H, Raheem AA, AbdelRahman IFS, Johnson M, Abdel-Raheem T. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6(1):135-142. https://doi.org/10.1016/j.sxmr.2017.07.008</Citation></Reference><Reference><Citation>Punjani N, Campbell J, De Young L, et al. 032 An evolving hypothesis on the mechanism and efficacy of intracavernosal injection of botulinum toxin to improve erectile function: an animal study in aging rats. J Sex Med. 2018;15(7):S137-S138.</Citation></Reference><Reference><Citation>De Young L, Campbell J, Radomski S, Alzubaidi R, Brock G. 142 intracavernosal injection of botulinum toxin to improve erectile function in older rats. J Sex Med. 2017;14(1):S40-S41. https://doi.org/10.1016/j.jsxm.2016.11.091</Citation></Reference><Reference><Citation>Giuliano F, Joussain C, Denys P. Safety and efficacy of intracavernosal injections of AbobotulinumtoxinA (Dysport&#xae;) as add on therapy to phosphosdiesterase type 5 inhibitors or prostaglandin E1 for erectile dysfunction-case studies. Toxins (Basel). 2019;11(5): https://doi.org/10.3390/toxins11050283</Citation></Reference><Reference><Citation>Stridh A, Pont&#xe9;n M, Arver S, Kirsch I, Ab&#xe9; C, Jensen KB. Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials: a systematic review and meta-analysis. JAMA Netw open. 2020;3(3):e201423. https://doi.org/10.1001/jamanetworkopen.2020.1423</Citation></Reference><Reference><Citation>Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol. 2016;195(5):1550-1555. https://doi.org/10.1016/j.juro.2015.12.049</Citation></Reference><Reference><Citation>Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187(5):1769-1775. https://doi.org/10.1016/j.juro.2011.12.117</Citation></Reference><Reference><Citation>Bearelly P, Phillips EA, Pan S, et al. Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. Int J Impot Res. 2020;32(3):345-351. https://doi.org/10.1038/s41443-019-0186-z</Citation></Reference><Reference><Citation>Krzastek SC, Bopp J, Smith RP, Kovac JR. Recent advances in the understanding and management of erectile dysfunction [version 1; referees: 2 approved]. F1000Research. 2019;8:102. https://doi.org/10.12688/f1000research.16576.1</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33658014</PMID><DateRevised><Year>2021</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2051-4190</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Basic and clinical andrology</Title><ISOAbbreviation>Basic Clin Androl</ISOAbbreviation></Journal><ArticleTitle>Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience.</ArticleTitle><Pagination><StartPage>4</StartPage><MedlinePgn>4</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12610-021-00123-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 130 patients received a PP (median age: 62.5&#x2009;years [IQR: 58-69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5-7]). Median follow-up was 6.3&#x2009;years [IQR: 4-9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p&#x2009;=&#x2009;0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frydman</LastName><ForeName>Valentine</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, GRC n 5, Predictive Onco-Urology, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinar</LastName><ForeName>Ugo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, GRC n 5, Predictive Onco-Urology, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdessater</LastName><ForeName>Maher</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, GRC n 5, Predictive Onco-Urology, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akakpo</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, APHP, H&#xf4;pitaux universitaires Piti&#xe9;-Salp&#xea;tri&#xe8;re-Charles Foix, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grande</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, APHP, H&#xf4;pitaux universitaires Piti&#xe9;-Salp&#xea;tri&#xe8;re-Charles Foix, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audouin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, APHP, H&#xf4;pital Tenon, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozer</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, APHP, H&#xf4;pitaux universitaires Piti&#xe9;-Salp&#xea;tri&#xe8;re-Charles Foix, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chartier-Kastler</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, APHP, H&#xf4;pitaux universitaires Piti&#xe9;-Salp&#xea;tri&#xe8;re-Charles Foix, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seisen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, GRC n 5, Predictive Onco-Urology, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roupret</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Sorbonne Universit&#xe9;, GRC n 5, Predictive Onco-Urology, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, F-75013, Paris, France. morgan.roupret@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Basic Clin Androl</MedlineTA><NlmUniqueID>101640161</NlmUniqueID><ISSNLinking>2051-4190</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText>R&#xe9;SUM&#xe9;: CONTEXTE: La proth&#xe8;se p&#xe9;nienne (PP) est. le traitement de r&#xe9;f&#xe9;rence de la dysfonction &#xe9;rectile (DE) r&#xe9;fractaire aux m&#xe9;dicaments. Le but de ce travail est. d&#x2019;&#xe9;valuer les r&#xe9;sultats &#xe0; long terme chez les patients trait&#xe9;s par proth&#xe8;ses p&#xe9;niennes (PP) dans notre h&#xf4;pital. R&#xe9;SULTATS: Un total de 130 patients a eu une pose de PP (&#xe2;ge m&#xe9;dian: 62,5 ans [IQR: 58&#x2013;69]; score m&#xe9;dian de l&#x2019;indice international de la fonction &#xe9;rectile (IEEF-5): 6 [IQR: 5&#x2013;7]). Le suivi m&#xe9;dian &#xe9;tait de 6.3 ans [IQR: 4&#x2013;9.4]. Trente-deux (24,6%) patients ont eu une reprise chirurgicale, dont 20 &#xe9;taient des retraits de PP (15,4%). La dur&#xe9;e de vie global des PP &#xe9;tait de 84,6% et la pose ant&#xe9;rieure de PP &#xe9;tait un facteur de risque pour l&#x2019;ablation (p&#x2009;=&#x2009;0,02). Il y a eu six (4,6%) &#xe9;v&#xe9;nements perop&#xe9;ratoires ne mettant pas la vie en danger, dont deux qui ont emp&#xea;ch&#xe9; la pose de PP (1,5%). Le score EAUiaic &#xe9;tait de 0 pour 124 proc&#xe9;dures (95,4%), 1 pour quatre proc&#xe9;dures (3,1%) et 2 pour deux proc&#xe9;dures (1,5%). Parmi les patients qui avaient encore leur PP &#xe0; la fin de l&#x2019;&#xe9;tude, 91 (80,5%) ont exprim&#xe9; leur satisfaction. CONCLUSIONS: L&#x2019;implantation de PP est. un traitement de dernier recours pour la dysfonction &#xe9;rectile avec un r&#xe9;sultat satisfaisant. Les PP sont bien accept&#xe9;s par les patients.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Functional results</Keyword><Keyword MajorTopicYN="N">Intraoperative events</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword></KeywordList><CoiStatement>The authors declare the gave no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33658014</ArticleId><ArticleId IdType="pmc">PMC7931532</ArticleId><ArticleId IdType="doi">10.1186/s12610-021-00123-x</ArticleId><ArticleId IdType="pii">10.1186/s12610-021-00123-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50&#x2013;56. doi: 10.1046/j.1464-410x.1999.00142.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.1999.00142.x</ArticleId><ArticleId IdType="pubmed">10444124</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572&#x2013;3588. doi: 10.1111/j.1743-6109.2010.02062.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02062.x</ArticleId><ArticleId IdType="pubmed">21040491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsker A, Saljoghi R, Lecuelle D, et al. Evolution of the number and type of penile prostheses implanted in France for erectile dysfunction: analysis of French national coding database (2006-2013) Prog Urol. 2016;26:485&#x2013;491. doi: 10.1016/j.purol.2016.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.purol.2016.08.001</ArticleId><ArticleId IdType="pubmed">27590101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralla B, Goranova I, B&#xf6;rnstein N, et al. Complications, functional and quality of life outcomes following primary and secondary implantation of penile prosthesis at a tertiary referral center. Int J Impot Res. 2018;30:49&#x2013;53. doi: 10.1038/s41443-017-0005-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-017-0005-3</ArticleId><ArticleId IdType="pubmed">29203844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AC, Sausville J, Schweber A Practice patterns of urologists performing penile prosthesis surgery vary based on surgeon volume: results of a practice pattern survey. Int J Impot Res. 2010;22:262&#x2013;266. doi: 10.1038/ijir.2010.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2010.13</ArticleId><ArticleId IdType="pubmed">20555345</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: current recommendations from the international consultation on sexual medicine. J Sex Med. 2016;13:489&#x2013;518. doi: 10.1016/j.jsxm.2016.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Biyani CS, Pecanka J, Roupr&#xea;t M, et al. Intraoperative adverse incident classification (EAUiaiC) by the European Association of Urology ad hoc complications guidelines panel. Eur Urol. 2020;77:601&#x2013;610. doi: 10.1016/j.eururo.2019.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2019.11.015</ArticleId><ArticleId IdType="pubmed">31787430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169:1429&#x2013;1433. doi: 10.1097/01.ju.0000056047.74268.9c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000056047.74268.9c</ArticleId><ArticleId IdType="pubmed">12629377</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;748. doi: 10.1111/j.1743-6109.2006.00278.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00278.x</ArticleId><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, Corty EW, Levine SB, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793&#x2013;799. doi: 10.1016/S0090-4295(98)00582-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(98)00582-2</ArticleId><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardenne E, Manach Q, Grande P, et al. Satisfaction and surgical outcomes in patients undergoing penile prosthesis implantation for drug-refractory erectile dysfunction: mid-term results in a single center French cohort. Can J Urol. 2019;26:10039&#x2013;10044.</Citation><ArticleIdList><ArticleId IdType="pubmed">31860421</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213. doi: 10.1097/01.sla.0000133083.54934.ae.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000133083.54934.ae</ArticleId><ArticleId IdType="pmc">PMC1360123</ArticleId><ArticleId IdType="pubmed">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitropoulos D, Artibani W, Graefen M, et al. Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol. 2012;61:341&#x2013;349. doi: 10.1016/j.eururo.2011.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.10.033</ArticleId><ArticleId IdType="pubmed">22074761</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Rolle L, Ceruti C, et al. Prospective analysis of the surgical outcomes and patients&#x2019; satisfaction rate after the AMS spectra penile prosthesis implantation. Urology. 2013;82:373&#x2013;376. doi: 10.1016/j.urology.2013.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.04.027</ArticleId><ArticleId IdType="pubmed">23791218</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Ansari A, Talib RA, Canguven O, Shamsodini A. Axial penile rigidity influences patient and partner satisfaction after penile prosthesis implantation. Arch Ital Urol Androl. 2013;85:138&#x2013;142. doi: 10.4081/aiua.2013.3.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2013.3.138</ArticleId><ArticleId IdType="pubmed">24085236</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalheira A, Santana R, Pereira NM. Why are men satisfied or dissatisfied with penile implants? A mixed method study on satisfaction with penile prosthesis implantation. J Sex Med. 2015;12:2474&#x2013;2480. doi: 10.1111/jsm.13054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13054</ArticleId><ArticleId IdType="pubmed">26639576</ArticleId></ArticleIdList></Reference><Reference><Citation>Narang GL, Figler BD, Coward RM. Preoperative counseling and expectation management for inflatable penile prosthesis implantation. Transl Androl Urol. 2017;6:S869&#x2013;S880. doi: 10.21037/tau.2017.07.04.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.07.04</ArticleId><ArticleId IdType="pmc">PMC5715186</ArticleId><ArticleId IdType="pubmed">29238666</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero JR, Cruz CR, G&#xf3;mez BG, et al. Comparison of the patient and partner satisfaction with 700CX and titan penile prostheses. Asian J Androl. 2017;19:321&#x2013;325. doi: 10.4103/1008-682X.172822.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1008-682X.172822</ArticleId><ArticleId IdType="pmc">PMC5427788</ArticleId><ArticleId IdType="pubmed">26806085</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK, Delk JR, et al. Penile prosthesis cultures during revision surgery: a multicenter study. J Urol. 2004;172:153&#x2013;156. doi: 10.1097/01.ju.0000132141.48587.f1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000132141.48587.f1</ArticleId><ArticleId IdType="pubmed">15201759</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery BD, Lomas DJ, Ziegelmann MJ, Trost LW. Infection risk of undergoing multiple penile prostheses: an analysis of referred patient surgical histories. Int J Impot Res. 2018;30:147&#x2013;152. doi: 10.1038/s41443-018-0026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0026-6</ArticleId><ArticleId IdType="pubmed">29795529</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MJ, et al. Impact of surgeon case volume on reoperation rates after inflatable penile prosthesis surgery. J Urol. 2017;197:223&#x2013;229. doi: 10.1016/j.juro.2016.08.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.08.083</ArticleId><ArticleId IdType="pubmed">27545573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Solomon M, DeYoung L, Brock GB. Comparison between AMS 700&#x2122; CX and Coloplast&#x2122; titan inflatable penile prosthesis for Peyronie&#x2019;s disease treatment and remodeling: clinical outcomes and patient satisfaction. J Sex Med. 2013;10:2855&#x2013;2860. doi: 10.1111/jsm.12009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12009</ArticleId><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahon J, Dornbier R, Wegrzyn G, et al. Infectious adverse events following the placement of a penile prosthesis: a systematic review. Sex Med Rev. 2020;8:348&#x2013;354. doi: 10.1016/j.sxmr.2019.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.07.005</ArticleId><ArticleId IdType="pubmed">31519461</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol. 2016;13:33&#x2013;46. doi: 10.1038/nrurol.2015.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2015.270</ArticleId><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande P, Antonini G, Cristini C, et al. Penoscrotal versus minimally invasive infrapubic approach for inflatable penile prosthesis placement: a single-center matched-pair analysis. World J Urol. 2018;36:1167&#x2013;1174. doi: 10.1007/s00345-018-2249-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-018-2249-z</ArticleId><ArticleId IdType="pubmed">29492584</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int. 2006;97:129&#x2013;133. doi: 10.1111/j.1464-410X.2005.05907.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33610493</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>New Advancements in Inflatable Penile Prosthesis.</ArticleTitle><Pagination><StartPage>507</StartPage><EndPage>514</EndPage><MedlinePgn>507-514</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2020.09.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(20)30109-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Inflatable penile prosthesis (IPP) technology is a mainstay in the treatment of erectile dysfunction refractory to medical management. Technological advancements in the design of 3-piece IPPs have been improved to optimize concealability and surgical placement since the 1980s. Recent advancements over the past 10 years include pump, reservoir, tubing, and cylinder updates.</AbstractText><AbstractText Label="OBJECTIVES">This review examines the latest updates in IPP technology, reviews recent relevant research, and is based on over 32 years of experience performing IPP surgery in addition to concurrent postoperative management.</AbstractText><AbstractText Label="METHODS">A literature review was conducted for studies published over the last 10 years through March 2020 with an emphasis on technical updates of IPP, specifically the pump, reservoir, tubing, and cylinder, and their functional outcomes. Anti-infective coating and transgender innovations, in addition to postoperative management, are also reviewed.</AbstractText><AbstractText Label="RESULTS">Technological advancements include a flat reservoir designed for improved discreteness and a prosthesis with optimized tubing length, a one-touch deflatable&#xa0;3-piece system, narrow-base cylinders, a 0&#xb0; angle design between the cylinders and tubing to aid in cylinder placement, a soft molding cylinder tip redesign that better mimics human anatomy, and a 3-piece IPP specifically designed for neophallus use. Furthermore, the Food and Drug Administration approved the submuscular reservoir placement.</AbstractText><AbstractText Label="CONCLUSION">Penile prosthesis has evolved over time to improve functional outcomes, ease of use, and minimize postoperative complications and pain. Penile prosthesis implantation continues to be a life-changing procedure for patients and it is imperative for surgeons to be up-to-date on the latest developments and research in order to provide the best functional outcomes for those they take care of. Dinerman BF, Telis L, Eid JF. New Advancements in Inflatable Penile Prosthesis. Sex Med Rev 2021;9:507-514.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dinerman</LastName><ForeName>Brian F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Urology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telis</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>Jean Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Urology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, New York, NY; Advanced Urological Care, PC, New York, NY. Electronic address: jfeid@urologicalcare.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2022 Apr;207(4):911-913</RefSource><PMID Version="1">34991332</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Transgender</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>21</Day><Hour>20</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33610493</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2020.09.007</ArticleId><ArticleId IdType="pii">S2050-0521(20)30109-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33599772</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>e2036337</StartPage><MedlinePgn>e2036337</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2036337</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.36337</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Combining 2 first-line treatments for erectile dysfunction (ED) or initiating other modalities in addition to a first-line therapy may produce beneficial outcomes.</AbstractText><AbstractText Label="OBJECTIVE">To assess whether different ED combination therapies were associated with improved outcomes compared with first-line ED monotherapy in various subgroups of patients with ED.</AbstractText><AbstractText Label="DATA SOURCES">Studies were identified through a systematic search in MEDLINE, Cochrane Library, and Scopus from inception of these databases to October 10, 2020.</AbstractText><AbstractText Label="STUDY SELECTION">Randomized clinical trials or prospective interventional studies of the outcomes of combination therapy vs recommended monotherapy in men with ED were identified. Only comparative human studies, which evaluated the change from baseline of self-reported erectile function using validated questionnaires, that were published in any language were included.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS">Data extraction and synthesis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">A meta-analysis was conducted that included randomized clinical trials that compared outcomes of combination therapy with phosphodiesterase type 5 (PDE5) inhibitors plus another agent vs PDE5 inhibitor monotherapy. Separate analyses were performed for the mean International Index of Erectile Function (IIEF) score change from baseline and the number of adverse events (AEs) by different treatment modalities and subgroups of patients.</AbstractText><AbstractText Label="RESULTS">A total of 44 studies included 3853 men with a mean (SD) age of 55.8 (11.9) years. Combination therapy compared with monotherapy was associated with a mean IIEF score improvement of 1.76 points (95% CI, 1.27-2.24; I2&#x2009;=&#x2009;77%; 95% PI, -0.56 to 4.08). Adding daily tadalafil, low-intensity shockwave therapy, vacuum erectile device, folic acid, metformin hydrochloride, or angiotensin-converting enzyme inhibitors was associated with a significant IIEF score improvement, but each measure was based on only 1 study. Specifically, the weighted mean difference (WMD) in IIEF score was 1.70 (95% CI, 0.79-2.61) for the addition of daily tadalafil, 3.50 (95% CI, 0.22-6.78) for the addition of low-intensity shockwave therapy, 8.40 (95% CI, 4.90-11.90) for the addition of a vacuum erectile device, 3.46 (95% CI, 2.16-4.76) for the addition of folic acid, 4.90 (95% CI, 2.82-6.98) for the addition of metformin hydrochloride and 2.07 (95% CI, 1.37-2.77) for the addition of angiotensin-converting enzyme inhibitors. The addition of &#x3b1;-blockers to PDE5 inhibitors was not associated with improvement in IIEF score (WMD, 0.80; 95% CI, -0.06 to 1.65; I2&#x2009;=&#x2009;72%). Compared with monotherapy, combination therapy was associated with improved IIEF score in patients with hypogonadism (WMD, 1.61; 95% CI, 0.99-2.23; I2&#x2009;=&#x2009;0%), monotherapy-resistant ED (WMD, 4.38; 95% CI, 2.37-6.40; I2&#x2009;=&#x2009;52%), or prostatectomy-induced ED (WMD, 5.47; 95% CI, 3.11-7.83; I2&#x2009;=&#x2009;53%). The treatment-related AEs did not differ between combination therapy and monotherapy (odds ratio, 1.10; 95% CI, 0.66-1.85; I2&#x2009;=&#x2009;78%). Despite multiple subgroup and sensitivity analyses, the levels of heterogeneity remained high.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found that combination therapy of PDE5 inhibitors and antioxidants was associated with improved ED without increasing the AEs. Treatment with PDE5 inhibitors and daily tadalafil, shockwaves, or a vacuum device was associated with additional improvement, but this result was based on limited data. These findings suggest that combination therapy is safe, associated with improved outcomes, and should be considered as a first-line therapy for refractory, complex, or difficult-to-treat cases of ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mykoniatis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology, Faculty of Medicine, Aristotle University of Thessaloniki School of Health Sciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyrgidis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, Faculty of Medicine, Aristotle University of Thessaloniki School of Health Sciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolakis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouranidis</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sountoulides</LastName><ForeName>Petros</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Faculty of Medicine, Aristotle University of Thessaloniki School of Health Sciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haidich</LastName><ForeName>Anna-Bettina</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Hygiene, Social-Preventive Medicine &amp; Medical Statistics, Aristotle University of Thessaloniki Medical School, University Campus, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Renterghem</LastName><ForeName>Koenraad</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, Jessa Hospital, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatzichristodoulou</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatzichristou</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, Faculty of Medicine, Aristotle University of Thessaloniki School of Health Sciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12001-76-2</RegistryNumber><NameOfSubstance UI="D014803">Vitamin B Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>935E97BOY8</RegistryNumber><NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Netw Open. 2021 Feb 1;4(2):e2037292</RefSource><PMID Version="1">33599768</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004864" MajorTopicYN="Y">Equipment and Supplies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074059" MajorTopicYN="Y">Extracorporeal Shockwave Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014803" MajorTopicYN="N">Vitamin B Complex</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33599772</ArticleId><ArticleId IdType="pmc">PMC7893498</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36337</ArticleId><ArticleId IdType="pii">2776549</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. doi:10.1016/S0022-5347(17)34871-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)34871-1</ArticleId><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratzke C, Angulo J, Chitaley K, et al. . Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7(1 pt 2):445-475. doi:10.1111/j.1743-6109.2009.01624.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01624.x</ArticleId><ArticleId IdType="pubmed">20092448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Staubli SEL, Schneider MP, et al. . Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674-680. doi:10.1016/j.eururo.2015.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.03.031</ArticleId><ArticleId IdType="pubmed">25817916</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Bettochi C, Carvalho J, et al.  EAU guidelines on sexual and reproductive health. 2020.  Accessed October 5, 2020. https://uroweb.org/guideline/sexual-and-reproductive-health/</Citation></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. . Erectile dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Giraldi A, Hackett G, et al. . The 2018 revision to the process of care model for evaluation of erectile dysfunction. J Sex Med. 2018;15(9):1280-1292. doi:10.1016/j.jsxm.2018.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.06.005</ArticleId><ArticleId IdType="pubmed">30057280</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Rastrelli G, Burri A, et al. . First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. Andrology. 2016;4(6):1002-1009. doi:10.1111/andr.12255</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12255</ArticleId><ArticleId IdType="pubmed">27636710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D, Moysidis K, Apostolidis A, et al. . Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005;47(4):518-522.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774252</ArticleId></ArticleIdList></Reference><Reference><Citation>Stridh A, Pont&#xe9;n M, Arver S, Kirsch I, Ab&#xe9; C, Jensen KB. Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(3):e201423. doi:10.1001/jamanetworkopen.2020.1423</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.1423</ArticleId><ArticleId IdType="pmc">PMC7084170</ArticleId><ArticleId IdType="pubmed">32196105</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhir RR, Lin H-C, Canfield SE, Wang R. Combination therapy for erectile dysfunction: an update review. Asian J Androl. 2011;13(3):382-390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739353</ArticleId><ArticleId IdType="pubmed">21423198</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Buvat J, Corona G, et al. . A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65(1):99-112. doi:10.1016/j.eururo.2013.08.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2013.08.048</ArticleId><ArticleId IdType="pubmed">24050791</ArticleId></ArticleIdList></Reference><Reference><Citation>Munk NE, Knudsen JS, Comerma-Steffensen S, Simonsen U. Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails. Sex Med Rev. 2019;7(3):430-441. doi:10.1016/j.sxmr.2018.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.11.007</ArticleId><ArticleId IdType="pubmed">30711478</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncada I, Martinez-Salamanca J, Ruiz-Casta&#xf1;e E, Romero J. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int J Impot Res. 2018;30(5):203-208. doi:10.1038/s41443-018-0046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0046-2</ArticleId><ArticleId IdType="pubmed">30050072</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions 2nd ed. John Wiley &amp; Sons; 2019.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, et al. . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. ; GRADE Working Group . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolyosr A, Elsagheer GA, Abdel-Kader MS, Hassan AM, Abou-Zeid AMM. Evaluation of the effect of sildenafil and/or doxazosin on benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann. 2013;5(4):237-240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835979</ArticleId><ArticleId IdType="pubmed">24311901</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003;58(5):632-638.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699447</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccaglini W, Pazeto CL, Corr&#xea;a Barros EA, et al. . The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med. 2020;17(4):688-694. doi:10.1016/j.jsxm.2019.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.12.024</ArticleId><ArticleId IdType="pubmed">32007430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar Z, Albayrak S. Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study. Int Urol Nephrol. 2019;51(9):1491-1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">31230261</ArticleId></ArticleIdList></Reference><Reference><Citation>Buvat J, Montorsi F, Maggi M, et al. . Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284-293. doi:10.1111/j.1743-6109.2010.01956.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01956.x</ArticleId><ArticleId IdType="pubmed">20704642</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology. 2005;66(5):1080-1085. doi:10.1016/j.urology.2005.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2005.05.014</ArticleId><ArticleId IdType="pubmed">16286128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cui S, Lin H, et al. . Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24(6):217-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">22931760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H, Liu B, Song Z, et al. . Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia. 2015;47(1):20-24. doi:10.1111/and.12216</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/and.12216</ArticleId><ArticleId IdType="pubmed">24387078</ArticleId></ArticleIdList></Reference><Reference><Citation>El Taieb M, Hegazy E, Ibrahim A. Daily oral l-arginine plus tadalafil in diabetic patients with erectile dysfunction: a double-blinded, randomized, controlled clinical trial. J Sex Med. 2019;16(9):1390-1397. doi:10.1016/j.jsxm.2019.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.06.009</ArticleId><ArticleId IdType="pubmed">31326304</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu El-Hamd M, Hegazy EM. Comparison of the clinical efficacy of daily use of L-arginine, tadalafil and combined L-arginine with tadalafil in the treatment of elderly patients with erectile dysfunction. Andrologia. 2020;52(7):e13640. doi:10.1111/and.13640</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/and.13640</ArticleId><ArticleId IdType="pubmed">32441833</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Wakeel LM, Fouad FA, Saleem MD, Saber-Khalaf M. Efficacy and tolerability of sildenafil/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction. Andrology. 2020;8(1):143-147. doi:10.1111/andr.12671</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12671</ArticleId><ArticleId IdType="pubmed">31267684</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel JD Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol. 2011;18(3):5721-5725.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo L, Pecoraro S, Sarnacchiaro P, Silvani M, Antonini G. The daily therapy with L-arginine 2,500 mg and tadalafil 5 mg in combination and in monotherapy for the treatment of erectile dysfunction: a prospective, randomized multicentre study. Sex Med. 2020;8(2):178-185. doi:10.1016/j.esxm.2020.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2020.02.003</ArticleId><ArticleId IdType="pmc">PMC7261690</ArticleId><ArticleId IdType="pubmed">32192966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004;20(9):1377-1384. doi:10.1185/030079904X2394</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/030079904X2394</ArticleId><ArticleId IdType="pubmed">15383186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi Madani A, Asadolahzade A, Mokhtari G, Shahrokhi Damavand R, Farzan A, Esmaeili S. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. J Sex Med. 2013;10(4):1146-1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">23347176</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann HC, Levine LA, Macaluso J Jr, et al. . Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? hypothesis and pilot trial results. J Sex Med. 2006;3(2):303-308.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490024</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Zhang Z-C, Liu J-H, et al. . An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Asian J Androl. 2011;13(4):630-635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739607</ArticleId><ArticleId IdType="pubmed">21602833</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung G-W, Heo J. Combination of an alfuzosin xl and tadalafil is superior to monotherapy in treating erectile dysfunction (ED) and lower urinary tract symptoms (LUTS). Eur Urol Suppl. 2008;7(3):161. doi:10.1016/S1569-9056(08)60358-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1569-9056(08)60358-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717-1723. doi:10.1016/j.eururo.2007.01.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2007.01.033</ArticleId><ArticleId IdType="pubmed">17258855</ArticleId></ArticleIdList></Reference><Reference><Citation>Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 2016;13(6):2920-2926.</Citation><ArticleIdList><ArticleId IdType="pubmed">27928815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SW, Park NC, Lee SW, et al. . Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med. 2017;14(8):1018-1027. doi:10.1016/j.jsxm.2017.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.06.006</ArticleId><ArticleId IdType="pubmed">28760246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Roat R, Agrawal S, Jayant K, Mavuduru RS, Kumar S. Combination therapy of tadalafil and pentoxifylline in severe erectile dysfunction; a prospective randomized trial. Pol Przegl Chir. 2015;87(8):377-383. doi:10.1515/pjs-2015-0075</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pjs-2015-0075</ArticleId><ArticleId IdType="pubmed">26495912</ArticleId></ArticleIdList></Reference><Reference><Citation>Law YXT, Tai BC, Tan YQ, Lata RNM, Lee KCJ. A small group randomized double-blind placebo-controlled study to evaluate the efficacy of daily pentoxifylline in the management of patients with erectile dysfunction with suboptimal treatment response to sildenafil. Sex Med. 2020;8(1):14-20. doi:10.1016/j.esxm.2019.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2019.08.012</ArticleId><ArticleId IdType="pmc">PMC7042165</ArticleId><ArticleId IdType="pubmed">31585802</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori G, Trombetta C, De Giorgi G, et al. . Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6(2):544-552. doi:10.1111/j.1743-6109.2008.01109.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01109.x</ArticleId><ArticleId IdType="pubmed">19138360</ArticleId></ArticleIdList></Reference><Reference><Citation>Morano S, Mandosi E, Fallarino M, et al. . Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol. 2007;52(6):1768-1774. doi:10.1016/j.eururo.2007.04.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2007.04.042</ArticleId><ArticleId IdType="pubmed">17478034</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey-Valzacchi GJ, Costanzo PR, Finger LA, et al. . Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance: a prospective, randomized, double-blind pilot study. J Androl. 2012;33(4):608-614.</Citation><ArticleIdList><ArticleId IdType="pubmed">22016348</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172(2):658-663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Ghanem H, Fahmy I, et al. . Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med. 2005;2(4):559-564. doi:10.1111/j.1743-6109.2005.00071.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00071.x</ArticleId><ArticleId IdType="pubmed">16422854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirai M, Hiramatsu I, Aoki Y, et al. . Oral L-citrulline and transresveratrol supplementation improves erectile function in men with phosphodiesterase 5 inhibitors: a randomized, double-blind, placebo-controlled crossover pilot study. Sex Med. 2018;6(4):291-296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6302103</ArticleId><ArticleId IdType="pubmed">30150102</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer M, Basaria S, Travison TG, et al. . Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681-691.</Citation><ArticleIdList><ArticleId IdType="pubmed">23165659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28(1):17-22. doi:10.1007/s00345-009-0484-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-009-0484-z</ArticleId><ArticleId IdType="pubmed">19855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicari E, La Vignera S, Condorelli R, Calogero AE. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med. 2010;7(3):1247-1253. doi:10.1111/j.1743-6109.2009.01420.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01420.x</ArticleId><ArticleId IdType="pubmed">19674252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Sofer M, Kaver I, Matzkin H, Greenstein A. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol. 2004;171(1):292-295. doi:10.1097/01.ju.0000098460.02560.fe</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000098460.02560.fe</ArticleId><ArticleId IdType="pubmed">14665897</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res. 2005;17(4):354-358. doi:10.1038/sj.ijir.3901290</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901290</ArticleId><ArticleId IdType="pubmed">15703770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TI-S, Chen H-E, Tsai T-F, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18(4):400-404. doi:10.1038/sj.ijir.3901446</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901446</ArticleId><ArticleId IdType="pubmed">16395321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JW, Oh MM, Park MG, et al. . Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency. Int J Impot Res. 2013;25(1):29-33. doi:10.1038/ijir.2012.32</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2012.32</ArticleId><ArticleId IdType="pubmed">22971615</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999;162(6):1992-1997. doi:10.1016/S0022-5347(05)68085-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)68085-8</ArticleId><ArticleId IdType="pubmed">10569554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18(5):446-451. doi:10.1038/sj.ijir.3901448</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901448</ArticleId><ArticleId IdType="pubmed">16482200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdal OL, Ozden C, Gokkaya S, Urgancioglu G, Aktas BK, Memis A. The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction. Int Urol Nephrol. 2008;40(1):133-136. doi:10.1007/s11255-007-9255-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-007-9255-1</ArticleId><ArticleId IdType="pubmed">17764032</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri A, Arcaniolo D, Palumbo F, et al. ; SIA-Low Intensity Shock Wave for Erectile Dysfunction (LED) Study Group . Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial. Int J Impot Res. Published July 18, 2020. doi:10.1038/s41443-020-0332-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-020-0332-7</ArticleId><ArticleId IdType="pubmed">32683417</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Agarwal A, Allamaneni SS, Lakin MM, Zippe CD. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology. 2005;65(2):360-364. doi:10.1016/j.urology.2004.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2004.09.013</ArticleId><ArticleId IdType="pubmed">15708053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffo A, Stanojevic N, Romeo G, Riccardo F, Trama F, Iacono F. Management of erectile dysfunction using a combination treatment of low-intensity shock waves (LISW) and platelet rich plasma (PRP) intracavernosal injections. J Sex Med. 2020;17(6):S133&#x2013;S134. doi:10.1016/j.jsxm.2020.04.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2020.04.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastianelli A, Spatafora P, Frizzi J, et al. . Tadalafil 5 mg alone or in combination with tamsulosin 0.4 mg for the management of men with lower urinary tract symptoms and erectile dysfunction: results of a prospective observational trial. J Clin Med. 2019;8(8):E1126. doi:10.3390/jcm8081126</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8081126</ArticleId><ArticleId IdType="pmc">PMC6723816</ArticleId><ArticleId IdType="pubmed">31362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Peng F-L, Yu Z-L, Liu C-L, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol. 2014;21(12):1263-1267. doi:10.1111/iju.12564</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iju.12564</ArticleId><ArticleId IdType="pubmed">25039272</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54(2):346-351. doi:10.1016/S0090-4295(99)00099-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(99)00099-0</ArticleId><ArticleId IdType="pubmed">10443736</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe&#xf1;a BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326. doi:10.1038/sj.ijir.3900472</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900472</ArticleId><ArticleId IdType="pubmed">10637462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011;60(5):1010-1016. doi:10.1016/j.eururo.2011.07.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.07.053</ArticleId><ArticleId IdType="pubmed">21855209</ArticleId></ArticleIdList></Reference><Reference><Citation>McVary KT Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005;47(6):838-845. doi:10.1016/j.eururo.2005.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2005.02.001</ArticleId><ArticleId IdType="pubmed">15925081</ArticleId></ArticleIdList></Reference><Reference><Citation>Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 2003;91(9):873-877. doi:10.1046/j.1464-410X.2003.04229.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410X.2003.04229.x</ArticleId><ArticleId IdType="pubmed">12780851</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger S, Behr-Roussel D, Gorny D, et al. . Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med. 2009;6(3):836-847. doi:10.1111/j.1743-6109.2008.01138.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01138.x</ArticleId><ArticleId IdType="pubmed">19143907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallidonis P, Adamou C, Kotsiris D, Ntasiotis P, Verze P, Athanasopoulos A; Young Academic Urologists of the European Association of Urology-Endourology Working Party . Combination therapy with alpha-blocker and phosphodiesterase-5 inhibitor for improving lower urinary tract symptoms and erectile dysfunction in comparison with monotherapy: a systematic review and meta-analysis. Eur Urol Focus. 2020;6(3):537-558.</Citation><ArticleIdList><ArticleId IdType="pubmed">31133414</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Benson RC Jr, Bilhartz DL, Minich PJ, Furlow WL. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol. 1996;155(1):144-146.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490815</ArticleId></ArticleIdList></Reference><Reference><Citation>de Tejada IS Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res. 2004;16(suppl 1):S40-S42. doi:10.1038/sj.ijir.3901215</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901215</ArticleId><ArticleId IdType="pubmed">15224136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhim HC, Kim MS, Park Y-J, et al. . The potential role of arginine supplements on erectile dysfunction: a systemic review and meta-analysis. J Sex Med. 2019;16(2):223-234. doi:10.1016/j.jsxm.2018.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.12.002</ArticleId><ArticleId IdType="pubmed">30770070</ArticleId></ArticleIdList></Reference><Reference><Citation>Capogrosso P, Vertosick EA, Benfante NE, et al. . Are we improving erectile function recovery after radical prostatectomy? analysis of patients treated over the last decade. Eur Urol. 2019;75(2):221-228. doi:10.1016/j.eururo.2018.08.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2018.08.039</ArticleId><ArticleId IdType="pmc">PMC6339580</ArticleId><ArticleId IdType="pubmed">30237021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. Int J Impot Res. 2019;31(3):177-194. doi:10.1038/s41443-019-0117-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-019-0117-z</ArticleId><ArticleId IdType="pubmed">30664671</ArticleId></ArticleIdList></Reference><Reference><Citation>Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-rich plasma therapy for male sexual dysfunction: myth or reality? Sex Med Rev. 2020;8(1):106-113. doi:10.1016/j.sxmr.2019.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.02.002</ArticleId><ArticleId IdType="pubmed">30898594</ArticleId></ArticleIdList></Reference><Reference><Citation>Verze P, Capece M, Creta M, et al. . Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl. 2020;22(4):379-382. doi:10.4103/aja.aja_121_19</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aja.aja_121_19</ArticleId><ArticleId IdType="pmc">PMC7406094</ArticleId><ArticleId IdType="pubmed">31696836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu GQ, Jeon SH, Bae WJ, et al. . Efficient promotion of autophagy and angiogenesis using mesenchymal stem cell therapy enhanced by the low-energy shock waves in the treatment of erectile dysfunction. Stem Cells Int. 2018;2018:1302672. doi:10.1155/2018/1302672</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1302672</ArticleId><ArticleId IdType="pmc">PMC6136471</ArticleId><ArticleId IdType="pubmed">30228820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33460908</PMID><DateRevised><Year>2021</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Melanotan Tanning Injection: A Rare Cause of Priapism.</ArticleTitle><Pagination><StartPage>100298</StartPage><MedlinePgn>100298</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100298</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2020.100298</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(20)30185-9</ELocationID><Abstract><AbstractText>Melanotan II, an injectable melanocortin analog, is illicitly available on the internet to generate a sunless tan through melanocyte induction. It is also used as a sexual stimulant in unlicensed performance enhancement clinics, and has been investigated as a possible treatment agent in erectile dysfunction. We describe in this case report a patient presenting with acute ischemic priapism after subcutaneous injection of melanotan II. The patient was initially managed with cavernosal aspiration and irrigation, and intracavernous injection of phenylephrine without achieving detumescence. After failing initial management, the patient underwent operative management with penoscrotal decompression, a promising alternative technique for the management of refractory ischemic priapism. Priapism after melanotan II injection has only been reported in the literature twice before. This case report highlights a rare presentation of acute ischemic priapism after melanotan II use, managed with surgical decompression. Future therapeutic applications of these agents and updated management guidelines should consider priapism as a possible side effect. CW. Mallory, DM Lopategui, BH. Cordon. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med 2021;9:100298.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mallory</LastName><ForeName>Chase W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. Electronic address: Cmall024@fiu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopategui</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Urology, Mount Sinai Medical Center, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordon</LastName><ForeName>Billy H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Division of Urology, Mount Sinai Medical Center, Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Melanocortin</Keyword><Keyword MajorTopicYN="N">Melanotan</Keyword><Keyword MajorTopicYN="N">Penoscrotal Decompression</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>18</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33460908</ArticleId><ArticleId IdType="pmc">PMC7930850</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2020.100298</ArticleId><ArticleId IdType="pii">S2050-1161(20)30185-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dreyer B.A., Amer T., Fraser M. Melanotan-induced priapism: a Hard-Earned tan. BMJ Case Rep. 2019;12:e227644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6388891</ArticleId><ArticleId IdType="pubmed">30796078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadley M.E. Discovery that a melanocortin Regulates sexual functions in male and female Humans. Peptides. 2005;26:1687&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996790</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson M.E., Bryant S.M., Aks S.E. Melanotan II injection resulting in systemic toxicity and Rhabdomyolysis 2012. Clin Toxicol. 2012;50:1169&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">23121206</ArticleId></ArticleIdList></Reference><Reference><Citation>Monague D.K., Jarrow J., Broderick G.A. Guideline on the management of priapism. J Urol. 2003;170 (4 Pt 1):1318-1324.</Citation></Reference><Reference><Citation>Baumgarten A.S., VanDyke M.E., Yi Y.A. Favorable multi-institutional experience with penoscrotal decompression for prolonged ischemic priapism. BJU Int. 2020;126:441&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">32501654</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine  Role of the melanocortin-4 receptor in Hypoactive sexual Desire Disorder. 2019. https://clinicaltrials.gov/ct2/show/NCT04179734</Citation></Reference><Reference><Citation>U.S. National Library of Medicine  Setmelanotide (RM-493), melanocortin-4 receptor (MCR4) agonist, in Bardet-biedl Syndrome (BBS) and Alstrom Syndrome (AS) patients with Moderate to severe obesity. 2018. https://clinicaltrials.gov/ct2/show/NCT03746522</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33420928</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-6285</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>Current urology reports</Title><ISOAbbreviation>Curr Urol Rep</ISOAbbreviation></Journal><ArticleTitle>Current Status for Semirigid Penile Prosthetic Devices.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11934-020-01028-4</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The goal of this paper was to evaluate the current use of semirigid penile prosthesis (SRPP), surgical techniques for insertion of SRPP, and how to prevent and approach surgical complications.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">SRPP is a valid option for those who are refractory to medical therapy for erectile dysfunction (ED) and even more appropriate for specific subsets of patient populations. It is important for urologists to know which patient population SRPP is preferred for. Several studies have shown good patient outcomes and patient satisfaction with those who underwent SRPP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez-Crespo</LastName><ForeName>Raul E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA. raulf@usf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of South Florida, Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA. raulf@usf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscaino</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of South Florida, Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of South Florida, Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrion</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of South Florida, Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Urol Rep</MedlineTA><NlmUniqueID>100900943</NlmUniqueID><ISSNLinking>1527-2737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Semirigid penile prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33420928</ArticleId><ArticleId IdType="doi">10.1007/s11934-020-01028-4</ArticleId><ArticleId IdType="pii">10.1007/s11934-020-01028-4</ArticleId></ArticleIdList><ReferenceList><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: &#x2022; Of importance &#x2022;&#x2022; Of major importance</Title><Reference><Citation>Carrion H, Martinez D, Parker J, Hakky T, Bickell M, Boyle A, et al. A history of the penile implant to 1974. Sex Med Rev. 2016;4(3):285&#x2013;93 A concise history of the development of penile implants, before and after 1974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2016.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B, Burnett AL. Evolution of penile prosthetic devices. Korean J Urol. 2015;56(3):179&#x2013;86. https://doi.org/10.4111/kju.2015.56.3.179 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/kju.2015.56.3.179</ArticleId><ArticleId IdType="pubmed">25763121</ArticleId><ArticleId IdType="pmc">4355428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman RT, Howard AH, Barnes RW. Plastic reconstruction of the penis. J Urol. 1948;59(6):1174&#x2013;82. https://doi.org/10.1016/s0022-5347(17)69495-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(17)69495-3</ArticleId><ArticleId IdType="pubmed">18858063</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin WE, Scott WW. Phalloplasty. J Urol. 1952;68(6):903&#x2013;8. https://doi.org/10.1016/s0022-5347(17)68301-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(17)68301-0</ArticleId><ArticleId IdType="pubmed">13000938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash H. Silicone implant for impotence. J Urol. 1968;100(5):709&#x2013;10. https://doi.org/10.1016/s0022-5347(17)62605-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(17)62605-3</ArticleId><ArticleId IdType="pubmed">5682555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. The development of modern penile implants. Sex Med Rev. 2016;4(2):177&#x2013;89. https://doi.org/10.1016/j.sxmr.2015.11.003 In-depth historical description of the development of penile implant, including all the modifications as well as many complications from current and previous penile implants.</Citation></Reference><Reference><Citation>Martinez DR, Terlecki R, Brant WO. The evolution and utility of the small-carrion prosthesis, its impact, and progression to the modern-day malleable penile prosthesis. J Sex Med. 2015;12:423&#x2013;30. https://doi.org/10.1111/jsm.13014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13014</ArticleId><ArticleId IdType="pubmed">26565570</ArticleId></ArticleIdList></Reference><Reference><Citation>Genesis&#xae; Malleable Penile Prosthesis. Instructions [Package insert] for use. Coloplast; 2017.</Citation></Reference><Reference><Citation>Levine LA, Becher E, Bella AJ, Brant WO, Kohler TS, Martinez-Salamanca JI, et al. Penile prosthesis surgery: current recommendations from the international consultation on sexual medicine. J Sex Med. 2016;13(4):489&#x2013;518. https://doi.org/10.1016/j.jsxm.2016.01.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId><ArticleId IdType="pmc">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nealon S, Baumgarten A, Mendez M, DiGiorgio L, Patel P, Ramasamy R, et al. 107 initial experience with the Boston Scientific Tactra semi-rigid penile prosthesis: a multi-institutional case series. J Sex Med. 2020;1(suppl 1):S26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.11.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L. Future considerations in prosthetic urology. Asian J Androl. 2020;22(1):70&#x2013;5. https://doi.org/10.4103/aja.aja_103_19 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aja.aja_103_19</ArticleId><ArticleId IdType="pubmed">31571642</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Rolle L, Ceruti C, Timpano M, Sedigh O, Preto M, et al. Prospective analysis of the surgical outcomes and patients&#x2019; satisfaction rate after the AMS spectra penile prosthesis implantation. Urology. 2013;82(2):373&#x2013;6. https://doi.org/10.1016/j.urology.2013.04.027 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.04.027</ArticleId><ArticleId IdType="pubmed">23791218</ArticleId></ArticleIdList></Reference><Reference><Citation>Spectra&#x2122; Concealable Penile Prosthesis. Instructions [Package insert] for use: American Medical Systems, Inc. 2017.</Citation></Reference><Reference><Citation>Mulcahy JJ, Austoni E, Barada JH, Choi HK, Hellstrom WJG, Krishnamurti S, et al. The penile implant for erectile dysfunction. J Sex Med. 2004;1(1):98&#x2013;109. https://doi.org/10.1111/j.1743-6109.2004.10115.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2004.10115.x</ArticleId><ArticleId IdType="pubmed">16422990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tactra&#x2122; Malleable Penile Prosthesis. Directions [Package insert] of use. Boston Scientific; 2018.</Citation></Reference><Reference><Citation>Coloplast. MRI compatibility for penile prosthesis. Accessed April 12, 2010. https://www.coloplastmd.com/wp-content/uploads/2018/02/MRI-Compatibility-10_23_18.pdf</Citation></Reference><Reference><Citation>Lowe G, Smith RP, Costabile RA. A catalog of magnetic resonance imaging compatibility of penile prostheses. J Sex Med. 2012;9(5):1482&#x2013;7. https://doi.org/10.1111/j.1743-6109.2012.02689.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02689.x</ArticleId><ArticleId IdType="pubmed">22429734</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil AY, Nerli RB, Hiremath MB. Satisfaction with the semirigid penile prosthesis among couples from a semiurban Indian population. J Sci Soc. 2018;45(1):26&#x2013;9. https://doi.org/10.4103/jss.JSS_29_18 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jss.JSS_29_18</ArticleId></ArticleIdList></Reference><Reference><Citation>Eardley I. Malleable vs inflatable implant? Which one to choose. J Sex Med. 2017;14(8):975&#x2013;6. https://doi.org/10.1016/j.jsxm.2017.05.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.05.015</ArticleId><ArticleId IdType="pubmed">28760256</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53(4):793&#x2013;9. https://doi.org/10.1016/s0090-4295(98)00582-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(98)00582-2</ArticleId><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>Akakpo W, Pineda MA, Burnett AL. Critical analysis of satisfaction assessment after penile prosthesis surgery. Sex Med Rev. 2017;5(2):244&#x2013;51. https://doi.org/10.1016/j.sxmr.2017.01.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.01.001</ArticleId><ArticleId IdType="pubmed">28143706</ArticleId><ArticleId IdType="pmc">28143706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi F, Huynh L, Ahlering T, Rosen R. What is a &#x201c;validated questionnaire&#x201d;? A critical review of erectile function assessment. J Sex Med. 2020;17(5):849&#x2013;60. https://doi.org/10.1016/j.jsxm.2020.02.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2020.02.005</ArticleId><ArticleId IdType="pubmed">32146130</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;ayan S, A&#x15f;c&#x131; R, Efesoy O, Bolat MS, Akbay E, Yaman &#xd6;. Comparison of long-term results and couples&#x2019; satisfaction with penile implant types and brands: lessons learned from 883 patients with erectile dysfunction who underwent penile prosthesis implantation. J Sex Med. 2019;16(7):1092&#x2013;7. https://doi.org/10.1016/j.jsxm.2019.04.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.04.013</ArticleId><ArticleId IdType="pubmed">31155387</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, Aziz M, Sherif H, Mahmoud S, et al. Predictors of satisfaction in men after penile implant surgery. J Sex Med. 2018;15(8):1180&#x2013;6. https://doi.org/10.1016/j.jsxm.2018.05.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.05.011</ArticleId><ArticleId IdType="pubmed">30017718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt IH, Arslan B, Yonguc T, Kozacioglu Z, Degirmenci T, Gunlusoy B, et al. Patient and partner outcome of inflatable and semi-rigid penile prosthesis in a single institution. Int Braz J Urol. 2015;41(3):535&#x2013;41. https://doi.org/10.1590/S1677-5538.IBJU.2014.0241 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1677-5538.IBJU.2014.0241</ArticleId><ArticleId IdType="pubmed">26200547</ArticleId><ArticleId IdType="pmc">4752147</ArticleId></ArticleIdList></Reference><Reference><Citation>Casab&#xe9; AR, Sarotto N, Gutierrez C, Bechara AJ. Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis&#xae; (Coloplast) models. Int J Impot Res. 2016;28(6):228&#x2013;33. https://doi.org/10.1038/ijir.2016.33 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2016.33</ArticleId><ArticleId IdType="pubmed">27557609</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdemir F, Okulu E, Kay&#x131;gil &#xd6;. Long-term outcomes of AMS Spectra&#xae; penile prosthesis implantation and satisfaction rates. Int J Impot Res. 2017;29(5):184&#x2013;8. https://doi.org/10.1038/ijir.2017.16 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2017.16</ArticleId><ArticleId IdType="pubmed">28424506</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Ansari A, Talib RA, Canguven O, Shamsodini A. Axial penile rigidity influences patient and partner satisfaction after penile prosthesis implantation. Archivio Ital Di Urol Androl. 2013;85(3):138&#x2013;42. https://doi.org/10.4081/aiua.2013.3.138 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2013.3.138</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal V, Ralph D. An audit of implanted penile prostheses in the UK. BJU Int. 2006;98(2):393&#x2013;5. https://doi.org/10.1111/j.1464-410x.2006.06261.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.2006.06261.x</ArticleId><ArticleId IdType="pubmed">16879684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakky TS, Wilson SK, Salem EA, Parker J, Carrion R, Mulcahy JJ. Subcoronal rod penile prosthesis placement with scrotoplasty. J Sex Med. 2012;9(9):2202&#x2013;5. https://doi.org/10.1111/j.1743-6109.2012.02900.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02900.x</ArticleId><ArticleId IdType="pubmed">22947330</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Sousa A, Keating M, Moreira S, Baker M, Carrion R. Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery. J Sex Med. 2007;4(5):1494&#x2013;9. https://doi.org/10.1111/j.1743-6109.2007.00551.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00551.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaazaa A, Mostafa T. Spontaneous penile tumescence by sparing cavernous tissue in the course of malleable penile prosthesis implantation. J Sex Med. 2019;16(3):474&#x2013;8. https://doi.org/10.1016/j.jsxm.2019.01.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.01.012</ArticleId><ArticleId IdType="pubmed">30773500</ArticleId></ArticleIdList></Reference><Reference><Citation>Usta M, Bivalacqua T, Tokatli Z, Rivera F, Gulkesen KH, Sikka SC, et al. Stratification of penile vascular pathologies in patients with Peyronie&#x2019;s disease and in men with erectile dysfunction according to age: a comparative study. J Urol. 2004;172(1):259&#x2013;62. https://doi.org/10.1097/01.ju.0000132154.38285.c7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000132154.38285.c7</ArticleId><ArticleId IdType="pubmed">15201789</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic ML, Kojovic V. Penile prosthesis implantation and tunica albuginea incision without grafting in the treatment of Peyronie's disease with erectile dysfunction. Asian J Androl. 2013;15(3):391&#x2013;4. https://doi.org/10.1038/aja.2012.149 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aja.2012.149</ArticleId><ArticleId IdType="pubmed">23435473</ArticleId><ArticleId IdType="pmc">3739639</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tealab A, Farag M, Soliman T, Williamson B, Mahmoud S, et al. Malleable penile implant is an effective therapeutic option in men with Peyronie&#x2019;s disease and erectile dysfunction. Sex Med. 2018;6(1):24&#x2013;9. https://doi.org/10.1016/j.esxm.2017.10.004 In this publication, the efficacy and the safety of the malleable penile prosthesis for the correction of penile curvature was clearly demonstrated, as well as the performance of adjuvant intraoperative maneuvers for correction of residual curvature. Patient satisfaction was the same when compared to those patients that underwent placement of inflatable penile prosthesis.</Citation></Reference><Reference><Citation>Yavuz U, Ciftci S, Ustuner M, Yilmaz H, Culha M. Surgical treatment of erectile dysfunction and Peyronie&#x2019;s disease using malleable prosthesis. Urol J. 2015;12(6):2428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">26706740</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011;108(7):1152&#x2013;6. https://doi.org/10.1111/j.1464-410x.2010.10023.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.2010.10023.x</ArticleId><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Wilson SK. Management of Peyronie&#x2019;s disease with penile prostheses. Int J Impot Res. 2002;14(5):384&#x2013;8. https://doi.org/10.1038/sj.ijir.3900865 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900865</ArticleId><ArticleId IdType="pubmed">12454690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi A, Silvani M, Pecoraro S. Corporoplasty with small soft axial prosthesis (Virilis I) and bovine pericardial graft (Hydrix) in Peyronie&#x2019;s disease. Asian J Androl. 2013;15:275&#x2013;9. https://doi.org/10.1038/aja.2012.156 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aja.2012.156</ArticleId><ArticleId IdType="pubmed">23353721</ArticleId><ArticleId IdType="pmc">3739159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegelmann MJ, Bajic P, Levine LA. Peyronie&#x2019;s disease: contemporary evaluation and management. Int J Urol. 2020;2020:1&#x2013;13. https://doi.org/10.1111/iju.14230 Accessed April 21, 2020. https://onlinelibrary.wiley.com/doi/full/10.1111/iju.14230 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iju.14230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie&#x2019;s disease surgery: a comprehensive review. J Sex Med. 2007;4(3):581&#x2013;95. https://doi.org/10.1111/j.1743-6109.2007.00461.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00461.x</ArticleId><ArticleId IdType="pubmed">17419820</ArticleId></ArticleIdList></Reference><Reference><Citation>Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, et al. A systematic review on ischemic priapism and immediate implantation: do we need more data? Sex Med Rev. 2019;7(3):530&#x2013;4. https://doi.org/10.1016/j.sxmr.2018.10.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.10.007</ArticleId><ArticleId IdType="pubmed">30898595</ArticleId></ArticleIdList></Reference><Reference><Citation>Y&#xfc;cel &#xd6;B, Paz&#x131;r Y, Kad&#x131;o&#x11f;lu A. Penile prosthesis implantation in priapism. Sex Med Rev. 2018;6(2):310&#x2013;8. https://doi.org/10.1016/j.sxmr.2017.08.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.08.002</ArticleId><ArticleId IdType="pubmed">28916463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Borley NC, Allen C, Kirkham A, Freeman A, Minhas S, et al. The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int. 2010;106(11):1714&#x2013;8. https://doi.org/10.1111/j.1464-410x.2010.09368.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.2010.09368.x</ArticleId><ArticleId IdType="pubmed">20438564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra K, Loeb A, Bukavina L, Baumgarten A, Beilan J, Mendez M, et al. Management of priapism: a contemporary review. Sex Med Rev. 2020;8(1):131&#x2013;9. https://doi.org/10.1016/j.sxmr.2019.01.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.01.001</ArticleId><ArticleId IdType="pubmed">30898593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002;90(9):893&#x2013;7. https://doi.org/10.1046/j.1464-410x.2002.03058.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.2002.03058.x</ArticleId><ArticleId IdType="pubmed">12460352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, Freeman A, Rees R, Christopher AN, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033&#x2013;8. https://doi.org/10.1016/j.eururo.2008.09.044 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2008.09.044</ArticleId><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Zhao LC, Morey AF, Siegel JA, Belsante MJ, Seideman CA, et al. Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism. J Sex Med. 2015;12(3):824&#x2013;6. https://doi.org/10.1111/jsm.12803 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12803</ArticleId><ArticleId IdType="pubmed">25536880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, De Luca F, Raheem AA, Garaffa G, Christopher N, Muneer A, et al. Early insertion of a malleable penile prosthesis in ischaemic priapism allows later upsizing of the cylinders. Scand J Urol. 2015;49(6):468&#x2013;71. https://doi.org/10.3109/21681805.2015.1059359 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21681805.2015.1059359</ArticleId><ArticleId IdType="pubmed">26116193</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010;183(6):2300&#x2013;3. https://doi.org/10.1016/j.juro.2010.02.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.02.014</ArticleId><ArticleId IdType="pubmed">20400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, Garaffa G, Raheem AA, Christopher AN, Muneer A, Ralph DJ. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014;114(4):576&#x2013;81. https://doi.org/10.1111/bju.12686 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.12686</ArticleId><ArticleId IdType="pubmed">25383397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, Freeman A, Rees R, Christopher AN, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033&#x2013;8. https://doi.org/10.1016/j.eururo.2008.09.044 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2008.09.044</ArticleId><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Sluis WB, Pigot GL, El-Tamimi M, Ronkes BL, de Haseth KB, &#xd6;zer M, et al. A retrospective cohort study on surgical outcomes of penile prosthesis implantation surgery in transgender men after phalloplasty. Urology. 2019;132:195&#x2013;201. https://doi.org/10.1016/j.urology.2019.06.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2019.06.010</ArticleId><ArticleId IdType="pubmed">31229517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooker SA, Vyas KS, DiFilippo EC, Nolan IT, Morrison SD, Santucci RA. The Rise of the Neophallus: A Systematic Review of Penile Prosthetic Outcomes and Complications in Gender-Affirming Surgery. J Sex Med. 2019;16(5):661&#x2013;72. https://doi.org/10.1016/j.jsxm.2019.03.009 A very thorough review regarding the timing, selection, and placement of penile prosthesis after phalloplasty in trans men. Also, intraoperative and postoperative complications as well as recommendations for prevention of these are discussed.</Citation></Reference><Reference><Citation>Kocjancic E, Iacovelli V. Penile prostheses. Clin Plast Surg. 2018;45(3):407&#x2013;14. https://doi.org/10.1016/j.cps.2018.03.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cps.2018.03.012</ArticleId><ArticleId IdType="pubmed">29908630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang A, Aizen JM, Cohen AJ, Bales GT, Pariser JJ. Techniques and considerations of prosthetic surgery after phalloplasty in the transgender male. Transl Androl Urol. 2019;8(3):273&#x2013;82. https://doi.org/10.21037/tau.2019.06.02 .</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2019.06.02</ArticleId><ArticleId IdType="pubmed">31380234</ArticleId><ArticleId IdType="pmc">6626310</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison SD, Chen ML, Crane CN. An overview of female-to-male gender-confirming surgery. Nat Rev Urol. 2017;14(8):486&#x2013;500. https://doi.org/10.1038/nrurol.2017.64 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2017.64</ArticleId><ArticleId IdType="pubmed">28508877</ArticleId><ArticleId IdType="pmc">28508877</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic ML, Bencic M, Kojovic V, Stojanovic B, Bizic M, Kojic S, et al. Musculocutaneous latissimus dorsi flap for phalloplasty in female to male gender affirmation surgery. World J Urol. 2019;37(4):631&#x2013;7. https://doi.org/10.1007/s00345-019-02641-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-019-02641-w</ArticleId><ArticleId IdType="pubmed">30673829</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic ML, Bizic MR, Duisin D, Bouman M-B, Buncamper M. Reversal surgery in regretful male-to-female transsexuals after sex reassignment surgery. J Sex Med. 2016;13(6):1000&#x2013;7. https://doi.org/10.1016/j.jsxm.2016.02.173 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.02.173</ArticleId><ArticleId IdType="pubmed">27156012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoebeke PB, Decaestecker K, Beysens M, Opdenakker Y, Lumen N, Monstrey SM. Erectile implants in female-to-male transsexuals: our experience in 129 patients. Eur Urol. 2010;57(2):334&#x2013;41. https://doi.org/10.1016/j.eururo.2009.03.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2009.03.013</ArticleId><ArticleId IdType="pubmed">19303200</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer ND, Dick B, Gabrielson AT, Alzweri LM, Hellstrom WJG. Penile prosthesis complications: planning, prevention, and decision making. Sex Med Rev. 2019;7(2):349&#x2013;59. https://doi.org/10.1016/j.sxmr.2018.04.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.04.002</ArticleId><ArticleId IdType="pubmed">30033128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YD, Yang SO, Lee JK, Jung TY, Shim HB. Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol. 2008;15(10):919&#x2013;23. https://doi.org/10.1111/j.1442-2042.2008.02115.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02115.x</ArticleId><ArticleId IdType="pubmed">18651861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zermann D-H, Kutzenberger J, Sauerwein D, Schubert J, Loeffler U. Penile prosthetic surgery in neurologically impaired patients: long-term followup. J Urol. 2006;175(3):1041&#x2013;4. https://doi.org/10.1016/s0022-5347(05)00344-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(05)00344-7</ArticleId><ArticleId IdType="pubmed">16469612</ArticleId><ArticleId IdType="pmc">16469612</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khallaf HH. Analysis of sexual functions in male nondiabetic hemodialysis patients and renal transplant recipients. Transpl Int. 2010;23(2):176&#x2013;81. https://doi.org/10.1111/j.1432-2277.2009.00972.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-2277.2009.00972.x</ArticleId><ArticleId IdType="pubmed">19778342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota RL, Fonseca R, Santos JC, Covita AM, Marques N, Matias P, et al. Sexual dysfunction and satisfaction in kidney transplant patients. J Sex Med. 2019;16(7):1018&#x2013;28. https://doi.org/10.1016/j.jsxm.2019.03.266 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.03.266</ArticleId><ArticleId IdType="pubmed">31010779</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry JM. Treating erectile dysfunction in renal transplant recipients. Drugs. 2007;67(7):975&#x2013;83. https://doi.org/10.2165/00003495-200767070-00003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200767070-00003</ArticleId><ArticleId IdType="pubmed">17488143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuellar DC, Sklar GN. Penile prosthesis in the organ transplant recipient. Urology. 2001;57(1):138&#x2013;41. https://doi.org/10.1016/s0090-4295(00)00876-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(00)00876-1</ArticleId><ArticleId IdType="pubmed">11164159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun AY, Babbar P, Gill BC, Angermeier KW, Montague DK. Penile prosthesis in solid organ transplant recipients &#x2013; a matched cohort study. Urology. 2018;117:86&#x2013;8. https://doi.org/10.1016/j.urology.2018.03.048 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2018.03.048</ArticleId><ArticleId IdType="pubmed">29656065</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumavalavan N, Gross MS, Munarriz R. Techniques of ectopic reservoir placement and their pitfalls. TJ Sex Med. 2017;14(11):1451&#x2013;4. https://doi.org/10.1016/j.jsxm.2017.09.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S, Delk J. Historical advances in penile prostheses. Int J Impot Res. 2000;12(S4):S101&#x2013;7. https://doi.org/10.1038/sj.ijir.3900586 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900586</ArticleId><ArticleId IdType="pubmed">11035395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Treatment alternatives for the infected penile implant. Int J Impot Res. 2003;15(suppl 5):S147&#x2013;9. https://doi.org/10.1038/sj.ijir.3901092 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901092</ArticleId><ArticleId IdType="pubmed">14551595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. 2000;163(2):481&#x2013;2. https://doi.org/10.1016/s0022-5347(05)67906-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-5347(05)67906-2</ArticleId><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD. Historical review of penile prosthesis design and surgical techniques: part 1 of a three-part review series on penile prosthetic surgery. J Sex Med. 2009;6(3):675&#x2013;81. https://doi.org/10.1111/j.1743-6109.2008.01145.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01145.x</ArticleId><ArticleId IdType="pubmed">19207278</ArticleId></ArticleIdList></Reference><Reference><Citation>Selph JP, Carson CC. Penile prosthesis infection: approaches to prevention and treatment. Urol Clin North Am. 2011;38(2):227&#x2013;35. https://doi.org/10.1016/j.ucl.2011.02.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ucl.2011.02.007</ArticleId><ArticleId IdType="pubmed">21621089</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters CE, Carlos EC, Lentz AC. Purulent inflatable penile prostheses can be safely immediately salvaged in insulin-dependent diabetics. J Sex Med. 2018;15(12):1673&#x2013;7. https://doi.org/10.1016/j.jsxm.2018.10.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.10.002</ArticleId><ArticleId IdType="pubmed">30446468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Carrasquillo RJ, Thornton A, Greenfield JM, Levine LA, et al. Multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis. J Sex Med. 2017;14(3):455&#x2013;63. https://doi.org/10.1016/j.jsxm.2017.01.007 A retrospective multi-institutional study in which 227 cultures were obtained in explantation or salvage procedures. A high incidence of Candida species as well as anaerobes was found, and how the antibiotics recommended by the American Urological Association and the European Urological Association do not cover many of the organisms that were grown.</Citation></Reference><Reference><Citation>Gross MS, Phillips EA, Balen A, Eid JF, Yang C, Simon R, et al. The malleable implant salvage technique: infection outcomes after Mulcahy salvage procedure and replacement of infected inflatable penile prosthesis with malleable prosthesis. J Urol. 2016;195(3):694&#x2013;8. https://doi.org/10.1016/j.juro.2015.08.091 A retrospective multi-institution study, in which employment of the Mulcahy salvage technique was used but with insertion of a malleable implant. Ninety-three percent of the patients that underwent this modified technique remained infection free in the postoperative period.</Citation></Reference><Reference><Citation>Lopategui DM, Balise RR, Bouzoubaa LA, Wilson SK, Kava BR. The impact of immediate salvage surgery on corporeal length preservation in patients presenting with penile implant infections. J Urol. 2018;200(1):171&#x2013;7. https://doi.org/10.1016/j.juro.2018.01.082 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.01.082</ArticleId><ArticleId IdType="pubmed">29408215</ArticleId></ArticleIdList></Reference><Reference><Citation>Swords K, Martinez DR, Lockhart JL, Carrion R. A preliminary report on the usage of an intracorporal antibiotic cast with synthetic high purity CaSO4 for the treatment of infected penile implant. J Sex Med. 2013;10(4):1162&#x2013;9. https://doi.org/10.1111/jsm.12060 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12060</ArticleId><ArticleId IdType="pubmed">23347377</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O, Shaeer K, Soliman AbdelRahman IF. Salvage and extracapsular implantation for penile prosthesis infection or extrusion. J Sex Med. 2019;16(5):755&#x2013;9. https://doi.org/10.1016/j.jsxm.2019.02.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.02.005</ArticleId><ArticleId IdType="pubmed">30898492</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler TS, Modder JK, Dupree JM, Bush NC, McVary KT. Malleable implant substitution for the management of penile prosthesis pump erosion: a pilot study. J Sex Med. 2009;6(5):1474&#x2013;8. https://doi.org/10.1111/j.1743-6109.2009.01236.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01236.x</ArticleId><ArticleId IdType="pubmed">19453933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta NK, Sulaver R, Welliver C, Kottwitz M, Frederick L, Dynda D, et al. Scrotoplasty at time of penile implant is at high risk for dehiscence in diabetics. J Sex Med. 2019;16(4):602&#x2013;8. https://doi.org/10.1016/j.jsxm.2019.02.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.02.001</ArticleId><ArticleId IdType="pubmed">30852109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Surgical techniques: crural perforation during penile prosthetic surgery. J Sex Med. 2006;3(1):177&#x2013;80. https://doi.org/10.1111/j.1743-6109.2005.00199.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00199.x</ArticleId><ArticleId IdType="pubmed">16409235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. The prevention and management of noninfectious complications of penile implants. Sex Med Rev. 2015;3(3):203&#x2013;13. https://doi.org/10.1002/smrj.41 Excellent summary for the prevention and the management of most intraoperative and postoperative complications of penile implant surgery.</Citation></Reference><Reference><Citation>Anele UA, Le BV, Burnett AL. Suprapubic cystostomy for the management of urethral injuries during penile prosthesis implantation. Sex Med. 2014;2(4):178&#x2013;81. https://doi.org/10.1002/sm2.44 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sm2.44</ArticleId><ArticleId IdType="pubmed">25548649</ArticleId><ArticleId IdType="pmc">4272249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Fam M. Penile prosthesis surgery in the management of erectile dysfunction. Arab J Urol. 2013;11(3):245&#x2013;53. https://doi.org/10.1016/j.aju.2013.05.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aju.2013.05.002</ArticleId><ArticleId IdType="pubmed">26558089</ArticleId><ArticleId IdType="pmc">4442986</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpman E, DiGiorgio L, Carrion RE. Distal biologic cap for impending erosion. J Sex Med. 2020;17:551&#x2013;5. https://doi.org/10.1016/j.jsxm.2019.11.265 A novel technique for the management of impending erosion with the use of a biological cap placed in the distal end of the penile implant.</Citation></Reference><Reference><Citation>Pinheiro MA, Barroso Filho HB, Mesquita FJ, Teixeira de Souza I, Silva Gumaraes R, Moura Santos E, et al. Multiple site fracture of both rods in a malleable penile implant. Case Rep Urol. 2016;2016:9564904&#x2013;3. https://doi.org/10.1155/2016/9564904 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9564904</ArticleId><ArticleId IdType="pubmed">27066289</ArticleId><ArticleId IdType="pmc">4811081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt IH, Yonguc T, Arslan B, Kozacioglu Z, Degirmenci T, Polat S. Minareci S Spontaneous bilateral rod fracture of malleable penile prosthesis. Can Urol Assoc J. 2014;8(9&#x2013;10):E739&#x2013;40. https://doi.org/10.5489/cuaj.2005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.2005</ArticleId><ArticleId IdType="pubmed">25408816</ArticleId><ArticleId IdType="pmc">4216308</ArticleId></ArticleIdList></Reference><Reference><Citation>Akand M, &#xd6;zayar A, Yaman &#xd6;, Demirel C. Mechanical failure with malleable penile prosthesis. Urology. 2007;70(5):1007.e11&#x2013;2. https://doi.org/10.1016/j.urology.2007.08.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar IG, Dilli A, Keyik B, Hekimo&#x11f;lu B. Fracture of a semirigid penile prosthesis: MRI findings and review of the literature. CausaPedia. 2014;3:734 Accessed April 29, 2019. http://causapedia.com/manuscript/734/makale/radyoloji/fracture-of-a-semirigid-penile-prosthesis-mri-findings-and-review-of-the-literature.htm .</Citation></Reference><Reference><Citation>Silverstein AD, Henry GD, Evans B, Pasmore M, Simmons CJ, Donatucci CF. Biofilm formation on clinically noninfected penile prostheses. J Urol. 2006;176(3):1008&#x2013;11. https://doi.org/10.1016/j.juro.2006.04.034 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.04.034</ArticleId><ArticleId IdType="pubmed">16890680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Costerton JW. Biofilm and penile prosthesis infections in the era of coated implants: a review. J Sex Med. 2012;9(1):44&#x2013;53. https://doi.org/10.1111/j.1743-6109.2011.02428.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02428.x</ArticleId><ArticleId IdType="pubmed">21951338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Efficacy of antibiotic impregnation of inflatable penile prosthesis in decreasing infection in original implants. J Urol. 2004;171(4):1611&#x2013;4. https://doi.org/10.1097/01.ju.0000118245.66976.e1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000118245.66976.e1</ArticleId><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahon J, Dornbier R, Wegrzyn G, Faraday MM, Sadeghi-Nejad H, Hakim L, et al. Infectious adverse events following the placement of a penile prosthesis: a systematic review. Sex Med Rev. 2020;8(2):348&#x2013;54. https://doi.org/10.1016/j.sxmr.2019.07.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.07.005</ArticleId><ArticleId IdType="pubmed">31519461</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Carson CC, Chapin AK, Ginkel AM. Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol. 2012;188(3):899&#x2013;903. https://doi.org/10.1016/j.juro.2012.04.116 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.04.116</ArticleId><ArticleId IdType="pubmed">22819402</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33382371</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1911-6470</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Canadian Urological Association journal = Journal de l'Association des urologues du Canada</Title><ISOAbbreviation>Can Urol Assoc J</ISOAbbreviation></Journal><ArticleTitle>Access to penile prostheses differ across provinces in Canada: A survey of Canadian urologists.</ArticleTitle><Pagination><StartPage>E346</StartPage><EndPage>E349</EndPage><MedlinePgn>E346-E349</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5489/cuaj.6867</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Surgical implantation of a penile prosthesis is the gold standard treatment for refractory erectile dysfunction. The purpose of this study was to investigate the use of and access to these procedures in Canada.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Canadian urologists known to perform penile prostheses procedures were surveyed on areas such as surgical volume, type of device used, and the direct cost to patients for both malleable and inflatable devices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 50 urologists invited to participate in the study, 34 (68%) completed the online survey. Participants represented nine Canadian provinces and included a mix of academic (65%) and community (35%) urologists. Most participants (79%) performed less than 10 procedures per year. Roughly three-quarters of participants (74%) used inflatable devices in over 90% of cases, while half implanted inflatable devices exclusively. The most common devices implanted were American Medical Systems (AMS). Participants from Alberta, Manitoba, New Brunswick, and Newfoundland reported full coverage for both malleable and inflatable devices. Saskatchewan was the only province where no coverage was reported. The remaining provinces were found to have variable degrees of coverage. Across all centers without full coverage, the median reported cost to patients for a malleable and inflatable device was $5000 and $6000, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The urologists surveyed most commonly perform inflatable penile prostheses procedures. Significant geographical differences exist with respect to reported coverage for these procedures. This study highlights the need for continued advocacy on behalf of the urological community towards the goal of equity in coverage for penile prostheses across Canada.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whalen</LastName><ForeName>Stewart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Halifax, NS Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langille</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Saint John, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Josh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Halifax, NS Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailly</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Halifax, NS Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Urol Assoc J</MedlineTA><NlmUniqueID>101312644</NlmUniqueID><ISSNLinking>1911-6470</ISSNLinking></MedlineJournalInfo><CoiStatement><b>Competing interests:</b> The authors report no competing personal or financial interests related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>12</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33382371</ArticleId><ArticleId IdType="pmc">PMC8279244</ArticleId><ArticleId IdType="doi">10.5489/cuaj.6867</ArticleId><ArticleId IdType="pii">cuaj.6867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213&#x2013;9. doi: 10.1001/archinte.166.2.213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.2.213</ArticleId><ArticleId IdType="pubmed">16432091</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Klein LT, Seidman S, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52(5):848&#x2013;52. doi: 10.1016/S0090-4295(98)00292-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(98)00292-1</ArticleId><ArticleId IdType="pubmed">9801112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CJ, Mulhall JP, Roth AJ, et al. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011;8:560&#x2013;6. doi: 10.1111/j.1743-6109.2010.02127.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02127.x</ArticleId><ArticleId IdType="pubmed">21155979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella AJ, Lee JC, Carrier S, et al. 2015 CUA practice guidelines for erectile dysfunction. Can Urol Assoc J. 2015;9:23&#x2013;9. doi: 10.5489/cuaj.2699.</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.2699</ArticleId><ArticleId IdType="pmc">PMC4336024</ArticleId><ArticleId IdType="pubmed">25737750</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Rigatti P, Carmignani G, et al. AMS three-piece inflatable implants for erectile dysfunction: A long-term, multi-institutional study in 200 consecutive patients. Eur Urol. 2000;37:50&#x2013;5. doi: 10.1159/000020099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000020099</ArticleId><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD. Historical review of penile prosthesis design and surgical techniques: Part 1 of a three-part review series on penile prosthetic surgery. J Sex Med. 2009;6:675&#x2013;81. doi: 10.1111/j.1743-6109.2008.01145.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01145.x</ArticleId><ArticleId IdType="pubmed">19207278</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: Current recommendations from the international consultation on sexual medicine. J Sex Med. 2016;13:489&#x2013;518. doi: 10.1016/j.jsxm.2016.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol. 2016;13:33&#x2013;46. doi: 10.1038/nrurol.2015.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2015.270</ArticleId><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Natali A, Olianas R, Fisch M. Penile implantation in Europe: Successes and complications with 253 implants in Italy and Germany. J Sex Med. 2008;5:1503&#x2013;12. doi: 10.1111/j.1743-6109.2008.00819.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00819.x</ArticleId><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chierigo F, Capogrosso P, Deh&#xf2; F, et al. Long-term follow-up after penile prosthesis implantation-survival and quality of life outcomes. J Sex Med. 2019;16:1827&#x2013;33. doi: 10.1016/j.jsxm.2019.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.08.001</ArticleId><ArticleId IdType="pubmed">31501062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YD, Yang SO, Lee JK, et al. Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol. 2008;15:919&#x2013;23. doi: 10.1111/j.1442-2042.2008.02115.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02115.x</ArticleId><ArticleId IdType="pubmed">18651861</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: Experience with 504 procedures. BJU Int. 2006;97:129&#x2013;33. doi: 10.1111/j.1464-410X.2005.05907.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses RA, Anderson RE, Kim J, et al. Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: A cost-effectiveness analysis. Transl Androl Urol. 2019;8:387&#x2013;94. doi: 10.21037/tau.2019.03.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2019.03.10</ArticleId><ArticleId IdType="pmc">PMC6732088</ArticleId><ArticleId IdType="pubmed">31555563</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Brandes ER, Chang SL, et al. Trends in penile prosthesis implantation and analysis of predictive factors for removal. World J Urol. 2019;37:639&#x2013;46. doi: 10.1007/s00345-018-2491-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-018-2491-4</ArticleId><ArticleId IdType="pubmed">30251052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashanian JA, Golan R, Sun T, et al. Trends in penile prosthetics: Influence of patient demographics, surgeon volume, and hospital volume on type of penile prosthesis inserted in New York State. J Sex Med. 2018;15:245&#x2013;50. doi: 10.1016/j.jsxm.2017.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.12.005</ArticleId><ArticleId IdType="pubmed">29292061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajic P, Mahon J, Faraday M, et al. Etiology of erectile dysfunction and duration of symptoms in patients undergoing penile prosthesis: A systematic review. Sex Med Rev. 2020;8:333&#x2013;7. doi: 10.1016/j.sxmr.2019.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.05.003</ArticleId><ArticleId IdType="pubmed">31278064</ArticleId></ArticleIdList></Reference><Reference><Citation>Menard J, Tremeaux J, Faix A, et al. Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: A comparison with patients with vasculogenic erectile dysfunction. J Sex Med. 2011;8:3479&#x2013;86. doi: 10.1111/j.1743-6109.2011.02466.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02466.x</ArticleId><ArticleId IdType="pubmed">21951645</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay B, Moon D, Love C, et al. Quality of life, psychological functioning, and treatment satisfaction of men who have undergone penile prosthesis surgery following robot-assisted radical prostatectomy. J Sex Med. 2017;14:1612&#x2013;20. doi: 10.1016/j.jsxm.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.10.001</ArticleId><ArticleId IdType="pubmed">29111200</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33368421</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0272</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Andrologia</Title><ISOAbbreviation>Andrologia</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the caverno-dorsal vein shunt (Barry shunt) on prolonged ischaemic priapism and its effect on the post-operative long-term erectile function.</ArticleTitle><Pagination><StartPage>e13945</StartPage><MedlinePgn>e13945</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/and.13945</ELocationID><Abstract><AbstractText>Ischaemic priapism is the most common form of priapism and requires urgent treatment. In this study, we evaluated the effectiveness of the caverno-dorsal vein shunt on resolution&#xa0;of ischaemic&#xa0;priapism and on the post-operative long-term erectile function in patients presenting with priapism. The study included 10 patients admitted to our hospital for priapism between 2010 and 2018. The median age of the patients was 31 (24-66) years. The median priapism time was 13.5 (7-38) hours. The blood gas measurements were taken from the corpus cavernosum, and the drainage of the corpus cavernosum was performed as an emergency intervention. Then, the corpus cavernosum was irrigated with 0.01% adrenaline 5 times in 20-min intervals. The caverno-dorsal vein shunt procedure was performed in cases without regression of priapism. Two months after, the operation shunt was closed. Detumescence occurred in all patients. Eight of 10 patients maintained their erectile function. In 2 patients, severe erectile dysfunction occurred at post-operative 2&#xa0;months following a priapism attack and penile prosthesis implantation was performed in these 2 patients. Our study showed that caverno-dorsal vein shunt procedure is effective in providing detumescence and maintaining potency in cases with ischaemic priapism. In our opinion, caverno-dorsal vein shunt can be considered as the first treatment of choice for refractory low-flow priapism.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley-VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Micoogullari</LastName><ForeName>Uygar</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-4729-6104</Identifier><AffiliationInfo><Affiliation>Department of Urology, Tepecik Education and Research Hospital, University of Health Sciences, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unal</LastName><ForeName>Selman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, School of Medicine, Ankara City Hospital, Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alijla</LastName><ForeName>Amjad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Medisun Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okulu</LastName><ForeName>Emrah</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, School of Medicine, Ankara City Hospital, Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micoogullari</LastName><ForeName>Lutfiye Dilsad</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Pathology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayigil</LastName><ForeName>Onder</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Urology, School of Medicine, Ankara City Hospital, Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Andrologia</MedlineTA><NlmUniqueID>0423506</NlmUniqueID><ISSNLinking>0303-4569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="Y">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Barry shunt</Keyword><Keyword MajorTopicYN="N">caverno-dorsal vein shunt</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">ischaemic priapism</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33368421</ArticleId><ArticleId IdType="doi">10.1111/and.13945</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Aizid, I. H., &amp; Lawrence, S. H. (1994). Deep dorsal vein to corporal body shunt: An operation for recurrent priapism. Journal of Andrology, 15, 74S. https://doi.org/10.1002/j.1939-4640.1994.tb01715.x</Citation></Reference><Reference><Citation>Barry, J. M. (1976). Priapism: Treatment with corpus cavernosum to dorsal vein of penis shunts. The Journal of Urology, 116(6), 754-756. https://doi.org/10.1016/s0022-5347(17)58998-3</Citation></Reference><Reference><Citation>Brant, W. O., Garcia, M. M., Bella, A. J., Chi, T., &amp; Lue, T. F. (2009). T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. The Journal of Urology, 181(4), 1699-1705. https://doi.org/10.1016/j.juro.2008.12.021</Citation></Reference><Reference><Citation>Broderick, G. A., Kadioglu, A., Bivalacqua, T. J., Ghanem, H., Nehra, A., &amp; Shamloul, R. (2010). Priapism: Pathogenesis, epidemiology, and management. The Journal of Sexual Medicine, 7(1 Pt 2), 476-500. https://doi.org/10.1111/j.1743-6109.2009.01625.x</Citation></Reference><Reference><Citation>El-Bahnasawy, M. S., Dawood, A., &amp; Farouk, A. (2002). Low-flow priapism: Risk factors for erectile dysfunction. BJU International, 89(3), 285-290. https://doi.org/10.1046/j.1464-4096.2001.01510.x</Citation></Reference><Reference><Citation>Garcia, M. M., Shindel, A. W., &amp; Lue, T. F. (2008). T-shunt with or without tunnelling for prolonged ischaemic priapism. BJU International, 102(11), 1754-1764. https://doi.org/10.1111/j.1464-410X.2008.08174.x</Citation></Reference><Reference><Citation>Grayhack, J. T., McCullough, W., O'Conor, V. J. Jr, &amp; Trippel, O. (1964). Venous bypass to control priapism. Investigative Urology, 1, 509-513.</Citation></Reference><Reference><Citation>Klugo, R. C., &amp; Olsson, C. A. (1972). Urethrocavernous fistula: Complication of cavernospongiosal shunt. The Journal of Urology, 108(5), 750-751. https://doi.org/10.1016/s0022-5347(17)60858-9</Citation></Reference><Reference><Citation>Kulmala, R. V., Lehtonen, T. A., Lindholm, T. S., &amp; Tammela, T. L. (1995). Permanent open shunt as a reason for impotence or reduced potency after surgical treatment of priapism in 26 patients. International Journal of Impotence Research, 7(3), 175-180.</Citation></Reference><Reference><Citation>Lue, T. F., &amp; Pescatori, E. S. (2006). Distal cavernosum-glans shunts for ischemic priapism. The Journal of Sexual Medicine, 3(4), 749-752. https://doi.org/10.1111/j.1743-6109.2006.00281.x</Citation></Reference><Reference><Citation>Melman, A., &amp; Serels, S. (2000). Priapism. International Journal of Impotence Research, 12(Suppl 4), S133-S139. https://doi.org/10.1038/sj.ijir.3900592</Citation></Reference><Reference><Citation>Montague, D. K., Jarow, J., Broderick, G. A., Dmochowski, R. R., Heaton, J. P. W., Lue, T. F., Nehra, A., &amp; Sharlip, I. D., Members of the Erectile Dysfunction Guideline Update Panel &amp; American Urological Association. (2003). American Urological Association guideline on the management of priapism. The Journal of Urology, 170(4 Pt 1), 1318-1324. https://doi.org/10.1097/01.ju.0000087608.07371.ca</Citation></Reference><Reference><Citation>Nixon, R. G., O'Connor, J. L., &amp; Milam, D. F. (2003). Efficacy of shunt surgery for refractory low flow priapism: A report on the incidence of failed detumescence and erectile dysfunction. The Journal of Urology, 170(3), 883-886. https://doi.org/10.1097/01.ju.0000081291.37860.a5</Citation></Reference><Reference><Citation>Osmonov, D. K., Aksenov, A., Guerra Sandoval, A. N., Kalz, A., &amp; Juenemann, K. P. (2014). Barry shunt for treatment of a 76-hour stuttering priapism without subsequent erectile dysfunction. Research and Reports in Urology, 6, 91-95. https://doi.org/10.2147/RRU.S60557</Citation></Reference><Reference><Citation>Pryor, J., Akkus, E., Alter, G., Jordan, G., Lebret, T., Levine, L., Mulhall, J., Perovic, S., Ralph, D., &amp; Stackl, W. (2004). Priapism. The Journal of Sexual Medicine, 1(1), 116-120. https://doi.org/10.1111/j.1743-6109.2004.10117.x</Citation></Reference><Reference><Citation>Quackels, R. (1964). Cure d'un cas de pr&#x131;ap&#x131;sme par anastomose cavernospong&#x131;euse [treatment of a case of pr&#x131;ap&#x131;sm by cavernospong&#x131;ous anastomos&#x131;s]. Acta Urologica Belgica, 32, 5-13.</Citation></Reference><Reference><Citation>Rosen, R. C., Cappelleri, J. C., Smith, M. D., Lipsky, J., &amp; Pe&#xf1;a, B. M. (1999). Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International Journal of Impotence Research, 11(6), 319-326. https://doi.org/10.1038/sj.ijir.3900472</Citation></Reference><Reference><Citation>Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., &amp; Mishra, A. (1997). The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49(6), 822-830. https://doi.org/10.1016/s0090-4295(97)00238-0</Citation></Reference><Reference><Citation>Sacher, E. C., Sayegh, E., Frensilli, F., Crum, P., &amp; Akers, R. (1972). Cavernospongiosum shunt in the treatment of priapism. The Journal of Urology, 108(1), 97-100. https://doi.org/10.1016/s0022-5347(17)60651-7</Citation></Reference><Reference><Citation>Salonia, A., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Vardi, Y., Wespes, E., Hatzimouratidis, K., &amp; European Association of Urology. (2014). European Association of Urology guidelines on priapism. European Urology, 65(2), 480-489. https://doi.org/10.1016/j.eururo.2013.11.008</Citation></Reference><Reference><Citation>Spycher, M. A., &amp; Hauri, D. (1986). The ultrastructure of the erectile tissue in priapism. The Journal of Urology, 135(1), 142-147. https://doi.org/10.1016/s0022-5347(17)45549-2</Citation></Reference><Reference><Citation>Tabibi, A., Abdi, H., &amp; Mahmoudnejad, N. (2010). Erectile function and dysfunction following low flow priapism: A comparison of distal and proximal shunts. Urology Journal, 7(3), 174-177.</Citation></Reference><Reference><Citation>Tay, Y. K., Spernat, D., Rzetelski-West, K., Appu, S., &amp; Love, C. (2012). Acute management of priapism in men. BJU International, 109(Suppl 3), 15-21. https://doi.org/10.1111/j.1464-410X.2012.11039.x</Citation></Reference><Reference><Citation>Winter, C. C. (1976). Cure of idiopathic priapism: New procedure for creating fistula between glans penis and corpora cavernosa. Urology, 8(4), 389-391. https://doi.org/10.1016/0090-4295(76)90498-2</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33206574</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-2422</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Expert review of medical devices</Title><ISOAbbreviation>Expert Rev Med Devices</ISOAbbreviation></Journal><ArticleTitle>Device profile of the Ambicor two-piece inflatable penile prosthesis for treatment of erectile dysfunction: overview of its safety and efficacy.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>14</EndPage><MedlinePgn>9-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17434440.2021.1853524</ELocationID><Abstract><AbstractText><b>Introduction</b>: Erectile dysfunction is one of the most common forms of male sexual dysfunction worldwide. Over the past several decades, the inflatable penile prosthesis has emerged as the gold standard surgical treatment for refractory erectile dysfunction. The vast majority of current penile implants are three-piece inflatable penile prostheses. However, the design of the two-piece inflatable penile prosthesis offers certain advantages for both the patient and surgeon, and may be the preferred penile implant for certain patient populations.<b>Areas covered</b>: The Ambicor two-piece inflatable penile prosthesis (Men's Health Division, Boston Scientific, Marlborough, MA, USA) was introduced in 1994 by American Medical Systems (Minnetonka, MN, USA, now a subsidiary of Boston Scientific) and received further design improvements in 1998 to address early mechanical issues with the device. Currently, the Ambicor is the only two-piece inflatable penile prosthesis available in the United States. This review article aims to provide an overview of the Ambicor device and summarize the best available clinical data regarding outcomes and safety.<b>Expert opinion</b>: While two-piece devices account for a small minority of current penile implants, the Ambicor should be considered a safe, reliable, and effective option for appropriately selected patients with the advantage of avoiding blind reservoir placement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Urology, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush Medical College, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajic</LastName><ForeName>Petar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Urology, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Med Devices</MedlineTA><NlmUniqueID>101230445</NlmUniqueID><ISSNLinking>1743-4440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004864" MajorTopicYN="Y">Equipment and Supplies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="Y">Prosthesis Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ambicor</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">inflatable penile prosthesis</Keyword><Keyword MajorTopicYN="N">penile implant</Keyword><Keyword MajorTopicYN="N">sexual dysfunction</Keyword><Keyword MajorTopicYN="N">two-piece penile prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>17</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33206574</ArticleId><ArticleId IdType="doi">10.1080/17434440.2021.1853524</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33204007</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>409</EndPage><MedlinePgn>401-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-020-00374-8</ELocationID><Abstract><AbstractText>Radical prostatectomy (RP) represents one of the most commonly used first-line treatment modalities in men with localized prostate cancer. One of the most feared post-surgical complications is erectile dysfunction (ED), usually caused by direct damage to the cavernous nerves or due to neuropraxia. Penile rehabilitation is an emerging concept that was proposed to stimulate and accelerate recovery of erectile function after RP. The goal is to improve blood flow to the penis, increasing cavernous oxygenation and avoiding fibrosis. The most common used modalities include oral phosphodiesterase type 5 inhibitors (PDE5-I), vacuum erection devices (VEDs), intracorporeal injection (ICI) therapy, medicated urethral system for erections (MUSE), and a combination of these treatments. For those patients with severe ED, ED refractory to medical therapy and/or seeking long term reliable results, the penile prosthesis implant remains an excellent alternative. We conducted a broad review of post-prostatectomy ED prevalence with different techniques and the success rates of the different therapeutic approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Thiago Fernandes Negris</ForeName><Initials>TFN</Initials><Identifier Source="ORCID">0000-0002-7410-7025</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States of America. thiagofernandesnl@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bitran</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frech</LastName><ForeName>Fabio Stefano</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0002-0689-6464</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Ranjith</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33204007</ArticleId><ArticleId IdType="doi">10.1038/s41443-020-00374-8</ArticleId><ArticleId IdType="pii">10.1038/s41443-020-00374-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Cancer Society. Facts &amp; Figures 2020. Atlanta, GA: American Cancer Society; 2020.</Citation></Reference><Reference><Citation>Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618&#x2013;29.</Citation></Reference><Reference><Citation>Borregales LD, Berg WT, Tal O, Wambi C, Kaufman S, Gaya JM, et al. &#x2018;Trifecta&#x2019; after radical prostatectomy: is there a standard definition? BJU Int. 2013;112:60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23759009</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol. 2010;57:179&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19931974</ArticleId></ArticleIdList></Reference><Reference><Citation>Masterson TA, Serio AM, Mulhall JP, Vickers AJ, Eastham JA. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. BJU Int. 2008;101:1217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18279446</ArticleId><ArticleId IdType="pmc">2568897</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman L, Godoy G, Lepor H. Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol. 2009;181:731&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19091349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62:418&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SC, Song C, Kim W, Kang T, Park J, Jeong IG, et al. Factors determining functional outcomes after radical prostatectomy: robot-assisted versus retropubic. Eur Urol. 2011;60:413&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21612859</ArticleId></ArticleIdList></Reference><Reference><Citation>Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, Blute ML, et al. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int. 2009;103:448&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18778350</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162:433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer. 2001;91:2046&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391584</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillonneau B, Cathelineau X, Doublet JD, Baumert H, Vallancien G. Laparoscopic radical prostatectomy: assessment after 550 procedures. Crit Rev Oncol Hematol. 2002;43:123&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12191734</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz R, Salomon L, Hoznek A, de la Taille A, Vordos D, Cicco A, et al. Patient reported sexual function following laparoscopic radical prostatectomy. J Urol. 2002;168:2078&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12394713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172:2227&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538237</ArticleId></ArticleIdList></Reference><Reference><Citation>Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubbelman YD, Dohle GR, Schr&#xf6;der FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol. 2006;50:711&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16846679</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasiadis AG, Salomon L, Katz R, Hoznek A, Chopin D, Abbou CC. Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology. 2003;62:292&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12893338</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumeguere T, Bollens R, Vanden Bossche M, Rochet D, Bialek D, Hoffman P, et al. Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol. 2003;20:360&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682770</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph JV, Vicente I, Madeb R, Erturk E, Patel HR. Robot-assisted vs pure laparoscopic radical prostatectomy: are there any differences? BJU Int. 2005;96:39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15963117</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuleman EJH, Mulders PFA. Erectile function after radical prostatectomy: a review. Eur Urol. 2003;43:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565764</ArticleId></ArticleIdList></Reference><Reference><Citation>Geary ES, Dendinger TE, Freiha FS, Stamey TA. Nerve sparing radical prostatectomy: a different view. J Urol. 1995;154:145&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7776409</ArticleId></ArticleIdList></Reference><Reference><Citation>Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, et al. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer. 2002;95:1773&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12365027</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647798</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlucci JR, Nabizada-Pace F, Samadi DB. Robot-assisted laparoscopic radical prostatectomy: technique and outcomes of 700 cases. Int J Biomed Sci. 2009;5:201&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23675138</ArticleId><ArticleId IdType="pmc">3614793</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez E Jr., Finley DS, Skarecky D, Ahlering TE. Single institution 2-year patient reported validated sexual function outcomes after nerve sparing robot assisted radical prostatectomy. J Urol. 2009;181:259&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">19013596</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikanov SA, Zorn KC, Zagaja GP, Shalhav AL. Trifecta outcomes after robotic-assisted laparoscopic prostatectomy. Urology. 2009;74:619&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19592075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploussard G, Xylinas E, Salomon L, Vordos D, Hoznek A, Abbou CC, et al. Robot-assisted extraperitoneal laparoscopic radical prostatectomy: experience in a high-volume laparoscopy reference centre. BJU Int. 2010;105:1155&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19888970</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7:445&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092448</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128:492&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7120554</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiglione F, Ralph DJ, Muneer A. Surgical techniques for managing post-prostatectomy erectile dysfunction. Curr Urol Rep. 2017;18:90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28965315</ArticleId><ArticleId IdType="pmc">5622908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol. 2002;167:1371&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832735</ArticleId></ArticleIdList></Reference><Reference><Citation>Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24:239&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634311</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz, et al. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest. 1993;91:437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679408</ArticleId><ArticleId IdType="pmc">287949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553617</ArticleId></ArticleIdList></Reference><Reference><Citation>van Poppel H, Everaerts W, Tosco L, Joniau S. Open and robotic radical prostatectomy. Asian J Urol. 2019;6:125&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31061797</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CJ, Scardino PT, Eastham JA, Mulhall JP. Back to baseline: erectile function recovery after radical prostatectomy from the patients&#x2019; perspective. J Sex Med. 2013;10:1636&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23551767</ArticleId><ArticleId IdType="pmc">4742368</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Sexual rehabilitation after treatment for prostate cancer-part 1: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017;14:285&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28262099</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Lopez DS, Chen M, Wang R. Penile rehabilitation therapy following radical prostatectomy: a meta-analysis. J Sex Med. 2017;14:1496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">29122494</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandaglia G, Suardi N, Cucchiara V, Bianchi M, Shariat SF, Roupret M, et al. Penile rehabilitation after radical prostatectomy: does it work? Transl Androl Urol. 2015;4:110&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26816818</ArticleId><ArticleId IdType="pmc">4708129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl J Med. 2008;358:1250&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354103</ArticleId></ArticleIdList></Reference><Reference><Citation>Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68:600&#x2013;8.</Citation></Reference><Reference><Citation>Chambers SK, Occhipinti S, Stiller A, Zajdlewicz L, Nielsen L, Wittman D, et al. Five-year outcomes from a randomised controlled trial of a couples-based intervention for men with localised prostate cancer. Psychooncology. 2019;28:775&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30716188</ArticleId></ArticleIdList></Reference><Reference><Citation>Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer. 2005;104:2689&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">16294343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int. 2010;105:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19659465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo JK, Jeong SJ, Oh JJ, Lee SW, Lee S, Hong SK, et al. Effect of starting penile rehabilitation with sildenafil immediately after robot-assisted laparoscopic radical prostatectomy on erectile function recovery: a prospective randomized trial. J Urol. 2018;199:1600&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29307683</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T. 2013;38:407&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24049429</ArticleId><ArticleId IdType="pmc">3776492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fode M, Ohl DA, Ralph D, S&#xf8;nksen J. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int. 2013;112:998&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">23826962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res. 2008;20:202&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17882231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422848</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Brock G, Oelke M, Fode M, Probst KA, Henneges C, et al. Effects of tadalafil once-daily or on-demand vs placebo on return to baseline erectile function after bilateral nerve-sparing radical prostatectomy-results from a randomized controlled trial (REACTT). J Sex Med. 2016;13:679&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045264</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, Montague DK, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2006;18:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16107868</ArticleId></ArticleIdList></Reference><Reference><Citation>Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int. 2013;111:658&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23186312</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrfeld T, Lee DI. The role of vacuum erection devices in penile rehabilitation after radical prostatectomy. Int J Impot Res. 2009;21:158&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225465</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Hoang AN, Romero CA, Lin H, Dai Y, Wang R. Vacuum therapy in erectile dysfunction&#x2014;science and clinical evidence. Int J Impot Res. 2010;22:211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N, Azadzoi KM, Goldstein I, Saenz, de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest. 1991;88:112&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1647413</ArticleId><ArticleId IdType="pmc">296010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl J Med. 1992;326:90&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1309211</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Biotechnology Information. PubChem Compound Summary for CID 5775, Phentolamine.&#xa0; https://pubchem.ncbi.nlm.nih.gov/compound/Phentolamine . Accessed Nov. 13, 2020.</Citation></Reference><Reference><Citation>Melanie R, Hew VG. Prostaglandin E1. Treasure Island, FL: StatPearls Publishing; 2020.</Citation></Reference><Reference><Citation>National Center for Biotechnology Information. PubChem Compound Summary for CID 4680, Papaverine.&#xa0; https://pubchem.ncbi.nlm.nih.gov/compound/Papaverine . Accessed Nov. 13, 2020.</Citation></Reference><Reference><Citation>Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N. Engl J Med. 1996;334:873&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596569</ArticleId></ArticleIdList></Reference><Reference><Citation>Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671107</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158:1408&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302132</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133:39&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578067</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveci S, Mulhall JP. Chapter 37 - Male sexual dysfunction. In: Legato MJ, editor. Principles of gender-specific medicine. Second Edition San Diego: Academic Press; 2010. p 408&#x2013;13.</Citation></Reference><Reference><Citation>Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7:524&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092451</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">23343170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol. 1990;143:1138&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2342174</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama &#xe0; Nijeholt GA, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998;81:889&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666777</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough AR, Hellstrom WG, Wang R, Lepor H, Wagner KR, Engel JD. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol. 2010;183:2451&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20403617</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007;100:1317&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17850385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654905</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4:1074&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, Lucarelli G, Palazzo S, Battaglia M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med. 2010;7:304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19758282</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. 2000;164:376&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas W, O&#x2019;Connor B, Welliver C, Stahl PJ, Stember DS, Wilson SK, et al. Worldwide trends in penile implantation surgery: data from over 63,000 implants. Transl Androl Urol. 2020;9:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32055463</ArticleId><ArticleId IdType="pmc">6995940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajic P, Patel PM, Nelson MH, Dornbier RA, Kirshenbaum EJ, Baker MS, et al. Penile prosthesis implantation and timing disparities after radical prostatectomy: results from a statewide claims database. J Sex Med. 2020;17:1175&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">32229093</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol. 2005;174:646&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006930</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal R, Jacks LM, Elkin E, Mulhall JP. Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. J Sex Med. 2011;8:1797&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">21426495</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. Management of erectile dysfunction: Eauropean Association of Urology; 2016. https://uroweb.org/guideline/sexual-and-reproductive-health/#5 .</Citation></Reference><Reference><Citation>Karpman E, Sadeghi-Nejad H, Henry G, Khera M, Morey AF. Current opinions on alternative reservoir placement for inflatable penile prosthesis among members of the Sexual Medicine Society of North America. J Sex Med. 2013;10:2115&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">23679798</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry G, Hsiao W, Karpman E, Bella AJ, Carrion R, Jones L, et al. A guide for inflatable penile prosthesis reservoir placement: pertinent anatomical measurements of the retropubic space. J Sex Med. 2014;11:273&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24274160</ArticleId></ArticleIdList></Reference><Reference><Citation>Stember DS, Garber BB, Perito PE. Outcomes of abdominal wall reservoir placement in inflatable penile prosthesis implantation: a safe and efficacious alternative to the space of Retzius. J Sex Med. 2014;11:605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24286533</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumavalavan N, Gross MS, Munarriz R. Techniques of ectopic reservoir placement and their pitfalls. J Sex Med. 2017;14:1451&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28993147</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito PE, Wilson SK. Traditional (retroperitoneal) and abdominal wall (ectopic) reservoir placement. J Sex Med. 2011;8:656&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21711485</ArticleId></ArticleIdList></Reference><Reference><Citation>Steege JF, Stout AL, Carson CC. Patient satisfaction in Scott and Small-Carrion penile implant recipients: a study of 52 patients. Arch Sex Behav. 1986;15:393&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3789903</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefilli MV, Dubocq F, Rajpurkar A, Gheiler EL, Tiguert R, Barton C, et al. Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Urology. 1998;52:1106&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836564</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Serefoglu EC, Mandava SH, Gokce A, Chouhan JD, Wilson SK, Hellstrom WJ. Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med. 2012;9:2182&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22759917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Montague DK, Moncada I, Carson C, Minhas S, Faria G, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7:501&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR 2nd. Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. J Urol. 1999;162:715&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10458350</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC 3rd, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185:614&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, Brock G, Broderick GA, Burnett AL, et al. North American consensus document on infection of penile prostheses. Urology. 2013;82:937&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zargaroff S, Sharma V, Berhanu D, Pearl JA, Meeks JJ, Dupree JM, et al. National trends in the treatment of penile prosthesis infections by explantation alone vs. immediate salvage and reimplantation. J Sex Med. 2014;11:1078&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24628707</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll P, Rai S, Talluri S, Bezinque A, Micciche R, Rao G, et al. A survey of usage of penile prosthesis. J Sex Med. 2020;17:2287&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">32883632</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Castagna G, Capogrosso P, Castiglione F, Briganti A, Montorsi F. Prevention and management of post prostatectomy erectile dysfunction. Transl Androl Urol. 2015;4:421&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">26816841</ArticleId><ArticleId IdType="pmc">4708594</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Bivalacqua TJ, Burnett AL. Current penile-rehabilitation strategies: clinical evidence. Arab J Urol. 2013;11:230&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26558087</ArticleId><ArticleId IdType="pmc">4443015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18:446&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482200</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007;100:858&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17822466</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impot Res. 1997;9:187&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9442415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33049191</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1195-9479</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Canadian journal of urology</Title><ISOAbbreviation>Can J Urol</ISOAbbreviation></Journal><ArticleTitle>Inflatable penile prosthesis outcomes after pelvic radiation.</ArticleTitle><Pagination><StartPage>10382</StartPage><EndPage>10387</EndPage><MedlinePgn>10382-10387</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">INTRODUCTION Few studies have compared surgical outcomes after 3-piece inflatable penile prosthesis (IPP) surgery in patients exposed to pelvic radiation therapy (RT) compared to a radiation na&#xef;ve control group.</AbstractText><AbstractText Label="MATERIALS AND METHODS">A total of 715 consecutive patients underwent 3-piece IPP placement between 2007-2018. There were 101 men exposed to pelvic RT before or after IPP for a variety of malignancies and 153 men met inclusion criteria for the control group, which included men undergoing IPP surgery with a history of radical prostatectomy but no exposure to pelvic RT.</AbstractText><AbstractText Label="RESULTS">Patients in the RT group had a higher body mass index (kg/m&#xb2;) (28.7 versus 27.8, p = 0.003) and higher Charlson co-morbidity index score (6 versus 5; p &lt; 0.001). At a median follow up of 5 years (IQR 2-8 years), there was an 18.4% surgical complication rate in the radiation group compared to 11.5% in the control group, though this was not statistically significant (p = 0.141). Timing of radiation, prior artificial urinary sphincter (AUS) status, co-implantation of an AUS, and brand of prosthesis were not associated with increased rate of complications. On multivariable logistic regression analysis, exposure to RT was not significantly associated with increased risks of complications (OR: 1.31; CI 0.55-3.12).</AbstractText><AbstractText Label="CONCLUSIONS">This study shows no significant increase in risk of surgical complication in patients exposed to pelvic RT and supports the use of IPP in men with a history of RT and refractory erectile dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dave</LastName><ForeName>Chirag N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Brady Urological Institute, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohn</LastName><ForeName>Taylor P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Hiten D</ForeName><Initials>HD</Initials></Author><Author ValidYN="Y"><LastName>Arafa</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Urol</MedlineTA><NlmUniqueID>9515842</NlmUniqueID><ISSNLinking>1195-9479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010386" MajorTopicYN="N">Pelvic Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069079" MajorTopicYN="N">Radiation Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>13</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33049191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33047918</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1677-6119</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>International braz j urol : official journal of the Brazilian Society of Urology</Title><ISOAbbreviation>Int Braz J Urol</ISOAbbreviation></Journal><ArticleTitle>A prospective randomized study comparing bipolar plasmakinetic transurethral resection of the prostate and monopolar transurethral resection of the prostate for the treatment of Benign Prostatic Hyperplasia: efficacy, sexual function, Quality of Life, and complications.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>144</EndPage><MedlinePgn>131-144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1677-5538.IBJU.2019.0766</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To generate high-quality data comparing the clinical efficacy and safety profile between monopolar transurethral resection of the prostate (M-TURP) and bipolar plasmakinetic resection of the prostate (PK-TURP) for benign prostatic hyperplasia (BPH).</AbstractText><AbstractText Label="MATERIALS AND METHODS">Prospective, randomized, single-blinded study conducted in a tertiary-care public institution (Dec/2014-Aug/2016).</AbstractText><AbstractText Label="INCLUSION CRITERIA">prostate of &lt;80g in patients with drug-refractory lower urinary tract symptoms (LUTS), complications derived from BPH, or both.</AbstractText><AbstractText Label="EXCLUSION CRITERIA">a history of pelvic surgery/radiotherapy, neurogenic bladder dysfunction or documented/suspected prostate carcinoma. Treatment efficacy evaluated at 1, 3, 6 and 12 months. Efficacy outcomes: international prostate symptom score (IPSS), quality-of-life (QoL) score, international index of erectile function-5 (IIEF-5), maximum urinary flow rate (Qmax), postvoid residual urine (PVRU) volume, and prostate volume (PV). Complications and sequelae also assessed. Comparisons performed with parametric/non-parametric tests.</AbstractText><AbstractText Label="RESULTS">Out of the 100 hundred patients, 84 qualified for the analysis (45 M-TURP/39 PK-TURP). No significant differences found in baseline characteristics or operative data, except for a longer operative time in PK-TURP (MD:7.9min; 95%CI:0.13-15.74; p=0.04). No differences found in IPSS, Qmax or PVRU volume. QoL score at 12 months was higher in PK-TURP (MD:0,9points; 95%CI:0.18-1.64; p=0.01). No differences in sexual function, PV, complications or sequelae were found. This study is "rigorous" (Jadad-scale) and has a low risk of bias (Cochrane-Handbook).</AbstractText><AbstractText Label="CONCLUSIONS">Based on this controlled trial, there is not significant variation in effectiveness and safety between M-TURP and PK-TURP for the treatment of BPH. The small difference in QoL between PK-TURP and M-TURP at the one-year follow-up is not perceivable by the patients and, therefore, not clinically relevant.</AbstractText><CopyrightInformation>Copyright&#xae; by the International Brazilian Journal of Urology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Otaola-Arca</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urology, Cl&#xed;nica Alemana, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Doctoral School, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Cl&#xed;nica Alemena-Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-Ardura</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Doctoral School, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Escudero</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Mario I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Urology, Cl&#xed;nica Alemana, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Cl&#xed;nica Alemena-Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;ez-Borda</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Doctoral School, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Int Braz J Urol</MedlineTA><NlmUniqueID>101158091</NlmUniqueID><ISSNLinking>1677-5538</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int Braz J Urol. 2021 Jan-Feb;47(1):145-148</RefSource><PMID Version="1">33047919</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="Y">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020728" MajorTopicYN="Y">Transurethral Resection of Prostate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prostatic Hyperplasia </Keyword><Keyword MajorTopicYN="N">Quality of Life</Keyword><Keyword MajorTopicYN="N">Transurethral Resection of Prostate </Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33047918</ArticleId><ArticleId IdType="pmc">PMC7712692</ArticleId><ArticleId IdType="doi">10.1590/S1677-5538.IBJU.2019.0766</ArticleId><ArticleId IdType="pii">IBJU20190766</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58:384&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825758</ArticleId></ArticleIdList></Reference><Reference><Citation>1. Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58:384-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravas S, Cornu J-N, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al.  EAU Guidelines: Management of Nonneurogenic Male LUTS European Association of Urology. [Internet] 2019 Available at. &lt; https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/&gt;.</Citation></Reference><Reference><Citation>2. Gravas S, Cornu J-N, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU Guidelines: Management of Nonneurogenic Male LUTS. European Association of Urology [Internet]. 2019; Available at. &lt;https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/&gt;</Citation></Reference><Reference><Citation>Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015;67:1066&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">24972732</ArticleId></ArticleIdList></Reference><Reference><Citation>3. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015;67:1066-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24972732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009;56:798&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595501</ArticleId></ArticleIdList></Reference><Reference><Citation>4. Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009;56:798-809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Lin WC, Chang HK, Hsu JM, Lin WR, Chow YC, et al. Gyrus plasmasect: is it better than monopolar transurethral resection of prostate? Urol Int. 2004;73:258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">15539847</ArticleId></ArticleIdList></Reference><Reference><Citation>5. Yang S, Lin WC, Chang HK, Hsu JM, Lin WR, Chow YC, et al. Gyrus plasmasect: is it better than monopolar transurethral resection of prostate? Urol Int. 2004;73:258-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15539847</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturhan S, Erbagci A, Seckiner I, Yagci F, Ustun A. Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up. Prostate Cancer Prostatic Dis. 2007;10:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16926854</ArticleId></ArticleIdList></Reference><Reference><Citation>6. Erturhan S, Erbagci A, Seckiner I, Yagci F, Ustun A. Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up. Prostate Cancer Prostatic Dis. 2007;10:97-100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16926854</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuho&#x11f;lu B, Ayyildiz A, Karag&#xfc;zel E, Cebeci O, Germiyano&#x11f;lu C. Plasmakinetic prostate resection in the treatment of benign prostate hyperplasia: results of 1-year follow-up. Int J Urol. 2006;13:21&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448427</ArticleId></ArticleIdList></Reference><Reference><Citation>7. Nuho&#x11f;lu B, Ayyildiz A, Karag&#xfc;zel E, Cebeci O, Germiyano&#x11f;lu C. Plasmakinetic prostate resection in the treatment of benign prostate hyperplasia: results of 1-year follow-up. Int J Urol. 2006;13:21-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448427</ArticleId></ArticleIdList></Reference><Reference><Citation>Patankar S, Jamkar A, Dobhada S, Gorde V. PlasmaKinetic Superpulse transurethral resection versus conventional transurethral resection of prostate. J Endourol. 2006;20:215&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">16548733</ArticleId></ArticleIdList></Reference><Reference><Citation>8. Patankar S, Jamkar A, Dobhada S, Gorde V. PlasmaKinetic Superpulse transurethral resection versus conventional transurethral resection of prostate. J Endourol. 2006;20:2159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16548733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhansali M, Patankar S, Dobhada S, Khaladkar S. Management of large (&gt;60 g) prostate gland: PlasmaKinetic Superpulse (bipolar) versus conventional (monopolar) transurethral resection of the prostate. J Endourol. 2009;23:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19178175</ArticleId></ArticleIdList></Reference><Reference><Citation>9. Bhansali M, Patankar S, Dobhada S, Khaladkar S. Management of large (&gt;60 g) prostate gland: PlasmaKinetic Superpulse (bipolar) versus conventional (monopolar) transurethral resection of the prostate. J Endourol. 2009;23:141-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19178175</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie CY, Zhu GB, Wang XH, Liu XB. Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate prostate. Yonsei Med J. 2012;53:734&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381470</ArticleId><ArticleId IdType="pubmed">22665339</ArticleId></ArticleIdList></Reference><Reference><Citation>10. Xie CY, Zhu GB, Wang XH, Liu XB. Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Yonsei Med J. 2012;53:734-41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381470</ArticleId><ArticleId IdType="pubmed">22665339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Vasudeva P, Kumar N, Nanda B, Jha SK, Mohanty N. A prospective randomized comparative study of monopolar and bipolar transurethral resection of the prostate and photoselective vaporization of the prostate in patients who present with benign prostatic obstruction: a single center experience. J Endourol. 2013;27:1245&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746047</ArticleId></ArticleIdList></Reference><Reference><Citation>11. Kumar A, Vasudeva P, Kumar N, Nanda B, Jha SK, Mohanty N. A prospective randomized comparative study of monopolar and bipolar transurethral resection of the prostate and photoselective vaporization of the prostate in patients who present with benign prostatic obstruction: a single center experience. J Endourol. 2013;27:1245-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746047</ArticleId></ArticleIdList></Reference><Reference><Citation>Iori F, Franco G, Leonardo C, Laurenti C, Tubaro A, D-Amico F, et al. Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. Urology. 2008;71:252&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">18308095</ArticleId></ArticleIdList></Reference><Reference><Citation>12. Iori F, Franco G, Leonardo C, Laurenti C, Tubaro A, D-Amico F, et al. Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. Urology. 2008;71:252-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18308095</ArticleId></ArticleIdList></Reference><Reference><Citation>Seckiner I, Yesilli C, Akduman B, Altan K, Mungan NA. A prospective randomized study for comparing bipolar plasmakinetic resection of the prostate with standard TURP. Urol Int. 2006;76:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493215</ArticleId></ArticleIdList></Reference><Reference><Citation>13. Seckiner I, Yesilli C, Akduman B, Altan K, Mungan NA. A prospective randomized study for comparing bipolar plasmakinetic resection of the prostate with standard TURP. Urol Int. 2006;76:139-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493215</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhania P, Nandini D, Sarita F, Hemant P, Hemalata I. Transurethral resection of prostate: a comparison of standard monopolar versus bipolar saline resection. Int Braz J Urol. 2010;36:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">20450503</ArticleId></ArticleIdList></Reference><Reference><Citation>14. Singhania P, Nandini D, Sarita F, Hemant P, Hemalata I. Transurethral resection of prostate: a comparison of standard monopolar versus bipolar saline resection. Int Braz J Urol. 2010;36:183-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20450503</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulianelli R, Albanesi L, Attisani F, Gentile BC, Vincenti G, Pisanti F, et al. Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique 3 year follow-up. Arch Ital Urol Androl. 2013;85:86&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23820656</ArticleId></ArticleIdList></Reference><Reference><Citation>15. Giulianelli R, Albanesi L, Attisani F, Gentile BC, Vincenti G, Pisanti F, et al. Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up. Arch Ital Urol Androl. 2013;85:86-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23820656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong CH, Ibrahim MF, Zainuddin ZM. A prospective, randomized clinical trial comparing bipolar plasma kinetic resection of the prostate versus conventional monopolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Ann Saudi Med. 2009;29:429&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881428</ArticleId><ArticleId IdType="pubmed">19847078</ArticleId></ArticleIdList></Reference><Reference><Citation>16. Kong CH, Ibrahim MF, Zainuddin ZM. A prospective, randomized clinical trial comparing bipolar plasma kinetic resection of the prostate versus conventional monopolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Ann Saudi Med. 2009;29:429-32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881428</ArticleId><ArticleId IdType="pubmed">19847078</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Clinical Excellence. Lower urinary tract symptoms in men: management (Clinical Guidelines 97) 2010 [No authors] Available at. &lt; https://www.nice.org.uk/guidance/cg97&gt;.</Citation></Reference><Reference><Citation>17. [No authors]. National Institute for Health and Clinical Excellence. Lower urinary tract symptoms in men: management (Clinical Guidelines 97). 2010; Available at. &lt;https://www.nice.org.uk/guidance/cg97&gt;</Citation></Reference><Reference><Citation>Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol. 2017;71:570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337128</ArticleId><ArticleId IdType="pubmed">27717522</ArticleId></ArticleIdList></Reference><Reference><Citation>18. Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol. 2017;71:570-81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337128</ArticleId><ArticleId IdType="pubmed">27717522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Moon KH, Yoon CJ, Park TC. Bipolar transurethral resection of the prostate: A comparative study with monopolar transurethral resection. Korean J Urol. 2006;47:493&#x2013;497.</Citation></Reference><Reference><Citation>19. Kim JY, Moon KH, Yoon CJ, Park TC. Bipolar transurethral resection of the prostate: A comparative study with monopolar transurethral resection. Korean J Urol. 2006;47:493-7.</Citation></Reference><Reference><Citation>Huang X, Wang L, Wang XH, Shi HB, Zhang XJ, Yu ZY. Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy. Urology. 2012;80:1116&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22990062</ArticleId></ArticleIdList></Reference><Reference><Citation>20. Huang X, Wang L, Wang XH, Shi HB, Zhang XJ, Yu ZY. Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy. Urology. 2012;80:1116-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22990062</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Wang XH, Wang HP, Qu LJ. Comparison of the microvessel diameter of hyperplastic prostate and the coagulation depth achieved with mono- and bipolar transurethral resection of the prostate. A pilot study on hemostatic capability. Scand J Urol Nephrol. 2008;42:265&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934987</ArticleId></ArticleIdList></Reference><Reference><Citation>21. Huang X, Wang XH, Wang HP, Qu LJ. Comparison of the microvessel diameter of hyperplastic prostate and the coagulation depth achieved with mono- and bipolar transurethral resection of the prostate. A pilot study on hemostatic capability. Scand J Urol Nephrol. 2008;42:265-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934987</ArticleId></ArticleIdList></Reference><Reference><Citation>Issa MM. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol. 2008;22:1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721041</ArticleId></ArticleIdList></Reference><Reference><Citation>22. Issa MM. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol. 2008;22:1587-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho HS, Cheng CW. Bipolar transurethral resection of prostate: a new reference standard? Curr Opin Urol. 2008;18:50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090490</ArticleId></ArticleIdList></Reference><Reference><Citation>23. Ho HS, Cheng CW. Bipolar transurethral resection of prostate: a new reference standard? Curr Opin Urol. 2008;18:50-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090490</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul P, Schlenker B, Gratzke C, Stief CG, Reich O, Hahn RG. Clinical and technical aspects of bipolar transurethral prostate resection. Scand J Urol Nephrol. 2008;42:318&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">18622807</ArticleId></ArticleIdList></Reference><Reference><Citation>24. Faul P, Schlenker B, Gratzke C, Stief CG, Reich O, Hahn RG. Clinical and technical aspects of bipolar transurethral prostate resection. Scand J Urol Nephrol. 2008;42:318-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18622807</ArticleId></ArticleIdList></Reference><Reference><Citation>Autorino R, Damiano R, Di Lorenzo G, Quarto G, Perdon&#xe0; S, D'Armiento M, et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol. 2009;55:922&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">19185975</ArticleId></ArticleIdList></Reference><Reference><Citation>25. Autorino R, Damiano R, Di Lorenzo G, Quarto G, Perdon&#xe0; S, D'Armiento M, et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol. 2009;55:922-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19185975</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J Endourol. 2005;19:333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">15865523</ArticleId></ArticleIdList></Reference><Reference><Citation>26. Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J Endourol. 2005;19:333-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15865523</ArticleId></ArticleIdList></Reference><Reference><Citation>Abascal Junquera JM, Cecchini Rosell L, Salvador Lacambra C, Martos Calvo R, Celma Domenech A, et al. [Bipolar versus monopolar transurethral resection of the prostate: peroperative analysis of the results] Actas Urol Esp. 2006;30:661&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">17058610</ArticleId></ArticleIdList></Reference><Reference><Citation>27. Abascal Junquera JM, Cecchini Rosell L, Salvador Lacambra C, Martos Calvo R, Celma Domenech A, et al. [Bipolar versus monopolar transurethral resection of the prostate: peroperative analysis of the results]. Actas Urol Esp. 2006;30:661-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17058610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33023863</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Surgical Planning and Strategies for Peyronie's Disease.</ArticleTitle><Pagination><StartPage>478</StartPage><EndPage>487</EndPage><MedlinePgn>478-487</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2020.07.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(20)30083-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Peyronie's disease results in penile curvature, shortening, instability, or pain upon erection-hindering sexual performance and leading to psychological distress. Despite extensive research, surgery is still the mainstay of treatment.</AbstractText><AbstractText Label="OBJECTIVE">To present an organized description of the most common surgical techniques used in the correction of Peyronie's disease and to propose a surgical algorithm to guide management.</AbstractText><AbstractText Label="METHODS">Using PubMed, we reviewed the published literature regarding surgical treatment of Peyronie's disease and its outcomes. We identified original articles, review articles, and editorials addressing the subject, with a focus on surgical techniques, their indications, and outcomes.</AbstractText><AbstractText Label="RESULTS">Peyronie's disease can be treated by corporoplasty or penile prosthesis implantation. Corporoplasty includes convex side-shortening procedures and concave side lengthening procedures. It is indicated when the erectile function is adequate. Shortening procedures include excisional, incisional, and plication-only techniques, and lengthening procedures include partial excision or incision followed by grafting. When refractory erectile dysfunction is present, placement of a penile prosthesis with or without further straightening maneuvers is recommended. We reviewed the indications, advantages, disadvantages, and outcomes of the available techniques and proposed a surgical algorithm to guide management.</AbstractText><AbstractText Label="CONCLUSION">Penile shortening procedures are usually indicated in curvatures &lt;60&#xb0;, in penises with adequate length. Partial excision/incision and grafting are indicated for curvatures &gt;60&#xb0;, hourglass or hinge deformities, and short penises, if the patient's erectile function is adequate. The presence of "borderline" erectile function and/or ventral curvature tilts the choice toward shortening procedures, and refractory erectile dysfunction is an indication for penile prosthesis placement. Peyronie's disease management remains challenging with many options available, making an accurate risk/benefit assessment of each case and meticulous patient counseling critically important. Almeida JL, Fel&#xed;cio J, Martins FE. Surgical Planning and Strategies for Peyronie's Disease. Sex Med Rev 2021;9:478-487.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Jo&#xe3;o L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hospital de Santa Maria - Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Department of Urology, Lisboa, Portugal. Electronic address: jplfalmeida@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fel&#xed;cio</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital de Santa Maria - Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Department of Urology, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Francisco E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Hospital de Santa Maria - Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Department of Urology, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Grafting</Keyword><Keyword MajorTopicYN="N">Penile Curvature</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Peyronie's Disease</Keyword><Keyword MajorTopicYN="N">Plaque Incision</Keyword><Keyword MajorTopicYN="N">Plication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33023863</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2020.07.008</ArticleId><ArticleId IdType="pii">S2050-0521(20)30083-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32883632</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>A Survey of Usage of Penile Prosthesis.</ArticleTitle><Pagination><StartPage>2287</StartPage><EndPage>2290</EndPage><MedlinePgn>2287-2290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2020.07.082</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(20)30833-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Implantation of an inflatable penile prosthesis (IPP) has high success and satisfaction rates, but there remains a paucity of evidence examining non-usage of IPP and reasons for discontinuation.</AbstractText><AbstractText Label="AIM">To identify how frequent patients use their prosthesis and their personal reasons for no longer using it.</AbstractText><AbstractText Label="METHODS">We conducted a survey of all patients who underwent an IPP implantation by a single surgeon over a 6-year period, between 2012 and 2018. After application of inclusion and exclusion criteria, a total of 114 patients formed the final cohort. Patients were initially surveyed via mail with a questionnaire; those who did not respond were surveyed via telephone. The factors determining patient selection for IPP implantation included suitability for general anesthesia, manual dexterity to use the device by the patient or their partner on a demonstration device, and presence of refractory erectile dysfunction, HbA1C lower than 8.5, or need for a revision of a previously placed IPP. Universally, a 3-piece AMS 700 Series implant was placed via the penoscrotal approach. Data were analyzed with Pearson chi square test, and survivability of the device was assessed with Kaplan-Meier survival curve.</AbstractText><AbstractText Label="OUTCOMES">The main outcomes of this study are the frequency of IPP usage and reasons for discontinuation.</AbstractText><AbstractText Label="RESULTS">The survey participation rate was 97%. The mean age of patient was 64&#xa0;years (range 34-83&#xa0;years), and the mean time between surgery and completion of survey was 2.98&#xa0;years (range 0.25-7.4&#xa0;years). Kaplan-Meier curve demonstrated that 68% of the patients were using the IPP at 5&#xa0;years after implantation. Using the age 70 years as a cutoff, 18 (22%) patients younger than 70 years and 14 (42%) patients older than 70 years discontinued using the IPP (P&#xa0;=&#xa0;.029). The commonest reasons for discontinuation were poor health to engage in sexual activity (2.6%), loss of companion (19%), loss of interest in sex (2.6%), and device malfunction with no further interest in revision of prosthesis (14%).</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">The clinical implication of this study was improved patient selection for device implantation.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS">To our knowledge, no other study has investigated reasons for patients no longer using their prosthesis. Our study has several limitations including that it is a cross-sectional analysis, our survey is not validated, this is a single-surgeon experience, we have a small sample size, and we did not differentiate between virgin implant and reimplantation.</AbstractText><AbstractText Label="CONCLUSION">Our study shows a high rate (28%) of non-usage of IPP, more so in men older than the age of 70&#xa0;years in the first 5&#xa0;years of implantation. Knoll P, Rai S, Talluri S, et&#xa0;al. A Survey of Usage of Penile Prosthesis. J Sex Med 2020;17:2287-2290.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knoll</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Samarpit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talluri</LastName><ForeName>Sriharsha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezinque</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micciche</LastName><ForeName>Ross</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Ganesh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ankem</LastName><ForeName>Murali K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Louisville School of Medicine, Louisville, KY, USA. Electronic address: murali.ankem@louisville.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2021 Jun;205(6):1805-1807</RefSource><PMID Version="1">33792366</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Non-Usage</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Satisfaction Survey</Keyword><Keyword MajorTopicYN="N">Usage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32883632</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2020.07.082</ArticleId><ArticleId IdType="pii">S1743-6095(20)30833-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32701436</PMID><DateRevised><Year>2021</Year><Month>01</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1911-6470</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Canadian Urological Association journal = Journal de l'Association des urologues du Canada</Title><ISOAbbreviation>Can Urol Assoc J</ISOAbbreviation></Journal><ArticleTitle>The scope, presentation, and management of genitourinary complications in patients presenting with high-grade urethral complications after radiotherapy for prostate cancer.</ArticleTitle><Pagination><StartPage>E6</StartPage><EndPage>E10</EndPage><MedlinePgn>E6-E10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5489/cuaj.6599</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The scope of complications arising after radiotherapy (RT) treatment for prostate cancer is under-recognized and not well-described. The objective of this study is to describe the presentation, scope, and management of genitourinary (GU) complications in patients referred for high-grade urethral complications or sphincter weakness incontinence after prostate RT.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review was performed of patients referred to a reconstructive urologist for management of grade 4 urethral complications and sphincter weakness incontinence after prostate RT from December 2004 to December 2015. Patients' signs, symptoms, complications, and treatments are described.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 120 patients were identified, with a mean age of 67.8 years; 55.8% (n=67) received external beam radiotherapy (EBRT), 38.3% (n=46) brachytherapy (BT), and 5.8% (n=7) combination RT. The mean time to first complication after RT was 57.7 months (1-219) and number of complications per patient was 5.1&#xb1;2.2. The most common associated complications were urethral stenosis (n=106, 88.3%), sphincter weakness urinary incontinence (n=55, 45.8%), radiation cystitis (n=61, 50.8%), refractory storage lower urinary tract symptoms (n=106, 88.3%), GU pain (n=28, 23.3%), and prostate necrosis/abscess (n=17, 14.2%). Patients required a mean of 7.4&#xb1;4.4 treatments over a 33-month period, including urethral dilation/urethrotomy (n= 93, 77.5%), urethroplasty (n=53, 44.2%), transurethral resection (n=52, 43.3%), cystolithopaxy (n=14, 11.7%), artificial urinary sphincter (n=8, 6.7%), and urinary diversion (n=8, 6.7%). Patients with RT combined with other modalities had more complications (6.2 vs. 4.2, p=0.001), higher rates of incontinence (93.8% vs. 29.5%, p=0.001), necrosis (31.3% vs. 8.0%, p=0.003), erectile dysfunction (84.4% vs. 51.1%, p=0.001), and hematuria (59.4% vs. 36.4%, p=0.04).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Urethral complications related to prostate RT are seldom an isolated problem and require a substantial amount of urological resources and interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doiron</LastName><ForeName>R Christopher</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witten</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rourke</LastName><ForeName>Keith F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Urol Assoc J</MedlineTA><NlmUniqueID>101312644</NlmUniqueID><ISSNLinking>1911-6470</ISSNLinking></MedlineJournalInfo><CoiStatement><b>Competing interests:</b> Dr. Rourke has been an advisory board member for and is a shareholder in Boston Scientific; and has participated in clinical trials supported by Red Leaf Medical. The remaining authors report no competing personal or financial interests related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32701436</ArticleId><ArticleId IdType="pmc">PMC7769525</ArticleId><ArticleId IdType="doi">10.5489/cuaj.6599</ArticleId><ArticleId IdType="pii">cuaj.6599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemel A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7&#x2013;34. doi: 10.3322/caac.21551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21551</ArticleId><ArticleId IdType="pubmed">30620402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: A population-based cohort study. Lancet Oncol. 2014;15:223&#x2013;31. doi: 10.1016/S1470-2045(13)70606-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(13)70606-5</ArticleId><ArticleId IdType="pubmed">24440474</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta R, Chapple CR, Fisch M, et al. Pelvic complications after prostate cancer radiation therapy and their management: An international collaborative narrative review. Eur Urol. 2019;75:464&#x2013;76. doi: 10.1016/j.eururo.2018.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2018.12.003</ArticleId><ArticleId IdType="pubmed">30573316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosek SL, Virnig BA, Chu H, et al. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol. 2015;67:273&#x2013;80. doi: 10.1016/j.eururo.2014.08.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2014.08.061</ArticleId><ArticleId IdType="pubmed">25217421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis CJD, Herschorn S, Saskin R, et al. Complications after radical prostatectomy or radiotherapy for prostate cancer: Results of a population-based, propensity score-matched analysis. Urology. 2015;85:621&#x2013;8. doi: 10.1016/j.urology.2014.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2014.11.037</ArticleId><ArticleId IdType="pubmed">25733275</ArticleId></ArticleIdList></Reference><Reference><Citation>Buda&#xfc;s L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol. 2012;61:112&#x2013;27. doi: 10.1016/j.eururo.2011.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.09.027</ArticleId><ArticleId IdType="pubmed">22001105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis CJ, Mahar A, Cheung P, et al. New rates of interventions to manage complications of modern prostate cancer treatment in older men. Eur Urol. 2016;69:933&#x2013;41. doi: 10.1016/j.eururo.2015.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.10.043</ArticleId><ArticleId IdType="pubmed">26572707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: An international collaborative review. Eur Urol. 2018;73:11&#x2013;20. doi: 10.1016/j.eururo.2017.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2017.05.055</ArticleId><ArticleId IdType="pubmed">28610779</ArticleId></ArticleIdList></Reference><Reference><Citation>Heemsbergen WD, Al-Mamgani A, Witte MG, et al. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): Relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys. 2010;78:19&#x2013;25. doi: 10.1016/j.ijrobp.2009.07.1680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2009.07.1680</ArticleId><ArticleId IdType="pubmed">20056354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu I-C, Bae K, Shinohara K, et al. Phase 2 trial of combined high dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78:751&#x2013;8. doi: 10.1016/j.ijrobp.2009.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2009.08.048</ArticleId><ArticleId IdType="pmc">PMC2946454</ArticleId><ArticleId IdType="pubmed">20207506</ArticleId></ArticleIdList></Reference><Reference><Citation>Herschorn S, Elliott S, Coburn M, et al. SIU/ICUD consultation on urethral strictures: Posterior urethral stenosis after treatment of prostate cancer. Urology. 2014;83:S59&#x2013;70. doi: 10.1016/j.urology.2013.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.08.036</ArticleId><ArticleId IdType="pubmed">24361008</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad MA, Gaither TW, Osterberg EC, et al. Prostate cancer radiation and urethral strictures: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:168&#x2013;74. doi: 10.1038/s41391-017-0028-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41391-017-0028-3</ArticleId><ArticleId IdType="pubmed">29296018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu R, Arango JDO, Beckendorf V, et al. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. World J Urol. 2014;32:743&#x2013;51. doi: 10.1007/s00345-013-1146-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-013-1146-8</ArticleId><ArticleId IdType="pubmed">23990073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanguineti G, Arcidiacono F, Landoni V, et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: Results from a prospective phase 3 study. Int J Radiat Oncol Biol Phys. 2016;96:304&#x2013;12. doi: 10.1016/j.ijrobp.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2016.05.017</ArticleId><ArticleId IdType="pubmed">27475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wortel RC, Incrocci L, Pos FJ, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3D conformal radiation therapy for prostate cancer: Results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. 2016;95:680&#x2013;9. doi: 10.1016/j.ijrobp.2016.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2016.01.031</ArticleId><ArticleId IdType="pubmed">27055398</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JG, Stone NN, Stock RG. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy. Int J Radiat Oncol. 2013;86:842&#x2013;7. doi: 10.1016/j.ijrobp.2013.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2013.04.033</ArticleId><ArticleId IdType="pubmed">23845840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiation Oncology Biol Phys. 1995;31:1341&#x2013;6. doi: 10.1016/0360-3016(95)00060-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0360-3016(95)00060-C</ArticleId><ArticleId IdType="pubmed">7713792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32696128</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8726</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>World journal of urology</Title><ISOAbbreviation>World J Urol</ISOAbbreviation></Journal><ArticleTitle>Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial.</ArticleTitle><Pagination><StartPage>2217</StartPage><EndPage>2222</EndPage><MedlinePgn>2217-2222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-020-03373-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Over the last decade, penile low-intensity extracorporeal shockwave therapy (LI-ESWT) has emerged as a promising alternative for the treatment of erectile dysfunction (ED). The aim of this trial is to assess the effect of electromagnetic LI-ESWT on the erectile function of vascular phosphodiesterase type 5 inhibitor (PDE5I) refractory ED patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Randomized, double-blind, sham-controlled study. 76 patients with vascular PDE5I-refractory ED completed the study. 40 men were treated with LI-ESWT (1 session/week for 4&#xa0;weeks, 5000 shocks/session, 0.09&#xa0;mJ/mm<sup>2</sup> energy density) and 36 were treated with a sham probe. Baseline and post-treatment (1, 3 and 6&#xa0;months) evaluations were performed using validated erectile function questionnaires (IIEF-EF, EHS, SEP2, SEP3 and GAQ1). The groups were compared using Mann-Whitney-Wilcoxon and chi-squared tests, with results considered statistically significant at p&#x2009;&lt;&#x2009;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the 3-month follow-up, median change in IIEF-EF score for active and sham groups was 3.5 (IQR 0-10) and -&#x2009;0.5 (IQR -&#x2009;11 to 1), respectively (p&#x2009;&lt;&#x2009;0.05). Six months after treatment, 52.5% of patients (21/40) in the active group and 27.8% of patients (10/36) in the sham group presented an EHS&#x2009;&gt;&#x2009;2 (p&#x2009;&lt;&#x2009;0.05). At the same evaluation, 40.0% (16/40) and 13.9% (5/36) of patients had positive answers to GAQ-1, in the treated and sham groups, respectively (p&#x2009;&lt;&#x2009;0.05). No adverse events were observed during the study.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study showed that penile electromagnetic shockwave therapy may improve erectile function, to a modest extent, on certain patients that do not respond to PDE5I; making it an alternative for vascular ED patients that reject more invasive therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vinay</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7883-1782</Identifier><AffiliationInfo><Affiliation>Andrology Department, Fundaci&#xf3; Puigvert/Universidad Aut&#xf2;noma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain. jose.vinay@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Urology Department, University of Chile Clinical Hospital, Santiago, Chile. jose.vinay@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Andrology Unit, Shady Grove Fertility, Santiago, Chile. jose.vinay@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Andrology Department, Fundaci&#xf3; Puigvert/Universidad Aut&#xf2;noma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajmil</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Andrology Department, Fundaci&#xf3; Puigvert/Universidad Aut&#xf2;noma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Casta&#xf1;e</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Andrology Department, Fundaci&#xf3; Puigvert/Universidad Aut&#xf2;noma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Curbelo</LastName><ForeName>Josvany</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Andrology Department, Fundaci&#xf3; Puigvert/Universidad Aut&#xf2;noma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>World J Urol</MedlineTA><NlmUniqueID>8307716</NlmUniqueID><ISSNLinking>0724-4983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074059" MajorTopicYN="N">Extracorporeal Shockwave Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Low intensity extracorporeal shockwave therapy</Keyword><Keyword MajorTopicYN="N">Neo-angiogenesis</Keyword><Keyword MajorTopicYN="N">Nerve regeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32696128</ArticleId><ArticleId IdType="doi">10.1007/s00345-020-03373-y</ArticleId><ArticleId IdType="pii">10.1007/s00345-020-03373-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fode M, Hatzichristodoulou G, Serefoglu EC et al (2017) Low-intensity shockwave therapy for erectile dysfunction: Is the evidence strong enough? Nat Rev Urol 14:593&#x2013;606. https://doi.org/10.1038/nrurol.2017.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2017.119</ArticleId><ArticleId IdType="pubmed">28741629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I et al (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57:804&#x2013;814. https://doi.org/10.1016/j.eururo.2010.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2010.02.020</ArticleId><ArticleId IdType="pubmed">20189712</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoofs E, Fode M, Capogrosso P, Albersen M (2019) Current guideline recommendations and analysis of evidence quality on low-intensity shockwave therapy for erectile dysfunction. Int J Impot Res 31:209&#x2013;217. https://doi.org/10.1038/s41443-019-0132-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-019-0132-0</ArticleId><ArticleId IdType="pubmed">30911110</ArticleId></ArticleIdList></Reference><Reference><Citation>Besiroglu H, Otunctemur A, Ozbek E (2015) The relationship between metabolic syndrome, its components, and erectile dysfunction: a systematic review and a meta-analysis of observational studies. J Sex Med 12:1309&#x2013;1318. https://doi.org/10.1111/jsm.12885</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12885</ArticleId><ArticleId IdType="pubmed">25872648</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Jacob G et al (2010) Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 58:243&#x2013;248. https://doi.org/10.1016/j.eururo.2010.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2010.04.004</ArticleId><ArticleId IdType="pubmed">20451317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenwald I, Kitrey ND, Appel B, Vardi Y (2013) Low-intensity extracorporeal shock wave therapy in vascular disease and erectile dysfunction: theory and outcomes. Sex Med Rev 1:83&#x2013;90. https://doi.org/10.1002/smrj.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.9</ArticleId><ArticleId IdType="pubmed">27784587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenwald I, Appel B, Vardi Y (2012) Low-intensity extracorporeal shock wave therapy-a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 9:259&#x2013;264. https://doi.org/10.1111/j.1743-6109.2011.02498.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02498.x</ArticleId><ArticleId IdType="pubmed">22008059</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson C, Giuliano F, Goldstein I et al (2004) The &#x201c;effectiveness&#x201d; scale&#x2014;Therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 16:207&#x2013;213. https://doi.org/10.1038/sj.ijir.3901227</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901227</ArticleId><ArticleId IdType="pubmed">15164088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitrey ND, Gruenwald I, Appel B et al (2016) Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 195:1550&#x2013;1555. https://doi.org/10.1016/j.juro.2015.12.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.12.049</ArticleId><ArticleId IdType="pubmed">26694904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fojecki GL, Tiessen S, Osther PJS (2018) Effect of linear low-intensity extracorporeal shockwave therapy for erectile dysfunction&#x2014;12-month follow-up of a randomized, double-blinded, sham-controlled study. Sex Med 6:1&#x2013;7. https://doi.org/10.1016/j.esxm.2017.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2017.09.002</ArticleId><ArticleId IdType="pubmed">29275957</ArticleId></ArticleIdList></Reference><Reference><Citation>Capogrosso P, Frey A, Jensen CFS et al (2019) Low-intensity shock wave therapy in sexual medicine&#x2014;clinical recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med 16:1490&#x2013;1505. https://doi.org/10.1016/j.jsxm.2019.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.07.016</ArticleId><ArticleId IdType="pubmed">31447380</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Huang C, Molina M, Ramasamy R (2019) Clinical trial update on shockwave therapy and future of erectile function restoration. Int J Impot Res 31:206&#x2013;208. https://doi.org/10.1038/s41443-019-0115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-019-0115-1</ArticleId><ArticleId IdType="pubmed">30670840</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH et al (2018) Erectile dysfunction: AUA guideline. J Urol 200:633&#x2013;641. https://doi.org/10.1016/j.juro.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Bettocchi C, Carvalho J CG, Jones TH, Kadioglu A M-SJ, Minhas S, Serefoglu EC (2020) VP EAU guidelines on sexual and reproductive health. Eur Assoc Urol</Citation></Reference><Reference><Citation>Qiu X, Lin G, Xin Z et al (2013) Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med 10:738&#x2013;746. https://doi.org/10.1111/jsm.12024</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12024</ArticleId><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciampa AR, De Prati AC, Amelio E et al (2005) Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS Lett 579:6839&#x2013;6845. https://doi.org/10.1016/j.febslet.2005.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2005.11.023</ArticleId><ArticleId IdType="pubmed">16325181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausner T, Pajer K, Halat G et al (2012) Improved rate of peripheral nerve regeneration induced by extracorporeal shock wave treatment in the rat. Exp Neurol 236:363&#x2013;370. https://doi.org/10.1016/j.expneurol.2012.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.04.019</ArticleId><ArticleId IdType="pubmed">22575596</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuh C, Hausner T, Redl H (2016) A therapeutic shock propels Schwann cells to proliferate in peripheral nerve injury. Brain Circ 2:138. https://doi.org/10.4103/2394-8108.192520</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2394-8108.192520</ArticleId><ArticleId IdType="pubmed">30276290</ArticleId><ArticleId IdType="pmc">6126275</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepek&#xf6;yl&#xfc; C, Wang FS, Kozaryn R et al (2013) Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J Thorac Cardiovasc Surg 146:971&#x2013;978. https://doi.org/10.1016/j.jtcvs.2013.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.01.017</ArticleId><ArticleId IdType="pubmed">23395097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei H, Xin H, Guan R et al (2015) Low-intensity Pulsed ultrasound improves erectile function in streptozotocin-induced type i diabetic rats. Urology 86:1241.e11&#x2013;1241.e18. https://doi.org/10.1016/j.urology.2015.07.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2015.07.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Srini VS, Reddy RK, Shultz T, Denes B (2015) Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol 22:7614&#x2013;7622</Citation><ArticleIdList><ArticleId IdType="pubmed">25694008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Seftel AD (2019) Controversies in low intensity extracorporeal shockwave therapy for erectile dysfunction. Int J Impot Res 31:239&#x2013;242</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-019-0124-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Kilchevsky A, Gruenwald I (2012) Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 187:1769&#x2013;1775. https://doi.org/10.1016/j.juro.2011.12.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2011.12.117</ArticleId><ArticleId IdType="pubmed">22425129</ArticleId></ArticleIdList></Reference><Reference><Citation>Fojecki GL, Tiessen S, Osther PJS (2017) Effect of Low-energy linear shockwave therapy on erectile dysfunction&#x2014;a double-blinded, sham-controlled, randomized clinical trial. J Sex Med 14:106&#x2013;112. https://doi.org/10.1016/j.jsxm.2016.11.307</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.11.307</ArticleId><ArticleId IdType="pubmed">27938990</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CH, Chan ESY, Hou SSM, Ng CF (2014) Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Int J Urol 21:1041&#x2013;1045. https://doi.org/10.1111/iju.12506</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iju.12506</ArticleId><ArticleId IdType="pubmed">24942563</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen AB, Persiani M, Boie S et al (2015) Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol 49:329&#x2013;333. https://doi.org/10.3109/21681805.2014.984326</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21681805.2014.984326</ArticleId><ArticleId IdType="pubmed">25470423</ArticleId></ArticleIdList></Reference><Reference><Citation>Motil I, Kubis I, Sramkova T (2016) Treatment of vasculogenic erectile dysfunction with piezowave2 device. application of low intensity shockwaves using novel linear shockwave tissue coverage (LSTC-ED<sup>&amp;reg;</sup>) technique. A prospective, multicentric placebo-controlled study. Adv Sex Med 06:15&#x2013;18. https://doi.org/10.4236/asm.2016.62002</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/asm.2016.62002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yama&#xe7;ake KGR, Carneiro F, Cury J et al (2019) Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. Int J Impot Res 31:195&#x2013;203. https://doi.org/10.1038/s41443-018-0062-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0062-2</ArticleId><ArticleId IdType="pubmed">30108337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyvianakis D, Hatzichristou D (2017) Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. J Sex Med 14:891&#x2013;897. https://doi.org/10.1016/j.jsxm.2017.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.05.012</ArticleId><ArticleId IdType="pubmed">28673433</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccaglini W, Pazeto CL, Corr&#xea;a Barros EA et al (2020) The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med 17:688&#x2013;694. https://doi.org/10.1016/j.jsxm.2019.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.12.024</ArticleId><ArticleId IdType="pubmed">32007430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sramkova T, Motil I, Jarkovsky J, Sramkova K (2019) Erectile dysfunction treatment using focused linear low-intensity extracorporeal shockwaves: single-blind, sham-controlled, randomized clinical trial. Urol Int. https://doi.org/10.1159/000504788</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000504788</ArticleId><ArticleId IdType="pubmed">31825926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Lin G, Reed-Maldonado A et al (2017) Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol 71:223&#x2013;233</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2016.05.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Man L, Li G (2018) Low-intensity extracorporeal shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Urology 119:97&#x2013;103. https://doi.org/10.1016/j.urology.2017.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2017.09.011</ArticleId><ArticleId IdType="pubmed">28962876</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavijo RI, Kohn TP, Kohn JR, Ramasamy R (2017) Effects of Low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 14:27&#x2013;35</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo JC, Arance I, de Heras MM et al (2017) Efficacy of low-intensity shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Actas Urol Esp 41:479&#x2013;490. https://doi.org/10.1016/j.acuroe.2017.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acuroe.2017.07.001</ArticleId><ArticleId IdType="pubmed">27521134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZJ, Tang LY, Liu ZH et al (2017) Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. Int Braz J Urol 43:805&#x2013;821</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1677-5538.ibju.2016.0245</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulakis V, Skriapas K, de Vries R et al (2006) Extracorporeal shockwave therapy for Peyronie&#x2019;s disease: an alternative treatment? Asian J Androl 8:361&#x2013;366. https://doi.org/10.1111/j.1745-7262.2006.00138.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7262.2006.00138.x</ArticleId><ArticleId IdType="pubmed">16625288</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32669249</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Exosome Released From Schwann Cells May Be Involved in Microenergy Acoustic Pulse-Associated Cavernous Nerve Regeneration.</ArticleTitle><Pagination><StartPage>1618</StartPage><EndPage>1628</EndPage><MedlinePgn>1618-1628</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2020.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(20)30655-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neurogenic erectile dysfunction (ED) is often refractory to treatment because of insufficient functional nerve recovery after injury or insult. Noninvasive mechano-biological intervention, such as microenergy acoustic pulse (MAP), low-intensity pulsed ultrasound, and low-intensity extracorporeal shockwave treatment, is an optimal approach to stimulate nerve regeneration.</AbstractText><AbstractText Label="AIM">To establish a new model in&#xa0;vitro to simulate nerve injury in neurogenic ED and to explore the mechanisms of MAP in&#xa0;vitro.</AbstractText><AbstractText Label="METHODS">Sprague-Dawley rats were used to isolate Schwann cells (SCs), major pelvic ganglion (MPG), and cavernous nerve with MPG (CN/MPG). SCs were then treated with MAP (0.033&#xa0;mJ/mm<sup>2</sup>, 1&#xa0;Hz, 100 pulses), and SC exosomes were isolated. The MPG and CN/MPG were treated with MAP (0.033&#xa0;mJ/mm<sup>2</sup>, 1&#xa0;Hz) at different dosages (25, 50, 100, 200, or 300 pulses) or exosomes derived from MAP-treated SCs in&#xa0;vitro.</AbstractText><AbstractText Label="OUTCOMES">Neurite growth from the MPG fragments and CN was photographed and measured. Expression of neurotropic factors (brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3) was checked.</AbstractText><AbstractText Label="RESULTS">Neurite outgrowth from MPG and CN/MPG was enhanced by MAP in a dosage response manner, peaking at 100 pulses. MAP promoted SC proliferation, neurotropic factor (brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3) expression, and exosome secretion. SC-derived exosomes significantly enhanced neurite outgrowth from MPG in&#xa0;vitro.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">MAP may have utility in the treatment of neurogenic ED by SC-derived exosomes.</AbstractText><AbstractText Label="STRENGTH &amp; LIMITATIONS">We confirmed that MAP enhances penile nerve regeneration through exsomes. Limitations of this study include that our study did not explore the exact mechanisms of how MAP increases SC exosome secretion nor whether MAP modulates the content of exosomes.</AbstractText><AbstractText Label="CONCLUSION">This study revealed that neurite outgrowth from MPG was enhanced by MAP and by SC-derived exosomes which were isolated after MAP treatment. Our findings indicate that one mechanism by which MAP induces nerve regeneration is by stimulation of SCs to secrete exosomes. Peng D, Reed-Maldonado AB, Zhou F, et&#xa0;al. Exosome Released From Schwann Cells May Be Involved in Microenergy Acoustic Pulse-Associated Cavernous Nerve Regeneration. J Sex Med 2020;17:1618-1628.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Dongyi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA; Department of Urology, Third Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed-Maldonado</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Huixing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banie</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guifang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Leye</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Third Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guiting</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Tom F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA. Electronic address: tom.lue@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK105097</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 DK105097</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000162" MajorTopicYN="N">Acoustics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012583" MajorTopicYN="N">Schwann Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Exosome</Keyword><Keyword MajorTopicYN="N">Major Pelvic Ganglion</Keyword><Keyword MajorTopicYN="N">Microenergy Acoustic Pulse</Keyword><Keyword MajorTopicYN="N">Nerve Regeneration</Keyword><Keyword MajorTopicYN="N">Schwann Cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32669249</ArticleId><ArticleId IdType="mid">NIHMS1598404</ArticleId><ArticleId IdType="pmc">PMC7483773</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2020.05.018</ArticleId><ArticleId IdType="pii">S1743-6095(20)30655-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Calabro RS, Polimeni G, Bramanti P. Recent advances in the treatment of neurogenic erectile dysfunction. Recent Pat CNS Drug Discov. 2014;9: 41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">24483711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciaramitaro P, Mondelli M, Logullo F, et al. Traumatic peripheral nerve injuries: epidemiological findings, neuropathic pain and quality of life in 158 patients. J Peripher Nerv Syst 2010;15: 120&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626775</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres RY, Miranda GE. Epidemiology of Traumatic Peripheral Nerve Injuries Evaluated by Electrodiagnostic Studies in a Tertiary Care Hospital Clinic. Bol Asoc Med P R 2015;107: 79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26742202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D, d'Anzeo G, Porst H, et al. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. BMC Urol 2015;15: 111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643510</ArticleId><ArticleId IdType="pubmed">26563171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusovan A, Kanje M. Magnetic fields stimulate peripheral nerve regeneration in hypophysectiomized rats. Neuroreport. 1992;3:1039&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">1493213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sene GA, Sousa FF, Fazan VS. Barbieri CH. Effects of laser therapy in peripheral nerve regeneration. Acta Ortop Bras 2013;21; 266&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874995</ArticleId><ArticleId IdType="pubmed">24453680</ArticleId></ArticleIdList></Reference><Reference><Citation>Elzinga K, Tyreman N, Ladak A, Savaryn B, Olson J, Gordon T. Brief electrical stimulation improves nerve regeneration after delayed repair in Sprague Dawley rats. Exp Neurol. 2015;269: 142&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25842267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F, Xiao Z, Chen B, Hou X, Dai J, Xu R. Linear ordered collagen scaffolds loaded with collagen-binding basic fibroblast growth factor facilitate recovery of sciatic nerve injury in rats. Tissue Eng Part A. 2014;20:1253&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993059</ArticleId><ArticleId IdType="pubmed">24188561</ArticleId></ArticleIdList></Reference><Reference><Citation>Montava M, Garcia S, Mancini J, et al. Vitamin D3 potentiates myelination and recovery after facial nerve injury. Eur Arch Otorhinolaryngol. 2015;272: 2815&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25261104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Shen W, Yang L, Zhao H, Gu W, Yuan Y. The protective effects of Achyranthes bidentata polypeptides on rat sciatic nerve crush injury causes modulation of neurotrophic factors. Neurochem Res. 2013;38: 538&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">23242788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausner T, Pajer K, Halat G, et al. Improved rate of peripheral nerve regeneration induced by extracorporeal shock wave treatment in the rat. Exp Neurol. 2012;236: 363&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">22575596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausner T, Nogradi A. The use of shock waves in peripheral nerve regeneration: new perspectives? Int Rev Neurobiol 2013;109: 85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">24093607</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy-a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 2012;9: 259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">22008059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71: 223&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27321373</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58: 243&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451317</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187: 1769&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZJ, Liang JY, Liu ZH, Gao R, Lu YP. Low-intensity extracorporeal shock wave therapy for erectile dysfunction after radical prostatectomy: a review of preclinical studies. Int J Impot Res. 2018;30: 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29180799</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey A, Sonksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol. 2016;50: 123&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26493542</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Matheu MP, Sun F, et al. Low-energy Shock Wave Therapy Ameliorates Erectile Dysfunction in a Pelvic Neurovascular Injuries Rat Model. J Sex Med 2016;13: 22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26755082</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillaud M, Richard L, Vallat JM, Desmouliere A, Billet F. Peripheral nerve regeneration and intraneural revascularization. Neural Regen Res. 2019;14: 24&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6263011</ArticleId><ArticleId IdType="pubmed">30531065</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaumburg HH, Zotova E, Cannella B, et al. Structural and functional investigations of the murine cavernosal nerve: a model system for serial spatio-temporal study of autonomic neuropathy. BJU Int. 2007;99: 916&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17378850</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichert F, Saada A, Rotshenker S. Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci. 1994;14: 3231&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577489</ArticleId><ArticleId IdType="pubmed">8182468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchi G, Nicolino S, Raimondo S, et al. Functional and morphological assessment of a standardized crush injury of the rat median nerve. J Neurosci Methods. 2009;179: 51&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19428511</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrbova G, Mehra N, Shanmuganathan H, Tyreman N, Schachner M, Gordon T. Chemical communication between regenerating motor axons and Schwann cells in the growth pathway. Eur J Neurosci. 2009;30: 366&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19656172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rath EM, Kelly D, Bouldin TW, Popko B. Impaired peripheral nerve regeneration in a mutant strain of mice (Enr) with a Schwann cell defect. J Neurosci. 1995;15: 7226&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578080</ArticleId><ArticleId IdType="pubmed">7472477</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber C, Zochodne D. The nerve regenerative microenvironment: early behavior and partnership of axons and Schwann cells. Exp Neurol. 2010;223: 51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19501085</ArticleId></ArticleIdList></Reference><Reference><Citation>Toews AD, Barrett C, Morell P. Monocyte chemoattractant protein 1 is responsible for macrophage recruitment following injury to sciatic nerve. J Neurosci Res. 1998;53: 260&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671983</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein D, Martini R. Myelin and macrophages in the PNS: An intimate relationship in trauma and disease. Brain Res. 2016;1641:130&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631844</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu SY, Gordon T. The cellular and molecular basis of peripheral nerve regeneration. Mol Neurobiol. 1997;14: 67&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9170101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Zhang H, Sun F, et al. Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells. Translational andrology and urology 2016;5: 167&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837308</ArticleId><ArticleId IdType="pubmed">27141442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Ning H, Reed-Maldonado AB, et al. Low-Intensity Extracorporeal Shock Wave Therapy Enhances Brain-Derived Neurotrophic Factor Expression through PERK/ATF4 Signaling Pathway. International journal of molecular sciences. 2017;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343967</ArticleId><ArticleId IdType="pubmed">28212323</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing L, Chen H, Tang J, Jia X. Exosomes and Their MicroRNA Cargo: New Players in Peripheral Nerve Regeneration. Neurorehabil Neural Repair. 2018;32: 765&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6146407</ArticleId><ArticleId IdType="pubmed">30223738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leal R, Court FA. Schwann Cell Exosomes Mediate Neuron-Glia Communication and Enhance Axonal Regeneration. Cell Mol Neurobiol. 2016;36: 429&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Verrilli MA, Picou F, Court FA. Schwann cell-derived exosomes enhance axonal regeneration in the peripheral nervous system. Glia. 2013;61: 1795&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">24038411</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9: 581&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19498381</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Technologies for Analysis of Extracellular Vesicles. Chemical Reviews. 2018;118: 1917&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029891</ArticleId><ArticleId IdType="pubmed">29384376</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Lin G, Xin Z, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. The journal of sexual medicine. 2013;10: 738&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593747</ArticleId><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y, Zhou J, Kang N, et al. The effect of low-intensity extracorporeal shockwave therapy in an obesity-associated erectile dysfunction rat model. BJU international 2018;122: 133&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">29573106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Reed-Maldonado AB, Wang B, et al. In Situ Activation of Penile Progenitor Cells With Low-Intensity Extracorporeal Shockwave Therapy. J Sex Med 2017;14: 493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258952</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng D, Yuan H, Liu T, et al. Smooth Muscle Differentiation of Penile Stem/Progenitor Cells Induced by Microenergy Acoustic Pulses In Vitro. J Sex Med 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885549</ArticleId><ArticleId IdType="pubmed">31585805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Chen KC, Hsieh PS, Yeh CH, Lue TF, Lin CS. Neurotrophic effects of vascular endothelial growth factor and neurotrophins on cultured major pelvic ganglia. BJU Int. 2003;92: 631&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Shindel AW, Fandel TM, Bella AJ, Lin CS, Lue TF. Neurotrophic effects of brain-derived neurotrophic factor and vascular endothelial growth factor in major pelvic ganglia of young and aged rats. BJU international 2010;105: 114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001390</ArticleId><ArticleId IdType="pubmed">19493269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbs R, Kalmanek E, Choe S, et al. Sonic hedgehog regulation of cavernous nerve regeneration and neurite formation in aged pelvic plexus. Exp Neurol. 2019;312: 10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342483</ArticleId><ArticleId IdType="pubmed">30391523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilby MJ, Muir EM, Fok-Seang J, Gour BJ, Blaschuk OW, Fawcett JW. N-Cadherin inhibits Schwann cell migration on astrocytes. Mol Cell Neurosci. 1999;14: 66&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Xin Z, Zhang H, et al. Identification of active and quiescent adipose vascular stromal cells. Cytotherapy. 2012;14: 240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22070603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Wang G, Banie L, et al. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy. 2010;12: 88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871776</ArticleId><ArticleId IdType="pubmed">19878076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Shindel AW, Banie L, et al. Molecular mechanisms related to parturition-induced stress urinary incontinence. European urology. 2009;55: 1213&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001389</ArticleId><ArticleId IdType="pubmed">18372098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Huang YC, Shindel AW, et al. Labeling and tracking of mesenchymal stromal cells with EdU. Cytotherapy 2009;11: 864&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862589</ArticleId><ArticleId IdType="pubmed">19903099</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Castagna G, Capogrosso P, Castiglione F, Briganti A, Montorsi F. Prevention and management of post prostatectomy erectile dysfunction. Transl Androl Urol. 2015;4: 421&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4708594</ArticleId><ArticleId IdType="pubmed">26816841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009;6: 2538&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4097184</ArticleId><ArticleId IdType="pubmed">19515209</ArticleId></ArticleIdList></Reference><Reference><Citation>Murinson BB, Griffin JW. C-fiber structure varies with location in peripheral nerve. J Neuropathol Exp Neurol. 2004;63: 246&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15055448</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Zhang R, Yuan Y, et al. MiR-340 Regulates Fibrinolysis and Axon Regrowth Following Sciatic Nerve Injury. Mol Neurobiol. 2017;54: 4379&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27344331</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Zhou S, Wang Y, et al. miR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 after sciatic nerve injury. J Cell Sci. 2012;125: 2675&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22393241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32641777</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Home modeling after penile prosthesis implantation in the management of residual curvature in Peyronie's disease.</ArticleTitle><Pagination><StartPage>616</StartPage><EndPage>619</EndPage><MedlinePgn>616-619</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-020-0325-6</ELocationID><Abstract><AbstractText>The aim of this study was to study the clinical effectiveness of a structured home modeling (HM) protocol in Peyronie's disease (PD) patients who have residual curvature up to 45&#xb0; after inflatable penile prosthesis (PP) placement. A total of 92 patients with PD and coexistent refractory erectile dysfunction received inflatable PP. If residual curvature after manual modeling (MM) was more than 45&#xb0;, incision-grafting was performed. If curvature was &lt;45&#xb0; after MM, patients were instructed to perform HM daily for 6 months, after 4 weeks from PP implantation. The mean preoperative penile curvature was 39.4&#x2009;&#xb1;&#x2009;5.7&#xb0; (30-60). Sixteen (17.4%) patients required incision-grafting and the remaining 76(82.6%) patients followed HM protocol. The mean postoperative residual curvature after MM was 29.7&#x2009;&#xb1;&#x2009;3.2&#xb0; (5-50). Sixty-five (85.5%) patients who underwent HM had 10&#xb0; or less residual curvature after 3 months and 72 (94.7%) patients had 10&#xb0; or less residual curvature after 6 months. Seventy (92.1%) patients responded as satisfied or very satisfied on the questionnaire with the outcome after 6 months. HM of the penis over Inflatable PP may straighten the penis without the need for an additional surgical maneuver in vast majority of the PD patients having residual curvature of &lt;45&#xb0;.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moncada</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology and Robotic Surgery, Hospital Universitario La Zarzuela, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnappa</LastName><ForeName>Pramod</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9614-9218</Identifier><AffiliationInfo><Affiliation>Department of Urology and Andrology, NU Hospitals, Bengaluru, India. Pramod23dr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascencios</LastName><ForeName>Julmar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology and Robotic Surgery, Hospital Universitario La Zarzuela, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Inigo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology and Robotic Surgery, Hospital Universitario La Zarzuela, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Salamanca</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital Puerta De Hierro Majadahonda &amp; Lyx Institute of Urology, Universidad Francisco de Vitoria, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32641777</ArticleId><ArticleId IdType="doi">10.1038/s41443-020-0325-6</ArticleId><ArticleId IdType="pii">10.1038/s41443-020-0325-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hellstrom W. History, epidemiology, and clinical presentation of Peyronie&#x2019;s disease. Int J Impot Res. 2003;15 Suppl 5:S91&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma KL, Alom M, Trost L. The etiology of Peyronie&#x2019;s disease: pathogenesis and genetic contributions. Sex Med Rev. 2020;8:314&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2019.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Khatib FM, Towe M, Yafi FA. Management of Peyronie&#x2019;s disease with collagenase clostridium histolyticum in the acute phase. World J Urol. 2020;38:299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-019-02791-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L. Acute phase peyronie&#x2019;s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11:506&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12400</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie&#x2019;s disease. Transl Androl Urol. 2016;5:342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.04.04</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa P, Fernandez-Pascual E, Carballido J, Moncada I, Lledo-Garcia E, Martinez-Salamanca JI. Surgical management of Peyronie&#x2019;s disease with co-existent erectile dysfunction. Sex Med. 2019;7:361e370.</Citation></Reference><Reference><Citation>Mulhall J, Ahmed A, Anderson M. Penile prosthetic surgery for Peyronie&#x2019;s disease: defining the need for intraoperative adjuvant maneuvers. J Sex Med. 2004;1:318&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.04046.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR 2nd. A new treatment for Peyronie&#x2019;s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)32519-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Burnett AL. Standard operating procedures for Peyronie&#x2019;s disease. J Sex Med. 2013;10:230&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.03003.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristodoulou G, Tsambarlis P, K&#xfc;bler H, Levine LA. Peyronie&#x2019;s graft surgery-tips and tricks from the masters in andrologic surgery. Transl Androl Urol. 2017;6:645&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2017.07.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Penile reconstructive surgery in Peyronie disease: challenges in restoring normal penis size, shape, and function. World J Mens Health. 2020;38:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.5534/wjmh.170056</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011;108:1152&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2010.10023.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2013.01.087</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G, Kuehhas FE, De Luca F, Ralph DJ. Long-term results of reconstructive surgery for Peyronie&#x2019;s disease. Sex Med Rev. 2015;3:113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.42</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristodoulou G, Osmonov D, K&#xfc;bler H, Hellstrom WJG, Yafi FA. Contemporary review of grafting techniques for the surgical treatment of Peyronie&#x2019;s disease. Sex Med Rev. 2017;5:544&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.01.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice PG, Somani BK, Rees RW. Twenty years of plaque incision and grafting for Peyronie&#x2019;s disease: a review of literature. Sex Med. 2019;7:115&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2019.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gomez B, Ralph D, Levine L, Moncada-Iribarren I, Djinovic R, Albersen M, et al. Grafts for Peyronie&#x2019;s disease: a comprehensive review. Andrology. 2018;6:117&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12421</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier JE, Tal R, Nelson CJ, Mulhall JP. Penile sensory changes after plaque incision and grafting surgery for Peyronie&#x2019;s disease. J Sex Med. 2018;15:1491&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.07.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie&#x2019;s disease: AUA guideline. J Urol. 2015;194:745&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.05.098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Mulcahy JJ, Cleves M, Salem EA. Upsizing of inflatable penile implant cylinders in patients with corporal fibrosis. J Sex Med. 2006;3:736&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00263.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Carrion R, Jennermann C, Wang R. Prospective evaluation of postoperative penile rehabilitation: penile length/girth maintenance 1 year following Coloplast Titan inflatable penile prosthesis. J Sex Med. 2015;12:1298&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12833</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung PH, Siegel JA, Tausch TJ, Klein AK, Scott JM, Morey AF. Inflatable penile prosthesis as tissue expander: what is the evidence? Int Braz J Urol. 2017;43:911&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1677-5538.ibju.2016.0528</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela R, Ziegelmann M, Tokar S, Hillelsohn J. The use of penile traction therapy in the management of Peyronie&#x2019;s disease: current evidence and future prospects. Ther Adv Urol. 2019;11:1756287219838139. https://doi.org/10.1177/1756287219838139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287219838139.</ArticleId><ArticleId IdType="pubmed">30956689</ArticleId><ArticleId IdType="pmc">6444402</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device &#x2018;Penimaster PRO&#x2019; is effective and safe in the stable phase of Peyronie&#x2019;s disease: a controlled multicentre study. BJU Int. 2019;123:694&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.14602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU guidelines: male sexual dysfunction [Internet]. Uroweb. http://uroweb.org/guideline/male-sexual-dysfunction/ . Accessed 1 Oct 2019.</Citation></Reference><Reference><Citation>Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE. 2002;2002:pe6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilizarov GA, So&#x12d;bel&#x2019;man LM. Clinical and experimental data on bloodless lengthening of lower extremities. Eksp Khir Anesteziol. 1969;14:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">5376256</ArticleId></ArticleIdList></Reference><Reference><Citation>Alman BA, Greel DA, Ruby LK, Goldberg MJ, Wolfe HJ. Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J Orthop Res. 1996;14:722&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jor.1100140507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, De Young L, Brock GB. Penile traction and Peyronie&#x2019;s disease: in-vitro analysis of the efficacy of traction on cellular changes in Peyronie&#x2019;s plaque in a strain culture system. J Sex Med. 2012;9(Suppl 2):130.</Citation></Reference><Reference><Citation>Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie&#x2019;s disease. J Urol. 2016;195:1051&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.10.065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32641224</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>A Systematic Review of Penile Prosthesis Surgery in Organ Transplant Recipients.</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>640</EndPage><MedlinePgn>636-640</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2020.05.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(20)30049-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION">There is an increased prevalence of erectile dysfunction in patients with solid organ transplant (SOT) compared with the general population. Many of these patients may become refractory to medical treatment of erectile dysfunction and penile prosthesis (PP) is often recommended. Concerns regarding the safety of PP in patients with SOT are due to their immunosuppressed state.</AbstractText><AbstractText Label="OBJECTIVE">We aim to review all current literature on the outcomes of patients with SOT who have received PP.</AbstractText><AbstractText Label="METHODS">A PubMed search was performed to identify articles pertaining to the outcomes of PP in patients with SOT.</AbstractText><AbstractText Label="RESULTS">We identified and included 14 studies that report on outcomes of PP placement in 143 patients with SOT and 191 non-SOT controls from interval period from 1979 to 2019. Studies included retrospective cohort studies, case series, and case reports. Compared with non-SOT controls who had PP, aggregate analysis demonstrated that patients with SOT who had PP did not develop significantly increased overall complications. However, they were significantly more likely to experience future surgical complications.</AbstractText><AbstractText Label="CONCLUSION">Our aggregate analysis demonstrated that patients with SOT are not at a significantly increased risk of overall complications when receiving a PP. Nevertheless, there is an increased risk of experiencing PP injury during subsequent surgeries, which may be mitigated by the earlier involvement of a urologist. Given the lack of recent data, large studies are prerequisite to further evaluate the safety and overall outcome of PP surgery in patients with SOT. Dick B, Greenberg JW, Polchert M, et&#xa0;al. A Systematic Review of Penile Prosthesis Surgery in Organ Transplant Recipients. Sex Med Rev 2021;9:636-640.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polchert</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natale</LastName><ForeName>Caleb</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJG</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>Omer A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University, New Orleans, LA, USA. Electronic address: oraheem@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="Y">Organ Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Organ Transplant Recipients</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32641224</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2020.05.006</ArticleId><ArticleId IdType="pii">S2050-0521(20)30049-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32366984</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Laparoscopic treatment of pudendal nerve and artery entrapment improves erectile dysfunction in healthy young males.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>5</EndPage><MedlinePgn>1-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-020-0287-8</ELocationID><Abstract><AbstractText>Erectile dysfunction (ED) is increasingly becoming more common in young healthy males and is attributed mainly to psychogenic causes in these patients. Recent studies have reported that ED could be secondary to pudendal nerve or artery entrapment. This perspective assessed the efficacy of laparoscopic pudendal nerve and artery decompression in young patients suffering from refractory ED, associated to a pudendal nerve entrapment syndrome. After excluding patients with psychological ED and venous leakage, five young male patients with a history of both ED and pudendal nerve entrapment syndrome diagnosed based on the Nantes criteria were recruited. Pudendal nerve and artery release was performed using a laparoscopic transperitoneal approach. International Index for Erectile Function (IIEF-5) and erectile hardness score (EHS) improved significantly in all patients, 3 months after surgery. Pudendal nerve and artery entrapment could be therefore a reversible cause of ED in young healthy males, and its treatment by laparoscopic pudendal nerve and artery decompression seems to be safe and effective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aoun</LastName><ForeName>Fouad</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Urology Department, Institut Jules Bordet, Brussels, Belgium. fouad.aoun@bordet.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotel-Dieu de France, Universit&#xe9; Saint Joseph, Beirut, Lebanon. fouad.aoun@bordet.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Lebanon Hospital, Beirut, Lebanon. fouad.aoun@bordet.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mjaess</LastName><ForeName>Georges</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8703-4611</Identifier><AffiliationInfo><Affiliation>Hotel-Dieu de France, Universit&#xe9; Saint Joseph, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daher</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rizk Hospital (LAU Medical Center), Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakr</LastName><ForeName>Ghazi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mount Lebanon Hospital, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chemaly</LastName><ForeName>Anthony Kallas</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Hotel-Dieu de France, Universit&#xe9; Saint Joseph, Beirut, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Lebanon Hospital, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salameh</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mount Lebanon Hospital, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albisinni</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Urology Department, University Clinics of Brussels, H&#xf4;pital Erasme, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Absil</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gynecology Department, EpiCURA Hospital, Ath, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roumeguere</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Urology Department, University Clinics of Brussels, H&#xf4;pital Erasme, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollens</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Universit&#xe9; Nord de France, St Phillibert Hospital, GHICL, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallonie Picarde Hospital, Tournai, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060525" MajorTopicYN="Y">Pudendal Nerve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060545" MajorTopicYN="Y">Pudendal Neuralgia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32366984</ArticleId><ArticleId IdType="doi">10.1038/s41443-020-0287-8</ArticleId><ArticleId IdType="pii">10.1038/s41443-020-0287-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res. 1999;11:141&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngdorf P, Hemmingsen L. Epidemiology of erectile dysfunction and its risk factors: a practice-based study in Denmark. Int J Impot Res. 2004;16:105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastrelli G, Maggi M. Erectile dysfunction in fit and healthy young men: psychological or pathological? Transl Androl Urol. 2017;6:79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.09.06</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med. 2013;10:2627&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-C, Lee Y-S, Seo K-K, Jung G-W, Kim T-H. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res. 2014;26:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2013.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Israilov S, et al. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res. 2002;14:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900812</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini G, et al. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. Int J Impot Res. 2016;28:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2015.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltaci S, Aydos K, Kosar A, Anafarta K. Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol. 1995;76:757&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.1995.tb00769.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Donatucci CF, Lue TF. Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res. 1993;5:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">8348217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemery JM, Nangia AK, Mamourian AC, Reid SK. Digital three-dimensional modelling of the male pelvis and bicycle seats: impact of rider position and seat design on potential penile hypoxia and erectile dysfunction. BJU Int. 2007;99:135&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2007.06542.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherington M. Hazards of bicycling: from handlebars to lightning. Semin Neurol. 2000;20:247&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2000-9834</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovitch I, Mor Y. The vicious cycling: bicycling related urogenital disorders. Eur Urol. 2005;47:277&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2004.10.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Naouar S, Braiek S, Kamel RE. Erectile dysfunction secondary to pudendal nerve injury complicating orthopedic surgery: practical recommandations. J Curr Surg. 2017;7:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jcs322e</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafik A. Pudendal artery syndrome with erectile dysfunction: treatment by pudendal canal decompression. Arch Androl. 1995;34:83&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01485019508987835</ArticleId></ArticleIdList></Reference><Reference><Citation>Labat J-J, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27:306&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.20505</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16:452&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901248</ArticleId></ArticleIdList></Reference><Reference><Citation>Arafa M, Shamloul R. The arabic version of the erection hardness score. J Sex Med. 2009;6:3501&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01501.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdogru T, Avci E, Akand M. Laparoscopic pudendal nerve decompression and transposition combined with omental flap protection of the nerve (Istanbul technique): technical description and feasibility analysis. Surg Endosc. 2014;28:925&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-013-3248-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama H, et al. Extended clavien-dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00595-015-1236-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med. 2011;8:310&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02450.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Popeney C, Ansell V, Renney K. Pudendal entrapment as an etiology of chronic perineal pain: diagnosis and treatment. Neurourol Urodyn. 2007;26:820&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.20421</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan MW, et al. Pudendal nerve and internal pudendal artery damage may contribute to radiation-induced erectile dysfunction. Int J Radiat Oncol Biol Phys. 2015;91:796&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2014.12.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cvetanovich GL, et al. Anatomy of the pudendal nerve and other neural structures around the proximal hamstring origin in males. Arthroscopy. 2018;34:2105&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2018.02.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricard T, Munier P, Story F, Lang H, Saussine C. The drug-resistant pudendal neuralgia management: a systematic review. Neurourol Urodyn. 2019;38:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.23824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafik A. Pudendal canal decompression in the treatment of erectile dysfunction. Arch Androl. 1994;32:141&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01485019408987779</ArticleId></ArticleIdList></Reference><Reference><Citation>Luther RD, Castellanos ME. Successful treatment of penile numbness and erectile dysfunction resulting from pudendal nerve entrapment. Urology. 2019;134:228&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2019.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Menorca RMG, Fussell TS, Elfar JC. Peripheral nerve trauma: mechanisms of injury and recovery. Hand Clin. 2013;29:317&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hcl.2013.04.002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32363085</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2156-7514</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Journal of clinical imaging science</Title><ISOAbbreviation>J Clin Imaging Sci</ISOAbbreviation></Journal><ArticleTitle>Concurrent, Bilateral Presentation of Immature and Mature Ovarian Teratomas with Refractory Hyponatremia: A Case Report.</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.25259/JCIS_13_2020</ELocationID><Abstract><AbstractText>We present the imaging and histopathological findings in a 32-year-old female who presented to the erectile dysfunction with progressively worsening abdominal pain over the past 2 months. Computed tomography abdomen and pelvis revealed bilateral ovarian teratomas, left significantly larger than right. There was associated fat stranding, mesenteric/omental stranding, and ascites worrisome for rupture versus peritoneal carcinomatosis. Histopathology confirmed a left immature teratoma (Grade 2), right mature teratoma, and peritoneal gliomatosis from possible tumor rupture before surgery.</AbstractText><CopyrightInformation>&#xa9; 2020 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tejani</LastName><ForeName>Ali Shah</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Departments of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, United.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Wenxin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijay</LastName><ForeName>Kanupriya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Departments of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, United.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Imaging Sci</MedlineTA><NlmUniqueID>101564708</NlmUniqueID><ISSNLinking>2156-5597</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neoplasm</Keyword><Keyword MajorTopicYN="N">Ovarian</Keyword><Keyword MajorTopicYN="N">Teratoma</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32363085</ArticleId><ArticleId IdType="pmc">PMC7193198</ArticleId><ArticleId IdType="doi">10.25259/JCIS_13_2020</ArticleId><ArticleId IdType="pii">JCIS-10-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kudela E, Nachajova M, Biringer K, Slavik P, Plank L, Danko J. Bilateral ovarian angiosarcoma arising from the mature cystic teratomas-a case report and review of the literature. Int J Surg Case Rep. 2018;42:90&#x2013;3. doi: 10.1016/j.ijscr.2017.11.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijscr.2017.11.064</ArticleId><ArticleId IdType="pmc">PMC5726881</ArticleId><ArticleId IdType="pubmed">29227858</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha SE, Byun JY, Jung SE, Kim HL, Oh SN, Kim H, et al. Atypical CT and MRI manifestations of mature ovarian cystic teratomas. AJR Am J Roentgenol. 2004;183:743&#x2013;50. doi: 10.2214/ajr.183.3.1830743.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.183.3.1830743</ArticleId><ArticleId IdType="pubmed">15333365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurman RJ, Carcangiu ML, Herrington CS, Young RH. Lyon: IARC; 2014. WHO Classification of Tumors of the Female Reproductive Organs.</Citation></Reference><Reference><Citation>Young RH, Clement PB, Suilly RE. The Ovary, in Diagnostic Surgical Pathology. In: Sternberg SS, editor. New York: Ravan Press; 1994. p. 2195.</Citation></Reference><Reference><Citation>Shalev C, Bustan M, Romeno S, Goldberg Y, Ben-Shlomo I. Laparoscopic resection of ovarian benign cystic teratomas: Experience with 84 cases. Hum Reprod. 1998;13:1810&#x2013;2. doi: 10.1093/humrep/13.7.1810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/13.7.1810</ArticleId><ArticleId IdType="pubmed">9740429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida M, Kawano Y, Yuge A, Nasu K, Matsumoto H, Narahara H. Three cases of immature teratoma diagnosed after laparoscopic operation. Clin Med Insights Case Rep. 2014;7:91&#x2013;4. doi: 10.4137/CCRep.S17455.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CCRep.S17455</ArticleId><ArticleId IdType="pmc">PMC4159361</ArticleId><ArticleId IdType="pubmed">25232281</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa L, Francisco AM, Archangelo Sde C, Soares FC, Ferreira MC, Maia RL. Bilateral immature ovarian teratoma in a 12-year-old girl: A case report. Rev Assoc Med Bras. 2012;58:138&#x2013;40. doi: 10.1016/S0104-4230(12)70172-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0104-4230(12)70172-0</ArticleId><ArticleId IdType="pubmed">22569606</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Quick CM, Fadare O, Zheng W. Germ cell tumors and mixed germ cell-sex cord-stromal tumors of the ovary. In: Zheng W, Fadare O, Quick CM, Shen D, Guo D, editors. Gynecologic and Obstetric Pathology. Vol. 2. Singapore: Springer; 2019. pp. 231&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-13-3019-3_8</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon NR, Lee JW, Kim BG, Bae DS, Sohn I, Sung CO, et al. Gliomatosis peritonei is associated with frequent recurrence, but does not affect overall survival in patients with ovarian immature teratoma. Virchows Arch. 2012;461:299&#x2013;304. doi: 10.1007/s00428-012-1285-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-012-1285-0</ArticleId><ArticleId IdType="pubmed">22820986</ArticleId></ArticleIdList></Reference><Reference><Citation>Comerci JT, Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: A clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol. 1994;84:22&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8008317</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson WF, Prevost EC, Edmunds FT, Hundley JM, Jr, Morris FK. Benign cystic teratomas of the ovary; a clinico-statistical study of 1,007 cases with a review of the literature. Am J Obstet Gynecol. 1955;70:368&#x2013;82. doi: 10.1016/S0002-9378(16)37681-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9378(16)37681-5</ArticleId><ArticleId IdType="pubmed">13238472</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoja E, Noy MA, Axtmayer RW, Colon FE, Pelegrina I. Ovarian dermoids and their complications. Comprehensive historical review. Obstet Gynecol Surv. 1975;30:1&#x2013;20. doi: 10.1097/00006254-197501000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006254-197501000-00001</ArticleId><ArticleId IdType="pubmed">1089224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Takei Y, Saga Y, Machida S, Takahasi Y, Fujiwara H. Immature ovarian teratoma with hyponatremia and low serum vasopressin level. J Obstet Gynaecol Res. 2016;42:1400&#x2013;4. doi: 10.1111/jog.13057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.13057</ArticleId><ArticleId IdType="pubmed">27277383</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, Kim JK, Kim KR, Cho KS. Imaging findings of complications and unusual manifestations of ovarian teratomas. Radiographics. 2008;28:969&#x2013;83. doi: 10.1148/rg.284075069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.284075069</ArticleId><ArticleId IdType="pubmed">18635624</ArticleId></ArticleIdList></Reference><Reference><Citation>Saba L, Guerrierod S, Sulcisc R, Virgiliod B, Melisd GB, Mallarini G. Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol. 2009;72:454&#x2013;63. doi: 10.1016/j.ejrad.2008.07.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2008.07.044</ArticleId><ArticleId IdType="pubmed">18804932</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso PA, Marsh MR, Minkowitz S, Karten G. An intense clinicopathologic study of 305 teratomas of the ovary. Cancer. 1971;27:343&#x2013;8. doi: 10.1002/1097-0142(197102)27:2&lt;343::AID-CNCR2820270215&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(197102)27:2&lt;343::AID-CNCR2820270215&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">5100397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32354643</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5786</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Analysis of preoperative and postoperative expectations of penile implant candidates.</ArticleTitle><Pagination><StartPage>345</StartPage><EndPage>350</EndPage><MedlinePgn>345-350</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuro.2020.01.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-4806(20)30022-X</ELocationID><Abstract><AbstractText>Penile prosthesis implantation is a good option for the treatment of refractory erectile dysfunction. However, the patient's expectations, among other factors, condition his satisfaction after surgery. This review article aims to present the scientific evidence available concerning patient satisfaction with penile prosthesis surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 AEU. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fraile Poblador</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a y Urolog&#xed;a Reconstructiva, Servicio de Urolog&#xed;a, Hospital Universitario Ram&#xf3;n y Cajal, Instituto de Investigaci&#xf3;n Sanitaria IRYCIS, Madrid, Espa&#xf1;a. Electronic address: agustinfraile78@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az P&#xe9;rez</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a y Urolog&#xed;a Reconstructiva, Servicio de Urolog&#xed;a, Hospital Universitario Ram&#xf3;n y Cajal, Instituto de Investigaci&#xf3;n Sanitaria IRYCIS, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hevia Palacios</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a y Urolog&#xed;a Reconstructiva, Servicio de Urolog&#xed;a, Hospital Universitario Ram&#xf3;n y Cajal, Instituto de Investigaci&#xf3;n Sanitaria IRYCIS, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgos Revilla</LastName><ForeName>F J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a y Urolog&#xed;a Reconstructiva, Servicio de Urolog&#xed;a, Hospital Universitario Ram&#xf3;n y Cajal, Instituto de Investigaci&#xf3;n Sanitaria IRYCIS, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Evaluaci&#xf3;n de las expectativas preoperatorias y postoperatorias del candidato a pr&#xf3;tesis peneana. Estudios de satisfacci&#xf3;n.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp (Engl Ed)</MedlineTA><NlmUniqueID>101771154</NlmUniqueID><ISSNLinking>2173-5786</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057234" MajorTopicYN="N">Preoperative Period</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acortamiento peneano</Keyword><Keyword MajorTopicYN="N">Expectativas del paciente</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Patient expectations</Keyword><Keyword MajorTopicYN="N">Patient satisfaction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Penile shortening</Keyword><Keyword MajorTopicYN="N">Pr&#xf3;tesis pene</Keyword><Keyword MajorTopicYN="N">Resultados</Keyword><Keyword MajorTopicYN="N">Satisfacci&#xf3;n del paciente</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32354643</ArticleId><ArticleId IdType="doi">10.1016/j.acuro.2020.01.007</ArticleId><ArticleId IdType="pii">S0210-4806(20)30022-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32327742</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Postoperative penile prosthesis pain: is it worse in diabetic patients?</ArticleTitle><Pagination><StartPage>286</StartPage><EndPage>290</EndPage><MedlinePgn>286-290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-020-0284-y</ELocationID><Abstract><AbstractText>Inflatable penile prosthesis (IPP) surgery is an effective, safe and satisfactory treatment option for medication-refractory erectile dysfunction. Postoperative complications include infection, mechanical failure, erosion, and pain. Current literature suggests the need for a better approach to postoperative pain management after IPP surgery. Clinical studies have demonstrated that postoperative pain is different in diabetic patients. We sought to determine if there is a difference in pain after IPP placement in diabetics. This is a single-institution retrospective review. The main outcome measure was the number of 30-day postoperative visits for pain. The secondary outcome included differences in how pain was managed. The top HbA1c quartile was compared with the other HbA1c quartiles. Diabetes was present in 92 (54.4%) patients and 96% of these had HbA1c&#x2009;&gt;&#x2009;8. Significant postoperative pain was more common in patients with HbA1c&#x2009;&gt;&#x2009;8 (41% vs 13%, p&#x2009;=&#x2009;0.047) and resulted in more unplanned visits (27% vs 11%, p&#x2009;=&#x2009;0.042). Patients with HbA1c&#x2009;&gt;&#x2009;8 with significant postoperative pain were more likely to be managed with opioids and gabapentin (30% vs 14%, p&#x2009;=&#x2009;0.05). There were no statistical differences in age between diabetics and non-diabetics (mean 59 vs 61, p&#x2009;=&#x2009;0.193). Hispanic and African-American patients represented 87% of the poorly controlled diabetics compared with only 13% of white patients (p&#x2009;&lt;&#x2009;0.001). Poorly controlled diabetics had more medical comorbidities (p&#x2009;&lt;&#x2009;0.001). On logistic regression, a HbA1c&#x2009;&gt;&#x2009;8 was predictive of an unplanned visit for pain with an OR of 2.83 (p&#x2009;=&#x2009;0.04). Significant pain after IPP surgery was higher in diabetics with HbA1c&#x2009;&gt;&#x2009;8, which resulted in more unplanned 30-day postoperative visits. Patients with significant postoperative pain were managed with a combination of opioids and gabapentin. Future studies are required to optimize pain management in diabetics following IPP placement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinstatler</LastName><ForeName>Lael</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1559-8837</Identifier><AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, New Hampshire, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Dayron</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>Briana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, New Hampshire, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apoj</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaee</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, New Hampshire, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, New Hampshire, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munarriz</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA. munarriz@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32327742</ArticleId><ArticleId IdType="doi">10.1038/s41443-020-0284-y</ArticleId><ArticleId IdType="pii">10.1038/s41443-020-0284-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Erectile Dysfunction Guideline Update Panel et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174:230&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000164463.19239.19</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, European Association of Urology et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2010.02.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakalopoulos I, Kampantais S, Ioannidis S, Laskaridis L, Dimopoulos P, Toutziaris C, et al. High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. J Sex Med. 2013;10:2774&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12311</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer ND, Dick B, Gabrielson AT, Alzweri LM, Hellstrom WJG. Penile prosthesis complications: planning, prevention, and decision making. Sex Med Rev. 2019;7:349&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.04.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross M. Penile prosthesis infection. AUA Update Ser. 2018;37:109&#x2013;16.</Citation></Reference><Reference><Citation>Berglund DD, Kurowicki J, Giveans MR, Horn B, Levy JC. Comorbidity effect on speed of recovery after arthroscopic rotator cuff repair. JSES Open Access. 2018;2:60&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jses.2017.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbera L, Sutradhar R, Howell D, Corn E, O&#x2019;Brien MA, Seow H, et al. Factors associated with opioid use in long term cancer survivors. J Pain Symptom Manag. 2019;58:100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2019.02.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk JK, Hunter JC, Mihalko SL, Danhauer SC, Shumaker SA. Perspectives of pain in patients with type 2 diabetes. Expert Rev Endocrinol Metab. 2019;14:215&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17446651.2019.1592674</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwathmey KG, Pearson KT. Diagnosis and management of sensory polyneuropathy. BMJ. 2019;365:l1108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1108</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson-Papp J, George MC, Dorfman D, Simpson DM. Barriers to chronic pain measurement: a qualitative study of patient perspectives. Pain Med. 2015;16:1256&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pme.12717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3:345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmrj.2011.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams AS, Parker MM, Moffet HH, Jaffe M, Schillinger D, Callaghan B, et al. Communication barriers and the clinical recognition of diabetic peripheral neuropathy in a diverse cohort of adults: the DISTANCE study. J Health Commun. 2016;21:544&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10810730.2015.1103335</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, Hu Y, Li C, Wu D, Ge S, Liu T. Predictors of depressive symptoms among mid-aged and older men with diabetes in China. Res Theory Nurs Pr. 2019;33:6&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1891/1541-6577.33.1.6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use&#x2014;United States, 2006&#x2013;2015. MMWR Morb Mortal Wkly Rep. 2017;66:265&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6610a1</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherrer JF, Salas J, Schneider FD, Bucholz KK, Sullivan MD, Copeland LA, et al. Characteristics of new depression diagnoses in patients with and without prior chronic opioid use. J Affect Disord. 2017;210:125&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.12.027</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#x103;descu SV, T&#x103;taru C, Kobylinska L, Georgescu EL, Zahiu DM, Z&#x103;grean AM, et al. The association between diabetes mellitus and depression. J Med Life. 2016;9:120&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27453739</ArticleId><ArticleId IdType="pmc">4863499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32323225</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1720-8386</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of endocrinological investigation</Title><ISOAbbreviation>J Endocrinol Invest</ISOAbbreviation></Journal><ArticleTitle>People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction.</ArticleTitle><Pagination><StartPage>1391</StartPage><EndPage>1408</EndPage><MedlinePgn>1391-1408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40618-020-01257-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To systematically review the impact of smoking habits on cardiovascular (CV) as well as on male sexual and reproductive function and to provide updated evidence on the role of electronic cigarettes (e-Cig) on the same topics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive Medline, Embase, and Cochrane search was performed including the following words: smoking, CV system, CV risk, erectile dysfunction (ED), and male fertility. Publications from January 1, 1969 up to February 29, 2020 were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Smoking has a tremendous negative impact on CV mortality and morbidity. Current smoking behavior is also negatively associated with erectile dysfunction (ED) and impaired sperm parameters. E-Cig can release significantly lower concentrations of harmful substances when compared to regular combustible cigarettes. Whether or not the latter can result in positive CV, sexual, and fertility outcomes is still under study. Preliminary studies showed that exposure to e-Cig leads to lower vascular damage when compared to the traditional cigarette use. However, data on the long-term effects of e-Cig are lacking. Similarly, preliminary data, obtained in animal models, have suggested a milder effect of e-Cig on erectile function and sperm parameters.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Available evidence showed that e-Cig are much less dangerous when compared to the traditional tobacco use. However, it should be recognized that the risk related to e-Cig is still higher when compared to that observed in non-smoking patients. Hence, e-Cig should be considered as a potential tool, in the logic of harm reduction, to reduce the CV, sexual and fertility risk in patients refractory to the fundamental, healthy choice to definitively quit smoking.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corona</LastName><ForeName>G</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9894-2885</Identifier><AffiliationInfo><Affiliation>Medical Department, Endocrinology Unit, Maggiore-Bellaria Hospital, Azienda-Usl Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansone</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1210-2843</Identifier><AffiliationInfo><Affiliation>Chair of Endocrinology &amp; Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallotti</LastName><ForeName>F</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6042-6474</Identifier><AffiliationInfo><Affiliation>Laboratory of Seminology-Sperm Bank "Loredana Gandini", Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferlin</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5817-8141</Identifier><AffiliationInfo><Affiliation>Unit of Endocrinology and Metabolism, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pivonello</LastName><ForeName>R</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9632-1348</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Universit&#xe0; Degli Studi Di Napoli "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isidori</LastName><ForeName>A M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-9037-5417</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3267-4221</Identifier><AffiliationInfo><Affiliation>Department of Experimental, Clinical and Biomedical Sciences, Endocrinology Unit, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jannini</LastName><ForeName>E A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-5874-039X</Identifier><AffiliationInfo><Affiliation>Chair of Endocrinology &amp; Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. eajannini@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy. eajannini@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>J Endocrinol Invest</MedlineTA><NlmUniqueID>7806594</NlmUniqueID><ISSNLinking>0391-4097</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8007-45-2</RegistryNumber><NameOfSubstance UI="D003033">Coal Tar</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073865" MajorTopicYN="N">Cigarette Smoking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003033" MajorTopicYN="N">Coal Tar</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012098" MajorTopicYN="N">Reproduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060728" MajorTopicYN="N">Reproductive Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014029" MajorTopicYN="N">Tobacco Use Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular risk</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Harm reduction</Keyword><Keyword MajorTopicYN="N">Male fertility</Keyword><Keyword MajorTopicYN="N">Smoking</Keyword><Keyword MajorTopicYN="N">e-cigarette</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32323225</ArticleId><ArticleId IdType="doi">10.1007/s40618-020-01257-x</ArticleId><ArticleId IdType="pii">10.1007/s40618-020-01257-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32300529</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2214-4420</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Urology case reports</Title><ISOAbbreviation>Urol Case Rep</ISOAbbreviation></Journal><ArticleTitle>Penile implant surgery for conservative therapy resistant erectile dysfunction in a 19y-old.</ArticleTitle><Pagination><StartPage>101161</StartPage><MedlinePgn>101161</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eucr.2020.101161</ELocationID><Abstract><AbstractText>A 19y-old male with a history of &#x3b2;-thalassemia presented with lifelong Erectile Dysfunction (ED), refractory to different PDE-5i's and both intra-urethral and intra cavernosal prostaglandins. Pelvic arteriography showed a severe hypogenesis of the left cavernous artery. Psychological and other organic causes were excluded. After informing the patient and his family thoroughly during several visits, he agreed on performing penile implant surgery. An AMS Cx 21cm +2cm rear tip extenders was implanted via penoscrotal incision. The procedure was uncomplicated and with 1 year of post-operative follow-up, the patient is very satisfied.</AbstractText><CopyrightInformation>&#xa9; 2020 Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weckx</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Jessa Ziekenhuis, Urology Department, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Renterghem</LastName><ForeName>Koenraad</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Jessa Ziekenhuis, Urology Department, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universiteit Hasselt, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urol Case Rep</MedlineTA><NlmUniqueID>101626357</NlmUniqueID><ISSNLinking>2214-4420</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile implant surgery</Keyword><Keyword MajorTopicYN="N">Sexual medicine</Keyword><Keyword MajorTopicYN="N">Urology</Keyword></KeywordList><CoiStatement>No conflict of interest to be declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32300529</ArticleId><ArticleId IdType="pmc">PMC7152716</ArticleId><ArticleId IdType="doi">10.1016/j.eucr.2020.101161</ArticleId><ArticleId IdType="pii">S2214-4420(20)30049-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gabrielsen J.S., Lamb D.J., Lipschultz L.I. Iron and a man's reproductive health: the good, the bad, and the ugly. Curr Urol Rep. 2018;19:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902410</ArticleId><ArticleId IdType="pubmed">29858708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.G., Lin T.Y., Lin C.L. Risk of erectile dysfunction in transfusion-naive thalassemia men. Medicine. 2015;94(13) (Baltimore)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4554026</ArticleId><ArticleId IdType="pubmed">25837766</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris C.R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology. 2008:177&#x2013;185. the Education Program of the American Society of Hematology American Society of Hematology Education Program.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.H., Hsu G.L., Chang S.J. Surgical niche for the treatment of erectile dysfunction. Int J Urol. 2019;27(2):117&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">31812157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., Delk J.R., Salem E.A. Long-term survival of inflatable penile protheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4(4):1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32253786</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1442-2042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of urology : official journal of the Japanese Urological Association</Title><ISOAbbreviation>Int J Urol</ISOAbbreviation></Journal><ArticleTitle>Peyronie's disease: Contemporary evaluation and management.</ArticleTitle><Pagination><StartPage>504</StartPage><EndPage>516</EndPage><MedlinePgn>504-516</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/iju.14230</ELocationID><Abstract><AbstractText>Peyronie's disease is a common yet poorly understood condition characterized by penile pain, curvature, sexual dysfunction and psychological bother. Peyronie's disease represents a penile wound healing disorder, and is thought to arise from exuberant scarring in response to penile trauma in genetically predisposed men. In the absence of active treatment, the majority of men experience stable or worsening symptoms, with few reporting spontaneous resolution in penile curvature or other deformity. In contrast, penile pain improves or resolves in the majority of men. Treatment options vary based on symptom severity and stability. Several oral therapies are commonly prescribed, although to date there are no strong data to support any oral agents as monotherapy for Peyronie's disease. Other options including penile traction therapy and intralesional injections result in modest improvements for many patients, particularly when used early after symptom onset. Penile straightening through approaches, such as penile plication and plaque incision or partial excision and grafting, represent the most rapid and reliable approach to correct penile curvature once the symptoms have stabilized. Side-effects vary based on the type of surgery carried out, and include penile shortening, sensation changes and erectile dysfunction in the minority of men. In patients with drug refractory erectile dysfunction and Peyronie's disease, placement of a penile prosthesis will address both issues, and is associated with high levels of patient satisfaction. The current review provides a practical approach to the modern evaluation and management of patients presenting with Peyronie's disease.</AbstractText><CopyrightInformation>&#xa9; 2020 The Japanese Urological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ziegelmann</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Urology, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajic</LastName><ForeName>Petar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Urology, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Urology, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Urol</MedlineTA><NlmUniqueID>9440237</NlmUniqueID><ISSNLinking>0919-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Urol. 2020 Jun;27(6):516-517</RefSource><PMID Version="1">32314443</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015552" MajorTopicYN="N">Injections, Intralesional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="Y">Penile Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="Y">Penile Induration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Xiaflex</Keyword><Keyword MajorTopicYN="N">collagenase</Keyword><Keyword MajorTopicYN="N">grafting</Keyword><Keyword MajorTopicYN="N">penile curvature</Keyword><Keyword MajorTopicYN="N">plication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32253786</ArticleId><ArticleId IdType="doi">10.1111/iju.14230</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>de la Peyronie F. Sur quelques obstacles qui s' opposent a l'ejaculation naturelle de la semence. Mem. Acad. R. Chir. 1743; 1: 425-34.</Citation></Reference><Reference><Citation>Akkus E. Historical review of Peyronie&#x2019;s disease. In: Levine LA (ed.). Peyronie&#x2019;s Disease. Humana Press, Totowa, 2007; 1-8.</Citation></Reference><Reference><Citation>Mohede DCJ, de Jong IJ, van Driel MF. Medical treatments of Peyronie's disease: past, present, and future. Urology 2019; 125: 1-5.</Citation></Reference><Reference><Citation>Musitelli S, Bossi M, Jallous H. A brief historical survey of &#x201c;Peyronie&#x2019;s disease.&#x201d; J. Sex. Med. 2008; 5: 1737-46.</Citation></Reference><Reference><Citation>De Rose AF, Mantica G, Bocca B, Szpytko A, Van der Merwe A, Terrone C. Supporting the role of penile trauma and micro-trauma in the etiology of Peyronie&#x2019;s disease. Prospective observational study using the electronic microscope to examine two types of plaques. Aging Male 2019; https://doi.org/10.1080/13685538.2019.1586870.</Citation></Reference><Reference><Citation>Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006; 97: 570-4.</Citation></Reference><Reference><Citation>Gelbard M, Goldstein I, Hellstrom WJ et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013; 190: 199-207.</Citation></Reference><Reference><Citation>Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie&#x2019;s plaque fibroblasts. J Urol. 2008; 179: 2447-55.</Citation></Reference><Reference><Citation>Mateus M, Ilg MM, Stebbeds WJ et al. Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie's disease. J. Sex. Med. 2018; 15: 947-57.</Citation></Reference><Reference><Citation>Bias WB, Nyberg LM Jr, Hochberg MC, Walsh PC. Peyronie&#x2019;s disease: a newly recognized autosomal-dominant trait. Am. J. Med. Genet. 1982; 12: 227-35.</Citation></Reference><Reference><Citation>Al-Thakafi S, Al-Hathal N. Peyronie&#x2019;s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl. Androl. Urol. 2016; 5: 280-9.</Citation></Reference><Reference><Citation>Nehra A, Alterowitz R, Culkin DJ et al. Peyronie's disease: AUA guideline. J Urol. 2015; 194: 745-53.</Citation></Reference><Reference><Citation>Tal R, Hall MS, Alex B, Choi J, Mulhall JP. Peyronie&#x2019;s disease in teenagers. J. Sex. Med. 2012; 9: 302-8.</Citation></Reference><Reference><Citation>Mulhall JP, Creech SD, Boorjian SA et al. Subjective and objective analysis of the prevalence of Peyronie&#x2019;s disease in a population of men presenting for prostate cancer screening. J. Urol. 2004; 171: 2350-3.</Citation></Reference><Reference><Citation>Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie&#x2019;s disease: results of a large survey. BJU Int. 2001; 88: 727-30.</Citation></Reference><Reference><Citation>Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie&#x2019;s disease following radical prostatectomy: incidence and predictors. J. Sex. Med. 2010; 7: 1254-61.</Citation></Reference><Reference><Citation>Kadioglu A, Sanli O, Akman T et al. Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients. J. Androl. 2011; 32: 502-8.</Citation></Reference><Reference><Citation>Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie&#x2019;s disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J. Sex. Med. 2012; 9: 2716-23.</Citation></Reference><Reference><Citation>Nelson CJ, Mulhall JP. Psychological impact of Peyronie&#x2019;s disease: a review. J. Sex. Med. 2013; 10: 653-60.</Citation></Reference><Reference><Citation>Davis SN, Ferrar S, Sadikaj G, Gerard M, Binik YM, Carrier S. Female partners of men with Peyronie&#x2019;s disease have impaired sexual function, satisfaction, and mood, while degree of sexual interference is associated with worse outcomes. J. Sex. Med. 2016; 13: 1095-103.</Citation></Reference><Reference><Citation>Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie&#x2019;s disease: validation of the Peyronie's disease questionnaire. J. Urol. 2013; 190: 627-34.</Citation></Reference><Reference><Citation>Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie&#x2019;s Disease Questionnaire (PDQ). J. Sex. Med. 2015; 12: 1072-9.</Citation></Reference><Reference><Citation>Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie&#x2019;s disease. J. Urol. 2006; 175: 2115-8.</Citation></Reference><Reference><Citation>Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie&#x2019;s disease (PD). Int. J. Impot. Res. 2018; 30: 171-8.</Citation></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH et al. Erectile dysfunction: AUA guideline. J. Urol. 2018; 200: 633-41.</Citation></Reference><Reference><Citation>Allen MS, Walter EE. Erectile dysfunction: an umbrella review of meta-analyses of risk-factors, treatment, and prevalence outcomes. J. Sex. Med. 2019; 16: 531-41.</Citation></Reference><Reference><Citation>Wiggins A, Farrell MR, Tsambarlis P, Levine LA. The penile sensitivity ratio: a novel application of biothesiometry to assess changes in penile sensitivity. J. Sex. Med. 2019; 16: 447-51.</Citation></Reference><Reference><Citation>Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie&#x2019;s disease patients: comparison of three methods. J. Sex. Med. 2007; 4: 199-203.</Citation></Reference><Reference><Citation>Nascimento B, Cerqueira I, Miranda EP et al. Impact of camera deviation on penile curvature assessment using 2D pictures. J. Sex. Med. 2018; 15: 1638-44.</Citation></Reference><Reference><Citation>Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie&#x2019;s disease. Urology 2018; 119: 109-14.</Citation></Reference><Reference><Citation>Levine L, Rybak J, Corder C, Farrel MR. Peyronie&#x2019;s disease plaque calcification-prevalence, time to identification, and development of a new grading classification. J. Sex. Med. 2013; 10: 3121-8.</Citation></Reference><Reference><Citation>Gelbard MK, Dorey F, James K. The natural history of Peyronie&#x2019;s disease. J. Urol. 1990; 144: 1376-9.</Citation></Reference><Reference><Citation>Martinez-Salamanca JI, Egui A, Moncada I et al. Acute phase Peyronie&#x2019;s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J. Sex. Med. 2014; 11: 506-15.</Citation></Reference><Reference><Citation>El-Khatib FM, Towe M, Yafi FA. Management of Peyronie&#x2019;s disease with collagenase Clostridium histolyticum in the acute phase. World J. Urol. 2020; 38: 299-304.</Citation></Reference><Reference><Citation>Levine LA, Larsen SM. Surgery for Peyronie&#x2019;s disease. Asian J. Androl. 2013; 15: 27-34.</Citation></Reference><Reference><Citation>Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie&#x2019;s disease and congenital penile curvature. Can. Urol. Assoc. J. 2018; 12: E197-209.</Citation></Reference><Reference><Citation>Tsambarlis P, Levine LA. Nonsurgical management of Peyronie&#x2019;s disease. Nat. Rev. Urol. 2019; 16: 172-86.</Citation></Reference><Reference><Citation>Porst H, Burri A. Current strategies in the management of Peyronie&#x2019;s disease (PD)-results of a survey of 401 sexual medicine experts across Europe. J. Sex. Med. 2019; 16: 901-8.</Citation></Reference><Reference><Citation>Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J. Sex. Med. 2011; 8: 1472-7.</Citation></Reference><Reference><Citation>Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 2006; 97: 625-33.</Citation></Reference><Reference><Citation>Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie&#x2019;s fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-44.</Citation></Reference><Reference><Citation>Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie&#x2019;s disease. J. Sex. Med. 2012; 9: 288-95.</Citation></Reference><Reference><Citation>Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal&#x2019;s variant angina. N.. Engl. J. Med. 1981; 304: 862-6.</Citation></Reference><Reference><Citation>Leone M, Giustiniani A, Cecchini AP. Cluster headache: present and future therapy. Neurol. Sci. 2017; 38: 45-50.</Citation></Reference><Reference><Citation>Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J. Surg. Res. 1990; 49: 463-6.</Citation></Reference><Reference><Citation>Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J. Cell Biol. 1984; 98: 1662-71.</Citation></Reference><Reference><Citation>Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie&#x2019;s disease-a placebo-controlled pilot study. J. Sex. Med. 2007; 4: 477-84.</Citation></Reference><Reference><Citation>Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J. Urol. 2002; 168: 2483-5.</Citation></Reference><Reference><Citation>Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J. Urol. 2003; 169: 1775-8.</Citation></Reference><Reference><Citation>Di Stasi SM, Giannantoni A, Stephen RL et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie&#x2019;s disease. J. Urol. 2004; 171: 1605-8.</Citation></Reference><Reference><Citation>Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie&#x2019;s disease: a double-blind, placebo controlled trial. J. Urol. 2007; 177: 972-5.</Citation></Reference><Reference><Citation>Twidwell J, Levine L. Topical treatment for acute phase Peyronie&#x2019;s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int. J. Impot. Res. 2016; 28: 41-5.</Citation></Reference><Reference><Citation>Chung E, Wang J. A state-of-art review of low intensity extracorporeal shock wave therapy and lithotripter machines for the treatment of erectile dysfunction. Expert Rev. Med. Devices 2017; 14: 929-34.</Citation></Reference><Reference><Citation>Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie&#x2019;s disease. &#x200e;Int. J. Impot. Res. 2016; 28: 161-6.</Citation></Reference><Reference><Citation>Krieger JR, Rizk PJ, Kohn TP, Pastuszak A. Shockwave therapy in the treatment of Peyronie&#x2019;s disease. Sex. Med. Rev. 2019; 7: 499-507.</Citation></Reference><Reference><Citation>Brandes G, Messina A, Reale E. The palmar fascia after treatment by the continuous extension technique for Dupuytren&#x2019;s contracture. J. Hand Surg. 1994; 19: 528-33.</Citation></Reference><Reference><Citation>Chung E, De Young L, Solomon M, Brock GB. Peyronie&#x2019;s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system. J. Sex. Med. 2013; 10: 1259-67.</Citation></Reference><Reference><Citation>Lin H, Liu C, Wang R. Effect of penile traction and vacuum erectile device for Peyronie&#x2019;s disease in an animal model. J Sex Med. 2017; 14: 1270-6.</Citation></Reference><Reference><Citation>Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med. 2008; 5: 1468-73.</Citation></Reference><Reference><Citation>Gontero P, Di Marco M, Giubilei G et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie&#x2019;s disease. Results of a phase II prospective study. J Sex Med. 2009; 6: 558-66.</Citation></Reference><Reference><Citation>Yafi FA, Pinsky MR, Stewart C et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease. J. Urol. 2015; 194: 754-8.</Citation></Reference><Reference><Citation>Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology. 2017; 104: 102-9.</Citation></Reference><Reference><Citation>Moncada I, Krishnappa P, Romero J et al. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie&#x2019;s disease: a controlled multicentre study. BJU Int. 2019; 123: 694-702.</Citation></Reference><Reference><Citation>Ziegelmann M, Savage J, Toussi A et al. Outcomes of a novel penile traction device in men with Peyronie&#x2019;s disease: A randomized, single-blind, controlled trial. J. Urol. 2019; 202: 599-610.</Citation></Reference><Reference><Citation>Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie&#x2019;s disease: a systematic review of the literature. Eur. Urol. 2018; 74: 767-81.</Citation></Reference><Reference><Citation>Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie&#x2019;s disease. J. Sex. Med. 2019; 16: 891-900.</Citation></Reference><Reference><Citation>Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie&#x2019;s disease. J. Urol. 1994; 151: 1522-4.</Citation></Reference><Reference><Citation>Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie&#x2019;s disease. J. Urol. 2002; 168: 621-5.</Citation></Reference><Reference><Citation>Levine LA. Treatment of Peyronie&#x2019;s disease with intralesional verapamil injection. J. Urol. 1997; 158: 1395-9.</Citation></Reference><Reference><Citation>Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie&#x2019;s disease. Urology 2007; 69: 1181-4.</Citation></Reference><Reference><Citation>Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie&#x2019;s disease: a randomized single-blind, placebo-controlled study. Int. Urol. Nephrol. 2009; 41: 467-71.</Citation></Reference><Reference><Citation>Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie&#x2019;s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand. J. Urol. Nephrol. 1991; 25: 89-94.</Citation></Reference><Reference><Citation>Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie&#x2019;s disease with local interferon-alpha 2b. Eur. Urol. 1995; 28: 236-40.</Citation></Reference><Reference><Citation>Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie&#x2019;s disease. J. Androl. 1999; 20: 444-8.</Citation></Reference><Reference><Citation>Hellstrom WJ, Kendirci M, Matern R et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie&#x2019;s disease. J. Urol. 2006; 176: 394-8.</Citation></Reference><Reference><Citation>Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie&#x2019;s disease. J. Sex. Med. 2005; 2: 709-15.</Citation></Reference><Reference><Citation>Stewart CA, Yafi FA, Knoedler M et al. Intralesional Injection of Interferon-alpha2b improves penile curvature in men with Peyronie&#x2019;s disease independent of plaque location. J. Urol. 2015; 194: 1704-7.</Citation></Reference><Reference><Citation>Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie's and Dupuytren's disease. &#x200e;Int. J. Impot. Res. 2011; 23: 142-5.</Citation></Reference><Reference><Citation>Mills SA, Gelbard MK. Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond. World J. Urol. 2020; 38: 269-77.</Citation></Reference><Reference><Citation>Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie&#x2019;s disease. J. Urol. 1985; 134: 280-3.</Citation></Reference><Reference><Citation>Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease. Urology 1980; 15: 536.</Citation></Reference><Reference><Citation>Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J. Urol. 2012; 187: 2268-74.</Citation></Reference><Reference><Citation>Lipshultz LI, Goldstein I, Seftel AD et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie&#x2019;s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015; 116: 650-6.</Citation></Reference><Reference><Citation>Ziegelmann MJ, Levine LA. A modern approach to the clinical evaluation of Peyronie&#x2019;s disease in the era of collagenase. J. Sex. Med. 2019; 16: 483-8.</Citation></Reference><Reference><Citation>Abdel Raheem A, Capece M, Kalejaiye O et al. Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int. 2017; 120: 717-23.</Citation></Reference><Reference><Citation>Alom M, Meng Y, Sharma KL, Savage J, Kohler T, Trost L. Safety and efficacy of collagenase Clostridium histolyticum in Peyronie&#x2019;s disease men with ventral curvatures. Urology 2019; 129: 119-25.</Citation></Reference><Reference><Citation>Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie&#x2019;s disease. &#x200e;Int. J. Impot. Res. 2019; 31: 15-9.</Citation></Reference><Reference><Citation>Yafi FA, Diao L, DeLay KJ et al. Multi-institutional prospective analysis of intralesional injection of collagenase Clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie&#x2019;s disease. Urology 2018; 120: 138-42.</Citation></Reference><Reference><Citation>Carson CC 3rd, Sadeghi-Nejad H, Tursi JP et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie&#x2019;s disease (PD). BJU Int. 2015; 116: 815-22.</Citation></Reference><Reference><Citation>Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie&#x2019;s disease. J. Sex. Med. 2016; 13: 684-9.</Citation></Reference><Reference><Citation>Levine LA, Larsen SM. Surgical correction of persistent Peyronie&#x2019;s disease following collagenase Clostridium histolyticum treatment. J. Sex. Med. 2015; 12: 259-64.</Citation></Reference><Reference><Citation>Chung E, Wang R, Ralph D, Levine L, Brock G. A worldwide survey on Peyronie's disease surgical practice patterns among surgeons. J. Sex. Med. 2018; 15: 568-75.</Citation></Reference><Reference><Citation>Mobley EM, Fuchs ME, Myers JB, Brant WO. Update on plication procedures for Peyronie&#x2019;s disease and other penile deformities. Ther. Adv. Urol. 2012; 4: 335-46.</Citation></Reference><Reference><Citation>Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie&#x2019;s disease. J. Urol. 1979; 122: 622-3.</Citation></Reference><Reference><Citation>Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J. Urol. 1965; 93: 230-2.</Citation></Reference><Reference><Citation>Yachia D. Modified corporoplasty for the treatment of penile curvature. J. Urol. 1990; 143: 80-2.</Citation></Reference><Reference><Citation>Essed E, Schroeder FH. New surgical treatment for Peyronie disease. Urology 1985; 25: 582-7.</Citation></Reference><Reference><Citation>Knispel HH, Gonnermann D, Huland H. Modified surgical technique to correct congenital and acquired penile curvature. Eur. Urol. 1991; 20: 107-12.</Citation></Reference><Reference><Citation>Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J. Urol. 2006; 175: 238-41.</Citation></Reference><Reference><Citation>Baskin LS, Duckett JW. Dorsal tunica albuginea plication for hypospadias curvature. J. Urol. 1994; 151: 1668-71.</Citation></Reference><Reference><Citation>Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J. Urol. 2002; 167: 2066-9.</Citation></Reference><Reference><Citation>Dugi DD 3rd, Morey AF. Penoscrotal plication as a uniform approach to reconstruction of penile curvature. BJU Int. 2010; 105: 1440-4.</Citation></Reference><Reference><Citation>Papagiannopoulos D, Phelps J, Yura E, Levine LA. Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie&#x2019;s disease. Int. J. Impot. Res. 2017; 29: 258-61.</Citation></Reference><Reference><Citation>Schwarzer JU, Steinfatt H. Tunica albuginea underlap-a new modification of the Nesbit procedure: description of the technique and preliminary results. J. Sex. Med. 2012; 9: 2970-4.</Citation></Reference><Reference><Citation>Basiri A, Sarhangnejad R, Ghahestani SM, Radfar MH. Comparing absorbable and nonabsorbable sutures in corporeal plication for treatment of congenital penile curvature. Urol. J. 2011; 8: 302-6.</Citation></Reference><Reference><Citation>Reddy RS, McKibben MJ, Fuchs JS, Shakir N, Scott J, Morey AF. Plication for severe Peyronie's deformities has similar long-term outcomes to milder cases. J. Sex. Med. 2018; 15: 1498-505.</Citation></Reference><Reference><Citation>Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie&#x2019;s disease: measured lengths and patient perceptions. J. Sex. Med. 2012; 9: 2396-403.</Citation></Reference><Reference><Citation>Ralph D, Gonzalez-Cadavid N, Mirone V et al. The management of Peyronie&#x2019;s disease: evidence-based 2010 guidelines. J. Sex. Med. 2010; 7: 2359-74.</Citation></Reference><Reference><Citation>Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie's disease. J. Urol. 1997; 158: 2149-52.</Citation></Reference><Reference><Citation>Leungwattanakij S, Bivalacqua TJ, Reddy S, Hellstrom WJ. Long-term follow-up on use of pericardial graft in the surgical management of Peyronie's disease. Int. J. Impot. Res. 2001; 13: 183-6.</Citation></Reference><Reference><Citation>Kadioglu A, Kucukdurmaz F, Sanli O. Current status of the surgical management of Peyronie&#x2019;s disease. Nat. Rev. Urol. 2011; 8: 95-106.</Citation></Reference><Reference><Citation>Levine LA. Partial plaque excision and grafting (PEG) for Peyronie&#x2019;s disease. J. Sex. Med. 2011; 8: 1842-5.</Citation></Reference><Reference><Citation>Hatzichristodoulou G, Tsambarlis P, Kubler H, Levine LA. Peyronie&#x2019;s graft surgery-tips and tricks from the masters in andrologic surgery. Transl. Androl. Urol. 2017; 6: 645-56.</Citation></Reference><Reference><Citation>Kozacioglu Z, Degirmenci T, Gunlusoy B et al. Effect of tunical defect size after Peyronie&#x2019;s plaque excision on postoperative erectile function: do centimeters matter? Urology 2012; 80: 1051-5.</Citation></Reference><Reference><Citation>Chow AK, Sidelsky SA, Levine LA. Surgical outcomes of plaque excision and grafting and supplemental tunica albuginea plication for treatment of Peyronie&#x2019;s disease with severe compound curvature. J. Sex. Med. 2018; 15: 1021-9.</Citation></Reference><Reference><Citation>Lentz AC, Carson CC 3rd. Peyronie&#x2019;s surgery: graft choices and outcomes. Curr. Urol. Rep. 2009; 10: 460-7.</Citation></Reference><Reference><Citation>Brannigan RE, Kim ED, Oyasu R, McVary KT. Comparison of tunica albuginea substitutes for the treatment of Peyronie&#x2019;s disease. J. Urol. 1998; 159: 1064-8.</Citation></Reference><Reference><Citation>Garcia-Gomez B, Ralph D, Levine L et al. Grafts for Peyronie&#x2019;s disease: a comprehensive review. Andrology 2018; 6: 117-26.</Citation></Reference><Reference><Citation>Hatzichristodoulou G, Osmonov D, Kubler H, Hellstrom WJG, Yafi FA. Contemporary review of grafting techniques for the surgical treatment of Peyronie&#x2019;s disease. Sex. Med. Rev. 2017; 5: 544-52.</Citation></Reference><Reference><Citation>Hatzichristodoulou G. Evolution of the surgical sealing patch TachoSil((R)) in Peyronie&#x2019;s disease reconstructive surgery: technique and contemporary literature review. World J. Urol. 2020; 38: 315-21.</Citation></Reference><Reference><Citation>Chung E, Clendinning E, Lessard L, Brock G. Five-year follow-up of Peyronie&#x2019;s graft surgery: outcomes and patient satisfaction. J. Sex. Med. 2011; 8: 594-600.</Citation></Reference><Reference><Citation>Rice PG, Somani BK, Rees RW. Twenty years of plaque incision and grafting for Peyronie&#x2019;s disease: a review of literature. Sex. Med. 2019; 7: 115-28.</Citation></Reference><Reference><Citation>Terrier JE, Tal R, Nelson CJ, Mulhall JP. Penile sensory changes after plaque incision and grafting surgery for Peyronie&#x2019;s disease. J. Sex. Med. 2018; 15: 1491-7.</Citation></Reference><Reference><Citation>Lue TF, El-Sakka AI. Lengthening shortened penis caused by Peyronie's disease using circular venous grafting and daily stretching with a vacuum erection device. J. Urol. 1999; 161: 1141-4.</Citation></Reference><Reference><Citation>Flores S, Choi J, Alex B, Mulhall JP. Erectile dysfunction after plaque incision and grafting: short-term assessment of incidence and predictors. J. Sex. Med. 2011; 8: 2031-7.</Citation></Reference><Reference><Citation>Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie&#x2019;s disease. J. Urol. 2003; 170: 2359-62.</Citation></Reference><Reference><Citation>Taylor FL, Abern MR, Levine LA. Predicting erectile dysfunction following surgical correction of Peyronie&#x2019;s disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factors. J. Sex. Med. 2012; 9: 296-301.</Citation></Reference><Reference><Citation>Papagiannopoulos D, Yura E, Levine L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie&#x2019;s disease: a single-institution retrospective review. J. Sex. Med. 2015; 12: 1474-80.</Citation></Reference><Reference><Citation>Montorsi F, Guazzoni G, Bergamaschi F, Rigatti P. Patient-partner satisfaction with semirigid penile prostheses for Peyronie&#x2019;s disease: a 5-year followup study. J. Urol. 1993; 150: 1819-21.</Citation></Reference><Reference><Citation>Ghanem HM, Fahmy I, El-Meliegy A. Malleable penile implants without plaque surgery in the treatment of Peyronie&#x2019;s disease. Int. J. Impot. Res. 1998; 10: 171-3.</Citation></Reference><Reference><Citation>Habous M, Tealab A, Farag M et al. Malleable penile implant is an effective therapeutic option in men with Peyronie&#x2019;s disease and erectile dysfunction. Sex. Med. 2018; 6: 24-9.</Citation></Reference><Reference><Citation>Chung E, Solomon M, DeYoung L, Brock GB. Comparison between AMS 700 CX and Coloplast Titan inflatable penile prosthesis for Peyronie&#x2019;s disease treatment and remodeling: clinical outcomes and patient satisfaction. J. Sex. Med. 2013; 10: 2855-60.</Citation></Reference><Reference><Citation>Montague DK, Angermeier KW, Lakin MM, Ingleright BJ. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie&#x2019;s disease: comparison of CX and Ultrex cylinders. J. Urol. 1996; 156: 1633-5.</Citation></Reference><Reference><Citation>Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie&#x2019;s disease and drug-resistant erectile dysfunction: a single-center study. J. Sex. Med. 2010; 7: 3775-83.</Citation></Reference><Reference><Citation>Mulhall J, Ahmed A, Anderson M. Penile prosthetic surgery for Peyronie&#x2019;s disease: defining the need for intraoperative adjuvant maneuvers. J. Sex. Med. 2004; 1: 318-21.</Citation></Reference><Reference><Citation>Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011; 108: 1152-6.</Citation></Reference><Reference><Citation>Wilson SK, Delk JR 2nd. A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J. Urol. 1994; 152: 1121-3.</Citation></Reference><Reference><Citation>Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie's disease. J. Sex. Med. 2014; 11: 1593-8.</Citation></Reference><Reference><Citation>Shaeer O, Shaeer K, AbdelRahman IFS, Raheem A. Dorsal phalloplasty accompanying penile prosthesis implantation minimizes penile shortening and improves patient satisfaction. Int. J. Impot. Res. 2019; 31: 276-81.</Citation></Reference><Reference><Citation>Hakim LS, Kulaksizoglu H, Hamill BK, Udelson D, Goldstein I. A guide to safe corporotomy incisions in the presence of underlying inflatable penile cylinders: results of in vitro and in vivo studies. J. Urol. 1996; 155: 918-23.</Citation></Reference><Reference><Citation>Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie&#x2019;s disease. BJU Int. 2014; 113: 704-13.</Citation></Reference><Reference><Citation>Farrell MR, Abdelsayed GA, Ziegelmann MJ, Levine LA. A comparison of hemostatic patches versus pericardium allograft for the treatment of complex Peyronie&#x2019;s disease with penile prosthesis and plaque incision. Urology 2019; 129: 113-8.</Citation></Reference><Reference><Citation>Falcone M, Preto M, Ceruti C et al. A Comparative study between 2 different grafts used as patches after plaque incision and inflatable penile prosthesis implantation for end-stage Peyronie&#x2019;s disease. J. Sex. Med. 2018; 15: 848-52.</Citation></Reference><Reference><Citation>Hatzichristodoulou G. The PICS technique: a novel approach for residual curvature correction during penile prosthesis implantation in patients with severe Peyronie&#x2019;s disease using the collagen fleece TachoSil. J. Sex. Med. 2018; 15: 416-21.</Citation></Reference><Reference><Citation>Bernal RM, Henry GD. Contemporary patient satisfaction rates for three-piece inflatable penile prostheses. Adv. Urol. 2012; 2012: 707321.</Citation></Reference><Reference><Citation>Barton GJ, Carlos EC, Lentz AC. Sexual quality of life and satisfaction with penile prostheses. Sex. Med. Rev. 2019; 7: 178-88.</Citation></Reference><Reference><Citation>Pillay B, Moon D, Love C et al. Quality of life, psychological functioning, and treatment satisfaction of men who have undergone penile prosthesis surgery following robot-assisted radical prostatectomy. J. Sex. Med. 2017; 14: 1612-20.</Citation></Reference><Reference><Citation>Vakalopoulos I, Kampantais S, Ioannidis S et al. High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. J. Sex. Med. 2013; 10: 2774-81.</Citation></Reference><Reference><Citation>Khera M, Bella A, Karpman E et al. Penile prosthesis implantation in patients with Peyronie&#x2019;s disease: results of the PROPPER study demonstrates a decrease in patient-reported depression. J. Sex. Med. 2018; 15: 786-8.</Citation></Reference><Reference><Citation>Segal RL, Cabrini MR, Bivalacqua TJ, Burnett AL. Penile straightening maneuvers employed during penile prosthesis surgery: technical options and outcomes. Int. J. Impot. Res. 2014; 26: 182-5.</Citation></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR 2nd. Long-term followup of treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J. Urol. 2001; 165: 825-9.</Citation></Reference><Reference><Citation>Sansalone S, Garaffa G, Djinovic R et al. Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie&#x2019;s disease, refractory erectile dysfunction, and severe penile shortening. J. Sex. Med. 2012; 9: 316-21.</Citation></Reference><Reference><Citation>Rolle L, Falcone M, Ceruti C et al. A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the 'sliding' technique for end-stage Peyronie&#x2019;s disease with severe shortening of the penis and erectile dysfunction. BJU Int. 2016; 117: 814-20.</Citation></Reference><Reference><Citation>Egydio PH, Kuehhas FE. The multiple-slit technique (MUST) for penile length and girth restoration. J. Sex. Med. 2018; 15: 261-9.</Citation></Reference><Reference><Citation>Egydio PH, Kuehhas FE, Valenzuela RJ. Modified sliding technique (MoST) for penile lengthening with insertion of inflatable penile prosthesis. J. Sex. Med. 2015; 12: 1100-4.</Citation></Reference><Reference><Citation>Wilson SK, Mora-Estaves C, Egydio P et al. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology 2017; 107: 144-8.</Citation></Reference><Reference><Citation>Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620-6.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32091336</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4294</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Current topics in medicinal chemistry</Title><ISOAbbreviation>Curr Top Med Chem</ISOAbbreviation></Journal><ArticleTitle>Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines.</ArticleTitle><Pagination><StartPage>847</StartPage><EndPage>854</EndPage><MedlinePgn>847-854</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1568026620666200224100730</ELocationID><Abstract><AbstractText>Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone- refractory prostate cancer is making progress, for almost all men with metastases will proceed to hormone-refractory prostate cancer. Smoking cigarettes along with the presence of prostate cancer has been shown to cause a higher risk of mortality in prostate cancer. The serious outcome of incontinence and erectile dysfunction result from the cancer treatment of surgery and radiation, particularly for prostate- specific antigen detected cancers that will not cause morbidity or mortality. Families of patients, as well as patients, are profoundly affected following the diagnosis of prostate cancer. Poor communication between spouses during prostate cancer increases the risk for poor adjustment to prostate cancer. The use of serum prostate-specific antigen to screen for prostate cancer has led to a greater detection, in its early stage, of this cancer. Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% of all cancer deaths. A shortened course of hormonal therapy with docetaxel following radical prostatectomy (or radiation therapy) for high-risk prostate cancer has been shown to be both safe and feasible. Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Cancer vaccines are an immune-based cancer treatment that may provide the promise of a non-toxic but efficacious therapeutic alternative for cancer patients. Further studies will elucidate improved methods of detection and treatment.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartzatt</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Durham Science Center, College of Arts and Sciences, University of Nebraska at Omaha, 6001 Dodge Street, Omaha, Nebraska 68182, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Top Med Chem</MedlineTA><NlmUniqueID>101119673</NlmUniqueID><ISSNLinking>1568-0266</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>35LT29625A</RegistryNumber><NameOfSubstance UI="D004961">Estramustine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019496" MajorTopicYN="N">Cancer Vaccines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004961" MajorTopicYN="N">Estramustine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Hormone-refractory</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Prostate cancer</Keyword><Keyword MajorTopicYN="N">Radiation therapy</Keyword><Keyword MajorTopicYN="N">Vaccines.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32091336</ArticleId><ArticleId IdType="doi">10.2174/1568026620666200224100730</ArticleId><ArticleId IdType="pii">CTMC-EPUB-104750</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32055463</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Worldwide trends in penile implantation surgery: data from over 63,000 implants.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>37</EndPage><MedlinePgn>31-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2019.09.26</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Penile prosthesis implantation represents the gold standard of treatment for severe or medically refractory erectile dysfunction (ED). We sought to address the paucity of currently available literature about global penile prosthesis usage in regard to geography, patient age, surgical approach, implanter volume, and etiology of ED.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From device manufacturer information, we compiled data on over 63,000 implants performed worldwide. Data was grouped and then analyzed to examine trends in penile implantation between the years of 2005-2012.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of implants was seen to steadily increase over the study period. Of the 63,013 total procedures recorded, 85.9% were performed within the United States. 60-78% of procedures were done using the penoscrotal (PS) approach, with only Belgium/Netherlands as an outlier with an infrapubic (INF) majority. The US was notable for having an increasing number of implanters doing 16-30, 31-50, or &gt;100 implants yearly. Etiology of ED worldwide was variable, but "organic," post-prostatectomy, and diabetes accounted for the vast majority of cases worldwide.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Penile prosthesis implantation is an increasing practice, as evidenced by a steady increase in the number of implants performed over a 7-year study period. Acceptance of this treatment option for ED is variable by region with the US leading the annual number of implantations by a wide margin. Worldwide, there appears to be a predominance of surgeons placing implants via the PS approach.</AbstractText><CopyrightInformation>2020 Translational Andrology and Urology. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baas</LastName><ForeName>Wesley</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welliver</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Urology, Albany Medical Center, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stember</LastName><ForeName>Doron S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Urology, Mount Sinai Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Steven K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Institute for Urologic Excellence, La Quinta, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;hler</LastName><ForeName>Tobias S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2021 Mar;205(3):912-914</RefSource><PMID Version="1">33356458</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction (ED)</Keyword><Keyword MajorTopicYN="N">penile implant</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword></KeywordList><CoiStatement>Conflicts of Interest: Dr. K&#xf6;hler is a consultant for both Coloplast and Boston Scientific. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32055463</ArticleId><ArticleId IdType="pmc">PMC6995940</ArticleId><ArticleId IdType="doi">10.21037/tau.2019.09.26</ArticleId><ArticleId IdType="pii">tau-09-01-31</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9. 10.1111/j.1743-6109.2007.00540.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal RM, Henry GD. Contemporary patient satisfaction rates for three-piece inflatable penile prostheses. Adv Urol 2012;2012:707321. 10.1155/2012/707321</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/707321</ArticleId><ArticleId IdType="pmc">PMC3412090</ArticleId><ArticleId IdType="pubmed">22899909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010;7:304-9. 10.1111/j.1743-6109.2009.01499.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01499.x</ArticleId><ArticleId IdType="pubmed">19758282</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkman MJ, Henry GD, Wilson SK, et al. A survey of patients with inflatable penile prostheses for satisfaction. J Urol 2005;174:253-7. 10.1097/01.ju.0000161608.21337.8d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000161608.21337.8d</ArticleId><ArticleId IdType="pubmed">15947649</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000;164:376-80. 10.1016/S0022-5347(05)67364-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67364-8</ArticleId><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrini L. Subrini penile implants: surgical, sexual and psychological results. Eur Urol 1982;8:222-6. 10.1159/000473522</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000473522</ArticleId><ArticleId IdType="pubmed">7094964</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Henry G, Culkin D, et al. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med 2009;6:1773-8. 10.1111/j.1743-6109.2009.01251.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01251.x</ArticleId><ArticleId IdType="pubmed">19473458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler T, Welliver R. Optimizing Outcomes and Patient Satisfaction with Penile Implants. AUA Update Series 2014;33:50-63.</Citation></Reference><Reference><Citation>Lee DJ, Najari BB, Davison WL, et al. Trends in the Utilization of Penile Prostheses in the Treatment of Erectile Dysfunction in the United States. J Sex Med 2015;12:1638-45. 10.1111/jsm.12921</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12921</ArticleId><ArticleId IdType="pubmed">26096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberlin DT, Matulewicz RS, Bachrach L, et al. National practice patterns of treatment of erectile dysfunction with penile prosthesis implantation. J Urol 2015;193:2040-4. 10.1016/j.juro.2014.11.095</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.11.095</ArticleId><ArticleId IdType="pubmed">25457477</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Karpman E, Brant W, et al. The Who, How and What of Real-World Penile Implantation in 2015: The PROPPER Registry Baseline Data. J Urol 2016;195:427-33. 10.1016/j.juro.2015.07.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.07.109</ArticleId><ArticleId IdType="pubmed">26292043</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31937310</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>24</StartPage><MedlinePgn>24</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-019-02195-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bone marrow mononuclear cells have been successfully utilized for numerous regenerative purposes. In the current study, patients suffering from erectile dysfunction (ED) unresponsive to phosphodiesterase 5 inhibitors were administered autologous bone marrow concentrate delivered intracavernously utilizing a point of care FDA cleared medical device.</AbstractText><AbstractText Label="METHODS">A total of 40 patients were treated in the primary trial and 100 in the clinical registry, with the longest follow up of 12&#xa0;months.</AbstractText><AbstractText Label="RESULTS">Minimal treatment associated adverse effects where observed related to short term bruising at the site of harvest or injection. No long-term adverse events were noted related to the intervention. Mean improvements in IIEF-5 score were 2 in the Caverstem 1.0 low dose group, 3 in the high dose Caverstem 1.0 group and 9 in the Caverstem 2.0 group. Furthermore, improvements peaked by 3 months and maintained at 6&#xa0;months follow-up.</AbstractText><AbstractText Label="CONCLUSION">These data support the safety and efficacy of point of care, minimally to non-manipulated, non-expanded bone marrow concentrate for the treatment of ED. Trial registration Funded by Creative Medical Health, Inc.; Clinicaltrials.gov number: NCT03699943; https://clinicaltrials.gov/ct2/show/NCT03699943?term=caverstem&amp;rank=1; initially registered December 12, 2015.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regenerative Health LLC, Las Cruces, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Said</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regenerative Health LLC, Las Cruces, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Anonini Urology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Donald</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Creative Medical Health, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuma</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Monterrico Clinic &amp; San Felipe Clinic, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Courtney E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Amit N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>University of Utah - Bioengineering, Salt Lake City, UT, USA. dallaspatel@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gershman</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Advanced Urology LLC/University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03699943</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="Y">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone</Keyword><Keyword MajorTopicYN="N">Dysfunction</Keyword><Keyword MajorTopicYN="N">Erectile</Keyword><Keyword MajorTopicYN="N">Marrow</Keyword></KeywordList><CoiStatement>ANP and DD are a board members of Creative Medical Health. The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31937310</ArticleId><ArticleId IdType="pmc">PMC6958721</ArticleId><ArticleId IdType="doi">10.1186/s12967-019-02195-w</ArticleId><ArticleId IdType="pii">10.1186/s12967-019-02195-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Irwin GM. Erectile dysfunction. Prim Care. 2019;46(2):249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">31030826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolini Y, et al. Back to stir it up: erectile dysfunction in an evolutionary, developmental, and clinical perspective. J Sex Res. 2019;56(3):378&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">29932774</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza-Gangemi AM, Sotomayor-de Zavaleta M. Erectile dysfunction therapy in countries where implant is economically not feasible. Transl Androl Urol. 2017;6(2):176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422700</ArticleId><ArticleId IdType="pubmed">28540224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajo R, et al. Erectile dysfunction in patients with chronic pain treated with opioids. Med Clin (Barc) 2017;149(2):49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28236471</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivananda MJ, Rao TS. Sexual dysfunction in medical practice. Curr Opin Psychiatry. 2016;29(6):331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">27636599</ArticleId></ArticleIdList></Reference><Reference><Citation>Raharinavalona SA, et al. What is the best biological parameter to predict erectile dysfunction in men aged &gt; 55 years with type 2 diabetes? J Diabetes Investig. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944840</ArticleId><ArticleId IdType="pubmed">31148390</ArticleId></ArticleIdList></Reference><Reference><Citation>Faselis C, et al. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31057114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahbub MI, et al. Frequency and predictors of erectile dysfunction in Bangladeshi men with type 2 diabetes mellitus: experience from a tertiary center. Mymensingh Med J. 2019;28(1):137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">30755562</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabakan M, et al. A new proof for the relationship between erectile dysfunction and atherosclerosis: fragmented QRS? Int J Impot Res. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31243353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res. 2002;14(Suppl 1):S17&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850730</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019;210(10):469&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">31099420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Hatzichristou DG. Phosphodiesterase type 5 inhibitors: unmet needs. Curr Pharm Des. 2009;15(30):3476&#x2013;3485.</Citation><ArticleIdList><ArticleId IdType="pubmed">19860693</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew KK, et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med. 2010;7(1 Pt 1):192&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">19912508</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, et al. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol. 2010;17(1):38&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">20002226</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JH, Rocha-Singh KJ. Endovascular therapy for vasculogenic erectile dysfunction. Curr Treat Options Cardiovasc Med. 2012;14(2):193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">22367595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendirci M, et al. Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol. 2010;184(4):1560&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014289</ArticleId><ArticleId IdType="pubmed">20728109</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XY, et al. The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol Cell Biochem. 2009;332(1&#x2013;2):25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19507001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabbir A, et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol. 2009;296(6):H1888&#x2013;H1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716100</ArticleId><ArticleId IdType="pubmed">19395555</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008;3(4):e1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270908</ArticleId><ArticleId IdType="pubmed">18382669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, Crawford R, Xiao Y. The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization. Differentiation. 2011;81(3):181&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">21236558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang SY, Xie XT, Zhou JJ. Gene profile and fibroblast growth factor 2 expression in mesenchymal stem cell. Chin J Pediatr. 2009;47(3):218&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichim TE, et al. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol. 2010;260(2):75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">19917503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae KS, et al. Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. Yonsei Med J. 2011;52(3):401&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101055</ArticleId><ArticleId IdType="pubmed">21488182</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med. 2011;8(2):427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">21091881</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiorino MI, et al. Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. Endocrine. 2015;49(2):415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">25411101</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao CH, et al. Restoration of erectile function with intracavernous injections of endothelial progenitor cells after bilateral cavernous nerve injury in rats. Andrology. 2015;3(5):924&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311341</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto K, et al. Rat cavernous nerve reconstruction with CD133&#x2009;+&#x2009;cells derived from human bone marrow. J Sex Med. 2014;11(5):1148&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">24576198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden EL, et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14(4):245&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman JM, et al. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Multi-institutional study. Urology. 1993;41(5):445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">8488613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W, et al. In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma. PLoS ONE. 2012;7(7):e40833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395629</ArticleId><ArticleId IdType="pubmed">22808272</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Demour S, et al. Safety and potential therapeutic effect of two intracavernous autologous bone marrow derived mesenchymal stem cells injections in diabetic patients with erectile dysfunction: an open label phase i clinical trial. Urol Int. 2018;101(3):358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">30173210</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney NM, et al. The use of stromal vascular fraction in the treatment of male sexual dysfunction: a review of preclinical and clinical studies. Sex Med Rev. 2019;7(2):313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">29960873</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.sciencedirect.com/science/article/pii/B9780128012383060621?via%3Dihub.</Citation></Reference><Reference><Citation>Yiou R, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2016;69(6):988&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">26439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpone M, et al. Isolation of clinically relevant concentrations of bone marrow mesenchymal stem cells without centrifugation. J Transl Med. 2019;17(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6321705</ArticleId><ArticleId IdType="pubmed">30611285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31882614</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse.</ArticleTitle><Pagination><StartPage>20072</StartPage><MedlinePgn>20072</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20072</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-54431-4</ELocationID><Abstract><AbstractText>Extracellular vesicles (EVs) have attracted particular interest in various fields of biology and medicine. However, one of the major hurdles in the clinical application of EV-based therapy is their low production yield. We recently developed cell-derived EV-mimetic nanovesicles (NVs) by extruding cells serially through filters with diminishing pore sizes (10, 5, and 1&#x2009;&#x3bc;m). Here, we demonstrate in diabetic mice that embryonic stem cell (ESC)-derived EV-mimetic NVs (ESC-NVs) completely restore erectile function (~96% of control values) through enhanced penile angiogenesis and neural regeneration in vivo, whereas ESC partially restores erectile function (~77% of control values). ESC-NVs promoted tube formation in primary cultured mouse cavernous endothelial cells and pericytes under high-glucose condition in vitro; and accelerated microvascular and neurite sprouting from aortic ring and major pelvic ganglion under high-glucose condition ex vivo, respectively. ESC-NVs enhanced the expression of angiogenic and neurotrophic factors (hepatocyte growth factor, angiopoietin-1, nerve growth factor, and neurotrophin-3), and activated cell survival and proliferative factors (Akt and ERK). Therefore, it will be a better strategy to use ESC-NVs than ESCs in patients with erectile dysfunction refractory to pharmacotherapy, although it remains to be solved for future clinical application of ESC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Mi-Hye</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kang-Moon</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0001-8900-3301</Identifier><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limanjaya</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Min-Ji</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghatak</LastName><ForeName>Kalyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Nhat Minh</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-4471-2056</Identifier><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ock</LastName><ForeName>Jiyeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Guo Nan</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ju-Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Medicinal Toxicology Research Center, Inha University School of Medicine, Incheon, 22212, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Man Ryul</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Soonchunhyang Institute of Medi-bio Science (SIMS) and Institute of Tissue Regeneration, College of Medicine, Soon Chun Hyang University, Cheonan-si, Chungcheongnam-do, 31151, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gho</LastName><ForeName>Yong Song</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0003-3366-2345</Identifier><AffiliationInfo><Affiliation>Department of Life Sciences, Pohang University of Science and Technology, Pohang, Kyeongsangbuk-do, 37673, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Ji-Kan</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea. rjk0929@inha.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jun-Kyu</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, 22332, Korea. jksuh@inha.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5W494URQ81</RegistryNumber><NameOfSubstance UI="D013311">Streptozocin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="Y">Nanostructures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000294" MajorTopicYN="Y">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013311" MajorTopicYN="N">Streptozocin</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31882614</ArticleId><ArticleId IdType="pmc">PMC6934510</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-54431-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-54431-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersson K-E. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011;63:811&#x2013;859. doi: 10.1124/pr.111.004515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.111.004515</ArticleId><ArticleId IdType="pubmed">21880989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF. Erectile dysfunction. N Engl J of Med. 2000;342:1802&#x2013;1813. doi: 10.1056/NEJM200006153422407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200006153422407</ArticleId><ArticleId IdType="pubmed">10853004</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin GN, et al. The pericyte as a cellular regulator of penile erection and a novel therapeutic target for erectile dysfunction. Sci Rep. 2015;5:10891. doi: 10.1038/srep10891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10891</ArticleId><ArticleId IdType="pmc">PMC4456662</ArticleId><ArticleId IdType="pubmed">26044953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouidrat Y, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta&#x2010;analysis of 145 studies. Diabet Med. 2017;34:1185&#x2013;1192. doi: 10.1111/dme.13403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.13403</ArticleId><ArticleId IdType="pubmed">28722225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Jabaloyas JM, et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol. 2001;40:641&#x2013;647. doi: 10.1159/000049850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000049850</ArticleId><ArticleId IdType="pubmed">11805410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasker, G. F., Maley, J. H. &amp; Kadowitz, P. J. A review of the pathophysiology and novel treatments for erectile dysfunction. Adv Pharmacol Sci. 2010 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997760</ArticleId><ArticleId IdType="pubmed">21152267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu J-K, Suh J-K, Burnett AL. Research in pharmacotherapy for erectile dysfunction. Transl Androl Urol. 2017;6:207. doi: 10.21037/tau.2016.11.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.11.17</ArticleId><ArticleId IdType="pmc">PMC5422707</ArticleId><ArticleId IdType="pubmed">28540228</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373&#x2013;383. doi: 10.1083/jcb.201211138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201211138</ArticleId><ArticleId IdType="pmc">PMC3575529</ArticleId><ArticleId IdType="pubmed">23420871</ArticleId></ArticleIdList></Reference><Reference><Citation>Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31:27&#x2013;33. doi: 10.1161/ATVBAHA.110.218123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.218123</ArticleId><ArticleId IdType="pubmed">21160065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim OY, Lee J, Gho YS. Extracellular vesicle mimetics: Novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines. Semin Cell Dev Biol. 2018;67:74&#x2013;82. doi: 10.1016/j.semcdb.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2016.12.001</ArticleId><ArticleId IdType="pubmed">27916566</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DS, Kim DK, Kim YK, Gho YS. Proteomics of extracellular vesicles: exosomes and ectosomes. Mass Spectrom Rev. 2015;34:474&#x2013;490. doi: 10.1002/mas.21420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mas.21420</ArticleId><ArticleId IdType="pubmed">24421117</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular vesicles in angiogenesis. Circ Res. 2017;120:1658&#x2013;1673. doi: 10.1161/CIRCRESAHA.117.309681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.309681</ArticleId><ArticleId IdType="pmc">PMC5426696</ArticleId><ArticleId IdType="pubmed">28495996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CP-K, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol. 2012;3:228. doi: 10.3389/fphys.2012.00228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00228</ArticleId><ArticleId IdType="pmc">PMC3384085</ArticleId><ArticleId IdType="pubmed">22754538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalani A, Tyagi A, Tyagi N. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol. 2014;49:590&#x2013;600. doi: 10.1007/s12035-013-8544-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8544-1</ArticleId><ArticleId IdType="pmc">PMC3951279</ArticleId><ArticleId IdType="pubmed">23999871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez&#x2010;Verrilli MA, Picou F, Court FA. Schwann cell&#x2010;derived exosomes enhance axonal regeneration in the peripheral nervous system. Glia. 2013;61:1795&#x2013;1806. doi: 10.1002/glia.22558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22558</ArticleId><ArticleId IdType="pubmed">24038411</ArticleId></ArticleIdList></Reference><Reference><Citation>EL Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Dis. 2013;12:347&#x2013;357. doi: 10.1038/nrd3978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3978</ArticleId><ArticleId IdType="pubmed">23584393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, et al. Adipose-derived stem cell-derived exosomes ameliorate erectile dysfunction in a rat model of type 2 diabetes. J Sex Med. 2017;14:1084&#x2013;1094. doi: 10.1016/j.jsxm.2017.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.07.005</ArticleId><ArticleId IdType="pubmed">28781215</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang SC, et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. 2013;7:7698&#x2013;7710. doi: 10.1021/nn402232g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn402232g</ArticleId><ArticleId IdType="pubmed">24004438</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K, et al. In Vivo Differentiation of Therapeutic Insulin-Producing Cells from Bone Marrow Cells via Extracellular Vesicle-Mimetic Nanovesicles. ACS Nano. 2015;9:11718&#x2013;27. doi: 10.1021/acsnano.5b02997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.5b02997</ArticleId><ArticleId IdType="pubmed">26513554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix R, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 2007;110:2432&#x2013;2439. doi: 10.1182/blood-2007-02-069997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-069997</ArticleId><ArticleId IdType="pmc">PMC2495018</ArticleId><ArticleId IdType="pubmed">17606760</ArticleId></ArticleIdList></Reference><Reference><Citation>Taraboletti G, et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol. 2002;160:673&#x2013;680. doi: 10.1016/S0002-9440(10)64887-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64887-0</ArticleId><ArticleId IdType="pmc">PMC1850663</ArticleId><ArticleId IdType="pubmed">11839588</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri C, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171&#x2013;1180. doi: 10.1016/S0092-8674(00)81813-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81813-9</ArticleId><ArticleId IdType="pubmed">8980224</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin HG, Koh GY, Thurston G, Alitalo KJNRMCB. Control of vascular morphogenesis and homeostasis through the angiopoietin&#x2013;Tie system. Nat Rev Mol Cell Biol. 2009;10:165. doi: 10.1038/nrm2639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2639</ArticleId><ArticleId IdType="pubmed">19234476</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H-R, et al. Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. Diabetes. 2011;60:969&#x2013;80. doi: 10.2337/db10-0354.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0354</ArticleId><ArticleId IdType="pmc">PMC3046858</ArticleId><ArticleId IdType="pubmed">21270241</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H-R, et al. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med. 2010;7:3635&#x2013;3646. doi: 10.1111/j.1743-6109.2010.01925.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01925.x</ArticleId><ArticleId IdType="pubmed">20584113</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant DS, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 1993;90:1937&#x2013;1941. doi: 10.1073/pnas.90.5.1937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1937</ArticleId><ArticleId IdType="pmc">PMC45995</ArticleId><ArticleId IdType="pubmed">7680481</ArticleId></ArticleIdList></Reference><Reference><Citation>Das ND, et al. Effectiveness of intracavernous delivery of recombinant human hepatocyte growth factor on erectile function in the streptozotocin-induced diabetic mouse. J Sex Med. 2016;13:1618&#x2013;1628. doi: 10.1016/j.jsxm.2016.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.09.017</ArticleId><ArticleId IdType="pubmed">27770854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshenker S. Wallerian degeneration: the innate-immune response to traumatic nerve injury. J Neuroinflammation. 2011;8:109. doi: 10.1186/1742-2094-8-109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-109</ArticleId><ArticleId IdType="pmc">PMC3179447</ArticleId><ArticleId IdType="pubmed">21878125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosse F. Extrinsic cellular and molecular mediators of peripheral axonal regeneration. Cell Tissue Res. 2012;349:5&#x2013;14. doi: 10.1007/s00441-012-1389-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-012-1389-5</ArticleId><ArticleId IdType="pubmed">22476657</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261&#x2013;1274. doi: 10.1016/j.cell.2007.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.06.009</ArticleId><ArticleId IdType="pmc">PMC2756685</ArticleId><ArticleId IdType="pubmed">17604717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, et al. Differential function of Tie2 at cell&#x2013;cell contacts and cell&#x2013;substratum contacts regulated by angiopoietin-1. Nature Cell Biol. 2008;10:513&#x2013;26. doi: 10.1038/ncb1714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1714</ArticleId><ArticleId IdType="pubmed">18425120</ArticleId></ArticleIdList></Reference><Reference><Citation>Saharinen P, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell&#x2013;cell and cell&#x2013;matrix contacts. Nature Cell Biol. 2008;10:527. doi: 10.1038/ncb1715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1715</ArticleId><ArticleId IdType="pubmed">18425119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo G, et al. Activated Stat5 trafficking via endothelial cell-derived extracellular vesicles controls IL-3 pro-angiogenic paracrine action. Sci Rep. 2016;6:25689. doi: 10.1038/srep25689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25689</ArticleId><ArticleId IdType="pmc">PMC4860593</ArticleId><ArticleId IdType="pubmed">27157262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. Exosomes derived from human endothelial progenitor cells accelerate cutaneous wound healing by promoting angiogenesis through Erk1/2 signaling. Int J Biol Sci. 2016;12:1472. doi: 10.7150/ijbs.15514.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.15514</ArticleId><ArticleId IdType="pmc">PMC5166489</ArticleId><ArticleId IdType="pubmed">27994512</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Jiang C, Zhao J. Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function. J Diabetes Complications. 2016;30:986&#x2013;992. doi: 10.1016/j.jdiacomp.2016.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2016.05.009</ArticleId><ArticleId IdType="pubmed">27236748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, et al. Exosomes derived from AKt&#x2010;modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet&#x2010;derived growth factor D. Stem Cells Transl. 2017;6:51&#x2013;59. doi: 10.5966/sctm.2016-0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2016-0038</ArticleId><ArticleId IdType="pmc">PMC5442756</ArticleId><ArticleId IdType="pubmed">28170176</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd AK, et al. Evidence that G-quadruplex DNA accumulates in the cytoplasm and participates in stress granule assembly in response to oxidative stress. J Biol Chem. 2016;291:18041&#x2013;57. doi: 10.1074/jbc.M116.718478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.718478</ArticleId><ArticleId IdType="pmc">PMC5016190</ArticleId><ArticleId IdType="pubmed">27369081</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng X, et al. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem. 2015;37:2415&#x2013;2424. doi: 10.1159/000438594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000438594</ArticleId><ArticleId IdType="pubmed">26646808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopatina T, et al. Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell Commun Signal. 2014;12:26. doi: 10.1186/1478-811X-12-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-811X-12-26</ArticleId><ArticleId IdType="pmc">PMC4022079</ArticleId><ArticleId IdType="pubmed">24725987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin HR, et al. Functional and morphologic characterizations of the diabetic mouse corpus cavernosum: Comparison of a multiple low&#x2010;dose and a single high&#x2010;dose streptozotocin protocols. J Sex Med. 2009;6:3289&#x2013;3304. doi: 10.1111/j.1743-6109.2009.01464.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01464.x</ArticleId><ArticleId IdType="pubmed">19732306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, et al. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res. 2005;17:326&#x2013;34. doi: 10.1038/sj.ijir.3901314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901314</ArticleId><ArticleId IdType="pubmed">15800653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin GN, et al. Pericyte-Derived Dickkopf2 Regenerates Damaged Penile Neurovasculature Through an Angiopoietin-1-Tie2 Pathway. Diabetes. 2018;67:1149&#x2013;1161. doi: 10.2337/db17-0833.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db17-0833</ArticleId><ArticleId IdType="pubmed">29559443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, et al. Neurotrophic effects of vascular endothelial growth factor and neurotrophins on cultured major pelvic ganglia. BJU Int. 2003;92:631&#x2013;635. doi: 10.1046/j.1464-410X.2003.04439.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410X.2003.04439.x</ArticleId><ArticleId IdType="pubmed">14511050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31860421</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1195-9479</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Canadian journal of urology</Title><ISOAbbreviation>Can J Urol</ISOAbbreviation></Journal><ArticleTitle>Satisfaction and surgical outcomes in patients undergoing penile prosthesis implantation for drug-refractory erectile dysfunction: mid-term results in a single center French cohort.</ArticleTitle><Pagination><StartPage>10039</StartPage><EndPage>10044</EndPage><MedlinePgn>10039-10044</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">To investigate the mid-term results of penile prosthesis (PP) implantation in patients with erectile dysfunction (ED) from a "real-life" historic cohort in a French academic center.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">All patients receiving an inflatable PP between 2004 and 2014 in our institution were included in this study. ED was assessed preoperatively using the IEEF-5 questionnaire. Postoperative satisfaction with the PP was assessed using the EDITS questionnaire at each follow up visit. Postoperative complications were classed according to the Clavien classification. Surgical and functional outcomes were recorded prospectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-six men received a PP during the 10 year study period. Median (IQR) age was 62 (58-69) years. The main causes of ED were radical prostatectomy (n = 40; 53%) and diabetes mellitus (n = 28; 36.8%). Five patients (6.6%) had a non-functioning PP in place requiring complete substitution or a previous penile implant which had already been removed at the time of surgery. Sixty-nine (90.8%) patients received an AMS 700 CX device and seven (9.2%) a Coloplast Titan. The surgical approach was penoscrotal in 45 (59.2%) and infrapubic in 31 (40.8%). Intraoperative complications occurred in four (5%) patients, without compromising the intervention. Postoperative complications occurred in 27 (35.5%) patients: 17 (22%) were Clavien I-II and 10 (15%) Clavien III. All major complications resulted in prosthesis removal (n = 9; 11.8%) or revision (n = 1; 1.3%). Median (IQR) follow up was 43 (34-55) months. At the end of follow up, 70 (92.1%) patients had a functional implant. Fifty-four (71.1%) patients were satisfied with the device at the 6 month follow up visit and beyond. Early satisfaction (at 3 months) was reported by 44 (57.9%) patients. A previous PP was the only significant risk factor for prosthesis removal (p = 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PP implantation is a safe and satisfactory treatment for ED. However, patient selection remains crucial in determining the post-surgical success of this procedure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dardenne</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universite, GRC no5, ONCOTYPE-URO, AP-HP, Urology, Hopital Pitie-Salpetriere, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manach</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Grande</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Campi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Florie</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Misrai</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bitker</LastName><ForeName>Marc-Olivier</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Mozer</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Roupret</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Urol</MedlineTA><NlmUniqueID>9515842</NlmUniqueID><ISSNLinking>1195-9479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31860421</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31780332</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1698-0409</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Revista internacional de andrologia</Title><ISOAbbreviation>Rev Int Androl</ISOAbbreviation></Journal><ArticleTitle>[Penile prostheses: Description of a series of implants with and without dilatation of the corpora cavernosa].</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>24</EndPage><MedlinePgn>16-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.androl.2019.07.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1698-031X(19)30059-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Penile prosthesis (PP) implantation is the treatment of choice for refractory erectile dysfunction (ED). They show a high satisfaction rate (75%-100%) and a complication rate that varies between 2.1% and 28.8%. The standard surgical technique includes dilatation of the corpora cavernosa (CC) prior to the insertion of the cylinders. This step takes time and is critical for the occurrence of complications. The aim of this study is to describe the results of a series of PP implanted using the techniques with and without dilatation of the CC.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">One-hundred and 20 patients with refractory ED in whom a PP was implanted by 2 surgeons in different centers. Comorbidities, operative characteristics, satisfaction and postoperative complications were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The average age was 61&#xb1;9.6 years. The most prevalent comorbidities were: history of radical prostatectomy, high-blood pressure and diabetes mellitus. Forty-two malleable and 78 hydraulic prostheses were implanted. Eleven patients had a previous PP. The median operative time was 70minutes (35-140). The satisfaction reported was 95.8%. Ten patients presented complications. In the group in which the surgery was performed without dilatation of the CC (n=80), the operative time was shorter (62.5minutes [35-105] versus 90minutes [60-140] respectively, p&lt;0.0001). There was no difference in complications (p=0.73) or levels of satisfaction (p=0.196) when comparing the technique with and without dilatation of the CC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In our series, a shorter operative time was observed with the technique without dilatation of the CC, but there were no differences in complications. A prospective and randomized study is required to make a stronger recommendation regarding to dilatation of the CC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Asociaci&#xf3;n Espa&#xf1;ola de Androlog&#xed;a, Medicina Sexual y Reproductiva. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleck-Lavergne</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital San Jos&#xe9;, Santiago, Regi&#xf3;n Metropolitana, Chile. Electronic address: danielafleck@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marconi</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a, Departamento de Urolog&#xed;a, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Regi&#xf3;n Metropolitana, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercado-Campero</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Regi&#xf3;n Metropolitana, Chile; Departamento de Urolog&#xed;a, Cl&#xed;nica Las Condes, Santiago, Regi&#xf3;n Metropolitana, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Regi&#xf3;n Metropolitana, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchant</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Regi&#xf3;n Metropolitana, Chile; Departamento de Urolog&#xed;a, Cl&#xed;nica Las Condes, Santiago, Regi&#xf3;n Metropolitana, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma-Ceppi</LastName><ForeName>Cristi&#xe1;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Regi&#xf3;n Metropolitana, Chile; Departamento de Urolog&#xed;a, Cl&#xed;nica Las Condes, Santiago, Regi&#xf3;n Metropolitana, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pr&#xf3;tesis penianas: descripci&#xf3;n de una serie de implantes con y sin dilataci&#xf3;n de cuerpos cavernosos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Int Androl</MedlineTA><NlmUniqueID>101500934</NlmUniqueID><ISSNLinking>1698-031X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004106" MajorTopicYN="N">Dilatation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Corpus cavernosum</Keyword><Keyword MajorTopicYN="N">Cuerpo cavernoso</Keyword><Keyword MajorTopicYN="N">Dilataci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Dilatation</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Implante peniano</Keyword><Keyword MajorTopicYN="N">Penile implant</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Pr&#xf3;tesis peniana</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31780332</ArticleId><ArticleId IdType="doi">10.1016/j.androl.2019.07.002</ArticleId><ArticleId IdType="pii">S1698-031X(19)30059-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31754245</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>51</EndPage><MedlinePgn>43-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0215-y</ELocationID><Abstract><AbstractText>Peyronie's disease, or fibrous transformations of the tunica albuginea of the corpora cavernosa that cause penile curvature, is estimated to affect 3.2-8.9% of the male population. Treatment options for PD are based on the severity of the penile deformity and erectile function; of which surgical options include manual modeling during penile prosthesis implantation, plication, plaque incision, and grafting. Multiple approaches may be employed; each with its own advantages, limitations, and risk/benefit ratios. In this regard, we sought to review and highlight the current approaches for the management of residual curvature, optimal patient selection, and preoperative planning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Khatib</LastName><ForeName>Farouk M</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0001-8324-2547</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yafi</LastName><ForeName>Faysal A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA. fyafi@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31754245</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0215-y</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0215-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31723451</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>A novel approach to treatment of priapism refractory to non-surgical methods: A single-case experience.</ArticleTitle><Pagination><StartPage>326</StartPage><EndPage>328</EndPage><MedlinePgn>326-328</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/2090598X.2019.1626130</ELocationID><Abstract><AbstractText>Ischaemic priapism is a rarely encountered urological emergency that can lead to erectile dysfunction if not treated. Treatment strategies for ischaemic priapism include: cavernosal sympathomimetic injections; percutaneous shunts; and surgical procedures including shunts and penile prostheses. We present a case of a middle-aged man presenting with ischaemic priapism refractory to cavernosal injections and percutaneous T-shunt procedure. After refusal of surgery, a continuous cavernosal infusion of phenylephrine was successfully performed with resolution of erection and no sequelae. For the treatment of ischaemic priapism, adherence to management guidelines should be encouraged; however, it is still a disease entity that is not well understood and new treatment protocols may have a role in the future. <b>Abbreviation</b>: ED: erectile dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abou Heidar</LastName><ForeName>Nassib</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3811-5543</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degheili</LastName><ForeName>Jad A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-1624-1189</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustros</LastName><ForeName>Gerges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wazzan</LastName><ForeName>Wassim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulbul</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arab J Urol. 2019 Jul 31;17(4):329</RefSource><PMID Version="1">31724574</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Priapism</Keyword><Keyword MajorTopicYN="N">cavernosal infusion</Keyword><Keyword MajorTopicYN="N">phenylephrine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31723451</ArticleId><ArticleId IdType="pmc">PMC6830259</ArticleId><ArticleId IdType="doi">10.1080/2090598X.2019.1626130</ArticleId><ArticleId IdType="pii">1626130</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7:476&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgley J, Raison N, Sheikh MI, et al. Ischaemic priapism: a clinical review. Turk J Urol. 2017;43:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330261</ArticleId><ArticleId IdType="pubmed">28270944</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170:1318&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501756</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Eardley I, Giuliano F, et al. European Association of Urology. European Association of Urology guidelines on priapism. Eur Urol. 2014;65:480&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24314827</ArticleId></ArticleIdList></Reference><Reference><Citation>Song PH, Moon KH.. Priapism: current updates in clinical management. Korean J Urol. 2013;54:816&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866283</ArticleId><ArticleId IdType="pubmed">24363861</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YC, Harraz AM, Shindel AW, et al. Evaluation and management of priapism: 2009 update. Nat Rev Urol. 2009;6:262&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905796</ArticleId><ArticleId IdType="pubmed">19424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor J, Akkus E, Alter G, et al. Priapism. J Sex Med. 2004;1:116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac JR, Mak SK, Garcia MM, et al. A pathophysiology-based approach to the management of early priapism. Asian J Androl. 2013;15:20&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739130</ArticleId><ArticleId IdType="pubmed">23202699</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruve N, Hosking DH.. Intracorporeal phenylephrine in the treatment of priapism. J Urol. 1996;155:141&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31685942</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Two-piece inflatable and semi-rigid penile implants: an effective alternative?</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>29</EndPage><MedlinePgn>24-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0213-0</ELocationID><Abstract><AbstractText>Penile prostheses (PPs) are an excellent treatment to be considered for patients suffering from erectile dysfunction (ED), refractory to oral medications, or unwilling to consider intracavernosal injections or other therapeutic strategies. Nowadays the market is dominated by three-piece inflatable penile prosthesis (IPP), which are considered the best option available. However, in some specific cases three-piece IPP may be superseded by semi-rigid penile prosthesis (SRPP) and two-piece IPP. Despite the advantages of these implants, the literature is quite scarce, not robust and rarely takes into consideration the partner's satisfaction. This clearly affects the strength of our conviction. Most of the studies confirm that SRPPs and two-piece IPPs can be considered a valid alternative in patients with hand dexterity issues, refractory ischaemic priapism, neophallus and in cases of complex anatomies. In addition, the ease of placement and the high confidence level of surgeons make them a powerful tool in the armamentarium of urologists.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verze</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. pverze@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1951-404X</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Califano</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Rocca</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31685942</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0213-0</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0213-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31570823</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>The surgical management of ischaemic priapism.</ArticleTitle><Pagination><StartPage>81</StartPage><EndPage>88</EndPage><MedlinePgn>81-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0197-9</ELocationID><Abstract><AbstractText>Priapism is a urological emergency that is defined as a prolonged penile erection lasting more than 4&#x2009;h, remaining despite orgasm and in the absence of sexual stimulation. Without prompt and complete detumescence, time-dependent changes occur to the smooth muscle of the corpus cavernosa that can result in permanent erectile dysfunction and penile deformity (curvature, shortening and loss of girth). The diagnosis is confirmed with a hypoxic and acidotic blood sample from the corpus cavernosa. The trapped blood inside the corpus cavernosa is aspirated and can be irrigated with 0.9% normal saline. Intracavernosal injection of a sympathomimetic agent is used to cause smooth muscle contraction if the previous measures fail. Failure or recurrence of priapism following these conservative measures is an indication for surgical management. Shunt procedures that create a connection with the corpus cavernosa and a neighbouring structure are often used first line. Multiple shunt procedures have been described and these are summarised in this article. Distal shunt procedures are the most commonly used as they are easier to perform and seem to have at least comparable detumescence and potency rates. Refractory or prolonged (&gt;48&#x2009;h) ischaemic priapism maybe an indication of immediate placement of a penile prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mark James</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9023-1632</Identifier><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristinsson</LastName><ForeName>Sverrir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiriaco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1967-5983</Identifier><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK. david@andrology.co.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014656" MajorTopicYN="N">Vascular Surgical Procedures</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31570823</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0197-9</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0197-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31551575</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of penile implants in patients with vasculogenic erectile dysfunction versus postradical prostatectomy erectile dysfunction.</ArticleTitle><Pagination><StartPage>606</StartPage><EndPage>610</EndPage><MedlinePgn>606-610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0198-8</ELocationID><Abstract><AbstractText>Penile prosthesis is the treatment of choice for erectile dysfunction (ED) refractory to medical treatment; vasculogenic ED and ED postradical prostatectomy (PRP) are the main aetiologies. Few studies have compared surgical outcomes of penile prosthesis placement for vasculogenic versus PRP severe erectile dysfunction. This study includes 117 cases corresponding to virgin implants for ED of either vasculogenic aetiology or PRP (58 for PRP and 59 for vasculogenic cases). We analysed data corresponding to: age, comorbidity, type of prosthesis, presence of fibrosis that hinders dilation, need for modelling, size of implanted cylinders and complications (intra and postoperative). In the results the rate of hypertension, diabetes, dyslipidaemia and ischemic heart disease was higher in vasculogenic ED. All of the prostheses were hydraulic; 24.1% of two components and 75.9% of three in the PRP group; 39% components of two and 61% of three in the vasculogenic group. With regard to the presence of cavernous fibrosis and need for modelling, no significant differences were found. However, significant differences were observed in the size of the implanted cylinders; PRP of 18.30&#x2009;&#xb1;&#x2009;2.11&#x2009;cm versus 19.21&#x2009;&#xb1;&#x2009;1.71&#x2009;cm in vasculogenic ED (p&#x2009;=&#x2009;0.01643). There were no significant differences between the groups in infection rates, mechanical failure or extrusion. In conclusion the implantation of penile prosthesis in ED after PRP is associated with a shorter cylinder length compared with vasculogenic origin. Although there was a certain non-significant tendency to the need for modelling manoeuvres in PRP, there were no significant differences in postoperative outcomes including infection or mechanical failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cocera</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torremade</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, Bellvitge University Hospital, IDIBELL, Barcelona, Spain. jtorremade@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarez</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Concha</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vigues</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Urology and Renal Transplantation, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Impot Res. 2020 Nov;32(6):638</RefSource><PMID Version="1">32286527</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31551575</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0198-8</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0198-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Das S. Urology in ancient India. Indian J Urol. 2007;23:2.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0970-1591.30253</ArticleId><ArticleId IdType="pubmed">19675749</ArticleId><ArticleId IdType="pmc">19675749</ArticleId></ArticleIdList></Reference><Reference><Citation>Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis. Urology. 1975;5:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(75)90071-0</ArticleId><ArticleId IdType="pubmed">1093303</ArticleId><ArticleId IdType="pmc">1093303</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId><ArticleId IdType="pmc">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Atienza Merino G. La pr&#xf3;tesis de pene en el tratamiento de la disfunci&#xf3;n er&#xe9;ctil. Actas Urol Esp. 2006;30:159&#x2013;69.</Citation></Reference><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)34871-1</ArticleId><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa074311</ArticleId><ArticleId IdType="pubmed">18354103</ArticleId></ArticleIdList></Reference><Reference><Citation>Berookhim BM, Nelson CJ, Kunzel B, Mulhall JP, Narus JB. Prospective analysis of penile length changes after radical prostatectomy. BJU Int 2014;113:E131&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.12443</ArticleId><ArticleId IdType="pubmed">24053766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadono Y, Machioka K, Nakashima K, Iijima M, Shigehara K, Nohara T, et al. Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism. BJU Int 2017;120:293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13777</ArticleId><ArticleId IdType="pubmed">28181381</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiman MC, Lepor H, McCullough AR. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical retropubic prostatectomy. Mol Urol. 1999;3:109&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP. Penile length changes after radical prostatectomy. BJU Int. 2005;96:472&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05666.x</ArticleId><ArticleId IdType="pubmed">16104892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciancio SJ, Kim ED. Penile fibrotic changes after radical retropubic prostatectomy. BJU Int. 2000;85:101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410x.2000.00364.x</ArticleId><ArticleId IdType="pubmed">10619955</ArticleId></ArticleIdList></Reference><Reference><Citation>Menard J, Tremeaux J-C, Faix A, Pierrevelcin J, Staerman F. Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. J Sex Med. 2011;8:3479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02466.x</ArticleId><ArticleId IdType="pubmed">21951645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR. A new treatment for Peyronie&#x2019;s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)32519-3</ArticleId><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontero P, Galzerano M, Bartoletti R, Magnani C, Tizzani A, Frea B, et al. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. J Urol. 2007;178:602&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2007.03.119</ArticleId><ArticleId IdType="pubmed">17570431</ArticleId></ArticleIdList></Reference><Reference><Citation>Briganti A, Fabbri F, Salonia A, Gallina A, Chun FK-H, Deh&#xf2; F, et al. Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. Eur Urol. 2007;52:702&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2007.03.050</ArticleId><ArticleId IdType="pubmed">17418936</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00278.x</ArticleId><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveci S, Martin D, Parker M, Mulhall JP. Penile length alterations following penile prosthesis surgery. Eur Urol. 2007;51:1128&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.10.026</ArticleId><ArticleId IdType="pubmed">17084508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31542379</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis Implantation in an Exstrophy-Epispadias Complex Patient: A Case Report.</ArticleTitle><Pagination><StartPage>540</StartPage><EndPage>542</EndPage><MedlinePgn>540-542</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2019.08.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(19)30125-4</ELocationID><Abstract><AbstractText>Penile prosthesis implantation (PPI) is a definitive treatment option for patients with medically refractory erectile dysfunction (ED). It is a safe, reliable operation with high patient satisfaction and few complications. We report a novel case of an adult patient with exstrophy-epispadias complex who underwent PPI for ED and discuss the surgical challenges presented by the unique anatomic constraints of this condition. Sotimehin AE, Burnett AL. Penile Prosthesis Implantation in an Exstrophy-Epispadias Complex Patient: A Case Report. Sex Med 2019;7:540-542.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sotimehin</LastName><ForeName>Ayodeji E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: aburnet1@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Exstrophy-Epispadias Complex</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31542379</ArticleId><ArticleId IdType="pmc">PMC6963112</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2019.08.001</ArticleId><ArticleId IdType="pii">S2050-1161(19)30125-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta N.K., Ring J., Trost L. The penoscrotal surgical approach for inflatable penile prosthesis placement. Transl Androl Urol. 2017;6:628&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583046</ArticleId><ArticleId IdType="pubmed">28904895</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal R.L., Cabrini M.R., Bivalacqua T.J. Penile straightening maneuvers employed during penile prosthesis surgery: Technical options and outcomes. Int J Impot Res. 2014;26:182&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">24646675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch I.H., Moy M.L. Glandular-tunical stabilization to repair SST deformity of the inflatable penile prosthesis. Tech Urol. 2000;6:212&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963491</ArticleId></ArticleIdList></Reference><Reference><Citation>Partin A.W., Wein A.J., Kavoussi L.R. Eleventh Edition. Elsevier; New York, NY: 2016. Campbell-Walsh Urology.</Citation></Reference><Reference><Citation>Woodhouse C.R. Sexual function in boys born with exstrophy, myelomeningocele, and micropenis. Urology. 1998;52:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671861</ArticleId></ArticleIdList></Reference><Reference><Citation>Castagnetti M., Tocco A., Capizzi A. Sexual function in men born with classic bladder exstrophy: A norm related study. J&#xa0;Urol. 2010;183:1118&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatipo&#x11f;lu N., Kurto&#x11f;lu S. Micropenis: Etiology, diagnosis and treatment approaches. J&#xa0;Clin Res Pediatr Endocrinol. 2013;5:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890219</ArticleId><ArticleId IdType="pubmed">24379029</ArticleId></ArticleIdList></Reference><Reference><Citation>Massanyi E.Z., Gupta A., Goel S. Radial forearm free flap phalloplasty for penile inadequacy in patients with exstrophy. J&#xa0;Urol. 2013;190(4 Suppl):1577&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pubmed">23270911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31541647</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Color Doppler Duplex Ultrasound Parameters in Men Without Organic Erectile Dysfunction.</ArticleTitle><Pagination><StartPage>66</StartPage><EndPage>70</EndPage><MedlinePgn>66-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2019.09.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(19)30811-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define age-specific normal Color Doppler Duplex Ultrasound (CDDU) parameters based on a large institutional database of men referred for vascular erectile testing, but found to have normal and sustained rigidity following penile injection of alprostadil.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review of patients who underwent CDDU from January 1, 2005 to December 31, 2014 was conducted. The indications for CDDU assessments included complaint of erectile dysfunction refractory to PDE-5 inhibitors, new-onset penile curvature, or secondary consultation for erectile dysfunction. Pearson correlation test was used to evaluate the association between ordinal age groups with peak systolic velocity (PSV) and resistive index (RI) measurements to determine the effect of age on erectile response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2043 patients underwent CDDU from January 1, 2005 to December 31, 2014. 259 patients (12.7%) with a mean age 53.7 and a mean BMI of 27.2 were noted to have normal erectile rigidity and normal Doppler parameters (PSV &gt;35 cm/s, RI &gt;0.90). Prolonged erection, defined by need to inject phenylephrine reversal agent at 1-2 hours, occurred in 93% of patients. When age was categorized by decade, a negative correlation coefficient was obtained for previsual sexual stimulation PSV (-0.09, P&#x202f;=&#x202f;.164) and postvisual sexual stimulation PSV (-0.23, P&#x202f;=&#x202f;.005).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In men with normal vascular erections there appears to be a significant, age-related decline in postvisual sexual stimulation PSV without compromise to cavernous venous occlusion as measured by RI. We have used Doppler parameters in patients without vascular ED to define age-specific normalcy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Ram A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broderick</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Mayo Clinic Florida, Department of Urology, Jacksonville, FL. Electronic address: Broderick.Gregory@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064804">Urological Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1WS297W6MV</RegistryNumber><NameOfSubstance UI="D010656">Phenylephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2020 Dec;204(6):1362-1363</RefSource><PMID Version="1">32960710</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010656" MajorTopicYN="N">Phenylephrine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018615" MajorTopicYN="Y">Ultrasonography, Doppler, Color</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064804" MajorTopicYN="N">Urological Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31541647</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2019.09.002</ArticleId><ArticleId IdType="pii">S0090-4295(19)30811-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31540882</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Surgical Management of Peyronie's Disease With Co-Existent Erectile Dysfunction.</ArticleTitle><Pagination><StartPage>361</StartPage><EndPage>370</EndPage><MedlinePgn>361-370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2019.08.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(19)30178-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Surgical intervention in Peyronie's disease (PD) should ideally be delayed until the resolution of acute inflammatory phase.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The objective of this review was to highlight the results of penile prosthesis to correct refractory erectile dysfunction (ED) in patients with PD, and the secondary procedures that may be required to correct the penile curvature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search on PubMed online database using Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations was done using the MeSH terms "Peyronie's disease" and "erectile dysfunction."</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Success and satisfaction rates of various procedures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search yielded 324 language-specific (English and Spanish language) articles and 58 articles were retained for final review. The following variables were assessed in different studies: number of patients, types of secondary procedure to correct the curvature, satisfaction rates, and follow-up period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The aim of the surgery in PD should be to achieve a functionally straight penis (&lt;20 degree curvature) with good erection. Patients with refractory ED in PD are candidates for penile prosthesis. Secondary procedures, like manual modeling, plication, plaque incision, or excision grafting, may be required depending on the degree of penile curvature and penile length. In quest for the best graft, TachoSil graft seems to have gained popularity in Europe. Krishnappa P, Fernandez-Pascual E, Carballido J, et&#xa0;al. Surgical Management of Peyronie's Disease With Co-Existent Erectile Dysfunction. Sex Med 2019;7:361-370.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnappa</LastName><ForeName>Pramod</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, NU Hospitals, Bangalore, India. Electronic address: Pramod23dr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Pascual</LastName><ForeName>Esau</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Lyx Institute of Urology, Universidad Francisco de Victoria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carballido</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lyx Institute of Urology, Universidad Francisco de Victoria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moncada</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology and Robotic Surgery, Hospital La Zarzuela, c/Pl&#xe9;yades, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lledo-Garcia</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Salamanca</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Lyx Institute of Urology, Universidad Francisco de Victoria, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int Braz J Urol. 2020 Jan-Feb;46(1):130-131</RefSource><PMID Version="1">31851472</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Grafts</Keyword><Keyword MajorTopicYN="N">Penile Induration</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Peyronie's Disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31540882</ArticleId><ArticleId IdType="pmc">PMC6963125</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2019.08.009</ArticleId><ArticleId IdType="pii">S2050-1161(19)30178-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hatzimouratidis K., Eardley I., Giuliano F. EAU Guidelines: Male Sexual Dysfunction [Internet]. Uroweb. http://uroweb.org/guideline/male-sexual-dysfunction/ Available at:</Citation></Reference><Reference><Citation>Stuntz M., Perlaky A., des Vignes F. The prevalence of Peyronie&#x2019;s Disease in the United States: A population-based study. PLoS One. 2016;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764365</ArticleId><ArticleId IdType="pubmed">26907743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiraishi K., Shimabukuro T., Matsuyama H. The prevalence of Peyronie&#x2019;s disease in Japan: A study in men undergoing maintenance hemodialysis and routine health checks. J&#xa0;Sex Med. 2012;9:2716&#x2013;2723.</Citation><ArticleIdList><ArticleId IdType="pubmed">22897619</ArticleId></ArticleIdList></Reference><Reference><Citation>La Pera G., Pescatori E.S., Calabrese M. Peyronie&#x2019;s disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001;40:525&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall J.P., Schiff J., Guhring P. An analysis of the natural history of Peyronie&#x2019;s disease. J&#xa0;Urol. 2006;175:2115&#x2013;2118. [discussion 2118]</Citation><ArticleIdList><ArticleId IdType="pubmed">16697815</ArticleId></ArticleIdList></Reference><Reference><Citation>Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/20171303 Available at:</Citation></Reference><Reference><Citation>Hellstrom W.J., Feldman R., Rosen R.C. Bother and distress associated with Peyronie&#x2019;s disease: Validation of the Peyronie&#x2019;s disease questionnaire. J&#xa0;Urol. 2013;190:627&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">23376705</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen R.C., Riley A., Wagner G. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual E.F., Mart&#xed;nez-Salamanca J.I., Cerezo E. Ultrasound predictive factors for efficacy and safety of the use of Collagenase Clostridium Histolyticum (CCH) in the treatment of Peyronie&#x2019;s disease (PD): Impact on patient&#x2019;s selection. Eur Urol Suppl. 2018;17</Citation></Reference><Reference><Citation>Penile Traction Therapy and Vacuum Erection Devices in Peyronie&#x2019;s Disease. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/29631979 Available at:</Citation></Reference><Reference><Citation>Nehra A., Alterowitz R., Culkin D.J. Peyronie&#x2019;s disease: AUA Guideline. J&#xa0;Urol. 2015;194:745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027990</ArticleId><ArticleId IdType="pubmed">26066402</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Becher E., Bella A. Penile prosthesis surgery: Current recommendations from the International Consultation on Sexual Medicine. J&#xa0;Sex Med. 2016;13:489&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi F.A., Hatzichristodoulou G., DeLay K.J. Review of management options for patients with atypical Peyronie&#x2019;s disease. Sex Med Rev. 2017;5:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">27544298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E., Wang R., Ralph D. A&#xa0;worldwide survey on Peyronie&#x2019;s disease surgical practice patterns among surgeons. J&#xa0;Sex Med. 2018;15:568&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">29550462</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyronie&#x2019;s Disease  Still a Surgical Disease. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/?term=Peyronie%27s+Disease%3A+Still+a+Surgical+Disease Available at:</Citation></Reference><Reference><Citation>Chung E., Solomon M., DeYoung L. Comparison between AMS 700TM CX and ColoplastTM Titan inflatable penile prosthesis for Peyronie&#x2019;s disease treatment and remodeling: Clinical outcomes and patient satisfaction. J&#xa0;Sex Med. 2013;10:2855&#x2013;2860.</Citation><ArticleIdList><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M., Tealab A., Farag M. Malleable penile implant is an effective therapeutic option in men with Peyronie&#x2019;s disease and erectile dysfunction. Sex Med. 2018;6:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815935</ArticleId><ArticleId IdType="pubmed">29336942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca J.I., Mueller A., Moncada I. Penile prosthesis surgery in patients with corporal fibrosis: A state of the art review. J&#xa0;Sex Med. 2011;8:1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G., Kuehhas F.E., De Luca F. Long-term results of reconstructive surgery for Peyronie&#x2019;s disease. Sex Med Rev. 2015;3:113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784545</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera M., Bella A., Karpman E. Penile prosthesis implantation in patients with Peyronie&#x2019;s disease: Results of the PROPPER study demonstrates a decrease in patient-reported depression. J&#xa0;Sex Med. 2018;15:786&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">29653913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., Delk J.R. A&#xa0;new treatment for Peyronie&#x2019;s disease: Modeling the penis over an inflatable penile prosthesis. J&#xa0;Urol. 1994;152:1121&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>DiBlasio C.J., Kurta J.M., Botta S. Peyronie&#x2019;s disease compromises the durability and component-malfunction rates in patients implanted with an inflatable penile prosthesis. BJU Int. 2010;106:691&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">20128775</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G., Minervini A., Christopher N.A. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011;108:1152&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague D.K., Angermeier K.W., Lakin M.M. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie&#x2019;s disease: Comparison of CX and Ultrex cylinders. J&#xa0;Urol. 1996;156:1633&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863557</ArticleId></ArticleIdList></Reference><Reference><Citation>Usta M.F., Bivalacqua T.J., Sanabria J. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie&#x2019;s disease. Urology. 2003;62:105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837432</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary M., Sheikh N., Asterling S. Peyronie&#x2019;s disease with erectile dysfunction: Penile modeling over inflatable penile prostheses. Urology. 2005;65:760&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15833523</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Benson J., Hoover C. Inflatable penile prosthesis placement in men with Peyronie&#x2019;s disease and drug-resistant erectile dysfunction: A single-center study. J&#xa0;Sex Med. 2010;7:3775&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20722782</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi F.A., Hatzichristodoulou G., Wang J. Outcomes of surgical management of men with Peyronie&#x2019;s disease with hourglass deformity. Urology. 2016;91:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">26876465</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J., Yafi F.A. A&#xa0;review of surgical strategies for penile prosthesis implantation in patients with Peyronie&#x2019;s disease. Transl Androl Urol. 2016;5:342&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893506</ArticleId><ArticleId IdType="pubmed">27298781</ArticleId></ArticleIdList></Reference><Reference><Citation>New surgical treatment for Peyronie's disease - ScienceDirect [Internet] https://www.sciencedirect.com/science/article/pii/0090429585902857 Available at:</Citation></Reference><Reference><Citation>Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/?term=Correction+of+penile+curvature+using+the+16-dot+plication+technique%3A+a+review+of+132+patients Available at:</Citation></Reference><Reference><Citation>Chung P.H., Scott J.F., Morey A.F. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie&#x2019;s disease. J&#xa0;Sex Med. 2014;11:1593&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">24708140</ArticleId></ArticleIdList></Reference><Reference><Citation>Grafts for Peyronie&#x2019;s disease: A comprehensive review. -&#xa0;PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/29266877 Available at:</Citation></Reference><Reference><Citation>Perovic S.V., Djinovic R.P. Current surgical management of severe Peyronie&#x2019;s disease. Arch Esp Urol. 2010;63:755&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">21098900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansalone S., Garaffa G., Djinovic R. Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie&#x2019;s disease, refractory erectile dysfunction, and severe penile shortening. J&#xa0;Sex Med. 2012;9:316&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">22023552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue T.F., El-Sakka A.I. Venous patch graft for Peyronie&#x2019;s disease. Part I: Technique. J&#xa0;Urol. 1998;160(6 Pt 1):2047&#x2013;2049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817320</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sakka A.I., Rashwan H.M., Lue T.F. Venous patch graft for Peyronie&#x2019;s disease. Part II: Outcome analysis. J&#xa0;Urol. 1998;160(6 Pt 1):2050&#x2013;2053.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817321</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F., Salonia A., Maga T. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie&#x2019;s disease. J&#xa0;Urol. 2000;163:1704&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799165</ArticleId></ArticleIdList></Reference><Reference><Citation>Austoni E., Colombo F., Roman&#xf2; A.L. Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie&#x2019;s disease: A 5-year experience and long-term follow-up on 145 operated patients. Eur Urol. 2005;47:223&#x2013;229. [discussion 229]</Citation><ArticleIdList><ArticleId IdType="pubmed">15661418</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvani M., Pecoraro S., Zucchi A. Corporoplasty for induratio penis plastica with soft axial tutors, single relaxing albugineal incision and safenous grafting. A 3-year follow up. Arch Ital Urol Androl. 2012;84:84&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">22908777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom W.J., Reddy S. Application of pericardial graft in the surgical management of Peyronie&#x2019;s disease. J&#xa0;Urol. 2000;163:1445&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">10751854</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio P.H., Kuehhas F.E., Sansalone S. Penile length and girth restoration in severe Peyronie&#x2019;s disease using circular and longitudinal grafting. BJU Int. 2013;111(4 Pt B):E213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">23107452</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Estrada C.R. Human cadaveric pericardial graft for the surgical correction of Peyronie&#x2019;s disease. J&#xa0;Urol. 2003;170(6 Pt 1):2359&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">14634416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L., Falcone M., Ceruti C. A&#xa0;prospective multicentric international study on the surgical outcomes and patients&#x2019; satisfaction rates of the &#x201c;sliding&#x201d; technique for end-stage Peyronie&#x2019;s disease with severe shortening of the penis and erectile dysfunction. BJU Int. 2016;117:814&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">26688436</ArticleId></ArticleIdList></Reference><Reference><Citation>Use of small intestinal submucosa graft for the surgical management of Peyronie&#x2019;s disease. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/17976656 Available at:</Citation></Reference><Reference><Citation>Knoll L.D. Use of porcine small intestinal submucosal graft in the surgical management of tunical deficiencies with penile prosthetic surgery. Urology. 2002;59:758&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">11992915</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgical therapy of Peyronie&#x2019;s disease by partial plaque excision and grafting with collagen fleece: Feasibility study of a new technique. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/?term=Surgical+therapy+of+Peyronie%27s+disease+by+partial+plaque+excision+and+grafting+with+collagen+fleece%3A+feasibility+study+of+a+new+technique Available at:</Citation><ArticleIdList><ArticleId IdType="pubmed">23446807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristodoulou G. The PICS technique: A novel approach for residual curvature correction during penile prosthesis implantation in patients with severe Peyronie&#x2019;s disease using the collagen fleece TachoSil. J&#xa0;Sex Med. 2018;15:416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">29325832</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M., Preto M., Ceruti C. A&#xa0;comparative study between 2 different grafts used as patches after plaque incision and inflatable penile prosthesis implantation for end-stage Peyronie&#x2019;s disease. J&#xa0;Sex Med. 2018;15:848&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">29753801</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual E.F., Portillo L.D., Cerezo E. PS-05-016 Initial experience with incision and collagen-fleece grafting in the treatment of Peyronie&#x2019;s disease. J&#xa0;Sex Med. 2017;14:e123.</Citation></Reference><Reference><Citation>Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie&#x2019;s Disease. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/28258933 Available at:</Citation></Reference><Reference><Citation>Kadioglu A., Sanli O., Akman T. Surgical treatment of Peyronie&#x2019;s disease: A single center experience with 145 patients. Eur Urol. 2008;53:432&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467161</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio P.H., Kuehhas F.E. The Multiple-Slit Technique (MUST) for penile length and girth restoration. J&#xa0;Sex Med. 2018;15:261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">29275049</ArticleId></ArticleIdList></Reference><Reference><Citation>Growth factor content in PRP and their applicability in medicine. - PubMed - NCBI [Internet] https://www.ncbi.nlm.nih.gov/pubmed/23648195 Available at:</Citation><ArticleIdList><ArticleId IdType="pubmed">23648195</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco M., Garcia-Cruz E. PRP (platelet enriched plasma) and&#xa0;erectile dysfunction: How far along we are? ESSM. 2018;38:5&#x2013;6.</Citation></Reference><Reference><Citation>Matz E.L., Pearlman A.M., Terlecki R.P. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59:61&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754585</ArticleId><ArticleId IdType="pubmed">29333517</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak A.S., Chang J.H., Parekh A.R. Use of rectus fascia graft for corporeal reconstruction during placement of penile implant. Urology. 2005;65:1198&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15913723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi A., Silvani M., Pecoraro S. Corporoplasty with small soft axial prostheses (VIRILIS I&#xae;) and bovine pericardial graft (HYDRIX&#xae;) in Peyronie&#x2019;s disease. Asian J Androl. 2013;15:275&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739159</ArticleId><ArticleId IdType="pubmed">23353721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang A., Wang R. Nondegloving technique for Peyronie&#x2019;s disease with penile prosthesis implantation and double dorsal-ventral patch graft. Asian J Androl. 2018;20:90&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753562</ArticleId><ArticleId IdType="pubmed">28959941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31537910</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Infrapubic approach for placement of inflatable penile prosthesis: contemporary review of technique and implications.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>17</EndPage><MedlinePgn>10-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0193-0</ELocationID><Abstract><AbstractText>Inflatable penile prosthesis (IPP) is an effective treatment for erectile dysfunction refractory to nonsurgical management. The infrapubic approach for IPP placement is less frequently employed than the penoscrotal approach, with only about 25% of IPPs placed via this method. Underutilization of the infrapubic method may be due to fear of injuring the penile dorsal neurovascular bundle, perceived difficulties of scrotal pump placement through a distant location, or insufficient distal corporal exposure. However, this approach appears to result in favorable operative times, faster time to device activation, equivalent postoperative satisfaction and quality of life, and similar complication rates. We provide a contemporary review of literature published before May 2019 regarding the infrapubic approach for IPP placement, technical considerations, and postoperative expectations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayadevan</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleswarapu</LastName><ForeName>Sriram V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Jesse N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Los Angeles, CA, USA. jnmills@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012611" MajorTopicYN="N">Scrotum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31537910</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0193-0</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0193-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31489849</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Risk profiling in patients undergoing penile prosthesis implantation.</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>14</EndPage><MedlinePgn>8-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/aja.aja_92_19</ELocationID><Abstract><AbstractText>Penile prosthesis implantation is the gold standard of surgical therapy for patients with medication-refractory erectile dysfunction. However, this umbrella definition includes significant heterogeneity and associated risk profiles that should be candidly discussed and addressed perioperatively. Factors associated with operative success and patient satisfaction are often surgery specific; however, risk profiling via patient selection, preoperative optimization, proper device selection, and intraoperative consideration are highly correlated. Some examples of common risk profiles include comorbidity(ies) such as cardiovascular disease, diabetes mellitus, prior abdominal surgery, Peyronie's disease, and psychological risk factors. Similarly, integration of surgeon- and patient-amenable characteristics is key to decreasing risk of infection, complication, and need for revision. Finally, patient risk profiling provides a unique context for proper device selection and evidence-based intraoperative considerations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA 92868, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Mohamad M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA 92868, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yafi</LastName><ForeName>Faysal A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California, Irvine Medical Center, Orange, CA 92868, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2020 Dec;204(6):1364</RefSource><PMID Version="1">32960709</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">patient selection</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31489849</ArticleId><ArticleId IdType="pmc">PMC6958986</ArticleId><ArticleId IdType="doi">10.4103/aja.aja_92_19</ArticleId><ArticleId IdType="pii">266178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Small MP, Carrion HM. Penile prosthesis: new implant for management of impotence. J Fla Med Assoc. 1975;62:21&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1176930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4:1074&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor MB, Carrion R, Wang R, Henry G. Patient satisfaction and penile morphology changes with postoperative penile rehabilitation 2 years after Coloplast Titan prosthesis. Asian J Androl. 2016;18:754&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5000799</ArticleId><ArticleId IdType="pubmed">26459782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile G, Franceschelli A, Massenio P, Tuccio A, Cocci A, et al. Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: an Italian multicentric study. Arch Ital Urol Androl. 2016;88:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27072167</ArticleId></ArticleIdList></Reference><Reference><Citation>Akakpo W, Pineda MA, Burnett AL. Critical analysis of satisfaction assessment after penile prosthesis surgery. Sex Med Rev. 2017;5:244&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28143706</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda M, Burnett AL. Penile prosthesis infections-a review of risk factors, prevention, and treatment. Sex Med Rev. 2016;4:389&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">27872031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RP, Kawashima A, Takahashi N, LeRoy AJ, King BF. Inflatable penile prosthesis (IPP): diagnosis of complications. Abdom Radiol (NY) 2016;41:1187&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">26907716</ArticleId></ArticleIdList></Reference><Reference><Citation>Narang GL, Figler BD, Coward RM. Preoperative counseling and expectation management for inflatable penile prosthesis implantation. Transl Androl Urol. 2017;6:S869&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715186</ArticleId><ArticleId IdType="pubmed">29238666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac JR. Informed consent for penile prosthesis surgery. Transl Androl Urol. 2017;6:881&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715182</ArticleId><ArticleId IdType="pubmed">29239402</ArticleId></ArticleIdList></Reference><Reference><Citation>American Urological Association Education and Research, Inc. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>International Society for Sexual Medicine. Penile prosthesis surgery: current recommendations from the international consultation on sexual medicine. J Sex Med. 2016;13:489&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Cordova AD, Kershaw K, Liu K, Herrington D, Lloyd-Jones DM. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2017;30:815&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861595</ArticleId><ArticleId IdType="pubmed">28430921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratu O, Oprea I, Marcu D, Spinu D, Niculae A. Erectile dysfunction post-radical prostatectomy &#x2013; a challenge for both patient and physician. J Med Life. 2017;10:13&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304365</ArticleId><ArticleId IdType="pubmed">28255370</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol. 2017;6:46&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313310</ArticleId><ArticleId IdType="pubmed">28217450</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Chen Y, Chen G, Dai Y, Yao Z. Altered brain networks in psychogenic erectile dysfunction: a resting-state fMRI study. Andrology. 2017;5:1073&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29073337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Luo X, Zou KH, Stecher V, Galaznik A. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int J Clin Pract. 2016;70:1012&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5540144</ArticleId><ArticleId IdType="pubmed">28032424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastrelli G, Corona G, Mannucci E, Maggi M. Vascular and chronological age in men with erectile dysfunction: a longitudinal study. J Sex Med. 2016;13:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26953832</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. Curr Opin Cardiol. 2015;30:416&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26049392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha E. Cardiovascular risk scores: usefulness and limitations. Rev Port Cardiol. 2016;35:15&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26755402</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward M. On validation of cardiovascular risk scores. BMJ. 2016;354:i4483.</Citation><ArticleIdList><ArticleId IdType="pubmed">27530313</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YL, Cheng CL, Huang JL, Yang NI, Chang HC. Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. Medicine (Baltimore) 2017;96:e8338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5671841</ArticleId><ArticleId IdType="pubmed">29069008</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol. 2017;120:2182&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AD, Streiff M, Resar J, Schoenberg M. Coronary stent management in elective genitourinary surgery. BJU Int. 2012;110:480&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22192977</ArticleId></ArticleIdList></Reference><Reference><Citation>Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther. 2017;102:209&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28295269</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston BA, Kalathiya RJ, Kim DA, Zakaria S. Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention. Mayo Clin Proc. 2015;90:1247&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26189443</ArticleId></ArticleIdList></Reference><Reference><Citation>Culkin DJ, Exaire EJ, Green D, Soloway MS, Gross AJ, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014;192:1026&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24859439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Latona J. New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents. Aust Fam Physician. 2014;43:861&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25705736</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. Clin Microbiol Infect. 2015;21:S27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26198368</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung M, Leung DY. Coronary microvascular function in patients with type 2 diabetes mellitus. EuroIntervention. 2016;11:1111&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26874336</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki DB, Yadava SK, Pant S, Thusa N, Dangol E, et al. Prevalence of sensory neuropathy in type 2 diabetes mellitus and its correlation with duration of disease. Kathmandu Univ Med J (KUMJ) 2016;14:120&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28166066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol. 1992;147:386&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, Soliman T, Nassar M, et al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int. 2018;121:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478354</ArticleId><ArticleId IdType="pubmed">29124870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Carson CC, Cleves MA, Delk JR. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159:1537&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Canguven O, Talib R, El Ansari W, Khalafalla K, Al Ansari A. Is Hba1c level of diabetic patients associated with penile prosthesis implantation infections? Aging Male. 2018;9:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29523037</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M, Pearce I. Infection of penile prostheses in patients with diabetes mellitus. Surg Infect (Larchmt) 2016;17:2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Mora-Estaves C, Egydio P, Ralph D, Habous M. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology. 2017;107:144&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28648967</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Camper SB, Ma L, Burnett AL. Prediction model for penile prosthesis implantation for erectile dysfunction management. Curr Med Res Opin. 2014;30:2131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24945719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet N, Huang IS. Inflatable penile prosthesis in the radical prostatectomy patient: a review. F1000Res. 2018;7:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039953</ArticleId><ArticleId IdType="pubmed">30026935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadhich P, Hockenberry M, Kirby EW, Lipshultz L. Penile prosthesis in the management of erectile dysfunction following cancer therapy. Transl Androl Urol. 2017;6:S883&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715185</ArticleId><ArticleId IdType="pubmed">29238667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RJ, Jr, Helfand BT, McVary KT. Outcomes of lateral retroperitoneal reservoir placement of three-piece penile prosthesis in patients following radical prostatectomy. Int J Impot Res. 2010;22:279&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20574433</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito PE. Ectopic reservoir placement &#x2013; no longer in the space of the Retzius. J Sex Med. 2011;8:2395&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21884425</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh-Doyle J, Patil MB, Sawkar H, Wayne K, Boyd SD. 3-piece inflatable penile prosthesis placement following radical cystoprostatectomy and urinary diversion: technique and outcomes. J Sex Med. 2018;17:907&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29452979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindel W, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: a nationwide survey. J Sex Med. 2008;5:954&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042214</ArticleId></ArticleIdList></Reference><Reference><Citation>American Urological Association Education and Research, Inc. Peyronie's Disease: AUA Guideline. J Urol. 2015;194:745&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027990</ArticleId><ArticleId IdType="pubmed">26066402</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Guazzoni F, Bergamaschi F, Rigatti P. Patient-partner satisfaction with semirigid penile prostheses for Peyronie's disease: a 5-year followup study. J Urol. 1993;153:1819&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8230513</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. Transl Androl Urol. 2016;5:342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893506</ArticleId><ArticleId IdType="pubmed">27298781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L, Ceruti C, Timpano M, Sedigh O, Destefanis P, et al. A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the &#x201c;sliding technique&#x201d;. J Sex Med. 2012;9:2389&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22429331</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, Baum N, Hellstrom WJ. Managing the difficult penile prosthesis patient. J Sex Med. 2013;10:893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol. 2016;13:33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, Wilson SK, Hellstrom WJ. Infection retardant coated inflatable penile prostheses decrease the incidence of infection: A systematic review and meta-analysis. J Urol. 2012;188:1855&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, Salem EA, Delk JR, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology. 2007;70:337&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lujan S, Rogel R, Broseta E, Boronat F. Local treatment of penile prosthesis infection as alternative to immediate salvage surgery. Sex Med. 2016;4:e255&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5121535</ArticleId><ArticleId IdType="pubmed">27484916</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Kansal NS, Callaway M, Grisby T, Henderson J, et al. Centers of excellence concept and penile prostheses: an outcome analysis. J Urol. 2009;181:1264&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19152945</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MG, Weinberg AC, James MB, et al. Impact of surgeon case volume on reoperation rates after inflatable penile prosthesis surgery. J Urol. 2017;197:223&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27545573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegemann M, Kohler TS, Bailey GC, Miest T, Alom M, et al. Surgical patient selection and counseling. Transl Androl Urol. 2017;6:609&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583047</ArticleId><ArticleId IdType="pubmed">28904893</ArticleId></ArticleIdList></Reference><Reference><Citation>McAbee KE, Pearlman AM, Terlecki RP. Infection following penile prosthesis placement at an academic training center remains low despite involvement of surgeons-in-training. Investig Clin Urol. 2018;59:342&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121020</ArticleId><ArticleId IdType="pubmed">30182080</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwaal A, Harris CR, Hussein AA, Sanford TH, McCulloch CE, et al. The decline of inpatient penile prosthesis over the 10-year period, 2000-2010. J Sex Med. 2015;3:280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721026</ArticleId><ArticleId IdType="pubmed">26797062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Bloom K. Comparison of in-patient and out-patient penile prosthesis surgery. Int J Impot Res. 2001;13:251&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11890510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Sarti E, Giubilei G, Gavazzi A, Costanzi A, et al. Penile prosthesis surgery in out-patient setting: Effectiveness and costs in the &#x201c;spending review&#x201d; era. Arch Ital Urol Androl. 2014;86:161&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25308576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirshenbaum EJ, Nelson M, Hehemann MC, Kothari AN, Eguia E, et al. Impact of post-hospital syndrome on penile prosthesis outcomes: a period of global health risk. J Urol. 2019;201:154&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30125569</ArticleId></ArticleIdList></Reference><Reference><Citation>American Urological Association Education and Research, Inc. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, Brock G, Broderick GA, et al. North American consensus document on infection of penile prostheses. Urology. 2013;82:937&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmussareh M, Goddard JC, Summerton DJ, Terry TR. Minimising the risk of device infection in penile prosthetic surgery: a UK perspective. J Clin Urol. 2013;6:280&#x2013;8.</Citation></Reference><Reference><Citation>Selph JP, Carsson CC., 3rd Penile prosthesis infection: approaches to prevention and treatment. Urol Clin North Am. 2011;38:227&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621089</ArticleId></ArticleIdList></Reference><Reference><Citation>Balen A, Gross MS, Phillips EA, Henry GD, Munarriz R. Active polysubstance abuse concurrent with surgery as a possible newly identified infection risk factor in inflatable penile prosthesis placement based on a retrospective analysis of health and socioeconomic factors. J Sex Med. 2016;13:697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">26928774</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg. 2012;147:373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22508785</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell L. The importance of patients&#x2019; nutritional status in wound healing. Br J Nurs. 2001;10:S44&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12070399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossein SN. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med. 2007;4:296&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, Palazzo S, Saracino GA. Penile prostheses. Ther Adv Urol. 2010;2:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126066</ArticleId><ArticleId IdType="pubmed">21789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou S, Reyes-Valejo L, Morgentaler A. Technical advances in penile prostheses. J Long Term Eff Med Implants. 2006;16:235&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17073566</ArticleId></ArticleIdList></Reference><Reference><Citation>Scovell JM, Liehui G, Barrera EV, Wilson SK, Carrion RE, et al. Longitudinal and horizontal load testing of inflatable penile implant cylinders of two manufacturers: an ex vivo demonstration of inflated rigidity. J Sex Med. 2016;13:1750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654325</ArticleId><ArticleId IdType="pubmed">27770856</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Wall MJ, Jr, Itani KM, Otterson MF, Webb AL, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">20054046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, Lai HH, Brandes SB, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol. 2013;189:136&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober ED, Domes T, Fanipour M, Copp JE. Preoperative hair removal on the male genitalia: clippers vs. razors. J Sex Med. 2013;10:589&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22908852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexual Medicine Society of North America; Position Statements: Razors and Preoperative Preparation of the Male Genitalia.  [Last accessed on 2019 Jun 11].  Available from: http://www.smsna.org/ V1/about/position-statements .</Citation></Reference><Reference><Citation>Wosnitzer MW, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med. 2011;8:1521&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Ilbeigi P, Wilson SK, Delk JR, Siegel A, et al. Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res. 2005;17:535&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. No-touch technique. J Sex Med. 2011;8:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. Penile implant: review of &#x201c;no-touch&#x201d; technique. Sex Med Rev. 2016;4:294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">27871962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31489848</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Updates in penile prosthesis infections.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>33</EndPage><MedlinePgn>28-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/aja.aja_84_19</ELocationID><Abstract><AbstractText>Inflatable penile prostheses are an important tool in the treatment of medically refractory erectile dysfunction. One of the major complications associated with these prostheses is infections, which ultimately require device explanation and placement of a new device. Over the past several decades, significant work has been done to reduce infection rates and optimize treatment strategies to reduce patient morbidity. This article reviews the current state of knowledge surrounding penile prosthesis infections, with attention to the evidence for methods to prevent infection and best practices for device reimplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swanton</LastName><ForeName>Amanda R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03766, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munarriz</LastName><ForeName>Ricardo M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Urology, Boston Medical Center, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03766, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000891">Anti-Infective Agents, Local</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020099">Coated Materials, Biocompatible</NameOfSubstance></Chemical><Chemical><RegistryNumber>R4KO0DY52L</RegistryNumber><NameOfSubstance UI="D002710">Chlorhexidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000891" MajorTopicYN="N">Anti-Infective Agents, Local</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001458" MajorTopicYN="N">Bandages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002353" MajorTopicYN="N">Carrier State</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002710" MajorTopicYN="N">Chlorhexidine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020099" MajorTopicYN="N">Coated Materials, Biocompatible</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016905" MajorTopicYN="N">Gram-Negative Bacterial Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006204" MajorTopicYN="N">Hair Removal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013203" MajorTopicYN="N">Staphylococcal Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013212" MajorTopicYN="N">Staphylococcus epidermidis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058636" MajorTopicYN="N">Surgical Drapes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013525" MajorTopicYN="N">Surgical Instruments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31489848</ArticleId><ArticleId IdType="pmc">PMC6958973</ArticleId><ArticleId IdType="doi">10.4103/aja.aja_84_19</ArticleId><ArticleId IdType="pii">266177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mobley DF. Early history of inflatable penile prosthesis surgery: a view from someone who was there. Asian J Androl. 2015;17:225&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4650450</ArticleId><ArticleId IdType="pubmed">25432494</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res. 2003;15(Suppl 5):S139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551594</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res. 2001;13:326&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11918248</ArticleId></ArticleIdList></Reference><Reference><Citation>Licht MR, Montague DK, Angermeier KW, Lakin MM. Cultures from genitourinary prostheses at reoperation: questioning the role of Staphylococcusepidermidis in periprosthetic infection. J Urol. 1995;154:387&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">7609104</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK, Delk JR, 2nd, Carson CC, Silverstein A, et al. Penile prosthesis cultures during revision surgery: a multicenter study. J Urol. 2004;172:153&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15201759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Current approach to the treatment of penile implant infections. Ther Adv Urol. 2010;2:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126071</ArticleId><ArticleId IdType="pubmed">21789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Costerton JW. Biofilm and penile prosthesis infections in the era of coated implants: a review. J Sex Med. 2012;9:44&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21951338</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmussareh M, Goddard JC, Summerton JD, Terry TR. Minimising the risk of device infection in penile prosthetic surgery: a UK perspective. J Clin Urol. 2013;6:280&#x2013;8.</Citation></Reference><Reference><Citation>Welliver RC, Jr, Hanerhoff BL, Henry GD, Kohler TS. Significance of biofilm for the prosthetic surgeon. Curr Urol Rep. 2014;15:411.</Citation><ArticleIdList><ArticleId IdType="pubmed">24740272</ArticleId></ArticleIdList></Reference><Reference><Citation>von Eiff C, Heilmann C, Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis. 1999;18:843&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10691193</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo RJ, Munarriz RM, Gross MS. Infection prevention considerations for complex penile prosthesis recipients. Curr Urol Rep. 2019;20:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">30707308</ArticleId></ArticleIdList></Reference><Reference><Citation>Balen A, Gross MS, Phillips EA, Henry GD, Munarriz R. Active polysubstance abuse concurrent with surgery as a possible newly identified infection risk factor in inflatable penile prosthesis placement based on a retrospective analysis of health and socioeconomic factors. J Sex Med. 2016;13:697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">26928774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Carson CC, Cleves MA, Delk JR., 2nd Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159:1537&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, Soliman T, Nassar M, et al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int. 2018;121:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478354</ArticleId><ArticleId IdType="pubmed">29124870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR., 2nd Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol. 1995;153:659&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky MJ, Onyeji I, Golan R, Munarriz R, Kashanian JA, et al. Diabetes is a risk factor for inflatable penile prosthesis infection: analysis of a large statewide database. Sex Med. 2019;7:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377380</ArticleId><ArticleId IdType="pubmed">30674445</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters CE, Carlos EC, Lentz AC. Purulent inflatable penile prostheses can be safely immediately salvaged in insulin-dependent diabetics. J Sex Med. 2018;15:1673&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30446468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuellar DC, Sklar GN. Penile prosthesis in the organ transplant recipient. Urology. 2001;57:138&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun AY, Babbar P, Gill BC, Angermeier KW, Montague DK. Penile prosthesis in solid organ transplant recipients-a matched cohort study. Urology. 2018;117:86&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29656065</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Brandes ER, Chang SL, Leow JJ, Chung BI, et al. Trends in penile prosthesis implantation and analysis of predictive factors for removal. World J Urol. 2019;37:639&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">30251052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Carrasquillo RJ, Thornton A, Greenfield JM, et al. Multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis. J Sex Med. 2017;14:455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28189561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavoussi NL, Siegel JA, Viers BR, Pagliara TJ, Hofer MD, et al. Preoperative urine culture results correlate poorly with bacteriology of urologic prosthetic device infections. J Sex Med. 2017;14:163&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28065350</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sluis WB, Bouman MB, de Boer NK, Buncamper ME, van Bodegraven AA, et al. Long-term follow-up of transgender women after secondary intestinal vaginoplasty. J Sex Med. 2016;13:702&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26928775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chlebicki MP, Safdar N, O&#x2019;Horo JC, Maki DG. Preoperative chlorhexidine shower or bath for prevention of surgical site infection: a meta-analysis. Am J Infect Control. 2013;41:167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722008</ArticleId></ArticleIdList></Reference><Reference><Citation>Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992;326:281&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1728731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawn MT, Richman JS, Vick CC, Deierhoi RJ, Graham LA, et al. Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg. 2013;148:649&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">23552769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Balen A, Eid JF, Yang C, et al. The malleable implant salvage technique: infection outcomes after Mulcahy salvage procedure and replacement of infected inflatable penile prosthesis with malleable prosthesis. J Urol. 2016;195:694&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26343986</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD. The Henry Mummy Wrap&#x2122; and the Henry Finger Sweep&#x2122; surgical techniques. J Sex Med. 2009;6:619&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19284470</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP. Risk factors for penile prosthetic infection. J Urol. 1996;156:402&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Nehra A. Dual implantation of penile and sphincter implants in the post-prostatectomy patient. Curr Urol Rep. 2007;8:477&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendirci M, Gupta S, Shaw K, Morey A, Jones L, et al. Synchronous prosthetic implantation through a transscrotal incision: an outcome analysis. J Urol. 2006;175:2218&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697843</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz BF, Gaunay GS, Barazani Y, Nelson CJ, Moreira DM, et al. Use of a preoperative checklist reduces risk of penile prosthesis infection. J Urol. 2014;192:130&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24384159</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. No-touch technique. J Sex Med. 2011;8:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, Salem EA. Coated implants and &#x201c;no touch&#x201d; surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46% Urology. 2012;79:1310&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner J, Norrie P, Melen K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev. 2011 doi: CD004122.</Citation><ArticleIdList><ArticleId IdType="pubmed">22071812</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober ED, Domes T, Fanipour M, Copp JE. Preoperative hair removal on the male genitalia: clippers vs razors. J Sex Med. 2013;10:589&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22908852</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Wall MJ, Jr, Itani KM, Otterson MF, Webb AL, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">20054046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, Lai HH, Brandes SB. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol. 2013;189:136&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, Wilson SK, Hellstrom WJ. Infection retardant coated inflatable penile prostheses decrease the incidence of infection: a systematic review and meta-analysis. J Urol. 2012;188:1855&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastuszak AW, Lentz AC, Farooq A, Jones L, Bella AJ. Technological improvements in three-piece inflatable penile prosthesis design over the past 40 years. J Sex Med. 2015;12(Suppl 7):415&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26565568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokeshwar SD, Bitran J, Madhusoodanan V, Kava B, Ramasamy R. A surgeon's guide to the various antibiotic dips available during penile prosthesis implantation. Curr Urol Rep. 2019;20:11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30701340</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK, Delk JR, 2nd, Carson CC, Wiygul J, et al. Revision washout decreases penile prosthesis infection in revision surgery: a multicenter study. J Urol. 2005;173:89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinds PR, Wilson SK, Sadeghi-Nejad H. Dilemmas of inflatable penile prosthesis revision surgery: what practices achieve the best outcomes and the lowest infection rates.(CME)? J Sex Med. 2012;9:2483&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosnitzer MS, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med. 2011;8:1521&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521487</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger LH, Politano AD, Sawyer RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg Infect (Larchmt) 2011;12:163&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702424</ArticleId><ArticleId IdType="pubmed">21767148</ArticleId></ArticleIdList></Reference><Reference><Citation>Finney RP. Coring fibrotic corpora for penile implants. Urology. 1984;24:73&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">6740852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopategui DM, Balise RR, Bouzoubaa LA, Wilson SK, Kava BR. The impact of immediate salvage surgery on corporeal length preservation in patients presenting with penile implant infections. J Urol. 2018;200:171&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29408215</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: immediate replacement of the infected penile prosthesis. J Urol. 1996;155:155&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. 2000;163:481&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, Alhammali E, Hakky TS, Carrion R. The &#x201c;carrion cast&#x201d;: an intracavernosal antimicrobial cast for the treatment of infected penile implant. J Sex Med. 2014;11:1355&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24905248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zargaroff S, Sharma V, Berhanu D, Pearl JA, Meeks JJ, et al. National trends in the treatment of penile prosthesis infections by explantation alone vs immediate salvage and reimplantation. J Sex Med. 2014;11:1078&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24628707</ArticleId></ArticleIdList></Reference><Reference><Citation>Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, et al. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259139</ArticleId><ArticleId IdType="pubmed">14617746</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11463434</ArticleId></ArticleIdList></Reference><Reference><Citation>Herati AS, Lo EM. Penile prosthesis biofilm formation and emerging therapies against them. Transl Androl Urol. 2018;7:960&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256047</ArticleId><ArticleId IdType="pubmed">30505734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawn LE, Henry GD, Tan GK, Wilson SK. Biofilm and infectious agents present at the time of penile prosthesis revision surgery: times are a changing. Sex Med Rev. 2017;5:236&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28242178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jani K, Smith C, Delk JR, 2nd, Carson CC, Donatucci CF, et al. Infection retardant coatings impact on bacterial presence in penile prosthesis surgery: a multicenter study. Urology. 2018;119:104&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29894775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31470689</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">91</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci7090091</ELocationID><Abstract><AbstractText>Contemporary treatment algorithms for erectile dysfunction (ED) involve the use of medical therapies such as phosphodiesterase type 5 (PDE5) inhibitors and intracavernosal injection therapy of vasoactive agents, as well as vacuum erection devices and penile prosthesis implants in medically refractory cases. However, the current therapeutic options only address the symptoms of ED and not the underlying pathogenesis that results in ED. Newer and novel ED therapies aspire to reverse ED conditions by preventing cavernosal fibrosis, promoting endothelial revascularization and modulating various neuro-hormonal pathways. Regenerative therapeutic strategies such as low-intensity shock wave, gene and cellular-based therapies, and penile transplants are designed to improve penile hemodynamics and revitalize the cavernosal smooth muscle to mitigate and/or reverse underlying ED. This state-of-art article evaluates current and emerging therapeutic options for ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AndroUrology Centre, Brisbane, QLD 4000, Australia. ericchg@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia. ericchg@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Macquarie University Hospital, Sydney, NSW 2109, Australia. ericchg@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">intracavernosal injection</Keyword><Keyword MajorTopicYN="N">low-intensity shock wave</Keyword><Keyword MajorTopicYN="N">microvascular stent</Keyword><Keyword MajorTopicYN="N">penile prosthesis implant</Keyword><Keyword MajorTopicYN="N">penile transplant</Keyword><Keyword MajorTopicYN="N">phosphodiesterase type 5</Keyword><Keyword MajorTopicYN="N">platelet rich plasma</Keyword><Keyword MajorTopicYN="N">stem cell</Keyword></KeywordList><CoiStatement>The author declares no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31470689</ArticleId><ArticleId IdType="pmc">PMC6780857</ArticleId><ArticleId IdType="doi">10.3390/medsci7090091</ArticleId><ArticleId IdType="pii">medsci7090091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lewis R.W., Fugl-Meyer K.S., Bosch R., Fugl-Meyer A.R., Laumann E.O., Lizza E., Martin-Morales A. Epidemiology/risk factors of sexual dysfunction. J. Sex Med. 2004;1:35&#x2013;39. doi: 10.1111/j.1743-6109.2004.10106.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2004.10106.x</ArticleId><ArticleId IdType="pubmed">16422981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A., Jackson G., Miner M., Billups K.L., Burnett A.L., Buvat J., Billups K.L., Burnett A.L., Buvat J., Carson C.C., et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin. Proc. Mayo Clin. 2012;7:766&#x2013;778. doi: 10.1016/j.mayocp.2012.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2012.06.015</ArticleId><ArticleId IdType="pmc">PMC3498391</ArticleId><ArticleId IdType="pubmed">22862865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K., Salonia A., Adaikan G., Buvat J., Carrier S., El-Meliegy A., McCullough A., Torres L.O., Khera M. Pharmacotherapy for erectile dysfunction: Recommendations from the fourth international consultation for sexual medicine (ICSM 2015) J. Sex Med. 2016;13:465&#x2013;488. doi: 10.1016/j.jsxm.2016.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.016</ArticleId><ArticleId IdType="pubmed">27045254</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Harrison L.I., Patel A., Smith R.P. The devil is in the details: An analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. Transl. Androl. Urol. 2016;5:181&#x2013;186. doi: 10.21037/tau.2016.03.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.03.01</ArticleId><ArticleId IdType="pmc">PMC4837309</ArticleId><ArticleId IdType="pubmed">27141444</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg D.R., Richardson M.T., Tijerina J.D., Bass M.B., Eisenberg M.L. The Quality of Systematic Reviews and Meta-Analyses in Erectile Dysfunction Treatment and Management Published in the Sexual Medicine Literature. J. Sex Med. 2019;16:394&#x2013;401. doi: 10.1016/j.jsxm.2019.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2019.01.009</ArticleId><ArticleId IdType="pubmed">30773501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Zhang R., Yang Z., Lee J., Liu Y., Tian J., Qin X., Ren Z., Ding H., Chen Q. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: A systematic review and network meta-analysis. Eur. Urol. 2013;63:902&#x2013;912. doi: 10.1016/j.eururo.2013.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2013.01.012</ArticleId><ArticleId IdType="pubmed">23395275</ArticleId></ArticleIdList></Reference><Reference><Citation>Limoncin E., Gravina G.L., Corona G., Maggi M., Ciocca G., Lenzi A., Jannini E.A. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: A systematic review of placebo-controlled randomized trials with trial sequential analysis. Andrology. 2017;5:863&#x2013;872. doi: 10.1111/andr.12403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12403</ArticleId><ArticleId IdType="pubmed">28787547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Qian S., Liu L., Pu C., Yuan H., Han P., Wei Q. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: A systematic review and meta-analysis. Urol Int. 2013;90:339&#x2013;341. doi: 10.1159/000343730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343730</ArticleId><ArticleId IdType="pubmed">23221333</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi M., Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst. Rev. 2007:CD002187. doi: 10.1002/14651858.CD002187.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002187.pub3</ArticleId><ArticleId IdType="pmc">PMC6718223</ArticleId><ArticleId IdType="pubmed">17253475</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X., Qiu S., Bao Y., Wang W., Yang L., Wei Q. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: A Bayesian network meta-analysis of randomized controlled trials. World J. Urol. 2019;37:1061&#x2013;1074. doi: 10.1007/s00345-018-2583-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-018-2583-1</ArticleId><ArticleId IdType="pubmed">30523399</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannini E.A., DeRogatis L.R., Chung E., Brock G.B. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J. Sex Med. 2012;9:26&#x2013;33. doi: 10.1111/j.1743-6109.2011.02611.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02611.x</ArticleId><ArticleId IdType="pubmed">22221307</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bachmann L.M., Kessler T.M. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. Eur. Urol. 2015;68:674&#x2013;680. doi: 10.1016/j.eururo.2015.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.03.031</ArticleId><ArticleId IdType="pubmed">25817916</ArticleId></ArticleIdList></Reference><Reference><Citation>Belew D., Klaassen Z., Lewis R.W. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: A review. Sex Med. Rev. 2015;3:11&#x2013;23. doi: 10.1002/smrj.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.35</ArticleId><ArticleId IdType="pubmed">27784568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie M.G. The anatomy of drug development: Invicorp, a product before its time. BJU Int. 2010;106:723&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">21050351</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett A.L., Nehra A., Breau R.H., Culkin D.J., Faraday M.M., Hakim L.S., Heidelbaugh J., Khera M., McVary K.T., Miner M.M. Erectile dysfunction: AUA guideline. J. Urol. 2018;200:633&#x2013;641. doi: 10.1016/j.juro.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sakka A.I. What is the current role of intracavernosal injection in management of erectile dysfunction. Int. J. Import Res. 2016;28:88&#x2013;95. doi: 10.1038/ijir.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2016.14</ArticleId><ArticleId IdType="pubmed">27076113</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa P., Potempa A.J. Intraurethral alprostadil for erectile dysfunction: A review of the literature. Drugs. 2012;72:2243&#x2013;2254. doi: 10.2165/11641380-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11641380-000000000-00000</ArticleId><ArticleId IdType="pubmed">23170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R., Agarwal A., Zaramo C.E., Ausmundson S., Mansour D., Zippe C.D. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int. J. Impot Res. 2005;17:86&#x2013;90. doi: 10.1038/sj.ijir.3901284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901284</ArticleId><ArticleId IdType="pubmed">15526008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney M., Pfister W., Mahoney M., Nelson M., Yeager J., Steidle C. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J. Sex Med. 2009;6:520&#x2013;534. doi: 10.1111/j.1743-6109.2008.01118.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01118.x</ArticleId><ArticleId IdType="pubmed">19138370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai T., Palumbo F., Liguori G., Mondaini N., Scroppo F.I., Di Trapani D., Cocci A., Zucchi A., Verze P., Salonia A. The intra-meatal application of alprostadil cream (Vitaros&#xae;) improves drug efficacy and patient&#x2019;s satisfaction: Results from a randomized, two-administration route, cross-over clinical trial. Int. J. Impot Res. 2019;31:119&#x2013;125. doi: 10.1038/s41443-018-0087-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0087-6</ArticleId><ArticleId IdType="pubmed">30323234</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott F.B., Bradley W.E., Timm G.W. Management of erectile impotence: Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;82. doi: 10.1016/0090-4295(73)90224-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Penile prosthesis implant: Scientific advances and technological innovations over the last four decades. Transl. Androl. Urol. 2017;6:37&#x2013;45. doi: 10.21037/tau.2016.12.06.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.12.06</ArticleId><ArticleId IdType="pmc">PMC5313299</ArticleId><ArticleId IdType="pubmed">28217449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Translating penile erectile hydraulics to clinical application in inflatable penile prosthesis implant. Curr. Sex. Health Rep. 2017;9:84&#x2013;89. doi: 10.1007/s11930-017-0107-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11930-017-0107-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastuszak A.W., Lentz A.C., Farooq A., Jones L., Bella A.J. Technological improvements in three-piece inflatable penile prosthesis design over the past 40 years. J. Sex Med. 2015;12:415&#x2013;421. doi: 10.1111/jsm.13004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13004</ArticleId><ArticleId IdType="pubmed">26565568</ArticleId></ArticleIdList></Reference><Reference><Citation>Michal V., Kramar R., Pospichal J. Femoro-pudendal bypass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull. Soc. Int. Chir. 1974;33:343&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">4434623</ArticleId></ArticleIdList></Reference><Reference><Citation>Virag R. Revascularization of the Penis. In: Bennett A.H., editor. Management of Male Impotence. Williams &amp; Wilkins; Baltimore, MD, USA: 1982. pp. 219&#x2013;233.</Citation></Reference><Reference><Citation>Trost L.W., Munarriz R., Wang R., Morey A., Levine L. External mechanical devices and vascular surgery for erectile dysfunction. J. Sex Med. 2016;13:1579&#x2013;1617. doi: 10.1016/j.jsxm.2016.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.09.008</ArticleId><ArticleId IdType="pubmed">27770853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasch J.P., Schmidt P.M., Nedvetsky P.I., Nedvetskaya T.Y., Arun Kumar H.S., Meurer S. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Investig. 2006;116:2552&#x2013;2561. doi: 10.1172/JCI28371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28371</ArticleId><ArticleId IdType="pmc">PMC1555649</ArticleId><ArticleId IdType="pubmed">16955146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasker G.F., Pankey E.A., Frink T.J., Zeitzer J.R., Walter K.A., Kadowitz P.J. The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am. J. Physiol. Heart Circ. Physiol. 2013;304:H1670&#x2013;H1679. doi: 10.1152/ajpheart.00062.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00062.2013</ArticleId><ArticleId IdType="pmc">PMC3680766</ArticleId><ArticleId IdType="pubmed">23585129</ArticleId></ArticleIdList></Reference><Reference><Citation>Estancial C.S., Rodrigues R.L., De Nucci G., Antunes E., M&#xf3;nica F.Z. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum. BJU Int. 2015;116:657&#x2013;664. doi: 10.1111/bju.13105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13105</ArticleId><ArticleId IdType="pubmed">25715977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E., Brock G.B. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr. Urol. Rep. 2011;12:432&#x2013;443. doi: 10.1007/s11934-011-0216-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11934-011-0216-y</ArticleId><ArticleId IdType="pubmed">21922167</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L., Burnett A.L. RhoA/Rho-kinase in erectile tissue: Mechanisms of disease and therapeutic insights. Clin. Sci. 2006;110:153&#x2013;165. doi: 10.1042/CS20050255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20050255</ArticleId><ArticleId IdType="pubmed">16411892</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K., Kim S.W., Rhu K.S., Paick J.S. Chronic administration of an oral Rho-kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J. Sex Med. 2006;3:996&#x2013;1003. doi: 10.1111/j.1743-6109.2006.00327.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00327.x</ArticleId><ArticleId IdType="pubmed">17100932</ArticleId></ArticleIdList></Reference><Reference><Citation>Guagnini F., Ferazzini M., Grazzo M., Blanco S., Croci T. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J. Transl. Med. 2012;10:59. doi: 10.1186/1479-5876-10-59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-10-59</ArticleId><ArticleId IdType="pmc">PMC3328245</ArticleId><ArticleId IdType="pubmed">22444253</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel H., Rai P., Rana V. Orally disintegrating systems: Innovations in formulation and technology. Recent Pat. Drug Deliv. Formul. 2008;2:258&#x2013;274. doi: 10.2174/187221108786241660.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187221108786241660</ArticleId><ArticleId IdType="pubmed">19075912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocci A., Capece M., Cito G., Russo G.I., Falcone M., Timpano M., Rizzo M., Della Camera P.A., Morselli S., Campi R. Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film. J. Sex Med. 2017;14:1606&#x2013;1611. doi: 10.1016/j.jsxm.2017.10.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.10.066</ArticleId><ArticleId IdType="pubmed">29153580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E., Brock G.B. A state of art review on vardenafil and erectile dysfunction. Expert Opin. Pharmother. 2011;12:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21548725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurakula M., Ahmed O.A., Fahmy U.A., Ahmed T.A. Solid lipid nanoparticles for transdermal delivery of avanafil: Optimization, formulation, in-vitro and ex-vivo studies. J. Liposome Res. 2016;26:288&#x2013;296. doi: 10.3109/08982104.2015.1117490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08982104.2015.1117490</ArticleId><ArticleId IdType="pubmed">26784833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala M., Diab R., Elaissari A., Fessi H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Int. J. Pharm. 2018;535:1&#x2013;17. doi: 10.1016/j.ijpharm.2017.10.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2017.10.046</ArticleId><ArticleId IdType="pubmed">29111097</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahmy U.A. Nanoethosomal transdermal delivery of vardenafil for treatment of erectile dysfunction: Optimization, characterization, and in vivo evaluation. Drug Des. Devel. Ther. 2015;9:6129&#x2013;6137. doi: 10.2147/DDDT.S94615.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S94615</ArticleId><ArticleId IdType="pmc">PMC4655965</ArticleId><ArticleId IdType="pubmed">26604700</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk&#xf3; S., Zsik&#xf3; S., De&#xe1;k G., G&#xe1;csi A., Kov&#xe1;cs A., Budai-Sz&#x171;cs M., Pajor L., Bajory Z., Cs&#xe1;nyi E. Papaverine hydrochloride containing nanostructured lyotropic liquid crystal formulation as a potential drug delivery system for the treatment of erectile dysfunction. Drug Des. Devel. Ther. 2018;12:2923&#x2013;2931. doi: 10.2147/DDDT.S168218.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S168218</ArticleId><ArticleId IdType="pmc">PMC6140742</ArticleId><ArticleId IdType="pubmed">30254422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Zhao Y., Wang M., Song W., Li B., Liu W., Jin X., Zhang H. Defocused low-energy shock wave activates adipose tissue-derived stem cells in vitro via multiple signaling pathways. Cytotherapy. 2016;18:1503&#x2013;1514. doi: 10.1016/j.jcyt.2016.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2016.08.009</ArticleId><ArticleId IdType="pubmed">27727017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K., Fukumoto Y., Shimokawa H. Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Tokohu J. Exp. Med. 2009;219:1&#x2013;9. doi: 10.1620/tjem.219.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.219.1</ArticleId><ArticleId IdType="pubmed">19713678</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavijo R.I., Kohn T.P., Kohn J.R., Ramasamy R. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: A systematic review and meta-analysis. J. Sex Med. 2017;14:27&#x2013;35. doi: 10.1016/j.jsxm.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.11.001</ArticleId><ArticleId IdType="pubmed">27986492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z., Lin G., Reed-Maldonado A., Wang C., Lee Y.C., Lue T.F. Low intensity extracorporeal shockwave therapy improves erectile dysfunction: A systematic review and meta-analysis. Eur. Urol. 2017;71:223&#x2013;233. doi: 10.1016/j.eururo.2016.05.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2016.05.050</ArticleId><ArticleId IdType="pubmed">27321373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E., Wang J. A state-of-art review of low intensity extracorporeal shock wave therapy and lithotripter machines for the treatment of erectile dysfunction. Expert. Rev. Med. Devices. 2017;14:929&#x2013;934. doi: 10.1080/17434440.2017.1403897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434440.2017.1403897</ArticleId><ArticleId IdType="pubmed">29119841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Stem-cell-based therapy in the file of urology: A review of stem cell basic science, clinical applications and future directions in the treatment of various sexual and urinary conditions. Expert. Opin. Biol. Ther. 2015;15:1623&#x2013;1632. doi: 10.1517/14712598.2015.1075504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2015.1075504</ArticleId><ArticleId IdType="pubmed">26243575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. Stem cell therapy in diabetic men with erectile dysfunction: A step closer to safe and effective regenerative technology. Ann. Transl. Med. 2019;7(Suppl. 1):S40. doi: 10.21037/atm.2019.02.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2019.02.28</ArticleId><ArticleId IdType="pmc">PMC6462616</ArticleId><ArticleId IdType="pubmed">31032319</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.S., Xin Z., Dai J., Huang Y.C., Lue T.F. Stem-cell based therapy for erectile dysfunction. Expert. Opin. Biol. Ther. 2013;13:1585&#x2013;1597. doi: 10.1517/14712598.2013.847085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2013.847085</ArticleId><ArticleId IdType="pubmed">24090162</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X., Sun C., Yu W., Lin H., Sun Z., Chen Y., Wang R., Dai Y. Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for treatment of diabetes-associated erectile dysfunction. J. Androl. 2012;33:37&#x2013;44. doi: 10.2164/jandrol.110.012666.</Citation><ArticleIdList><ArticleId IdType="doi">10.2164/jandrol.110.012666</ArticleId><ArticleId IdType="pubmed">21311050</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., He W., Qin G., Luo J., Xiao M. Transplantation KCNMA1 modified bone marrow mesenchymal stem cell therapy for diabetes mellitus-induced erectile dysfunction. Andrologica. 2013:479&#x2013;486. doi: 10.1111/and.12104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/and.12104</ArticleId><ArticleId IdType="pubmed">23646921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.J., Park S.H., Sung Y.C., Kim S.W. Effect of mesenchymal stem cells associated to matrixen on the erectile function in the rat model with bilateral cavernous nerve crushing injury. Int. Braz. J. Urol. 2012;38:833&#x2013;841. doi: 10.1590/1677-553820133806833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1677-553820133806833</ArticleId><ArticleId IdType="pubmed">23302404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiou R., Hamidou L., Birebent B., Bitari D., Lecorvoisier P., Contremoulins I., Khodari M., Rodriguez A.M., Augustin D., Roudot-Thoraval F. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study. Eur. Urol. 2016;69:988&#x2013;991. doi: 10.1016/j.eururo.2015.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.09.026</ArticleId><ArticleId IdType="pubmed">26439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Demour S., Jafar H., Adwan S., AlSharif A., Alhawari H., Alrabadi A., Zayed A., Jaradat A., Awidi A. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. Urol Int. 2018;101:358&#x2013;365. doi: 10.1159/000492120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492120</ArticleId><ArticleId IdType="pubmed">30173210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Yu Z., Zhang Y., Zang G.H., Zhuan L., Tang Z., Liu Y., Wang T., Wang S.G., Liu J.H. Preconditioning of adipose-derived stem cells by phosphodiesterase-5 inhibition enhances therapeutic efficacy against diabetes-induced erectile dysfunction. Andrology. 2019 doi: 10.1111/andr.12661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12661</ArticleId><ArticleId IdType="pubmed">31218843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.N., Wu C.C., Sheu M.T., Chen K.C., Ho H.O., Chiang H.S. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J. Tissue Eng. Regen. Med. 2016;10:E294&#x2013;E304. doi: 10.1002/term.1806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/term.1806</ArticleId><ArticleId IdType="pubmed">23950105</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sharkawy H., Kantarci A., Deady J., Hasturk H., Liu H., Alshahat M., Van Dyke T.E. Platelet rich plasma: Growth factors and pro- and anti-inflammatory properties. J. Periodontol. 2007;78:661&#x2013;669. doi: 10.1902/jop.2007.060302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1902/jop.2007.060302</ArticleId><ArticleId IdType="pubmed">17397313</ArticleId></ArticleIdList></Reference><Reference><Citation>Epifanova M.V., Chalyi M.E., Krasnov A.O. Investigation of mechanisms of action of growth factors of autologous factors platelet-rich plasma used to treat erectile dysfunction. Urologiia. 2017:46&#x2013;48. doi: 10.18565/urology.2017.4.46-48.</Citation><ArticleIdList><ArticleId IdType="doi">10.18565/urology.2017.4.46-48</ArticleId><ArticleId IdType="pubmed">28952692</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz E.L., Pearlman A.M., Terlecki R.P. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Invest. Clin. Urol. 2018;59:61&#x2013;65. doi: 10.4111/icu.2018.59.1.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/icu.2018.59.1.61</ArticleId><ArticleId IdType="pmc">PMC5754585</ArticleId><ArticleId IdType="pubmed">29333517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahla J., Cinque M.E., Piuzzi N.S., Mannava S., Geeslin A.G., Murray I.R., Dornan G.J., Muschler G.F., LaPrade R.F. A call for standardization in platelet-rich Plasma preparation protocols and composition reporting: A systematic review of the clinical orthopaedic literature. J. Bone Joint Surg Am. 2017;99:1769&#x2013;1779. doi: 10.2106/JBJS.16.01374.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.16.01374</ArticleId><ArticleId IdType="pubmed">29040132</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S., Roberts M., Chung E. Platelet-rich plasma and treatment of erectile dysfunction: Critical review of literature and global trends in platelet-rich plasma clinics. Sex Med. Rev. 2019;7:306&#x2013;312. doi: 10.1016/j.sxmr.2018.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.12.006</ArticleId><ArticleId IdType="pubmed">30833169</ArticleId></ArticleIdList></Reference><Reference><Citation>Protogerou V., Mihalopoulos E., Mallis P., Gontika I., Dimou Z., Liakouras C., Stavropoulos-Giokas C., Kostakopoulos N., Chrisofos M., Deliveliotis C. Administration of Adipose Derived Mesenchymal Stem Cells and Platelet Lysate in Erectile Dysfunction: A Single Center Pilot Study. Bioengineering. 2019;6:21. doi: 10.3390/bioengineering6010021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering6010021</ArticleId><ArticleId IdType="pmc">PMC6466012</ArticleId><ArticleId IdType="pubmed">30841525</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura N., Kato R., Chancellor M.B., Nelson J.B., Glorioso J.C. Gene therapy as future treatment of erectile dysfunction. Expert Opin. Biol. Ther. 2010;10:1305&#x2013;1314. doi: 10.1517/14712598.2010.510510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2010.510510</ArticleId><ArticleId IdType="pmc">PMC3064945</ArticleId><ArticleId IdType="pubmed">20662742</ArticleId></ArticleIdList></Reference><Reference><Citation>Melman A., Bar-Charma N., McCullough A., Davies K., Christ G. The first human trial of gene transder therapy for the treatment of erectile dysfunction: Preliminary results. Eur. Urol. 2005;48:314&#x2013;318. doi: 10.1016/j.eururo.2005.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2005.05.005</ArticleId><ArticleId IdType="pubmed">15964135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.H., Karimi H., Kao J., Link D., Javidan J., Yamasaki D.S., Dolan M., Laird J.R., Low R.I. Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv. 2010;76:882&#x2013;887. doi: 10.1002/ccd.22646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.22646</ArticleId><ArticleId IdType="pubmed">20928837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T.D., Lee W.J., Yang S.C., Lin P.C., Tai H.C., Liu S.P., Huang C.H., Chen W.J., Chen M.F., Hsieh J.T. Clinical and Imaging Outcomes up to 1 Year Following Balloon Angioplasty for Isolated Penile Artery Stenoses in Patients With Erectile Dysfunction: The PERFECT-2 Study. J. Endovac Ther. 2016;23:867&#x2013;877. doi: 10.1177/1526602816669337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1526602816669337</ArticleId><ArticleId IdType="pubmed">27629440</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.N., Atala A. Tissue engineering of the penis. Sci. World J. 2011;11:2567&#x2013;2578. doi: 10.1100/2011/323989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1100/2011/323989</ArticleId><ArticleId IdType="pmc">PMC3253692</ArticleId><ArticleId IdType="pubmed">22235188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Lu J., Zhang L. A preliminary report of penile transplantation. Eur. Urol. 2006;50:851&#x2013;853. doi: 10.1016/j.eururo.2006.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.07.026</ArticleId><ArticleId IdType="pubmed">16930814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Lu J., Zhang L. A preliminary report of penile transplantation: Part 2. Eur. Urol. 2006;50:1115&#x2013;1116. doi: 10.1016/j.eururo.2006.07.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.07.038</ArticleId><ArticleId IdType="pubmed">17106949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopko N.A., Tuffaha S., Lough D., Brandacher G., Lee W.P.A., Bivalacqua T.J., Redett R.J., Burnett A.L. Penile allotransplantation for complex genitourinary reconstruction. J. Urol. 2017;198:274&#x2013;280. doi: 10.1016/j.juro.2016.10.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.10.134</ArticleId><ArticleId IdType="pubmed">28286074</ArticleId></ArticleIdList></Reference><Reference><Citation>Szafran A.A., Redett R., Burnett A.L. Penile transplantation: The US experience and institutional program set-up. Transl. Androl. Urol. 2018;7:639&#x2013;645. doi: 10.21037/tau.2018.03.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2018.03.14</ArticleId><ArticleId IdType="pmc">PMC6127561</ArticleId><ArticleId IdType="pubmed">30211053</ArticleId></ArticleIdList></Reference><Reference><Citation>Modern Medicine Feature Articles Penile transplant: Procedure raises technical, ethical issues. Urology Times. 2016;44:8&#x2013;34.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31407332</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-1167</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Sexual function in people with epilepsy: Similarities and differences with the general population.</ArticleTitle><Pagination><StartPage>1984</StartPage><EndPage>1992</EndPage><MedlinePgn>1984-1992</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/epi.16311</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The potential impact of epilepsy on sexual function is important for patient welfare, but often neglected. This study explored the occurrences of different sexual problems in patients with both well-controlled and mostly refractory epilepsy, and compared these with equivalent information from the general population.</AbstractText><AbstractText Label="METHODS">Between 2015 and 2017, a total of 221 adult inpatients and outpatients, mostly with intractable epilepsy, at the National Centre for Epilepsy in Norway, and 78 outpatients with well-controlled epilepsy at Lillehammer hospital participated in a questionnaire survey on sexual function. Information on the individual patient's epilepsy was collected. The results were compared with equivalent data on sexual function from 1671 adult Norwegians in the general population.</AbstractText><AbstractText Label="RESULTS">Patients with epilepsy reported a significantly higher frequency of problems with orgasm, dyspareunia, erectile dysfunction, and feelings of sexual deviance. However, reduced sexual desire, premature ejaculation/climax, and vaginal dryness occurred at similar frequencies in the general population. After controlling for gender, we found no significant association between sexual problems and seizure control or use of enzyme-inducing antiepileptic drugs. In both genders, feelings of sexual deviance were associated with lower quality of life. Fewer patients with epilepsy were satisfied with their sex lives. The perception of sex as an important part of daily life was similar among women with epilepsy and women from the general population, whereas significantly fewer men with epilepsy than men in the general population reported that sex was an important part of their daily lives. Women with mostly refractory epilepsy reported asking for help with their sexual problems significantly more often than women in the other groups.</AbstractText><AbstractText Label="SIGNIFICANCE">Some sexual problems occur significantly more often in patients with epilepsy than in the general population and feelings of sexual deviancy occur more frequently. No epilepsy-related factors could be identified as specific predictors.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5562-0854</Identifier><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannessen Landmark</LastName><ForeName>Cecilie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programme for Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traeen</LastName><ForeName>Bente</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svendsen</LastName><ForeName>Torleiv</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8986-1020</Identifier><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farmen</LastName><ForeName>Anette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakken</LastName><ForeName>Karl O</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lossius</LastName><ForeName>Morten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuroscience, National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Faculty, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="N">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">comorbidity</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">sexual dysfunction</Keyword><Keyword MajorTopicYN="N">sexual problems</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31407332</ArticleId><ArticleId IdType="doi">10.1111/epi.16311</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gastaut H, Collomb H. Sexual behavior in psychomotor epileptics. Ann Med Psychol. 1954;112:657-96.</Citation></Reference><Reference><Citation>Kaufman KR, Wong S, Sivaraaman K, Anim C, Delatte D. Epilepsy and AED-induced decreased libido - The unasked psychosocial comorbidity. Epilepsy Behav. 2015;52:236-8.</Citation></Reference><Reference><Citation>Heiman JR. Sexual dysfunction: overview of prevalence, etiological factors, and treatments. J Sex Res. 2002;39:73-8.</Citation></Reference><Reference><Citation>Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-44.</Citation></Reference><Reference><Citation>Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112:970-8.</Citation></Reference><Reference><Citation>Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et&#xa0;al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39-57.</Citation></Reference><Reference><Citation>Jensen P, Jensen SB, Sorensen PS, Bjerre BD, Rizzi DA, S&#xf8;rensen AS, et&#xa0;al. Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. Arch Sex Behav. 1990;19:1-14.</Citation></Reference><Reference><Citation>Svalheim S, Tauboll E, Luef G, Lossius A, Rauchenzauner M, Sandvand F, et&#xa0;al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009;16:281-7.</Citation></Reference><Reference><Citation>Bergen D, Daugherty S, Eckenfels E. Reduction of sexual activities in females taking antiepileptic drugs. Psychopathology. 1992;25:1-4.</Citation></Reference><Reference><Citation>Karan V, Harsha S, Keshava BS, Pradeep R, Sathyanarayana Rao TS, Andrade C. Sexual dysfunction in women with epilepsy. Indian J Psychiatry. 2015;57:301-4.</Citation></Reference><Reference><Citation>Henning OJ, Nakken KO, Traeen B, Mowinckel P, Lossius M. Sexual problems in people with refractory epilepsy. Epilepsy Behav. 2016;61:174-9.</Citation></Reference><Reference><Citation>Morrell MJ, Flynn KL, Done S, Flaster E, Kalayjian L, Pack AM. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav. 2005;6:360-5.</Citation></Reference><Reference><Citation>Tao L, Zhang X, Duan Z, Wang Y, Liu J, Hou H. Sexual dysfunction and associated factors in Chinese Han women with epilepsy. Epilepsy Behav. 2018;85:150-6.</Citation></Reference><Reference><Citation>Calabro RS, Grisolaghi J, Quattrini F, Bramanti P, Magaudda A. Prevalence and clinical features of sexual dysfunction in male with epilepsy: the first southern Italy hospital-based study. Int J Neurosci. 2013;123:732-7.</Citation></Reference><Reference><Citation>Ogunjimi L, Yaria J, Makanjuola A, Ogunniyi A. Sexual dysfunction among Nigerian women with epilepsy. Epilepsy Behav. 2018;83:108-12.</Citation></Reference><Reference><Citation>Traeen B, Stigum H. Sexual problems in 18-67-year-old Norwegians. Scand J Public Health. 2010;38:445-56.</Citation></Reference><Reference><Citation>Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8:254-67.</Citation></Reference><Reference><Citation>Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006;5:399-405.</Citation></Reference><Reference><Citation>Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62:23-7.</Citation></Reference><Reference><Citation>Hosmer DW. Lemeshow S. USA: Applied logistic regression John Wiley &amp; sons New York; 2000: pp. 89-150.</Citation></Reference><Reference><Citation>Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW, et&#xa0;al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav. 2003;4:407-13.</Citation></Reference><Reference><Citation>Luef G, Madersbacher H. Sexual dysfunction in patients with epilepsy. Handb Clin Neurol. 2015;130:383-94.</Citation></Reference><Reference><Citation>Crawford P, Duncan S. Gender issues. Handb Clin Neurol. 2012;108:759-81.</Citation></Reference><Reference><Citation>Herzog AG, Drislane FW, Schomer DL, Pennell PB, Bromfield EB, Kelly KM, et&#xa0;al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology. 2005;65:1016-20.</Citation></Reference><Reference><Citation>Morrell MJ, Sperling MR, Stecker M, Dichter MA. Sexual dysfunction in partial epilepsy: a deficit in physiologic sexual arousal. Neurology. 1994;44:243-7.</Citation></Reference><Reference><Citation>Joyal CC, Black DN, Dassylva B. The neuropsychology and neurology of sexual deviance: a review and pilot study. Sex Abuse. 2007;19:155-73.</Citation></Reference><Reference><Citation>Miller BL, Cummings JL, McIntyre H, Ebers G, Grode M. Hypersexuality or altered sexual preference following brain injury. J Neurol Neurosurg Psychiatry. 1986;49:867-73.</Citation></Reference><Reference><Citation>Stein DJ, Hugo F, Oosthuizen P, Hawkridge SM, van Heerden B. Neuropsychiatry of hypersexuality. CNS Spectr. 2000;5:36-46.</Citation></Reference><Reference><Citation>Blumer D. Hypersexual episodes in temporal lobe epilepsy. Am J Psychiatry. 1970;126:1099-106.</Citation></Reference><Reference><Citation>Burns JM, Swerdlow RH. Right orbitofrontal tumor with pedophilia symptom and constructional apraxia sign. Arch Neurol. 2003;60:437-40.</Citation></Reference><Reference><Citation>Zelena V, Kuba R, Pohanka M, Soska V, Rektor I. Sexual functions in women with focal epilepsy. A Preliminary Study. Epileptic Disord. 2007;9(Suppl 1):S83-92.</Citation></Reference><Reference><Citation>Herzog AG, Drislane FW, Schomer DL, Levesque LA, Ives J, Blume HW, et&#xa0;al. Abnormal pulsatile secretion of luteinizing hormone in men with epilepsy: relationship to laterality and nature of paroxysmal discharges. Neurology. 1990;40:1557-61.</Citation></Reference><Reference><Citation>Harden CL. Sexual dysfunction in women with epilepsy. Seizure. 2008;17:131-5.</Citation></Reference><Reference><Citation>Brock G, Moreira ED Jr, Glasser DB. Gingell C; GSSAB Investigators&#x2019; Group. Sexual disorders and associated help-seeking behaviors in Canada. Can J Urol. 2006;13:2953-61.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31405769</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Association Between Post-Ejaculatory Refractory Time (PERT) and Premature Ejaculation (PE).</ArticleTitle><Pagination><StartPage>1364</StartPage><EndPage>1370</EndPage><MedlinePgn>1364-1370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2019.06.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(19)31275-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Patients with premature ejaculation (PE) often complain of difficulty in having second erection, which is not yet investigated using scientific methodology.</AbstractText><AbstractText Label="AIM">Evaluation of the association between post-ejaculation refractory time (PERT) with PE by comparing PERT in premature ejaculators with their age-matched control subjects.</AbstractText><AbstractText Label="METHODS">After ethical committee approval and written informed consent from the participants were obtained, men in a monogamous stable sexual relationship and reporting PE were recruited into the study. Sexually active, matched control subjects were recruited for comparison. Exclusion criteria were erectile dysfunction, diabetes mellitus, cardiovascular diseases, hypogonadism, psychiatric conditions, instrumentation of the genitourinary tract, genitourinary anomalies, and genitourinary infections. Both the premature ejaculators and their control subjects were evaluated with the PE diagnostic tool before initiation of the study. They were asked to record their IELT and PERT over 4 weeks. The statistical analysis was done to obtain descriptive statistics, namely, mean and SD, paired t-tests, and logistic regression analysis. P &lt; .001 was considered significant.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">There was a statistically significant association between prolonged PERT and PE in patients with PE compared with their age-matched control subjects.</AbstractText><AbstractText Label="RESULTS">102 premature ejaculators and an equal number of matched control subjects were evaluated from January 2016-December 2017. The average PERT in premature ejaculators and control subjects was 330 &#xb1;&#xa0;296.63 minutes and 105.64 &#xb1; 98.59 minutes, respectively (P &lt; .0001). Increasing age was associated with increasing PERT. PE was more common in patients when PERT exceeded a threshold of 590 minutes.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">Until now, the association between PE and PERT with matched-pair analysis was not reported. Our study addresses this association, which can add a new paradigm in the evaluation and management of PE.</AbstractText><AbstractText Label="STRENGTH &amp; LIMITATIONS">The association between PE and prolonged PERT using a statistically appropriate, adequately powered methodology is the strength of the study. The inability to address the causal association between prolonged PERT and PE because of the paucity of evidence at present is the limitation of the study. We believe that the results of this study could trigger further research into such an association, so the mystery of such an association can be unraveled.</AbstractText><AbstractText Label="CONCLUSIONS">The association between prolonged PERT and PE, as seen in our study, is a finding, that needs further research to establish a causal association. However, reporting such an association is necessary because it is contrary to the present understanding. Bhat GS, Shastry A. Association Between Post-Ejaculatory Refractory Time (PERT) and Premature Ejaculation (PE). J Sex Med 2019;16:1364-1370.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Gajanan S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Urology, Andrology and Sexual Medicine, TSS Shripad Hegde Kadave Institute of Medical Sciences, Sirsi, Uttara Kannada District, Karnataka State, India. Electronic address: gajubhatru@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shastry</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Andrology and Sexual Medicine, TSS Shripad Hegde Kadave Institute of Medical Sciences, Sirsi, Uttara Kannada District, Karnataka State, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008393" MajorTopicYN="N">Marriage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061686" MajorTopicYN="N">Premature Ejaculation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Post-Ejaculatory Refractory Time</Keyword><Keyword MajorTopicYN="N">Premature Ejaculation</Keyword><Keyword MajorTopicYN="N">Premature Ejaculation Diagnostic Tool</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31405769</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2019.06.016</ArticleId><ArticleId IdType="pii">S1743-6095(19)31275-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31395986</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Radical prostatectomy and simultaneous penile prosthesis implantation: a narrative review.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>280</EndPage><MedlinePgn>274-280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0176-1</ELocationID><Abstract><AbstractText>Radical prostatectomy (RP) represents one of the most commonly used first-line treatment modalities in men with localized prostate cancer (PCa). Despite efforts to preserve the neurovascular bundles with nerve sparing (NS) surgery, erectile dysfunction (ED) remains common after RP and this may significantly affect patients' quality of life (QoL). The aim of this paper is to evaluate the outcome of simultaneous placement of penile prosthesis and RP. The ideal candidates for simultaneous penile prosthesis implantation are those who report pre-existent refractory ED and patients in whom there is a high risk of extracapsular disease, such as any cT2c or cT3, and undergo non-nerve sparing RP. If the patient chooses to undergo PPI to treat his refractory ED it is clear that this procedure will be associated with higher patients' satisfaction rates, if carried out simultaneously with RP rather than at a later stage. A simultaneous procedure would avoid two admissions, reduce hospitalization time and guarantee a faster recovery of sexual function, preventing the otherwise unavoidable loss of penile length. Since the urologist does not need to preserve the neurovascular bundles, as the penile implant will take care of postoperative rigidity, RP can be performed more radically from an oncological point of view, thus reducing the risk of recurrence and metastasis, especially in patients with high risk of locally advanced disease. In conclusion, simultaneous PPI with RP provides early sexual rehabilitation, improving patients' quality of life, without compromising surgical outcomes. However, larger series will be necessary, to better identify the patients who are more likely to benefit from nerve sparing surgery and postoperative penile rehabilitation from those who would are more likely to develop refractory ED post RP and would therefore benefit from simultaneous implantation of a penile prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cocci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0138-6294</Identifier><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. cocci.andrea@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cito</LastName><ForeName>Gianmartin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7526-4025</Identifier><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Largan&#xe0;</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vignolini</LastName><ForeName>Graziano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minervini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Maida</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5237-0888</Identifier><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mondaini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Andrology Center, Villa Donatello Hospital, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Giorgio Ivan</ForeName><Initials>GI</Initials><Identifier Source="ORCID">0000-0003-4687-7353</Identifier><AffiliationInfo><Affiliation>Department of Urology, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31395986</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0176-1</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0176-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012. https://doi.org/10.1016/j.eururo.2012.02.054 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2012.02.054</ArticleId><ArticleId IdType="pubmed">22424666</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Van Der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent&#x2014;update 2013. Eur Urol 2014;65:124&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2013.09.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014. https://doi.org/10.1056/NEJMoa1311593 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1311593</ArticleId><ArticleId IdType="pubmed">24869729</ArticleId><ArticleId IdType="pmc">4118145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012. https://doi.org/10.1016/j.eururo.2012.05.046 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2012.05.046</ArticleId><ArticleId IdType="pubmed">23253772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, et al. Treatment decision-making for localized prostate cancer: What younger men choose and why. Prostate 2012;2:58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.21406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010. https://doi.org/10.1016/j.eururo.2010.02.020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2010.02.020</ArticleId><ArticleId IdType="pubmed">20945547</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012;62:273&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2012.04.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005;2:658&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00117.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang X, Liu T, He Q, Wang Y, Zhang X. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. PLoS ONE. 2014;9:e91327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091327</ArticleId></ArticleIdList></Reference><Reference><Citation>Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010. https://doi.org/10.1111/j.1743-6109.2009.01627.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01627.x</ArticleId><ArticleId IdType="pubmed">21040491</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12023</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Sprecher E, Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol. 2000;163:467&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67902-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008. https://doi.org/10.1016/j.eururo.2007.09.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2007.09.002</ArticleId><ArticleId IdType="pubmed">19058907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Mueller A, Moncada I, Carballido J, Mulhall JP. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med. 2011. https://doi.org/10.1111/j.1743-6109.2011.02281.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02281.x</ArticleId><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am. 2011;38:217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ucl.2011.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Casab&#xe9; AR, Sarotto N, Gutierrez C, Bechara AJ. Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models. Int J Impot Res. 2016;28:228&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2016.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, Lucarelli G, Palazzo S, Battaglia M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med. 2010;7:304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01499.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, Cartmill RA. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol. 2013;31:591&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisano F, Falcone M, Abbona A, Oderda M, Soria F, Peraldo F, et al. The importance of psychosexual counselling in the re-establishment of organic and erotic functions after penile prosthesis implantation. Int J Impot Res. 2015;27:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2015.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2013. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">23295957</ArticleId><ArticleId IdType="pmc">5114123</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoudary KP, Dewolf WC, Bruning CO, Morgentaler A. Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: Initial results in 50 patients. Urology. 1997;50:395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(97)00280-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Cai T, Sarti E, Polloni G, Gavazzi A, Conti D, et al. A case series of patients who underwent laparoscopic extraperitoneal radical prostatectomy with the simultaneous implant of a penile prosthesis: focus on penile length preservation. World J Mens Health. 2018;36:132&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.5534/wjmh.17043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Sarti E, Giubilei G, Gavazzi A, Costanzi A, Belba A, et al. Penile prosthesis surgery in out-patient setting: Effectiveness and costs in the &#x201c;spending review&#x201d; era. Arch Ital Di Urol e Androl. 2014;86:161&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2014.3.161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gompertz P, Harwood R, Ebrahim S, Dickinson E. Validating the SF-36. Brit Med J. 2009. https://doi.org/10.1136/bmj.305.6854.645-c .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.305.6854.645-c</ArticleId><ArticleId IdType="pubmed">19564192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol. 2005;174:1395&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000173939.86858.d6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceruti C, Sedigh O, Timpano M, Sibona M, Falcone M, Preto M, et al. Treatment of prostate cancer and sexual rehabilitation when a nerve-sparing procedure is not feasible: Placement of the reservoir for a three-component penile implant during robotic extra-aponeurotic radical prostatectomy. J Sex Med. 2016. https://doi.org/10.1016/j.jsxm.2016.03.179 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.03.179</ArticleId></ArticleIdList></Reference><Reference><Citation>H.W. K, J.Y. L, J.K. K, S.U. J, H.D. J. Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol. 2014. https://doi.org/10.4111/kju.2014.55.10.629 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/kju.2014.55.10.629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31372371</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2352-0779</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Urology practice</Title><ISOAbbreviation>Urol Pract</ISOAbbreviation></Journal><ArticleTitle>Commercial Insurance Coverage for Inflatable Penile Prosthesis at a Tertiary Care Center.</ArticleTitle><Pagination><StartPage>155</StartPage><EndPage>158</EndPage><MedlinePgn>155-158</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urpr.2018.07.002</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prosthesis has become an important treatment modality for men with erectile dysfunction that is refractory to medication. Despite high levels of patient satisfaction following inflatable penile prosthesis placement and inflatable penile prosthesis coverage by Medicare, coverage by commercial insurance providers is unknown. The purpose of this study was to determine the coverage of inflatable penile prosthesis by commercial insurance providers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following institutional review board approval all men with erectile dysfunction interested in obtaining inflatable penile prosthesis at our tertiary care center between January 2016 and December 2017 were evaluated. We reviewed billing records for CPT code 54405 during the study period to evaluate the insurance provider for all men who received an inflatable penile prosthesis. We also reviewed a manually maintained record of excluded or denied inflatable penile prosthesis claims for men who desired inflatable penile prosthesis but could not obtain it. Through medical record review we recorded the etiology of erectile dysfunction and the specific type of insurance policy for each man.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Medicare is the most common insurer for inflatable penile prosthesis, insuring 87 of 220 (39.5%) men seeking inflatable penile prosthesis between 2016 and 2017. Among the remaining 127 men seeking inflatable penile prosthesis with commercial insurance coverage 61 (48.0%) were unable to obtain the device due to exclusions in their coverage or denials. Among commercially insured men seeking inflatable penile prosthesis 77 (62.6%) and 37 (30.0%) had health maintenance organization and preferred provider organization plans, respectively. The most prevalent indications for inflatable penile prosthesis among the entire study population were radical prostatectomy (30.9%), organic erectile dysfunction (30.5%) and diabetes mellitus (20.9%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The largest insurer for inflatable penile prosthesis in the Miami region is Medicare. While some patients seeking inflatable penile prostheses can receive insurance coverage, a large percentage (48.0%) are not able to receive coverage despite having a medical necessity for the treatment of erectile dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masterson</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kava</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Ranjith</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urol Pract</MedlineTA><NlmUniqueID>101635343</NlmUniqueID><ISSNLinking>2352-0779</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">insurance</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31372371</ArticleId><ArticleId IdType="mid">NIHMS1043239</ArticleId><ArticleId IdType="pmc">PMC6675033</ArticleId><ArticleId IdType="doi">10.1016/j.urpr.2018.07.002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morales PA, Suarez JB, Delgado J et al.: Penile implant for erectile impotence. J Urol 1973; 109: 641.</Citation><ArticleIdList><ArticleId IdType="pubmed">4695104</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Camper SB and Burnett AL: Modern utilization of penile prosthesis surgery: a national claim registry analysis. Int J Impot Res 2014; 26: 167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24830674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefilli MV, Dubocq F, Rajpurkar A et al.: Assessment of psycho-sexual adjustment after insertion of inflatable penile prosthesis. Urology 1998; 52: 1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DJ, Najari BB, Davison WL et al.: Trends in the utilization of penile prostheses in the treatment of erectile dysfunction in the United States. J Sex Med 2015; 12: 1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">26096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez KM, Kohn TP, Davis AB et al.: Penile implants: a look into the future. Transl Androl Urol, suppl, 2017; 6: S860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715181</ArticleId><ArticleId IdType="pubmed">29238665</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B and Burnett AL: Evolution of penile prosthetic devices. Korean J Urol 2015; 56: 179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355428</ArticleId><ArticleId IdType="pubmed">25763121</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B, McAchran S, Paolone D et al.: Assessing the variability in insurance coverage transparency for male sexual health conditions in the United States. Urology 2017; 102: 126.</Citation><ArticleIdList><ArticleId IdType="pubmed">28024968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31294138</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2466-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Investigative and clinical urology</Title><ISOAbbreviation>Investig Clin Urol</ISOAbbreviation></Journal><ArticleTitle>Synergistic effects of extracorporeal shockwave therapy and modified Ojayeonjonghwan on erectile dysfunction in an animal model of diabetes.</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>294</EndPage><MedlinePgn>285-294</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4111/icu.2019.60.4.285</ELocationID><Abstract><AbstractText Label="PURPOSE">We investigated the synergy effect of extracorporeal shock wave therapy (ESWT) with modified Ojayeonjonghwan (Korean herbal formula, KH-204) in an animal model of diabetes mellitus (DM)-induced erectile dysfunction (ED).</AbstractText><AbstractText Label="MATERIALS AND METHODS">Eight-week-old male Sprague-Dawley rats were used in this study. DM was induced by an intraperitoneal injection of streptozotocin. DM rats were divided into 5 groups (n=10 per group): group 1, control; group 2, DM; group 3, DM+ESWT; group 4, DM+KH-204; and group 5, DM+ESWT+KH-204. In ESWT groups, rats were treated with ESWT at the penis 3 times a week for 2 weeks under anesthesia. The KH-204 groups were treated with a daily oral dose of KH-204 for 12 weeks. After all treatments, intracavernosal pressure (ICP) was measured, and the cavernous tissues were evaluated by Masson's trichrome, immunohistochemistry and western blot analysis.</AbstractText><AbstractText Label="RESULTS">ICP was evaluated as a measurement of erectile function. The DM+ESWT, DM+KH-204, and DM+ESWT+KH-204 groups showed significantly restored erectile function compared with the DM group (p&lt;0.05). Among these groups, the DM+ESWT+KH-204 group showed the highest ICP. Moreover, ESWT and KH-204 treatment restored smooth muscle contents and many parameters related to potency (vascular endothelial growth factor, neuronal nitric oxide synthase (NOS), endothelial [NOS] and platelet endothelial cell adhesion molecule-1) compared with the DM group (p&lt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS">We confirmed the potential efficacy of ESWT and KH-204 in the treatment of ED patients using an animal model. The combination treatment of KH-204 and ESWT is expected to have good potential clinical results in the future treatment of refractory ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyun Cheol</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Urology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Woong Jin</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic Integrative Medicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guan Qun</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Seung Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sae Woong</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Su Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyuk Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Sung-Hoo</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Youl</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Sung Yeoun</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>KEMIMEDI, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sae Woong</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-9127-9400</Identifier><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic Integrative Medicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Investig Clin Urol</MedlineTA><NlmUniqueID>101674989</NlmUniqueID><ISSNLinking>2466-0493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000615578">KH-204 herbal formula</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074059" MajorTopicYN="Y">Extracorporeal Shockwave Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="Y">Phytotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Animals</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Extracorporeal shockwave therapy</Keyword><Keyword MajorTopicYN="N">Herbal medicine</Keyword></KeywordList><CoiStatement>CONFLICTS OF INTEREST: The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31294138</ArticleId><ArticleId IdType="pmc">PMC6607077</ArticleId><ArticleId IdType="doi">10.4111/icu.2019.60.4.285</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Song WH, Park J, Yoo S, Oh S, Cho SY, Cho MC, et al. Changes in the prevalence and risk factors of erectile dysfunction during a decade: the Korean Internet Sexuality Survey (KISS), a 10-year-interval web-based survey. World J Mens Health. 2019;37:199&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6479078</ArticleId><ArticleId IdType="pubmed">30588782</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WB, 2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67:768&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">23869678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D, d'Anzeo G, Porst H, Buvat J, Henneges C, Rossi A, et al. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. BMC Urol. 2015;15:111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643510</ArticleId><ArticleId IdType="pubmed">26563171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazan-Molina H, Reznick AZ, Kaufman H, Aizenbud D. Periodontal cytokines profile under orthodontic force and extracorporeal shock wave stimuli in a rat model. J Periodontal Res. 2015;50:389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">25073624</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker M, Goetzenich A, Roehl AB, Huebel C, de la Fuente M, Dietz-Laursonn K, et al. Myocardial effects of local shock wave therapy in a Langendorff model. Ultrasonics. 2014;54:131&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23896623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi D, Kawakami K, Ito K, Ishii K, Tanno H, Imai Y, et al. Low-energy extracorporeal shock wave therapy enhances skin wound healing in diabetic mice: a critical role of endothelial nitric oxide synthase. Wound Repair Regen. 2012;20:887&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">23110611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D. Low-Intensity Extracorporeal Shock Waves Therapy (LI-ESWT) for the treatment of erectile dysfunction: where do we stand. Eur Urol. 2017;71:234&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">27402058</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451317</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial. BJU Int. 2015;115(Suppl 5):46&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">25828173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei H, Xin H, Guan R, Xu Y, Li H, Tian W, et al. Low-intensity pulsed ultrasound improves erectile function in streptozotocin-induced type I diabetic rats. Urology. 2015;86:1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">26383610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon SH, Shrestha KR, Kim RY, Jung AR, Park YH, Kwon O, et al. Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology. 2016;88:226.</Citation><ArticleIdList><ArticleId IdType="pubmed">26522972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HC, Jeon SH, Qun ZG, Kim KS, Choi SW, Bashraheel F, et al. Effects of next-generation low-energy extracorporeal shockwave therapy on erectile dysfunction in an animal model of diabetes. World J Mens Health. 2017;35:186&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5746490</ArticleId><ArticleId IdType="pubmed">29164834</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyton CC, Colaco MA, Kovell RC, Kim JH, Terlecki RP. Erectile dysfunction is predictive of endothelial dysfunction in a well visit population. J Urol. 2016;195:1045&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">26614890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N, Shen H, Liu H, Wang Y, Bai Y, Han P. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo. Cardiovasc Diabetol. 2016;15:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974767</ArticleId><ArticleId IdType="pubmed">27496150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae WJ, Ha US, Choi JB, Kim KS, Kim SJ, Cho HJ, et al. Protective effects of KH-204 in the bladder of androgen-deprived rats. World J Mens Health. 2015;33:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550599</ArticleId><ArticleId IdType="pubmed">26331123</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SW, Jeon SH, Kwon EB, Zhu GQ, Lee KW, Choi JB, et al. Effect of Korean herbal formula (modified Ojayeonjonghwan) on androgen receptor expression in an aging rat model of late onset hypogonadism. World J Mens Health. 2019;37:105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305862</ArticleId><ArticleId IdType="pubmed">30584994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Bae WJ, Kim SJ, Cho HJ, Yuk SM, Han DS, et al. The herbal formula KH-204 is protective against erectile dysfunction by minimizing oxidative stress and improving lipid profiles in a rat model of erectile dysfunction induced by hypercholesterolaemia. BMC Complement Altern Med. 2017;17:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324223</ArticleId><ArticleId IdType="pubmed">28235412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim IG, Piao S, Lee JY, Hong SH, Hwang TK, Kim SW, et al. Effect of an adipose-derived stem cell and nerve growth factor-incorporated hydrogel on recovery of erectile function in a rat model of cavernous nerve injury. Tissue Eng Part A. 2013;19:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530933</ArticleId><ArticleId IdType="pubmed">22834730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">27321373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol. 2016;195:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26694904</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422959</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;enz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25:2159&#x2013;2164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepek&#xf6;yl&#xfc; C, Wang FS, Kozaryn R, Albrecht-Schgoer K, Theurl M, Schaden W, et al. Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J Thorac Cardiovasc Surg. 2013;146:971&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395097</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013;10:738&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593747</ArticleId><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber RE, Vita JA, Ganz P, Wager CG, Araujo AB, Rosen RC, et al. Association of peripheral microvascular dysfunction and erectile dysfunction. J Urol. 2015;193:612&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">25196657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110:3055&#x2013;3061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15520304</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Matheu MP, Sun F, Wang L, Sanford MT, Ning H, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. J Sex Med. 2016;13:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26755082</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Tian W, Uwais Z, Li G, Li H, Guan R, et al. AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats. J Sex Med. 2014;11:1452&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">24766706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31243354</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>An outcomes analysis of penile prosthesis implantation following radical cystoprostatectomy and urinary diversion: a multicentric retrospective cohort study.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>132</EndPage><MedlinePgn>126-132</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0171-6</ELocationID><Abstract><AbstractText>There is limited scientific literature regarding the management outcomes for end-stage erectile dysfunction (ED) following radical cystoprostatectomy (RCP). This study aims to evaluate the surgical outcomes of penile prosthesis (PP) implantation. A retrospective analysis over 17 years (2004-2017) was performed from the clinical records of patients in four tertiary referral centres, whom previously had undergone RCP, followed by PP implantation for end-stage ED. Outcome measures include both intra and postoperative complications, operative duration, a 5-point Likert hematoma scale as well as length of hospital stay. Additionally, a matched-pair cohort analysis was performed, dividing patients in 2 groups according to the type of urinary diversion (neobladder versus ileal conduit/cutaneous ureterostomy). The median time elapsed between RCP and PP implantation was 38 months (IQR 20-56). The median follow-up was 18 months (IQR 12-156). A 3-piece inflatable PP was implanted in 43 patients (91.5%) whereas a semirigid device was implanted in the remainder. Reservoir position was extra-peritoneal (utilising a separate abdominal incision) in 24 patients (54.8%), while an ectopic high-submuscular placement was preferred in the remainder. PP infection and mechanical failure occurred in 1 (2.1%) and 3 cases (6.3%) respectively. The comparative analysis of surgical outcomes did not show any statistically significant difference between the two groups. Our evidence suggests that PP implantation in patients with refractory ED following RCP may represent a safe and effective procedure associated with a low incidence of complications. The main limitation of this study is represented by the non-randomised, retrospective nature as well as the lack of patients' functional outcomes and the limited follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Urology department, Cardarelli Hospital, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Urology department, University College of London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Urology department, Careggi Hospital, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillo</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Urology department, Parini Hospital, Aosta, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology department, Federico II Hospital, University of Naples, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceruti</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timpano</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedigh</LastName><ForeName>Omid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preto</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy. mirko.preto@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blecher</LastName><ForeName>Gideon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Urology department, University College of London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiancone</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Urology department, Cardarelli Hospital, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrino</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology department, Cardarelli Hospital, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolle</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gontero</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Urology Clinic - "Citt&#xe0; della Salute e della Scienza" - Molinette Hospital, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015653" MajorTopicYN="N">Cystectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014547" MajorTopicYN="N">Urinary Diversion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31243354</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0171-6</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0171-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31230939</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Anatomic and Functional Outcome Following Distal Shunt and Tunneling for Treatment &#x130;schemic Priapism: A Single-Center Experience.</ArticleTitle><Pagination><StartPage>1290</StartPage><EndPage>1296</EndPage><MedlinePgn>1290-1296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2019.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(19)31215-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Ischemic priapism (IP) is a urologic emergency that requires early intervention. The main aim of IP treatment is to relieve the cavernosal pressure and provide erectile function.</AbstractText><AbstractText Label="AIM">The aim of this study was to determine the correlation between preoperative risk factors (patient's age, duration of priapism, preoperative erectile function) and postoperative erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS">This retrospective study consisted of 25 patients diagnosed with refractory IP between 2009-2017. The diagnosis of IP was confirmed by medical history, physical examination, and cavernosal blood gas analysis. All of the patients underwent the T-shunt procedure &#xb1; tunneling after a failed initial intervention.</AbstractText><AbstractText Label="RESULTS">The mean age at the time of the IP diagnosis was 46.84 years (range 23-77). The average follow-up time of the study population was 40.4 months (range 3-114), and the median time from the occurrence of IP to surgery was 58 hours (range 24-240). In all cases, rapid resolution of the erection was achieved with the T-shunt &#xb1; tunneling procedure. In 1 patient, priapism recurred after 12 hours. Postoperative ED was reported by 16 (84.21%) patients, with degrees of mild, mild to moderate, and severe in 6, 1, and 9 of these cases, respectively. During the follow-up, the mean International Index of Erectile Function-5 (IIEF-5) score was 12.68 (range 5-23). Only 3 (15.78%) patients achieved successful sexual intercourse without any treatment. 6 (31.5%) patients required the aid of phosphodiesterase type 5 inhibitors, and 1 (5.26%) patient required the aid of a vacuum erection device. The 9 (47.36%) patients with severe ED failed to respond to medical treatment and were considered candidates for a penile implant. According to Kendall's tau-b correlation coefficient analysis, there was a positive correlation between the preoperative and postoperative IIEF-5 scores (P&#xa0;= .005), whereas the patient's age and duration of priapism were negatively correlated with the postoperative IIEF-5 score (P&#xa0;= .016 and P&#xa0;= .046, respectively).</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">Treatment options of IP should be discussed with patients in terms of both preoperative erectile function and the duration of priapism.</AbstractText><AbstractText Label="STRENGTHS &amp; LIMITATIONS">The small sample size and retrospective nature of this study were the main limitations.</AbstractText><AbstractText Label="CONCLUSIONS">Despite high success and low complication rates of T-shunt surgery, the rate of undisturbed erectile function is only 14.6%. The patient's age, the existence of preoperative ED, and the duration of priapism are associated with postoperative IIEF-5 scores. Orta&#xe7; M, &#xc7;evik G, Akdere H, et&#xa0;al. Anatomic and Functional Outcome Following Distal Shunt and Tunneling for Treatment &#x130;schemic Priapism: A Single-Center Experience. J Sex Med 2019;16:1290-1296.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orta&#xe7;</LastName><ForeName>Mazhar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;evik</LastName><ForeName>G&#xf6;khan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Trakya University, Medical Faculty, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdere</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urology, Trakya University, Medical Faculty, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erme&#xe7;</LastName><ForeName>Bahad&#x131;r</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kad&#x131;o&#x11f;lu</LastName><ForeName>Ate&#x15f;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: kadiogluates@ttmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Function</Keyword><Keyword MajorTopicYN="N">Ischemic Priapism</Keyword><Keyword MajorTopicYN="N">Risk Factors</Keyword><Keyword MajorTopicYN="N">T-Shunt Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31230939</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2019.05.011</ArticleId><ArticleId IdType="pii">S1743-6095(19)31215-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31139864</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1433-0563</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Der Urologe. Ausg. A</Title><ISOAbbreviation>Urologe A</ISOAbbreviation></Journal><ArticleTitle>[Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].</ArticleTitle><Pagination><StartPage>634</StartPage><EndPage>639</EndPage><MedlinePgn>634-639</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00120-019-0949-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sacral neuromodulation (SNM) has been used in the treatment of refractory overactive bladder syndrome, nonobstructive urinary retention and faecal incontinence for almost 40&#xa0;years now. It is not to be confused with the sacral anterior root stimulation which is exclusively used for bladder dysfunction due to spinal paraplegia.</AbstractText><AbstractText Label="MECHANISM OF ACTION" NlmCategory="RESULTS">The principles of SNM are yet to be fully understood. Nevertheless, there is proof of modulating the activity of several micturition-associated, afferent neurons in the spine, brainstem and cerebrum. Thus, premature detrusor contractions are suppressed, the desire to void is delayed and detrusor-sphincter coordination improves.</AbstractText><AbstractText Label="TECHNIQUES OF IMPLANTATION AND STIMULATION" NlmCategory="UNASSIGNED">Motor reactions are an important indicator of correct electrode placement. The implantation procedure consists of two stages with an initial trial phase to determine the best possible treatment response through an external generator before implanting the whole stimulating device. Yearly check-up examinations are recommended; wireless adjustments allow for long-lasting symptom reduction.</AbstractText><AbstractText Label="INDICATION AND OUTCOME" NlmCategory="UNASSIGNED">Success rates in the treatment of the refractory overactive bladder syndrome and the non-obstructive urinary retention lie above 70% and can still be perceived as sufficient after 5&#xa0;years of ongoing SNM therapy. There is also profound evidence of SNM being an effective option for patients with faecal incontinence or chronic obstipation.</AbstractText><AbstractText Label="CONTRAINDICATIONS AND RISKS" NlmCategory="UNASSIGNED">Children, pregnant women and patients in need of frequent MRI examinations are usually not eligible for SNM therapy. Infection of the implant, technical failure (including lead displacement and battery depletion) and pain in the implantation site are important adverse effects which might require surgical revision.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The indications for SNM in the German health care system can be expected to be expanded upon the chronic pelvic pain syndrome, erectile dysfunction and additional gastrointestinal conditions. Technical progress will continue to improve the risk-benefit ratio of SNM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girtner</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Urologie am Caritas Krankenhaus St.&#xa0;Josef, Universit&#xe4;t Regensburg, Landshuter Stra&#xdf;e&#xa0;65, 93053, Regensburg, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burger</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Urologie am Caritas Krankenhaus St.&#xa0;Josef, Universit&#xe4;t Regensburg, Landshuter Stra&#xdf;e&#xa0;65, 93053, Regensburg, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Urologie am Caritas Krankenhaus St.&#xa0;Josef, Universit&#xe4;t Regensburg, Landshuter Stra&#xdf;e&#xa0;65, 93053, Regensburg, Deutschland. rmayr@caritasstjosef.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Sakrale Neuromodulation bei unter- und &#xfc;beraktivem Detrusor &#x2013; quo vadis? : Prinzipien und Entwicklungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Urologe A</MedlineTA><NlmUniqueID>1304110</NlmUniqueID><ISSNLinking>0340-2592</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="N">Electric Stimulation Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005242" MajorTopicYN="N">Fecal Incontinence</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058542" MajorTopicYN="Y">Implantable Neurostimulators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008160" MajorTopicYN="N">Lumbosacral Plexus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017699" MajorTopicYN="N">Pelvic Pain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012447" MajorTopicYN="N">Sacrum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001743" MajorTopicYN="N">Urinary Bladder</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="Y">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053201" MajorTopicYN="Y">Urinary Bladder, Overactive</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077295" MajorTopicYN="N">Urinary Bladder, Underactive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016055" MajorTopicYN="N">Urinary Retention</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Detrusor activity</Keyword><Keyword MajorTopicYN="N">Electric stimulation therapy</Keyword><Keyword MajorTopicYN="N">Faecal incontinence</Keyword><Keyword MajorTopicYN="N">Overactive bladder</Keyword><Keyword MajorTopicYN="N">Urinary retention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31139864</ArticleId><ArticleId IdType="doi">10.1007/s00120-019-0949-7</ArticleId><ArticleId IdType="pii">10.1007/s00120-019-0949-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BJU Int. 2008 Feb;101(3):325-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18070199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Sep;5(9):2135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18637993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurourol Urodyn. 2011 Apr;30(4):547-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21488095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2011 Aug;186(2):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21683381</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2014 May;113(5):789-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24238278</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2015 Dec;116(6):945-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25407358</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2015 Aug 24;(8):CD004464</Citation><ArticleIdList><ArticleId IdType="pubmed">26299888</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurol Surg. 2015;29:192-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26394134</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurourol Urodyn. 2017 Feb;36(2):385-389</Citation><ArticleIdList><ArticleId IdType="pubmed">26633852</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Androl Urol. 2012 Mar;1(1):44-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26816686</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurourol Urodyn. 2017 Mar;36(3):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">27062384</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2016 Nov;97:13-19</Citation><ArticleIdList><ArticleId IdType="pubmed">27233933</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2017 Jan;99:14-22</Citation><ArticleIdList><ArticleId IdType="pubmed">27298200</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Devices (Auckl). 2017 Jun 01;10:109-122</Citation><ArticleIdList><ArticleId IdType="pubmed">28615976</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2018 Jan;199(1):229-236</Citation><ArticleIdList><ArticleId IdType="pubmed">28709886</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurourol Urodyn. 2018 Feb;37(S2):S9-S16</Citation><ArticleIdList><ArticleId IdType="pubmed">29315785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Urol. 2018 Feb 22;10(5):165-173</Citation><ArticleIdList><ArticleId IdType="pubmed">29623108</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Obstet Gynecol. 2018 Jul;219(1):78.e1-78.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">29630890</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Neurourol J. 2018 Dec;22(4):228-236</Citation><ArticleIdList><ArticleId IdType="pubmed">30599493</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2019 Jun;31(6):e13570</Citation><ArticleIdList><ArticleId IdType="pubmed">30793441</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 2019 Feb 26;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">30809700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31104902</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7732</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of vascular and interventional radiology : JVIR</Title><ISOAbbreviation>J Vasc Interv Radiol</ISOAbbreviation></Journal><ArticleTitle>Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies.</ArticleTitle><Pagination><StartPage>1251</StartPage><EndPage>1258.e2</EndPage><MedlinePgn>1251-1258.e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvir.2019.01.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1051-0443(19)30068-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To systematically review and perform a meta-analysis on the safety and efficacy of endovascular therapy in the treatment of&#xa0;the two most common etiologies of vasculogenic erectile dysfunction (ED): veno-occlusive dysfunction (VOD) and arterial insufficiency (AI).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">PubMed, Web of Science, ScienceDirect, and Scopus databases were searched for published English literature regarding endovascular ED treatments. Case series (n &#x2265; 3) were included. Multiple data points were obtained, including demographic data, etiology, diagnosis method, imaging studies, treatment approach, technical success, clinical success, complications, and follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixteen relevant articles were obtained and a total of 212 patients with VOD and 162 with AI were identified. The VOD cohort were treated either percutaneously (60.4%; n&#xa0;= 128) or after surgical exposure of the deep dorsal vein (33.5%, n&#xa0;= 71), or it was unspecified (6.1%; n&#xa0;= 13). The most common embolic used was n-butyl cyanoacrylate (51.9%; n&#xa0;= 109). Meta-analysis found an overall clinical success rate of 59.8% in VOD patients. Complications occurred in 5.2% of patients (n&#xa0;= 11), with 9 considered to be mild and 2 considered to be severe. The AI cohort contained 162 patients most commonly treated via stenting of the internal pudendal artery (40.1%; n&#xa0;= 65). Meta-analysis found an overall clinical success rate of 63.2% in AI patients. Complications occurred in 4.9% of patients (n&#xa0;= 8), with 4 considered to be mild and 4 considered to be severe.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Endovascular therapy for medically refractory ED is safe and may provide a treatment alternative to more invasive surgical management; however, conclusions are limited by the heterogeneity of clinical success definitions among the included studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 SIR. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doppalapudi</LastName><ForeName>Sai K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Focal Therapy and Interventional Urologic Oncology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers New Jersey Medical School, Newark, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wajswol</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Focal Therapy and Interventional Urologic Oncology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers New Jersey Medical School, Newark, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Pratik A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers New Jersey Medical School, Newark, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolber</LastName><ForeName>Marcin K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Interventional Radiology, Department of Radiology, UT Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Manu K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Vascular and Interventional Radiology, Department of Radiology, Santa Barbara Cottage Hospital, Santa Barbara, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers New Jersey Medical School, Newark, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischman</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastinehad</LastName><ForeName>Ardeshir R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Department of Radiology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022; Division of Focal Therapy and Interventional Urologic Oncology, Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 625 Madison Avenue, New York, NY 10022. Electronic address: art.rastinehad@mountsinai.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Interv Radiol</MedlineTA><NlmUniqueID>9203369</NlmUniqueID><ISSNLinking>1051-0443</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="Y">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016491" MajorTopicYN="N">Peripheral Vascular Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31104902</ArticleId><ArticleId IdType="doi">10.1016/j.jvir.2019.01.024</ArticleId><ArticleId IdType="pii">S1051-0443(19)30068-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31029440</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1698-0409</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Revista internacional de andrologia</Title><ISOAbbreviation>Rev Int Androl</ISOAbbreviation></Journal><ArticleTitle>[Adjuvant surgical maneuvers in penile prostheses implant to improve their aesthetic and functional outcomes].</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>77</EndPage><MedlinePgn>68-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.androl.2017.12.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1698-031X(18)30015-3</ELocationID><Abstract><AbstractText>Penile prosthetic surgery is the definitive treatment for those patients with erectile dysfunction refractory to medical treatment. Although it associates satisfaction rates&gt;90%, it is known that men with Peyronie's disease, body mass index&gt;30kg/m<sup>2</sup> or those previously operated on radical prostatectomy have lower satisfaction rates than the general population. The main reasons for dissatisfaction are the subjective loss of penile length and glans' flaccidity. Given such circumstance, several adjuvant surgical techniques have been described to improve aesthetic and functional outcomes after the implant. In our review, we wanted to investigate the different maneuvers used in patients with Peyronie's disease, those used to avoid the reduction of penile length and those used to avoid the floppy glans syndrome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Asociaci&#xf3;n Espa&#xf1;ola de Androlog&#xed;a, Medicina Sexual y Reproductiva. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreiro</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a, Servicio de Urolog&#xed;a, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Espa&#xf1;a. Electronic address: cristina.ferreiro.pareja@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torremad&#xe9;</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a, Servicio de Urolog&#xed;a, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujol</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a, Servicio de Urolog&#xed;a, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vigu&#xe9;s</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unidad de Androlog&#xed;a, Servicio de Urolog&#xed;a, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Maniobras quir&#xfa;rgicas adyuvantes en el implante de pr&#xf3;tesis de pene para mejorar su resultado est&#xe9;tico y funcional.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Int Androl</MedlineTA><NlmUniqueID>101500934</NlmUniqueID><ISSNLinking>1698-031X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004954" MajorTopicYN="N">Esthetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complicaciones</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Pr&#xf3;tesis de pene</Keyword><Keyword MajorTopicYN="N">Satisfacci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Satisfaction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31029440</ArticleId><ArticleId IdType="doi">10.1016/j.androl.2017.12.001</ArticleId><ArticleId IdType="pii">S1698-031X(18)30015-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30926460</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Shockwave Therapy in the Treatment of Peyronie's Disease.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>507</EndPage><MedlinePgn>499-507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2019.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(19)30007-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Peyronie's disease is an acquired condition of the connective tissue of the penis that affects 0.5-20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, painful erections, and sexual dysfunction. Several treatment modalities have been proposed, with studies from the past decade investigating extracorporeal shockwave therapy's (ESWT) potential efficacy in Peyronie's management.</AbstractText><AbstractText Label="AIMS">To investigate the effects of ESWT on Peyronie's disease parameters such as penile curvature, plaque size, erectile function, and penile pain.</AbstractText><AbstractText Label="METHODS">We reviewed the literature examining the effects of ESWT on Peyronie's disease.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The main outcome measures after receiving extracoporeal shockwave therapy included changes in degree of penile curvature, penile plaque size, International Index of Erectile Function-5 questionnaire score, and visual analogue scale score.</AbstractText><AbstractText Label="RESULTS">Randomized controlled trials examining the efficacy of ESWT in Peyronie's disease do not show a statistically significant benefit in curvature reduction, plaque size, or erectile function, although a recent meta-analysis demonstrates a benefit in plaque size reduction. A statistically significant reduction in penile pain has been observed across multiple studies.</AbstractText><AbstractText Label="CONCLUSION">Extracorporeal shockwave therapy may be beneficial in the management of Peyronie's disease for refractory penile pain and plaque size reduction. However, penile pain typically resolves spontaneously over time, and shockwave therapy can pose a substantial financial burden to patients. A multi-institutional randomized controlled trial with standardization of methods and strict inclusion criteria regarding disease duration would prove beneficial in determining the true efficacy of shockwave therapy in Peyronie's disease. Krieger JR, Rizk PJ, Kohn TP, et&#xa0;al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev 2019;7:499-507.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizk</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohn</LastName><ForeName>Taylor P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastuszak</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: alexander.pastuszak@hsc.utah.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000074059" MajorTopicYN="N">Extracorporeal Shockwave Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019220" MajorTopicYN="N">High-Energy Shock Waves</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Curvature</Keyword><Keyword MajorTopicYN="N">Penile Pain</Keyword><Keyword MajorTopicYN="N">Peyronie&#x2019;s Disease</Keyword><Keyword MajorTopicYN="N">Plaque</Keyword><Keyword MajorTopicYN="N">Shockwave Therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30926460</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2019.02.001</ArticleId><ArticleId IdType="pii">S2050-0521(19)30007-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30910509</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2050-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Sexual medicine</Title><ISOAbbreviation>Sex Med</ISOAbbreviation></Journal><ArticleTitle>Extracellular Vesicles From Human Urine-Derived Stem Cells Ameliorate Erectile Dysfunction in a Diabetic Rat Model by Delivering Proangiogenic MicroRNA.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>250</EndPage><MedlinePgn>241-250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.esxm.2019.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-1161(19)30027-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Stem cell therapies represent a promising new frontier for the treatment of refractory diabetic erectile dysfunction (DED). The use of stem cell-derived extracellular vesicles (EVs) is a novel strategy for cell-free stem cell therapy. We have reported that urine-derived stem cells (USCs) can improve DED; however, the therapeutic effects of EVs secreted by USCs (USC-EVs) remain unknown.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine the therapeutic effects of USC-EVs on DED in a rat model.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">USC-EVs were isolated from conditioned medium by ultracentrifugation. DED was induced in male Sprague-Dawley rats via an intraperitoneal injection of streptozotocin. Sixteen DED rats were divided into phosphate-buffered saline (PBS) and USC-EV groups. Eight normal rats served as the normal control group. PBS or USC-EVs were transplanted into the corpora cavernosa in the corresponding groups.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Intracavernosal pressure (ICP), mean arterial pressure (MAP), expression of endothelial markers (CD31), endothelial nitric oxide synthase (eNOS), phospho-eNOS, and neural nitric oxide synthase (nNOS) were assessed in each group. Masson's trichrome staining was used to determine the collagen deposition and ratio of smooth muscle cells to collagen. The microRNA (miRNA) cargo of USC-EVs was characterized by high-throughput RNA sequencing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recovery of erectile function was observed in the USC-EV group, as represented by improved ICP and ICP/MAP ratio. CD31, eNOS, phospho-eNOS, and nNOS expression in the penis was significantly improved in the USC-EV group. In addition, the ratio of smooth muscle to collagen was significantly increased in the USC-EV group. RNA sequencing revealed that USC-EVs were enriched for distinct classes of miRNA (miR-21-5p, let-7 family, miR-10 family, miR-30 family, and miR-148a-3p) that promote angiogenesis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">USC-EV transplantation can ameliorate DED in rats. Its mechanism may involve the delivery of proangiogenic miRNA. Ouyang B, Xie Y, Zhang C, et&#xa0;al. Extracellular Vesicles From Human Urine-Derived Stem Cells Ameliorate Erectile Dysfunction in a Diabetic Rat Model by Delivering Proangiogenic MicroRNA. Sex Med 2019;7:241-250.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Andrology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China; Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Andrology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Andrology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Cuncan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Research Center, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Linyan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Research Center, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Andrology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Andrology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China; Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guihua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Research Center, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Junhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Andrology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China; Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. Electronic address: drdjh@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Andrology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sex Med</MedlineTA><NlmUniqueID>101631053</NlmUniqueID><ISSNLinking>2050-1161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Endothelial Dysfunction</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Extracellular Vesicles</Keyword><Keyword MajorTopicYN="N">Sexual Dysfunction</Keyword><Keyword MajorTopicYN="N">Stem Cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30910509</ArticleId><ArticleId IdType="pmc">PMC6522949</ArticleId><ArticleId IdType="doi">10.1016/j.esxm.2019.02.001</ArticleId><ArticleId IdType="pii">S2050-1161(19)30027-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giugliano F., Maiorino M., Bellastella G. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res. 2010;22:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">20147958</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorve V.S., Kshirsagar A.D., Vyawahare N.S. Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management. J&#xa0;Diabetes Complicat. 2011;25:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">20462773</ArticleId></ArticleIdList></Reference><Reference><Citation>Castela A., Costa C. Molecular mechanisms associated with diabetic endothelial-erectile dysfunction. Nat Rev Urol. 2016;13:266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">26878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman R.R., Paul S.K., Bethel M.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N&#xa0;Engl J Med. 2008;359:1577&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriello A. The emerging challenge in diabetes: The &#x201c;metabolic memory&#x201d;. Vasc Pharmacol. 2012;57:133&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakalopoulos I., Memmos D., Mykoniatis I. Stem cell therapy in erectile dysfunction: Science fiction or realistic treatment option? Hormones. 2018;17:315&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">30132303</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwaal A., Zaid U.B., Lin C. Stem cell treatment of erectile dysfunction. Adv Drug Deliver Rev. 2015;82-83:137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446142</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Demour S., Jafar H., Adwan S. Safety and potential therapeutic effect of two intracavernous autologous bone marrow&#x2013;derived mesenchymal stem cell injections in diabetic patients with erectile dysfunction: An open-label phase I clinical trial. Urol Int. 2018;101:358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">30173210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Luo L., Feng L. B&#xa0;cell lymphoma-2&#x2013;modified bone marrow&#x2013;derived mesenchymal stem cell transplantation for the treatment of diabetes mellitus&#x2013;induced erectile dysfunction in a rat model. Urol Int. 2017;98:358&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">27894122</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Li H., Ruan Y. Stem cell therapy for diabetic erectile dysfunction in rats: A meta-analysis. PloS One. 2016;11:e154341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844188</ArticleId><ArticleId IdType="pubmed">27111659</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Sun X., Bian J. Correction of diabetic erectile dysfunction with adipose-derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PloS One. 2013;8:e72790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758339</ArticleId><ArticleId IdType="pubmed">24023647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Yang Q., Zheng T. Neurotrophic effect of adipose tissue-derived stem cells on erectile function recovery by pigment epithelium&#x2013;derived factor secretion in a rat model of cavernous nerve injury. Stem Cells Int. 2016;2016:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691496</ArticleId><ArticleId IdType="pubmed">26783403</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., McNeill E., Tian H. Urine-derived cells are a potential source for urological tissue reconstruction. J&#xa0;Urol. 2008;180:2226&#x2013;2233.</Citation><ArticleIdList><ArticleId IdType="pubmed">18804817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang B., Sun X., Han D. Human urine-derived stem cells alone or genetically modified with FGF2 improve type 2 diabetic erectile dysfunction in a rat model. PloS One. 2014;9:e92825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963968</ArticleId><ArticleId IdType="pubmed">24663037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Chen X., Zheng T. Transplantation of human urine-derived stem cells transfected with pigment epithelium&#x2013;derived factor to protect erectile function in a rat model of cavernous nerve injury. Cell Transplant. 2016;25:1987&#x2013;2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">27075964</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the in&#xa0;vivo identity of mesenchymal stem cells. Stem Cells. 2008;26:2287&#x2013;2299.</Citation><ArticleIdList><ArticleId IdType="pubmed">18566331</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C., Sun X., Liu L. Exosomes and their therapeutic potentials of stem cells. Stem Cells Int. 2016;2016:1&#x2013;11.</Citation></Reference><Reference><Citation>Ouyang X., Han X., Chen Z. MSC-derived exosomes ameliorate erectile dysfunction by alleviation of corpus cavernosum smooth muscle apoptosis in a rat model of cavernous nerve injury. Stem Cell Res Ther. 2018;9:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158845</ArticleId><ArticleId IdType="pubmed">30257719</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Lei H., Xu Y. Exosomes derived from mesenchymal stem cells exert therapeutic effect in a rat model of cavernous nerves injury. Andrology. 2018;6:927&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">30009463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Zhang H., Wang Z. Adipose-derived stem cell&#x2013;derived exosomes ameliorate erectile dysfunction in a rat model of type 2 diabetes. J&#xa0;Sex Med. 2017;14:1084&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">28781215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L.L., Huang X., Yu W. Transplantation of adipose tissue&#x2013;derived stem cell&#x2013;derived exosomes ameliorates erectile function in diabetic rats. Andrologia. 2018;50:e12871.</Citation><ArticleIdList><ArticleId IdType="pubmed">29057541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z., Liu Y., Niu X. Exosomes secreted by human urine&#x2013;derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res Ther. 2016;7:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744390</ArticleId><ArticleId IdType="pubmed">26852014</ArticleId></ArticleIdList></Reference><Reference><Citation>Prattichizzo F., Giuliani A., De Nigris V. Extracellular microRNAs and endothelial hyperglycaemic memory: A therapeutic opportunity? Diabetes Obes Metab. 2016;18:855&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094499</ArticleId><ArticleId IdType="pubmed">27161301</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D.C., Bayik D., Srivatsan A. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials. 2016;105:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156278</ArticleId><ArticleId IdType="pubmed">27522254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J., Zheng J., Cai J. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response. FASEB J. 2018:201800131R.</Citation><ArticleIdList><ArticleId IdType="pubmed">30226809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Ma L., Gong M. Protein profiling and sizing of extracellular vesicles from colorectal cancer patients via flow cytometry. ACS Nano. 2018;12:671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">29300458</ArticleId></ArticleIdList></Reference><Reference><Citation>Musicki B., Burnett A.L. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res. 2007;19:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16775612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukreja R.C., Xi L. eNOS phosphorylation: A pivotal molecular switch in vasodilation and cardioprotection? J&#xa0;Mol Cell Cardiol. 2007;42:280&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031790</ArticleId><ArticleId IdType="pubmed">17174975</ArticleId></ArticleIdList></Reference><Reference><Citation>Witwer K.W., Buz&#xe1;s E.I., Bemis L.T. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J&#xa0;Extracell Vesicles. 2013;2:20360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760646</ArticleId><ArticleId IdType="pubmed">24009894</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo K.W., Li N., Makani V. Large-scale preparation of extracellular vesicles enriched with specific microRNA. Tissue Eng Part C Methods. 2018;24:637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916128</ArticleId><ArticleId IdType="pubmed">30306827</ArticleId></ArticleIdList></Reference><Reference><Citation>Eulalio A., Huntzinger E., Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C., Yen M., Liao S. Dual role of MiR-21-mediated signaling in HUVECs and rat surgical flap under normoxia and hypoxia condition. Int J Mol Sci. 2017;18:1917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618566</ArticleId><ArticleId IdType="pubmed">28880208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S., Yu W., Qu X. Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. J&#xa0;Hematol Oncol. 2014;7:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108130</ArticleId><ArticleId IdType="pubmed">24886719</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka M., Zheng M., Hayashi M. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J&#xa0;Clin Invest. 2008;118:1944&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289794</ArticleId><ArticleId IdType="pubmed">18398510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Ling C.C., Li L. MicroRNA-10a/10b represses a novel target gene mib1 to regulate angiogenesis. Cardiovasc Res. 2016;110:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">26825552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridge G., Monteiro R., Henderson S. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood. 2012;120:5063&#x2013;5072.</Citation><ArticleIdList><ArticleId IdType="pubmed">23086751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge H., Shrestha A., Liu C. MicroRNA 148a-3p promotes Thrombospondin-4 expression and enhances angiogenesis during tendinopathy development by inhibiting Kruppel-like factor 6. Biochem Biophys Res Commun. 2018;502:276&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">29807011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30898595</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data?</ArticleTitle><Pagination><StartPage>530</StartPage><EndPage>534</EndPage><MedlinePgn>530-534</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2018.10.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(19)30002-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Ischemic priapism (IP) is the most common form of priapism. In cases of priapism persisting for &gt;36 hours, conservative management usually fails, and the patients' erectile tissue will be inevitably compromised, resulting in corporal fibrosis, shortening of the penis, and refractory erectile dysfunction. In this subset of patients, early implantation of a penile prosthesis (PP) could be a solution for both the priapic episode and the erectile dysfunction.</AbstractText><AbstractText Label="AIM">To analyze the current literature with regard to the correlation between refractory ischemic priapism and immediate implantation of PP.</AbstractText><AbstractText Label="METHODS">An extensive literature research was conducted to retrieve studies focusing on immediate PP implantation in patients suffering from refractory ischemic priapism (RIP).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">We evaluated the functional outcomes of patients who have undergone the immediate insertion of a PP as treatment for an acute episode of IP refractory to medical therapy or shunt surgery.</AbstractText><AbstractText Label="RESULTS">Nine studies were included in this systematic review, including 3 case reports and 6 retrospective analyses. All studies agreed that in patients with RIP, early insertion of a PP is a safe and effective procedure, and all studies but 1 preferred malleable implants to inflatable implants.</AbstractText><AbstractText Label="CONCLUSION">The systematic review does not demonstrate superiority of immediatePP implantation over delayed PP implantation, because none of the studies was designed with this purpose. However, considering the reduced complication rate and the ease of the procedure, all studies are in favor of early implantation over delayed implantation. Capece M, La Rocca R, Mirone V, et al. A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data? Sex Med Rev 2018;7:530-534.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Naples Federico II, Naples, Italy. Electronic address: drmarcocapece@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Rocca</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirone</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bivalacqua</LastName><ForeName>Trinity J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castiglione</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albersen</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Andrology Department, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Early Implantation</Keyword><Keyword MajorTopicYN="N">Immediate Implant</Keyword><Keyword MajorTopicYN="N">Low-Flow Priapism</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword><Keyword MajorTopicYN="N">Refractory Ischemic Priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30898595</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2018.10.007</ArticleId><ArticleId IdType="pii">S2050-0521(19)30002-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30898593</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Management of Priapism: A Contemporary Review.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>139</EndPage><MedlinePgn>131-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2019.01.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(19)30004-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Current management of ischemic priapism revolves around 3 principles: resolving the acute event, preserving erectile function, and reducing the risk of future recurrences. Although more conservative management options, such as aspiration, irrigation, and surgical shunts, are effective in many patients, those who are refractory to these interventions or have prolonged priapism may benefit from placement of a penile prosthesis (PP).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To provide a comprehensive overview of priapism management, highlight the current literature on the utility of penile implants for refractory priapism, and provide insight from a high-volume center on surgical decision making and technique.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A complete review of the current guidelines and associated literature was performed. Associated algorithms were evaluated, and our experience was overlaid on the data present in the literature.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The current management algorithm for priapism was evaluated. Subsequently, the data on acute and delayed PP placement were assessed. Rates of postoperative infection, erectile dysfunction, and patient satisfaction were also examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, both delayed and early PP implants are associated with higher rates of failure than routine PP implants. In patients with refractory or prolonged priapism, early implantation may be technically easier, with decreased loss of penile length and associated complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients should be evaluated on an individual basis and counseled on the risks and benefits of PP&#xa0;implantation in early and delayed time frames. Although there is no definitive evidence at this time regarding the ideal device or timing of implantation, there are well-established pros and cons of malleable vs inflatable prostheses and of acute vs delayed implantation. Mishra K, Loeb A, Bukavina L, et&#xa0;al. Management of Priapism: A Contemporary Review. Sex Med Rev 2020;8:131-139.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Kirtishri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeb</LastName><ForeName>Aram</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address: Aram.Loeb@UHhospitals.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukavina</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgarten</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beilan</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiGiorgio</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Liying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrion</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Implant</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30898593</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2019.01.001</ArticleId><ArticleId IdType="pii">S2050-0521(19)30004-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30898042</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-2422</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert review of medical devices</Title><ISOAbbreviation>Expert Rev Med Devices</ISOAbbreviation></Journal><ArticleTitle>An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>286</EndPage><MedlinePgn>281-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17434440.2019.1598259</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Penile prosthesis placement is the gold standard for the treatment of erectile dysfunction (ED) refractory to medical therapy; however, limited data exist on the long-term outcomes of these devices.</AbstractText><AbstractText Label="AREAS COVERED">A PubMed search focused on long-term outcomes of penile prosthetics was performed. Studies with a follow-up of less than 5 years were excluded. Included studies were arranged chronologically by implant date to identify trends in device lifetime. Data were further scrutinized to separate device failure secondary to mechanical malfunction from device failure secondary to infection.</AbstractText><AbstractText Label="EXPERT OPINION">Limited data prevent accurate 15-year predictions for modern prosthetics. The 5- and 10-year overall survival of modern prosthetics is estimated to be 90.4% and 86.6%, respectively. Infection rates are estimated to be 1.5% and 1.8% at 8 and 10 years, respectively. While great strides have been made in device design, there is still potential for advancement in both infection rate reduction and mechanical improvement. The combination of increased collaboration between implanting urologists and engineers from prosthetic device companies and improved, prospectively collected data will usher prosthetic urology into its next era.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>a Urology , Tulane University Medical Center , New Orleans , LA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsambarlis</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>a Urology , Tulane University Medical Center , New Orleans , LA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Urology , Tulane University Medical Center , New Orleans , LA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne Jg</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>a Urology , Tulane University Medical Center , New Orleans , LA , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Med Devices</MedlineTA><NlmUniqueID>101230445</NlmUniqueID><ISSNLinking>1743-4440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">device survival</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">semirigid device</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30898042</ArticleId><ArticleId IdType="doi">10.1080/17434440.2019.1598259</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30895359</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8726</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>World journal of urology</Title><ISOAbbreviation>World J Urol</ISOAbbreviation></Journal><ArticleTitle>Erectile dysfunction: a global review of intracavernosal injectables.</ArticleTitle><Pagination><StartPage>1007</StartPage><EndPage>1014</EndPage><MedlinePgn>1007-1014</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-019-02727-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluate clinical efficacy, continuation rates and adverse event profiles of each injectable agent as monotherapy or in combination. The secondary outcome measurement was to discuss available guidelines that inform clinical practice for injectable agents.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ICIs demonstrate clinical efficacy in 54-100% of patients, early discontinuation rates of &#x2264;&#x2009;38% and adverse events in &#x2264;&#x2009;26%. Discontinuation rates are typically greatest within 3-6&#xa0;months of commencement. Anxiety related to the initial injection occurs in approximately 65% and anxiety levels can remain high for 4&#xa0;months. Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. Although combination therapies are attractive alternative options, their formulations are variable and should be standardised before widespread acceptance is achieved.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ICIs are associated with good clinical efficacy rates, high discontinuation rates and a moderate side-effect profile. They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>North Eastern Urology, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Young Urologists Research Organization (YURO), Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omran</LastName><ForeName>Ghadir J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Young Urologists Research Organization (YURO), Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teh</LastName><ForeName>Jiasian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Young Urologists Research Organization (YURO), Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Niall F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolton</LastName><ForeName>Damien M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrentschuk</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8553-5618</Identifier><AffiliationInfo><Affiliation>Department of Urology, Austin Health, Heidelberg, VIC, Australia. lawrentschuk@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC, Australia. lawrentschuk@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Austin Hospital, University of Melbourne, Melbourne, VIC, Australia. lawrentschuk@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>World J Urol</MedlineTA><NlmUniqueID>8307716</NlmUniqueID><ISSNLinking>0724-4983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>37221-79-7</RegistryNumber><NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>A67JUW790C</RegistryNumber><NameOfSubstance UI="C438273">aviptadil</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z468598HBV</RegistryNumber><NameOfSubstance UI="D010646">Phentolamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015552" MajorTopicYN="N">Injections, Intralesional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010646" MajorTopicYN="N">Phentolamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014660" MajorTopicYN="N">Vasoactive Intestinal Peptide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction (ED)</Keyword><Keyword MajorTopicYN="N">Intracavernosal injections</Keyword><Keyword MajorTopicYN="N">Treatment of ED</Keyword><Keyword MajorTopicYN="N">Treatment of erectile dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30895359</ArticleId><ArticleId IdType="doi">10.1007/s00345-019-02727-5</ArticleId><ArticleId IdType="pii">10.1007/s00345-019-02727-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Impot Res. 2017 Nov;29(6):225-228</Citation><ArticleIdList><ArticleId IdType="pubmed">28747647</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2008 Sep;102(8):933-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18485029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2018 Sep;200(3):633-641</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Aug;5(8):1841-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18298470</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25737750</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 May;49(5):806-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16530932</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Urol. 2008 Jul;15(7):564-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18643781</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Mens Health. 2013 Aug;31(2):83-102</Citation><ArticleIdList><ArticleId IdType="pubmed">24044105</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2012 Dec;110(11):1787-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22564343</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2018 Jul;27(7):583-593</Citation><ArticleIdList><ArticleId IdType="pubmed">29969332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Nov;158(5):1760-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9334595</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Oct;10(10):2559-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23898886</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiology. 1984 Feb;35(2):79-87</Citation><ArticleIdList><ArticleId IdType="pubmed">6696289</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2016 Apr;13(4):465-88</Citation><ArticleIdList><ArticleId IdType="pubmed">27045254</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1996 Apr 4;334(14):873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8596569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30828431</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>Recent advancements in penile prosthetics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">F1000 Faculty Rev-193</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.17407.1</ELocationID><Abstract><AbstractText>Since the original inflatable penile prosthesis in the 1970s, several enhancements to penile prosthesis implant design, implant surgical technique, and post-operative care have been developed to increase overall patient (and partner) satisfaction rates.&#xa0;We, in this communication, seek to discuss these advancements and the overall impact in combating erectile dysfunction.&#xa0;As we continue to pursue avenues of effective and definitive treatment modalities for erectile dysfunction refractory to medical therapy, rates of infection and mechanical failure will hopefully continue to decline in the perioperative setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fakhoury</LastName><ForeName>Mathew Q</ForeName><Initials>MQ</Initials><AffiliationInfo><Affiliation>Department of Urology, Cook County Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpern</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Nelson</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7436-3184</Identifier><AffiliationInfo><Affiliation>Department of Urology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30828431</ArticleId><ArticleId IdType="pmc">PMC6381800</ArticleId><ArticleId IdType="doi">10.12688/f1000research.17407.1</ArticleId><ArticleId IdType="pii">F1000 Faculty Rev-193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott FB, Bradley WE, Timm GW: Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2(1):80&#x2013;2. 10.1016/0090-4295(73)90224-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ: Current approach to the treatment of penile implant infections. Ther Adv Urol. 2010;2(2):69&#x2013;75. 10.1177/1756287210370330</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287210370330</ArticleId><ArticleId IdType="pmc">PMC3126071</ArticleId><ArticleId IdType="pubmed">21789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal RM, Henry GD: Contemporary patient satisfaction rates for three-piece inflatable penile prostheses. Adv Urol. 2012;2012: 707321. 10.1155/2012/707321</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/707321</ArticleId><ArticleId IdType="pmc">PMC3412090</ArticleId><ArticleId IdType="pubmed">22899909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Wilson SK: Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006;7(6):485&#x2013;9. 10.1007/s11934-006-0059-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11934-006-0059-0</ArticleId><ArticleId IdType="pubmed">17052446</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. : Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633&#x2013;41. 10.1016/j.juro.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.05.004</ArticleId><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher EF, Bella AJ, et al. : Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine. J Sex Med. 2016;13(4):489&#x2013;518. 10.1016/j.jsxm.2016.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, et al. : Infection retardant coated inflatable penile prostheses decrease the incidence of infection: a systematic review and meta-analysis. J Urol. 2012;188(5):1855&#x2013;60. 10.1016/j.juro.2012.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.07.022</ArticleId><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Costerton JW: Biofilm and penile prosthesis infections in the era of coated implants: a review. J Sex Med. 2012;9(1):44&#x2013;53. 10.1111/j.1743-6109.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02428.x</ArticleId><ArticleId IdType="pubmed">21951338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, et al. : Penile prostheses. Ther Adv Urol. 2010;2(1):35&#x2013;40. 10.1177/1756287209359174</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287209359174</ArticleId><ArticleId IdType="pmc">PMC3126066</ArticleId><ArticleId IdType="pubmed">21789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Henry GD, Delk JR, Jr, et al. : The Mentor Alpha 1 Penile Prosthesis With Reservoir Lock-out Valve: Effective Prevention of Auto-inflation With Improved Capability For Ectopic Reservoir Placement. J Urol. 2002;168(4 Pt 1):1475&#x2013;8. 10.1016/S0022-5347(05)64477-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)64477-1</ArticleId><ArticleId IdType="pubmed">12352421</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett-Harlow B, Clavell-Hernandez J, Wang R: New Developments in Surgical Treatment for Penile Size Preservation in Peyronie's Disease. Sex Med Rev. 2019;7(1):156&#x2013;66. 10.1016/j.sxmr.2018.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.07.001</ArticleId><ArticleId IdType="pubmed">30301708</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaissie J, Yafi FA: A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. Transl Androl Urol. 2016;5(3):342&#x2013;50. 10.21037/tau.2016.04.04</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau.2016.04.04</ArticleId><ArticleId IdType="pmc">PMC4893506</ArticleId><ArticleId IdType="pubmed">27298781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliara TJ, Smith DW, Viers BR, et al. : Alternative Reservoir and Balloon Placement in Complex Patients Undergoing Urologic Prostheses. Curr Urol Rep. 2018;19(6):40. 10.1007/s11934-018-0789-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11934-018-0789-9</ArticleId><ArticleId IdType="pubmed">29654383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakky TS, Wilson SK, Salem EA, et al. : Subcoronal rod penile prosthesis placement with scrotoplasty. J Sex Med. 2012;9(9):2202&#x2013;5. 10.1111/j.1743-6109.2012.02900.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02900.x</ArticleId><ArticleId IdType="pubmed">22947330</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito P, Wilson S: The History of Nontraditional or Ectopic Placement of Reservoirs in Prosthetic Urology. Sex Med Rev. 2016;4(2):190&#x2013;3. 10.1016/j.sxmr.2015.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2015.10.008</ArticleId><ArticleId IdType="pubmed">27530384</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavell Hernandez J, Ring J, Trost L, et al. : PD18-02 EMERGING COMPLICATIONS AFTER ECTOPIC PLACEMENT OF RESERVOIRS DURING INFLATABLE PENILE PROSTHESIS SURGERY: A MULTI-INSTITUTIONAL EXPERIENCE. J Urol. 2018;199(4s): e390. 10.1016/j.juro.2018.02.979</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2018.02.979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi FA, Andrianne R, Alzweri L, et al. : Andrianne Mini-Jupette Graft at the Time of Inflatable Penile Prosthesis Placement for the Management of Post-Prostatectomy Climacturia and Minimal Urinary Incontinence. J Sex Med. 2018;15(5):789&#x2013;96. 10.1016/j.jsxm.2018.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.01.015</ArticleId><ArticleId IdType="pubmed">29523479</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Preto M, Ceruti C, et al. : A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease. J Sex Med. 2018;15(6):848&#x2013;52. 10.1016/j.jsxm.2018.04.632</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.04.632</ArticleId><ArticleId IdType="pubmed">29753801</ArticleId></ArticleIdList></Reference><Reference><Citation>Theisen K, Jacobs B, Macleod L, et al. : The United States opioid epidemic: a review of the surgeon's contribution to it and health policy initiatives. BJU Int. 2018;122(5):754&#x2013;9. 10.1111/bju.14446</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.14446</ArticleId><ArticleId IdType="pubmed">29896932</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AS, Blackwell RH, Kuo PC, et al. : Rates and Risk Factors for Opioid Dependence and Overdose after Urological Surgery. J Urol. 2017;198(5):1130&#x2013;6. 10.1016/j.juro.2017.05.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2017.05.037</ArticleId><ArticleId IdType="pubmed">28506855</ArticleId></ArticleIdList></Reference><Reference><Citation>Matulewicz RS, Patel M, Jordan BJ, et al. : Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy. Bladder Cancer. 2018;4(2):161&#x2013;7. 10.3233/BLC-170157</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/BLC-170157</ArticleId><ArticleId IdType="pmc">PMC5929302</ArticleId><ArticleId IdType="pubmed">29732387</ArticleId></ArticleIdList></Reference><Reference><Citation>Deniz MN, Erakgun A, Sergin D, et al. : Evaluation of a Multimodal Approach to Postoperative Pain in Patients Undergoing Flank Incision in the Urology Operating Room. Turk J Anaesthesiol Reanim. 2014;42(1):19&#x2013;22. 10.5152/TJAR.2013.54</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/TJAR.2013.54</ArticleId><ArticleId IdType="pmc">PMC4894101</ArticleId><ArticleId IdType="pubmed">27366383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternlicht A, Shapiro M, Robelen G, et al. : Infiltration of liposome bupivacaine into the transversus abdominis plane for postsurgical analgesia in robotic laparoscopic prostatectomy: a pilot study. Local Reg Anesth. 2014;7:69&#x2013;74. 10.2147/LRA.S64515</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/LRA.S64515</ArticleId><ArticleId IdType="pmc">PMC4270354</ArticleId><ArticleId IdType="pubmed">25540595</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinstatler L, Shee K, Gross MS: Pain Management in Penile Prosthetic Surgery: A Review of the Literature. Sex Med Rev. 2018;6(1):162&#x2013;9. 10.1016/j.sxmr.2017.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2017.05.005</ArticleId><ArticleId IdType="pubmed">28735683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotta BH, Welliver C, Brahmamdam A, et al. : Long-acting liposomal bupivacaine decreases inpatient narcotic requirements in men undergoing penile prosthesis implantation. Turk J Urol. 2016;42(4):230&#x2013;4. 10.5152/tud.2016.44442</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tud.2016.44442</ArticleId><ArticleId IdType="pmc">PMC5125735</ArticleId><ArticleId IdType="pubmed">27909614</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie D, Nicholson M, Azaiza M, et al. : Effect of operative local anesthesia on postoperative pain outcomes of inflatable penile prosthesis: prospective comparison of two medications. Int J Impot Res. 2018;30(3):93&#x2013;6. 10.1038/s41443-018-0025-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0025-7</ArticleId><ArticleId IdType="pubmed">29795532</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong CMC, Lucas J, Shah A, et al. : Novel Multi-Modal Analgesia Protocol Significantly Decreases Opioid Requirements in Inflatable Penile Prosthesis Patients. J Sex Med. 2018;15(8):1187&#x2013;94. 10.1016/j.jsxm.2018.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.05.017</ArticleId><ArticleId IdType="pubmed">30017719</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Ponchietti R, Gontero P, et al. : Penile length is normal in most men seeking penile lengthening procedures. Int J Impot Res. 2002;14(4):283&#x2013;6. 10.1038/sj.ijir.3900887</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900887</ArticleId><ArticleId IdType="pubmed">12152118</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Sousa A, Keating M, Moreira S, et al. : Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery. J Sex Med. 2007;4(5):1494&#x2013;9. 10.1111/j.1743-6109.2007.00551.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00551.x</ArticleId><ArticleId IdType="pubmed">17727355</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O, Shaeer K, AbdelRahman IFS, et al. : Dorsal phalloplasty accompanying penile prosthesis implantation minimizes penile shortening and improves patient satisfaction. Int J Impot Res. 2018;3:743. 10.1038/s41443-018-0085-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0085-8</ArticleId><ArticleId IdType="pubmed">30337695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegelmann MJ, Alom M, Bole R, et al. : Modified Glanulopexy Technique for Supersonic Transporter Deformity and Glanular Hypermobility in Men With Penile Prostheses. J Sex Med. 2018;15(6):914&#x2013;9. 10.1016/j.jsxm.2018.04.633</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.04.633</ArticleId><ArticleId IdType="pubmed">29731427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L, Ceruti C, Timpano M, et al. : A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the "sliding technique". J Sex Med. 2012;9(9):2389&#x2013;95. 10.1111/j.1743-6109.2012.02675.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02675.x</ArticleId><ArticleId IdType="pubmed">22429331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Mora-Estaves C, Egydio P, et al. : Glans Necrosis Following Penile Prosthesis Implantation: Prevention and Treatment Suggestions. Urology. 2017;107:144&#x2013;8. 10.1016/j.urology.2017.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2017.06.020</ArticleId><ArticleId IdType="pubmed">28648967</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio PH, Kuehhas FE: The Multiple-Slit Technique (MUST) for Penile Length and Girth Restoration. J Sex Med. 2018;15(2):261&#x2013;9. 10.1016/j.jsxm.2017.11.223</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2017.11.223</ArticleId><ArticleId IdType="pubmed">29275049</ArticleId></ArticleIdList></Reference><Reference><Citation>Biardeau X, Hached S, Loutochin O, et al. : Montreal electronic artificial urinary sphincters: Our futuristic alternatives to the AMS800&#x2122;. Can Urol Assoc J. 2017;11(10):E396&#x2013;E404. 10.5489/cuaj.4493</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.4493</ArticleId><ArticleId IdType="pmc">PMC5963454</ArticleId><ArticleId IdType="pubmed">29384472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag HJ, Ruthmann O, Doll A, et al. : Development of a novel, remote-controlled artificial bowel sphincter through microsystems technology. Artif Organs. 2006;30(11):855&#x2013;62. 10.1111/j.1525-1594.2006.00312.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2006.00312.x</ArticleId><ArticleId IdType="pubmed">17062108</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrion RE: The &#x201c;Carrion Cast&#x201d;:Intracorporal Antimicrobial Cast Using Synthetic High Purity CaSO4 for theTreatment of Infected Penile Implant &#x2013; &#x201c;Updated&#x201d; Surgeon Protocol.</Citation><ArticleIdList><ArticleId IdType="pubmed">23347377</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B, McVary K, McKenna K, et al. : A Novel Thermal-activated Shape Memory Penile Prosthesis: Comparative Mechanical Testing. Urology. 2017;99:136&#x2013;41. 10.1016/j.urology.2016.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.09.007</ArticleId><ArticleId IdType="pubmed">27639798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. : Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4(4 Pt 1):1074&#x2013;9. 10.1111/j.1743-6109.2007.00540.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30745567</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Postoperative vacuum therapy following AMS&#x2122; LGX 700&#xae; inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>139</EndPage><MedlinePgn>133-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0125-z</ELocationID><Abstract><AbstractText>Penile shortening after inflatable penile prosthesis for erectile dysfunction is a common postoperative patient complaint and can reduce overall satisfaction with the procedure. In this prospective study we report our results regarding penile dimensions and patient satisfaction outcomes after 1 year of follow-up from AMS&#x2122;LGX700&#xae; penile prosthesis implant with 6 months of vacuum erectile device therapy. Seventy-four selected patients with medically refractory erectile dysfunction underwent AMS&#x2122; LGX 700&#xae; IPP placement. Postoperatively, patients were assigned vacuum device therapy for 5&#x2009;min twice daily. Follow-up continued for 1 year after surgery. Dimensional and functional results were assessed. Baseline median preoperative stretched penile length and girth were 14&#x2009;cm (range 10-17) and 9&#x2009;cm (range 7-12), respectively. At the end of the study penile median dimensional outcomes were 17&#x2009;cm (range 13-23) for length and 11&#x2009;cm (range 10-13) for girth while a median number of 24 pumps (range 18-29) to fully inflate the device was seen. Baseline median International Index of Erectile Function (IIEF-5) score was 9 (range 5-11), at 6 months 20 (range 18-26) and at 1 year was 25 (range 20-27) (p&#x2009;&lt;&#x2009;0.0001). Median Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) score at the end of the follow-up was 74 (range 66-78). Our postoperative rehabilitation program is feasible and should be recommended after prothesis surgery in order to increase overall satisfaction with the procedure. Penile postoperative dimensional outcomes were statistically significant improved and complications were negligible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Sapienza Rome University, Policlinico Umberto I, Viale del Policlinico 155, Rome, 00161, Italy. gabrieleantoninimd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Berardinis</LastName><ForeName>Ettore</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Sapienza Rome University, Policlinico Umberto I, Viale del Policlinico 155, Rome, 00161, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busetto</LastName><ForeName>Gian Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Urology, Sapienza Rome University, Policlinico Umberto I, Viale del Policlinico 155, Rome, 00161, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Giudice</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3865-5988</Identifier><AffiliationInfo><Affiliation>Department of Urology, Sapienza Rome University, Policlinico Umberto I, Viale del Policlinico 155, Rome, 00161, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Biostatistical Unit, IRCSS, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Simon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Urology, Stanford University Medical Center, 300 Pasteur Dr, Palo Alto, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferro</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Urology, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musi</LastName><ForeName>Gennaro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Urology, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragas</LastName><ForeName>Ramiro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinica Central Cira Garcia, Ave. Lazaro e/ 18y 20, Pya, La, C&#xe1;rdenas, La Habana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Cobelli</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Urology, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperduti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biostatistical Unit, IRCSS, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Section of Urology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH, 03766, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perito</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Urology, Coral Gables Hospital, 3100 Douglas Rd, Coral Gables, FL, 33134, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Impot Res. 2020 Jan;32(1):142-143</RefSource><PMID Version="1">31474752</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014618" MajorTopicYN="N">Vacuum</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30745567</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0125-z</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0125-z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30705435</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Additional procedures performed at time of penile prosthesis implantation: a review of current literature.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>98</EndPage><MedlinePgn>89-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-019-0118-y</ELocationID><Abstract><AbstractText>Penile prosthesis implantation for treatment of medical refractory erectile dysfunction remains the gold standard. However, some men have additional pathology present such as Peyronie's Disease, penile shortening, penoscrotal webbing, buried penis or other penoscrotal anatomical abnormalities that may be addressed at the time of prosthesis implantation. Although several techniques are described, there remains a lack of data regarding the outcomes. We sought to identify the results of available literature regarding the additional procedures performed at the time of penile prosthesis implantation that provide defined surgical outcomes rather than merely describe surgical techniques. Surgical outcomes to procedures provide more realistic clinical outcome for readers than simply the description of novel techniques or expert opinions. We performed a review of the MEDLINE database to identify additional procedures performed in conjunction with penile prosthesis placement. Many procedures are described in review articles, however, with limited data regarding their outcomes. The included articles must describe additional procedures performed in conjunction with penile prosthesis placement. Perioperative office techniques and management were included if it changed the surgical technique. All abstracts obtained through search criteria were reviewed. Only articles written in English, on human subjects with documented surgical results and relevant articles were included in this study. After a thorough literature search, a total of 24 articles were identified. Penile lengthening procedures at the time of penile prosthesis comprise most of the literature on this subject. Lengthening procedures are as simple as Peyronie's plaque excision and grafting to complex sliding and lengthening procedures requiring complete neurovascular bundle and partial urethral mobilization. Additionally, aggressive cylinder sizing and prolonged postoperative cycling at home are also described. Glanulopexy may be necessary when malpositioning of the glans is present. Other options such as scrotoplasty are also available options for those patients with scrotal webs. Notably there is a paucity of published literature regarding girth enhancement, buried penis repair, hernia repair, and vasectomy at time of penile prosthesis placement. There are numerous procedures that can be performed in the same operative setting as penile prosthesis. Although the procedures do have a common goal to provide optimal postoperative natural appearance, length, straightness, girth and function, the techniques employed must be tailored to each patient as there is not a one-procedure fits all in this patient population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whelan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Rush University Medical Center, 1725 W Harrison Street, Suite 352, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, Rush University Medical Center, 1725 W Harrison Street, Suite 352, Chicago, IL, 60612, USA. drlevine@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012611" MajorTopicYN="N">Scrotum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30705435</ArticleId><ArticleId IdType="doi">10.1038/s41443-019-0118-y</ArticleId><ArticleId IdType="pii">10.1038/s41443-019-0118-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30691962</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-4569</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European urology focus</Title><ISOAbbreviation>Eur Urol Focus</ISOAbbreviation></Journal><ArticleTitle>Immediate Placement of a Penile Prosthesis as First-line Treatment for the Management of Ischaemic Priapism.</ArticleTitle><Pagination><StartPage>529</StartPage><EndPage>530</EndPage><MedlinePgn>529-530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euf.2019.01.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2405-4569(19)30009-4</ELocationID><Abstract><AbstractText>In refractory cases of priapism, prolonged ischaemia is associated with smooth muscle necrosis with the development of cavernosal fibrosis. Acute prosthesis placement allows maintenance of penile length and girth and treatment of the inevitable erectile dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Andrology University College London Hospital, London, UK; NIHR Biomedical Research Centre UCLH. Electronic address: Asif.Muneer@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Andrology University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Urol Focus</MedlineTA><NlmUniqueID>101665661</NlmUniqueID><ISSNLinking>2405-4569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30691962</ArticleId><ArticleId IdType="doi">10.1016/j.euf.2019.01.009</ArticleId><ArticleId IdType="pii">S2405-4569(19)30009-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30689132</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-6285</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>Current urology reports</Title><ISOAbbreviation>Curr Urol Rep</ISOAbbreviation></Journal><ArticleTitle>Penile Implant Considerations in the Bladder Cancer Survivor.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11934-019-0873-9</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">After radical cystoprostatectomy, patients often develop erectile dysfunction refractory to first- and second-line treatments. In this review, we summarize and analyze the literature describing the technical considerations and outcomes of penile implant surgery in bladder cancer patients with history of radical cystectomy and urinary diversion.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Penile prosthesis surgery in patients after radical cystectomy and urinary diversion has been infrequently described in the literature. Recent studies have shown that the three-piece inflatable penile prosthesis can be placed safely after significant prior intraabdominal surgery due to the development and refinement of several techniques to place the reservoir. Further studies are needed to objectively determine the impact of penile prosthetic surgery on functional outcomes in this historically undertreated yet increasingly significant patient population. As health-related quality of life outcomes continue to gain increasing importance after radical cystectomy, urologists should offer motivated bladder cancer survivors the inflatable penile prosthesis as the treatment of choice for refractory erectile dysfunction due to its safety and unmatched ability to restore erectile function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loh-Doyle</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA, 90089-9178, USA. jeffrey.loh-doyle@med.usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Urol Rep</MedlineTA><NlmUniqueID>100900943</NlmUniqueID><ISSNLinking>1527-2737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073116" MajorTopicYN="N">Cancer Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015653" MajorTopicYN="N">Cystectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014547" MajorTopicYN="N">Urinary Diversion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bladder cancer</Keyword><Keyword MajorTopicYN="N">Cystectomy</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Survivorship</Keyword><Keyword MajorTopicYN="N">Urinary diversion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30689132</ArticleId><ArticleId IdType="doi">10.1007/s11934-019-0873-9</ArticleId><ArticleId IdType="pii">10.1007/s11934-019-0873-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Urol. 2000 Jan;37(1):50-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2006 Jun 1;106(11):2355-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16649218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2008 Jul;180(1):336</Citation><ArticleIdList><ArticleId IdType="pubmed">18495172</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2010 Jul-Aug;22(4):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20574433</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Urol. 2012;2012:707321</Citation><ArticleIdList><ArticleId IdType="pubmed">22899909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Feb;10(2):603-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23216955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Sep;10(9):2343-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23889925</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2014 Jan;191(1):48-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23911603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Feb;11(2):605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24286533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Urol. 2014 Aug;11(8):445-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24980191</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Apr;12(4):1092-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25664424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2016 Mar;195(3):694-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26343986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Oct;12(10):1984-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26481595</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2017 Jul-Aug;19(4):477-481</Citation><ArticleIdList><ArticleId IdType="pubmed">27121195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2016 Sep;13(9):1432-1437</Citation><ArticleIdList><ArticleId IdType="pubmed">27555513</ArticleId></ArticleIdList></Reference><Reference><Citation>Investig Clin Urol. 2016 Sep;57(5):364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27617319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2017 Jun;14(6):810-817</Citation><ArticleIdList><ArticleId IdType="pubmed">28460994</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2017 Jul;14(7):968-973</Citation><ArticleIdList><ArticleId IdType="pubmed">28595821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sex Med Rev. 2018 Apr;6(2):319-327</Citation><ArticleIdList><ArticleId IdType="pubmed">28874326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2018 Feb;15(2):245-250</Citation><ArticleIdList><ArticleId IdType="pubmed">29292061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2018 Mar;15(3):410-415</Citation><ArticleIdList><ArticleId IdType="pubmed">29339015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2018 Jun;15(6):907-913</Citation><ArticleIdList><ArticleId IdType="pubmed">29452979</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2018 Jul;117:86-88</Citation><ArticleIdList><ArticleId IdType="pubmed">29656065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sex Med Rev. 2018 Oct;6(4):631-639</Citation><ArticleIdList><ArticleId IdType="pubmed">29730314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2018 Jul;15(7):1049-1054</Citation><ArticleIdList><ArticleId IdType="pubmed">29731428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2018 Oct 23;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">30366022</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2019 Jan 18;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">30664894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Feb;137(2):297-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3806825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30671142</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1756-2872</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2019</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in urology</Title><ISOAbbreviation>Ther Adv Urol</ISOAbbreviation></Journal><ArticleTitle>An update on the best approaches to prevent complications in penile prosthesis recipients.</ArticleTitle><Pagination><StartPage>1756287218818076</StartPage><MedlinePgn>1756287218818076</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1756287218818076</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/1756287218818076</ELocationID><Abstract><AbstractText>Placement of inflatable penile prosthesis is a procedure frequently performed for medication-refractory erectile dysfunction. Device implantation is not without risks, and as the frequency of device implantation increases, so do associated complications. The aim of this work is to review the most frequent operative complications associated with implantation of inflatable penile prostheses, and to review the best approaches to prevent these most common complications. Complications can broadly be categorized as infectious, noninfectious tissue-related, device-related, or related to patient and partner satisfaction. With understanding of these complications and ways to avoid them, as well as with appropriate patient selection and counseling, the inflatable penile prosthesis is an excellent option for the treatment of erectile dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krzastek</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Virginia School of Medicine, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Virginia School of Medicine, Charlottesville, VA 22908-0422, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Urol</MedlineTA><NlmUniqueID>101487328</NlmUniqueID><ISSNLinking>1756-2872</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inflatable penile prosthesis</Keyword><Keyword MajorTopicYN="N">prosthesis complications</Keyword><Keyword MajorTopicYN="N">prosthesis infection</Keyword><Keyword MajorTopicYN="N">salvage therapy</Keyword></KeywordList><CoiStatement>Conflict of interest statement: The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30671142</ArticleId><ArticleId IdType="pmc">PMC6329024</ArticleId><ArticleId IdType="doi">10.1177/1756287218818076</ArticleId><ArticleId IdType="pii">10.1177_1756287218818076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gurtner K, Saltzman A, Hebert K, et al. Erectile dysfunction: a review of historical treatments with a focus on the development of the inflatable penile prosthesis. Am J Mens Health 2017; 11: 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5675239</ArticleId><ArticleId IdType="pubmed">26206161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas U. The history of erectile dysfunction management. Int J Impot Res 2001; 13(Suppl. 3): S3&#x2013;S7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477486</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973; 2: 80&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am 2011; 38: 217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621088</ArticleId></ArticleIdList></Reference><Reference><Citation>Penile implants or penile prosthesis market &#x2013; global industry analysis, size, share, trends and forecast, 2015&#x2013;2023, https://www.marketresearch.com/Infinium-Global-Research-v4127/Penile-Implants-Prosthesis-Global-Size-10925565/ (2017, accessed 20 July 2018).</Citation></Reference><Reference><Citation>Serefoglu EC, Mandava SH, Gokce A, et al. Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med 2012; 9: 2182&#x2013;2186.</Citation><ArticleIdList><ArticleId IdType="pubmed">22759917</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol 2011; 185: 614&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery BD, Lomas DJ, Ziegelmann MJ, et al. Infection risk of undergoing multiple penile prostheses: an analysis of referred patient surgical histories. Int J Impot Res. Epub ahead of print 25 May 2018. DOI: 10.1038/s41443-018-0026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41443-018-0026-6.</ArticleId><ArticleId IdType="pubmed">29795529</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. Surgery for erectile dysfunction. In: Wein AJ, Kavoussi LR, Partin AW, et al. (eds) Campbell-Walsh Urol. 11 ed Elsevier, pp.709&#x2013;721.</Citation></Reference><Reference><Citation>Pineda M, Burnett AL. Penile prosthesis infections-a review of risk factors, prevention, and treatment. Sex Med Rev 2016; 4: 389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">27872031</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanyi RM, Alzubaidi R, Leung EJY, et al. Inflatable penile prostheses implantation: does antibiotic exposure matter? Sex Med. Epub ahead of print 12 July 2018. DOI: 10.1016/j.esxm.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esxm.2018.05.004.</ArticleId><ArticleId IdType="pmc">PMC6085404</ArticleId><ArticleId IdType="pubmed">30017599</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol 2018; 200: 633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf JS, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Urology 2009; 74: 236&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19567306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross MS, Phillips EA, Carrasquillo RJ, et al. Multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis. J Sex Med 2017; 14: 455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">28189561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta S, Hadley S, Hutzler L, et al. Impact of preoperative MRSA screening and decolonization on hospital-acquired MRSA burden. Clin Orthop 2013; 471: 2367&#x2013;2371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676612</ArticleId><ArticleId IdType="pubmed">23423618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995; 31: 13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499817</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzen CJ, Lloyd LK. Complications of intracavernous injections and penile prostheses in spinal cord injured men. Arch Phys Med Rehabil 1992; 73: 652&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1622321</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M, Pearce I. Infection of penile prostheses in patients with diabetes mellitus. Surg Infect 2016; 17: 2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, et al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int 2018; 121: 293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478354</ArticleId><ArticleId IdType="pubmed">29124870</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo RJ, Gross MS. Infection prevention strategies prior to penile implant surgery. Eur Urol Focus. Epub ahead of print 12 July 2018. DOI: 10.1016/j.euf.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2018.07.002.</ArticleId><ArticleId IdType="pubmed">30017899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol 2013; 189: 136&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmisano F, Boeri L, Cristini C, et al. Comparison of infrapubic vs penoscrotal approaches for 3-piece inflatable penile prosthesis placement: do we have a winner? Sex Med Rev. Epub ahead of print 2 May 2018. DOI: 10.1016/j.sxmr.2018.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.03.007.</ArticleId><ArticleId IdType="pubmed">29730314</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, et al. Coated implants and &#x2018;no touch&#x2019; surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology 2012; 79: 1310&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg AC, Pagano MJ, Deibert CM, et al. Sub-coronal inflatable penile prosthesis placement with modified no-touch technique: a step-by-step approach with outcomes. J Sex Med 2016; 13: 270&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">26805939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol 2000; 163: 481&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopategui DM, Balise RR, Bouzoubaa LA, et al. The impact of immediate salvage surgery on corporeal length preservation in patients presenting with penile implant infections. J Urol 2018; 200: 171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">29408215</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Penile prosthesis infection: progress in prevention and treatment. Curr Urol Rep 2010; 11: 400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">20821356</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, et al. North American consensus document on infection of penile prostheses. Urology 2013; 82: 937&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer ND, Dick B, Gabrielson AT, et al. Penile prosthesis complications: planning, prevention, and decision making. Sex Med Rev. Epub ahead of print 19 July 2018. DOI: 10.1016/j.sxmr.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.04.002.</ArticleId><ArticleId IdType="pubmed">30033128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooreville M, Adrian S, Delk JR, et al. Implantation of inflatable penile prosthesis in patients with severe corporeal fibrosis: introduction of a new penile cavernotome. J Urol 1999; 162: 2054&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569568</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlman AM, Terlecki RP. Proximal corporal perforation during penile prosthesis surgery: prevention, recognition, and review of historical and novel management strategies. J Sex Med 2018; 15: 1055&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">29729971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma D, Smith RP. Troubleshooting intraoperative complications of penile prosthesis placement. Transl Androl Urol 2017; 6: S892&#x2013;S897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715183</ArticleId><ArticleId IdType="pubmed">29238668</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Le BV, Burnett AL. Suprapubic cystostomy for the management of urethral injuries during penile prosthesis implantation. Sex Med 2014; 2: 178&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272249</ArticleId><ArticleId IdType="pubmed">25548649</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos EC, Sexton SJ, Lentz AC. Urethral injury and the penile prosthesis. Sex Med Rev. Epub ahead of print 2 August 2018. DOI: 10.1016/j.sxmr.2018.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2018.06.003.</ArticleId><ArticleId IdType="pubmed">30078620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. The prevention and management of noninfectious complications of penile implants. Sex Med Rev 2015; 3: 203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher E, Bella A, et al. Penile prosthesis surgery: current recommendations from the international consultation on sexual medicine. J Sex Med 2016; 13: 489&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zermann D-H, Kutzenberger J, Sauerwein D, et al. Penile prosthetic surgery in neurologically impaired patients: long-term followup. J Urol 2006; 175: 1041&#x2013;1044; discussion 1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Mora-Estaves C, Egydio P, et al. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology 2017; 107: 144&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">28648967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Ilbeigi P, Wilson SK, et al. Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res 2005; 17: 535&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin North Am 2007; 34: 535&#x2013;547, vi.</Citation><ArticleIdList><ArticleId IdType="pubmed">17983893</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD. The Henry mummy wrap and the Henry finger sweep surgical techniques. J Sex Med 2009; 6: 619&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19284470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Henry GD. Hematoma formation following penile prosthesis implantation: to drain or not to drain. J Urol 1996; 55: 643A.</Citation></Reference><Reference><Citation>Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med 2007; 4: 296&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000; 164: 376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Henry GD, Delk JR, et al. The mentor Alpha 1 penile prosthesis with reservoir lock-out valve: effective prevention of auto-inflation with improved capability for ectopic reservoir placement. J Urol 2002; 168: 1475&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakky T, Lentz A, Sadeghi-Nejad H, et al. The evolution of the inflatable penile prosthesis reservoir and surgical placement. J Sex Med 2015; 12(Suppl. 7): 464&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">26565579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallen JJ, Barrera EV, Ge L, et al. Biomechanical comparison of inflatable penile implants: a cadaveric pilot study. J Sex Med 2018; 15: 1034&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">29960627</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, Baum N, Hellstrom WJG. Managing the difficult penile prosthesis patient. J Sex Med 2013; 10: 893&#x2013;906; quiz 907.</Citation><ArticleIdList><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexual Medicine Society of North America. Position Statement: Penile Prosthesis Information Form. SMSNAIPP-policy-ws.pdf, http://www.smsna.org/V1/images/SMSNAIPP-policy-ws.pdf (2008, accessed 25 July 2018).</Citation></Reference><Reference><Citation>Vakalopoulos I, Kampantais S, Ioannidis S, et al. High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. J Sex Med 2013; 10: 2774&#x2013;2781.</Citation><ArticleIdList><ArticleId IdType="pubmed">24034543</ArticleId></ArticleIdList></Reference><Reference><Citation>Capogrosso P, Pescatori E, Caraceni E, et al. Satisfaction rate at one-year follow-up in patients treated with penile implants - data from the multicenter prospective registry INSIST-ED. BJU Int. Epub ahead of print 29 June 2018. DOI: 10.1111/bju.14462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.14462.</ArticleId><ArticleId IdType="pubmed">29956870</ArticleId></ArticleIdList></Reference><Reference><Citation>Habous M, Tal R, Tealab A, et al. Predictors of satisfaction in men after penile implant surgery. J Sex Med. Epub ahead of print 12 July 2018. DOI: 10.1016/j.jsxm.2018.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2018.05.011.</ArticleId><ArticleId IdType="pubmed">30017718</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, et al. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med 2006; 3: 743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveci S, Martin D, Parker M, et al. Penile length alterations following penile prosthesis surgery. Eur Urol 2007; 51: 1128&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac J. Informed consent for penile prosthesis surgery. Transl Androl Urol 2017; 6(Suppl. 5): S881&#x2013;S882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715182</ArticleId><ArticleId IdType="pubmed">29239402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AC, Schweber A. Patient expectations prior to Coloplast titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med 2010; 7: 2261&#x2013;2266.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367767</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30655195</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Biomechanical Studies of the Inflatable Penile Prosthesis: A Review.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>375</EndPage><MedlinePgn>369-375</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2018.11.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(18)30133-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The penile prosthesis remains the primary surgical treatment for refractory erectile dysfunction. Over the decades, inflatable penile prostheses' mechanical reliability, patient satisfaction, safety, and functional erectile restoration have greatly improved. During this time, many studies of biomechanical properties of the prosthesis have been conducted to better understand their biomimicry to the erect human phallus.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review all current literature on the biomechanical properties of the penile prosthesis, including prosthesis biomechanical function, and variability in model-related performance.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A Medline PubMed search was used to identify all articles of interest related to subjects involving the penile prosthesis and its related biomechanical properties. The following were included in the search for articles of interest: "biomechanics," "mechanics," "mechanical properties," "axial rigidity," "penile implant," and "penile prosthesis." Articles were further screened for content and English language.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Here we perform a literature review of the bio-mechenical function, performance, and patient satisfaction of penile implants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Axial rigidity helps determine the ability of an erect penis to complete vaginal intromission and pelvic thrusting without buckling. Recent cadaveric data show that at maximum inflation, Coloplast and American Medical Systems (AMS) implants had comparable performance. Variability was seen at various lower fill pressures, where more severe buckling was observed. Coloplast Titan showed a tendency toward better resistance to longitudinal and horizontal forces. The AMS CX device showed similar performance to the Titan, and the AMS LGX device was shown to be most sensitive to fill pressure variation. Additionally, rear tip extenders (RTEs) appear to negatively affect axial loading, especially in settings of larger implants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Current research suggests that circumferentially expanding devices, such as AMS CX and Coloplast Titan, show better resistance to longitudinal (penetration) and horizontal (gravity) forces and, unlike the AMS LGX device, are less sensitive to device fill pressure. Additionally, RTEs have been shown to negatively impact axial loading, especially in larger cylinder inflatable penile prostheses &gt;20 cm in length. Madiraju SK, Wallen JJ, Rydelek SP, et&#xa0;al. Biomechanical Studies of the Inflatable Penile Prosthesis: A Review. Sex Med Rev 2019;7:369-375.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madiraju</LastName><ForeName>SriGita K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Charles E. Schmidt College of Medicine of Florida Atlantic University, Boca Raton, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallen</LastName><ForeName>Jared J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Florida Hospital Tampa Urology, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rydelek</LastName><ForeName>Stanley P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>One Man LLC, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrion</LastName><ForeName>Rafael E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>University of South Florida Department of Urology, Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perito</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Perito Urology, Coral Gables, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakky</LastName><ForeName>Tariq S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Advanced Urology, Atlanta, GA, USA. Electronic address: tariq7@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Axial Rigidity</Keyword><Keyword MajorTopicYN="N">Biomechanics</Keyword><Keyword MajorTopicYN="N">Mechanics</Keyword><Keyword MajorTopicYN="N">Penile Implant</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30655195</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2018.11.006</ArticleId><ArticleId IdType="pii">S2050-0521(18)30133-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30534437</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>The first Iraqi experience in sacral neuromodulation for patients with lower urinary tract dysfunction.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>396</EndPage><MedlinePgn>391-396</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aju.2018.05.006</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To present our experience, in Iraq, with sacral neuromodulation (SNM) in patients with refractory lower urinary tract dysfunction, with discussion of the factors that affect the response rate.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In this prospective, clinical, interventional study, 24 patients were evaluated and treated by a team comprised of a Urologist and a Neurosurgeon with SNM over a 1.5-year period. The gender, age, pathology, and clinical presentation, were all studied and evaluated. Successful clinical response was defined as achieving a &#x2265;50% improvement in voiding diary variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of those that responded to SNM was 28&#x202f;years, with females responding better than males (10 of 14 vs four of 10). The SNM response rate according to presentation was six of 10 in those with overactive bladder/urge urinary incontinence, six of nine of those with urinary retention, and two of five in those with a mixed presentation. The response rate in idiopathic voiding dysfunctions was 11 of 13, whilst for neurogenic dysfunctions it was three of 11. Other benefits such as in bowel motion, erectile function, menstruation, power of lower limbs, and quality of life (QoL), were also recorded. The complications were reasonable for this minimally invasive procedure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SNM offers a good and durable solution for some functional bladder problems, if patients are well selected. There may also be additional extra-urinary benefits that contribute to improvements in QoL. SNM was well tolerated by our patients with an encouraging response rate, especially in psychologically stable patients with idiopathic dysfunctions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Azzawi</LastName><ForeName>Issam S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Urology, Al-Mustansiriya University, Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Tamimi</LastName><ForeName>Mohamed A J</ForeName><Initials>MAJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Al-Mustansiriya University, Baghdad, Iraq.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(U)UI, (urge) urinary incontinence</Keyword><Keyword MajorTopicYN="N">IPG, implantable pulse generator</Keyword><Keyword MajorTopicYN="N">Lower urinary tract dysfunction</Keyword><Keyword MajorTopicYN="N">NOUR, non-obstructive urinary retention</Keyword><Keyword MajorTopicYN="N">Neuromodulation</Keyword><Keyword MajorTopicYN="N">OAB, overactive bladder</Keyword><Keyword MajorTopicYN="N">Overactive bladder</Keyword><Keyword MajorTopicYN="N">QoL, quality of life</Keyword><Keyword MajorTopicYN="N">SNM, sacral neuromodulation</Keyword><Keyword MajorTopicYN="N">Urge urinary incontinence</Keyword><Keyword MajorTopicYN="N">Urinary retention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30534437</ArticleId><ArticleId IdType="pmc">PMC6277263</ArticleId><ArticleId IdType="doi">10.1016/j.aju.2018.05.006</ArticleId><ArticleId IdType="pii">S2090-598X(18)30072-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li L.F., Ka-Kit Leung G., Lui W.M. Sacral nerve stimulation for neurogenic bladder. World Neurosurg. 2016;90:236&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">26960284</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559262</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossaerts J., Rademakers K., van Koeveringe G., van Kerrebroeck P. The value of urodynamic tools to guide patient selection in sacral neuromodulation. World J Urol. 2015;33:1889&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617837</ArticleId><ArticleId IdType="pubmed">25680936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler T.M., W&#xf6;llner J., Kozomara M., Mordasini L., Mehnert U. Sacral neuromodulation for neurogenic bladder dysfunction. Urologe A. 2012;51:179&#x2013;183. [Article in German]</Citation><ArticleIdList><ArticleId IdType="pubmed">22269992</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kerrebroeck P.E., Marcelissen T.A. Sacral neuromodulation for lower urinary tract dysfunction. World J Urol. 2012;30:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassouna M.M., Siegel S.W., N&#xff;eholt A.A., Elhilali M.M., van Kerrebroeck P.E., Das A.K. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799197</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazzelli M., Murray A., Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175:835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469561</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui N.Y., Wu J.M., Amundsen C.L. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review. Neurourol Urodyn. 2010;29:S18&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20419795</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil E.H., Ruiz-Cerd&#xe1; J.L., Eerdmans P.H., Janknegt R.A., Van Kerrebroeck P.E. Clinical results of sacral Neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes. World J Urol. 1998;16:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">9833310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch J.L., Groen J. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. J Urol. 2000;163:1219&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vapnek J.M., Schmidt R.A. Restoration of voiding in chronic urinary retention using neuroprosthesis. World J Urol. 1991;9:142&#x2013;144.</Citation></Reference><Reference><Citation>Shaker H.S., Hassouna M. Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention. J Urol. 1998;159:1476&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554336</ArticleId></ArticleIdList></Reference><Reference><Citation>Amundsen C.L., Romero A.A., Jamison M.G., Webster G.D. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66:746&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230129</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kerrebroeck P.E., van Voskuilen A.C., Heesakkers J.P., Lycklama &#xe1; Nijholt A.A., Siegel S., Jonas U. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029&#x2013;2034.</Citation><ArticleIdList><ArticleId IdType="pubmed">17869298</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams P., Andersson K.E., Birder L., Brubaker L., Cardozo L., Chapple C. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">20025020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace P.A., Lane F.L., Noblett K.L. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(96):91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17618775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Kastler E.J., Ruud Bosch J.L., Perrigot M., Chancellor M.B., Richard F., Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164:1476&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pubmed">11025686</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters K., Sahai A., De Ridder D., Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">24238278</ArticleId></ArticleIdList></Reference><Reference><Citation>Blandon R.E., Gebhart J.B., Lightner D.J., Klingele C.J. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int. 2008;101:1119&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190624</ArticleId></ArticleIdList></Reference><Reference><Citation>Blok B.F., Groen J., Bosch J.L., Veltman D.J., Lammertsma A.A. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int. 2006;98:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034500</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kerrebroeck P.E. Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(Suppl. 2):S467&#x2013;S474.</Citation><ArticleIdList><ArticleId IdType="pubmed">20972546</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30527055</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Simultaneous Suprapubic Lipectomy and Penile Prosthesis Implantation.</ArticleTitle><Pagination><StartPage>1818</StartPage><EndPage>1823</EndPage><MedlinePgn>1818-1823</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2018.10.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(18)31271-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION">A shorter penis is a frequent complaint following penile prosthesis implantation (PPI), and a large redundant suprapubic fat pad can conceal the penis and possibly compromise patient and partner satisfaction with length.</AbstractText><AbstractText Label="AIM">To evaluate feasibility and outcome of same-session, same-incision, PPI and suprapubic lipectomy (SPL).</AbstractText><AbstractText Label="METHODS">In 22 patients, SPL was performed through an abdominal crease incision. Through the same incision, the superficial perineal pouch was opened to gain access to the base of the penis. Penile prosthesis was implanted (semirigid in 16 patients and girth-expanding 3-piece inflatable in 6). Scarpa's fascia, subcutaneous fat, and the abdominal crease skin incision were closed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">Evaluation was in terms of implant survival, preoperative vs postoperative patient and partner satisfaction with penile length on a 5-point rating scale, subjective opinion over penile length postoperatively, compared with recall of erect length before erectile dysfunction (ED) had set in (longer, same, or shorter), and penile length with the implant rigid, compared in the supine and standing positions postoperatively (pubic skin to tip, using a rigid ruler).</AbstractText><AbstractText Label="RESULTS">No infections or extrusions or mechanical failures were encountered. There was a 53.3% increase in patient satisfaction with length comparing preoperative (2.55 &#xb1; 0.67) to postoperative (4.77 &#xb1; 0.43) ratings, P&#xa0;&lt;&#xa0;.0001. Partner satisfaction showed a 40.2% increase, from 1.77 &#xb1; 0.61 to 4.41 &#xb1; 0.50, P &lt; .0001. 19 of 22 patients reported that postoperative length was longer than their recall of erect length before ED had set in, and 3&#xa0;patients reported that length was the same. With the implant rigid, there was no statistically significant difference in visible length between the supine and standing positions (14.1 cm &#xb1; 2.3 and 13.9 cm &#xb1; 2.3, respectively, P&#xa0;=&#xa0;.38).</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">Patients with refractory ED and a concealed penis can be counseled as to the option of simultaneous SPL and PPI (SPL-PPI), a modification that may help avoid patient and partner dissatisfaction with length.</AbstractText><AbstractText Label="STRENGTH &amp; LIMITATIONS">Strengths include objective evaluation of the efficacy of the procedure by comparing supine and standing penile length. Limitations of the current study include inability to evaluate erect length preoperatively owing to refractory ED, and subjectivity of patient and partner opinion.</AbstractText><AbstractText Label="CONCLUSION">Same-incision SPL-PPI appears to be a safe and effective procedure, with high patient and partner satisfaction rates. Shaeer O, Shaeer K, Abdel Rahman IF. Simultaneous suprapubic lipectomy and penile prosthesis implantation. J Sex Med 2018;15:1818-1823.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaeer</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Andrology, Kasr El Aini Faculty of Medicine, Cairo University, Egypt; Kamal Shaeer Hospital, Cairo, Egypt. Electronic address: dr.osama@alrijal.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaeer</LastName><ForeName>Kamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Andrology, Kasr El Aini Faculty of Medicine, Cairo University, Egypt; Kamal Shaeer Hospital, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AbdelRahman</LastName><ForeName>Islam Fathi</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Department of Andrology, Kasr El Aini Faculty of Medicine, Cairo University, Egypt; Kamal Shaeer Hospital, Cairo, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2019 Aug;202(2):203</RefSource><PMID Version="1">31021297</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015187" MajorTopicYN="N">Lipectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Liposuction</Keyword><Keyword MajorTopicYN="N">Penile Enhancement</Keyword><Keyword MajorTopicYN="N">Penile Implant</Keyword><Keyword MajorTopicYN="N">Penile Length</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Suprapubic Lipectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30527055</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2018.10.012</ArticleId><ArticleId IdType="pii">S1743-6095(18)31271-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30503795</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Placement of Inflatable Penile Implants in Patients With Prior Radical Pelvic Surgery: A Literature Review.</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>197</EndPage><MedlinePgn>189-197</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2018.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(18)30112-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Penile prosthesis for erectile restoration remains the only surgical option for medical refractory erectile dysfunction. Many expert prosthetic surgeons recommend special care when placing a reservoir in a patient who has undergone prior radical pelvic surgery (PRPS) due to distortion of anatomy and obliteration of the dead space in the traditionally used space of Retzius.</AbstractText><AbstractText Label="AIM">Review all the current literature on penile prosthesis implantation in patients with prior pelvic surgery, with an emphasis on tips and tricks for reservoir placement in this unique population.</AbstractText><AbstractText Label="METHODS">A Medline PubMed search was used to identify articles of interest related to all topics surrounding pelvic surgery and penile prostheses. The following terms were included in the search for articles of interest: "bladder cancer," "prostate cancer," "rectal cancer," "colon cancer," "pelvic surgery," "penile implants," "penile implant reservoir," and "penile prosthesis." Articles were further screened for content and English language.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">Outcomes and adverse event rates in this population. Review of options for reservoir placement.</AbstractText><AbstractText Label="RESULTS">The outcomes, satisfaction, and adverse event profiles are similar between patients in the PRPS group and those who are not, regardless of the cause for pelvic surgery. For surgeons uncomfortable with placing a reservoir in the compromised pelvis, a 2-piece inflatable penile implant (AMS Ambicor) is a viable option. For surgeons who recommend 3-piece implants in this patient population, alternative positions for the reservoir have been developed in the hope of avoiding catastrophic bowel, bladder, and vascular injuries.</AbstractText><AbstractText Label="CONCLUSION">In patients with PRPS, placing an inflatable penile prosthesis is not only feasible, it is definitive therapy with excellent patient satisfaction. Reservoir placement outside the space of Retzius or placing a 2-piece inflatable device can be easily performed with equivalent safety and efficacy. Madiraju SK, Hakky TS, Perito PE, et&#xa0;al. Placement of Inflatable Penile Implants in Patients With Prior Radical Pelvic Surgery: A Literature Review. Sex Med Rev 2019;7:189-197.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madiraju</LastName><ForeName>SriGita K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Charles E. Schmidt College of Medicine of FAU, Boca Raton, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakky</LastName><ForeName>Tariq S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Advanced Urology, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perito</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Perito Urology, Coral Gables, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallen</LastName><ForeName>Jared J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Florida Hospital Tampa Urology, Tampa, FL, USA. Electronic address: jaredjw5@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30503795</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2018.10.002</ArticleId><ArticleId IdType="pii">S2050-0521(18)30112-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30509508</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Delayed Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates Impaired Penile Hemodynamics in Rats Subjected to Pelvic Neurovascular Injury.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>26</EndPage><MedlinePgn>17-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2018.11.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(18)31283-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Erectile dysfunction (ED) caused by pelvic neurovascular injury (PNVI) is often refractory to treatment. In many cases, erectogenic therapy is administered in a delayed fashion.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate penile hemodynamic effects and histologic changes associated with delayed low-intensity extracorporeal shock wave therapy (Li-ESWT) after PNVI ED in a rat model. We visualized images using immunofluorescence and 3-dimensional imaging of solvent-cleared organs (3DISCO), a novel imaging technique.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 32 Sprague-Dawley male rats aged 12 weeks were divided equally into 4 groups: sham surgery as normal controls (NC), PNVI controls (PC), PNVI with very-low-energy Li-ESWT (PVL), and PNVI with low-energy Li-ESWT (PL). Bilateral cavernous nerve crush and internal pudendal bundle ligation were performed in the 3 PNVI groups. Li-ESWT was administered twice a week for 4 weeks in the PL and PVL groups starting at 4 weeks after PNVI.</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Intracavernous pressure (ICP) studies (normalized to mean arterial pressure [MAP]) were conducted in all subject animals. After testing, tissue was harvested for immunofluorescence staining and 3DISCO analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean ICP/MAP was lower in PC animals compared with NC animals (0.37 &#xb1; 0.03 vs 0.91 &#xb1; 0.03, respectively; P&#xa0;= .001). The ICP/MAP ratio was significantly higher in PVL and PL animals (0.66 &#xb1; 0.07 and 0.82 &#xb1; 0.05, respectively) compared with PC animals (P&#xa0;= .002 and .001, respectively). Detailed microstructures and trajectories of nerves and vessels were identified with immunofluorescence and 3DISCO. The PC group had lower density of nerves, axons, neuronal nitric oxide synthase-positive nerves, and Schwann cells in the dorsal penis. Animals in the PL group had significantly higher expression of all of these markers compared with PC animals.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS" NlmCategory="CONCLUSIONS">Li-EWST may have utility in the management of severe ED related to PNVI from severe pelvic injury or radical pelvic surgeries, even when administered in a delayed fashion.</AbstractText><AbstractText Label="STRENGTH &amp; LIMITATIONS" NlmCategory="UNASSIGNED">This study of a severe ED phenotype involved treatment administered in a delayed fashion, which is more consistent with how therapy likely would be delivered in a real-world clinical context. Moreover, because the treatment commenced at 4 weeks after injury, when nerve and tissue atrophy have already occurred, the results imply that Li-ESWT can be used for regenerative therapy. Additional studies on dose optimization and treatment interval are needed to inform the design of human clinical trials.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Li-ESWT ameliorates the negative functional and histologic effects of severe pelvic neurovascular injury in a rat model system. 3DISCO provides high-resolution images of neuroanatomy and neural regeneration. Wang HS, Ruan Y, Banie L, et&#xa0;al. Delayed Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates Impaired Penile Hemodynamics in Rats Subjected to Pelvic Neurovascular Injury. J Sex Med 2019;16:17-26.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hsun Shuan</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Hsiaokang Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banie</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Dongyi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tianshu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tianyu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bohan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guifang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shindel</LastName><ForeName>Alan W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guiting</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Tom F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA, USA. Electronic address: tom.lue@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK105097</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052248">Nitric Oxide Synthase Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074059" MajorTopicYN="N">Extracorporeal Shockwave Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052248" MajorTopicYN="N">Nitric Oxide Synthase Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012583" MajorTopicYN="N">Schwann Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020196" MajorTopicYN="N">Trauma, Nervous System</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3-Dimensional Imaging of Solvent-Cleared Organs</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Low-Intensity Shock Wave Therapy</Keyword><Keyword MajorTopicYN="N">Nerve Regeneration</Keyword><Keyword MajorTopicYN="N">Pelvic Neurovascular Injury</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30509508</ArticleId><ArticleId IdType="mid">NIHMS1515552</ArticleId><ArticleId IdType="pmc">PMC6326879</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2018.11.003</ArticleId><ArticleId IdType="pii">S1743-6095(18)31283-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151: 54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381: 153&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23040455</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F, Amar E, Chevallier D, et al. How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association. J Sex Med 2008;5: 448&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151: 650&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19884626</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72: 1000&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28434676</ArticleId></ArticleIdList></Reference><Reference><Citation>Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334: 873&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596569</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasiadis AG, Wilson SK, Burchardt M, et al. Long-term outcomes of inflatable penile implants: reliability, patient satisfaction and complication management. Curr Opin Urol 2001;11: 619&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani-Babu S, Morrissey D, Waugh C, et al. The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: a systematic review. Am J Sports Med 2015;43: 752&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24817008</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abbad H, Simon JV. The effectiveness of extracorporeal shock wave therapy on chronic achilles tendinopathy: a systematic review. Foot Ankle Int 2013;34: 33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23386759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann R, Cumpanas A, Hoeltl L, et al. Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: a feasibility study and the first clinical results. BJU Int 2008;102: 976&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510660</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Lin G, Xin Z, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med 2013;10: 738&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593747</ArticleId><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Kilchevsky A, et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012;187: 1769&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71: 223&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27321373</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Matheu MP, Sun F, et al. Low-energy Shock Wave Therapy Ameliorates Erectile Dysfunction in a Pelvic Neurovascular Injuries Rat Model. J Sex Med 2016;13: 22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26755082</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, Bradke F. High-resolution imaging of entire organs by 3-dimensional imaging of solvent cleared organs (3DISCO). Exp Neurol 2013;242: 57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23124097</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, Mauch CP, Hellal F, et al. Three-dimensional imaging of the unsectioned adult spinal cord to assess axon regeneration and glial responses after injury. Nat Med 2011;18: 166&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">22198277</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Fandel TM, Ferretti L, et al. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. Eur Urol 2012;62: 720&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542983</ArticleId><ArticleId IdType="pubmed">22397847</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, Lafkas D, Chalouni C. Imaging cleared intact biological systems at a cellular level by 3DISCO. J Vis Exp 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212806</ArticleId><ArticleId IdType="pubmed">25046566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahata K, Kanno H, Ozawa H, et al. Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury. J Neurosurg Spine 2016;25: 745&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">27367940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HS, Oh BS, Wang B, et al. Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates Diabetic Underactive Bladder in Streptozocin-Induced Diabetic Rats. BJU Int 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158099</ArticleId><ArticleId IdType="pubmed">29603534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtori S, Inoue G, Mannoji C, et al. Shock wave application to rat skin induces degeneration and reinnervation of sensory nerve fibres. Neurosci Lett 2001;315: 57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11711214</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata R, Ohtori S, Ochiai N, et al. Extracorporeal shockwaves induce the expression of ATF3 and GAP-43 in rat dorsal root ganglion neurons. Auton Neurosci 2006;128: 96&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716760</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JW, Thompson WJ. Biology and pathology of nonmyelinating Schwann cells. Glia 2008;56: 1518&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18803315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Ning H, Reed-Maldonado AB, et al. Low-Intensity Extracorporeal Shock Wave Therapy Enhances Brain-Derived Neurotrophic Factor Expression through PERK/ATF4 Signaling Pathway. Int J Mol Sci 2017;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343967</ArticleId><ArticleId IdType="pubmed">28212323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaya S, Ozawa H, Kanno H, et al. Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury. J Neurosurg 2014;121: 1514&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25280090</ArticleId></ArticleIdList></Reference><Reference><Citation>Myojo M, Ando J, Uehara M, et al. Feasibility of Extracorporeal Shock Wave Myocardial Revascularization Therapy for Post-Acute Myocardial Infarction Patients and Refractory Angina Pectoris Patients. Int Heart J 2017;58: 185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28320996</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood AE, Green J, Cayton T, et al. A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. J Vasc Surg 2018;67: 514&#x2013;21 e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">28943002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittermayr R, Hartinger J, Antonic V, et al. Extracorporeal shock wave therapy (ESWT) minimizes ischemic tissue necrosis irrespective of application time and promotes tissue revascularization by stimulating angiogenesis. Ann Surg 2011;253: 1024&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21372687</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigouroux RJ, Belle M, Chedotal A . Neuroscience in the third dimension: shedding new light on the brain with tissue clearing. Mol Brain 2017;10: 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520295</ArticleId><ArticleId IdType="pubmed">28728585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Reed-Maldonado AB, Wang B, et al. In Situ Activation of Penile Progenitor Cells With Low-Intensity Extracorporeal Shockwave Therapy. J Sex Med 2017;14: 493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30173304</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2366-0058</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Abdominal radiology (New York)</Title><ISOAbbreviation>Abdom Radiol (NY)</ISOAbbreviation></Journal><ArticleTitle>CT imaging of inflatable penile prosthesis complications: a pictorial essay.</ArticleTitle><Pagination><StartPage>739</StartPage><EndPage>748</EndPage><MedlinePgn>739-748</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00261-018-1764-0</ELocationID><Abstract><AbstractText Label="PURPOSE">Inflatable penile prostheses (IPPs) are widely used in the United States, for patients with erectile dysfunction refractory to other treatments. Complications subsequent to IPP insertion include infection, hematoma, fluid leak, component (cylinder/pump/reservoir) complications, and retained previous IPP components. Radiologists are often called upon to identify and characterize these complications utilizing CT prior to intervention. Our paper aims to provide a guide to familiarize radiologists with normal IPP component imaging and review the CT findings of commonly encountered complications.</AbstractText><AbstractText Label="METHODS">In this study, we retrospectively reviewed CT reports with descriptions of IPPs from 108 patients. We collected CT images of normal IPP components as well as reevaluated the CT findings of 33 patients with an IPP complication and correlated with immediately subsequent operative report.</AbstractText><AbstractText Label="RESULTS">The CT appearance of appropriately positioned normal IPP components in asymptomatic patients and each complication were described and compared to previous literature.</AbstractText><AbstractText Label="CONCLUSIONS">CT is a very useful modality to assess an IPP-related complication. It is inexpensive, fast, and immediately available in emergent situations, e.g., infection, hematoma, and component erosion. Additionally, CT is very sensitive and makes it easier to diagnose a system leak. It can identify most cylinder complications and pump malposition and can be extremely helpful to the surgeon in preoperative planning if revision is needed. After this review, the radiologist should be able to identify normal IPP components and their complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Huan L</ForeName><Initials>HL</Initials><Identifier Source="ORCID">0000-0002-1606-4354</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Urology, Hahnemann University Hospital, 230&#xa0;N Broad St, Philadelphia, PA, 19102, USA. helixloop84@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohsen</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Radiology and Urology, Hahnemann University Hospital, 230&#xa0;N Broad St, Philadelphia, PA, 19102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garber</LastName><ForeName>Bruce B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Radiology and Urology, Hahnemann University Hospital, 230&#xa0;N Broad St, Philadelphia, PA, 19102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldstein</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Radiology and Urology, Hahnemann University Hospital, 230&#xa0;N Broad St, Philadelphia, PA, 19102, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Abdom Radiol (NY)</MedlineTA><NlmUniqueID>101674571</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004868" MajorTopicYN="Y">Equipment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006406" MajorTopicYN="N">Hematoma</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complication</Keyword><Keyword MajorTopicYN="N">Computed tomography</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Inflatable penile prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30173304</ArticleId><ArticleId IdType="doi">10.1007/s00261-018-1764-0</ArticleId><ArticleId IdType="pii">10.1007/s00261-018-1764-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30173210</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0399</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>3</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Urologia internationalis</Title><ISOAbbreviation>Urol Int</ISOAbbreviation></Journal><ArticleTitle>Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial.</ArticleTitle><Pagination><StartPage>358</StartPage><EndPage>365</EndPage><MedlinePgn>358-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000492120</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This open label, phase I clinical trial (NCT02945462) using 2 consecutive intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the first time in the treatment of diabetic patients with erectile dysfunction (ED). The primary outcome is to assess the safety and tolerability of intracavernous autologous BM-MSCs, the secondary outcome is to assess efficacy of the procedure.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Four diabetic patients with refractory ED were included. Two consecutive intracavernous autologous BM-MSC injections were performed. Tolerability was assessed immediately and at 24 h, safety was evaluated for 2&#xa0;years. Efficacy was assessed using International Index of Erectile Function-15 (IIEF-15) and Erection Hardness Score (EHS) for 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">procedure was well tolerated and no patients reported significant adverse effects. There was significant improvement of IIEF-15 and EHS; IIEF-15 (p = 0.04), Erectile Function (p = 0.03), Sexual Desire (p = 0.04), Intercourse Satisfaction (p = 0.04), and Overall Satisfaction (p = 0.04).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first human study with proven tolerability, safety and efficacy of intracavernous autologous BM-MSC injections for treatment of diabetic patients with ED.</AbstractText><CopyrightInformation>&#xa9; 2018 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al Demour</LastName><ForeName>Saddam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Special Surgery/Division of Urology, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Histology, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adwan</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlSharif</LastName><ForeName>Abedallatif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology and Nuclear Medicine, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhawari</LastName><ForeName>Hussam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alrabadi</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Special Surgery/Division of Urology, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayed</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaradat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Special Surgery/Division of Urology, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awidi</LastName><ForeName>Abdalla</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Therapy Center, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, The University of Jordan, School of Medicine, Amman, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Urol Int</MedlineTA><NlmUniqueID>0417373</NlmUniqueID><ISSNLinking>0042-1138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2019 Mar;7(Suppl 1):S40</RefSource><PMID Version="1">31032319</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30173210</ArticleId><ArticleId IdType="doi">10.1159/000492120</ArticleId><ArticleId IdType="pii">000492120</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30079640</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2287-4208</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>The world journal of men's health</Title><ISOAbbreviation>World J Mens Health</ISOAbbreviation></Journal><ArticleTitle>Obesity and Erectile Dysfunction: From Bench to Clinical Implication.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>147</EndPage><MedlinePgn>138-147</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5534/wjmh.180026</ELocationID><Abstract><AbstractText>Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, concomitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Korean Society for Sexual Medicine and Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Ki Hak</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-8193-9022</Identifier><AffiliationInfo><Affiliation>Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>So Young</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-6018-0440</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong Woon</ForeName><Initials>YW</Initials><Identifier Source="ORCID">0000-0003-2868-9690</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Yeungnam University College of Medicine, Daegu, Korea. ywkim@med.yu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>World J Mens Health</MedlineTA><NlmUniqueID>101596899</NlmUniqueID><ISSNLinking>2287-4208</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase 5 inhibitors</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30079640</ArticleId><ArticleId IdType="pmc">PMC6479091</ArticleId><ArticleId IdType="doi">10.5534/wjmh.180026</ArticleId><ArticleId IdType="pii">36.e24</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">16506274</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kwon OS, Cho SY, Paick JS, Kim SW. Chronic administration of atorvastatin could partially ameliorate erectile function in streptozotocin-induced diabetic rats. PLoS One. 2017;12:e0172751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330475</ArticleId><ArticleId IdType="pubmed">28245261</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34:557&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">21720206</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza ILL, Barros BC, de Oliveira GA, Queiroga FR, Toscano LT, Silva AS, et al. Hypercaloric diet establishes erectile dysfunction in rat: mechanisms underlying the endothelial damage. Front Physiol. 2017;8:760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649200</ArticleId><ArticleId IdType="pubmed">29085300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol. 2006;176:217&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753404</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillo J, Levcikova M, Ondrusova M, Breza J, Labas P. Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence. Am J Mens Health. 2017;11:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5675278</ArticleId><ArticleId IdType="pubmed">27184064</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir O, Akgul K, Akar Z, Cakmak O, Ozdemir I, Bolukbasi A, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19326294</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleid M, Muneer A, Renshaw S, George J, Jenkinson AD, Adamo M, et al. Early effect of bariatric surgery on urogenital function in morbidly obese men. J Sex Med. 2017;14:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">28087357</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YS, Lee SK, Bae WJ, Kim SJ, Cho HJ, Hong SH, et al. Bariatric surgery improves the cavernosal neuronal, vasorelaxation, and contraction mechanisms for erectile dysfunction as result of amelioration of glucose homeostasis in a diabetic rat model. PLoS One. 2014;9:e104042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138031</ArticleId><ArticleId IdType="pubmed">25137300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kun L, Pin Z, Jianzhong D, Xiaodong H, Haoyong Y, Yuqian B, et al. Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction. Obes Surg. 2015;25:838&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">25361762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med. 2009;(6 Suppl 3):254&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">19170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Meldrum DR, Gambone JC, Morris MA, Esposito K, Giugliano D, Ignarro LJ. Lifestyle and metabolic approaches to maximizing erectile and vascular health. Int J Impot Res. 2012;24:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072232</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiorino MI, Bellastella G, Esposito K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl. 2015;17:5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291878</ArticleId><ArticleId IdType="pubmed">25248655</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel JP, Lee EH, Mena CI, Walker CN. Effects of metformin on endothelial health and erectile dysfunction. Transl Androl Urol. 2017;6:556&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503973</ArticleId><ArticleId IdType="pubmed">28725599</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh E, Song DK, Kim MS. Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp Mol Med. 2016;48:e216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4892882</ArticleId><ArticleId IdType="pubmed">26964832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YW, Choi DW, Park YH, Huh JY, Won KC, Choi KH, et al. Leptin-like effects of MTII are augmented in MSG-obese rats. Regul Pept. 2005;127:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes. 2006;55:716&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505235</ArticleId></ArticleIdList></Reference><Reference><Citation>Small CJ, Stanley SA, Bloom SR. Appetite control and reproduction: leptin and beyond. Semin Reprod Med. 2002;20:389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536362</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128:1538&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873875</ArticleId><ArticleId IdType="pubmed">29528335</ArticleId></ArticleIdList></Reference><Reference><Citation>de Git KC, Adan RA. Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes Rev. 2015;16:207&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">25589226</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan OK, Inglis MA, Anderson GM. Leptin signaling in AgRP neurons modulates puberty onset and adult fertility in mice. J Neurosci. 2017;37:3875&#x2013;3886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596709</ArticleId><ArticleId IdType="pubmed">28275162</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo PR, Knoblovits P. Male gonadal axis function in patients with type 2 diabetes. Horm Mol Biol Clin Investig. 2016;26:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071157</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao K, Iwata K, Takeshita T, Ozawa H. Expression of hypothalamic kisspeptin, neurokinin B, and dynorphin A neurons attenuates in female Zucker fatty rats. Neurosci Lett. 2018;665:135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">29203206</ArticleId></ArticleIdList></Reference><Reference><Citation>Quennell JH, Mulligan AC, Tups A, Liu X, Phipps SJ, Kemp CJ, et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. Endocrinology. 2009;150:2805&#x2013;2812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732287</ArticleId><ArticleId IdType="pubmed">19179437</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673&#x2013;3680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10523013</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-&#x3b1; and GPER signalling. Mol Cell Endocrinol. 2012;351:269&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">22233684</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoblovits P, Costanzo PR, Valzacchi GJ, Gueglio G, Layus AO, Kozak AE, et al. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl. 2010;31:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">19834133</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond) 2016;40:162&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722240</ArticleId><ArticleId IdType="pubmed">26219417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5530532</ArticleId><ArticleId IdType="pubmed">28750629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YW, Park SY, Kim JY, Huh JY, Jeon WS, Yoon CJ, et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl. 2007;28:555&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">17314235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY. AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008;106:394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">18360094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005;25:989&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu SY, Choi YJ, Park SY, Kim JY, Kim YD, Kim YW. Udenafil, a phosphodiesterase 5 inhibitor, reduces body weight in high-fat-fed mice. World J Mens Health. 2018;36:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756806</ArticleId><ArticleId IdType="pubmed">29164831</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Xu J, Yao W, Li H, Liu Q, Xiao F, et al. Sevoflurane pretreatment attenuates TNF-&#x3b1;-induced human endothelial cell dysfunction through activating eNOS/NO pathway. Biochem Biophys Res Commun. 2015;460:879&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">25838201</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest. 2004;27:665&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafez G, Gonulalan U, Kosan M, Arioglu E, Ozturk B, Cetinkaya M, et al. Acetylsalicylic acid protects erectile function in diabetic rats. Andrologia. 2014;46:997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">24428436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar Z, Albayrak S. Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: a prospective randomized double-blind placebo-controlled study. Int Urol Nephrol. 2018;50:411&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">29344879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mong PY, Petrulio C, Kaufman HL, Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol. 2008;180:550&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097057</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumegu&#xe8;re T, Van Antwerpen P, Fathi H, Rousseau A, Vanhamme L, Franck T, et al. Relationship between oxidative stress and erectile function. Free Radic Res. 2017;51:924&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">29041845</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro FS, Zemse S, Giachini FR, Carneiro ZN, Lima VV, Webb RC, et al. TNF-alpha infusion impairs corpora cavernosa reactivity. J Sex Med. 2009;(6 Suppl 3):311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701672</ArticleId><ArticleId IdType="pubmed">19267854</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro FS, Sturgis LC, Giachini FR, Carneiro ZN, Lima VV, Wynne BM, et al. TNF-alpha knockout mice have increased corpora cavernosa relaxation. J Sex Med. 2009;6:115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843140</ArticleId><ArticleId IdType="pubmed">19170842</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Voorde J, Pauwels B, Boydens C, Decaluw&#xe9; K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62:1513&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">23866981</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos G, Hirotsu C, Alvarenga TA, Cintra F, Bittencourt L, Tufik S, et al. The association between TNF-&#x3b1; and erectile dysfunction complaints. Andrology. 2013;1:872&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">24123864</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092513</ArticleId></ArticleIdList></Reference><Reference><Citation>Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18:E1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486142</ArticleId><ArticleId IdType="pubmed">28635626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Song SE, Kim YW, Kim JY, Park SC, Park YK, et al. Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol. 2010;207:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20675307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentili A, Zaibi MS, Alomar SY, De Vuono S, Ricci MA, Alaeddin A, et al. Circulating levels of the adipokines monocyte chemotactic protein-4 (MCP-4), macrophage inflammatory protein-1&#x3b2; (MIP-1&#x3b2;), and eotaxin-3 in severe obesity and following bariatric surgery. Horm Metab Res. 2016;48:847&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">27300476</ArticleId></ArticleIdList></Reference><Reference><Citation>Arent SM, Walker AJ, Pellegrino JK, Sanders DJ, McFadden BA, Ziegenfuss TN, et al. The combined effects of exercise, diet, and a multi-ingredient dietary supplement on body composition and adipokine changes in overweight adults. J Am Coll Nutr. 2018;37:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">29111889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747347</ArticleId></ArticleIdList></Reference><Reference><Citation>El Assar M, Angulo J, Santos-Ruiz M, Ruiz de Adana JC, Pindado ML, S&#xe1;nchez-Ferrer A, et al. Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans. J Physiol. 2016;594:3045&#x2013;3060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887698</ArticleId><ArticleId IdType="pubmed">26840628</ArticleId></ArticleIdList></Reference><Reference><Citation>El Assar M, Ruiz de Adana JC, Angulo J, Pindado Mart&#xed;nez ML, Hern&#xe1;ndez Mat&#xed;as A, Rodr&#xed;guez-Ma&#xf1;as L. Preserved endothelial function in human obesity in the absence of insulin resistance. J Transl Med. 2013;11:263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016214</ArticleId><ArticleId IdType="pubmed">24138787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Wu R, Huang Y, Zheng F, Ou Y, Tu X, et al. Insulin resistance is an independent determinate of ED in young adult men. PLoS One. 2013;8:e83951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877124</ArticleId><ArticleId IdType="pubmed">24391852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 2009;119:1284&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810548</ArticleId><ArticleId IdType="pubmed">19237660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang MH, Lee S. Insulin resistance: vascular function and exercise. Integr Med Res. 2016;5:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390417</ArticleId><ArticleId IdType="pubmed">28462118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dozio E, Barassi A, Dogliotti G, Malavazos AE, Colpi GM, D'Eril GV, et al. Adipokines, hormonal parameters, and cardiovascular risk factors: similarities and differences between patients with erectile dysfunction of arteriogenic and nonarteriogenic origin. J Sex Med. 2012;9:2370&#x2013;2377.</Citation><ArticleIdList><ArticleId IdType="pubmed">22616653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WH, Zhang XH. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. Asian J Androl. 2016;18:723&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5000795</ArticleId><ArticleId IdType="pubmed">26620458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor MS, Khan SA, Gupta SK, Choudhary R, Bodakhe SH. Animal models of erectile dysfunction. J Pharmacol Toxicol Methods. 2015;76:43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26279495</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillo J, Breza J, Lev&#x10d;&#xed;kova M, Luha J, Vachulova A, Durd&#xed;k &#x160;, et al. Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone? Int Urol Nephrol. 2012;44:1113&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22315154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015;12:856&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">25675988</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332:589&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1397768</ArticleId><ArticleId IdType="pubmed">16528082</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner LD, Dowling AR, Stuart RC, Nillni EA, Hill JW. Reduced melanocortin production causes sexual dysfunction in male mice with POMC neuronal insulin and leptin insensitivity. Endocrinology. 2015;156:1372&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399313</ArticleId><ArticleId IdType="pubmed">25590244</ArticleId></ArticleIdList></Reference><Reference><Citation>Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25105996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor-Villaescusa B, Ca&#xf1;ete MD, Caballero-Villarraso J, Hoyos R, Latorre M, V&#xe1;zquez-Cobela R, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017;140:e20164285.</Citation><ArticleIdList><ArticleId IdType="pubmed">28759403</ArticleId></ArticleIdList></Reference><Reference><Citation>Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15:196&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">25772174</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey-Valzacchi GJ, Costanzo PR, Finger LA, Layus AO, Gueglio GM, Litwak LE, et al. Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study. J Androl. 2012;33:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">22016348</ArticleId></ArticleIdList></Reference><Reference><Citation>Majithiya JB, Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci. 2006;78:2615&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">16318863</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Prieto CF, Gil-Ortega M, Ar&#xe1;nguez I, Ortiz-Besoain M, Somoza B, Fern&#xe1;ndez-Alfonso MS. Vascular AMPK as an attractive target in the treatment of vascular complications of obesity. Vascul Pharmacol. 2015;67-69:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25869500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chantler PD, Shrader CD, Tabone LE, d'Audiffret AC, Huseynova K, Brooks SD, et al. Cerebral cortical microvascular rarefaction in metabolic syndrome is dependent on insulin resistance and loss of nitric oxide bioavailability. Microcirculation. 2015;22:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551443</ArticleId><ArticleId IdType="pubmed">26014499</ArticleId></ArticleIdList></Reference><Reference><Citation>Labazi H, Wynne BM, Tostes R, Webb RC. Metformin treatment improves erectile function in an angiotensin II model of erectile dysfunction. J Sex Med. 2013;10:2154&#x2013;2164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429591</ArticleId><ArticleId IdType="pubmed">23889981</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Y, Wu F, Li D, Yang L, Li Q, Li R. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">28935544</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RB, Aroda VR, Bluemke DA, Barrett-Connor E, Budoff M, Crandall JP, et al. Effect of long-term metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium. Circulation. 2017;136:52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526695</ArticleId><ArticleId IdType="pubmed">28476766</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva FH, Alexandre EC, Calmasini FB, Calixto MC, Antunes E. Treatment with metformin improves erectile dysfunction in a murine model of obesity associated with insulin resistance. Urology. 2015;86:423.e1&#x2013;423.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26199165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Rastrelli G, et al. Metformin in vitro and in vivo increases adenosine signaling in rabbit corpora cavernosa. J Sex Med. 2014;11:1694&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">24844317</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005;258:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115299</ArticleId></ArticleIdList></Reference><Reference><Citation>Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabb&#xe0; C, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3:1094&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">26447645</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon KH, Kim SW, Moon du G, Kim JJ, Park NC, Lee SW, et al. A phase 3 study to evaluate the 1-year efficacy and safety of udenafil 75 mg once daily in patients with erectile dysfunction. J Sex Med. 2016;13:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">27319276</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC. Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One. 2012;7:e45243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448606</ArticleId><ArticleId IdType="pubmed">23028874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes AK, Rap&#xf4;so C, Rocha SW, Barbosa KP, Luna RL, da Cruz-H&#xf6;fling MA, et al. Involvement of AMPK, IK&#x3b2;&#x3b1;-NF&#x3ba;B and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model. Brain Res. 2015;1627:119&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">26404052</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi D, Granata AR, Guidi A, Pignatti E, Trenti T, Roli L, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol. 2016;174:513&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">26792933</ArticleId></ArticleIdList></Reference><Reference><Citation>De Toni L, Strapazzon G, Gianesello L, Caretta N, Pilon C, Bruttocao A, et al. Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo. J Endocrinol Invest. 2011;34:738&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">22234177</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, et al. PDE5 inhibition ameliorates visceral adiposity targeting the miR-22/SIRT1 pathway: evidence from the CECSID trial. J Clin Endocrinol Metab. 2016;101:1525&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pubmed">26964730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammi C, Pastore D, Lombardo MF, Ferrelli F, Caprio M, Consoli C, et al. Sildenafil reduces insulin-resistance in human endothelial cells. PLoS One. 2011;6:e14542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030559</ArticleId><ArticleId IdType="pubmed">21297971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, et al. Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. J Clin Endocrinol Metab. 2015;100:4533&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667163</ArticleId><ArticleId IdType="pubmed">26580240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JE, Arora P, Walford GA, Ghorbani A, Guanaga DP, Dhakal BP, et al. Effect of phosphodiesterase inhibition on insulin resistance in obese individuals. J Am Heart Assoc. 2014;3:e001001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323801</ArticleId><ArticleId IdType="pubmed">25213566</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutter MK, Kirby M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102:1750&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099221</ArticleId><ArticleId IdType="pubmed">27465053</ArticleId></ArticleIdList></Reference><Reference><Citation>Peuler JD, Phelps LE. Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. J Smooth Muscle Res. 2015;51:22&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137313</ArticleId><ArticleId IdType="pubmed">26004378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4027935</ArticleId><ArticleId IdType="pubmed">24868160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30063021</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1698-0409</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Revista internacional de andrologia</Title><ISOAbbreviation>Rev Int Androl</ISOAbbreviation></Journal><ArticleTitle>Pelvic chondro-sarcoma and erectile dysfunction: A challenging surgical case.</ArticleTitle><Pagination><StartPage>34</StartPage><EndPage>37</EndPage><MedlinePgn>34-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.androl.2017.02.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1698-031X(17)30032-8</ELocationID><Abstract><AbstractText>A 46 year-old male presented suffering from refractory erectile dysfunction. The patient had a past history of pelvic chondro-sarcoma. This case was a challenge for us; the surgery performed for excision of the sarcoma has resulted in the elimination of both pubic ramia together with excision of part of both corpora and left hemiscrotum. The procedure included a sling application on one side with a mesh sock wrapped around the rear part of the extendor cylinder. Another sling was applied on the contra lateral side without a mesh sock.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Asociaci&#xf3;n Espa&#xf1;ola de Androlog&#xed;a, Medicina Sexual y Reproductiva. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>GamalEl Din</LastName><ForeName>Sameh Fayek</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Cairo University, Egypt. Electronic address: samehfayek@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abo Sief</LastName><ForeName>Ahmed Fathy</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Beni-Suef University, Egypt; Cairo University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fawzy</LastName><ForeName>Emad Awny</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Cairo University, Egypt; Specialist of Andrology &amp; Dermatology, Ministry of Health, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Fatah</LastName><ForeName>Mohamed Abd</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Cairo University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abo Senna</LastName><ForeName>Wessam Gamal</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Cairo University, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Int Androl</MedlineTA><NlmUniqueID>101500934</NlmUniqueID><ISSNLinking>1698-031X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002813" MajorTopicYN="N">Chondrosarcoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010384" MajorTopicYN="N">Pelvic Bones</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Condrosarcoma de la pelvis</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Pelvic chondro-sarcoma</Keyword><Keyword MajorTopicYN="N">Surgical technique</Keyword><Keyword MajorTopicYN="N">T&#xe9;cnica quir&#xfa;rgica</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30063021</ArticleId><ArticleId IdType="doi">10.1016/j.androl.2017.02.006</ArticleId><ArticleId IdType="pii">S1698-031X(17)30032-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30033128</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis Complications: Planning, Prevention, and Decision Making.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>359</EndPage><MedlinePgn>349-359</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2018.04.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(18)30055-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prosthesis (IPP) is an established treatment option for men with erectile dysfunction (ED) refractory to medical therapy. Standardization of surgical technique and improvements in device construction have reduced all-cause complication rates to less than 5% in recent reports. Nonetheless, complications do exist, and can strongly impact morbidity and the quality of life of patients. Prosthetic urologists must be aware of the constellation of complications that can arise during or after IPP placement.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To provide a comprehensive review of penile prosthesis complications and discuss preventative strategies, as well as proper preoperative, intraoperative, and postoperative decision making.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A review of the available literature from 1973 to 2018 was performed using PubMed with regard to IPP complications.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">We reviewed publications that outlined preoperative planning strategies and the following IPP complications: hematoma, floppy glans, corporal fibrosis, corporal perforation and crossover, urethral injury, infection, impending erosion, and glandular ischemia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Careful patient and device selection, setting realistic expectations of postsurgical outcomes, and adherence to a perioperative checklist is essential in the preoperative period. Intraoperatively, anticipate corporal fibrosis situations and always dilate laterally during corporal passage to reduce the risk of crossover and urethral injury. Limit perioperative antiplatelet therapy, apply compressive dressing, use a closed suction drain if indicated, and leave the device partially inflated postoperatively to reduce risk of hematoma. After surgery, monitor patients for potential complications that may warrant device explantation or salvage: IPP infection, glans ischemia, and impending erosion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">By using evidence and expert opinion-based decision-making strategies in the preoperative, intraoperative, and postoperative period of IPP placement, surgeons can reduce the risk of complications and dissatisfaction, even in ED patients with multiple comorbid conditions. Scherzer ND, Dick B, Gabrielson AT, et&#xa0;al. Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sex Med Rev 2019;7:349-359.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Nickolas D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabrielson</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzweri</LastName><ForeName>Laith M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJG</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA. Electronic address: whellst@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006285" MajorTopicYN="N">Health Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007432" MajorTopicYN="N">Intraoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30033128</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2018.04.002</ArticleId><ArticleId IdType="pii">S2050-0521(18)30055-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29795529</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Infection risk of undergoing multiple penile prostheses: an analysis of referred patient surgical histories.</ArticleTitle><Pagination><StartPage>147</StartPage><EndPage>152</EndPage><MedlinePgn>147-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-018-0026-6</ELocationID><Abstract><AbstractText>Inflatable penile prosthesis (IPP) is the gold standard for medically refractory erectile dysfunction. Infectious complications remain a significant concern in IPP revision surgery. We sought to evaluate the impact of number of IPP surgeries on subsequent infection rates. A retrospective analysis was performed on all new patients (self or outside provider referred) presenting for consideration of IPP revision or salvage surgery between 2013 and 2015. Histories were reviewed including number of prior IPPs, reason for evaluation, and rate, number, and timing of prior IPP infections. No patients were operated on by the primary investigator prior to data acquisition. We identified 44 patients with at least one prior IPP presenting for consultation regarding IPP revision/salvage. There were 88 IPPs placed by 28 different surgeons. In patients with two or more devices, 55% had at least two different surgeons. The most common reason for presentation was malfunction (52%). The risk of specific device infection was strongly correlated and increased based on number of prior IPPs: 1st (6.8%; 3/44), 2nd (18.2%; 4/22), 3rd (33.3%; 4/12), 4th (50%; 4/8), and 5th (100%; 2/2) (R<sup>2</sup>&#x2009;=&#x2009;0.90, p&#x2009;=&#x2009;0.01). Similarly, overall rates of infection positively correlated with number of prior IPP-related surgeries performed (R<sup>2</sup>&#x2009;=&#x2009;0.97, p&#x2009;&lt;&#x2009;0.01). The median time to development of infection after most recent IPP surgery was 2&#x2009;months (IQR 1-3.3 months). Infection rates of revision/salvage IPP surgery increase with each subsequent IPP placement or following IPP-related surgeries. The majority of patients referred for penile implant surgery can expect to have experienced at least one infection by their 4th device. These data represent a change in paradigm on revision prosthetic surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Brian D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomas</LastName><ForeName>Derek J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegelmann</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Landon W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA. Trost.Landon@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Impot Res. 2018 Aug;30(4):189</RefSource><PMID Version="1">29895864</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29795529</ArticleId><ArticleId IdType="doi">10.1038/s41443-018-0026-6</ArticleId><ArticleId IdType="pii">10.1038/s41443-018-0026-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29732286</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of daily Revactin<sup>&#xae;</sup> in men with erectile dysfunction: a 3-month pilot study.</ArticleTitle><Pagination><StartPage>266</StartPage><EndPage>273</EndPage><MedlinePgn>266-273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2018.03.22</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The earliest sign of an ongoing change in a man's erectile function (EF) is the increase in his refractory period. This is due to the onset of an aging related apoptosis of the corporal smooth muscle cells (CSMC) as a result of oxidative stress (ROS) within the CSMC itself. In response, the CSMC begin to upregulate the inducible nitric oxide synthase (iNOS) enzyme presumably to achieve high levels of nitric oxide (NO) used to combat ROS. Treatment of aged rats for 2 months with the nutraceutical Revactin<sup>&#xae;</sup>, known to stimulate the iNOS-NO-cGMP pathway in CSMC, resulted in (I) an increase in CSMC content with a decrease in corporal fibrosis, (II) decrease in systemic ROS, and (III) improvement in EF. To determine whether Revactin<sup>&#xae;</sup> could be used in the clinical setting, a pilot safety study was conducted.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-four middle aged men (mean age 57.8&#xb1;10.7; range, 33-77 years) were recruited for this safety study. Patients were given Revactin<sup>&#xae;</sup> twice daily (total daily dose of 500 mg of ginger root, muira puama, and Paullinia cupana and 1,600 mg of L-citrulline) and were asked to complete the IIEF-15 questionnaire [domains: EF, orgasmic function (OF), sexual desire (SD), intercourse satisfaction (IS), overall satisfaction (OS)] at baseline (B), 1 month (M1), 2 months (M2) and 3 months (M3) and report any side effects. Those on erectogenic medications at B were requested to stop taking them during the trial. Data were analyzed using Wilcoxon paired test and Friedman rank test for trend.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Revactin<sup>&#xae;</sup> was safe with only 5 patients reporting treatment side effects (e.g., dyspepsia, heartburn, migraine) and none considered severe. For those who stayed on the regimen (M1 =32; M2 =22; M3 =16), there was an increase in median domain scores for EF, OF, SD, IS, and OS over 3 months compared to baseline median scores but statistical significance was found only in the EF, IS, and OS median domain scores. Trend analysis indicated significant trend in EF, OS &amp; IS (P&lt;0.05). For the EF domain, the median scores were: M1 =21, M2 =22, M3 =19 relative to the B =16, 15.5, and 14.5, respectively (P&lt;0.05). Overall, approximately 50% of the patients reported a significant improvement in EF (P&lt;0.05). The major reason for trial discontinuation (M1 =22, M2 =9 and M3 =6) was non-compliance with pro-erectile medications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Revactin<sup>&#xae;</sup>, a combination of 3 nutraceuticals packaged with L-citrulline, appears to have the same excellent safety profile known for each of its individual four components. The early improvement in EF seen in about 50% of these patients may be due to the elevated levels of cGMP produced via this iNOS-cGMP pathway. Further longitudinal studies with Revactin<sup>&#xae;</sup> appear warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajfer</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaheen</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, College of Medicine, Charles R Drew University, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 MD007598</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Revactin&#xae;</Keyword><Keyword MajorTopicYN="N">erectile function (EF)</Keyword><Keyword MajorTopicYN="N">nutraceutical</Keyword></KeywordList><CoiStatement>Conflicts of Interest: J Rajfer is a stockholder in KLRM, LLC which supplied Revactin for the study and has a US patent pending on Revactin&#xae;. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29732286</ArticleId><ArticleId IdType="pmc">PMC5911531</ArticleId><ArticleId IdType="doi">10.21037/tau.2018.03.22</ArticleId><ArticleId IdType="pii">tau-07-02-266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61. 10.1016/S0022-5347(17)34871-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)34871-1</ArticleId><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF, Takamura T, Schmidt RA, et al. Hemodynamics of erection in the monkey. J Urol 1983;130:1237-41. 10.1016/S0022-5347(17)51768-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)51768-1</ArticleId><ArticleId IdType="pubmed">6417346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol 1987;137:829-36. 10.1016/S0022-5347(17)44267-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)44267-4</ArticleId><ArticleId IdType="pubmed">3553617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier GR, Jr, Juenemann KP, Lue TF, et al. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol 1987;137:163-7. 10.1016/S0022-5347(17)43911-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)43911-5</ArticleId><ArticleId IdType="pubmed">3795360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res 2002;14 Suppl 1:S17-21. 10.1038/sj.ijir.3900792</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900792</ArticleId><ArticleId IdType="pubmed">11850730</ArticleId></ArticleIdList></Reference><Reference><Citation>Jevtich MJ, Khawand NY, Vidic B. Clinical significance of ultrastructural findings in the corpora cavernosa of normal and impotent men. J Urol 1990;143:289-93. 10.1016/S0022-5347(17)39936-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)39936-6</ArticleId><ArticleId IdType="pubmed">2299719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini M, Magee TR, Vernet D, et al. Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol Reprod 2001;64:974-82. 10.1095/biolreprod64.3.974</Citation><ArticleIdList><ArticleId IdType="doi">10.1095/biolreprod64.3.974</ArticleId><ArticleId IdType="pubmed">11207215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexual inadequacy in the Aging Male. In: Masters WH, Johnson VE. editors. Human Sexual Inadequacy, Chapter 12. Boston: Little, Brown &amp; Co.; 1970:316-22.</Citation></Reference><Reference><Citation>Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992;256:225-8. 10.1126/science.1373522</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1373522</ArticleId><ArticleId IdType="pubmed">1373522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesbitt JA, 3rd, Anderson WB, Miller Z, et al. Guanylate cyclase and cyclic guanosine 3':5'-monophosphate phosphodiesterase activities and cyclic guanosine 3':5'-monophosphate levels in normal and transformed fibroblasts in culture. J Biol Chem 1976;251:2344-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">4444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Kovanecz I, Sanchez S, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007;76:915-23. 10.1095/biolreprod.106.059642</Citation><ArticleIdList><ArticleId IdType="doi">10.1095/biolreprod.106.059642</ArticleId><ArticleId IdType="pubmed">17287493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Hlaing SM, Chan A, et al. Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat. Andrology (Los Angel) 2015;4. pii: 132. 10.4172/2167-0250.1000132</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2167-0250.1000132</ArticleId><ArticleId IdType="pmc">PMC4578663</ArticleId><ArticleId IdType="pubmed">26405615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Garcia E, Abraham A, et al. Effect of ginger, Paullinia cupana, muira puama and L-citrulline, singly or in combination, on modulation of the inducible nitric oxide NO-cGMP pathway in rat penile smooth muscle cells. Nitric Oxide 2018. [Epub ahead of print]. 10.1016/j.niox.2018.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2018.03.010</ArticleId><ArticleId IdType="pubmed">29551532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30. 10.1016/S0090-4295(97)00238-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(97)00238-0</ArticleId><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51. 10.1016/S0090-4295(99)00099-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(99)00099-0</ArticleId><ArticleId IdType="pubmed">10443736</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, Mazzilli F, Rossi T, et al. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000;15:131-4. 10.1093/humrep/15.1.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/15.1.131</ArticleId><ArticleId IdType="pubmed">10611201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Ponchietti R, Muir GH, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res 2003;15:225-8. 10.1038/sj.ijir.3901005</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901005</ArticleId><ArticleId IdType="pubmed">12904810</ArticleId></ArticleIdList></Reference><Reference><Citation>Donatucci CF, Lue TF. Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res 1993;5:97-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">8348217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajfer J, Valeriano J, Sinow R. Early onset erectile dysfunction is usually not associated with abnormal cavernosal arterial Inflow. Int J Impot Res 2013;25:217-20. 10.1038/ijir.2013.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2013.17</ArticleId><ArticleId IdType="pubmed">23575460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkwood TB. Understanding the odd science of aging. Cell 2005;120:437-47. 10.1016/j.cell.2005.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.01.027</ArticleId><ArticleId IdType="pubmed">15734677</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300. 10.1093/geronj/11.3.298</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/11.3.298</ArticleId><ArticleId IdType="pubmed">13332224</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi R, Perkins G. Dynamics of mitochondrial structure during apoptosis and the enigma of Opa1. Biochim Biophys Acta 2009;1787:963-72. 10.1016/j.bbabio.2009.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2009.02.005</ArticleId><ArticleId IdType="pmc">PMC2773558</ArticleId><ArticleId IdType="pubmed">19245786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012;2012:646354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3184498</ArticleId><ArticleId IdType="pubmed">21977319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenwald J, Brendler T, Jaenicke C. editors. PDR for Herbal Medicines. 2nd ed. Montvale, New Jersey: Medical Economics Co.; 2000:531-2.</Citation></Reference><Reference><Citation>Oliveira CH, Moraes ME, Moraes MO, et al. Clinical toxicology study of an herbal medicinal extract of Paullinia cupana, Trichilia catigua, Ptychopetalum olacoides and Zingiber officinale (Catuama) in healthy volunteers. Phytother Res 2005;19:54-7. 10.1002/ptr.1484</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.1484</ArticleId><ArticleId IdType="pubmed">15798997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29731428</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Three-Piece Inflatable Penile Prosthesis Placement Following Pelvic Radiation: Technical Considerations and Contemporary Outcomes.</ArticleTitle><Pagination><StartPage>1049</StartPage><EndPage>1054</EndPage><MedlinePgn>1049-1054</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2018.04.634</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(18)30937-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Pelvic radiation is a known risk factor for the development and progression of erectile dysfunction. When medical therapy fails, the 3-piece inflatable penile prosthesis (IPP) can offer patients a definitive treatment option. Because of radiation-induced vascular changes and tissue fibrosis, a careful surgical approach is necessary to avoid intraoperative complications and attain successful outcomes. Despite its widespread use in prostate cancer treatment, there are no contemporary studies examining the effects that pelvic radiation can have on 3-piece IPP placement and device survival.</AbstractText><AbstractText Label="AIM">To present technical considerations and contemporary outcomes of placing a 3-piece IPP for refractory erectile dysfunction in patients with a history of pelvic radiation.</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed 78 patients who underwent placement of a 3-piece IPP (AMS 700; Boston Scientific, Marlborough, MA, USA) after being treated with pelvic radiotherapy from 2003 through 2016. All patients had been treated with external beam and/or brachytherapy for treatment of prostate malignancy. An infrapubic approach was used in all patients, with reservoir placement in the space of Retzius or in the lateral retroperitoneal space. Patient demographics, perioperative data, and postoperative outcomes including prosthetic infection and mechanical failure were examined and statistical analysis was performed.</AbstractText><AbstractText Label="OUTCOMES">Rates of device infection, revision surgery, and reservoir complications.</AbstractText><AbstractText Label="RESULTS">No intraoperative complications were observed. After a mean follow-up of 49.0 months (6.6-116.8), 2 patients developed an infection of their prosthesis that required explantation. These patients underwent successful IPP removal and immediate reimplantation. 11 patients (14.1%) required revision surgery (pump replacement, n&#xa0;=&#xa0;4; pump relocation, n&#xa0;= 2; cylinder replacement, n&#xa0;= 4; reservoir replacement owing to leak, n&#xa0;= 1). No reservoir-related complications such as herniation or erosion into adjacent structures were observed.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">The 3-piece IPP can be placed safely in a broad range of patients treated with pelvic radiotherapy.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS">This study describes contemporary long-term outcomes of the IPP in patients treated with pelvic radiation and includes patients with prior pelvic surgery and artificial urinary sphincter, which are commonly encountered in practice. It is limited by its single-center experience and lacks a comparison group of patients. Objective patient satisfaction data were not available for inclusion.</AbstractText><AbstractText Label="CONCLUSIONS">The 3-piece IPP can be placed successfully in patients with a history of pelvic radiation without a significant increase in infectious complications, reservoir erosion, or mechanical failure compared with the global literature. Loh-Doyle J, Patil MB, Nakhoda Z, et&#xa0;al. Three-Piece Inflatable Penile Prosthesis Placement Following Pelvic Radiation: Technical Considerations and Contemporary Outcomes. J Sex Med 2018;15:1049-1054.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loh-Doyle</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: jeffrey.loh-doyle@med.usc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Mukul B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Tricounty Urology Associates, Washington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakhoda</LastName><ForeName>Zein</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassiri</LastName><ForeName>Nima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Wesley</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wayne</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doumanian</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Stuart D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001900" MajorTopicYN="N" Type="Geographic">Boston</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016741" MajorTopicYN="N">Urinary Sphincter, Artificial</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brachytherapy</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Radiation Therapy</Keyword><Keyword MajorTopicYN="N">Salvage Prostatectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29731428</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2018.04.634</ArticleId><ArticleId IdType="pii">S1743-6095(18)30937-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29464656</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1969</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Drugs &amp; aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.</ArticleTitle><Pagination><StartPage>175</StartPage><EndPage>187</EndPage><MedlinePgn>175-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40266-018-0528-4</ELocationID><Abstract><AbstractText>Phosphodiesterase type 5 inhibitors (PDE5Is) are the drug of choice for medical management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60-70% for ED; 30-35% of patients fail to respond to a PDE5I, and 30-50% of non-responders can be salvaged with detailed counseling on proper use and physician follow-up to ensure that the patient has been prescribed an appropriate and full PDE5I clinical trial. True non-responders may be offered intracavernosal injections of erectogenic drugs, intraurethral alprostadil, or surgical insertion of a penile prosthesis. Such options are not discreet and are associated with more adverse effects than PDE5Is. Thus patients may request additional non-invasive medical management options. This review describes published literature on patients who failed to respond to an on-demand PDE5I regimen and were treated with a non-invasive PDEI-based regimen, including switching from one PDE5I to another; increasing the dose of PDE5I above the labeled dosage range; using two PDE5Is concurrently; using a daily PDE5I regimen; or combining a PDE5I with a testosterone supplement, &#x3b1;-adrenergic antagonist, intraurethral or intracavernosal alprostadil, vacuum erection device, or low-intensity shock wave therapy. The limitations of published clinical trials do not allow for sufficient evidence to recommend one option over another. Therefore, in PDE5I-refractory patients, the choice of a specific next step should be individualized based on the preference of the patient and his sexual partner, the advantages and disadvantages of the various options, the concurrent medical illnesses and medications of the patient, and the patient's response to treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2584-2736</Identifier><AffiliationInfo><Affiliation>Pharmacy Practice, Pharmacy and Optometry Education, Midwestern University Chicago College of Pharmacy, Midwestern University, 555 31st Street, Downers Grove, IL, 60515, USA. mleexx@midwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharifi</LastName><ForeName>Roohollah</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Surgery and Urology, Jesse Brown Veterans Administration Medical Center, University of Illinois at Chicago College of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29464656</ArticleId><ArticleId IdType="doi">10.1007/s40266-018-0528-4</ArticleId><ArticleId IdType="pii">10.1007/s40266-018-0528-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Impot Res. 2005 Jul-Aug;17(4):354-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15703770</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ital Urol Androl. 2015 Sep 30;87(3):204-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26428641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Jun;11(6):1577-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24697970</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2006 Mar 11;332(7541):589-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16528082</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Vasc Pharmacol. 2006 Apr;4(2):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16611151</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Jun;11(6):1376-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24641632</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Urol. 2014 Dec;21(12):1263-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25039272</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2014 Feb;15(3):421-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24369066</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 1997;15(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9066090</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2014 Jun;83(6):1334-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24745797</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2007 Nov;61(11):1850-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17850306</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2006 Mar-Apr;18(2):146-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16094412</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Jul;11(7):1626-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24684744</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2013 May;63(5):902-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23395275</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Aug;14(4):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12152115</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2015 Apr;16(5):625-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25643866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Urol. 2009 Dec;1(5):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21789070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Jan 12;381(9861):153-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23040455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2009 Nov 3;151(9):650-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19884626</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2004 Dec;94(9):1301-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15610110</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2005 Apr;47(4):518-22; discussion 522-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15774252</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2012 Aug;66(8):813-820</Citation><ArticleIdList><ArticleId IdType="pubmed">22805273</ArticleId></ArticleIdList></Reference><Reference><Citation>Arab J Urol. 2016 May 18;14(2):84-93</Citation><ArticleIdList><ArticleId IdType="pubmed">27493808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 May;3(3):419-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16681467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2017 Jan;14 (1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">27986492</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2011 May;38(2):105-18</Citation><ArticleIdList><ArticleId IdType="pubmed">21621077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Male. 2016 Sep;19(3):155-160</Citation><ArticleIdList><ArticleId IdType="pubmed">27152882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Feb;5(2):469-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18086159</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2009 Jul;6(7):2039-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19453893</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2011 Nov;60(5):1010-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21855209</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2004 Nov;1(3):292-300</Citation><ArticleIdList><ArticleId IdType="pubmed">16422959</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2014 May-Jun;26(3):87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24305610</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2000 Jul;38(1):30-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10859438</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2017 Nov;109 :19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">28571949</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin North Am. 2011 Jan;95(1):201-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21095423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Jan;8(1):284-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20704642</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2017 Sep 26;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">28962876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2016 Apr;13(4):465-88</Citation><ArticleIdList><ArticleId IdType="pubmed">27045254</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Urol. 2006 Nov;16(6):449-59</Citation><ArticleIdList><ArticleId IdType="pubmed">17053526</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2010 Jun;105(12):1634-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20553468</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Jun 23;291(24):2978-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15213209</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Jan;10(1):130-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23343170</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Male. 2013 Sep;16(3):85-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23758451</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Dec;162(6):2205-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10569620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Feb;11(2):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24251448</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2009 May;103(9):1212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19154480</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2006 Sep-Oct;18(5):446-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16482200</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Feb;14 Suppl 1:S38-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11850734</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2006 Jul-Aug;18(4):400-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16395321</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 Aug;50(2):351-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16766116</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Dec;14(6):533-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12494291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2005 Nov;2(6):848-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16422809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Jan;171(1):292-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14665897</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2011 May;13(3):382-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21423198</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Dec;162(6):1992-7; discussion 1997-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10569554</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2005 Aug;48(2):326-31; discussion 331-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16005378</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 2017 Jan;35(1):167-171</Citation><ArticleIdList><ArticleId IdType="pubmed">27447990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2009 Sep;6(9):2561-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19627462</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Feb;14(1):50-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11896478</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 May;5(5):1198-1207</Citation><ArticleIdList><ArticleId IdType="pubmed">18312284</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2009 May;103(10):1392-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19154494</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2009;15(30):3476-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19860693</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2005 May;2(3):415-25; discussion 425-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16422874</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrology. 2014 Jan;2(1):45-50</Citation><ArticleIdList><ArticleId IdType="pubmed">24194017</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2000 Sep;86(4):469-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10971274</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 Feb 28;11:57</Citation><ArticleIdList><ArticleId IdType="pubmed">23448151</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2012 Jul;13(10):1481-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22725705</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2013 Jan;25(1):29-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22971615</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2011 Jan-Feb;23(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21191396</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 Jul;50(1):134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16527391</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2006 Aug;68(2):397-401</Citation><ArticleIdList><ArticleId IdType="pubmed">16904460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Apr;12(4):966-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25648342</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrologia. 2015 Feb;47(1):20-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24387078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Pract (1995). 2014 Dec;42(5):69-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25485919</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2014 Jul 17;349:g3743</Citation><ArticleIdList><ArticleId IdType="pubmed">25035309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2012 Nov 20;157(10):681-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23165659</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2014 Jan;65(1):99-112</Citation><ArticleIdList><ArticleId IdType="pubmed">24050791</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Clin Evid. 2011 Jun 29;2011:null</Citation><ArticleIdList><ArticleId IdType="pubmed">21711956</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Urol Assoc J. 2012 Aug;6(4):269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23093538</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Jun;11(6):1539-45</Citation><ArticleIdList><ArticleId IdType="pubmed">24621088</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Des Devel Ther. 2010 Sep 07;4:159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20856843</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2013 Jul;14(10):1333-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23675780</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2007 Nov;9(6):843-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17968472</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2010 Jan-Feb;22(1):51-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19865092</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2015 Oct;68(4):674-80</Citation><ArticleIdList><ArticleId IdType="pubmed">25817916</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2002 Sep;60(2 Suppl 2):28-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12414331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Apr;9(4):1182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21054791</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2012 Dec 3;72(17):2243-54</Citation><ArticleIdList><ArticleId IdType="pubmed">23170913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Dec;8(12):3418-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21995676</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2011 Apr 1;28(4):257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">21428461</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Mens Health. 2017 Nov;11(6):1781-1790</Citation><ArticleIdList><ArticleId IdType="pubmed">28884638</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2013 Feb;111(2):324-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22686292</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Urol Rep. 2013 Aug;14(4):269-78</Citation><ArticleIdList><ArticleId IdType="pubmed">23775467</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2014 May-Jun;16(3):461-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24556747</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 Mar;3(2):303-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16490024</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Urol. 2016 Jan;23 (1):80-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26501992</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2008 Mar-Apr;20(2):202-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17882231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29452979</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>3-Piece Inflatable Penile Prosthesis Placement Following Radical Cystoprostatectomy and Urinary Diversion: Technique and Outcomes.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>913</EndPage><MedlinePgn>907-913</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2018.01.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(18)30055-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">After radical cystoprostatectomy (RC), postoperative erectile dysfunction (ED) is a common consequence with multiple contributing etiologies. The inflatable penile prosthesis (IPP) offers patients a definitive treatment option when ED is refractory to medical therapies. Because of the hostile postoperative anatomy of these patients, a careful surgical approach is necessary for successful outcomes and to avoid adjacent organ injury. To date, there is no series describing the outcomes of 3-piece IPP placement in patients with urinary diversions.</AbstractText><AbstractText Label="AIM">To present contemporary outcomes and a description of our technique in placing a 3-piece IPP for postoperative ED in patients with a history of RC with orthotopic neobladder, ileal conduit, or continent cutaneous diversion.</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed 80 patients who underwent primary placement of a 3-piece IPP (AMS 700; American Medical Systems Inc, Minnetonka, MN, USA) after RC and urinary diversion from 2003 through 2016. 79 patients underwent RC in their treatment of urologic malignancy (71 for bladder cancer, 8 for prostate cancer) and 1 underwent RC for refractory interstitial cystitis. An infrapubic approach was used in most patients, with reservoir placement in the lateral retroperitoneal space through a counterincision medial to the anterior superior iliac spine. Patient demographics, perioperative data, and postoperative outcomes including prosthetic infection and mechanical failure were examined and statistical analysis was performed.</AbstractText><AbstractText Label="OUTCOMES">Rates of device infection, revision surgery, and reservoir complications.</AbstractText><AbstractText Label="RESULTS">After mean follow-up of 53.9 months (6.5-150.7 months), 4 patients developed infection of the prosthesis that required explantation. 3 of those patients underwent successful IPP reimplantation. 5 patients required revision surgery (pump replacement, n&#xa0;= 3; pump relocation, n&#xa0;= 1; cylinder replacement for cylinder aneurysm, n&#xa0;= 1) for mechanical failure. No statistically significant associations were found between infection and comorbidities, urinary diversion, exposure to chemotherapy, radiation, or presence of an artificial urinary sphincter.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">The 3-piece IPP is an effective treatment option for medication-refractory ED that can be placed safely in patients with all forms of urinary diversion.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS">This study represents the 1st series that describes a successful technique and long-term outcomes of patients with urinary diversion. It is limited by its single-surgeon, single-center experience and lacks validated patient satisfaction data in follow-up.</AbstractText><AbstractText Label="CONCLUSIONS">The 3-piece IPP, with reservoir placement in the lateral retroperitoneum, can be implanted successfully in patients with all forms of urinary diversion without a significant increase in infectious complications, reservoir erosion, or mechanical failure. Loh-Doyle J, Patil MB, Sawkar H, et&#xa0;al. 3-Piece Inflatable Penile Prosthesis Placement Following Radical Cystoprostatectomy and Urinary Diversion: Technique and Outcomes. J Sex Med 2018;15:907-913.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loh-Doyle</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: jeffrey.loh-doyle@med.usc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Mukul B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Tricounty Urology Associates, Washington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawkar</LastName><ForeName>Hari</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wayne</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Stuart D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015653" MajorTopicYN="N">Cystectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019738" MajorTopicYN="N">Surgically-Created Structures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014547" MajorTopicYN="N">Urinary Diversion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bladder Cancer</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Urinary Diversion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29452979</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2018.01.014</ArticleId><ArticleId IdType="pii">S1743-6095(18)30055-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29292061</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Trends in Penile Prosthetics: Influence of Patient Demographics, Surgeon Volume, and Hospital Volume on Type of Penile Prosthesis Inserted in New York State.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>250</EndPage><MedlinePgn>245-250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2017.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(17)31873-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Penile prostheses (PPs) are a discrete, well-tolerated treatment option for men with medical refractory erectile dysfunction. Despite the increasing prevalence of erectile dysfunction, multiple series evaluating inpatient data have found a decrease in the frequency of PP surgery during the past decade.</AbstractText><AbstractText Label="AIMS">To investigate trends in PP surgery and factors affecting the choice of different PPs in New York State.</AbstractText><AbstractText Label="METHODS">This study used the New York State Department of Health Statewide Planning and Research Cooperative (SPARCS) data cohort that includes longitudinal information on hospital discharges, ambulatory surgery, emergency department visits, and outpatient services. Patients older than 18 years who underwent inflatable or non-inflatable PP insertion from 2000 to 2014 were included in the study.</AbstractText><AbstractText Label="OUTCOMES">Influence of patient demographics, surgeon volume, and hospital volume on type of PP inserted.</AbstractText><AbstractText Label="RESULTS">Since 2000, 14,114 patients received PP surgery in New York State; 12,352 PPs (88%) were inflatable and 1,762 (12%) were non-inflatable, with facility-level variation from 0% to 100%. There was an increasing trend in the number of annual procedures performed, with rates of non-inflatable PP insertion decreasing annually (P &lt; .01). More procedures were performed in the ambulatory setting over time (P &lt; .01). Important predictors of device choice were insurance type, year of insertion, hospital and surgeon volume, and the presence of comorbidities.</AbstractText><AbstractText Label="CLINICAL IMPLICATIONS">Major influences in choice of PP inserted include racial and socioeconomic factors and surgeon and hospital surgical volume.</AbstractText><AbstractText Label="STRENGTHS AND LIMITATIONS">Use of the SPARCS database, which captures inpatient and outpatient services, allows for more accurate insight into trends in contrast to inpatient sampling alone. However, SPARCS is limited to patients within New York State and the results might not be generalizable to men in other states. Also, patient preference was not accounted for in these analyses, which can play a role in PP selection.</AbstractText><AbstractText Label="CONCLUSIONS">During the past 14 years, there has been an increasing trend in inflatable PP surgery for the management of erectile dysfunction. Most procedures are performed in the ambulatory setting and not previously captured by prior studies using inpatient data. Kashanian JA, Golan R, Sun T, et&#xa0;al. Trends in Penile Prosthetics: Influence of Patient Demographics, Surgeon Volume, and Hospital Volume on Type of Penile Prosthesis Inserted in New York State. J Sex Med 2018;15:245-250.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kashanian</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Urology, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA. Electronic address: jak9111@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golan</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Tianyi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Services and Policy Research, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Neal A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Urology, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsky</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Urology, New York Presbyterian-Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Urology, New York Presbyterian-Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedrakyan</LastName><ForeName>Art</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health Services and Policy Research, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 FD005478</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2018 Jun;199(6):1379</RefSource><PMID Version="1">29783561</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2018 Oct;200(4):691</RefSource><PMID Version="1">30227569</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066231" MajorTopicYN="N">Surgeons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Inflatable Prosthesis</Keyword><Keyword MajorTopicYN="N">New York State</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Semirigid Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29292061</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2017.12.005</ArticleId><ArticleId IdType="pii">S1743-6095(17)31873-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29289534</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Penile Length: Measurement Technique and Applications.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>271</EndPage><MedlinePgn>261-271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2017.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(17)30121-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Penile size has long been an important fixation in men's lives. On the one hand, a smaller penis has been associated with anxiety and apprehension; on the other hand, a larger penis has generally been related to virility and strength. These perceptions predominate during an erection, when penile size is representative of a man's masculinity.</AbstractText><AbstractText Label="AIM">To assess adult penile length and summarize average penile length assessments from the literature; analyze how various urologic diseases and therapies affect penile length and volume; and review how surgical treatments for Peyronie's disease, penile prosthesis implantation, and radical prostatectomy can affect penile size to appropriately counsel patients seeking such therapies and set realistic goals for patients.</AbstractText><AbstractText Label="METHODS">To achieve the aim of this review, we analyzed the literature on penile size and volume and how these can be affected by various urologic diagnoses and therapies. We summarize common diagnoses and therapies that can affect penile size.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">We thoroughly discuss how the aforementioned diagnoses and therapies can negatively affect penile size. In doing so, we allow readers to understand the intricacies of penile size when faced with such diagnoses and therapies in their patients.</AbstractText><AbstractText Label="RESULTS">Surgical treatments for Peyronie's disease, penile prosthesis implantation for refractory erectile dysfunction, and radical prostatectomy for prostate cancer can lead to a decrease in penile size.</AbstractText><AbstractText Label="CONCLUSION">Urologists must recognize that the different therapies they offer can affect a man's penile size, often negatively. This in turn can lead to poorer satisfaction outcomes in patients. Davoudzadeh EP, Davoudzadeh NP, Margolin E, et&#xa0;al. Penile Length: Measurement Technique and Applications. Sex Med Rev 2018;6:261-271.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davoudzadeh</LastName><ForeName>Ethan P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>SUNY Downstate College of Medicine, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davoudzadeh</LastName><ForeName>Natan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolin</LastName><ForeName>Ezra</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stember</LastName><ForeName>Doron S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: doronstember@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001837" MajorTopicYN="N">Body Weights and Measures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Penile Size</Keyword><Keyword MajorTopicYN="N">Penile Volume</Keyword><Keyword MajorTopicYN="N">Peyronie&#x2019;s Disease</Keyword><Keyword MajorTopicYN="N">Plaque Incision and Grafting</Keyword><Keyword MajorTopicYN="N">Radical Prostatectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29289534</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2017.10.002</ArticleId><ArticleId IdType="pii">S2050-0521(17)30121-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29238666</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>Suppl 5</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Preoperative counseling and expectation management for inflatable penile prosthesis implantation.</ArticleTitle><Pagination><StartPage>S869</StartPage><EndPage>S880</EndPage><MedlinePgn>S869-S880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2017.07.04</ELocationID><Abstract><AbstractText>The inflatable penile prosthesis (IPP) is the gold standard surgical treatment for medical refractory erectile dysfunction (ED). While the modern IPP has enjoyed high satisfaction rates as a product of its continued innovation, reliability, and performance, patient dissatisfaction can still occur. IPP implantation restores physiologic function with cosmetic and psychological consequences, both of which place inherent emphasis on preoperative counseling and expectation management. This review aims to highlight the complex nature of such counseling and provide practitioners with a roadmap to navigate the landscape. Preoperative counseling begins with appropriate patient selection and identification of those patients who are at risk for dissatisfaction as a result of personality characteristics. The informed consent provides a natural framework to discuss the host of complications and risks that are associated with surgery, including infection, device malfunction, damage to nearby structures, and device erosion. Device selection is a nuanced process that merges patient preference with clinical factors and consideration. We address device selection through a description of cylinder construction, pump design, and reservoir placement in the context of preoperative counseling. Lastly, we draw attention to expectation management with a specific focus on possible post-operative changes to penile length and sensation as well as partner involvement. The modern IPP provides excellent results with high patient and partner satisfaction. Ultimately, satisfaction is dependent on multiple factors, but providing accurate, realistic counseling and expectation management prepares patients for the best possible outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narang</LastName><ForeName>Gopal L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Urology, UNC School of Medicine, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figler</LastName><ForeName>Bradley D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Urology, UNC School of Medicine, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coward</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Urology, UNC School of Medicine, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UNC Fertility, LLC, Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Nov;6(Suppl 5):S881-S882</RefSource><PMID Version="1">29239402</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Expectation management</Keyword><Keyword MajorTopicYN="N">inflatable penile prosthesis (IPP)</Keyword><Keyword MajorTopicYN="N">preoperative counseling</Keyword></KeywordList><CoiStatement>Conflicts of Interest: RM Coward has received compensation for consulting services from both Coloplast Inc. and Boston Scientific. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29238666</ArticleId><ArticleId IdType="pmc">PMC5715186</ArticleId><ArticleId IdType="doi">10.21037/tau.2017.07.04</ArticleId><ArticleId IdType="pii">tau-06-S5-S869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol 2016;13:33-46. 10.1038/nrurol.2015.270</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2015.270</ArticleId><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisano F, Falcone M, Abbona A, et al. The importance of psychosexual counselling in the re-establishment of organic and erotic functions after penile prosthesis implantation. Int J Impot Res 2015;27:197-200. 10.1038/ijir.2015.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2015.17</ArticleId><ArticleId IdType="pubmed">26268774</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Donatucci CF, Conners W, et al. An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: A multicenter study. J Sex Med 2012;9:309-15. 10.1111/j.1743-6109.2011.02524.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02524.x</ArticleId><ArticleId IdType="pubmed">22082149</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, et al. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med 2006;3:743-8. 10.1111/j.1743-6109.2006.00278.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00278.x</ArticleId><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, Baum N, Hellstrom WJ. Managing the Difficult Penile Prosthesis Patient. J Sex Med 2013;10:893-906. 10.1111/jsm.12115</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12115</ArticleId><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>Caire AA, Boonjindasup A, Hellstrom WJ. Does a replacement or revision of an inflatable penile prosthesis lead to decreased patient satisfaction? Int J Impot Res 2011;23:39-42. 10.1038/ijir.2011.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2011.1</ArticleId><ArticleId IdType="pubmed">21307871</ArticleId></ArticleIdList></Reference><Reference><Citation>Penile prosthesis information form, 2008. Available online: http://www.smsna.org/V1/images/SMSNAIPP-policy-ws.pdf</Citation></Reference><Reference><Citation>Schover LR, von Eschenbach AC. Sex therapy and the penile prosthesis: a synthesis. J Sex Marital Ther 1985;11:57-66. 10.1080/00926238508405959</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00926238508405959</ArticleId><ArticleId IdType="pubmed">4039371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandava SH, Serefoglu EC, Freier MT, et al. Infection retardant coated inflatable penile prostheses decrease the incidence of infection: A systematic review and meta-analysis. J Urol 2012;188:1855-60. 10.1016/j.juro.2012.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.07.022</ArticleId><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007;70:337-40. 10.1016/j.urology.2007.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.03.058</ArticleId><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kava BR, Kanagarajah P, Ayyathurai R. Contemporary revision penile prosthesis surgery is not associated with a high risk of implant colonization or infection: A single-surgeon Series. J Sex Med 2011;8:1540-6. 10.1111/j.1743-6109.2011.02222.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02222.x</ArticleId><ArticleId IdType="pubmed">21366878</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins KP, Hackler RH. Complications of penile prostheses in the spinal cord injury population. J Urol 1988;140:984-5. 10.1016/S0022-5347(17)41905-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)41905-7</ArticleId><ArticleId IdType="pubmed">3172373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR., 2nd Inflatable Penile Implant Infection: Predisposing Factors and Treatment Suggestions. J Urol 1995;153:659-61. 10.1016/S0022-5347(01)67678-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)67678-X</ArticleId><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M, Pearce I. Infection of Penile Prostheses in Patients with Diabetes Mellitus. Surg Infect (Larchmt) 2016;17:2-8. 10.1089/sur.2015.164</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2015.164</ArticleId><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop JR, Moul JW, Sihelnik SA, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992;147:386-8. 10.1016/S0022-5347(17)37244-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)37244-0</ArticleId><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Carson CC, Cleves MA, et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998;159:1537-9; discussion 1539-40. 10.1097/00005392-199805000-00034</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005392-199805000-00034</ArticleId><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Carson CC. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011;60:167-72. 10.1016/j.eururo.2011.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.01.046</ArticleId><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg 2012;147:373-83. 10.1001/archsurg.2012.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2012.5</ArticleId><ArticleId IdType="pubmed">22508785</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda M, Burnett AL. Penile Prosthesis Infections&#x2014;A Review of Risk Factors, Prevention, and Treatment. Sex Med Rev 2016;4:389-98. 10.1016/j.sxmr.2016.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2016.03.003</ArticleId><ArticleId IdType="pubmed">27872031</ArticleId></ArticleIdList></Reference><Reference><Citation>Serefoglu EC, Mandava SH, Gokce A, et al. Long-Term Revision Rate due to Infection in Hydrophilic-Coated Inflatable Penile Prostheses: 11-Year Follow-up. J Sex Med 2012;9:2182-6. 10.1111/j.1743-6109.2012.02830.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02830.x</ArticleId><ArticleId IdType="pubmed">22759917</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: Up to 7.7 years of followup. J Urol 2011;185:614-8. 10.1016/j.juro.2010.09.094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.09.094</ArticleId><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. Penile Implant: Review of a &#x201c;No-Touch&#x201d; Technique. Sex Med Rev 2016;4:294-300. 10.1016/j.sxmr.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2016.01.002</ArticleId><ArticleId IdType="pubmed">27871962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf JS, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90. 10.1016/j.juro.2008.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.01.068</ArticleId><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, et al. North American consensus document on infection of penile prostheses. Urology 2013;82:937-42. 10.1016/j.urology.2013.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.05.048</ArticleId><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavoussi NL, Siegel JA, Viers BR, et al. Preoperative Urine Culture Results Correlate Poorly With Bacteriology of Urologic Prosthetic Device Infections. J Sex Med 2017;14:163-8. 10.1016/j.jsxm.2016.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.10.017</ArticleId><ArticleId IdType="pubmed">28065350</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, Safety and Patient Satisfaction Outcomes of hte AMS 700CX Inflatable Penile Prosthesis: Results of a Long-Term Multicenter Study. J Urol 2000;164:376-80. 10.1016/S0022-5347(05)67364-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67364-8</ArticleId><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9. 10.1111/j.1743-6109.2007.00540.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB. Inflatable penile prostheses for the treatment of erectile dysfunction: an update. Expert Rev Med Devices 2008;5:133-44. 10.1586/17434440.5.2.133</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17434440.5.2.133</ArticleId><ArticleId IdType="pubmed">18331176</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MJ, et al. Impact of Surgeon Case Volume on Reoperation Rates after Inflatable Penile Prosthesis Surgery. J Urol 2017;197:223-9. 10.1016/j.juro.2016.08.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.08.083</ArticleId><ArticleId IdType="pubmed">27545573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Solomon M, Deyoung L, et al. Comparison between AMS 700 CX and Coloplast Titan Inflatable Penile Prosthesis for Peyronie&#x2019;s Disease Treatment and Remodeling: Clinical Outcomes and Patient Satisfaction. J Sex Med 2013;10:2855-60. 10.1111/jsm.12009</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12009</ArticleId><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR., 2nd Long-term followup of treatment for Peyronie&#x2019;s disease: modeling the penis over an inflatable penile prosthesis. J Urol 2001;165:825-9. 10.1016/S0022-5347(05)66537-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)66537-8</ArticleId><ArticleId IdType="pubmed">11176479</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: Clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31:591-5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Le BV, Burnett AL. Suprapubic cystostomy for the management of urethral injuries during penile prosthesis implantation. Sex Med 2014;2:178-81. 10.1002/sm2.44</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sm2.44</ArticleId><ArticleId IdType="pmc">PMC4272249</ArticleId><ArticleId IdType="pubmed">25548649</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: Experience with 504 procedures. BJU Int 2006;97:129-33. 10.1111/j.1464-410X.2005.05907.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher E, Bella A, et al. Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine. J Sex Med 2016;13:489-518. 10.1016/j.jsxm.2016.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakalopoulos I, Kampantais S, Gkagkalidis K, et al. Complications of Inflatable Penile Prostheses Implantation Classified according to the Modified Clavien System. Adv Urol 2014;14:5.</Citation></Reference><Reference><Citation>Kim YD, Yang SO, Lee JK, et al. Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol 2008;15:919-23. 10.1111/j.1442-2042.2008.02115.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02115.x</ArticleId><ArticleId IdType="pubmed">18651861</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahlajani G, Raina R, Jones S, et al. Vacuum Erection Devices Revisited: Its Emerging Role in the Treatment of Erectile Dysfunction and Early Penile Rehabilitation Following Prostate Cancer Therapy. J Sex Med 2012;9:1182-9. 10.1111/j.1743-6109.2010.01881.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01881.x</ArticleId><ArticleId IdType="pubmed">21054791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Lin H, Wang G. Vacuum erectile device for penile rehabilitation. J Integr Nephrol Androl 2014;1:4-10. 10.4103/2225-1243.137541</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2225-1243.137541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers T, Dineen M, Salem EA, et al. Vacuum Preparation, Optimization of Cylinder Length and Postoperative Daily Inflation Reduces Complaints of Shortened Penile Length Following Implantation of Inflatable Penile Prosthesis. Adv Sex Med 2013;189:14-8. 10.4236/asm.2013.31003</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/asm.2013.31003</ArticleId></ArticleIdList></Reference><Reference><Citation>Canguven O, Talib RA, Campbell J, et al. Is the daily use of vacuum erection device for a month before penile prosthesis implantation beneficial? a randomized controlled trial. Andrology 2017;5:103-6. 10.1111/andr.12258</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/andr.12258</ArticleId><ArticleId IdType="pubmed">27654466</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Pain and Inflammation Associated with Genitourinary Prostheses. In: Potts JM. edtor. Genitourinary Pain And Inflammation. Current Clinical Urology. Humana Press, 2008:385-91.</Citation></Reference><Reference><Citation>Mulcahy JJ, Kramer A, Brant WO, et al. Current management of penile implant infections, device reliability, and optimizing cosmetic outcome. Curr Urol Rep 2014;15:413. 10.1007/s11934-014-0413-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11934-014-0413-6</ArticleId><ArticleId IdType="pubmed">24740273</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: immediate replacement of the infected penile prosthesis. J Urol 1996;155:155-7. 10.1016/S0022-5347(01)66580-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)66580-7</ArticleId><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Harsch MR. 7-year infection related revision rates for naive inflatable penile prosthesis implants: Antibiotic impregnated vs. non-impregnated. J Urol 2010;183:e488 10.1016/j.juro.2010.02.820</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.02.820</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001;166:932-7. 10.1016/S0022-5347(05)65867-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)65867-3</ArticleId><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito P, Wilson S. The History of Nontraditional or Ectopic Placement of Reservoirs in Prosthetic Urology. Sex Med Rev 2016;4:190-3. 10.1016/j.sxmr.2015.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2015.10.008</ArticleId><ArticleId IdType="pubmed">27530384</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveci S, Martin D, Parker M, et al. Penile Length Alterations Following Penile Prosthesis Surgery. Eur Urol 2007;51:1128-31. 10.1016/j.eururo.2006.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2006.10.026</ArticleId><ArticleId IdType="pubmed">17084508</ArticleId></ArticleIdList></Reference><Reference><Citation>Scovell JM, Ge L, Barrera EV, et al. Longitudinal and Horizontal Load Testing of Inflatable Penile Implant Cylinders of Two Manufacturers: An Ex Vivo Demonstration of Inflated Rigidity. J Sex Med 2016;13:1750-7. 10.1016/j.jsxm.2016.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5654325</ArticleId><ArticleId IdType="pubmed">27770856</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004;171:1611-4. 10.1097/01.ju.0000118245.66976.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000118245.66976.e1</ArticleId><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabuwala C, Sheth S, Zamzow B. Infection Rates of Rifampin/Gentamicin-Coated Titan Coloplast Penile Implants. Comparison with Inhibizone-Impregnated AMS Penile Implants. J Sex Med 2011;8:315-20. 10.1111/j.1743-6109.2010.02068.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02068.x</ArticleId><ArticleId IdType="pubmed">20946163</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Henry G, Culkin D, et al. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med 2009;6:1773-8. 10.1111/j.1743-6109.2009.01251.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01251.x</ArticleId><ArticleId IdType="pubmed">19473458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl DA, Brock G, Ralph D, et al. Prospective Evaluation of Patient Satisfaction, and Surgeon and Patient Trainer Assessment of the Coloplast Titan One Touch Release Three-Piece Inflatable Penile Prosthesis. J Sex Med 2012;9:2467-74. 10.1111/j.1743-6109.2012.02819.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02819.x</ArticleId><ArticleId IdType="pubmed">22759540</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpman E, Sadeghi-Nejad H, Henry G, et al. Current opinions on alternative reservoir placement for inflatable penile prosthesis among members of the sexual medicine society of North America. J Sex Med 2013;10:2115-20. 10.1111/jsm.12203</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12203</ArticleId><ArticleId IdType="pubmed">23679798</ArticleId></ArticleIdList></Reference><Reference><Citation>Morey AF, Cefalu CA, Hudak SJ. High Submuscular Placement of Urologic Prosthetic Balloons and Reservoirs via Transscrotal Approach. J Sex Med 2013;10:603-10. 10.1111/jsm.12000</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12000</ArticleId><ArticleId IdType="pubmed">23216955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung PH, Morey AF, Tausch TJ, et al. High submuscular placement of urologic prosthetic balloons and reservoirs: 2-year experience and patient-reported outcomes. Urology 2014;84:1535-40. 10.1016/j.urology.2014.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2014.08.029</ArticleId><ArticleId IdType="pubmed">25432851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Fam M. Penile prosthesis surgery in the management of erectile dysfunction. Arab J Urol 2013;11:245-53. 10.1016/j.aju.2013.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aju.2013.05.002</ArticleId><ArticleId IdType="pmc">PMC4442986</ArticleId><ArticleId IdType="pubmed">26558089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AC, Schweber A. Patient expectations prior to coloplast titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med 2010;7:2261-6. 10.1111/j.1743-6109.2010.01799.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01799.x</ArticleId><ArticleId IdType="pubmed">20367767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gittens P, Moskovic DJ, Avila D, Jr, et al. Favorable female sexual function is associated with patient satisfaction after inflatable penile prosthesis implantation. J Sex Med 2011;8:1996-2001. 10.1111/j.1743-6109.2011.02290.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02290.x</ArticleId><ArticleId IdType="pubmed">21569210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010;7:304-9. 10.1111/j.1743-6109.2009.01499.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01499.x</ArticleId><ArticleId IdType="pubmed">19758282</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB. Mentor alpha 1 inflatable penile prosthesis: Patient satisfaction and device reliability. Urology 1994;43:214-7. 10.1016/0090-4295(94)90047-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(94)90047-7</ArticleId><ArticleId IdType="pubmed">8116118</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Hellstrom WJ. History, contemporary outcomes, and future of penile prostheses: A review of the literature. Sex Med Rev 2013;1:150-63. 10.1002/smrj.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.8</ArticleId><ArticleId IdType="pubmed">27784554</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalheira A, Santana R, Pereira NM. Why Are Men Satisfied or Dissatisfied with Penile Implants? A Mixed Method Study on Satisfaction with Penile Prosthesis Implantation. J Sex Med 2015;12:2474-80. 10.1111/jsm.13054</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13054</ArticleId><ArticleId IdType="pubmed">26639576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulloa EW, Silberbogen AK, Brown K. Preoperative Psychosocial Evaluation of Penile Prosthesis Candidates Erin. Am J Mens Health 2008;2:68-75. 10.1177/1557988307313439</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1557988307313439</ArticleId><ArticleId IdType="pubmed">19477771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasman AJ. The psychological aspects of rhinoplasty. Curr Opin Otolaryngol Head Neck Surg 2010;18:290-4. 10.1097/MOO.0b013e32833b51e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOO.0b013e32833b51e6</ArticleId><ArticleId IdType="pubmed">20543695</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Rigatti P, Carmignani G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000;37:50-5. 10.1159/000020099</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000020099</ArticleId><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg EC, Maganty A, Ramasamy R, et al. Pharmacologically induced erect penile length and stretched penile length are both good predictors of post-inflatable prosthesis penile length. Int J Impot Res 2014;26:128-31. 10.1038/ijir.2013.50</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2013.50</ArticleId><ArticleId IdType="pmc">PMC4342061</ArticleId><ArticleId IdType="pubmed">24430278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Jahoda A, Aviv N, et al. The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. BJU Int. 2004;93:97-9. 10.1111/j.1464-410X.2004.04564.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2004.04564.x</ArticleId><ArticleId IdType="pubmed">14678377</ArticleId></ArticleIdList></Reference><Reference><Citation>Porena M, Mearini L, Mearini E, et al. Penile prosthesis implantation and couple&#x2019;s satisfaction. Urol Int 1999;63:185-7. 10.1159/000030444</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000030444</ArticleId><ArticleId IdType="pubmed">10738191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): Cross-Validation and Development of Clinical Cutoff Scores. J Sex Marital Ther 2005;31:1-20. 10.1080/00926230590475206</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00926230590475206</ArticleId><ArticleId IdType="pubmed">15841702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29238663</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>Suppl 5</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Prevention, identification, and management of post-operative penile implant complications of infection, hematoma, and device malfunction.</ArticleTitle><Pagination><StartPage>S832</StartPage><EndPage>S848</EndPage><MedlinePgn>S832-S848</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2017.06.07</ELocationID><Abstract><AbstractText>Penile prosthesis implant surgery is an effective management approach for a number of urological conditions, including medication refractory erectile dysfunction (ED). Complications encountered post-operatively include infection, bleeding/hematoma, and device malfunction. Since the 1970s, modifications to these devices have reduced complication rates through improvement in antisepsis and design using antibiotic coatings, kink-resistant tubing, lock-out valves to prevent autoinflation, and modified reservoir shapes. Device survival and complication rates have been investigated predominately by retrospective database-derived studies. This review article focuses on the identification and management of post-operative complications following penile prosthetic and implant surgery. Etiology for ED, surgical technique, and prosthesis type are variable among studies. The most common post-operative complications of infection, bleeding, and device malfunction may be minimized by adherence to consistent technique and standard protocol. Novel antibiotic coatings and standard antibiotic regimen may reduce infection rates. Meticulous hemostasis and intraoperative testing of devices may further reduce need for revision surgery. Additional prospective studies with consistent reporting of outcomes and comparison of surgical approach and prosthesis type in patients with variable ED etiology would be beneficial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Timothy K</ForeName><Initials>TK</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Quinnipiac University Frank H. Netter MD School of Medicine, Hamden, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erbella</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Quinnipiac University Frank H. Netter MD School of Medicine, Hamden, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Quinnipiac University Frank H. Netter MD School of Medicine, Hamden, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wosnitzer</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Quinnipiac University Frank H. Netter MD School of Medicine, Hamden, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Health-Northeast Medical Group Urology/Male Reproductive Medicine and Surgery, Fairfield, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Nov;6(Suppl 5):S849-S850</RefSource><PMID Version="1">29239398</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile implant</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">device malfunction</Keyword><Keyword MajorTopicYN="N">hematoma</Keyword><Keyword MajorTopicYN="N">infection</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29238663</ArticleId><ArticleId IdType="pmc">PMC5715191</ArticleId><ArticleId IdType="doi">10.21037/tau.2017.06.07</ArticleId><ArticleId IdType="pii">tau-06-S5-S832</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lash H, Zimmerman DC, Loeffler RA. Silicone implantation: inlay method. Plast Reconstr Surg 1964;34:75-80. 10.1097/00006534-196407000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006534-196407000-00011</ArticleId><ArticleId IdType="pubmed">14200523</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973;2:80-2. 10.1016/0090-4295(73)90224-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, et al. Penile prostheses. Ther Adv Urol 2010;2:35-40. 10.1177/1756287209359174</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287209359174</ArticleId><ArticleId IdType="pmc">PMC3126066</ArticleId><ArticleId IdType="pubmed">21789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Boolell M, Allen M, Ballard S, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858389</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404. 10.1056/NEJM199805143382001</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199805143382001</ArticleId><ArticleId IdType="pubmed">9580646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14. 10.1016/j.eururo.2010.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2010.02.020</ArticleId><ArticleId IdType="pubmed">20189712</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP. Risk factors for penile prosthetic infection. J Urol 1996;156:402-4. 10.1016/S0022-5347(01)65860-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)65860-9</ArticleId><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz A, Yu VL, O&#x2019;Donnell WF. Surgical complications related to insertion of penile prostheses with emphasis on infection and cost. Infect Control Hosp Epidemiol 1988;9:250-4. 10.2307/30144177</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/30144177</ArticleId><ArticleId IdType="pubmed">3403936</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: immediate replacement of the infected penile prosthesis. J Urol 1996;155:155-7. 10.1016/S0022-5347(01)66580-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)66580-7</ArticleId><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyeji IC, Sui W, Pagano MJ, et al. Impact of Surgeon Case Volume on Reoperation Rates after Inflatable Penile Prosthesis Surgery. J Urol 2017;197:223-9. 10.1016/j.juro.2016.08.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.08.083</ArticleId><ArticleId IdType="pubmed">27545573</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini G, Busetto GM, De Berardinis E, et al. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. Int J Impot Res 2016;28:4-8. 10.1038/ijir.2015.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2015.33</ArticleId><ArticleId IdType="pmc">PMC4709472</ArticleId><ArticleId IdType="pubmed">26657316</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Karpman E, Brant W, et al. The Who, How and What of Real-World Penile Implantation in 2015: The PROPPER Registry Baseline Data. J Urol 2016;195:427-33. 10.1016/j.juro.2015.07.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.07.109</ArticleId><ArticleId IdType="pubmed">26292043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirheydar H, Zhou T, Chang DC, et al. Reoperation Rates for Penile Prosthetic Surgery. J Sex Med 2016;13:129-33. 10.1016/j.jsxm.2015.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2015.11.013</ArticleId><ArticleId IdType="pubmed">26755095</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal S, Vetter J, Brandes SB, et al. A population-based analysis of contemporary rates of reoperation for penile prosthesis procedures. Urology 2014;84:112-6. 10.1016/j.urology.2014.02.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2014.02.028</ArticleId><ArticleId IdType="pmc">PMC4252045</ArticleId><ArticleId IdType="pubmed">24785986</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, et al. Coated implants and &#x201c;no touch&#x201d; surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology 2012;79:1310-5. 10.1016/j.urology.2011.11.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2011.11.076</ArticleId><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Carson CC., 3rd Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011;60:167-72. 10.1016/j.eururo.2011.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.01.046</ArticleId><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, 3rd, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol 2011;185:614-8. 10.1016/j.juro.2010.09.094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.09.094</ArticleId><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007;70:337-40. 10.1016/j.urology.2007.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.03.058</ArticleId><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter CE, Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med 2004;1:221-4. 10.1111/j.1743-6109.2004.04032.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2004.04032.x</ArticleId><ArticleId IdType="pubmed">16429621</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC., 3rd Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004;171:1611-4. 10.1097/01.ju.0000118245.66976.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000118245.66976.e1</ArticleId><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Bloom K. Comparison of in-patient and out-patient penile prosthesis surgery. Int J Impot Res 2001;13:251-4. 10.1038/sj.ijir.3900695</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900695</ArticleId><ArticleId IdType="pubmed">11890510</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabuwala C, Sheth S, Zamzow B. Infection rates of rifampin/gentamicin-coated Titan Coloplast penile implants. Comparison with Inhibizone-impregnated AMS penile implants. J Sex Med 2011;8:315-20. 10.1111/j.1743-6109.2010.02068.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02068.x</ArticleId><ArticleId IdType="pubmed">20946163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosnitzer MS, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med 2011;8:1521-8. 10.1111/j.1743-6109.2011.02207.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02207.x</ArticleId><ArticleId IdType="pubmed">21521487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf JS, Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90. 10.1016/j.juro.2008.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.01.068</ArticleId><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Droggin D, Shabsigh R, Anastasiadis AG. Antibiotic coating reduces penile prosthesis infection. J Sex Med 2005;2:565-8. 10.1111/j.1743-6109.2005.00073.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00073.x</ArticleId><ArticleId IdType="pubmed">16422855</ArticleId></ArticleIdList></Reference><Reference><Citation>Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol 2006;176:2471-3. 10.1016/j.juro.2006.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.08.010</ArticleId><ArticleId IdType="pubmed">17085132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Ditonno P, Palumbo F, et al. Penile prosthesis: what should we do about complications? Adv Urol 2008:573560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581729</ArticleId><ArticleId IdType="pubmed">19009029</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016;315:801-10. 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Droller MJ, Scott FB, Selim AM. Rescue procedure: an alternative to complete removal for treatment of infected penile prosthesis [Abstract 396]. J Urol 1987;137:202. 10.1016/S0022-5347(17)43953-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)43953-X</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol 2000;163:481-2. 10.1016/S0022-5347(05)67906-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67906-2</ArticleId><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellon MJ, Broghammer JR, Henry GD. The Mulcahy Salvage: Past and Present Innovations. J Sex Med 2015;12 Suppl 7:432-6. 10.1111/jsm.12986</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12986</ArticleId><ArticleId IdType="pubmed">26565572</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Penile prosthesis corporotomy closure: a new technique. J Urol 1993;150:924-5. 10.1016/S0022-5347(17)35650-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)35650-1</ArticleId><ArticleId IdType="pubmed">8345611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31:591-5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozza D, Pozza M, Musy M, et al. 500 penile prostheses implanted by a surgeon in Italy in the last 30 years. Arch Ital Urol Androl 2015;87:216-21. 10.4081/aiua.2015.3.216</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2015.3.216</ArticleId><ArticleId IdType="pubmed">26428644</ArticleId></ArticleIdList></Reference><Reference><Citation>Holloway FB, Farah RN. Intermediate term assessment of the reliability, function and patient satisfaction with the AMS700 Ultrex penile prosthesis. J Urol 1997;157:1687-91. 10.1016/S0022-5347(01)64835-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)64835-3</ArticleId><ArticleId IdType="pubmed">9112506</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Donatucci CF, Conners W, et al. An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: a multicenter study. J Sex Med 2012;9:309-15. 10.1111/j.1743-6109.2011.02524.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02524.x</ArticleId><ArticleId IdType="pubmed">22082149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Ilbeigi P, Wilson SK, et al. Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res 2005;17:535-8. 10.1038/sj.ijir.3901354</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901354</ArticleId><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB, Bickell M. Delayed postoperative hematoma formation after inflatable penile prosthesis implantation. J Sex Med 2015;12:265-9. 10.1111/jsm.12728</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12728</ArticleId><ArticleId IdType="pubmed">25349141</ArticleId></ArticleIdList></Reference><Reference><Citation>Natali A, Olianas R, Fisch M. Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med 2008;5:1503-12. 10.1111/j.1743-6109.2008.00819.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00819.x</ArticleId><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int 2006;97:129-33. 10.1111/j.1464-410X.2005.05907.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001;166:932-7. 10.1016/S0022-5347(05)65867-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)65867-3</ArticleId><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000;164:376-80. 10.1016/S0022-5347(05)67364-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67364-8</ArticleId><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, Newman L, Baum N, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997;157:833-9. 10.1016/S0022-5347(01)65058-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)65058-4</ArticleId><ArticleId IdType="pubmed">9072580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SC, Delk JI. Hematoma formation following penile prosthesis implantation: To drain or not to drain. J Urol 1996;55:634A.</Citation></Reference><Reference><Citation>Kramer A, Goldmark E, Greenfield J. Is a closed-suction drain advantageous for penile implant surgery? The debate continues. J Sex Med 2011;8:601-6. 10.1111/j.1743-6109.2010.02088.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02088.x</ArticleId><ArticleId IdType="pubmed">21054795</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin North Am 2007;34:535-47, vi. 10.1016/j.ucl.2007.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ucl.2007.08.015</ArticleId><ArticleId IdType="pubmed">17983893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Henry GD. Penoscrotal approach for three-piece and two-piece hydraulic penile implants. Urol Clin North Am 2002;10:169-80.</Citation></Reference><Reference><Citation>K&#xf6;hler TS, Hellstrom WJ. Using wound drains for the uncomplicated penile prosthesis. J Urol 2011;186:1187-9. 10.1016/j.juro.2011.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2011.07.042</ArticleId><ArticleId IdType="pubmed">21849194</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Munarriz R, Shah N. Intra-abdominal reservoir placement during penile prosthesis surgery in post-robotically assisted laparoscopic radical prostatectomy patients: a case report and practical considerations. J Sex Med 2011;8:1547-50. 10.1111/j.1743-6109.2011.02229.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02229.x</ArticleId><ArticleId IdType="pubmed">21385324</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Hoeh MP. Review of penile prosthetic reservoir: complications and presentation of a modified reservoir placement technique. J Sex Med 2012;9:2759-69. 10.1111/j.1743-6109.2012.02807.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02807.x</ArticleId><ArticleId IdType="pubmed">22672516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med 2007;4:296-309. 10.1111/j.1743-6109.2007.00434.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00434.x</ArticleId><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol 2016;13:33-46. 10.1038/nrurol.2015.270</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2015.270</ArticleId><ArticleId IdType="pubmed">26620609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pescatori E, Alei G, Antonini G, et al. INSIST-ED: Italian Society of Andrology registry on penile prosthesis surgery. First data analysis. Arch Ital Urol Androl 2016;88:122-7. 10.4081/aiua.2016.2.122</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2016.2.122</ArticleId><ArticleId IdType="pubmed">27377088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DS, Yang KM, Chung HJ, et al. AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term follow-up. J Sex Med 2010;7:2602-7. 10.1111/j.1743-6109.2010.01801.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01801.x</ArticleId><ArticleId IdType="pubmed">20384938</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Henry G, Culkin D, et al. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med 2009;6:1773-8. 10.1111/j.1743-6109.2009.01251.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01251.x</ArticleId><ArticleId IdType="pubmed">19473458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9. 10.1111/j.1743-6109.2007.00540.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar NB, Angermeier KW, Montague DK. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol 2006;176:2599-601; discussion 601. 10.1016/j.juro.2006.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.08.012</ArticleId><ArticleId IdType="pubmed">17085168</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuk Choi Y, Jin Choi Y, Hwan Kim J, et al. Mechanical reliability of the AMS 700CXM inflatable penile prosthesis for the treatment of male erectile dysfunction. J Urol 2001;165:822-4. 10.1016/S0022-5347(05)66536-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)66536-6</ArticleId><ArticleId IdType="pubmed">11176478</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Rigatti P, Carmignani G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000;37:50-5. 10.1159/000020099</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000020099</ArticleId><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR., 2nd Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. J Urol 1999;162:715-8. 10.1097/00005392-199909010-00022</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005392-199909010-00022</ArticleId><ArticleId IdType="pubmed">10458350</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubocq F, Tefilli MV, Gheiler EL, et al. Long-term mechanical reliability of multicomponent inflatable penile prosthesis: comparison of device survival. Urology 1998;52:277-81. 10.1016/S0090-4295(98)00174-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(98)00174-5</ArticleId><ArticleId IdType="pubmed">9697794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves M, Delk JR., 2nd Long-term results with Hydroflex and Dynaflex penile prostheses: device survival comparison to multicomponent inflatables. J Urol 1996;155:1621-3. 10.1016/S0022-5347(01)66145-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)66145-7</ArticleId><ArticleId IdType="pubmed">8627837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinds PR, Wilson SK, Sadeghi-Nejad H. Dilemmas of inflatable penile prosthesis revision surgery: what practices achieve the best outcomes and the lowest infection rates? (CME). J Sex Med 2012;9:2483-91; quiz 92. 10.1111/j.1743-6109.2012.02932.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02932.x</ArticleId><ArticleId IdType="pubmed">23046282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpurkar A, Bianco FF, Jr, Al-Omar O, et al. Fate of the retained reservoir after replacement of 3-piece penile prosthesis. J Urol 2004;172:664-6. 10.1097/01.ju.0000131454.51640.a3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000131454.51640.a3</ArticleId><ArticleId IdType="pubmed">15247756</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpman E, Brant WO, Kansas B, et al. Reservoir alternate surgical implantation technique: preliminary outcomes of initial PROPPER study of low profile or spherical reservoir implantation in submuscular location or traditional prevesical space. J Urol 2015;193:239-44. 10.1016/j.juro.2014.07.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.07.082</ArticleId><ArticleId IdType="pubmed">25066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Talib RA, Shamsodini A, Salem EA, et al. Isolated pump erosion of an inflatable penile prosthesis through the scrotum in a diabetic patient. Arch Ital Urol Androl 2013;85:53-5. 10.4081/aiua.2013.1.53</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2013.1.53</ArticleId><ArticleId IdType="pubmed">23695409</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Distal corporoplasty for lateral extrusion of penile prosthesis cylinders. J Urol 1999;161:193-5. 10.1016/S0022-5347(01)62094-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)62094-9</ArticleId><ArticleId IdType="pubmed">10037396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawczuk I, Wechsler M. Erosion of the pump mechanism of an inflatable penile prosthesis through the scrotum in a diabetic patient. J Natl Med Assoc 1985;77:577-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2571130</ArticleId><ArticleId IdType="pubmed">4046057</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie's disease and drug-resistant erectile dysfunction: A single-center study. J Sex Med 2010;7:3775-83. 10.1111/j.1743-6109.2010.01971.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01971.x</ArticleId><ArticleId IdType="pubmed">20722782</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlow WL, Goldwasser B. Salvage of the eroded inflatable penile prosthesis: a new concept. J Urol 1987;138:312-4. 10.1016/S0022-5347(17)43131-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)43131-4</ArticleId><ArticleId IdType="pubmed">3599246</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhail EF, Nehra A, Bruner BC, et al. MRI and its role in the evaluation and surgical decision making in patients with challenging IPP presentations: descriptions of MRI findings and algorithm for patient management. BJU Int 2012;109:1848-52. 10.1111/j.1464-410X.2011.10683.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2011.10683.x</ArticleId><ArticleId IdType="pubmed">22035451</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Noh CH. Distal penile prosthesis extrusion: treatment with distal corporoplasty or Gortex windsock reinforcement. Int J Impot Res 2002;14:81-4. 10.1038/sj.ijir.3900829</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900829</ArticleId><ArticleId IdType="pubmed">11979321</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter GJ, Greisman J, Werthman PE, et al. Use of a prefabricated tunica vaginalis fascia flap to reconstruct the tunica albuginea after recurrent penile prosthesis extrusion. J Urol 1998;159:128-32. 10.1016/S0022-5347(01)64034-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)64034-5</ArticleId><ArticleId IdType="pubmed">9400454</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler TS, Modder JK, Dupree JM, et al. Malleable implant substitution for the management of penile prosthesis pump erosion: a pilot study. J Sex Med 2009;6:1474-8. 10.1111/j.1743-6109.2009.01236.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01236.x</ArticleId><ArticleId IdType="pubmed">19453933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball TP., Jr Surgical repair of penile "SST" deformity. Urology 1980;15:603-4. 10.1016/0090-4295(80)90379-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(80)90379-9</ArticleId><ArticleId IdType="pubmed">7394993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickell M, Manimala N, Parker J, et al. Floppy Glans Syndrome: Pathogenesis and Treatment. Sex Med Rev 2016;4:149-56. 10.1016/j.sxmr.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2015.12.001</ArticleId><ArticleId IdType="pubmed">27872024</ArticleId></ArticleIdList></Reference><Reference><Citation>Morey AF. Reconstructing penile supersonic transporter (SST) deformity using glanulopexy (glans fixation). J Urol 2005;174:969.</Citation><ArticleIdList><ArticleId IdType="pubmed">16094013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Kim FJ. Reconstructing penile supersonic transporter (SST) deformity using glanulopexy (glans fixation). Urology 2001;57:1160-2. 10.1016/S0090-4295(01)00961-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(01)00961-X</ArticleId><ArticleId IdType="pubmed">11377333</ArticleId></ArticleIdList></Reference><Reference><Citation>Le B, McVary K, McKenna K, et al. A Novel Thermal-activated Shape Memory Penile Prosthesis: Comparative Mechanical Testing. Urology 2017;99:136-41. 10.1016/j.urology.2016.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.09.007</ArticleId><ArticleId IdType="pubmed">27639798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29238662</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>Suppl 5</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Medical pre-operative considerations for patients undergoing penile implantation.</ArticleTitle><Pagination><StartPage>S824</StartPage><EndPage>S829</EndPage><MedlinePgn>S824-S829</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2017.03.85</ELocationID><Abstract><AbstractText>Penile prosthesis surgery has become the standard treatment for patients with erectile dysfunction refractory to medical management. Refinements in the both the surgical technique and device manufacturing have made this a safe and reliable treatment with excellent patient satisfaction. In this review, we will overview the basic medical and pre-operative considerations for patients undergoing penile prosthesis implantation. We intend to provide a simple and practical checklist for the implanter to reference when considering implantation of a penile prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masterson</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>University of Miami Miller School of Medicine department of Urology, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Miami Miller School of Medicine department of Urology, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubin</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Miami Miller School of Medicine department of Urology, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Ranjith</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Miami Miller School of Medicine department of Urology, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Nov;6(Suppl 5):S830-S831</RefSource><PMID Version="1">29239401</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">penile prosthesis in diabetics</Keyword><Keyword MajorTopicYN="N">pre-operative management</Keyword><Keyword MajorTopicYN="N">skin preparation</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29238662</ArticleId><ArticleId IdType="pmc">PMC5715179</ArticleId><ArticleId IdType="doi">10.21037/tau.2017.03.85</ArticleId><ArticleId IdType="pii">tau-06-S5-S824</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Le B, Burnett AL. Evolution of penile prosthetic devices. Korean J Urol 2015;56:179-86. 10.4111/kju.2015.56.3.179</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/kju.2015.56.3.179</ArticleId><ArticleId IdType="pmc">PMC4355428</ArticleId><ArticleId IdType="pubmed">25763121</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, et al. North American consensus document on infection of penile prostheses. Urology 2013;82:937-42. 10.1016/j.urology.2013.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.05.048</ArticleId><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010;64:848-57. 10.1111/j.1742-1241.2010.02410.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-1241.2010.02410.x</ArticleId><ArticleId IdType="pubmed">20584218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett G, Krychman M, Baldwin D, et al. Coronary Heart Disease, Diabetes, and Sexuality in Men. J Sex Med 2016;13:887-904. 10.1016/j.jsxm.2016.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.023</ArticleId><ArticleId IdType="pubmed">27215685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AD, Streiff M, Resar J, et al. Coronary stent management in elective genitourinary surgery. BJU Int 2012;110:480-4. 10.1111/j.1464-410X.2011.10821.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2011.10821.x</ArticleId><ArticleId IdType="pubmed">22192977</ArticleId></ArticleIdList></Reference><Reference><Citation>Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014;192:1026-34. 10.1016/j.juro.2014.04.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.04.103</ArticleId><ArticleId IdType="pubmed">24859439</ArticleId></ArticleIdList></Reference><Reference><Citation>Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-50S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278059</ArticleId><ArticleId IdType="pubmed">22315266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakky TS, Kohn TP, Ramasamy R. Submuscular Abdominal Wall Placement of IPP Reservoir. J Sex Med 2016;13:1573-7. 10.1016/j.jsxm.2016.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.08.010</ArticleId><ArticleId IdType="pubmed">27641925</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpman E, Brant WO, Kansas B, et al. Reservoir alternate surgical implantation technique: preliminary outcomes of initial PROPPER study of low profile or spherical reservoir implantation in submuscular location or traditional prevesical space. J Urol 2015;193:239-44. 10.1016/j.juro.2014.07.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.07.082</ArticleId><ArticleId IdType="pubmed">25066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Stember DS, Garber BB, Perito PE. Outcomes of abdominal wall reservoir placement in inflatable penile prosthesis implantation: a safe and efficacious alternative to the space of Retzius. J Sex Med 2014;11:605-12. 10.1111/jsm.12408</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12408</ArticleId><ArticleId IdType="pubmed">24286533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Carson CC, Cleves MA, et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998;159:1537-9; discussion 1539-40. 10.1097/00005392-199805000-00034</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005392-199805000-00034</ArticleId><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop JR, Moul JW, Sihelnik SA, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992;147:386-8. 10.1016/S0022-5347(17)37244-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)37244-0</ArticleId><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ, Carson CC., 3rd Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011;60:167-72. 10.1016/j.eururo.2011.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2011.01.046</ArticleId><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cakan M, Demirel F, Karabacak O, et al. Risk factors for penile prosthetic infection. Int Urol Nephrol 2003;35:209-13. 10.1023/B:UROL.0000020300.23522.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:UROL.0000020300.23522.49</ArticleId><ArticleId IdType="pubmed">15072498</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M, Pearce I. Infection of Penile Prostheses in Patients with Diabetes Mellitus. Surg Infect (Larchmt) 2016;17:2-8. 10.1089/sur.2015.164</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2015.164</ArticleId><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WD, Yuan YM, Cui WS, et al. Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. Asian J Androl 2013;15:658-61. 10.1038/aja.2013.78</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aja.2013.78</ArticleId><ArticleId IdType="pmc">PMC3881644</ArticleId><ArticleId IdType="pubmed">23872664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31:591-5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>DiBlasio CJ, Kurta JM, Botta S, et al. Peyronie's disease compromises the durability and component-malfunction rates in patients implanted with an inflatable penile prosthesis. BJU Int 2010;106:691-4. 10.1111/j.1464-410X.2009.09194.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2009.09194.x</ArticleId><ArticleId IdType="pubmed">20128775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR., 2nd Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol 1995;153:659-61. 10.1016/S0022-5347(01)67678-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)67678-X</ArticleId><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001;13:326-8. 10.1038/sj.ijir.3900768</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900768</ArticleId><ArticleId IdType="pubmed">11918248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007;70:337-40. 10.1016/j.urology.2007.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.03.058</ArticleId><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabria A, Dom&#xed;nguez LC, Valdivieso E, et al. Prophylactic antibiotics for mesh inguinal hernioplasty: a meta-analysis. Ann Surg 2007;245:392-6. 10.1097/01.sla.0000250412.08210.8e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000250412.08210.8e</ArticleId><ArticleId IdType="pmc">PMC1877016</ArticleId><ArticleId IdType="pubmed">17435546</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell-Keely JP, Russo RR, March L, et al. Antibiotic prophylaxis in hip fracture surgery: a metaanalysis. Clin Orthop Relat Res 2004;(419):179-84. 10.1097/00003086-200402000-00029</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-200402000-00029</ArticleId><ArticleId IdType="pubmed">15021151</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. No-touch technique. J Sex Med 2011;8:5-8. 10.1111/j.1743-6109.2010.02137.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02137.x</ArticleId><ArticleId IdType="pubmed">21199375</ArticleId></ArticleIdList></Reference><Reference><Citation>Koulouvaris P, Sculco P, Finerty E, et al. Relationship between perioperative urinary tract infection and deep infection after joint arthroplasty. Clin Orthop Relat Res 2009;467:1859-67. 10.1007/s11999-008-0614-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-008-0614-8</ArticleId><ArticleId IdType="pmc">PMC2690738</ArticleId><ArticleId IdType="pubmed">19009324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence VA, Kroenke K. The unproven utility of preoperative urinalysis. Clinical use. Arch Intern Med 1988;148:1370-3. 10.1001/archinte.1988.00380060134025</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1988.00380060134025</ArticleId><ArticleId IdType="pubmed">3377621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-V&#xe9;lez D, Gonz&#xe1;lez-Fern&#xe1;ndez E, Esteban J, et al. Prevalence of asymptomatic bacteriuria in knee arthroplasty patients and subsequent risk of prosthesis infection. Eur J Orthop Surg Traumatol 2016;26:209-14. 10.1007/s00590-015-1720-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-015-1720-4</ArticleId><ArticleId IdType="pubmed">26559541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusk MH. Avoiding Unnecessary Preoperative Testing. Med Clin North Am 2016;100:1003-8. 10.1016/j.mcna.2016.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2016.04.011</ArticleId><ArticleId IdType="pubmed">27542420</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz DJ, Stember DS, Nelson CJ, et al. Perioperative prevention of penile prosthesis infection: practice patterns among surgeons of SMSNA and ISSM. J Sex Med 2012;9:1705-12; quiz 712-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zywiel MG, Daley JA, Delanois RE, et al. Advance pre-operative chlorhexidine reduces the incidence of surgical site infections in knee arthroplasty. Int Orthop 2011;35:1001-6. 10.1007/s00264-010-1078-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-010-1078-5</ArticleId><ArticleId IdType="pmc">PMC3167398</ArticleId><ArticleId IdType="pubmed">20563806</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober ED, Domes T, Fanipour M, et al. Preoperative hair removal on the male genitalia: clippers vs. razors. J Sex Med 2013;10:589-94. 10.1111/j.1743-6109.2012.02904.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02904.x</ArticleId><ArticleId IdType="pubmed">22908852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexual Medicine Society of North America; Position statements: Razors and Peroperative Preparation of the Male Genitalia. Available online: http://www.smsna.org/V1/about/position-statements</Citation></Reference><Reference><Citation>Wolf JS, Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90. 10.1016/j.juro.2008.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.01.068</ArticleId><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Costerton JW., et al. Biofilm and penile prosthesis infections in the era of coated implants: a review. J Sex Med 2012;9:44-53. 10.1111/j.1743-6109.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02428.x</ArticleId><ArticleId IdType="pubmed">21951338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosnitzer MS, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med 2011;8:1521-8. 10.1111/j.1743-6109.2011.02207.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02207.x</ArticleId><ArticleId IdType="pubmed">21521487</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO, Wall MJ, Jr, Itani KM, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010;362:18-26. 10.1056/NEJMoa0810988</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810988</ArticleId><ArticleId IdType="pubmed">20054046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung LL, Grewal S, Bullock A, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol 2013;189:136-40. 10.1016/j.juro.2012.08.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.08.086</ArticleId><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK, Delk JR, 2nd, et al. Penile prosthesis cultures during revision surgery: a multicenter study. J Urol 2004;172:153-6. 10.1097/01.ju.0000132141.48587.f1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000132141.48587.f1</ArticleId><ArticleId IdType="pubmed">15201759</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. Penile Implant: Review of a "No-Touch" Technique. Sex Med Rev 2016;4:294-300. 10.1016/j.sxmr.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sxmr.2016.01.002</ArticleId><ArticleId IdType="pubmed">27871962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29238659</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>Suppl 5</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>The use of penile prostheses in the management of priapism.</ArticleTitle><Pagination><StartPage>S797</StartPage><EndPage>S803</EndPage><MedlinePgn>S797-S803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2017.04.26</ELocationID><Abstract><AbstractText>Priapism is a relatively uncommon condition that can result in erectile dysfunction (ED) and corporal fibrosis. Cases of prolonged priapism are particularly prone to ED, which arises when priapism is treatment refractory or had a delayed presentation. Due to the emergent nature of priapism, it behooves urologists to be familiar with all potential treatment modalities to minimize adverse outcomes. In this review paper, we aim to summarize the literature regarding the use of penile prosthesis (PP) implantation in the setting of ischemic priapism (IP). In some patients who present later or have prolonged initial treatment, early insertion of PP may be indicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelan</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Saint John, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langille</LastName><ForeName>Gavin M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Urology, Dalhousie University, Saint John, NB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Nov;6(Suppl 5):S804-S805</RefSource><PMID Version="1">29239397</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Priapism</Keyword><Keyword MajorTopicYN="N">erectile dysfunction (ED)</Keyword><Keyword MajorTopicYN="N">penile prosthesis (PP)</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29238659</ArticleId><ArticleId IdType="pmc">PMC5715174</ArticleId><ArticleId IdType="doi">10.21037/tau.2017.04.26</ArticleId><ArticleId IdType="pii">tau-06-S5-S797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. Eur Urol 2014;65:480-9. 10.1016/j.eururo.2013.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2013.11.008</ArticleId><ArticleId IdType="pubmed">24314827</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. J Sex Med 2010;7:476-500. 10.1111/j.1743-6109.2009.01625.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01625.x</ArticleId><ArticleId IdType="pubmed">20092449</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol 2003;170:1318-24. 10.1097/01.ju.0000087608.07371.ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000087608.07371.ca</ArticleId><ArticleId IdType="pubmed">14501756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF. Shunting for prolonged ischemic priapism: a 50-year mistake? Transl Androl Urol 2014;3:AB06.</Citation></Reference><Reference><Citation>Garcia M, Porten S, Lue TF. Commentary on refractory ischemic priapism. Transl Androl Urol 2012;1:61-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713211</ArticleId><ArticleId IdType="pubmed">26813294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac JR, Mak SK, Garcia MM, et al. A pathophysiology-based approach to the management of early priapism. Asian J Androl 2013;15:20-6. 10.1038/aja.2012.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aja.2012.83</ArticleId><ArticleId IdType="pmc">PMC3739130</ArticleId><ArticleId IdType="pubmed">23202699</ArticleId></ArticleIdList></Reference><Reference><Citation>Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol 1986;135:142-7. 10.1016/S0022-5347(17)45549-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)45549-2</ArticleId><ArticleId IdType="pubmed">3941454</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Mauck R, Zhao LC, et al. Penile prosthesis insertion for acute priapism. Urol Clin North Am 2013;40:421-5. 10.1016/j.ucl.2013.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ucl.2013.04.010</ArticleId><ArticleId IdType="pubmed">23905940</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant WO, Garcia MM, Bella AJ, et al. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 2009;181:1699-705. 10.1016/j.juro.2008.12.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.12.021</ArticleId><ArticleId IdType="pubmed">19233430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, Raheem AA, Freeman A, et al. The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism. J Urol 2014;191:164-8. 10.1016/j.juro.2013.07.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2013.07.034</ArticleId><ArticleId IdType="pubmed">23892191</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Readal N, Pierorazio PM, et al. Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol 2013;189:1025-9. 10.1016/j.juro.2012.08.245</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.08.245</ArticleId><ArticleId IdType="pubmed">23017524</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med 2009;6:1171-6. 10.1111/j.1743-6109.2008.01176.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01176.x</ArticleId><ArticleId IdType="pubmed">19207268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian W, Lv J, Cui W, et al. Al-Ghorab Shunt plus intracavernous tunneling for prolonged ischemic priapism. J Androl 2010;31:466-71. 10.2164/jandrol.110.010132</Citation><ArticleIdList><ArticleId IdType="doi">10.2164/jandrol.110.010132</ArticleId><ArticleId IdType="pubmed">20467049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Mueller A, Moncada I, et al. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med 2011;8:1880-9. 10.1111/j.1743-6109.2011.02281.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02281.x</ArticleId><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, 2nd, Mulcahy JJ, et al. Upsizing of inflatable penile implant cylinders in patients with corporal fibrosis. J Sex Med 2006;3:736-42. 10.1111/j.1743-6109.2006.00263.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00263.x</ArticleId><ArticleId IdType="pubmed">16839331</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi FA, Sangkum P, McCaslin IR, et al. Strategies for penile prosthesis placement in Peyronie's disease and corporal fibrosis. Curr Urol Rep 2015;16:21. 10.1007/s11934-015-0491-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11934-015-0491-0</ArticleId><ArticleId IdType="pubmed">25712763</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooreville M, Adrian S, Delk JR, 2nd, et al. Implantation of inflatable penile prosthesis in patients with severe corporeal fibrosis: introduction of a new penile cavernotome. J Urol 1999;162:2054-7. 10.1016/S0022-5347(05)68099-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)68099-8</ArticleId><ArticleId IdType="pubmed">10569568</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossell&#xf3; Barbar&#xe1; M, Cavernotomy Carri&#xf3;n H. Arch Esp Urol 1991;44:185-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1867494</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Angermeier KW. Corporeal excavation: new technique for penile prosthesis implantation in men with severe corporeal fibrosis. Urology 2006;67:1072-5. 10.1016/j.urology.2005.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2005.11.001</ArticleId><ArticleId IdType="pubmed">16581112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansalone S, Garaffa G, Djinovic R, et al. Simultaneous total corporal reconstruction and implantation of a penile prosthesis in patients with erectile dysfunction and severe fibrosis of the corpora cavernosa. J Sex Med 2012;9:1937-44. 10.1111/j.1743-6109.2012.02748.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02748.x</ArticleId><ArticleId IdType="pubmed">22672346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes EJ, Kuwano AY, Guimaraes AN, et al. Corporoplasty using bovine pericardium grafts in complex penile prosthesis implantation surgery. Int Braz J Urol 2009;35:49-53; discussion 53-5. 10.1590/S1677-55382009000100008</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1677-55382009000100008</ArticleId><ArticleId IdType="pubmed">19254398</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese MA, Burnett AL. Corporoplasty using pericardium allograft (tutoplast) with complex penile prosthesis surgery. Urology 2001;58:1049-52. 10.1016/S0090-4295(01)01410-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(01)01410-8</ArticleId><ArticleId IdType="pubmed">11744489</ArticleId></ArticleIdList></Reference><Reference><Citation>George VK, Shah GS, Mills R, et al. The management of extensive penile fibrosis: a new technique of 'minimal scar-tissue excision'. Br J Urol 1996;77:282-4. 10.1046/j.1464-410X.1996.84421.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410X.1996.84421.x</ArticleId><ArticleId IdType="pubmed">8800900</ArticleId></ArticleIdList></Reference><Reference><Citation>Herschorn S, Ordorica RC. Penile prosthesis insertion with corporeal reconstruction with synthetic vascular graft material. J Urol 1995;154:80-4. 10.1016/S0022-5347(01)67233-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)67233-1</ArticleId><ArticleId IdType="pubmed">7776461</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Furlow WL. Corporeal reconstruction and prosthetic implantation for impotence associated with non-dilatable corporeal cavernosal fibrosis. Acta Urol Belg 1992;60:15-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">1414716</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O, Shaeer A. Corporoscopic excavation of the fibrosed corpora cavernosa for penile prosethesis implantation: optical corporotomy and trans-corporeal resection, Shaeer's technique. J Sex Med 2007;4:218-25. 10.1111/j.1743-6109.2006.00348.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00348.x</ArticleId><ArticleId IdType="pubmed">17081216</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Kim HJ, Kang MH, et al. Implantation of penile prosthesis in a patient with severe corporeal fibrosis induced by cavernosal injection therapy. Int J Impot Res 2002;14:545-6. 10.1038/sj.ijir.3900930</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900930</ArticleId><ArticleId IdType="pubmed">12494294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol 2009;56:1033-8. 10.1016/j.eururo.2008.09.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2008.09.044</ArticleId><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost L, Patil M, Kramer A. Critical Appraisal and Review of Management Strategies for Severe Fibrosis During Penile Implant Surgery. J Sex Med 2015;12 Suppl 7:439-47. 10.1111/jsm.12985</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12985</ArticleId><ArticleId IdType="pubmed">26565574</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazi MH, Jalal AA. Penile prosthesis implantation for treatment of postpriapism erectile dysfunction. Urol J 2008;5:115-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18592465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees RW, Kalsi J, Minhas S, et al. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int 2002;90:893-7. 10.1046/j.1464-410X.2002.03058.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-410X.2002.03058.x</ArticleId><ArticleId IdType="pubmed">12460352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedigh O, Rolle L, Negro CL, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res 2011;23:158-64. 10.1038/ijir.2011.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2011.23</ArticleId><ArticleId IdType="pubmed">21654814</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol 2010;183:2300-3. 10.1016/j.juro.2010.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.02.014</ArticleId><ArticleId IdType="pubmed">20400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, Garaffa G, Raheem AA, et al. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int 2014;114:576-81. 10.1111/bju.12686</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.12686</ArticleId><ArticleId IdType="pubmed">25383397</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Zhao LC, Morey AF, et al. Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism. J Sex Med 2015;12:824-6. 10.1111/jsm.12803</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12803</ArticleId><ArticleId IdType="pubmed">25536880</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey HR, Segal RL, Bivalacqua TJ. Management of priapism: an update for clinicians. Ther Adv Urol 2014;6:230-44. 10.1177/1756287214542096</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287214542096</ArticleId><ArticleId IdType="pmc">PMC4236300</ArticleId><ArticleId IdType="pubmed">25435917</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29238657</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>Suppl 5</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>30-day adverse event rates following penile prosthesis surgery: an American College of Surgeons National Surgical Quality Improvement Program based evaluation.</ArticleTitle><Pagination><StartPage>S767</StartPage><EndPage>S773</EndPage><MedlinePgn>S767-S773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2017.04.25</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Commonly utilized as a third-line therapy for erectile dysfunction (ED) management, the penile prostheses have become a staple treatment for ED refractory to pharmacological interventions. There is however a paucity of data in the literature pertaining to short-term adverse outcomes following penile prosthesis surgery. We thus sought to leverage the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) to evaluate such outcomes within 30 days of surgery in these patients. We hypothesized that such data will lead to a more informed patient-physician consultation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relying on the ACS-NSQIP database [2005-2013], patients undergoing penile prosthesis placement were identified utilizing the Current Procedural Terminology (CPT) codes: 54400, 54401, 54405, 54406, 54407, 54408, 54410, 54411, 54416 and 54417. Outcomes assessed included system-wise categorized complications, length-of-stay (LOS), and re-intervention, readmission and 30-day mortality rates. Descriptive statistics were used to analyze available data. Multivariate analysis could not be performed due to small sample size.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 98 cases of patients who underwent surgery for penile prosthesis placements between the years 2005 and 2013 were reported by the ACS-NSQIP affiliated hospitals. The median age was 65 years (interquartile range, 58-70 years). The overall 30-day complication rate was 11.3% (n=11); 5 of the 11 complications were infectious in etiology, and three were a postoperative blood transfusion event. The median LOS was 1 day. One (1.0%) patient needed to return to the operating room, two patients (2.6%) were readmitted and there was one (1.0%) death within 30 days of the original surgery.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Surgery for penile prosthesis appears to be a safe operation despite the routinely advanced age of the patients requiring it. Complications in the immediate postoperative setting are usually infectious. This data can be used in the clinical setting for a more informed patient-physician discussion and patient expectation management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palma-Zamora</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sood</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabaja</LastName><ForeName>Ali A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Nov;6(Suppl 5):S774-S775</RefSource><PMID Version="1">29239400</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Surgical complications</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29238657</ArticleId><ArticleId IdType="pmc">PMC5715172</ArticleId><ArticleId IdType="doi">10.21037/tau.2017.04.25</ArticleId><ArticleId IdType="pii">tau-06-S5-S767</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NIH consensus conference impotence. NIH consensus development panel on impotence. JAMA 1993;270:83-90. 10.1001/jama.1993.03510010089036</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1993.03510010089036</ArticleId><ArticleId IdType="pubmed">8510302</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the massachusetts male aging study. J Urol 1994;151:54-61. 10.1016/S0022-5347(17)34871-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(17)34871-1</ArticleId><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the massachusetts male aging study. J Urol 2000;163:460-3. 10.1016/S0022-5347(05)67900-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67900-1</ArticleId><ArticleId IdType="pubmed">10647654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zippe CD, Pahlajani G. Penile rehabilitation following radical prostatectomy: Role of early intervention and chronic therapy. Urol Clin North Am 2007;34:601-18, viii. 10.1016/j.ucl.2007.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ucl.2007.08.012</ArticleId><ArticleId IdType="pubmed">17983900</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. JAMA 2000;283:354-60. 10.1001/jama.283.3.354</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.3.354</ArticleId><ArticleId IdType="pubmed">10647798</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavina R, Borghesi M, Dababneh H, et al. Survival, continence and potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes. Eur J Surg Oncol 2014;40:1716-23. 10.1016/j.ejso.2014.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2014.06.015</ArticleId><ArticleId IdType="pubmed">25085795</ArticleId></ArticleIdList></Reference><Reference><Citation>Darouiche RO. Device-associated infections: A macroproblem that starts with microadherence. Clin Infect Dis 2001;33:1567-72. 10.1086/323130</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/323130</ArticleId><ArticleId IdType="pubmed">11577378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DJ, Najari BB, Davison WL, et al. Trends in the utilization of penile prostheses in the treatment of erectile dysfunction in the united states. J Sex Med 2015;12:1638-45. 10.1111/jsm.12921</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12921</ArticleId><ArticleId IdType="pubmed">26096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Camper SB, Burnett AL. Modern utilization of penile prosthesis surgery: A national claim registry analysis. Int J Impot Res 2014;26:167-71. 10.1038/ijir.2014.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2014.11</ArticleId><ArticleId IdType="pubmed">24830674</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS. American College of Surgeons National Surgical Quality Improvement Program: User Guide for the 2015 Participant Use Data File. Available online: https://www.facs.org/~/media/files/quality%20programs/nsqip/nsqip_puf_user_guide_2015.ashx</Citation></Reference><Reference><Citation>Henderson WG, Daley J. Design and statistical methodology of the National Surgical Quality Improvement Program: why is it what it is? Am J Surg 2009;198:S19-27. 10.1016/j.amjsurg.2009.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2009.07.025</ArticleId><ArticleId IdType="pubmed">19874930</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport DL, Holsapple CW, Conigliaro J. Assessing surgical quality using administrative and clinical data sets: a direct comparison of the University HealthSystem Consortium Clinical Database and the National Surgical Quality Improvement Program data set. Am J Med Qual 2009;24:395-402. 10.1177/1062860609339936</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1062860609339936</ArticleId><ArticleId IdType="pubmed">19584374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cima RR, Lackore KA, Nehring SA, et al. How best to measure surgical quality? Comparison of the Agency for Healthcare Research and Quality Patient Safety Indicators (AHRQ-PSI) and the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) postoperative adverse events at a single institution. Surgery 2011;150:943-9. 10.1016/j.surg.2011.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2011.06.020</ArticleId><ArticleId IdType="pubmed">21875734</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CG, Li L, Hixson E, et al. What are the real rates of postoperative complications: elucidating inconsistencies between administrative and clinical data sources. J Am Coll Surg 2012;214:798-805. 10.1016/j.jamcollsurg.2011.12.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2011.12.037</ArticleId><ArticleId IdType="pubmed">22421260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhojani N, Gandaglia G, Sood A, et al. Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol 2014;28:831-40. 10.1089/end.2013.0805</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/end.2013.0805</ArticleId><ArticleId IdType="pubmed">24517323</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Becher E, Bella A, et al. Penile prosthesis surgery: Current recommendations from the international consultation on sexual medicine. J Sex Med 2016;13:489-518. 10.1016/j.jsxm.2016.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.01.017</ArticleId><ArticleId IdType="pubmed">27045255</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: Clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31:591-5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Carson CC, 3rd, Chapin AK, et al. Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol 2012;188:899-903. 10.1016/j.juro.2012.04.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.04.116</ArticleId><ArticleId IdType="pubmed">22819402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. The prevention and management of noninfectious complications of penile implants. Sex Med Rev 2015;3:203-13. 10.1002/smrj.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smrj.41</ArticleId><ArticleId IdType="pubmed">27784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: Immediate replacement of the infected penile prosthesis. J Urol 1996;155:155-7. 10.1016/S0022-5347(01)66580-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)66580-7</ArticleId><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC., 3rd Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004;171:1611-4. 10.1097/01.ju.0000118245.66976.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000118245.66976.e1</ArticleId><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter CE, Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med 2004;1:221-4. 10.1111/j.1743-6109.2004.04032.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2004.04032.x</ArticleId><ArticleId IdType="pubmed">16429621</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, 3rd, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: Up to 7.7 years of followup. J Urol 2011;185:614-8. 10.1016/j.juro.2010.09.094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2010.09.094</ArticleId><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Serefoglu EC, Mandava SH, Gokce A, et al. Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med 2012;9:2182-6. 10.1111/j.1743-6109.2012.02830.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02830.x</ArticleId><ArticleId IdType="pubmed">22759917</ArticleId></ArticleIdList></Reference><Reference><Citation>Droggin D, Shabsigh R, Anastasiadis AG. Antibiotic coating reduces penile prosthesis infection. J Sex Med. 2005;2:565-8. 10.1111/j.1743-6109.2005.00073.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.00073.x</ArticleId><ArticleId IdType="pubmed">16422855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers CL, Morey AF, Jones LA. Cost and time benefits of dual implantation of inflatable penile and artificial urinary sphincter prosthetics by single incision. Urology 2005;65:852-3. 10.1016/j.urology.2004.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2004.11.017</ArticleId><ArticleId IdType="pubmed">15882709</ArticleId></ArticleIdList></Reference><Reference><Citation>Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol 2006;176:2471-3. 10.1016/j.juro.2006.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2006.08.010</ArticleId><ArticleId IdType="pubmed">17085132</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Wilson SK, Delk JR, 2nd, et al. Revision washout decreases penile prosthesis infection in revision surgery: A multicenter study. J Urol 2005;173:89-92. 10.1097/01.ju.0000146717.62215.6f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000146717.62215.6f</ArticleId><ArticleId IdType="pubmed">15592039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Zumbe J, Henry GD, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007;70:337-40. 10.1016/j.urology.2007.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.03.058</ArticleId><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson C. Complications of penile prostheses and complex implantations. In: Carson C, Kirby R, Goldstein I, et al. editors. Textbook of male erectile dysfunction. Oxford: Isis Medical Media, 1999:435-50.</Citation></Reference><Reference><Citation>Sadeghi-Nejad H. Penile prosthesis surgery: A review of prosthetic devices and associated complications. J Sex Med 2007;4:296-309. 10.1111/j.1743-6109.2007.00434.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00434.x</ArticleId><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Natali A, Olianas R, Fisch M. Penile implantation in europe: Successes and complications with 253 implants in italy and germany. J Sex Med 2008;5:1503-12. 10.1111/j.1743-6109.2008.00819.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00819.x</ArticleId><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Le BV, Burnett AL. Suprapubic cystostomy for the management of urethral injuries during penile prosthesis implantation. Sex Med 2014;2:178-81. 10.1002/sm2.44</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sm2.44</ArticleId><ArticleId IdType="pmc">PMC4272249</ArticleId><ArticleId IdType="pubmed">25548649</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD, Laborde E. A review of surgical techniques for impending distal erosion and intraoperative penile implant complications: Part 2 of a three-part review series on penile prosthetic surgery. J Sex Med 2012;9:927-36. 10.1111/j.1743-6109.2011.02606.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02606.x</ArticleId><ArticleId IdType="pubmed">22248013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Ditonno P, Palumbo F, et al. Penile Prosthesis: What Should We Do about Complications? Adv Urol 2008:573560. doi: .10.1155/2008/573560</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/573560</ArticleId><ArticleId IdType="pmc">PMC2581729</ArticleId><ArticleId IdType="pubmed">19009029</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB, Marcus SM. Does surgical approach affect the incidence of inflatable penile prosthesis infection? Urology 1998;52:291-3. 10.1016/S0090-4295(98)00186-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(98)00186-1</ArticleId><ArticleId IdType="pubmed">9697797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S, Cleves M, Delk JI. Hematoma formation following penile prosthesis implantation: to drain or not to drain. J Urol 1996:55:634A.</Citation></Reference><Reference><Citation>Antonini G, Busetto GM, De Berardinis E, et al. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: Evaluation of efficacy, satisfaction profile and complications. Int J Impot Res 2016;28:4-8. 10.1038/ijir.2015.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2015.33</ArticleId><ArticleId IdType="pmc">PMC4709472</ArticleId><ArticleId IdType="pubmed">26657316</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi-Nejad H, Ilbeigi P, Wilson SK, et al. Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res 2005;17:535-8. 10.1038/sj.ijir.3901354</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3901354</ArticleId><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB, Bickell M. Delayed postoperative hematoma formation after inflatable penile prosthesis implantation. J Sex Med 2015;12:265-9. 10.1111/jsm.12728</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12728</ArticleId><ArticleId IdType="pubmed">25349141</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29164834</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2287-4208</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The world journal of men's health</Title><ISOAbbreviation>World J Mens Health</ISOAbbreviation></Journal><ArticleTitle>Effects of Next-Generation Low-Energy Extracorporeal Shockwave Therapy on Erectile Dysfunction in an Animal Model of Diabetes.</ArticleTitle><Pagination><StartPage>186</StartPage><EndPage>195</EndPage><MedlinePgn>186-195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5534/wjmh.17024</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Gene therapy, stem cell therapy, and low-energy extracorporeal shockwave therapy (ESWT) have been investigated as treatments for refractory erectile dysfunction (ED), but inconclusive evidence has been obtained. We investigated the effect of a next-generation electromagnetic cylinder ESWT device on an animal model of ED.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Diabetes mellitus (DM)-induced rats were divided into 3 groups: group 1, control; group 2, DM; and group 3, DM+ESWT. Rats were treated with ESWT 3 times a week for 2 weeks. After the treatment course, intracavernous pressure was measured and the corpus cavernosum and cavernous nerve were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the DM group, all parameters predicted to be significantly lower in the ED model had statistically significantly decreased (p&lt;0.01). As a measurement of erectile function, intracavernous pressure was evaluated. The DM+ESWT group exhibited significantly restored erectile function compared to the DM group (p&lt;0.05). Moreover, ESWT treatment restored smooth muscle content, as assessed by Masson's trichrome staining (p&lt;0.05). Finally, corporal tissue and the dorsal nerve were evaluated by immunohistochemistry, Western blotting, and ELISA. After ESWT treatment, vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), platelet endothelial cell adhesion molecule-1, cyclic guanosine monophosphate, and neuronal nitric oxide synthase (nNOS) expression levels were restored to levels in the DM group (p&lt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Electromagnetic cylinder ESWT device resulted in increased VEGF, nNOS, and eNOS expression; reduced smooth muscle atrophy; and increased endothelial cell regeneration in a DM-associated ED model. Our data suggest that safe and effective application could be possible in future clinical studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Korean Society for Sexual Medicine and Andrology</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyun Cheol</ForeName><Initials>HC</Initials><Identifier Source="ORCID">0000-0001-8846-1351</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Seung Hwan</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0001-6695-6097</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qun</LastName><ForeName>Zhu Guan</ForeName><Initials>ZG</Initials><Identifier Source="ORCID">0000-0001-7841-8026</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kang Sup</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0002-9534-7829</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sae Woong</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-3829-939X</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashraheel</LastName><ForeName>Fahad</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1969-7720</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Woong Jin</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0001-7703-1161</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic Integrative Medicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Su Jin</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-1917-2780</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyuk Jin</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-2599-2950</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>U Syn</ForeName><Initials>US</Initials><Identifier Source="ORCID">0000-0001-9930-0588</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Sung Hoo</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-1952-4010</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Youl</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0001-6775-1157</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Du Geon</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0002-9031-9845</Identifier><AffiliationInfo><Affiliation>Department of Urology, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sae Woong</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-9127-9400</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catholic Integrative Medicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea. ksw1227@catholic.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>World J Mens Health</MedlineTA><NlmUniqueID>101596899</NlmUniqueID><ISSNLinking>2287-4208</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Animals</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Vascular endothelial growth factor</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29164834</ArticleId><ArticleId IdType="pmc">PMC5746490</ArticleId><ArticleId IdType="doi">10.5534/wjmh.17024</ArticleId><ArticleId IdType="pii">35.e18</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572&#x2013;3588.</Citation><ArticleIdList><ArticleId IdType="pubmed">21040491</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1496922</ArticleId><ArticleId IdType="pubmed">9541372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11:1109&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20402554</ArticleId></ArticleIdList></Reference><Reference><Citation>Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17134370</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ. Gene and stem cell therapy for erectile dysfunction. Int J Impot Res. 2005;17(Suppl 1):S57&#x2013;S63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet. 1980;2:1265&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">6108446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussy C, Schmiedt E. Shock wave treatment for stones in the upper urinary tract. Urol Clin North Am. 1983;10:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">6636387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussy C, Schmiedt E, Jocham D, Brendel W, Forssmann B, Walther V. First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. J Urol. 1982;127:417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">6977650</ArticleId></ArticleIdList></Reference><Reference><Citation>Young SR, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16:261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">1694604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CJ. An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J. 2003;26:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">12846521</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurzynska D, Di Meglio F, Castaldo C, Arcucci A, Marlinghaus E, Russo S, et al. Shock waves activate in vitro cultured progenitors and precursors of cardiac cell lineages from the human heart. Ultrasound Med Biol. 2008;34:334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913335</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013;10:738&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593747</ArticleId><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187:1769&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickenbach JR, Chism E. Selection and extended growth of murine epidermal stem cells in culture. Exp Cell Res. 1998;244:184&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9770361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MC, El-Sakka AI, Graziottin TM, Ho HC, Lin CS, Lue TF. The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol. 2002;167:761&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11792968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CS, Xin ZC, Wang Z, Deng C, Huang YC, Lin G, et al. Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012;21:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272247</ArticleId><ArticleId IdType="pubmed">21793654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden JA, T&#xf3;th-Kischkat A, Schultheiss R. Principles of shock wave therapy. Clin Orthop Relat Res. 2001;(387):8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11400898</ArticleId></ArticleIdList></Reference><Reference><Citation>Onose G, Daia Chendreanu C, Haras M, Spinu A, Andone I. Extracorporeal shock wave therapy: a new &#x201c;wave&#x201d; (also) in physiatry? Practica Medicala. 2011;6:35&#x2013;42.</Citation></Reference><Reference><Citation>Park K, Ahn KY, Kim MK, Lee SE, Kang TW, Ryu SB. Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats. Eur Urol. 2004;46:403&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol. 2005;173:318&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NH, Seo CS, Lee HY, Jung DY, Lee JK, Lee JA, et al. Hepatoprotective and antioxidative activities of cornus officinalis against acetaminophen-induced hepatotoxicity in mice. Evid Based Complement Alternat Med. 2012 doi: 10.1155/2012/804924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/804924</ArticleId><ArticleId IdType="pmc">PMC3159024</ArticleId><ArticleId IdType="pubmed">21869901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu J, Li L, Wang P, Ji X, Ai H, et al. Neuroprotective effect of morroniside on focal cerebral ischemia in rats. Brain Res Bull. 2010;83:196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20637265</ArticleId></ArticleIdList></Reference><Reference><Citation>Melis MR, Succu S, Mauri A, Argiolas A. Nitric oxide production is increased in the paraventricular nucleus of the hypothalamus of male rats during non-contact penile erections and copulation. Eur J Neurosci. 1998;10:1968&#x2013;1974.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dashwood MR, Crump A, Shi-Wen X, Loesch A. Identification of neuronal nitric oxide synthase (nNOS) in human penis: a potential role of reduced neuronally-derived nitric oxide in erectile dysfunction. Curr Pharm Biotechnol. 2011;12:1316&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">21506911</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications. 2011;25:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">20462773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Xin H, Liu T, Li GY, Gao ZZ, Liu J, et al. Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes. J Androl. 2012;33:832&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">22403279</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Lin G, Fandel TM, Zhang H, Qiu X, Lin CS, et al. Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction. Urology. 2011;78:476, 476.e1&#x2013;476.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152638</ArticleId><ArticleId IdType="pubmed">21624647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MH, Ryu JK, Kim WJ, Jin HR, Song KM, Kwon KD, et al. Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse. J Sex Med. 2013;10:2912&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937122</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhojani N, Mandeville JA, Hameed TA, Soergel TM, McAteer JA, Williams JC, Jr, et al. Lithotripter outcomes in a community practice setting: comparison of an electromagnetic and an electrohydraulic lithotripter. J Urol. 2015;193:875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412606</ArticleId><ArticleId IdType="pubmed">25305356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa M, Aburas H, Helo FM, Qarawi L. Electromagnetic and electrohydraulic shock wave lithotripsy-induced urothelial damage: is there a difference? J Endourol. 2017;31:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5312543</ArticleId><ArticleId IdType="pubmed">27899041</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28982618</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Three-piece Penile Prosthesis Implantation in Refractory Ischemic Priapism-Tips and Tricks.</ArticleTitle><Pagination><StartPage>233</StartPage><EndPage>235</EndPage><MedlinePgn>233-235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2017.04.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(17)30404-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">Implantation of a penile prosthesis in a patient with significant corporal fibrosis can pose a significant challenge to the surgeon, necessitating the knowledge of specific techniques used to dilate and close aggressively scarred corpora. The objective of our instructional video is to discuss 2 techniques used to approach corporal fibrosis: proper and safe use of cavernotomes for dilation and use of narrower prostheses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this video, we present a 53-year-old man with a history of priapism 3 years ago that lasted 4 days in the setting of trazodone use. He was managed with corporal irrigation and subsequently developed severe erectile dysfunction. Notably, the patient had a history of sickle cell anemia, and on physical examination was noted to have densely fibrotic corpora. After extensive counseling regarding options, he chose a penile implant. The surgical was planned using the "no touch technique." After the corporotomies were made, we began dilating the corpora. Hegar dilators and Dilamezinsert were attempted at first but met significant resistance. We switched to cutting cavernotomes and were able to dilate up to 11-Fr distally and up to 13-Fr proximally. The proper use of cavernotomes is highlighted in our video, with care being taken to aim the cutting edge of the cavernotome laterally away from the urethra. We also used the narrowest inflatable prosthesis available to us (Coloplast Titan narrow-base) and describe the narrower devices available in inflatable and malleable forms as an option for less-than-ideally dilated corpora. The pump and reservoir placement was completed uneventfully.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient was admitted overnight for observation and check of a complete blood count given his history of sickle cell anemia. He was able to be discharged after 23 hours of observation. The patient presented to the clinic 4 weeks later for pump activation. He was able to achieve good rigidity and had a penile length adequate for penetration after maximal activation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This video discusses the approach to penile prosthesis placement in patients with significant corporal fibrosis. It highlights the proper use of cutting cavernotomes and the availability of narrow-diameter prostheses, both malleable and inflatable.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clavijo</LastName><ForeName>Raul I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;vio</LastName><ForeName>Lu&#xed;s Felipe</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Nachiketh Soodana</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masterson</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>J Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Advanced Urological Care, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Ranjith</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Miami Miller School of Medicine, Miami, FL. Electronic address: ranjithrama@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28982618</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2017.04.032</ArticleId><ArticleId IdType="pii">S0090-4295(17)30404-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28920056</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2253-2447</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Research and reports in urology</Title><ISOAbbreviation>Res Rep Urol</ISOAbbreviation></Journal><ArticleTitle>Management of refractory ischemic priapism: current perspectives.</ArticleTitle><Pagination><StartPage>175</StartPage><EndPage>179</EndPage><MedlinePgn>175-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/RRU.S128003</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of the present manuscript is to review the current literature on priapism, focusing on the state-of-the-art knowledge of both the diagnosis and the treatment of the refractory ischemic priapism (IP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Pubmed and EMBASE search engines were used to search for words "priapism", "refractory priapism", "penile prosthesis", "diagnosis priapism", "priapism treatment", "penile fibrosis", "priapism therapy". All the studies were carefully examined by the authors and then included in the review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">First-line treatment involves ejaculation, physical exercise and cold shower followed by corporal blood aspiration and injection of &#x3b1;-adrenoceptor agonists. Subsequently, a distal or proximal shunt may be considered. If none of the treatment is effective or the priapism episode lasts &gt;48 hours penile prosthesis implantation could be the only option to solve the priapism and treat the ongoing erectile dysfunction.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The management of IP is to achieve detumescence of persistent penile erection and to preserve erectile function after resolution of the priapic episode. On the other hand, penile fibrosis and following shortening should be prevented. Early penile prosthesis implantation in patients with refractory IP is able to solve both the priapic episode and prevent the otherwise certain penile shortening. Penile prosthesis implantation is the actual gold standard of care in cases of refractory IP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Institute of Urology, University College of London Hospital (UCLH), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillo</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, "Umberto Parini" Hospital, Aosta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Careggi Hospital, Firenze.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Institute of Urology, University College of London Hospital (UCLH), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timpano</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Turin, Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Turin, Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Res Rep Urol</MedlineTA><NlmUniqueID>101576971</NlmUniqueID><ISSNLinking>2253-2447</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ischemic priapism</Keyword><Keyword MajorTopicYN="N">penile fibrosis</Keyword><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">priapism</Keyword><Keyword MajorTopicYN="N">shunt</Keyword></KeywordList><CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28920056</ArticleId><ArticleId IdType="pmc">PMC5587151</ArticleId><ArticleId IdType="doi">10.2147/RRU.S128003</ArticleId><ArticleId IdType="pii">rru-9-175</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. Eur Urol. 2014;65(2):480&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24314827</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Jarow J, Broderick GA, et al. Members of the Erectile Dysfunction Guideline Update Panel. Americal Urological Association American urological association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501756</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7(1 Pt 2):476&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med. 2012;9(1):79&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21554553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagoda G, Sezen SF, Cabrini MR, Musicki B, Burnett AL. Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis. J Urol. 2013;189(2):762&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4478587</ArticleId><ArticleId IdType="pubmed">22982429</ArticleId></ArticleIdList></Reference><Reference><Citation>Eland IA, Van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337305</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado PS, Costa MP, Ribeiro do Prado Valladares F, et al. The prevalence of priapism in children and adolescents with sickle cell disease in Brazil. Int J Hematol. 2012;95(6):648&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YH, Kim JJ, Stein NB, Khera M. Malignant priapism secondary to metastatic prostate cancer: a case report and review of literature. Rev Urol. 2011;13(2):90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176556</ArticleId><ArticleId IdType="pubmed">21935340</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">8583582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell disease complications: a clinical study of 179 cases. Haematologica. 2012;97(8):1136&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409809</ArticleId><ArticleId IdType="pubmed">22315500</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: a model for ischemic priapism. J Urol. 1994;151(1):259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254824</ArticleId></ArticleIdList></Reference><Reference><Citation>Spycher MA, Hauri D. The ultrastucture of the erectile tissue in priapism. J Urol. 1986;135(1):142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">3941454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, Garaffa G, Raheem AA, Christopher AN, Muneer A, Ralph DJ. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014;114(4):576&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383397</ArticleId></ArticleIdList></Reference><Reference><Citation>Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets. 2015;16(5):474&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430197</ArticleId><ArticleId IdType="pubmed">25392014</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruve N, Hosking DH. Intracorporeal phenylephrine in the treatment of priapism. J Urol. 1996;155(1):141&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490814</ArticleId></ArticleIdList></Reference><Reference><Citation>Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008;5(9):2152&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466270</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon DG, Lee DS, Kim JJ. Altered contractile response of penis under hypoxia with metabolic acidosis. Int J Impot Res. 1999;11(5):265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10553805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan G. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95(1):78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607688</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL. Surgical management of ischemic priapism. J Sex Med. 2012;9(1):114&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22221308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Faddan AA, Aksenov AV, Naumann CM, J&#xfc;nemann KP, Osmonov DK. Semi-rigid penile prosthesis as a salvage management of idiopathic ischemic stuttering priapism. Res Rep Urol. 2015;7:137&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567212</ArticleId><ArticleId IdType="pubmed">26380229</ArticleId></ArticleIdList></Reference><Reference><Citation>Monga M, Broderick GA, Hellstrom WJ. Priapism in sickle cell disease: the case for early implantation of the penile prosthesis. Eur Urol. 1996;30(1):54&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8854068</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Sexual dysfunction: immediate penile prosthesis for acute ischemic priapism. Nat Rev Urol. 2010;7(4):187&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">20383186</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002;90(9):893&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460352</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010;183(6):2300&#x2013;2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedigh O, Rolle L, Negro CL, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011;23(4):158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram CP, Fernandes ET, Ercole C, et al. Management of refractory priapism with penile prostheses. Br J Urol. 1997;79(4):659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Evans LA, Morey AF. Immediate insertion of a semirigid penile prosthesis for refractory ischemic priapism. Mil Med. 2007;172(11):1211&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18062399</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Mauck R, Zhao LC, Morey AF. Penile prosthesis insertion for acute priapism. Urol Clin North Am. 2013;40(3):421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23905940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Zausch LC, Morey AF, et al. Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism. J Sex Med. 2015;12(3):824&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">25536880</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay J, Shekarriz B, Dhabuwala CB. Penile implant for intractable priapism associated with sickle cell disease. Urology. 1998;51(4):638&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9586621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Borley NC, Allen C, et al. The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int. 2010;106(11):1714&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">20438564</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RG, O&#x2019;Connor JL, Milam DF. Efficacy of shunt surgery for refractory low flow priapism: a report on the incidence of failed detumescence and erectile dysfunction. J Urol. 2003;170(3):883&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">12913722</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Readal N, Pierorazio PM, Burnett AL, Bivalacqua TJ. Corporal Burnett &#x201c;Snake&#x201d; surgical maneuver for the treatment of ischemic priapism: long-term follow-up. J Urol. 2013;189(3):1025&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">23017524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharakis E, Raheem AA, Freeman A, et al. The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism. J Urol. 2014;191(1):164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23892191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Mueller A, Moncada I, Carballido J, Mulhall JP. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med. 2011;8(7):1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK. Reimplantation of inflatable penile prosthesis into scarred corporeal bodies. Int J Impot Res. 2003;15(Suppl 5):S125&#x2013;S128.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Surgical management of penile prosthesis complications. Int J Impot Res. 2000;12(Suppl 4):S108&#x2013;S111.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, 2nd, Mulcahy JJ, Cleves M, Salem EA. Upsizing of inflatable penile implant cylinders in patients with corporal fibrosis. J Sex Med. 2006;3(4):736&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28916463</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis Implantation in Priapism.</ArticleTitle><Pagination><StartPage>310</StartPage><EndPage>318</EndPage><MedlinePgn>310-318</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2017.08.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(17)30098-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Priapism is defined as a full or partial erection lasting longer than 4 hours after sexual stimulation and orgasm or unrelated to sexual stimulation. The main goal of priapism management is to resolve the episode immediately to preserve erectile function and penile length. Corporal smooth muscle necrosis is likely to have already occurred, and medically refractory erectile dysfunction is expected in patients with a protracted episode. Penile prosthesis implantation (PPI) in the early or late phase of priapism can restore erectile function.</AbstractText><AbstractText Label="AIM">To review the literature on PPI in priapism.</AbstractText><AbstractText Label="METHODS">A PubMed search of all English-language articles published before 2017 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement using the following search terms: penile prosthesis implantation, priapism, and corporal fibrosis. All publications reporting on PPI during or after priapism episodes were included for review.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Three types of priapism were reviewed for management using PPI. Surgical techniques, outcomes, and patient satisfaction were reported.</AbstractText><AbstractText Label="RESULTS">Early implantation (during the episode) is technically easier and has lower complication rates compared with delayed (electively, after the erectile dysfunction is observed) surgery. Immediate PPI also allows preservation of penile length, which is related to higher satisfaction rates.</AbstractText><AbstractText Label="CONCLUSIONS">The paradigm is shifting toward immediate PPI in the management of ischemic priapism. Patients with non-ischemic priapism or recurrent priapism, even without a major ischemic episode, are at high risk for erectile dysfunction and are candidates for PPI. Y&#xfc;cel &#xd6;B, Paz&#x131;r Y, Kad&#x131;o&#x11f;lu A. Penile Prosthesis Implantation in Priapism. Sex Med Rev 2018;6:310-318.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Y&#xfc;cel</LastName><ForeName>&#xd6;mer Bar&#x131;&#x15f;</ForeName><Initials>&#xd6;B</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz&#x131;r</LastName><ForeName>Ya&#x15f;ar</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kad&#x131;o&#x11f;lu</LastName><ForeName>Ate&#x15f;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: kadiogluates@ttmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="Y">Priapism</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Ischemic Priapism</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28916463</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2017.08.002</ArticleId><ArticleId IdType="pii">S2050-0521(17)30098-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28763176</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1066-2936</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Undersea &amp; hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc</Title><ISOAbbreviation>Undersea Hyperb Med</ISOAbbreviation></Journal><ArticleTitle>Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>465</EndPage><MedlinePgn>463-465</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED), defined as the inability to achieve or sustain an erection firm enough for sexual intercourse, is common in men older than 50 years of age whose medical history includes diabetes mellitus. This case report describes a male patient treated with hyperbaric oxygen (HBO&#x2082;) therapy as part of a comprehensive wound treatment plan for an open right foot wound. The patient's medical history included Type 1 diabetes mellitus and chronic ED refractory to previous trials of phosphodiesterase type 5 inhibitors. The patient completed a total of 60 HBO&#x2082; treatments over a 15-week period. He reported an improvement in his ED symptoms after the first 20 hyperbaric treatments, with morning tumescence being the first sign of a change. Patient continued to report morning tumescence 24 weeks after final HBO&#x2082; treatment.</AbstractText><CopyrightInformation>Copyright&#xa9; Undersea and Hyperbaric Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cormier</LastName><ForeName>Jolene</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Comprehensive Wound Center, Irving, Texas U.S.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theriot</LastName><ForeName>Maxine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Comprehensive Wound Center, Irving, Texas U.S.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Undersea Hyperb Med</MedlineTA><NlmUniqueID>9312954</NlmUniqueID><ISSNLinking>1066-2936</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">hyperbaric oxygen</Keyword></KeywordList><CoiStatement>The authors of this paper declare no conflicts of interest exist with this submission.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28763176</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28755962</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Are the Cavernous Tissue and Serum Levels of Micro RNAs 200a and 206 Elevated in Patients With Refractory Veno-occlusive Erectile Dysfunction? A Comparative Study.</ArticleTitle><Pagination><StartPage>108</StartPage><EndPage>113</EndPage><MedlinePgn>108-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2017.07.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(17)30761-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association between miRNAs and veno-occlusive erectile dysfunction. Recently, this association between miRNAs and erectile dysfunction was extensively studied using animal models. Our aim was to explore the miRNAs expressions and functions in the development of erectile dysfunction, especially veno-occlusive dysfunction, using a human tissue.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We prospectively recruited 60 patients with erectile dysfunction and controls between July 2015 and July 2016. The 30 patients had refractory veno-occlusive erectile dysfunction that was proven by investigations. They were scheduled for penile implant. The 30 controls were scheduled for repair of their fracture. We measured miRNAs (200a and 206) and nitric oxide in cavernous tissue and serum of both patients with erectile dysfunction and controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A significant association was found between the 2 mentioned miRNAs and erectile dysfunction (P&#x2009;&lt;.001). Mean level of nitric oxide in cavernous tissue of the controls was significantly higher than that in the patients (P&#x2009;&lt;.001). miRNA 200a showed a cutoff value of 1.135 with 95% sensitivity and 100% specificity, whereas miRNA 206 showed a cutoff value of 1.125 with 100% sensitivity and 100% specificity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To the best of our knowledge, our study is the first report to measure the level of miRNAs in the cavernous tissue, using a human tissue. Furthermore, this study can be considered a good step of deploying miRNAs through a blood test to detect early negative changes that lead to erectile dysfunction. Finally, we recommend more studies to be conducted to better understand if these miRNAs are involved in the pathophysiology of veno-occlusive erectile dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>GamalEl Din</LastName><ForeName>Sameh Fayek</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Andrology and STDs, Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: samehfayek@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashed</LastName><ForeName>Laila Ahmed</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghobary</LastName><ForeName>Hany Ahmed</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tawfik</LastName><ForeName>Lamiaa Tarek</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ElSheemy</LastName><ForeName>Mohammed Said</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Urology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C533896">MIRN200 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546087">MIRN206 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018608" MajorTopicYN="N">Ultrasonography, Doppler</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28755962</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2017.07.020</ArticleId><ArticleId IdType="pii">S0090-4295(17)30761-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30512730</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2101-017X</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[News in erectile dysfunction].</ArticleTitle><Pagination><StartPage>616</StartPage><EndPage>622</EndPage><MedlinePgn>616-622</MedlinePgn></Pagination><Abstract><AbstractText>News in erectile dysfunction. Erectile dysfunction (ED) is the most commonly treated sexual disorder affecting up to 20% of all men. As ED adversely affects the lives of millions of men, the public health implications of this condition are significant and represent a challenge for our healthcare system. Several options are available for treating ED : oral pharmacotherapy with phosphodiesterase 5 (PDE5) inhibitors represent so far the first-line option for many patients with ED. They are effective in three quarters of patients, with a similar response rate with the 4 available molecules (sildenafil, vardenafil, tadalafil and avanafil). Recently, an alprostadil cream (Vitaros) combining the active molecule with a skin enhancer has been allowed for usage in France. Low systemic adverse effects (3%), together with a high efficacy (up to 83%) make it a possible first-line therapeutic option for patients with ED who are reluctant to take systemic treatments. The intra-cavernous injections of alprostadil, the vacuum, and ultimately the penile implant (reserved for ED refractory to other treatments) remain effective therapeutic options that must be discussed with the patient. Other therapeutic options are currently under investigation, such as low-intensity shockwave lithotripsy, dopaminergic and melanocortin receptor agonists, which target central erectogenic pathways, soluble guanylate cyclases, rho-kinase inhibitors, and maxi-k channel activators that act peripherally. Newer formulations of existing medications, such as alprostadil and PDE5 inhibitors are also developed. Finally, stem cell regenerative techniques and gene therapy are promising new approaches to the treatment of erectile dysfunction. Most of these novel drugs have yet to reach Phase III studies. However, it is likely that in years to come, patients will be selectively treated with these novel agents as a monotherapy or in combination with others acting in a synergistic manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huyghe</LastName><ForeName>&#xc9;ric</ForeName><Initials>&#xc9;</Initials><AffiliationInfo><Affiliation>D&#xe9;partement d'urologie, CHU de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Nouveaut&#xe9;s dans la dysfonction &#xe9;rectile.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Nouveaut&#xe9;s dans la dysfonction &#xe9;rectile.La dysfonction &#xe9;rectile est le trouble sexuel le plus souvent pris en charge, affectant jusqu&#x2019;&#xe0; 20 % des hommes. &#xc9;tant donn&#xe9; qu&#x2019;elle affecte n&#xe9;gativement la vie de millions d&#x2019;hommes, son impact en termes de sant&#xe9; publique est important et repr&#xe9;sente un d&#xe9;fi pour notre syst&#xe8;me de sant&#xe9;. Plusieurs options sont disponibles pour traiter la dysfonction &#xe9;rectile : le traitement oral par les inhibiteurs de la phosphodiest&#xe9;rase 5 (PDE5) repr&#xe9;sente jusqu&#x2019;&#xe0; pr&#xe9;sent le traitement de premi&#xe8;re intention pour de nombreux patients. Il est efficace chez trois quarts des patients, avec un taux de r&#xe9;ponse similaire pour les quatre mol&#xe9;cules disponibles (sild&#xe9;nafil, vard&#xe9;nafil, tadalafil et avanafil). R&#xe9;cemment, une cr&#xe8;me d&#x2019;alprostadil (Vitaros) associant la mol&#xe9;cule active &#xe0; un activateur cutan&#xe9; a &#xe9;t&#xe9; autoris&#xe9;e en France pour application intra-ur&#xe9;trale. De faibles effets ind&#xe9;sirables syst&#xe9;miques (3 %) et une efficacit&#xe9; &#xe9;lev&#xe9;e (jusqu&#x2019;&#xe0; 83 %) en font une option th&#xe9;rapeutique de premi&#xe8;re intention pour les patients atteints de dysfonction &#xe9;rectile qui h&#xe9;sitent &#xe0; prendre des traitements syst&#xe9;miques. Les injections intracaverneuses d&#x2019;alprostadil, le vacuum, et in fine l&#x2019;implant p&#xe9;nien (r&#xe9;serv&#xe9; aux dysfonctions &#xe9;rectiles r&#xe9;fractaires aux autres traitements) demeurent des options th&#xe9;rapeutiques performantes qui doivent &#xea;tre discut&#xe9;es avec le patient. D&#x2019;autres options th&#xe9;rapeutiques sont &#xe0; l&#x2019;&#xe9;tude, comme la lithotripsie &#xe0; ondes de choc de faible intensit&#xe9;, les agonistes des r&#xe9;cepteurs dopaminergiques et la m&#xe9;lanocortine, qui ciblent les voies &#xe9;rectog&#xe8;nes centrales, les guanylates cyclases solubles, les inhibiteurs de Rho-kinase et les activateurs de canal maxi-k agissant en p&#xe9;riph&#xe9;rie. De nouvelles formes de m&#xe9;dicaments existants, tels que l&#x2019;alprostadil et les inhibiteurs de la PDE5, sont &#xe9;galement en d&#xe9;veloppement. Enfin, les techniques de r&#xe9;g&#xe9;n&#xe9;ration des cellules souches et la th&#xe9;rapie g&#xe9;nique sont de nouvelles approches prometteuses pour le traitement de la dysfonction &#xe9;rectile. La plupart de ces nouveaux m&#xe9;dicaments n&#x2019;ont pas encore atteint le stade d&#x2019;&#xe9;tudes de phase III. Cependant, il est probable que, dans les ann&#xe9;es &#xe0; venir, les patients seront s&#xe9;lectivement trait&#xe9;s avec ces nouveaux agents en monoth&#xe9;rapie ou en association avec d&#x2019;autres traitements agissant de mani&#xe8;re synergique.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword></KeywordList><CoiStatement>&#xc9;. Huyghe d&#xe9;clare avoir &#xe9;t&#xe9; pris en charge lors de congr&#xe8;s par Majorelle et Lilly.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30512730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28528136</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-7980</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp</ISOAbbreviation></Journal><ArticleTitle>The management of the acute ischemic priapism: A state of the art review.</ArticleTitle><Pagination><StartPage>607</StartPage><EndPage>613</EndPage><MedlinePgn>607-613</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuro.2017.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-4806(17)30045-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the current literature on early penile prosthesis implantation in patients with refractory ischemic priapism (IP).</AbstractText><AbstractText Label="ACQUISITION OF EVIDENCE" NlmCategory="METHODS">A systematic search for the terms "penile prosthesis", "priapism", "impotence", "fibrosis", "downsized prosthesis cylinders", and "patient satisfaction" has been carried out in PubMed, EMBASE, Cochrane, SCOPUS and Science Citation Index databases.</AbstractText><AbstractText Label="SYNTHESIS OF EVIDENCE" NlmCategory="RESULTS">Cavernosal tissue damage in IP is time related. Conservative measures and aspiration with or without intracorporeal instillation of &#x3b1;-adrenergic agonists are usually successful in the early stages. Shunt surgery in patients remains debatable, as the lack of response to aspiration and instillation of &#x3b1;-adrenergic agonists indicates that irreversible changes in the cavernosal smooth muscle are likely to have already occurred. Immediate penile prosthesis implantation in patients with refractory IP settles the priapic episode, maintains the long term rigidity necessary to engage in penetrative sexual intercourse and prevents the otherwise inevitable penile shortening. Although complication rates after penile prosthesis implantation in acute priapism are higher than in virgin cases, they are still lower than after implantation in patients with severe corporal fibrosis due to chronic priapism. Regardless of the complication rates, penile prosthesis implantation in refractory IP should be preferred as it allows the preservation of penile length, which is one of the main factors influencing postoperative patient's satisfaction following surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 AEU. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>St. Peter's Andrology and The Institute of Urology, University College of London Hospital (UCLH), Londres, Reino Unido; Department of Urology, University of Turin, Citt&#xe0; della Salute e della Scienza, Tur&#xed;n, Italia. Electronic address: mfalcone@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Umberto Parini Hospital, Aosta, Italia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>St. Peter's Andrology and The Institute of Urology, University College of London Hospital (UCLH), Londres, Reino Unido; Department of Urology, University of Naples, N&#xe1;poles, Italia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>St. Peter's Andrology and The Institute of Urology, University College of London Hospital (UCLH), Londres, Reino Unido; Department of Andrology, University of Cairo, Cairo, Egipto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St. Peter's Andrology and The Institute of Urology, University College of London Hospital (UCLH), Londres, Reino Unido.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>St. Peter's Andrology and The Institute of Urology, University College of London Hospital (UCLH), Londres, Reino Unido.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>El manejo del priapismo isqu&#xe9;mico agudo: una revisi&#xf3;n actualizada.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp</MedlineTA><NlmUniqueID>7704993</NlmUniqueID><ISSNLinking>0210-4806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword><Keyword MajorTopicYN="N">Priapismo</Keyword><Keyword MajorTopicYN="N">Pr&#xf3;tesis peniana</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28528136</ArticleId><ArticleId IdType="doi">10.1016/j.acuro.2017.02.004</ArticleId><ArticleId IdType="pii">S0210-4806(17)30045-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28460540</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7658</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert opinion on investigational drugs</Title><ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>675</EndPage><MedlinePgn>669-675</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2017.1324570</ELocationID><Abstract><AbstractText>Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of treatment-refractory ED. Areas covered: This review examines innovative treatments such as alternative vasoactive agents, trophic factors and bio-compounds as well as gene and stem cell therapy. All therapies are currently in some phase of development for the management of ED. Using the MedLine and FDA Clinical Trials Registry, recent developments in treatment of ED were queried. Expert opinion: Recent studies have demonstrated the potential for multiple, novel therapies in the treatment of ED. Much of the work requires further experimentation in large-scale, blinded, placebo-controlled studies. This will require a concerted effort to bring these products to market.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith-Harrison</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>a Department of Urology , University of Virginia , Charlottesville , VA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starke</LastName><ForeName>Nathan R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>a Department of Urology , University of Virginia , Charlottesville , VA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ryan P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>a Department of Urology , University of Virginia , Charlottesville , VA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovac</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>b Men's Health Center , Urology of Indiana , Indianapolis , IN , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Investig Drugs</MedlineTA><NlmUniqueID>9434197</NlmUniqueID><ISSNLinking>1354-3784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PDE-5i</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword><Keyword MajorTopicYN="N">trophic factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28460540</ArticleId><ArticleId IdType="doi">10.1080/13543784.2017.1324570</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28359097</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management.</ArticleTitle><Pagination><StartPage>1067</StartPage><EndPage>1075</EndPage><MedlinePgn>1067-1075</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2016-3580</ELocationID><Abstract><AbstractText Label="CONTEXT">Middle-aged and older men (&#x2265;50 years), especially those who are obese and suffer from comorbidities, not uncommonly present with clinical features consistent with androgen deficiency and modestly reduced testosterone levels. Commonly, such men do not demonstrate anatomical hypothalamic-pituitary-testicular axis pathology but have functional hypogonadism that is potentially reversible.</AbstractText><AbstractText Label="EVIDENCE ACQUISITION">Literature review from 1970 to October 2016.</AbstractText><AbstractText Label="EVIDENCE SYNTHESIS">Although definitive randomized controlled trials are lacking, evidence suggests that in such men, lifestyle measures to achieve weight loss and optimization of comorbidities, including discontinuation of offending medications, lead to clinical improvement and a modest increase in testosterone. Also, androgen deficiency-like symptoms and end-organ deficits respond to targeted treatments (such as phosphodiesterase-5 inhibitors for erectile dysfunction) without evidence that hypogonadal men are refractory. Unfortunately, lifestyle interventions remain difficult and may be insufficient even if successful. Testosterone therapy should be considered primarily for men who have significant clinical features of androgen deficiency and unequivocally low testosterone levels. Testosterone should be initiated either concomitantly with a trial of lifestyle measures, or after such a trial fails, after a tailored diagnostic work-up, exclusion of contraindications, and appropriate counseling.</AbstractText><AbstractText Label="CONCLUSIONS">There is modest evidence that functional hypogonadism responds to lifestyle measures and optimization of comorbidities. If achievable, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. Therefore, treatment of underlying causes of functional hypogonadism and of symptoms should be used either as an initial or adjunctive approach to testosterone therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grossmann</LastName><ForeName>Mathis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria 3081, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Endocrine Unit, Austin Health, Heidelberg, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Alvin M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, Seattle, Washington 98108.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004035" MajorTopicYN="Y">Diet Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28359097</ArticleId><ArticleId IdType="pmc">PMC5477803</ArticleId><ArticleId IdType="doi">10.1210/jc.2016-3580</ArticleId><ArticleId IdType="pii">2919025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536&#x2013;2559.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525905</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC; International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA) . Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18772485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88(2):622&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">12574191</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51(1):35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7189758</ArticleId></ArticleIdList></Reference><Reference><Citation>Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984;59(4):756&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">6434579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajar A, Forti G, O&#x2019;Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC; EMAS Group . Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95(4):1810&#x2013;1818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20173018</ArticleId></ArticleIdList></Reference><Reference><Citation>Basaria S. Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale. Endocr Pract. 2013;19(5):853&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">24014017</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo AB, O&#x2019;Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920&#x2013;5926.</Citation><ArticleIdList><ArticleId IdType="pubmed">15579737</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo AB, Esche GR, Kupelian V, O&#x2019;Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241&#x2013;4247.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O&#x2019;Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT; EMAS Group . Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">20554979</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">23591366</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto AM. Testosterone administration in older men. Endocrinol Metab Clin North Am. 2013;42(2):271&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">23702401</ArticleId></ArticleIdList></Reference><Reference><Citation>Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, O&#x2019;Donnell AB, McKinlay JB. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc. 2008;56(5):831&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556701</ArticleId><ArticleId IdType="pubmed">18454749</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am. 2011;40(3):655&#x2013;671, x.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889727</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER III, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS; Testosterone Trials Investigators . Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209754</ArticleId><ArticleId IdType="pubmed">26886521</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, Mazer NA, Knapp PE, Hanka S, Lakshman KM, Ulloor J, Zhang A, Orwoll K, Eder R, Collins L, Mohammed N, Rosen RC, DeRogatis L, Bhasin S. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">23165659</ArticleId></ArticleIdList></Reference><Reference><Citation>Travison TG, Araujo AB, Kupelian V, O&#x2019;Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92(2):549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148559</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring R, Xanthakis V, Coviello A, Sullivan L, Bhasin S, Wallaschofski H, Murabito JM, Vasan RS. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int J Androl. 2012;35(6):775&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434249</ArticleId><ArticleId IdType="pubmed">22640232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE, McKinlay JB. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870&#x2013;3877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579652</ArticleId><ArticleId IdType="pubmed">18664536</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341&#x2013;2353.</Citation><ArticleIdList><ArticleId IdType="pubmed">21646372</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">23482592</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho EM, Huhtaniemi IT, O&#x2019;Neill TW, Finn JD, Pye SR, Lee DM, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Keevil B, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC; EMAS Group . Age-associated changes in hypothalamic&#x2013;pituitary&#x2013;testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168(3):445&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">23425925</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D&#x2019;Andrea F, D&#x2019;Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978&#x2013;2984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing RR, Rosen RC, Fava JL, Bahnson J, Brancati F, Gendrano Iii IN, Kitabchi A, Schneider SH, Wadden TA. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010;7(1 Pt 1):156&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461030</ArticleId><ArticleId IdType="pubmed">19694925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171(20):1797&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pubmed">21911624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, Qin X, Ren Z, Ding H, Chen Q, Mao C, Tang J. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammoud A, Gibson M, Hunt SC, Adams TD, Carrell DT, Kolotkin RL, Meikle AW. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab. 2009;94(4):1329&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682482</ArticleId><ArticleId IdType="pubmed">19174499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora M, Aranda GB, de Hollanda A, Flores L, Puig-Domingo M, Vidal J. Weight loss is a major contributor to improved sexual function after bariatric surgery. Surg Endosc. 2013;27(9):3197&#x2013;3204.</Citation><ArticleIdList><ArticleId IdType="pubmed">23612762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattyn N, Cornelissen VA, Eshghi SR, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 2013;43(2):121&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693431</ArticleId><ArticleId IdType="pubmed">23329606</ArticleId></ArticleIdList></Reference><Reference><Citation>Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364(13):1218&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114602</ArticleId><ArticleId IdType="pubmed">21449785</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo J, Tian HH, Tan B, Chew K, Ng CS, Leong D, Teo RC, Chen RY. Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med. 2013;10(7):1823&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">23635309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Steiner M, Anglin R, Coote M, Pare G, Thabane L, Samaan Z. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;149:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25702934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamischke A, Kemper DE, Castel MA, L&#xfc;thke M, Rolf C, Behre HM, Magnussen H, Nieschlag E. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11(1):41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9543268</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20807333</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, Jerums G. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pubmed">18319314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittert G. The relationship between sleep disorders and testosterone. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">24739309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XB, Jiang XT, Du YP, Yuan YT, Chen B. Efficacy of continuous positive airway pressure on testosterone in men with obstructive sleep apnea: a meta-analysis. PLoS One. 2014;9(12):e115033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263732</ArticleId><ArticleId IdType="pubmed">25503098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyos CM, Melehan KL, Liu PY, Grunstein RR, Phillips CL. Does obstructive sleep apnea cause endothelial dysfunction? A critical review of the literature. Sleep Med Rev. 2015;20:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25088969</ArticleId></ArticleIdList></Reference><Reference><Citation>Melehan KL, Hoyos CM, Yee BJ, Wong KK, Buchanan PR, Grunstein RR, Liu PY. Increased sexual desire with exogenous testosterone administration in men with obstructive sleep apnea: a randomized placebo-controlled study. Andrology. 2016;4(1):55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035106</ArticleId><ArticleId IdType="pubmed">26610430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Brock GB, Glina S, Baygani S, Donatucci CF, Maggi M. Impact of baseline total testosterone level on successful treatment of sexual dysfunction in men taking once-daily tadalafil 5 mg for lower urinary tract symptoms and benign prostatic hyperplasia: an integrated analysis of three randomized controlled trials. J Sex Med. 2016;13(5):843&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480458</ArticleId><ArticleId IdType="pubmed">27017071</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer M, Bhasin S, Travison TG, Davda MN, Stroh H, Basaria S. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology. 2013;1(6):913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036338</ArticleId><ArticleId IdType="pubmed">24106072</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl. 1999;22(6):385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">10624607</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, Snow V, Denberg TD, Casey DE Jr, Forciea MA, Owens DK, Shekelle P; Clinical Efficacy Assessment Subcommittee of the American College of Physicians . Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2009;151(9):639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">19884625</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajar A, Huhtaniemi IT, O&#x2019;Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC; EMAS Group . Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">22419720</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, Laughlin G, Ohlsson C, Orwoll ES; Osteoporotic Fractures in Men Study Group . The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337&#x2013;3346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741717</ArticleId><ArticleId IdType="pubmed">19584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">10372695</ArticleId></ArticleIdList></Reference><Reference><Citation>Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764753</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">23113482</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MR, Egerdie B, Hern&#xe1;ndez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group . Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038121</ArticleId><ArticleId IdType="pubmed">19671656</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS; Endocrine Society . Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">22675062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Tang Fui M, Prendergast LA, Dupuis P, Raval M, Strauss BJ, Zajac JD, Grossmann M. Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial. BMC Med. 2016;14(1):153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5054608</ArticleId><ArticleId IdType="pubmed">27716209</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142768</ArticleId><ArticleId IdType="pubmed">24024838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28238678</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Penile Lengthening, Girth, and Size Preservation at the Time of Penile Prosthesis Insertion.</ArticleTitle><Pagination><StartPage>403</StartPage><EndPage>412</EndPage><MedlinePgn>403-412</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2016.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(17)30004-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Penile prosthetic devices are the gold standard treatment of medication-refractory erectile dysfunction. Inflatable penile prosthetic (IPP) devices have been available and used for more than four decades. Oftentimes, medical conditions causing erectile dysfunction also cause penile shortening, causing decreased patient quality of life.</AbstractText><AbstractText Label="AIM">To identify and review all available penile lengthening procedures that can be performed at time of IPP insertion.</AbstractText><AbstractText Label="METHODS">An extensive, systematic literature review was performed using PubMed searching for key terms penile lengthening, inflatable penile prosthesis, penile girth, corporoplasty, glans augmentation, and penile enhancement; all articles with subjective and/or objective penile length outcomes were reviewed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">A review of various techniques for penile length and girth preservation and enhancement during penile prosthesis insertion.</AbstractText><AbstractText Label="RESULTS">Several advanced and novel techniques were found for penile length preservation and enhancement at time of IPP insertion, including the sub-coronal IPP insertion technique, and adjuvant maneuvers during insertion, such as the sliding technique, modified sliding technique, multiple slice technique, and circumferential incision and grafting. Other adjuvant techniques that can enhance perception of increased length include ventral phalloplasty, suprapubic lipectomy, and suspensory ligament release. Further enhancement can be obtained using augmentation corporoplasty and glans augmentation with hyaluronic acid and other fillers. The different techniques vary in complexity and could require specialized training and experience. Maximum length gain appears to be limited by the length of the neurovascular bundles.</AbstractText><AbstractText Label="CONCLUSION">Overall, surgical penile lengthening procedures at time of IPP insertion appear safe and effective for treatment of patients with penile shortening and severe erectile dysfunction. These therapies can significantly improve patient self-esteem and quality of life in properly selected patients. Tran H, Goldfarb R, Ackerman A, Valenxuela RJ. Penile Lengthening, Girth and Size Preservation at the Time of Penile Prosthesis Insertion. Sex Med Rev 2017;5:403-412.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA. Electronic address: henryhyt@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldfarb</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackerman</LastName><ForeName>Anika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valenzuela</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Malleable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Penile Augmentation</Keyword><Keyword MajorTopicYN="N">Penile Implant</Keyword><Keyword MajorTopicYN="N">Penile Lengthening</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28238678</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2016.11.005</ArticleId><ArticleId IdType="pii">S2050-0521(17)30004-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28217449</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Penile prosthesis implant: scientific advances and technological innovations over the last four decades.</ArticleTitle><Pagination><StartPage>37</StartPage><EndPage>45</EndPage><MedlinePgn>37-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tau.2016.12.06</ELocationID><Abstract><AbstractText>Despite introduction of oral phosphodiesterase type 5 inhibitors and intracavernosal vasoactive agents, penile prosthesis implant remains a relevant and desired option with sales of penile prostheses continue to stay high, as many men became refractory to medical therapy and/or seeking a more effective and permanent therapy. There are two types of penile prosthesis implants: inflatable and non-inflatable types, and the inflatable penile implants can be subdivided into single-, two- and three-piece devices. Non-inflatable penile prosthesis (non-IPP) may be referred to as semi-rigid rod or malleable prosthesis. IPP is considered a superior option to malleable prosthesis as it produces penile rigidity and flaccidity that closely replicates a normal penile erectile function. Since the introduction of IPP by Scott in 1973, surgical landscape for penile prosthesis implantation has changed dramatically. Advances in prosthesis design, device technologies and surgical techniques have made penile prosthesis implant a more natural, durable and reliable device. The following article reviews the scientific advances and technological innovation in modern penile prosthesis implants over the last four decades.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia;; AndroUrology Centre, St Andrew's War Memorial Hospital, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile prosthesis implant</Keyword><Keyword MajorTopicYN="N">design technology</Keyword><Keyword MajorTopicYN="N">erectile dysfunction (ED)</Keyword><Keyword MajorTopicYN="N">scientific advances</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The author has no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28217449</ArticleId><ArticleId IdType="pmc">PMC5313299</ArticleId><ArticleId IdType="doi">10.21037/tau.2016.12.06</ArticleId><ArticleId IdType="pii">tau-06-01-037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973;2:80-2. 10.1016/0090-4295(73)90224-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(73)90224-0</ArticleId><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 1983;143:332-7. 10.1192/bjp.143.4.332</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.143.4.332</ArticleId><ArticleId IdType="pubmed">6626852</ArticleId></ArticleIdList></Reference><Reference><Citation>Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938. 10.1016/S0140-6736(82)90910-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(82)90910-2</ArticleId><ArticleId IdType="pubmed">6126784</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404. 10.1056/NEJM199805143382001</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199805143382001</ArticleId><ArticleId IdType="pubmed">9580646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee WF. A history of surgical treatment of impotence. Urology 1975;05:401-5. 10.1016/0090-4295(75)90168-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(75)90168-5</ArticleId><ArticleId IdType="pubmed">1091068</ArticleId></ArticleIdList></Reference><Reference><Citation>Frumkin AP. Reconstruction of the male genitalia. Am Rev Soviet Med 1944;2:14-7.</Citation></Reference><Reference><Citation>Bergman RT, Howard AH, Barnes RW. Plastic reconstruction of the penis. J Urol 1948;59:1174-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18858063</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin WE, Scott WW. Phalloplasty. J Urol 1952;68:903-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">13000938</ArticleId></ArticleIdList></Reference><Reference><Citation>Beheri GE. Surgical treatment of impotence. Plast Reconstr Surg 1966;38:92-7. 10.1097/00006534-196608000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006534-196608000-00002</ArticleId><ArticleId IdType="pubmed">5913185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash H. Silicone implant for impotence. J Urol 1968;100:709-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">5682555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash H, Zimmerman DC, Loeffler RA. Silicone implantation: inlay method. Plast Reconstr Surg 1964;34:75-80. 10.1097/00006534-196407000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006534-196407000-00011</ArticleId><ArticleId IdType="pubmed">14200523</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearman RO. Treatment of organic impotence by implantation of a penile prosthesis. J Urol 1967;97:716-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6022438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearman RO. Insertion of a silastic penile prosthesis for the treatment of organic sexual impotence. J Urol 1972;107:802-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">5022546</ArticleId></ArticleIdList></Reference><Reference><Citation>Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis. New implant for management of impotence. Urology 1975;5:479-86. 10.1016/0090-4295(75)90071-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(75)90071-0</ArticleId><ArticleId IdType="pubmed">1093303</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, Terlecki R, Brant WO. The Evolution and Utility of the Small-Carrion Prosthesis, Its Impact, and Progression to the Modern-Day Malleable Penile Prosthesis. J Sex Med 2015;12 Suppl 7:423-30. 10.1111/jsm.13014</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13014</ArticleId><ArticleId IdType="pubmed">26565570</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Rolle L, Ceruti C, et al. Prospective analysis of the surgical outcomes and patients' satisfaction rate after the AMS Spectra penile prosthesis implantation. Urology 2013;82:373-6. 10.1016/j.urology.2013.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2013.04.027</ArticleId><ArticleId IdType="pubmed">23791218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu GL, Chen HS, Huang SJ. Does tunica anatomy matter in penile implant? Transl Androl Urol 2015;4:406-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4708595</ArticleId><ArticleId IdType="pubmed">26816839</ArticleId></ArticleIdList></Reference><Reference><Citation>Casab&#xe9; AR, Sarotto N, Gutierrez C, et al. Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models. Int J Impot Res 2016;28:228-33. 10.1038/ijir.2016.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijir.2016.33</ArticleId><ArticleId IdType="pubmed">27557609</ArticleId></ArticleIdList></Reference><Reference><Citation>Finney RP. New hinged silicone penile implant. J Urol 1977;118:585-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">916054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas U, Jacobi GH. Silicone-silver penile prosthesis: description, operative approach and results. J Urol 1980;123:865-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7382003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas U. Silicone-silver penis prosthesis (Jonas-Eska), long-term experiences. A critical assessment. Urologe A 1991;30:277-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">1949433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathy A, Shamloul R, AbdelRahim A, et al. Experience with Tube (Promedon) malleable penile implant. Urol Int 2007;79:244-7. 10.1159/000107957</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107957</ArticleId><ArticleId IdType="pubmed">17940357</ArticleId></ArticleIdList></Reference><Reference><Citation>Patwardhan SK, Shah R, Kulkarni V, et al. Shah's Indian penile prosthesis placement after phallic reconstruction with radial forearm flap. Indian J Urol 2008;24:107-8. 10.4103/0970-1591.38613</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0970-1591.38613</ArticleId><ArticleId IdType="pmc">PMC2684244</ArticleId><ArticleId IdType="pubmed">19468370</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman TK, Macintyre RC. Mechanical failure of OmniPhase penile prosthesis. Urology 1988;31:515-6. 10.1016/0090-4295(88)90220-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(88)90220-8</ArticleId><ArticleId IdType="pubmed">3376379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. The OmniPhase and DuraPhase penile prostheses. Urol Clin North Am 1989;16:25-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">2916275</ArticleId></ArticleIdList></Reference><Reference><Citation>Randrup ER. Clinical experience with 180 inflatable penile prostheses. South Med J 1995;88:47-51. 10.1097/00007611-199501000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007611-199501000-00006</ArticleId><ArticleId IdType="pubmed">7817227</ArticleId></ArticleIdList></Reference><Reference><Citation>Riehmann M, Gasser TC, Bruskewitz RC. The Hydroflex penile prosthesis: a test case for the introduction of new urological technology. J Urol 1993;149:1304-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanisic TH, Dean JC, Donovan JM, et al. Clinical experience with a self-contained inflatable penile implant: the Flexi-Flate. J Urol 1988;139:947-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">3361670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabalin JN, Kessler R. Experience with the Hydroflex penile prosthesis. J Urol 1989;141:58-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908955</ArticleId></ArticleIdList></Reference><Reference><Citation>Anafarta K, Yaman O, Aydos K. Clinical experience with Dynaflex penile prostheses in 120 patients. Urology 1998;52:1098-100. 10.1016/S0090-4295(98)00406-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(98)00406-3</ArticleId><ArticleId IdType="pubmed">9836562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves M, Delk JR, 2nd. Long-term results with Hydroflex and Dynaflex penile prostheses: device survival comparison to multicomponent inflatables. J Urol 1996;155:1621-3. 10.1016/S0022-5347(01)66145-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)66145-7</ArticleId><ArticleId IdType="pubmed">8627837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fein RL. The G.F.S. Mark II inflatable penile prosthesis. J Urol 1992;147:66-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1729554</ArticleId></ArticleIdList></Reference><Reference><Citation>Fein RL. GFS Mark II inflatable penile prosthesis: four-year clinical study. Urology 1994;43:209-13. 10.1016/0090-4295(94)90046-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(94)90046-9</ArticleId><ArticleId IdType="pubmed">8116117</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001;166:932-7. 10.1016/S0022-5347(05)65867-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)65867-3</ArticleId><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry GD. Historical review of penile prosthesis design and surgical techniques: part 1 of a three-part review series on penile prosthetic surgery. J Sex Med 2009;6:675-81. 10.1111/j.1743-6109.2008.01145.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2008.01145.x</ArticleId><ArticleId IdType="pubmed">19207278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, 2nd. Historical advances in penile prostheses. Int J Impot Res 2000;12 Suppl 4:S101-7. 10.1038/sj.ijir.3900586</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900586</ArticleId><ArticleId IdType="pubmed">11035395</ArticleId></ArticleIdList></Reference><Reference><Citation>Boston Scientific. Penile prosthesis implant. Available online: http://www.bostonscientific.com/en-US/medical-specialties/urology.html</Citation></Reference><Reference><Citation>Liberman SN, Gomella LG, Hirsch IH. Experience with the Ultrex and Ultrex Plus inflatable penile prosthesis: new implantation techniques and surgical outcome. Int J Impot Res 1998;10:175-9. 10.1038/sj.ijir.3900337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900337</ArticleId><ArticleId IdType="pubmed">9788107</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Lakin MM. Early experience with the controlled girth and length expanding cylinder of the American Medical Systems Ultrex penile prosthesis. J Urol 1992;148:1444-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1433547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Use of CX cylinders in association with AMS700 inflatable penile prosthesis. J Urol 1988;140:1420-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">3193508</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro CL, Paradiso M, Rocca A, et al. Implantation of AMS 700 LGX penile prosthesis preserves penile length without the need for penile lengthening procedures. Asian J Androl 2016;18:114-7. 10.4103/1008-682X.154311</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1008-682X.154311</ArticleId><ArticleId IdType="pmc">PMC4736338</ArticleId><ArticleId IdType="pubmed">26112480</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch JA, Angermeier KW, Lakin MM, et al. Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: comparison of CX/CXM and Ultrex cylinders. J Urol 1997;158:1400-2. 10.1016/S0022-5347(01)64225-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)64225-3</ArticleId><ArticleId IdType="pubmed">9302130</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, Wilson SK, Neeb A, et al. Mechanical reliability of AMS 700 CX improved by parylene coating. J Sex Med 2009;6:2615-20. 10.1111/j.1743-6109.2009.01382.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01382.x</ArticleId><ArticleId IdType="pubmed">19619145</ArticleId></ArticleIdList></Reference><Reference><Citation>McKim SE, Carson CC, 3rd. AMS 700 inflatable penile prosthesis with InhibiZone. Expert Rev Med Devices 2010;7:311-7. 10.1586/erd.10.6</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erd.10.6</ArticleId><ArticleId IdType="pubmed">20420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004;171:1611-4. 10.1097/01.ju.0000118245.66976.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ju.0000118245.66976.e1</ArticleId><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Delk J, Knoll LD, McMurray J, et al. Early experience with the American Medical Systems new tactile pump: results of a multicenter study. J Sex Med 2005;2:266-71. 10.1111/j.1743-6109.2005.20238.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2005.20238.x</ArticleId><ArticleId IdType="pubmed">16422896</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll LD, Henry G, Culkin D, et al. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med 2009;6:1773-8. 10.1111/j.1743-6109.2009.01251.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01251.x</ArticleId><ArticleId IdType="pubmed">19473458</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DC. Mentor inflatable penile prostheses. Urol Clin North Am 1989;16:51-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">2916278</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DC, Javaheri P. Mentor inflatable penile prosthesis. Preliminary clinical results in 30 patients. Urology 1984;23:72-4. 10.1016/0090-4295(84)90245-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(84)90245-0</ArticleId><ArticleId IdType="pubmed">6719684</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloplast. Penile prosthesis implant. Available online: https://www.coloplast.us/</Citation></Reference><Reference><Citation>Wilson SK, Henry GD, Delk JR, Jr, et al. The mentor Alpha 1 penile prosthesis with reservoir lock-out valve: effective prevention of auto-inflation with improved capability for ectopic reservoir placement. J Urol 2002;168:1475-8. 10.1016/S0022-5347(05)64477-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)64477-1</ArticleId><ArticleId IdType="pubmed">12352421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter CE, Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med 2004;1:221-4. 10.1111/j.1743-6109.2004.04032.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2004.04032.x</ArticleId><ArticleId IdType="pubmed">16429621</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw T, Garber BB. Coloplast titan inflatable penile prosthesis with one-touch release pump: review of 100 cases and comparison with genesis pump. J Sex Med 2011;8:310-4. 10.1111/j.1743-6109.2010.02064.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02064.x</ArticleId><ArticleId IdType="pubmed">20946169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl DA, Brock G, Ralph D, et al. Prospective evaluation of patient satisfaction, and surgeon and patient trainer assessment of the Coloplast titan one touch release three-piece inflatable penile prosthesis. J Sex Med 2012;9:2467-74. 10.1111/j.1743-6109.2012.02819.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2012.02819.x</ArticleId><ArticleId IdType="pubmed">22759540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegelmann MJ, Viers BR, Lomas DJ, et al. Ectopic Penile Prosthesis Reservoir Placement: An Anatomic Cadaver Model of the High Submuscular Technique. J Sex Med 2016;13:1425-31. 10.1016/j.jsxm.2016.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2016.06.012</ArticleId><ArticleId IdType="pubmed">27475239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung PH, Morey AF, Tausch TJ, et al. High submuscular placement of urologic prosthetic balloons and reservoirs: 2-year experience and patient-reported outcomes. Urology 2014;84:1535-40. 10.1016/j.urology.2014.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2014.08.029</ArticleId><ArticleId IdType="pubmed">25432851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9. 10.1111/j.1743-6109.2007.00540.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00540.x</ArticleId><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Van CT, Wilson I, et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013;31:591-5. 10.1007/s00345-012-0859-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00345-012-0859-4</ArticleId><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol 2000;163:481-2. 10.1016/S0022-5347(05)67906-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(05)67906-2</ArticleId><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy JJ. Current approach to the treatment of penile implant infections. Ther Adv Urol 2010;2:69-75. 10.1177/1756287210370330</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287210370330</ArticleId><ArticleId IdType="pmc">PMC3126071</ArticleId><ArticleId IdType="pubmed">21789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastuszak AW, Lentz AC, Farooq A, et al. Technological Improvements in Three-Piece Inflatable Penile Prosthesis Design over the Past 40 Years. J Sex Med 2015;12 Suppl 7:415-21. 10.1111/jsm.13004</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.13004</ArticleId><ArticleId IdType="pubmed">26565568</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, Baum N, Hellstrom WJ. Managing the difficult penile prosthesis patient. J Sex Med 2013;10:893-906; quiz 907. 10.1111/jsm.12115</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jsm.12115</ArticleId><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28024968</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>129</EndPage><MedlinePgn>126-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2016.12.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(16)31018-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the degree of transparency of health insurance policies regarding coverage of male sexual health conditions, we examined the publicly available policy coverage documents of the largest U.S. medical insurance plans.</AbstractText><AbstractText Label="METHODS">We selected 2 index patients across the male sexual health spectrum: (1) a phosphodiesterase type 5 refractory erectile dysfunction (ED) patient requiring intracavernosal injection therapy or penile prosthesis and (2) a 50-year-old male patient with laboratory-confirmed, symptomatic hypogonadism requiring testosterone replacement therapy as defined by endocrine society criteria. We researched the policy documents regarding coverage for standard therapies. We used breast reconstruction after mastectomy as a control.</AbstractText><AbstractText Label="RESULTS">We queried the publicly available policy statements for 84 of the largest health-care plans in the United States. Whereas breast reconstruction policies are publicly available for 94% of the plans examined, policies of only 39% of the plans for advanced ED treatment options and 62% for hypogonadism are publicly available. Of the plans that had publicly accessible data for ED coverage, 85% viewed penile prosthesis and intracavernosal injection as medically necessary, whereas 91% viewed androgen replacement as medically necessary for our index patient.</AbstractText><AbstractText Label="CONCLUSION">There is a lack of transparency among medical insurers regarding coverage of ED and hypogonadism in stark contrast to reconstructive breast surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI. Electronic address: Leb@urology.wisc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAchran</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paolone</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gralnek</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>4th</Suffix><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bushman</LastName><ForeName>Wade</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019458" MajorTopicYN="N">Insurance Coverage</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28024968</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2016.12.031</ArticleId><ArticleId IdType="pii">S0090-4295(16)31018-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27900222</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>Surgical outcomes and complications of Tube&#xae; (Promedon) malleable penile prostheses in diabetic versus non-diabetic patients with erectile dysfunction.</ArticleTitle><Pagination><StartPage>305</StartPage><EndPage>311</EndPage><MedlinePgn>305-311</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate surgical outcome, complications, and patients satisfaction with the Tube&#xae; (Promedon, Cordoba, Argentina) malleable penile prosthesis in diabetic and non-diabetic patients with refractory erectile dysfunction (ED).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The records of 128 eligible patients who received Tube malleable penile prostheses at our institute between September 2008 and October 2015 were reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 128 patients, who received Tube penile prostheses at our institute, 53 were diabetics and 75 were non-diabetics. Both groups of patients were comparable for mean age, education level, marital status, hospital stay, time to commencing sexual intercourse, and median follow-up. Complications included: inter-corporeal septal perforation (2.3%), glanular urethral injury (1.5%), acute urinary retention (3.9%), superficial wound infection (7%), penile discomfort (9.4%), and penile prostheses infection (5.5%). Moreover, 3.9% developed atrophy of the cavernosal tissue, 5.5% experienced bad cosmesis, 6.3% experienced ejaculatory disorders, and 2.3% developed bladder calculi. In all, 13 prostheses (9.4%) were removed, seven of them due to infection, three on the patients' demand and three due to mechanical failure. The satisfaction rates with the prostheses were 77.3% and 79.4% in the diabetic and non-diabetic patients, respectively; with an overall satisfaction rate of 78.5%. There was no significant difference in the complication rate or prostheses infection between diabetic and non-diabetic patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tube malleable penile prostheses are associated with low complication and high satisfaction rates. There was no significant difference in the complication rate or prostheses infection between diabetic and non-diabetic patients. A prospective comparative study with a large number of patients is recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Elnisr Rashed</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammady</LastName><ForeName>Ahmed Rashed</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eldahshoury</LastName><ForeName>Mohamed Zaki</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsharkawi</LastName><ForeName>Ahmed Mamdouh</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riad</LastName><ForeName>Ahmed Mahmoud</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmogazy</LastName><ForeName>Hazem Mohamed</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussien</LastName><ForeName>Mohamed Mostafa</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamal</LastName><ForeName>Wael Mohamed</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Urology Department, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DM, diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Diabetic patients</Keyword><Keyword MajorTopicYN="N">ED, erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Malleable prostheses</Keyword><Keyword MajorTopicYN="N">NO, nitric oxide</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">PDE5I, phosphodiesterase type 5 inhibitor</Keyword><Keyword MajorTopicYN="N">PGE1, prostaglandin E1</Keyword><Keyword MajorTopicYN="N">US, ultrasonography</Keyword><Keyword MajorTopicYN="N">cGMP, cyclic guanosine monophosphate</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27900222</ArticleId><ArticleId IdType="pmc">PMC5122751</ArticleId><ArticleId IdType="doi">10.1016/j.aju.2016.07.002</ArticleId><ArticleId IdType="pii">S2090-598X(16)30061-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Laumann E.O., West S., Glasser D., Carson C., Rosen R., Kang J.H. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the Male Attitudes Regarding Sexual Health survey. J Sex Med. 2007;4:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17081223</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiann B.P., Yu C.C., Su C.C. Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales. Int J Impot Res. 2004;16:527&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy J.J., Austoni E., Barada J.H., Choi H.K., Hellstrom W.J.G., Krishnamurti S. The penile implant for erectile dysfunction. J Sex Med. 2004;1:98&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422990</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague D.K. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am. 2011;38:217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., Delk J.R., 2nd Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol. 1995;153:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow J.P. Risk factors for penile prosthetic infection. J Urol. 1996;156:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson C.C., Mulcahy J.J., Govier F.E. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. 2000;164:376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathy A., Shamloul R., AbdelRahim A., Zeidan A., El-Dakhly R., Ghanem H. Experience with Tube&#xae; (Promedon) malleable penile implant. Urol Int. 2007;79:244&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenov Z.A. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes. 2015;123:141&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">25502583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis R.W. Epidemiology of erectile dysfunction. Urol Clin North Am. 2001;28:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellek S., Rodrigo J., Lobos E., Fernandez P., Serrano J., Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus &#x2013; a nitric oxide-dependent phenomenon. Br J Pharmacol. 1999;128:1804&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1571816</ArticleId><ArticleId IdType="pubmed">10588937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegge N.C., Twomey A.M., Vaughton K., Gravenor M.B., Ramsey M.W., Price D.E. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med. 2006;23:873&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">16911625</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C. The use of penile prosthesis in the treatment of impotence. Br J Urol. 1998;81:591&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">9598633</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F., Deho F., Salonia A., Briganti A., Bua L., Fantini G.V. Penile implants in the era of oral drug treatment for erectile dysfunction. BJU Int. 2004;94:745&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., Carson C.C., Cleves M.A., Delk J.R. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159:1537&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cakan M., Demirel F., Karabacak O., Yal&#xe7;inkaya F., Altu&#x11f; U. Risk factors for penile prosthetic infection. Int Urol Nephrol. 2003;35:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">15072498</ArticleId></ArticleIdList></Reference><Reference><Citation>Teloken C., Souto J.C., Da Ros C., Thorel E., Souto C.A. Prosthetic penile infection: &#x201c;rescue procedure&#x201d; with rifamycin. J Urol. 1992;148:1905&#x2013;1906.</Citation><ArticleIdList><ArticleId IdType="pubmed">1433637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumming J., Pryor J.P. Treatment of organic impotence. Br J Urol. 1991;67:640&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">2070211</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A., Ralph D.J., Pryor J.P. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int. 2006;97:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W.D., Yuan Y.M., Cui W.S., Wu A.K., Zhu Y.C., Liu J. Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. Asian J Androl. 2013;15:658&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3881644</ArticleId><ArticleId IdType="pubmed">23872664</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulidou M., Pearce I. Infection of penile prosthesis in patients with diabetes mellitus. Surg Infect (Larchmt) 2016;17:2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26426099</ArticleId></ArticleIdList></Reference><Reference><Citation>Atienza Merino G. Penile prosthesis for the treatment of erectile dysfunction. Actas Urol Esp. 2006;30:159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">16700206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Dai Y., Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother. 2008;9:257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall J.P., Ahmed A., Branch J., Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27557609</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>233</EndPage><MedlinePgn>228-233</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ijir.2016.33</ELocationID><Abstract><AbstractText>The malleable prosthetic implant is widely accepted among patients and physicians owing to a lower degree of surgical complexity, its rare mechanic failures and lower cost. We have compared the degree of satisfaction with malleable prosthetic implant in 60 patients, 36 with Spectra (AMS) and 24 with Genesis (Coloplast). For assessment purposes, we implemented the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) satisfaction questionnaire adapted for penile prosthetic implants. The mean age and follow-up was 61.7 years (31-82) and 19.9 months (1-61), respectively. Mean EDITS scores did not indicate superiority of one implant over the other, overall satisfaction index being 77.1% and 75.6% for Genesis and Spectra prosthesis, respectively (P=0.4970). Our results revealed that these two models of malleable prostheses present a high level of satisfaction and confirm that the malleable prosthetic implant is an excellent option to treat patients with ED refractory to medical treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casab&#xe9;</LastName><ForeName>A R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n Urolog&#xed;a, Hospital Durand, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IME, Instituto M&#xe9;dico Especializado, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarotto</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n Urolog&#xed;a, Hospital Durand, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n Urolog&#xed;a, Hospital Durand, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechara</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n Urolog&#xed;a, Hospital Durand, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IME, Instituto M&#xe9;dico Especializado, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="Y">Prosthesis Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="Y">Urologic Surgical Procedures, Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27557609</ArticleId><ArticleId IdType="doi">10.1038/ijir.2016.33</ArticleId><ArticleId IdType="pii">ijir201633</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adv Urol. 2012;2012:707321</Citation><ArticleIdList><ArticleId IdType="pubmed">22899909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 Sep;166(3):932-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Jun;5(6):1503-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ital Urol Androl. 2013 Sep 26;85(3):133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24085235</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2004 Apr;16(2):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">14961064</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1999 Apr;53(4):793-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1994 Oct;152(4):1121-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Jul;170(1):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12796670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sex Med Rev. 2015 Oct;3(4):316-327</Citation><ArticleIdList><ArticleId IdType="pubmed">27784603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Apr;169(4):1429-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12629377</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1996 May;155(5):1621-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8627837</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Nov;7(11):3572-88</Citation><ArticleIdList><ArticleId IdType="pubmed">21040491</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2013 Aug;82(2):373-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23791218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Nov;12 Suppl 7:423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26565570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Apr;10(4):893-906; quiz 907</Citation><ArticleIdList><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Dec;12(12):2474-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26639576</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ital Urol Androl. 2013 Sep 26;85(3):138-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24085236</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Oct;12(10):1984-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26481595</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27496771</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-7980</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp</ISOAbbreviation></Journal><ArticleTitle>Adipocyte accumulation in corpus cavernosum: First clinical evidence and pathophysiological implications in erectile dysfunction.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>102</EndPage><MedlinePgn>97-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuro.2016.05.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-4806(16)30111-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Animal models have shown that erectile dysfunction is associated with adipocyte accumulation under tunica albug&#xed;nea, which could be involved in venous leakage and loss of penile rigidity. In the current sudy, we compared the histology of the penile sub-albuginean region of drug-refractory erectile dysfunction patients undergoing penile prosthesis implantation with potent patients with Peyronie's disease undergoing curvature correction procedures.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Seventeen refractory erectile dysfunction patients and fourteen potent patients with Peyronie's disease were recruited. Sub-albuginean tissue samples were taken in each surgery. An expert uropathologist analysed each section. A bivariate analysis was performed. Multivariate logistic regression was used to calculate adjusted odds ratios; P value&lt;.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven patients (11/17) in the case group presented cavernous fat cell accumulation, while only one patient (1/14) in the control group presented this finding (P&lt;.05). Adjusted odds ratio for erectile dysfunction was 40.72; 95% CI 2.28-727.29 (P=.012).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Different studies have shown that androgen disruption could be involved in penile structural changes, leading to trabecular smooth muscle apoptosis and trans or de-differentiation into adipocytes. This is the first prospective study in humans to report an association between erectile dysfunction and sub-albuginean adipocyte accumulation. Venous leakage secondary to this phenomenon could be a factor in the pathophysiology of erectile dysfunction, especially in patients that do not respond to medical therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 AEU. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vinay</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Androlog&#xed;a, Fundaci&#xf3;n Puigvert /Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a. Electronic address: jose.vinay@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarquella</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Androlog&#xed;a, Fundaci&#xf3;n Puigvert /Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Androlog&#xed;a, Fundaci&#xf3;n Puigvert /Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algaba</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Patolog&#xed;a, Fundaci&#xf3;n Puigvert /Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallegos</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departamento de Patolog&#xed;a, Hospital Cl&#xed;nico, Universidad de Chile , Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Casta&#xf1;e</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Androlog&#xed;a, Fundaci&#xf3;n Puigvert /Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Urolog&#xed;a, Hospital Cl&#xed;nico, Universidad de Chile, Santiago, Chile; Departamento de Urolog&#xed;a, Cl&#xed;nica Las Condes, Santiago, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Acumulaci&#xf3;n de adipocitos en el cuerpo cavernoso: primera evidencia cl&#xed;nica e implicaciones fisiopatol&#xf3;gicas en la disfunci&#xf3;n er&#xe9;ctil.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp</MedlineTA><NlmUniqueID>7704993</NlmUniqueID><ISSNLinking>0210-4806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017667" MajorTopicYN="Y">Adipocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acumulaci&#xf3;n de adipocitos</Keyword><Keyword MajorTopicYN="N">Adipocyte accumulation</Keyword><Keyword MajorTopicYN="N">Alteraci&#xf3;n en andr&#xf3;genos</Keyword><Keyword MajorTopicYN="N">Androgen disruption</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27496771</ArticleId><ArticleId IdType="doi">10.1016/j.acuro.2016.05.007</ArticleId><ArticleId IdType="pii">S0210-4806(16)30111-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27321890</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7732</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of vascular and interventional radiology : JVIR</Title><ISOAbbreviation>J Vasc Interv Radiol</ISOAbbreviation></Journal><ArticleTitle>Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients.</ArticleTitle><Pagination><StartPage>1115</StartPage><EndPage>1122</EndPage><MedlinePgn>1115-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvir.2016.04.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1051-0443(16)30034-3</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To confirm that prostatic artery embolization (PAE) has a positive medium- and long-term effect in symptomatic benign prostatic hyperplasia (BPH).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Between March 2009 and October 2014, 630 consecutive patients with BPH and moderate-to-severe lower urinary tract symptoms refractory to medical therapy for at least 6 months or who refused any medical therapy underwent PAE. Outcome parameters were evaluated at baseline; 1, 3, and 6 months; every 6 months between 1 and 3 years; and yearly thereafter up to 6.5 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean patient age was 65.1 years &#xb1; 8.0 (range, 40-89 y). There were 12 (1.9%) technical failures. Bilateral PAE was performed in 572 (92.6%) patients and unilateral PAE was performed in 46 (7.4%) patients. The cumulative clinical success rates at medium- and long-term follow-up were 81.9% (95% confidence interval [CI], 78.3%-84.9%) and 76.3% (95% CI, 68.6%-82.4%). There was a statistically significant (P &lt; .0001) change from baseline to last observed value in all clinical parameters: International Prostate Symptom Score (IPSS), quality-of-life (QOL), prostate volume, prostate-specific antigen, urinary maximal flow rate, postvoid residual, and International Index of Erectile Function. There were 2 major complications without sequelae.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PAE had a positive effect on IPSS, QOL, and all objective outcomes in symptomatic BPH. The medium- (1-3 y) and long-term (&gt; 3-6.5 y) clinical success rates were 81.9% and 76.3%, with no urinary incontinence or sexual dysfunction reported.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 SIR. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pisco</LastName><ForeName>Jo&#xe3;o M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilhim</LastName><ForeName>Tiago</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Department of Radiology, Nova Medical School, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Luis C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Department of Urology, Nova Medical School, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Department of Radiology, Nova Medical School, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Department of Radiology, Nova Medical School, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Nuno V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Department of Radiology, Nova Medical School, Lisbon, Portugal. Electronic address: nunovpcosta@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Ant&#xf3;nio G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Interv Radiol</MedlineTA><NlmUniqueID>9203369</NlmUniqueID><ISSNLinking>1051-0443</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C549870">KLK3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007610" MajorTopicYN="N">Kallikreins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="N">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015641" MajorTopicYN="N">Radiography, Interventional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014563" MajorTopicYN="N">Urodynamics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27321890</ArticleId><ArticleId IdType="doi">10.1016/j.jvir.2016.04.001</ArticleId><ArticleId IdType="pii">S1051-0443(16)30034-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28963839</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Ejaculatory duct dilation combined with seminal vesicle clysis for refractory hematospermia: A report of 32 cases].</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>515</EndPage><MedlinePgn>511-515</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of ejaculatory duct dilation combined with seminal vesicle clysis in the treatment of refractory hematospermia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using ureteroscopy, we treated 32 patients with refractory hematospermia by transurethral dilation of the ejaculatory duct combined with clysis of the seminal vesicle with diluent gentamicin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The operation was successfully accomplished in 31 cases, with the mean operation time of 32 (26&#xff0d;47) minutes. The patients were followed up for 6&#xff0d;39 (mean 23.6) months. No complications, such as urinary incontinence and retrograde ejaculation, were found after operation. Hematospermia completely disappeared in 27 cases, was relieved in 1, and recurred in 3 after 3 months postoperatively. Those with erectile dysfunction or mental anxiety symptoms showed significantly decreased scores of IIEF-Erectile Function (IIEF-EF) and Self-Rating Anxiety Scale (SAS).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ejaculatory duct dilation combined with seminal vesicle clysis under the ureteroscope, with its the advantages of high effectiveness and safety, minimal invasiveness, few complications, and easy operation, deserves general clinical application in the treatment of refractory hematospermia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xfc;</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie-Neng</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Hai-Dong</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yuan-Song</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Ming</ForeName><Initials>XM</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Hai-Bo</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wei-Lie</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004106" MajorTopicYN="N">Dilatation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004543" MajorTopicYN="N">Ejaculatory Ducts</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005832" MajorTopicYN="N">Genital Diseases, Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051516" MajorTopicYN="N">Hemospermia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012669" MajorTopicYN="N">Seminal Vesicles</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018666" MajorTopicYN="N">Ureteroscopy</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x76ee;&#x7684;&#xff1a; &#x63a2;&#x8ba8;&#x5c04;&#x7cbe;&#x7ba1;&#x6269;&#x5f20;&#x8054;&#x5408;&#x7cbe;&#x56ca;&#x51b2;&#x6d17;&#x6cbb;&#x7597;&#x987d;&#x56fa;&#x6027;&#x8840;&#x7cbe;&#x7684;&#x4e34;&#x5e8a;&#x4ef7;&#x503c;&#x3002; &#x65b9;&#x6cd5;&#xff1a; &#x91c7;&#x7528;&#x7ecf;&#x5c3f;&#x9053;&#x8f93;&#x5c3f;&#x7ba1;&#x955c;&#x6280;&#x672f;&#xff0c;&#x5bf9;32&#x4f8b;&#x987d;&#x56fa;&#x6027;&#x8840;&#x7cbe;&#x60a3;&#x8005;&#x76f4;&#x89c6;&#x4e0b;&#x884c;&#x7ecf;&#x5c3f;&#x9053;&#x6269;&#x5f20;&#x5c04;&#x7cbe;&#x7ba1;&#x3001;&#x6297;&#x751f;&#x7d20;&#x51b2;&#x6d17;&#x7cbe;&#x56ca;&#x6cbb;&#x7597;&#x3002;&#x7ed3;&#x679c;&#xff1a; 32&#x4f8b;&#x987d;&#x56fa;&#x6027;&#x8840;&#x7cbe;&#x60a3;&#x8005;&#x5747;&#x884c;&#x5c04;&#x7cbe;&#x7ba1;&#x6269;&#x5f20;&#xff0c;31&#x4f8b;&#x6210;&#x529f;&#xff0c;&#x5e73;&#x5747;&#x624b;&#x672f;&#x65f6;&#x95f4;32 min&#xff0c;&#x4e2d;&#x4f4d;&#x968f;&#x8bbf;23.6&#x4e2a;&#x6708;&#xff0c;&#x672f;&#x540e;&#x65e0;&#x9006;&#x884c;&#x5c04;&#x7cbe;&#x3001;&#x5c3f;&#x5931;&#x7981;&#x7b49;&#x5e76;&#x53d1;&#x75c7;&#x3002;&#x8840;&#x7cbe;&#x75c7;&#x72b6;&#x5b8c;&#x5168;&#x6d88;&#x5931;&#x4e14;&#x65e0;&#x590d;&#x53d1;27&#x4f8b;&#xff0c;1&#x4f8b;&#x60a3;&#x8005;&#x672f;&#x540e;&#x8840;&#x7cbe;&#x75c7;&#x72b6;&#x65e0;&#x51cf;&#x8f7b;&#xff0c;3&#x4f8b;&#x5206;&#x522b;&#x4e8e;&#x672f;&#x540e;3&#x3001;5&#x3001;8&#x4e2a;&#x6708;&#x540e;&#x590d;&#x53d1;&#x3002;&#x5bf9;&#x4f34;&#x6709;&#x52c3;&#x8d77;&#x529f;&#x80fd;&#x969c;&#x788d;&#x53ca;&#x7cbe;&#x795e;&#x7126;&#x8651;&#x75c7;&#x72b6;&#x7684;&#x60a3;&#x8005;&#xff0c;&#x672f;&#x540e;&#x5e73;&#x5747;IIEF-EF&#x8bc4;&#x5206;&#x663e;&#x8457;&#x63d0;&#x9ad8;&#xff0c;SAS&#x8bc4;&#x5206;&#x663e;&#x8457;&#x964d;&#x4f4e;&#x3002;&#x7ed3;&#x8bba;&#xff1a; &#x5e94;&#x7528;&#x7ecf;&#x5c3f;&#x9053;&#x8f93;&#x5c3f;&#x7ba1;&#x955c;&#x6280;&#x672f;&#x884c;&#x5c04;&#x7cbe;&#x7ba1;&#x6269;&#x5f20;&#x8054;&#x5408;&#x7cbe;&#x56ca;&#x51b2;&#x6d17;&#x6cbb;&#x7597;&#x987d;&#x56fa;&#x6027;&#x8840;&#x7cbe;&#xff0c;&#x5b89;&#x5168;&#x6027;&#x9ad8;&#x3001;&#x7597;&#x6548;&#x597d;&#x3001;&#x521b;&#x4f24;&#x8f83;&#x5c0f;&#x3001;&#x5e76;&#x53d1;&#x75c7;&#x53d1;&#x751f;&#x7387;&#x4f4e;&#xff0c;&#x64cd;&#x4f5c;&#x7b80;&#x4fbf;&#xff0c;&#x53ef;&#x4ee5;&#x540c;&#x65f6;&#x8fbe;&#x5230;&#x68c0;&#x67e5;&#x548c;&#x6cbb;&#x7597;&#x7684;&#x76ee;&#x7684;&#xff0c;&#x503c;&#x5f97;&#x5728;&#x4e34;&#x5e8a;&#x63a8;&#x5e7f;&#x5e94;&#x7528;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ejaculatory duct</Keyword><Keyword MajorTopicYN="N">hematospermia</Keyword><Keyword MajorTopicYN="N">refractory</Keyword><Keyword MajorTopicYN="N">seminal vesicle</Keyword><Keyword MajorTopicYN="N">ureteroscopy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28963839</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27188339</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-676X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature reviews. Disease primers</Title><ISOAbbreviation>Nat Rev Dis Primers</ISOAbbreviation></Journal><ArticleTitle>Erectile dysfunction.</ArticleTitle><Pagination><StartPage>16003</StartPage><MedlinePgn>16003</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrdp.2016.3</ELocationID><Abstract><AbstractText>Erectile dysfunction is a multidimensional but common male sexual dysfunction that involves an alteration in any of the components of the erectile response, including organic, relational and psychological. Roles for nonendocrine (neurogenic, vasculogenic and iatrogenic) and endocrine pathways have been proposed. Owing to its strong association with metabolic syndrome and cardiovascular disease, cardiac assessment may be warranted in men with symptoms of erectile dysfunction. Minimally invasive interventions to relieve the symptoms of erectile dysfunction include lifestyle modifications, oral drugs, injected vasodilator agents and vacuum erection devices. Surgical therapies are reserved for the subset of patients who have contraindications to these nonsurgical interventions, those who experience adverse effects from (or are refractory to) medical therapy and those who also have penile fibrosis or penile vascular insufficiency. Erectile dysfunction can have deleterious effects on a man's quality of life; most patients have symptoms of depression and anxiety related to sexual performance. These symptoms, in turn, affect his partner's sexual experience and the couple's quality of life. This Primer highlights numerous aspects of erectile dysfunction, summarizes new treatment targets and ongoing preclinical studies that evaluate new pharmacotherapies, and covers the topic of regenerative medicine, which represents the future of sexual medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yafi</LastName><ForeName>Faysal A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, Box SL 42, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albersen</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory for Experimental Urology, Gene and Stem Cells Applications, Department of Development and Regeneration, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corona</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isidori</LastName><ForeName>Andrea M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldfarb</LastName><ForeName>Shari</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp;Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp;Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parish</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salonia</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ronny</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Tan Tock Seng Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulhall</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Tulane University School of Medicine, Department of Urology, Box SL 42, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Dis Primers</MedlineTA><NlmUniqueID>101672103</NlmUniqueID><ISSNLinking>2056-676X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004700" MajorTopicYN="N">Endocrine System Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27188339</ArticleId><ArticleId IdType="mid">NIHMS815695</ArticleId><ArticleId IdType="pmc">PMC5027992</ArticleId><ArticleId IdType="doi">10.1038/nrdp.2016.3</ArticleId><ArticleId IdType="pii">nrdp20163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virag R, Zwang G, Dermange H, Legman M. Vasculogenic impotence: a review of 92 cases with 54 surgical operations. Vasc Surg. 1981;15:9&#x2013;17.</Citation></Reference><Reference><Citation>Glina S, Shindel A, Eardley I, Ghanem H. Cavernosal &#x3b1;-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. J Sex Med. 2008;5:1791&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">18774989</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal SA. Earl Sutherland (1915&#x2013;1974) [corrected] and the discovery of cyclic AMP. Perspect Biol Med. 2012;55:236&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">22643761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard SA, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164&#x2013;2171.</Citation><ArticleIdList><ArticleId IdType="pubmed">9598563</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandaglia G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65:968&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011423</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54&#x2013;61. This seminal manuscript defines the prevalence of erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS) J Sex Med. 2010;7:1362&#x2013;1380.</Citation><ArticleIdList><ArticleId IdType="pubmed">19929914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen R, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol. 2003;44:637&#x2013;649. This publication describes the relationship of LUTS and erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">14644114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolosi A, et al. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology. 2004;64:991&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533492</ArticleId></ArticleIdList></Reference><Reference><Citation>Laumann EO, et al. Sexual problems among women and men aged 40&#x2013;80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39&#x2013;57. An international study evaluating different aspect of sexual difficulties and some associated predictors.</Citation><ArticleIdList><ArticleId IdType="pubmed">15215881</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Perelman MA, Lockhart DC, Lue TF, Broderick GA. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol. 2005;174:662&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006943</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannes CB, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647654</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61:431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">12597962</ArticleId></ArticleIdList></Reference><Reference><Citation>Schouten BW, et al. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen study. Int J Impot Res. 2005;17:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15510192</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel AD, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67:32&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23082930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacci M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60:809&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">21726934</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Rastrelli G, Maseroli E, Forti G, Maggi M. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab. 2013;27:581&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">24054932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannini EA, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med. 2014;11:40&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24314303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig W, Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int. 2014;92:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24281298</ArticleId></ArticleIdList></Reference><Reference><Citation>Capogrosso P, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man &#x2014; worrisome picture from the everyday clinical practice. J Sex Med. 2013;10:1833&#x2013;1841.</Citation><ArticleIdList><ArticleId IdType="pubmed">23651423</ArticleId></ArticleIdList></Reference><Reference><Citation>Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J Sex Med. 2004;1:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders SA, et al. General erectile functioning among young, heterosexual men who do and do not report condom-associated erection problems (CAEP) J Sex Med. 2015;12:1897&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pubmed">26279414</ArticleId></ArticleIdList></Reference><Reference><Citation>Papagiannopoulos D, Khare N, Nehra A. Evaluation of young men with organic erectile dysfunction. Asian J Androl. 2015;17:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291852</ArticleId><ArticleId IdType="pubmed">25370205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao F, et al. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol. 2013;102:645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">23681359</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function&#x2013;Erectile Function domain. J Sex Med. 2012;9:2708&#x2013;2715.</Citation><ArticleIdList><ArticleId IdType="pubmed">22897643</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">7831397</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I. Regulation of adrenergic activity in penile corpus cavernosum. J Urol. 1989;142:1117&#x2013;1121. A seminal paper on cell signalling in the corpora cavernosum.</Citation><ArticleIdList><ArticleId IdType="pubmed">2795742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802&#x2013;1813.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553617</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man&#x2019;s inability to have sex? J Sex Med. 2014;11:347&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251371</ArticleId></ArticleIdList></Reference><Reference><Citation>Brackett NL, Lynne CM, Ibrahim E, Ohl DA, Sonksen J. Treatment of infertility in men with spinal cord injury. Nat Rev Urol. 2010;7:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157304</ArticleId></ArticleIdList></Reference><Reference><Citation>Leungwattanakij S, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie&#x2019;s disease. BJU Int. 2006;97:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009;6:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756287</ArticleId><ArticleId IdType="pubmed">19138364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008;5:1126&#x2013;1136. This manuscript describes the science behind the use of sildenafil to decrease erectile tissue damage after cavernous nerve injury.</Citation><ArticleIdList><ArticleId IdType="pubmed">18331274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupelian V, Araujo AB, Chiu GR, Rosen RC, McKinlay JB. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev Med. 2010;50:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813912</ArticleId><ArticleId IdType="pubmed">19944117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacon CG, et al. A prospective study of risk factors for erectile dysfunction. J Urol. 2006;176:217&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753404</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis ME, Kusek JW, Nyberg LM, Eggers PW. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol. 2007;178:591&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, et al. Total cholesterol and high-density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140:930&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">7977280</ArticleId></ArticleIdList></Reference><Reference><Citation>McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624&#x2013;1632. This publication examines the negative effects of smoking on erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">11586190</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland RB, et al. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-&#x3b2; 1 in human corpus cavernosum smooth muscle. J Urol. 1995;153:826&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">7861547</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647948</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8808863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal R, et al. Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. J Sex Med. 2009;6:2813&#x2013;2819.</Citation><ArticleIdList><ArticleId IdType="pubmed">19686421</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm RH, Jr, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women Treatment of Mild Hypertension Study (TOMHS) Hypertension. 1997;29:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039073</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskin LS, et al. The effect of testosterone on androgen receptors and human penile growth. J Urol. 1997;158:1113&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258152</ArticleId></ArticleIdList></Reference><Reference><Citation>Boas M, et al. Postnatal penile length and growth rate correlate to serum testosterone levels: a longitudinal study of 1962 normal boys. Eur J Endocrinol. 2006;154:125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382001</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi S, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6:3274&#x2013;3288.</Citation><ArticleIdList><ArticleId IdType="pubmed">19732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med. 2007;4:620&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17498101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull EM, et al. Hormone&#x2013;neurotransmitter interactions in the control of sexual behavior. Behav Brain Res. 1999;105:105&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">10553694</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment &#x2014; a systematic review. Eur Urol. 2014;65:99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">24050791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills TM, Lewis RW, Stopper VS. Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod. 1998;59:1413&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">9828186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugg J, Ng C, Rajfer J, Gonzalez-Cadavid N. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity. Am J Physiol. 1996;271:E354&#x2013;E361.</Citation><ArticleIdList><ArticleId IdType="pubmed">8770031</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F, Rampin O, Schirar A, Jardin A, Rousseau JP. Autonomic control of penile erection: modulation by testosterone in the rat. J Neuroendocrinol. 1993;5:677&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8680441</ArticleId></ArticleIdList></Reference><Reference><Citation>Traish AM, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140:1861&#x2013;1868.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098525</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CM, Lewis RW, Stopper VS, Mills TM. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl. 1997;18:588&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">9432131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopko NA, Hannan JL, Bivalacqua TJ. Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat Rev Urol. 2014;11:622&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4696116</ArticleId><ArticleId IdType="pubmed">25311680</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Huang W, Guo Y, Xin M, Fu X. Testosterone promotes vascular endothelial cell migration via upregulation of ROCK-2/moesin cascade. Mol Biol Rep. 2013;40:6729&#x2013;6735.</Citation><ArticleIdList><ArticleId IdType="pubmed">24065547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XH, Melman A, Disanto ME. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? J Sex Med. 2011;8:1865&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">21324096</ArticleId></ArticleIdList></Reference><Reference><Citation>di Villa BR, et al. Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther. 2006;316:703&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmori T, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res. 2003;58:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667959</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XH, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol. 2005;47:409&#x2013;416. This manuscript describes the animal model showing the effect of testosterone on cavernosal tissue.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716209</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R, et al. Lack of direct androgen regulation of PDE5 expression. Biochem Biophys Res Commun. 2009;380:758&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680179</ArticleId><ArticleId IdType="pubmed">19338748</ArticleId></ArticleIdList></Reference><Reference><Citation>Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl. 2005;26:242&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713830</ArticleId></ArticleIdList></Reference><Reference><Citation>Andric SA, Janjic MM, Stojkov NJ, Kostic TS. Testosterone-induced modulation of nitric oxide&#x2013;cGMP signaling pathway and androgenesis in the rat Leydig cells. Biol Reprod. 2010;83:434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">20463352</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CM, Stopper VS, Mills TM. Androgens modulate the &#x3b1;-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl. 1997;18:26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9089065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983;12:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">6838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray PB, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005;90:3838&#x2013;3846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15827094</ArticleId></ArticleIdList></Reference><Reference><Citation>Buena F, et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril. 1993;59:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8486184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">6874890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetta E, Gianfrilli D, Barbagallo F, Isidori AM, Lenzi A. Subclinical male hypogonadism. Best Pract Res Clin Endocrinol Metab. 2012;26:539&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">22863395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajar A, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing study. J Clin Endocrinol Metab. 2010;95:1810&#x2013;1818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20173018</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577&#x2013;1592. Meta-analysis that examines the relationship between testosterone therapy and sexual function.</Citation><ArticleIdList><ArticleId IdType="pubmed">24697970</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad F, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188848</ArticleId><ArticleId IdType="pubmed">21753068</ArticleId></ArticleIdList></Reference><Reference><Citation>Giltay EJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7:2572&#x2013;2582.</Citation><ArticleIdList><ArticleId IdType="pubmed">20524974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett G, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters versus placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pubmed">23551886</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2014;38:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282686</ArticleId><ArticleId IdType="pubmed">25384570</ArticleId></ArticleIdList></Reference><Reference><Citation>Basaria S, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314:570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">26262795</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgentaler A. Testosterone, cardiovascular risk, and hormonophobia. J Sex Med. 2014;11:1362&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pubmed">24787518</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9:e85805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905977</ArticleId><ArticleId IdType="pubmed">24489673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706&#x2013;2715.</Citation><ArticleIdList><ArticleId IdType="pubmed">26248567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone A, Romanelli F, Gianfrilli D, Lenzi A. Endocrine evaluation of erectile dysfunction. Endocrine. 2014;46:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">24705931</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Psychobiological correlates of smoking in patients with erectile dysfunction. Int J Impot Res. 2005;17:527&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">15931232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Gan Y, Dong X, Liu J, Lu Z. Association of quantity and duration of smoking with erectile dysfunction: a dose&#x2013;response meta-analysis. J Sex Med. 2004;11:2376&#x2013;2384.</Citation><ArticleIdList><ArticleId IdType="pubmed">25052869</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddi V, et al. Priapus is happier with Venus than with Bacchus. J Sex Med. 2010;7:2831&#x2013;2841.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Dai S, Wang M, Morrison H. Erectile dysfunction and fruit/vegetable consumption among diabetic Canadian men. Urology. 2013;82:1330&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JY, Ng EM, Ko JS, Chen RY. Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">16929337</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014;16:581&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104087</ArticleId><ArticleId IdType="pubmed">24713832</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol Cell Endocrinol. 2014;384:143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">24486698</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest. 2013;36:864&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">23686080</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med. 2014;11:2065&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">25041930</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med. 2012;9:1669&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pubmed">22489756</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010;7:2805&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367771</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">21920268</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6:99&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">23300267</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Hara K, Umematsu H, Suzuki R, Kadowaki T. Erectile dysfunction and cardiovascular events in diabetic men: a meta-analysis of observational studies. PLoS ONE. 2012;7:e4367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433443</ArticleId><ArticleId IdType="pubmed">22962586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766&#x2013;778. This manuscript details how erectile dysfunction is an early symptom of cardiovascular disease.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498391</ArticleId><ArticleId IdType="pubmed">22862865</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannini EA, McCabe MP, Salonia A, Montorsi F, Sachs BD. Organic versus psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med. 2010;7:1726&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">20537061</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med. 2009;6:2591&#x2013;2600.</Citation><ArticleIdList><ArticleId IdType="pubmed">19515208</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Male sexuality and cardiovascular risk A cohort study in patients with erectile dysfunction. J Sex Med. 2010;7:1918&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233287</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med. 2013;10:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22970717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanem HM, Salonia A, Martin-Morales A. SOP: physical examination and laboratory testing for men with erectile dysfunction. J Sex Med. 2013;10:108&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">22524416</ArticleId></ArticleIdList></Reference><Reference><Citation>Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10:245&#x2013;284. A detailed review of testosterone deficiency, including current management modalities.</Citation><ArticleIdList><ArticleId IdType="pubmed">22971200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastrelli G, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med. 2014;11:173&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433560</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med. 2008;5:2623&#x2013;2634.</Citation><ArticleIdList><ArticleId IdType="pubmed">18783349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med. 2013;10:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">22970798</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiorino MI, Bellastella G, Esposito K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl. 2015;17:5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291878</ArticleId><ArticleId IdType="pubmed">25248655</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito K, et al. Dietary factors in erectile dysfunction. Int J Impot Res. 2006;18:370&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16395326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan JL, Heaton JPW, Adams MA. Recovery of erectile function in aging hypertensive and normotensive rats using exercise and caloric restriction. J Sex Med. 2007;4:886&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolotkin RL, et al. Improvements in sexual quality of life after moderate weight loss. Int J Impot Res. 2008;20:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">18596703</ArticleId></ArticleIdList></Reference><Reference><Citation>Belardinelli R, Lacalaprice F, Faccenda E, Purcaro A, Perna G. Effects of short-term moderate exercise training on sexual function in male patients with chronic stable heart failure. Int J Cardiol. 2005;101:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15860388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupelian V, Link CL, McKinlay JB. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52:416&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139983</ArticleId><ArticleId IdType="pubmed">17383811</ArticleId></ArticleIdList></Reference><Reference><Citation>Polsky JY, Aronson KJ, Heaton JP, Adams MA. Smoking and other lifestyle factors in relation to erectile dysfunction. BJU Int. 2005;96:1355&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int. 2004;94:1310&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">15610111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew KK. Alcohol consumption and male erectile dysfunction: an unfounded reputation for risk? J Sex Med. 2009;6:2340&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">19493284</ArticleId></ArticleIdList></Reference><Reference><Citation>Arackal BS, Benegal V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J Psychiatry. 2007;49:109&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917074</ArticleId><ArticleId IdType="pubmed">20711392</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghighi A, Grigoryan VH, Delavar A. Psychological determinants of erectile dysfunction among middle-aged men. Int J Impot Res. 2014;27:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">25164317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HM, Munder T, Gerger H, Fruhauf S, Barth J. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J Sex Med. 2014;11:1376&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">24641632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189712</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397&#x2013;1404. This seminal paper was the first time that sildenafil was used as treatment for erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395275</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16:S4&#x2013;S7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15224127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53:S5&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874258</ArticleId><ArticleId IdType="pubmed">11879254</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran M, Keating G. Tadalafil. Drugs. 2003;63:2203&#x2013;2212. discussion 2213&#x2013;2214.</Citation><ArticleIdList><ArticleId IdType="pubmed">14498756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010;32:1178&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20637970</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23343170</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuckey BG, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547849</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44:1296&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11692178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med. 2005;2:785&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422803</ArticleId></ArticleIdList></Reference><Reference><Citation>Padma-Nathan H, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650827</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelefsky MJ, et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J Urol. 2014;192:868&#x2013;874. This manuscript shows the benefit of sidenafil in decreasing the incidence of erectile dysfunction in patients undergoing radiotherapy for prostate cancer.</Citation><ArticleIdList><ArticleId IdType="pubmed">24603102</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest. 2008;31:799&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">18997493</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810448</ArticleId><ArticleId IdType="pubmed">19900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol. 1995;75:786&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">7613837</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DE, et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med. 1991;8:964&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">1838050</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001;28:335&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402585</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltaci S, Aydos K, Kosar A, Anafarta K. Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol. 1995;76:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">8535721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganem JP, Lucey DT, Janosko EO, Carson CC. Unusual complications of the vacuum erection device. Urology. 1998;51:627&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9586618</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2006;18:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16107868</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland RB, Kim N, Nehra A, Goldstein I, Traish A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res. 2003;15:362&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">14562138</ArticleId></ArticleIdList></Reference><Reference><Citation>Padma-Nathan H, et al. Treatment of men with erectile dysfunction with transurethral alprostadil Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970933</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams G, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction MUSE Study Group. Br J Urol. 1998;81:889&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666777</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough AR, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethralalprostadil versus sildenafil citrate. J Urol. 2010;183:2451&#x2013;2456.</Citation><ArticleIdList><ArticleId IdType="pubmed">20403617</ArticleId></ArticleIdList></Reference><Reference><Citation>Guay AT, Perez JB, Velasquez E, Newton RA, Jacobson JP. Clinical experience with intraurethralalprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study Medicated urethral system for erection. Eur Urol. 2000;38:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11111182</ArticleId></ArticleIdList></Reference><Reference><Citation>Costabile RA, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol. 1998;160:1325&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751346</ArticleId></ArticleIdList></Reference><Reference><Citation>Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287&#x2013;292. discussion 292&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671107</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CJ, et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med. 2013;10:2559&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pubmed">23898886</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton JP, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13:317&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">11918246</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther. 1989;15:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">2769773</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res. 1994;6:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">7735362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol. 1999;162:1291&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">10492182</ArticleId></ArticleIdList></Reference><Reference><Citation>Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334:873&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal R, Teloken P, Mulhall JP. Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members. J Sex Med. 2011;8:2370&#x2013;2376.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679306</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, McCaslin R, Linder B, Hellstrom WJ. Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Rev Med Devices. 2013;10:353&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">23668707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zermann DH, Kutzenberger J, Sauerwein D, Schubert J, Loeffler U. Penile prosthetic surgery in neurologically impaired patients: long-term follow-up. J Urol. 2006;175:1041&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469612</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001;166:932&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Lenting E. A surgical algorithm for the treatment of Peyronie&#x2019;s disease. J Urol. 1997;158:2149&#x2013;2152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366333</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Guazzoni G, Bergamaschi F, Rigatti P. Patient&#x2013;partner satisfaction with semirigid penile prostheses for Peyronie&#x2019;s disease: a 5-year follow-up study. J Urol. 1993;150:1819&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pubmed">8230513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR., 2nd A new treatment for Peyronie&#x2019;s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121&#x2013;1123. This manuscript describes a technique used to correct Peyronie&#x2019;s disease and erectile dysfunction in the same procedure.</Citation><ArticleIdList><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Mueller A, Moncada I, Carballido J, Mulhall JP. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med. 2011;8:1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar NB, Angermeir KW, Montague DK. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol. 2006;176:2599&#x2013;2601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7:501&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost LW, Baum N, Hellstrom WJ. Managing the difficult penile prosthesis patient. J Sex Med. 2013;10:893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003;170:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796670</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y, et al. Evaluation of penile revascularization for erectile dysfunction: a 10-year follow-up. Int J Impot Res. 2004;16:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wespes E, Wildschutz T, Roumeguere T, Schulman CC. The place of surgery for vascular impotence in the third millennium. J Urol. 2003;170:1284&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501742</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning M, et al. Long-term follow up and selection criteria for penile revascularization in erectile failure. J Urol. 1998;160:1680&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pubmed">9783931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn M, Martin-Morales A. In: Surgical Treatment of Erectile Dysfunction. Porst JB, editor. 2006.</Citation></Reference><Reference><Citation>Montague DK, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol. 2005;174:230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15947645</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458&#x2013;465. This is an important study, as it helps to define the relationship between erectile dysfunction and depression. The MMAS provides population-based data that demonstrate sound evidence for this relationship.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011;8:560&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">21155979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52:848&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiri R, et al. Bidirectional relationship between depression and erectile dysfunction. J Urol. 2007;177:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallis D, et al. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol. 2005;174:1913&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">16217344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedon F. Anxiety and erectile dysfunction: a global approach to ED enhances results and quality of life. Int J Impot Res. 2003;15:S16&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale VE, Strassberg DS. The role of anxiety on sexual arousal. Arch Sex Behav. 1990;19:569&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082861</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck JG, Barlow DH. The effects of anxiety and attentional focus on sexual responding &#x2014; II: cognitive and affective patterns in erectile dysfunction. Behav Res Ther. 1986;24:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">3947308</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer BJ, Bots ML, Nijeholt AA, Moors JP, Verheij TJ. The prevalence of bother, acceptance, and need for help in men with erectile dysfunction. J Sex Med. 2005;2:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CJ, et al. Men&#x2019;s experience with penile rehabilitation following radical prostatectomy: a qualitative study with the goal of informing a therapeutic intervention. Psychooncology. 2015;24:1646&#x2013;1654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765804</ArticleId><ArticleId IdType="pubmed">25707812</ArticleId></ArticleIdList></Reference><Reference><Citation>Schover LR, et al. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer. 2002;95:1773&#x2013;1785.</Citation><ArticleIdList><ArticleId IdType="pubmed">12365027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram CP, et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology. 1997;49:932&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187703</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T. 2013;38:407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776492</ArticleId><ArticleId IdType="pubmed">24049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiann BP, Yu CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res. 2006;18:146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16094412</ArticleId></ArticleIdList></Reference><Reference><Citation>Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res. 2005;17:2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15201860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau S, Laumann E, Levinson W, Waite L. Synthesis of scientific disciplines in pursuit of health: the Interactive Biopsychosocial Model. Perspect Biol Med. 2003;46:S74&#x2013;S86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201376</ArticleId><ArticleId IdType="pubmed">14563076</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfarb S, Baron S, Lindau S. In: Women and Health. Goldman MB, Troisi R, Rexrode KM, editors. Academic Press; 2013. pp. 347&#x2013;357.</Citation></Reference><Reference><Citation>Lindau S, Sandbo S, Goldfarb S, Dickler M. In: Cancer and Sexual Health. Mulhall JP, Goldstein I, Incrocci L, Rosen R, editors. Springer; 2011. pp. 415&#x2013;455.</Citation></Reference><Reference><Citation>Fisher W, Rosen R, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men&#x2019;s attitudes to life events and sexuality (FEMALES) study. J Sex Med. 2005;2:675&#x2013;684. An important study that furthers our understanding of how erectile dysfunction can affect a couple&#x2019;s relationship and helps to define possible strategies that a couple could use to cope with the emotional strain caused by erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiann BP, Su CC, Tsai JY. Is female sexual function related to the male partners&#x2019; erectile function? J Sex Med. 2013;10:420&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">23171282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher WA, et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med. 2005;2:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422828</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, et al. Women&#x2019;s sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J Sex Med. 2005;2:819&#x2013;832. This manuscript describes the benefits to their female partner when erectile dysfunction is treated in their partner.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422806</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran SN, et al. Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation. Int J Impot Res. 2015;27:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">25588959</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010;15:467&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163612</ArticleId><ArticleId IdType="pubmed">20415601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim L, Van der Aa F, Bivalacqua TJ, Hedlund P, Albersen M. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol. 2012;9:520&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">22824778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol. 2007;51:75&#x2013;88. discussion 89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16949200</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, et al. Future sexual medicine physiological treatment targets. J Sex Med. 2010;7:3269&#x2013;3304. A good review summarizing future prospects being researched in the treatment of erectile dysfunction.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitaley K, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratzke C, et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol. 2010;184:2197&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">20851436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA. 2004;101:9121&#x2013;9126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC428483</ArticleId><ArticleId IdType="pubmed">15184671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L, et al. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. FASEB J. 2006;20:536&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">16396994</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, et al. Increased Rho-kinase 2 and an increase of synthetic smooth muscle-specific marker expression is observed in the corpus cavernosum of patients with severe erectile dysfunction. J Urol. 2014;191:e526.</Citation></Reference><Reference><Citation>Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011;60:1020&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839578</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013;10:1268&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">23421435</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Science. Multiple dose escalation study (14 days) to investigate safety, tolerability, PK and PD of vardenafil and BAY60-4552. ClinicalTrials.gov. 2010 [online],  https://clinicaltrials.gov/ct2/show/NCT01110590.</Citation></Reference><Reference><Citation>US National Library of Science. Clinical proof-of-concept study for the combination BAY60-4552 / vardenafil for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors. ClinicalTrials.gov. 2010 [online],  https://clinicaltrials.gov/ct2/show/NCT01168817?term=NCT01168817&amp;rank=1.</Citation></Reference><Reference><Citation>Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol. 2005;48:314&#x2013;318. This manuscript describes the first human trial of gene transfer therapy for erectile dysfunction treatment.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964135</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Weyne E, Bivalacqua TJ. Stem cell therapy for erectile dysfunction: progress and future directions. Sex Med Rev. 2013;1:50&#x2013;64. This manuscript discusses the current status and future outlook of stem cell therapy for erectile dysfunction treatment.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, et al. Potential of adipose-derived stem cells for treatment of erectile dysfunction. J Sex Med. 2009;6(Suppl. 3):320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895916</ArticleId><ArticleId IdType="pubmed">19267855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahk JY, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiou R, et al.  Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2015  http://dx.doi.org/10.1016/j.eururo.2015.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.09.026</ArticleId><ArticleId IdType="pubmed">26439886</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Science. Evaluate the use of liposuction and cell separation devices for autologous fat (adipose) derived cells to treat the symptoms of erectile dysfunction. ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT01601353.</Citation></Reference><Reference><Citation>US National Library of Science. Allogeneic human bone marrow derived mesenchymal stem cells in localized prostate cancer (MSC) ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT01983709.</Citation></Reference><Reference><Citation>US National Library of Science. Autologous adipose-derived stromal cells delivered into the corpus cavernous in patients with erectile dysfunction. ClinicalTrials.gov. 2014 [online],  https://clinicaltrials.gov/ct2/show/NCT02087397.</Citation></Reference><Reference><Citation>US National Library of Science. Can fat derived stem cells (SVF) be used in the treatment of erectile dysfunction after prostatectomy. ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT02240823.</Citation></Reference><Reference><Citation>US National Library of Science. Safety of autologous bone marrow derived mesenchymal stem cells in erectile dysfunction. ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT02344849.</Citation></Reference><Reference><Citation>US National Library of Science. Evaluate the safety and feasibility of injecting PMD-MSC into the penis to treat the symptoms of mild to moderate ED (PMD-MSC-ED-01) ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT02398370.</Citation></Reference><Reference><Citation>US National Library of Science. Safety and clinical outcomes study: SVF deployment for orthopedic, neurologic, urologic, and cardio-pulmonary conditions. ClinicalTrials.gov. 2015 [online],  https://clinicaltrials.gov/ct2/show/NCT01953523.</Citation></Reference><Reference><Citation>Michal V. Vascular surgery in the treatment of imporence; its present possibilities and prospects. Czech Med. 1980;3:213&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">7438942</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindley GS. Cavernosal &#x3b1;-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiaty. 1983;143:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">6626852</ArticleId></ArticleIdList></Reference><Reference><Citation>Campeau L. Grading of angina pectoria. Circulation. 1976;54:522&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">947585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27157506</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Superparamagnetic iron oxide nanoparticle targeting of adipose tissue-derived stem cells in diabetes-associated erectile dysfunction.</ArticleTitle><Pagination><StartPage>425</StartPage><EndPage>432</EndPage><MedlinePgn>425-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/1008-682X.179532</ELocationID><Abstract><AbstractText>Erectile dysfunction (ED) is a major complication of diabetes, and many diabetic men with ED are refractory to common ED therapies. Adipose tissue-derived stem cells (ADSCs) have been shown to improve erectile function in diabetic animal models. However, inadequate cell homing to damaged sites has limited their efficacy. Therefore, we explored the effect of ADSCs labeled with superparamagnetic iron oxide nanoparticles (SPIONs) on improving the erectile function of streptozotocin-induced diabetic rats with an external magnetic field. We found that SPIONs effectively incorporated into ADSCs and did not exert any negative effects on stem cell properties. Magnetic targeting of ADSCs contributed to long-term cell retention in the corpus cavernosum and improved the erectile function of diabetic rats compared with ADSC injection alone. In addition, the paracrine effect of ADSCs appeared to play the major role in functional and structural recovery. Accordingly, magnetic field-guided ADSC therapy is an effective approach for diabetes-associated ED therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lei-Lei</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>He-Song</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yu-Tian</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Andrology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017667" MajorTopicYN="Y">Adipocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060526" MajorTopicYN="N">Magnetic Fields</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058185" MajorTopicYN="Y">Magnetite Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="Y">Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27157506</ArticleId><ArticleId IdType="pmc">PMC5507087</ArticleId><ArticleId IdType="doi">10.4103/1008-682X.179532</ArticleId><ArticleId IdType="pii">179532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6:1232&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19210706</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep. 2002;2:501&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12643157</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006;8:675&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892168</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur S, Peak TC, Kadowitz PJ, Sikka SC, Hellstrom WJ. Review of erectile dysfunction in diabetic animal models. Curr Diabetes Rev. 2014;10:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002;14:466&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12494279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CS, Xin ZC, Wang Z, Deng C, Huang YC, et al. Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012;21:343&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272247</ArticleId><ArticleId IdType="pubmed">21793654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Sun X, Bian J, Wu R, Guan X, et al. Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS One. 2013;8:e72790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758339</ArticleId><ArticleId IdType="pubmed">24023647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang B, Sun X, Han D, Chen S, Yao B, et al. Human urine-derived stem cells alone or genetically-modified with FGF2 Improve type 2 diabetic erectile dysfunction in a rat model. PLoS One. 2014;9:e92825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963968</ArticleId><ArticleId IdType="pubmed">24663037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Lin H, Yu W, Li X, Chen Y, et al. Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats. Int J Androl. 2012;35:601&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22428616</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Lin H, Wang Y, Yu W, Chen Y, et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med. 2011;8:427&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">21091881</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SJ, Fu RH, Shyu WC, Liu SP, Jong GP, et al. Adipose-derived stem cells: isolation, characterization, and differentiation potential. Cell Transplant. 2013;22:701&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23068312</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med. 2010;7:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904063</ArticleId><ArticleId IdType="pubmed">20104670</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Guan R, Lei H, Li H, Wang L, et al. Therapeutic potential of adipose-derived stem cells-based micro-tissues in a rat model of postprostatectomy erectile dysfunction. J Sex Med. 2014;11:2439&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25042722</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri M, Maderna C, Cavazzin C, Deidda-Vigoriti V, Politi LS, et al. Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells. 2008;26:505&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17975226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xu F, Zhang C, Lei D, Tang Y, et al. High MR sensitive fluorescent magnetite nanocluster for stem cell tracking in ischemic mouse brain. Nanomedicine. 2011;7:1009&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">21530678</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Kim YJ, Kim YH, Roh J, Kim SU, et al. Using a neodymium magnet to target delivery of ferumoxide-labeled human neural stem cells in a rat model of focal cerebral ischemia. Hum Gene Ther. 2010;21:603&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20059319</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegler J, Liew A, Hynes SO, Ortega D, O&#x2019;Brien T, et al. Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials. 2013;34:1987&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23237516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer R, Bantleon R, Kehlbach R, Siegel G, Wiskirchen J, et al. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol. 2010;11:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871263</ArticleId><ArticleId IdType="pubmed">20370915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Lin YS, Fu YC, Wang CK, Wu SC, et al. Electromagnetic fields enhance chondrogenesis of human adipose-derived stem cells in a chondrogenic microenvironment in vitro. J Appl Physiol (1985) 2013;114:647&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23239875</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S, Yang XB, Tanner S, Curran S, Wood D, et al. The effects of iron oxide incorporation on the chondrogenic potential of three human cell types. J Tissue Eng Regen Med. 2013;7:461&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747461</ArticleId><ArticleId IdType="pubmed">22396122</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Feng G, Huang Z, Yan W. The application of super paramagnetic iron oxide-labeled mesenchymal stem cells in cell-based therapy. Mol Biol Rep. 2013;40:2733&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23269616</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Wan Z, Qiu XF, Chen Y, Dai YT. Resveratrol, an activator of SIRT1, restores erectile function in streptozotocin-induced diabetic rats. Asian J Androl. 2013;15:646&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3881649</ArticleId><ArticleId IdType="pubmed">23792339</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Villalta J, Ferretti L, Fandel TM, Albersen M, et al. Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction. J Sex Med. 2012;9:1834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389585</ArticleId><ArticleId IdType="pubmed">22548750</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Tang G, Xue S, He X, Miao P, et al. Silica-coated superparamagnetic iron oxide nanoparticles targeting of EPCs in ischemic brain injury. Biomaterials. 2013;34:4982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">23566799</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Fandel TM, Lin G, Wang G, Banie L, et al. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med. 2010;7:3331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885341</ArticleId><ArticleId IdType="pubmed">20561166</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7:445&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092448</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992;89:12043&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50694</ArticleId><ArticleId IdType="pubmed">1465438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremy JY, Jones RA, Koupparis AJ, Hotston M, Persad R, et al. Reactive oxygen species and erectile dysfunction: possible role of NADPH oxidase. Int J Impot Res. 2007;19:265&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053777</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaman O, Yilmaz E, Bozlu M, Anafarta K. Alterations of intracorporeal structures in patients with erectile dysfunction. Urol Int. 2003;71:87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12845268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahk JY, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2015 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">26439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Song YS, Ku JH, Song ES, Kim JH, Jeon JS, et al. Magnetic resonance evaluation of human mesenchymal stem cells in corpus cavernosa of rats and rabbits. Asian J Androl. 2007;9:361&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res. 2010;106:1570&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885138</ArticleId><ArticleId IdType="pubmed">20378859</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbab AS, Yocum GT, Wilson LB, Parwana A, Jordan EK, et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging. 2004;3:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15142409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Yin JJ, Zhou YT, Zhang Y, Song L, et al. Dual enzyme-like activities of iron oxide nanoparticles and their implication for diminishing cytotoxicity. ACS Nano. 2012;6:4001&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22533614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C, Shi B, Pei YY, Hong MH, Wu J, et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150582</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev. 2012;112:5818&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">23043508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie. 2013;95:2196&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">23880644</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Perez Lanzon M, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015;6:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529699</ArticleId><ArticleId IdType="pubmed">26129847</ArticleId></ArticleIdList></Reference><Reference><Citation>Slowing II, Vivero-Escoto JL, Zhao Y, Kandel K, Peeraphatdit C, et al. Exocytosis of mesoporous silica nanoparticles from mammalian cells: from asymmetric cell-to-cell transfer to protein harvesting. Small. 2011;7:1526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21520497</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Kim B, Shin JY, Ryu S, Noh M, et al. Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells&#x2019; therapeutic efficacy for myocardial infarction. ACS Nano. 2015;9:2805&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">25688594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27066289</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2090-696X</ISSN><JournalIssue CitedMedium="Print"><Volume>2016</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Case reports in urology</Title><ISOAbbreviation>Case Rep Urol</ISOAbbreviation></Journal><ArticleTitle>Multiple Site Fracture of Both Rods in a Malleable Penile Implant.</ArticleTitle><Pagination><StartPage>9564904</StartPage><MedlinePgn>9564904</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9564904</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2016/9564904</ELocationID><Abstract><AbstractText>Penile prosthesis implant is the definitive treatment for refractory erectile dysfunction. Fracture of malleable prosthesis is rarely described due to its low incidence. We describe a case of multiple, bilateral fracture of a malleable penile implant, ten years after implantation. After the diagnosis, a review surgery was performed and the implants were replaced. No corporal rupture or urethral lesion was observed. Review of the literature shows few articles reporting penile implant fractures, and to our knowledge no other article has described multiple, bilateral fractures of a penile prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Marcelo Almeida</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>School of Medicine, Unichristus University, 60190-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barroso Filho</LastName><ForeName>Haroldo Brasil</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>School of Medicine, Unichristus University, 60190-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesquita</LastName><ForeName>Francisco Jos&#xe9; Cabral</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira de Souza</LastName><ForeName>Ivon</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimar&#xe3;es</LastName><ForeName>Rafael Silva</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Everaldo Moura</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augusto da Silveira</LastName><ForeName>R&#xf4;mulo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Unichristus University, 60190-060 Fortaleza, CE, Brazil; Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regadas</LastName><ForeName>Rommel Prata</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Urology Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macedo</LastName><ForeName>Geraldo Munguba</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Sexual Medicine Department, Santa Casa da Miseric&#xf3;rdia de Fortaleza, 60025-060 Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Case Rep Urol</MedlineTA><NlmUniqueID>101580193</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27066289</ArticleId><ArticleId IdType="pmc">PMC4811081</ArticleId><ArticleId IdType="doi">10.1155/2016/9564904</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. Journal of Sexual Medicine. 2007;4(2):296&#x2013;309. doi: 10.1111/j.1743-6109.2007.00434.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00434.x</ArticleId><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C., Ditonno P., Palumbo F., et al. Penile prosthesis: what should we do about complications? Advances in Urology. 2008;2008:5. doi: 10.1155/2008/573560.573560</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/573560</ArticleId><ArticleId IdType="pmc">PMC2581729</ArticleId><ArticleId IdType="pubmed">19009029</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A., Ralph D. J., Pryor J. P. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU International. 2006;97(1):129&#x2013;133. doi: 10.1111/j.1464-410x.2005.05907.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.2005.05907.x</ArticleId><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas U. The history of erectile dysfunction management. International Journal of Impotence Research. 2001;13(supplement 3):S3&#x2013;S7. doi: 10.1038/sj.ijir.3900709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900709</ArticleId><ArticleId IdType="pubmed">11477486</ArticleId></ArticleIdList></Reference><Reference><Citation>Akand M., &#xd6;zayar A., Yaman &#xd6;., Demirel C. Mechanical failure with malleable penile prosthesis. Urology. 2007;70(5):1007.e11&#x2013;1007.e12. doi: 10.1016/j.urology.2007.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2007.08.005</ArticleId><ArticleId IdType="pubmed">18068466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W. H., Xin Z. C., Choi Y. D., Choi H. K. Spontaneous breakage of malleable penile prosthesis. International Journal of Impotence Research. 1998;10(4):255&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9884923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt I. H., Yonguc T., Arslan B., et al. Spontaneous bilateral rod fracture of malleable penile prosthesis. Journal of the Canadian Urological Association. 2014;8(9-10):e739&#x2013;e740. doi: 10.5489/cuaj.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.2005</ArticleId><ArticleId IdType="pmc">PMC4216308</ArticleId><ArticleId IdType="pubmed">25408816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar I. G., Dilli A., Keyik B., Hekimo&#x11f;lu B. Fracture of a semirigid penile prosthesis: MRI findings and review of the literature. CausaPedia. 2014;3, article 734</Citation></Reference><Reference><Citation>Wilson S. K., Carson C. C., Cleves M. A., Delk J. R., II Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. Journal of Urology. 1998;159(5):1537&#x2013;1540. doi: 10.1097/00005392-199805000-00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005392-199805000-00034</ArticleId><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zg&#xfc;r B. C., &#xd6;zayar A., Ekici M., &#xc7;ift&#xe7;i M., Bak&#x131;rta&#x15f; H. Fracture of both rods of a malleable penile prosthesis: a case report. Journal of Clinical and Analytical Medicine. 2014;5(2):154&#x2013;155. doi: 10.4328/jcam.753.</Citation><ArticleIdList><ArticleId IdType="doi">10.4328/jcam.753</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozza D., Pozza M., Musy M., Pozza C. 500 penile prostheses implanted by a surgeon in Italy in the last 30 years. Archivio Italiano di Urologia e Andrologia. 2015;87(3):216&#x2013;221. doi: 10.4081/aiua.2015.3.216.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2015.3.216</ArticleId><ArticleId IdType="pubmed">26428644</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranhos M., Andrade E., Antunes A. A., Barbieri A. L. N., Claro J. A., Srougi M. Penile prosthesis implantation in an academic institution in Latin America. International Braz J Urol. 2010;36(5):591&#x2013;600. doi: 10.1590/S1677-55382010000500009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1677-55382010000500009</ArticleId><ArticleId IdType="pubmed">21044376</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis L. O., Cartapatti M., Marmiroli R., Oliveira J&#xfa;nior E. J. D., Saade R. D., Fregonesi A. Mechanisms predisposing penile fracture and long-term outcomes on erectile and voiding functions. Advances in Urology. 2014;2014:4. doi: 10.1155/2014/768158.768158</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/768158</ArticleId><ArticleId IdType="pmc">PMC4005103</ArticleId><ArticleId IdType="pubmed">24822062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26816839</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-4691</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Translational andrology and urology</Title><ISOAbbreviation>Transl Androl Urol</ISOAbbreviation></Journal><ArticleTitle>Does tunica anatomy matter in penile implant?</ArticleTitle><Pagination><StartPage>406</StartPage><EndPage>412</EndPage><MedlinePgn>406-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3978/j.issn.2223-4683.2014.03.04</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Overall prosthesis survival is important in penile implant, which remains the final viable solution to many patients with refractory erectile dysfunction (ED). This paper is to retrospectively study the role of the anatomy of tunica albuginea (TA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From March 1987 to March 1991 while the TA was regarded as a circumferential single layer, 21 organically ED men, aged from 27 to 77, received penile prosthesis implantation and were allocated to conventional group. From August 1992 to March 2013 while the tip of Hegar's dilator was categorically directed medial-dorsally during corporal dilatation derived from newfound TA as a bi-layered structure with a 360&#xb0; complete inner circular layer and a 300&#xb0; incomplete outer longitudinal coat, 196 ED males, aged from 35 to 83, underwent penile implant and were categorized to advanced group. The model of prosthesis was recorded. Prosthesis loss rate and survival time were analyzed and the follow up period ranged from 22.4-26.4 (average 24.3) years and 0.4-20.6 (average 15.8) years to the conventional and advanced group respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">To the conventional and advanced group, the number of inflatable and rigid type prosthesis used were 2, 19 and 15, 181 respectively, whereas the prosthesis loss was encountered in 50.0% (1/2), 15.8% (3/19) and 0.0% (0/15), 0.6% (1/181) respectively. And the prosthesis survival time were 5.1-6.3 (5.7) years, 1.3-26.4 (15.2) years and 6.1-16.2 (11.2) years, 0.4-20.6 (15.3) years to the conventional and advanced group respectively. Statistical significance was noted on prosthesis loss in groups (P=0.01) while the Mentor Acuform stood out in prosthesis survival.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anatomy-based managing maneuver appears to deliver better surgery success in penile implant. Tunica anatomy is significant in performing implant surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Geng-Long</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>1 Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology and National Taiwan University, Taipei, Taiwan ; 2 National Taiwan University Hospital, Jin-Shan Branch, New Taipei, Taiwan ; 3 Department of Medical Informatics &amp; Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Heng-Shuen</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>1 Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology and National Taiwan University, Taipei, Taiwan ; 2 National Taiwan University Hospital, Jin-Shan Branch, New Taipei, Taiwan ; 3 Department of Medical Informatics &amp; Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sheng-Jean</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>1 Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology and National Taiwan University, Taipei, Taiwan ; 2 National Taiwan University Hospital, Jin-Shan Branch, New Taipei, Taiwan ; 3 Department of Medical Informatics &amp; Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Androl Urol</MedlineTA><NlmUniqueID>101581119</NlmUniqueID><ISSNLinking>2223-4683</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tunica albuginea in human penis (TA in human penis)</Keyword><Keyword MajorTopicYN="N">penile implant</Keyword><Keyword MajorTopicYN="N">prosthesis extrusion</Keyword><Keyword MajorTopicYN="N">prosthesis loss</Keyword></KeywordList><CoiStatement><i>Conflicts of Interest:</i> The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26816839</ArticleId><ArticleId IdType="pmc">PMC4708595</ArticleId><ArticleId IdType="doi">10.3978/j.issn.2223-4683.2014.03.04</ArticleId><ArticleId IdType="pii">tau-04-04-406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsu GL, Hsieh CH, Wen HS, et al. Formulas for determining the dimensions of venous graft required for penile curvature correction. Int J Androl 2006;29:515-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32:379-95, v.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351051</ArticleId><ArticleId IdType="pubmed">16291031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminetsky J. Epidemiology and pathophysiology of male sexual dysfunction. Int J Impot Res 2008;20:S3-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18552831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CH, Liu SP, Hsu GL, et al. Advances in understanding of mammalian penile evolution, human penile anatomy and human erection physiology: clinical implications for physicians and surgeons. Med Sci Monit 2012;18:RA118-25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560785</ArticleId><ArticleId IdType="pubmed">22739749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu GL, Lin CW, Hsieh CH, et al. Distal ligament in human glans: a comparative study of penile architecture. J Androl 2005;26:624-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088040</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA approves oral therapy for erectile dysfunction. Am J Health Syst Pharm 1998;55:981-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9606444</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am 2011;38:217-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007;4:1074-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman JJ, Lindner A, Raz S. Complications of penile prosthesis surgery for impotence. J Urol 1982;128:1192-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7154171</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Experience with semirigid rod and inflatable penile prostheses. J Urol 1983;129:967-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6854771</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin WE, Scott WW. Phalloplasty. J Urol 1952;68:903-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">13000938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinman F Jr. Penis and male urethra. In: Atlas of urological anatomy. WB Saunders. Philadephia, 1993.</Citation></Reference><Reference><Citation>Hsu GL, Brock GB, Martinez-Pineiro L, et al. The three-dimensional structure of the tunica albuginea: anatomical and ultra-structural levels. Int J Impot Res 1992;4:117-29.</Citation></Reference><Reference><Citation>Hsu GL, Brock G, Mart&#xed;nez-Pi&#xf1;eiro L, et al. Anatomy and strength of the tunica albuginea: its relevance to penile prosthesis extrusion. J Urol 1994;151:1205-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8158761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak TI, Oh M, Kim JJ, et al. The effects of penile girth enhancement using injectable hyaluronic acid gel, a filler. J Sex Med 2011;8:3407-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu GL, Chen HS, Hsieh CH, et al. Clinical experience of a refined penile venous stripping surgery procedure for patients with erectile dysfunction: is it a viable option? J Androl 2010;31:271-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19926885</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson RC, Jr, Barrett DM, Patterson DE. The Jonas prosthesis--technical considerations and results. J Urol 1983;130:920-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">6632100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26755095</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Reoperation Rates for Penile Prosthetic Surgery.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>133</EndPage><MedlinePgn>129-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2015.11.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(15)00022-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In patients with erectile dysfunction refractory to medical treatment, placement of a penile prosthesis is an effective treatment option. Despite advancements in prosthetic design, it is not without complications requiring reoperation.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the long-term reoperation rate of penile prosthesis implantation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A longitudinal analysis of the California Office of Statewide Health Planning and Development database from 1995 to 2010 was performed. Inclusion criteria were men who underwent their first penile prosthetic surgery. Patients were excluded if they underwent explantation of a prior prosthesis at the time of their first recorded surgery. Statistical analysis was performed by Kaplan-Meier plot, hazard curve, and multivariate analysis adjusting for age, race, comorbidities, insurance status, hospital volume, and hospital teaching status.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome was reoperation, specified as the removal or replacement of the prosthesis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 7,666 patients (40,932 patient-years) were included in the study. The 5- and 10-year cumulative reoperation rates were 11.2% (CI = 10.5-12.0) and 15.7% (CI = 14.7-16.8), respectively. Malfunction and infection accounted for 57% and 27% of reoperations. Reoperation rate was highest at 1 year postoperatively and steadily decreased until 2 years postoperatively. Multivariate analysis showed higher rates of reoperation in younger men (hazard ratio [HR] = 1.51, CI = 1.12-2.05), African-American men (HR = 1.30, CI = 1.05-1.62), and Hispanic men (HR = 1.32, CI = 1.12-1.57). Of the reoperations, 22.9% were performed at a hospital different from the initial implantation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Reoperation rate for penile prosthetic surgery is highest in the first year postoperatively. Patients with the highest risk for reoperation were African-American, Hispanic, and younger men. Nearly one fourth of reoperations occurred at a hospital different from the initial surgery, suggesting the existing literature does not reflect the true prevalence of penile prosthetic complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirheydar</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urology, University California-San Diego Health, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Tianzan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of California-San Diego School of Medicine, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Codman Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Tung-Chin</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Urology, University California-San Diego Health, San Diego, CA, USA. Electronic address: tmikehsieh@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2017 Feb;197(2):421</RefSource><PMID Version="1">28093159</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N">California</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complication</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Prosthetic Surgery</Keyword><Keyword MajorTopicYN="N">Reoperation</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26755095</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2015.11.013</ArticleId><ArticleId IdType="pii">S1743-6095(15)00022-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26688463</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0272</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Andrologia</Title><ISOAbbreviation>Andrologia</ISOAbbreviation></Journal><ArticleTitle>Herb formula enhances treatment of impotent patients after penile venous stripping: a randomised clinical trials.</ArticleTitle><Pagination><StartPage>754</StartPage><EndPage>760</EndPage><MedlinePgn>754-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/and.12508</ELocationID><Abstract><AbstractText>Herbs have been regarded as aphrodisiacs in treating impotence for many centuries despite little true scientific evidence. Our latest refined penile venous stripping (PVS) technique is effective in treating impotence, although this procedure remains controversial. A synergic effect of PVS and oral herbs was confirmed in our practice but lacked rigorous scientific proof. The objective of this report was to review our experience with this combination. From August 2010 to May 2014, 263 males underwent PVS. Among these, 67 unsatisfied men chose additional salvage therapy and were randomly assigned to oral herbs (n&#xa0;=&#xa0;35) or placebo treatment (n&#xa0;=&#xa0;32) which replaced herb eventually. All were evaluated with the international index of erectile function (IIEF-5) scoring and our dual pharmaco-cavernosography. The pre-op IIEF-5 score for the herb group was 9.7&#xa0;&#xb1;&#xa0;3.7, post-operative 13.9&#xa0;&#xb1;&#xa0;3.3 and post-herb 19.6&#xa0;&#xb1;&#xa0;3.4, while the control group scores were as follows: pre-op 9.3&#xa0;&#xb1;&#xa0;4.1, post-op 14.5&#xa0;&#xb1;&#xa0;3.6, post-placebo 15.1&#xa0;&#xb1;&#xa0;3.5 and post-herb 19.9&#xa0;&#xb1;&#xa0;3.2. Although there was no significant difference between the two groups pre-operatively, post-operatively and post-herb, a statistically significant difference was found post-salvage therapy (19.6&#xa0;&#xb1;&#xa0;3.4 versus 15.1&#xa0;&#xb1;&#xa0;3.6, P&#xa0;&lt;&#xa0;0.001). It appears that the combination of oral herbs and PVS treatment provides an enhanced outcome to impotent patients refractory to medicine and unsatisfied with PVS monotherapy alone.</AbstractText><CopyrightInformation>&#xa9; 2015 Blackwell Verlag GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>C-H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Urology, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>H-C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, National Taiwan University Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>G-L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Urology, College of Medicine, National Taiwan University Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>C-C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>C-Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Microsurgical Potency Reconstruction and Research Center, Hsu's Andrology, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Andrologia</MedlineTA><NlmUniqueID>0423506</NlmUniqueID><ISSNLinking>0303-4569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="Y">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010690" MajorTopicYN="N">Phlebography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014656" MajorTopicYN="N">Vascular Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014680" MajorTopicYN="N">Veins</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">herb formula</Keyword><Keyword MajorTopicYN="N">penile venous stripping</Keyword><Keyword MajorTopicYN="N">phosphodiesterase-5 inhibitor</Keyword><Keyword MajorTopicYN="N">synergic effect</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26688463</ArticleId><ArticleId IdType="doi">10.1111/and.12508</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26620609</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4820</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature reviews. Urology</Title><ISOAbbreviation>Nat Rev Urol</ISOAbbreviation></Journal><ArticleTitle>A practical overview of considerations for penile prosthesis placement.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>46</EndPage><MedlinePgn>33-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrurol.2015.270</ELocationID><Abstract><AbstractText>Penile prostheses have remained the gold-standard therapy for medically refractory erectile dysfunction (ED) since their popularization. Advances in device design and surgical techniques have yielded improved rates of infection, satisfaction, and mechanical survival of devices. Operative techniques in penile prosthesis surgery include the use of adjunctive procedures (such as ventral phalloplasty and release of the suspensory ligament), management of penile fibrosis, and manoeuvres to correct Peyronie's-disease-related curvature. Complications include urethral and corporal perforation, crossover, infection, impending erosion, and/or supersonic transporter deformity. Long-term data regarding mechanical, overall, and infection-free survival demonstrate excellent results, and, given the consistently high satisfaction rates and limited alternatives for medically refractory ED, penile prostheses are likely to remain a relevant and important treatment strategy for the foreseeable future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Landon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanzek</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Urol</MedlineTA><NlmUniqueID>101500082</NlmUniqueID><ISSNLinking>1759-4812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26620609</ArticleId><ArticleId IdType="doi">10.1038/nrurol.2015.270</ArticleId><ArticleId IdType="pii">nrurol.2015.270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Urol. 2009 Dec;56(6):1033-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2015 Jan;193(1):239-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2013 Oct;82(4):937-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Urol Nephrol. 2005;39(1):69-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15764275</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1998 Aug;52(2):291-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9697797</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2009 May;6(5):1474-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19453933</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2011 Oct;108(7):1152-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 Sep;166(3):932-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Jan;161(1):193-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10037396</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Jul;4(4 Pt 1):1074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Jan;9(1):316-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22023552</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2000 Jan;37(1):50-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Nov;7(11):3775-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20722782</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Jun;5(6):1503-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2013 Jan;189(1):136-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23164373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 Mar;12(3):824-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25536880</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Esp Urol. 1991 Mar;44(2):185-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1867494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2015 Feb 20;(2):CD004985</Citation><ArticleIdList><ArticleId IdType="pubmed">25927093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Aug;7(8):2884-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20384937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2015 May;12(5):1298-304</Citation><ArticleIdList><ArticleId IdType="pubmed">25872574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 May;8(5):1540-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21366878</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1952 Dec;68(6):903-8</Citation><ArticleIdList><ArticleId IdType="pubmed">13000938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2004 Sep;1(2):221-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16429621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Nov;10(11):2855-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ital Urol Androl. 2014 Jun 30;86(2):135-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25017596</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ital Urol Androl. 2013 Sep 26;85(3):133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24085235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Feb;11(2):605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24286533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Sep;9(9):2389-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22429331</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Urol. 2008 Oct;15(10):919-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18651861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Jan;9(1):309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">22082149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Aug;9(8):2175-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22759400</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2003 Oct;15 Suppl 5:S134-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2001 Dec;58(6):1049-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11744489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2005 Jan;2(1):132-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16422916</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2005 Sep;174(3):969</Citation><ArticleIdList><ArticleId IdType="pubmed">16094013</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2006 Aug;98 (2):393-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16879684</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Urol. 2008;:370947</Citation><ArticleIdList><ArticleId IdType="pubmed">19009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2005 Jun;65(6):1198-201</Citation><ArticleIdList><ArticleId IdType="pubmed">15913723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2016 Feb;195(2):427-33</Citation><ArticleIdList><ArticleId IdType="pubmed">26292043</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2006 Sep;176(3):1008-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16890680</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2010 Feb;57(2):334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19303200</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1994 Oct;152(4):1121-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2013 Nov;15(6):852-3</Citation><ArticleIdList><ArticleId IdType="pubmed">24013620</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2015 May-Jun;27(3):86-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25339138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sex Med. 2014 Dec;2(4):178-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25548649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2006 Mar;175(3 Pt 1):1041-4; discussion 1044</Citation><ArticleIdList><ArticleId IdType="pubmed">16469612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 May;5(5):1257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18331264</ArticleId></ArticleIdList></Reference><Reference><Citation>J La State Med Soc. 1996 Jul;148(7):296-301</Citation><ArticleIdList><ArticleId IdType="pubmed">8816024</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2007 Jan;177(1):262-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17162061</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Urol. 2015 Jun 26;:1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26116193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Jun;157(6):2259-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9146640</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1998 Aug;52(2):287-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9697796</ArticleId></ArticleIdList></Reference><Reference><Citation>Plast Reconstr Surg. 1964 Jul;34:75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">14200523</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2009 Jul;11(4):411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19525974</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2014 May-Jun;26(3):100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24305609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ir Med J. 2011 Feb;104(2):53-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21465879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Jan;8(1):5-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21199375</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2014 Dec;84(6):1535-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25432851</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Sep;8(9):2647-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21699668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2009 Mar;181(3):1264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19152945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Mar;7(3):1298-305</Citation><ArticleIdList><ArticleId IdType="pubmed">19929919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Dec;162(6):2054-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10569568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jun;7(6):2261-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20367767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sex Med Rev. 2013 Oct;1(3):150-163</Citation><ArticleIdList><ArticleId IdType="pubmed">27784554</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1994 May;151(5):1205-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8158761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 May;9(5):1482-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22429734</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1960 Oct;84:559-61</Citation><ArticleIdList><ArticleId IdType="pubmed">13763077</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1998 Dec;160(6 Pt 1):2037-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9817318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Mar;9(3):927-36</Citation><ArticleIdList><ArticleId IdType="pubmed">22248013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Feb;163(2):481-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10647660</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1995 Mar;153(3 Pt 1):659-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2012 Sep;62(3):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22658761</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2011 Jul;60(1):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2008 Oct;5(10):2470-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18624970</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Jan;4(1):218-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17081216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Jul;9(7):1937-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22672346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 Jul;3(4):736-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16839331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jul;7(7):2602-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20384938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Feb;137(2):294-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3543409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Sep;9(9):2467-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22759540</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2006 May;67(5):1072-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16581112</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2012 Jun;79(6):1310-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2013 Dec;190(6):2189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23845458</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Urol. 2008;:524392</Citation><ArticleIdList><ArticleId IdType="pubmed">19043562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Aug;9(8):2182-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22759917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1996 Aug;156(2 Pt 1):402-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Jul;172(1):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15201759</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Med Devices. 2013 May;10(3):353-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23668707</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2013 Aug;82(2):373-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23791218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1996 Jan;155(1):155-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7490819</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Urol. 2014 Feb;48(1):105-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23834377</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2007 Aug;70(2):337-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2014 Oct;114(4):576-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25383397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2008 Jan;179(1):186-90; discussion 190</Citation><ArticleIdList><ArticleId IdType="pubmed">18001797</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2003 Nov;62(5):918-21</Citation><ArticleIdList><ArticleId IdType="pubmed">14624920</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Aug;138(2):312-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3599246</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Dec;14(6):545-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12494294</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 May;3(3):550-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16681481</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2014 Jul-Aug;26(4):128-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24430278</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 2013 Jun;31(3):591-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22457032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Apr;10(4):893-906; quiz 907</Citation><ArticleIdList><ArticleId IdType="pubmed">23551538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2013 Mar 28;(3):CD003949</Citation><ArticleIdList><ArticleId IdType="pubmed">23543526</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2006 Dec;176(6 Pt 1):2599-601; discussion 2601</Citation><ArticleIdList><ArticleId IdType="pubmed">17085168</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Braz J Urol. 2007 Jan-Feb;33(1):74-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17335602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Jul;8(7):2112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21492409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Mar;7(3):1052-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20500445</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2005 Apr;65(4):760-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15833523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2014 Apr;11(4):1078-85</Citation><ArticleIdList><ArticleId IdType="pubmed">24628707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Apr;163(4):1203-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10737496</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2005 Jan;173(1):89-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15592039</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2001 Jun;57(6):1160-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11377333</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2013 Dec;82(6):1436-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24125688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jul;7(7):2359-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20497306</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2006 Jan;97(1):129-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Oct;168(4 Pt 1):1475-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12352421</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Apr;14(2):81-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11979321</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1999 Jul;54(1):145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10414742</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2000 Jun;12(3):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11045908</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2011 Feb;185(2):614-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1998 Mar;159(3):816-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9474157</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2016 Jan-Feb;18(1):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26112480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Sep;4(5):1494-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17727355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26620458</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.</ArticleTitle><Pagination><StartPage>723</StartPage><EndPage>731</EndPage><MedlinePgn>723-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/1008-682X.167721</ELocationID><Abstract><AbstractText>Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway for smooth muscle (SM) control in other urogenital tracts (UGTs) make PDE5-Is promising pharmacologic agents against other benign urological diseases. This article reviews the literature and contains some previously unpublished data about characterizations and activities of PDE5 and its inhibitors in treating urological disorders. Scientific discoveries have improved our understanding of cell-signaling pathway in NO/cGMP-mediated SM relaxation in UGTs. Moreover, the clinical applications of PDE5-Is have been widely recognized. On-demand PDE5-Is are efficacious for most cases of ED, while daily-dosing and combination with testosterone are recommended for refractory cases. Soluble guanylate cyclase (sGC) stimulators also have promising role in the management of severe ED conditions. PDE5-Is are also the first rehabilitation strategy for postoperation or postradiotherapy ED for prostate cancer patients. PDE5-Is, especially combined with &#x3b1;-adrenoceptor antagonists, are very effective for benign prostatic hyperplasia (BPH) except on maximum urinary flow rate (Q max ) with tadalafil recently proved for BPH with/without ED. Furthermore, PDE5-Is are currently under various phases of clinical or preclinical researches with promising potential for other urinary and genital illnesses, such as priapism, premature ejaculation, urinary tract calculi, overactive bladder, Peyronie's disease, and female sexual dysfunction. Inhibition of PDE5 is expected to be an effective strategy in treating benign urological diseases. However, further clinical studies and basic researches investigating mechanisms of PDE5-Is in disorders of UGTs are required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen-Hao</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan City 430071, Hubei Province, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin-Hua</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan City 430071, Hubei Province, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="N">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009126" MajorTopicYN="N">Muscle Relaxation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053201" MajorTopicYN="N">Urinary Bladder, Overactive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26620458</ArticleId><ArticleId IdType="pmc">PMC5000795</ArticleId><ArticleId IdType="doi">10.4103/1008-682X.167721</ArticleId><ArticleId IdType="pii">167721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 1999;63:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10506827</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer B. Nitric oxide/cyclic GMP-mediated signal transduction. Ann N Y Acad Sci. 1994;733:357&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">7526764</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998;338:1397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013;14:1333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23675780</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz EG, Tan RB, Rittenberg D, Hellstrom WJ. Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag. 2014;10:701&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155803</ArticleId><ArticleId IdType="pubmed">25210457</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23040455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60:967&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780568</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002;60:12&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12657355</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352386</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9:1122&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui YS, Li N, Zong HT, Yan HL, Zhang Y. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014;16:472&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023381</ArticleId><ArticleId IdType="pubmed">24589460</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl. 2007;9:134&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187165</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332:589&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1397768</ArticleId><ArticleId IdType="pubmed">16528082</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422959</ArticleId></ArticleIdList></Reference><Reference><Citation>De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol. 2008;54:213&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342431</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76:915&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med. 2007;4:908&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627738</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT) Eur Urol. 2014;65:587&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24169081</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumbe J, Porst H, Sommer F, Grohmann W, Beneke M, et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol. 2008;54:204&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18395326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol. 2003;170:S15&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12853767</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006;3:84&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409221</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172:2227&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R, Penson DF. Treatment outcomes in localized prostate cancer: a patient-oriented approach. Semin Urol Oncol. 2002;20:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11828359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zippe CD, Raina R, Thukral M, Lakin MM, Klein EA, et al. Management of erectile dysfunction following radical prostatectomy. Curr Urol Rep. 2001;2:495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084237</ArticleId></ArticleIdList></Reference><Reference><Citation>Briganti A, Montorsi F. Penile rehabilitation after radical prostatectomy. Nat Clin Pract Urol. 2006;3:400&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP. The role and structure of a postradical prostatectomy penile rehabilitation program. Curr Urol Rep. 2009;10:219&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19371480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med. 2007;4:1085&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17466058</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F, Amar E, Chevallier D, Montaigne O, Joubert JM, et al. How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association. J Sex Med. 2008;5:448&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042217</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Lakin MM, Agarwal A, Mascha E, Montague DK, et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology. 2004;63:960&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, et al. Role of viagra after radical prostatectomy. Urology. 2000;55:241&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10688087</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004;172:1036&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311032</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640769</ArticleId></ArticleIdList></Reference><Reference><Citation>Candy B, Jones L, Williams R, Tookman A, King M. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. BJU Int. 2008;102:426&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18410431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang X, Liu T, He Q, Wang Y, et al. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. PLoS One. 2014;9:e91327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949994</ArticleId><ArticleId IdType="pubmed">24618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick GS, Butler WM, Lief JH, Stipetich RL, Abel LJ, et al. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology. 1999;53:1112&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10367837</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:437&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890585</ArticleId></ArticleIdList></Reference><Reference><Citation>Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:439&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16965992</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647948</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003;170:1278&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501741</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, Bruzziches R, Spera G. A rationale for the use of testosterone &#x201c;salvage&#x201d; in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors. Endocrinologist. 2005;15:99&#x2013;105.</Citation></Reference><Reference><Citation>Ferreira FT, Dambros M, Bisogni S, Dambros MC, Scolfaro MR, et al. Effects of testosterone supplementation on prevention of age-related penile remodeling. Aging Male. 2014;17:12&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24397689</ArticleId></ArticleIdList></Reference><Reference><Citation>Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3:382&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">16681465</ArticleId></ArticleIdList></Reference><Reference><Citation>Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, et al. Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009;37:108&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19011292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XH, Melman A, Disanto ME. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? J Sex Med. 2011;8:1865&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">21324096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingard CJ, Johnson JA, Holmes A, Prikosh A. Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1572&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12573976</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, Morelli A, Filippi S, Ambrosini S, Mancina R, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med. 2007;4:620&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17498101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Kanika ND, Melman A, DiSanto ME. Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes. Am J Physiol Endocrinol Metab. 2012;302:E32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328089</ArticleId><ArticleId IdType="pubmed">21917637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol. 2005;47:409&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716209</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764637</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2008;179:S97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">18405769</ArticleId></ArticleIdList></Reference><Reference><Citation>Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study) J Sex Med. 2011;8:284&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20704642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin DJ, Yassin AA, Hammerer PG. Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone. J Sex Med. 2014;11:543&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6:94&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898793</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannini EA, Isidori AM, Aversa A, Lenzi A, Althof SE. Which is first?. The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med. 2013;10:2359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24112352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasker GF, Pankey EA, Kadowitz PJ. Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction. Physiology (Bethesda) 2013;28:262&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23817801</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabe J, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011;60:1020&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839578</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2225477</ArticleId><ArticleId IdType="pubmed">16955067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Brandish PE, Di Valentin M, Schelvis JP, Babcock GT, et al. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry. 2000;39:10848&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasker GF, Pankey EA, Frink TJ, Zeitzer JR, Walter KA, et al. The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol. 2013;304:H1670&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680766</ArticleId><ArticleId IdType="pubmed">23585129</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541338</ArticleId></ArticleIdList></Reference><Reference><Citation>McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">21420124</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 1995;45:440&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7879335</ArticleId></ArticleIdList></Reference><Reference><Citation>Drescher P, Eckert RE, Madsen PO. Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate. 1994;25:76&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7518597</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;ckert S, Oelke M, Stief CG, Andersson KE, Jonas U, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49:740&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">19796053</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;ckert S, Sormes M, Kedia G, Scheller F, Knapp WH, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology. 2008;71:526&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342202</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;ckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001;166:2484&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11696815</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zang N, Wei Y, Yin J, Teng R, et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab. 2012;302:E243&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340899</ArticleId><ArticleId IdType="pubmed">22028410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460342</ArticleId></ArticleIdList></Reference><Reference><Citation>McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17382741</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9:271&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21981682</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;56:727&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19409693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol. 2013;20:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">22958078</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M, Giuliano F, Mirone V, Xu L, Cox D, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297243</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int. 2014;114:568&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang X, Li S, Meng Z, Liu T, et al. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One. 2014;9:e107593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162615</ArticleId><ArticleId IdType="pubmed">25216271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">22405510</ArticleId></ArticleIdList></Reference><Reference><Citation>Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res. 1996;24:129&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8839479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara M, Andersson K, Persson K. Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation. Eur J Pharmacol. 2000;401:241&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajioka S, Nakayama S, Seki N, Naito S, Brading AF. Oscillatory membrane currents paradoxically induced via NO-activated pathways in detrusor cells. Cell Calcium. 2008;44:202&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18241917</ArticleId></ArticleIdList></Reference><Reference><Citation>Casabe A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191:727&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096118</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8:2746&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21812935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, et al. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology. 2014;84:412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24938580</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73:1391&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">23765639</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int. 2012;110:E259&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">22591258</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh DV, Mete UK, Mandal AK, Singh SK. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med. 2014;11:187&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24165272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, et al. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010;106:674&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184577</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, et al. Priapism in sickle-cell disease; incidence, risk factors and complications &#x2013; An international multicentre study. BJU Int. 2002;90:898&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460353</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger R, Billups K, Brock G, Broderick GA, Dhabuwala CB, et al. Report of the American Foundation for Urologic Disease (AFUD) thought leader panel for evaluation and treatment of priapism. Int J Impot Res. 2001;13(Suppl 5):S39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Melman A, DiSanto M. Pathophysiology of priapism with varied duration: a novel rat model study using the myosin II specific inhibitor blebbistatin(Abstract) J Urol. 2011;185:e452.</Citation></Reference><Reference><Citation>Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102:1661&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547836</ArticleId><ArticleId IdType="pubmed">15668387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl. 2008;10:88&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087648</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17100941</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67:1043&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698365</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085689</ArticleId><ArticleId IdType="pubmed">24680796</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2004;1:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422984</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;ckert S, Waldkirch ES, Sonnenberg JE, Sandner P, Kuczyk MA, et al. Expression and distribution of phosphodiesterase isoenzymes in the human seminal vesicles. J Sex Med. 2011;8:3058&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810184</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel AD. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. J Urol. 2005;174:1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">16094045</ArticleId></ArticleIdList></Reference><Reference><Citation>Machtens S, Ckert S, Stief CG, Tsikas D, Frlich JC, Jr, et al. Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro. Urology. 2003;61:479&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12597985</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;ckert S, Bazrafshan S, Scheller F, Mayer ME, Jonas U, et al. Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors. Urology. 2007;70:185&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17656245</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Hamid IA, El-Naggar EA, El-Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res. 2001;13:41&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313839</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res. 2009;21:221&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474796</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Ma L, Zhao L, Liu Y, Chen Z. [Clinical efficacy of Viagra with behavior therapy against premature ejaculation] Zhonghua Nan Ke Xue. 2004;10:366&#x2013;7, 70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathers MJ, Klotz T, Roth S, Lummen G, Sommer F. Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia. 2009;41:169&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19400851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos RM, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008;80:162&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokce A, Demirtas A, Halis F, Ekmekcioglu O. In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting. Int Urol Nephrol. 2010;42:881&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20174968</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokce A, Halis F, Demirtas A, Ekmekcioglu O. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int. 2011;107:1274&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21929518</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2:368&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422868</ArticleId></ArticleIdList></Reference><Reference><Citation>Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, et al. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology. 2006;67:388&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461091</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002;168:2486&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12441946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WF, Wang Y, Minhas S, Ralph DJ. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol. 2007;14:331&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int. 2007;79:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003;61:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med. 2013;10:2832&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937271</ArticleId></ArticleIdList></Reference><Reference><Citation>Asimakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation?. A systematic review and meta-analysis. J Sex Med. 2012;9:2404&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002;6:283&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 2006;97:625&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, et al. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci. 2014;183:449&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">24190613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stief CG, &#xdc;ckert S, Truss MC, Becker AJ, Machtens S, et al. A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urol Res. 1996;24:333&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530611</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, et al. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology. 2006;67:1111&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16635522</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, et al. Type 5 phosphodiesterase expression in the human vagina. Urology. 2002;60:191&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12100961</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG. 2001;108:623&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan SA, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology. 1999;53:481&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10096370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26511893</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-1550</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists</Title><ISOAbbreviation>J Endovasc Ther</ISOAbbreviation></Journal><ArticleTitle>Lesion Pattern in Patients With Erectile Dysfunction of Suspected Arterial Origin: An Angiographic Study.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>82</EndPage><MedlinePgn>76-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1526602815613789</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine the specific lesion pattern of supplying arteries in patients with cardiovascular risk factors suffering from treatment-refractory erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From May 2012 to August 2013, 26 men (median age 55 years) poorly responsive to phosphodiesterase-5 inhibitor therapy were evaluated for a possible vascular cause for their ED. The men were examined with penile duplex sonography and digital subtraction angiography (DSA). Arterial lesions in the common and internal iliac arteries and the internal pudendal arteries considered amenable to endovascular therapy were treated with angioplasty &#xb1; stents. Retrospectively, 2 blinded investigators independently evaluated the DSA images and categorized the vascular patterns of the erection-related arteries as normal, macroangiopathy (occlusive lesions of the internal pudendal arteries), or microangiopathy (smaller caliber arteries distal to the internal pudendal circulation with no distal arterial reconstitution).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventeen macroangiopathic lesions were successfully treated by angioplasty in 11 patients. The treated arterial lesions were mainly located in the internal (n=10) and common iliac arteries (n=2), whereas the internal pudendal artery were involved in 5 cases. Microangiopathic lesions lacking distal reconstitution were present in 7 patients, and the remaining 8 patients had normal vessels supplying the penis. Patients with macroangiopathy undergoing angioplasty had a higher prevalence of peripheral artery disease (63.6% vs 6.7%, p=0.003).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this preliminary series of ED patients with cardiovascular risk factors and pathologic duplex sonographic flow parameters, roughly 40% exhibited arterial lesions amenable to endovascular revascularization. In the patients with macroangiopathy, vessels upstream of the internal pudendal artery were most commonly affected. More studies are warranted to define the role of endovascular procedures in this ED subpopulation.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2015.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Allmen</LastName><ForeName>Regula S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Clinic for Vascular Surgery, Kantonsspital St Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospital Bern and University of Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birkh&#xe4;user</LastName><ForeName>Fr&#xe9;d&#xe9;ric D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospital Bern and University of Bern, Switzerland Urologie St. Anna, Hirslanden Klinik St Anna, Lucerne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednar</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Angiology, University Hospital Bern and University of Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kammer</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Angiology, University Hospital Bern and University of Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Dai-Do</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Angiology, University Hospital Bern and University of Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehm</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical and Interventional Angiology, Kantonsspital Aarau, Switzerland University of Applied Sciences, Furtwangen, Villingen-Schwenningen, Germany nicolas.a.diehm@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Endovasc Ther</MedlineTA><NlmUniqueID>100896915</NlmUniqueID><ISSNLinking>1526-6028</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015901" MajorTopicYN="Y">Angiography, Digital Subtraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017130" MajorTopicYN="N">Angioplasty</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007083" MajorTopicYN="N">Iliac Artery</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="N">Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018616" MajorTopicYN="N">Ultrasonography, Doppler, Duplex</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angioplasty</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">internal iliac artery</Keyword><Keyword MajorTopicYN="N">internal pudendal artery</Keyword><Keyword MajorTopicYN="N">microangiopathy</Keyword><Keyword MajorTopicYN="N">occlusion</Keyword><Keyword MajorTopicYN="N">peripheral artery disease</Keyword><Keyword MajorTopicYN="N">stenosis</Keyword><Keyword MajorTopicYN="N">stent</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26511893</ArticleId><ArticleId IdType="doi">10.1177/1526602815613789</ArticleId><ArticleId IdType="pii">1526602815613789</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26497349</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1195-9479</ISSN><JournalIssue CitedMedium="Internet"><Volume>22 Suppl 1</Volume><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Canadian journal of urology</Title><ISOAbbreviation>Can J Urol</ISOAbbreviation></Journal><ArticleTitle>Management of complications after surgical outlet reduction for benign prostatic obstruction.</ArticleTitle><Pagination><StartPage>88</StartPage><EndPage>92</EndPage><MedlinePgn>88-92</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lower urinary tract symptoms are a common complaint. Surgery to debulk hyperplastic prostate tissue is indicated for men with symptoms refractory to medical therapy, or for those who cannot tolerate first-line medications. In recent decades, new endoscopic techniques have been developed to reduce the morbidity of transurethral resection of the prostate (TURP). Nonetheless, complications are still frequently encountered in the immediate, early, and remote postoperative setting.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In this review, we perform an in-depth examination of contemporary treatment strategies for long term complications of surgical outlet reduction procedures. Complications encountered in the remote postoperative setting such as erectile dysfunction (ED), urethral stricture, refractory incontinence, and bladder neck contracture were identified in the literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment strategies for ED after TURP do not differ from algorithms applied for ED due to other causes. Management of urethral stricture following TURP depends on the size and location of narrowing and can range from simple dilation to complex excision with grafting techniques or perineal urethrostomy. Refractory urinary incontinence requires a full diagnostic evaluation, and artificial urinary sphincter placement is efficacious for cases that do not respond to first-line medical therapy. Finally, numerous therapies for bladder neck contracture exist and vary in their invasiveness.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Endoscopic reduction of the prostate for the male with benign prostatic obstruction via most contemporary modalities is a safe and effective means to decrease outlet resistance to urinary flow. However, late complications from these procedures still exist. Management of remote morbidity following TURP can be diagnostically and therapeutically complex, necessitating prompt referral to a genitourinary reconstruction specialist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simhan</LastName><ForeName>Jay</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Urol</MedlineTA><NlmUniqueID>9515842</NlmUniqueID><ISSNLinking>1195-9479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020728" MajorTopicYN="N">Transurethral Resection of Prostate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014524" MajorTopicYN="N">Urethral Obstruction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014525" MajorTopicYN="N">Urethral Stricture</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001748" MajorTopicYN="N">Urinary Bladder Neck Obstruction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014567" MajorTopicYN="N">Urography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26497349</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26480830</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6285</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current urology reports</Title><ISOAbbreviation>Curr Urol Rep</ISOAbbreviation></Journal><ArticleTitle>Minimizing Penile Implant Infection: A Literature Review of Patient and Surgical Factors.</ArticleTitle><Pagination><StartPage>81</StartPage><MedlinePgn>81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11934-015-0554-2</ELocationID><Abstract><AbstractText>Inflatable penile prosthesis (IPP) is an effective treatment for erectile dysfunction in patients' refractory to oral or injectable treatment. While the rate of infection has decreased over the past decade, it is still the most feared complication of IPP placement. Here, we assemble possible patient and surgical factors attributing to the risk of infection. Studies have been gathered addressing each of these factors, and an Oxford Level of Evidence is assigned to each recommendation based on strength of the study. The goal of this review is to inform surgeons of possible risks in order to further reduce the risk of infection and thus increase success of IPP placement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, PO Box 19665, Springfield, IL, 62794-9665, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohler</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, PO Box 19665, Springfield, IL, 62794-9665, USA. tkohler@siumed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Urol Rep</MedlineTA><NlmUniqueID>100900943</NlmUniqueID><ISSNLinking>1527-2737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Men&#x2019;s health</Keyword><Keyword MajorTopicYN="N">Penile implant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26480830</ArticleId><ArticleId IdType="doi">10.1007/s11934-015-0554-2</ArticleId><ArticleId IdType="pii">10.1007/s11934-015-0554-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urology. 2013 Oct;82(4):937-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1998 Aug;52(2):291-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9697797</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2005 Nov-Dec;17(6):535-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15988544</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2014 Sep;148(3):995-1003; discussion 1003-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25048633</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2009 May;30(5):420-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19320574</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2007 Nov;34(4):535-47, vi</Citation><ArticleIdList><ArticleId IdType="pubmed">17983893</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2012 Apr;147(4):373-83</Citation><ArticleIdList><ArticleId IdType="pubmed">22508785</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2011 Nov 09;(11):CD004122</Citation><ArticleIdList><ArticleId IdType="pubmed">22071812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Nov;140(5):984-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3172373</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Jun 23;303(24):2479-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20571014</ArticleId></ArticleIdList></Reference><Reference><Citation>Interact Cardiovasc Thorac Surg. 2009 Aug;9(2):282-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19416962</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Aug 14;288(6):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12169076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1998 May;159(5):1537-9; discussion 1539-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9554349</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2010 Apr;29(4):373-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20108109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Assoc Thai. 2009 Jul;92(7):898-902</Citation><ArticleIdList><ArticleId IdType="pubmed">19626807</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1992 Feb;147(2):386-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2014 Jul;192(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24384159</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Apr;137(4):681-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3560322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vasc Surg. 2015 Apr;61(4):933-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25600333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004985</Citation><ArticleIdList><ArticleId IdType="pubmed">22972080</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1984 Feb 17;251(7):903-10</Citation><ArticleIdList><ArticleId IdType="pubmed">6694291</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 7;362(1):9-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20054045</ArticleId></ArticleIdList></Reference><Reference><Citation>Top Spinal Cord Inj Rehabil. 2012 Spring;18(2):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23459635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2009 Mar;181(3):1264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19152945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1996 Apr 27;347(9009):1133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8609746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2008 Apr;179(4):1379-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 7;362(1):18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20054046</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Res. 1999;20(2):109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10580636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1995 Mar;153(3 Pt 1):659-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7861509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jan;7(1 Pt 1):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19758282</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2011 Jul;60(1):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1981 May;125(5):659-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7230335</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(8):e42254</Citation><ArticleIdList><ArticleId IdType="pubmed">22905120</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 2014 Feb;32(1):173-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23708698</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2012 Jun;79(6):1310-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1996 Aug;156(2 Pt 1):402-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8683689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Jul;172(1):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15201759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Am. 2014 Aug 20;96(16):1333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25143493</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2012 Nov;188(5):1855-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22999690</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Aug;164(2):376-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Urol. 2014 Feb;48(1):105-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23834377</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2007 Aug;70(2):337-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17826502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1992 Feb;147(2):383-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1732599</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Nov;158(5):1787-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9334602</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2011 Apr;114(4):837-46</Citation><ArticleIdList><ArticleId IdType="pubmed">21372682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Jul;138(1):68-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3599223</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Infect Control. 2013 Feb;41(2):167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22722008</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2010 Jan;164(1):78-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20048246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2001 Jan;233(1):26-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11141221</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Jul;138(1):65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3599222</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord. 2001 Sep;39(9):455-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11571657</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurourol Urodyn. 2016 Apr;35(4):528-34</Citation><ArticleIdList><ArticleId IdType="pubmed">25754324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 2001 Sep;70(3):395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">11527989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26475945</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-318X</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Urologic clinics of North America</Title><ISOAbbreviation>Urol Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Current Concepts in Infections Associated with Penile Prostheses and Artificial Sphincters.</ArticleTitle><Pagination><StartPage>485</StartPage><EndPage>492</EndPage><MedlinePgn>485-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2015.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0094-0143(15)00049-X</ELocationID><Abstract><AbstractText>Implantation of penile prostheses and artificial urinary sphincters have gained widespread acceptance for the treatment of refractory erectile dysfunction and incontinence, respectively. In the past 3 decades, improved device design and an increased understanding of the pathophysiology of device infections have contributed to a decrease in infection rates. However, understanding the concepts related to infection prevention and management remains critical. In this article, the authors review and discuss these concepts and provide outlines for the practicing urologists for both infection prevention and treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hofer</LastName><ForeName>Matthias D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Urology, Feinberg School of Medicine, Northwestern University, 675 North St Clair Street, Galter 20-150, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Chris M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Urology, Feinberg School of Medicine, Northwestern University, 675 North St Clair Street, Galter 20-150, Chicago, IL 60611, USA. Electronic address: cgonzalez@nmff.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urol Clin North Am</MedlineTA><NlmUniqueID>0423221</NlmUniqueID><ISSNLinking>0094-0143</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="Y">Device Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016741" MajorTopicYN="N">Urinary Sphincter, Artificial</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial urinary sphincter</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26475945</ArticleId><ArticleId IdType="doi">10.1016/j.ucl.2015.05.008</ArticleId><ArticleId IdType="pii">S0094-0143(15)00049-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26457680</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-2353</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical anatomy (New York, N.Y.)</Title><ISOAbbreviation>Clin Anat</ISOAbbreviation></Journal><ArticleTitle>Comprehensive review of the anatomy and physiology of male ejaculation: Premature ejaculation is not a disease.</ArticleTitle><Pagination><StartPage>111</StartPage><EndPage>119</EndPage><MedlinePgn>111-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ca.22655</ELocationID><Abstract><AbstractText>Human semen contains spermatozoa secreted by the testes and a mixture of components produced by the bulbo-urethral and Littre (paraurethral) glands, prostate, seminal vesicles, ampulla, and epididymis. Ejaculation is used as a synonym for the external ejection of semen, but it comprises two phases: emission and expulsion. As semen collects in the prostatic urethra, the rapid preorgasmic distension of the urethral bulb is pathognomonic of impeding orgasm, and the man experiences a sensation that ejaculation is inevitable (in women, emission is the only phase of orgasm). The semen is propelled along the penile urethra mainly by the bulbocavernosus muscle. With Kegel exercises, it is possible to train the perineal muscles. Immediately after the expulsion phase the male enters a refractory period, a recovery time during which further orgasm or ejaculation is physiologically impossible. Age affects the recovery time: as a man grows older, the refractory period increases. Sexual medicine experts consider premature ejaculation only in the case of vaginal intercourse, but vaginal orgasm has no scientific basis, so the duration of intercourse is not important for a woman's orgasm. The key to female orgasm are the female erectile organs; vaginal orgasm, G-spot, G-spot amplification, clitoral bulbs, clitoris-urethra-vaginal complex, internal clitoris and female ejaculation are terms without scientific basis. Female sexual dysfunctions are popular because they are based on something that does not exist, i.e. the vaginal orgasm. The physiology of ejaculation and orgasm is not impaired in premature ejaculation: it is not a disease, and non-coital sexual acts after male ejaculation can be used to produce orgasm in women. Teenagers and men can understand their sexual responses by masturbation and learn ejaculatory control with the stop-start method and the squeeze technique. Premature ejaculation must not be classified as a male sexual dysfunction. It has become the center of a multimillion dollar business: is premature ejaculation-and female sexual dysfunction-an illness constructed by sexual medicine experts under the influence of drug companies?</AbstractText><CopyrightInformation>&#xa9; 2015 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puppo</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centro Italiano Di Sessuologia, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puppo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Florence, Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Anat</MedlineTA><NlmUniqueID>8809128</NlmUniqueID><ISSNLinking>0897-3806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061686" MajorTopicYN="N">Premature Ejaculation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bulbocavernosus muscle</Keyword><Keyword MajorTopicYN="N">dapoxetine</Keyword><Keyword MajorTopicYN="N">ejaculation</Keyword><Keyword MajorTopicYN="N">orgasm</Keyword><Keyword MajorTopicYN="N">semen</Keyword><Keyword MajorTopicYN="N">sexual dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26457680</ArticleId><ArticleId IdType="doi">10.1002/ca.22655</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26439886</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study.</ArticleTitle><Pagination><StartPage>988</StartPage><EndPage>991</EndPage><MedlinePgn>988-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2015.09.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(15)00934-3</ELocationID><Abstract><AbstractText Label="UNLABELLED">Evidence from animal models replicating postradical prostatectomy erectile dysfunction (pRP-ED) suggests intracavernous injection of bone marrow-mononuclear cells (BM-MNCs) as a promising treatment approach for pRP-ED. We conducted a phase 1/2 pilot clinical trial of intracavernous autologous BM-MNC injection to treat pRP-ED (NCT01089387). Twelve patients with localized prostate cancer and vasculogenic pRP-ED refractory to maximal medical treatment were divided into four equal groups treated with escalating BM-MNC doses (2&#xd7;10(7), 2&#xd7;10(8), 1&#xd7;10(9), 2&#xd7;10(9)). Tolerance was the primary endpoint. Secondary endpoints were the effects on erectile function and penile vascularization at 6 mo, as assessed using the International Index of Erectile Function-15 and Erection Hardness Scale questionnaires, and color duplex Doppler ultrasound. We measured the peak systolic velocity in cavernous arteries and assessed endothelial function using the penile nitric oxide release test. No serious side effects occurred. At 6 mo versus baseline, significant improvements of intercourse satisfaction (6.8&#xb1;3.6, 3.9&#xb1;2.5, p=0.044) and erectile function (17.4&#xb1;8.9, 7.3&#xb1;4.5, p=0.006) domains of the International Index of Erectile Function-15 and Erection Hardness Scale (2.6&#xb1;1.1, 1.3&#xb1;0.8, p=0.008) were observed in the total population. Spontaneous erections showed significantly greater improvement with the higher doses. Clinical benefits were associated with improvement of peak systolic velocity and of % penile nitric oxide release test and sustained after 1 yr. Our results need to be confirmed by phase 2 clinical trials.</AbstractText><AbstractText Label="PATIENT SUMMARY">We report a phase 1/2 pilot clinical trial investigating cell therapy with injection of bone marrow mononucleated cells to treat postradical prostatectomy erectile dysfunction. No serious side effects occurred. Improvements of erectile function and penile vascularization were noted. Further studies are required to confirm these preliminary results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yiou</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>APHP, Urology Department, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France. Electronic address: rene.yiou@hmn.aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamidou</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>APHP, Department of Physiology, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birebent</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Etablissement Fran&#xe7;ais du Sang, Unit&#xe9; d'Ing&#xe9;nierie et de th&#xe9;rapie cellulaire, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bitari</LastName><ForeName>Dalila</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>APHP, CIC-P006, and CIC-BT 504, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecorvoisier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>APHP, CIC-P006, and CIC-BT 504, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contremoulins</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>APHP, Anesthesiology Department, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khodari</LastName><ForeName>Muhieddine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>APHP, Urology Department, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>INSERM, U955, UPEC, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustin</LastName><ForeName>D&#xe9;borah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>APHP, Urology Department, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roudot-Thoraval</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>APHP, Department of Public Health of Statistics, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Taille</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>APHP, Urology Department, Henri Mondor Teaching Hospital, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouard</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Etablissement Fran&#xe7;ais du Sang, Unit&#xe9; d'Ing&#xe9;nierie et de th&#xe9;rapie cellulaire, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018919" MajorTopicYN="N">Neovascularization, Physiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018615" MajorTopicYN="N">Ultrasonography, Doppler, Color</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone marrow</Keyword><Keyword MajorTopicYN="N">Cavernous nerves</Keyword><Keyword MajorTopicYN="N">Cell therapy</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Radical prostatectomy</Keyword><Keyword MajorTopicYN="N">Stem cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26439886</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2015.09.026</ArticleId><ArticleId IdType="pii">S0302-2838(15)00934-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26380229</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2253-2447</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Research and reports in urology</Title><ISOAbbreviation>Res Rep Urol</ISOAbbreviation></Journal><ArticleTitle>Semi-rigid penile prosthesis as a salvage management of idiopathic ischemic stuttering priapism.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>141</EndPage><MedlinePgn>137-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/RRU.S83361</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Priapism is the persistent erection resulting from dysfunction of the mechanisms that regulate penile swelling, stiffness, and sagging. It is a full or partial erection that persists for a period more than 4 hours beyond sexual stimulation and/or orgasm or is unrelated to sexual stimulation. Ischemic priapism should be managed in a step-by-step fashion.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To demonstrate step-by-step management of stuttering refractory ischemic priapism. We report a case of stuttering refractory ischemic priapism. Moreover, we reviewed different approaches to priapism management in the literature.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 53-year-old male presented with a painful erection of 29 hours' duration, probably caused by consumption of alcohol. The penile blood gas showed a pH of 7.08, PCO2 of 75 mmHg and PO2 of 39 mmHg. Aspiration was followed by irrigation of an &#x3b1;-adrenergic, Winter and T-shunt operations were preformed, and finally a semi-rigid penile prosthesis was implanted to overcome the refractory stuttering ischemic priapism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In case of stuttering refractory ischemic priapism, immediate implantation of a penile prosthesis is a simple and effective procedure that manages both the acute episode and the inevitable erectile dysfunction that would otherwise occur, while preserving penile length.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faddan</LastName><ForeName>Amr A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksenov</LastName><ForeName>Alexey V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>Carsten M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xfc;nemann</LastName><ForeName>Klaus P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osmonov</LastName><ForeName>Daniar K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Res Rep Urol</MedlineTA><NlmUniqueID>101576971</NlmUniqueID><ISSNLinking>2253-2447</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">penile prosthesis</Keyword><Keyword MajorTopicYN="N">priapism</Keyword><Keyword MajorTopicYN="N">shunting operation</Keyword><Keyword MajorTopicYN="N">stuttering priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26380229</ArticleId><ArticleId IdType="pmc">PMC4567212</ArticleId><ArticleId IdType="doi">10.2147/RRU.S83361</ArticleId><ArticleId IdType="pii">rru-7-137</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>El-Bahnasawy MS, Dawood A, Farouk A. Low-flow priapism: risk factors for erectile dysfunction. BJU Int. 2002;89(3):285&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856112</ArticleId></ArticleIdList></Reference><Reference><Citation>Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol. 1986;135(1):142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">3941454</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501756</ArticleId></ArticleIdList></Reference><Reference><Citation>Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337305</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7(1 Pt 2):476&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092449</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger R, Billups K, Brock G, et al. Report of the American Foundation for Urologic Disease (AFUD) thought leader panel for evaluation and treatment of priapism. Int J Impot Res. 2001;13(Suppl 5):S39&#x2013;S43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781746</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell MF, Wein AJ, Kavoussi LR. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders/Elsevier; 2012. pp. 760&#x2013;780.</Citation></Reference><Reference><Citation>Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res. 1995;7(2):131&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">7496442</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: a model for ischemic priapism. J Urol. 1994;151(1):259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254824</ArticleId></ArticleIdList></Reference><Reference><Citation>Juenemann KP, Lue TF, Abozeid M, Hellstrom WJ, Tanagho EA. Blood gas analysis in drug-induced penile erection. Urol Int. 1986;41(3):207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">3750584</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonia A, Eardley I, Giuliano F, et al. European Association of Urology Guidelines on Priapism. Eur Urol. 2014;65(2):480&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24314827</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter CC. Cure of idiopathic priapism: new procedure of creating fistula between glans penis and corpora cavernosa. Urology. 1976;8(4):389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">973296</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009;181(4):1699&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">19233430</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and surgical management. Urol Clin North Am. 2011;38(2):185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">21621085</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RG, Thomas CE, Tomskey GC. Cavernospongiosum shunts in treatment of priapism. Urology. 1976;7(3):292&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">943875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa Urdangarain O, Hermida P&#xe9;rez JA. [Priapism. Our experience] Priapismo. Nuestra experiencia. Arch Esp Urol. 1998;51:269&#x2013;276. Spanish.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel GL, Bender LI, Grove JS. Pulmonary embolism: a complication of corpus-saphenous shunt for priapism. J Urol. 1968;99(2):196&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">5641077</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Harraz AM, Shindel AW, Lue TF. Evaluation and management of priapism: 2009 update. Nat Rev Urol. 2009;6(5):262&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905796</ArticleId><ArticleId IdType="pubmed">19424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay J, Shekarriz B, Dhabuwala CB. Penile implant for intractable priapism associated with sickle cell disease. Urology. 1998;51(4):638&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9586621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930579</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010;183(6):2300&#x2013;2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees RW, Kalsi J, Minhas S, Peters J, Kell P, Ralph DJ. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int. 2002;90(9):893&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor J, Akkus E, Alter G, et al. Priapism. J Sex Med. 2004;1(1):116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram CP, Fernandes ET, Ercole C, Billups KL. Management of refractory priapism with penile prostheses. Br J Urol. 1997;79(4):659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126109</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int. 2006;97(1):129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16336342</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedigh O, Rolle L, Negro C, et al. Early insertion of inflatable penile prosthesis for intractable ischemic priapism: our experience and review of the literature. Urology. 2011;23(4):158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26303429</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4294</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Current topics in medicinal chemistry</Title><ISOAbbreviation>Curr Top Med Chem</ISOAbbreviation></Journal><ArticleTitle>Structure-Based Discovery of PDEs Inhibitors.</ArticleTitle><Pagination><StartPage>917</StartPage><EndPage>933</EndPage><MedlinePgn>917-33</MedlinePgn></Pagination><Abstract><AbstractText>Phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP, thereby regulating the cyclic nucleotide signalling pathways and biological responses. PDEs inhibitors can be used clinically for treatment of several diseases including central nervous system disorders, erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, and inflammatory diseases such as chronic obstructive pulmonary disease. However, the unfavourable risk-benefit ratio and side-effect profiles of non-selective PDEs inhibitors have impeded their therapeutic success and therefore spurred the pharmaceutical industry to develop family-selective PDE inhibitors. Given the recent remarkable advances in structure-based drug design, this review will summarize developments and achievements in structure-based search, design and optimization of PDEs inhibitors, and highlight the challenges that need to be addressed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wuyan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tiantian</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yechun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China. ycxu@simm.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Top Med Chem</MedlineTA><NlmUniqueID>101119673</NlmUniqueID><ISSNLinking>1568-0266</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.-</RegistryNumber><NameOfSubstance UI="D010727">Phosphoric Diester Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010727" MajorTopicYN="N">Phosphoric Diester Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26303429</ArticleId><ArticleId IdType="doi">10.2174/1568026615666150825142134</ArticleId><ArticleId IdType="pii">CTMC-EPUB-69848</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26251633</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1470</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Medical devices (Auckland, N.Z.)</Title><ISOAbbreviation>Med Devices (Auckl)</ISOAbbreviation></Journal><ArticleTitle>Special considerations for placement of an inflatable penile prosthesis for the patient with Peyronie's disease: techniques and patient preference.</ArticleTitle><Pagination><StartPage>331</StartPage><EndPage>340</EndPage><MedlinePgn>331-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/MDER.S57252</ELocationID><Abstract><AbstractText>Placement of an inflatable penile prosthesis (IPP) is the mainstay of surgical treatment for patients with Peyronie's disease (PD) and concomitant medication-refractory erectile dysfunction. Special considerations and adjunctive surgical techniques during the IPP procedure are often required for patients with PD to improve residual penile curvature, as well as postoperative penile length. The surgical outcomes and various adjunctive techniques are not significantly different from one another, and selection of the appropriate technique must be tailored to patient-specific factors including the extent of the deformity, the degree of penile shortening, and preoperative patient expectations. The aims of this review were to assess the current literature on published outcomes and surgical techniques involving IPP placement in the treatment of PD. Patient satisfaction and preferences are reported, along with the description and patient selection for surgical techniques that include manual penile modeling, management of refractory curvature with concurrent plication, and correction of severe residual curvature and penile shortening with tunica release and plaque incision and grafting. A thorough description of the available techniques and their associated outcomes may help guide surgeons to the most appropriate choice for their patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Urology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Culley C</ForeName><Initials>CC</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Urology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coward</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Med Devices (Auckl)</MedlineTA><NlmUniqueID>101566041</NlmUniqueID><ISSNLinking>1179-1470</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Peyronie&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">inflatable penile prosthesis</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">patient expectation</Keyword><Keyword MajorTopicYN="N">patient satisfaction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26251633</ArticleId><ArticleId IdType="pmc">PMC4524455</ArticleId><ArticleId IdType="doi">10.2147/MDER.S57252</ArticleId><ArticleId IdType="pii">mder-8-331</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie&#x2019;s disease: a critical analysis. Eur Urol. 2006;50(2):235&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Nehra A. Surgical and minimally invasive treatments for Peyronie&#x2019;s disease. Curr Opin Urol. 2009;19(6):589&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">19741538</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie&#x2019;s disease. BJU Int. 2014;113(5):704&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">24219080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie&#x2019;s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359&#x2013;2374.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497306</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie&#x2019;s disease and drug-resistant erectile dysfunction: A single-center study. J Sex Med. 2010;7(11):3775&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20722782</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie&#x2019;s disease. Int J Impot Res. 2000;12(3):147&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11045907</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2(1):80&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR. A new treatment for Peyronie&#x2019;s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152(4):1121&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8072079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR., 2nd Ultrex cylinders: problems with uncontrolled lengthening (the S-shaped deformity) J Urol. 1996;155(1):135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490811</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber BB. Mentor alpha-1 inflatable penile prosthesis cylinder aneurysm: an unusual complication. Int J Impot Res. 1995;7(1):13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7670588</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Penile prosthesis implantation in the treatment of Peyronie&#x2019;s disease and erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4):S122&#x2013;S126.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A, Sanli O, Akman T, Cakan M, Erol B, Mamadov F. Surgical treatment of Peyronie&#x2019;s disease: a single center experience with 145 patients. Eur Urol. 2008;53(2):432&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467161</ArticleId></ArticleIdList></Reference><Reference><Citation>Austoni E, Colombo F, Roman&#xf2; AL, Guarneri A, Kartalas Goumas I, Caz-zaniga A. Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie&#x2019;s disease: a 5-year experience and long-term follow-up on 145 operated patients. Eur Urol. 2005;47(2):223&#x2013;229. discussion 229.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661418</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O. Trans-corporal incision of Peyronie&#x2019;s plaques. J Sex Med. 2011;8(2):589&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955315</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso M, Lania C, Fortuna F, Blanco S, Piacentini I. Preservation of cavernosal erectile function after soft penile prosthesis implant in Peyronie&#x2019;s disease: long-term followup. Adv Urol. 2008;2008:646052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593409</ArticleId><ArticleId IdType="pubmed">19081839</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Guazzoni G, Bergamaschi F, Rigatti P. Patient-partner satisfaction with semirigid penile prostheses for Peyronie&#x2019;s disease: a 5-year followup study. J Urol. 1993;150(6):1819&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pubmed">8230513</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Guazzoni G, Barbieri L, et al. AMS 700 CX inflatable penile implants for Peyronie&#x2019;s disease: functional results, morbidity and patient-partner satisfaction. Int J Impot Res. 1996;8(2):81&#x2013;85. discussion 85&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858396</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3(4):743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Solomon M, DeYoung L, Brock GB. Comparison between AMS 700&#x2122; CX and Coloplast&#x2122; Titan inflatable penile prosthesis for Peyronie&#x2019;s disease treatment and remodeling: clinical outcomes and patient satisfaction. J Sex Med. 2013;10(11):2855&#x2013;2860.</Citation><ArticleIdList><ArticleId IdType="pubmed">23210973</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganstern SL. Long-term experience with the AMS 700CX inflatable penile prosthesis in the treatment of Peyronie&#x2019;s disease. Tech Urol. 1997;3(2):86&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9297768</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena AB, Seabury S, Lakdawalla D, Chandra A. Malpractice risk according to physician specialty. N Engl J Med. 2011;365(7):629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204310</ArticleId><ArticleId IdType="pubmed">21848463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan GW. Malpractice risks for urologists. Urology. 1998;51(2):183&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">9495695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunaryo PL, Colaco M, Terlecki R. Penile prostheses and the litigiouspatient: a legal database review. J Sex Med. 2014;11(10):2589&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">25070914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansalone S, Garaffa G, Djinovic R, et al. Simultaneous total corporal reconstruction and implantation of a penile prosthesis in patients with erectile dysfunction and severe fibrosis of the corpora cavernosa. J Sex Med. 2012;9(7):1937&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A, K&#xfc;&#xe7;&#xfc;kdurmaz F, Sanli O. Current status of the surgical management of Peyronie&#x2019;s disease. Nat Rev Urol. 2011;8(2):95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">21304544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salamanca JI, Mueller A, Moncada I, Carballido J, Mulhall JP. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med. 2011;8(7):1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicini P, De Marco F, Antonini G, et al. Use of inflatable penile prostheses AMS CX with momentary squeeze in a patient with Peyronie&#x2019;s disease after removal of two previously implanted penile prostheses. Arch Ital Urol Androl. 2014;86(1):46&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">24704933</ArticleId></ArticleIdList></Reference><Reference><Citation>Perito P, Wilson S. The Peyronie&#x2019;s plaque &#x201c;scratch&#x201d;: an adjunct to modeling. J Sex Med. 2013;10(5):1194&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">23750353</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal RL, Burnett AL. Surgical management for Peyronie&#x2019;s disease. World J Mens Health. 2013;31(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640147</ArticleId><ArticleId IdType="pubmed">23658860</ArticleId></ArticleIdList></Reference><Reference><Citation>Yafi FA, Sangkum P, McCaslin IR, Hellstrom WJ. Strategies for penile prosthesis placement in Peyronie&#x2019;s disease and corporal fibrosis. Curr Urol Rep. 2015;16(4):21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie&#x2019;s disease: a nationwide survey. J Sex Med. 2008;5(4):954&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042214</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie&#x2019;s disease. BJU Int. 2011;108(7):1152&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">21314814</ArticleId></ArticleIdList></Reference><Reference><Citation>Adibi M, Hudak SJ, Morey AF. Penile plication without degloving enables effective correction of complex Peyronie&#x2019;s deformities. Urology. 2012;79(4):831&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">22365444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudak SJ, Morey AF, Adibi M, Bagrodia A. Favorable patient reported outcomes after penile plication for wide array of peyronie disease abnormalities. J Urol. 2013;189(3):1019&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">23017514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Lesser TF, Aboseif SR. Subjective patient-reported experiences after surgery for Peyronie&#x2019;s disease: corporeal plication versus plaque incision with vein graft. Urology. 2008;71(4):698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie&#x2019;s disease. J Sex Med. 2014;11(6):1593&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">24708140</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine CJ, Jr, Horton CE. Surgical treatment of Peyronie&#x2019;s disease with a dermal graff. J Urol. 1974;111(1):44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">4273261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue TF, El-Sakka AI. Venous patch graft for Peyronie&#x2019;s disease. Part I: technique. J Urol. 1998;160(6 Pt 1):2047&#x2013;2049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817320</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CY, Kayes O, Kell PD, Christopher N, Minhas S, Ralph DJ. Penile suspensory ligament division for penile augmentation: indications and results. Eur Urol. 2006;49(4):729&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigaud G, Berger RE. Corrective procedures for penile shortening due to Peyronie&#x2019;s disease. J Urol. 1995;153(2):368&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7815586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L, Ceruti C, Tamagnone A, et al. T05-O-19 The &#x201c;Apollo&#x201d; tissue expander: a novel approach to penile shortening due to fibrosis. Sexologies. 2008;17(Suppl 1):S88.</Citation></Reference><Reference><Citation>Sansalone S, Garaffa G, Djinovic R, et al. Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie&#x2019;s disease, refractory erectile dysfunction, and severe penile shortening. J Sex Med. 2012;9(1):316&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">22023552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram RA, Carson CC, 3rd, Altaffer LF. Severe penile curvature after implantation of an inflatable penile prosthesis. J Urol. 1988;139(4):743&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">3352036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman IJ. Corporeal reconstruction procedures for complicated penile implants. Urol Clin North Am. 1989;16(1):73&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2916281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball TP., Jr Surgical repair of penile &#x201c;SST&#x201d; deformity. Urology. 1980;15(6):603&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">7394993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle L, Ceruti C, Timpano M, et al. A new, innovative, lengthening surgical procedure for Peyronie&#x2019;s disease by penile prosthesis implantation with double dorsal-ventral patch graft: the &#x201c;sliding technique&#x201d;. J Sex Med. 2012;9(9):2389&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pubmed">22429331</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio PH, Kuehhas FE, Sansalone S. Penile length and girth restoration in severe Peyronie&#x2019;s disease using circular and longitudinal grafting. BJU Int. 2013;111(4 Pt B):E213&#x2013;E219.</Citation><ArticleIdList><ArticleId IdType="pubmed">23107452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie&#x2019;s disease. J Urol. :S0022-5347(15)04143&#x2013;9. Epub June 9, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26242050</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].</ArticleTitle><Pagination><StartPage>561</StartPage><EndPage>565</EndPage><MedlinePgn>561-5</MedlinePgn></Pagination><Abstract><AbstractText>Premature ejaculation (PE) is a common male sexual disorder with an incidence rate of 20-30%. Recent clinical trials have demonstrated that phosphodiesterase type 5 inhibitors (PDE5i), as the first-line drug for erectile dysfunction (ED), can improve ejaculatory function probably by acting on the peripheral and central adrenergic nerves. The possible action mechanisms of PDE5i may involve lessening of the central sympathetic output, modulation of the contractile responses from the vas deferens, seminal vesicles, prostate and urethra, induction of peripheral analgesia, and prolonging of the total erectile duration, increasing the confidence of ejaculation control, and reducing the post-ejaculation refractory time. This review discusses the possible mechanisms and clinical application of PDE5i in the treatment of PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Dun-sheng</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Xue-jun</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-feng</ForeName><Initials>YF</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061686" MajorTopicYN="N">Premature Ejaculation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012669" MajorTopicYN="N">Seminal Vesicles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014649" MajorTopicYN="N">Vas Deferens</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26242050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26193766</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis First and Replacement Surgeries: Analysis of Patient and Partner Satisfaction.</ArticleTitle><Pagination><StartPage>1646</StartPage><EndPage>1653</EndPage><MedlinePgn>1646-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12932</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Among the many treatments for erectile dysfunction, implantation of a penile prosthesis has been associated with high patient satisfaction rates. Prosthesis replacement has become an accepted procedure in the event of device malfunction or complications, but to our knowledge, there are no data regarding the impact of implant replacement on patients and partner satisfaction.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of our study was to assess and to compare the level of satisfaction, with a first or second penile prosthesis implantation (PPI), in men with refractory erectile dysfunction and their partners.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A survey study based on a five-item questionnaire was carried out at our center between January 1999 and January 2012.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The main outcome measure used was the level of patient and partner satisfaction with sexual intercourse after PPI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 190 eligible patients, 149 (78%) completed the survey (110 underwent a first implant and 39 a reimplant). Seventy-nine percent of first-time implanted patients and 80% of the reimplanted patients (P&#x2009;&gt;&#x2009;0.05; not significant [ns]) reported satisfactory sexual intercourse (very or moderately satisfied), while 74% and 80% of their partners reported satisfactory intercourses, respectively (P&#x2009;&gt;&#x2009;0.05; ns). Overall, 73.7% of first implants and 70% of second implants reported that they would undergo the procedure again if the PPI failed (P&#x2009;&gt;&#x2009;0.05; ns). With regards to cosmetic aspects, 13% of the first implants' and 15% of second implants' partners reported either penile shortness or soft glans as the main causes of their dissatisfaction. Only 2.4% of first implants and 1% of reimplanted patients expressed difficulty in manipulating the device.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PPI is successful in returning the ability for satisfactory sexual intercourse to both first implant and reimplanted patients and their respective partners.</AbstractText><CopyrightInformation>&#xa9; 2015 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lled&#xf3;-Garc&#xed;a</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Andrology and Urethro-Genital Reconstructive Surgery Unit, Urology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jara-Rasc&#xf3;n</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Andrology and Urethro-Genital Reconstructive Surgery Unit, Urology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moncada Iribarren</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Urology Service, Hospital La Zarzuela, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;ero-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Andrology and Urethro-Genital Reconstructive Surgery Unit, Urology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n-Chamizo</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Andrology and Urethro-Genital Reconstructive Surgery Unit, Urology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Fern&#xe1;ndez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Andrology and Urethro-Genital Reconstructive Surgery Unit, Urology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2016 May;195(5):1510</RefSource><PMID Version="1">27186746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="Y">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012092" MajorTopicYN="N">Replantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012747" MajorTopicYN="N">Sexual Partners</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Implantation</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Satisfaction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26193766</ArticleId><ArticleId IdType="doi">10.1111/jsm.12932</ArticleId><ArticleId IdType="pii">S1743-6095(15)34161-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26116193</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-1813</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Scandinavian journal of urology</Title><ISOAbbreviation>Scand J Urol</ISOAbbreviation></Journal><ArticleTitle>Early insertion of a malleable penile prosthesis in ischaemic priapism allows later upsizing of the cylinders.</ArticleTitle><Pagination><StartPage>468</StartPage><EndPage>471</EndPage><MedlinePgn>468-471</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/21681805.2015.1059359</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Early insertion of a penile prosthesis in prolonged ischaemic priapism is easier to perform than late prosthesis placement, and preserves the penile length. The aim of this study was to assess whether a delayed exchange to an inflatable implant allows upsizing of the cylinders in patients who have undergone early insertion for refractory ischaemic priapism.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Over a 30 month period, 10 patients with ischaemic priapism underwent an early insertion of a malleable penile prosthesis. The mean age was 41.3 years and the mean duration of priapism was 188 h. Following a median period of 130.5 days, all of these patients underwent exchange of the malleable to an inflatable prosthesis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the time of penile implant exchange, a median upsize in the length of the cylinders of 1 cm in either one or both corporal bodies (range 0-3 cm) was recorded. Five patients had deliberate downsizing at the initial operation owing to a previous shunt. The mean score on the five-item International Index of Erectile Function (IIEF-5) before insertion of the malleable prosthesis was 24 (range 20-25). Three months after the initial insertion of a malleable penile implant the satisfaction rate according to the IIEF-5 score was 80%. Three months after the exchange, the patient satisfaction rate increased to 90%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Insertion of a malleable penile prosthesis is an acceptable option for patients with refractory ischaemic priapism. Although some patients deliberately have a shorter implant inserted initially owing to a previous distal shunt procedure, following a period of resolution the cylinders can be upsized at a later operation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zacharakis</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>a 1 Department of Urology, Guy's Hospital, King's College London , London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>a 1 Department of Urology, Guy's Hospital, King's College London , London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>Amr Abdul</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Nim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>b 2 Department of Urology, University College London Hospitals , London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Urol</MedlineTA><NlmUniqueID>101587186</NlmUniqueID><ISSNLinking>2168-1805</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cylinder upsizing</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">ischaemic priapism</Keyword><Keyword MajorTopicYN="N">penile implant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26116193</ArticleId><ArticleId IdType="doi">10.3109/21681805.2015.1059359</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26096365</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Trends in the Utilization of Penile Prostheses in the Treatment of Erectile Dysfunction in the United States.</ArticleTitle><Pagination><StartPage>1638</StartPage><EndPage>1645</EndPage><MedlinePgn>1638-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12921</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The utilization of penile prosthesis (PP) insertion in the general population for medically refractory erectile dysfunction (ED) has not been well-characterized. This study assessed the national temporal trends in the surgical management of ED utilizing PP.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An analysis of the 5% Medicare Public Use Files from 2001 to 2010 was performed to assess the use of PP. Regression analysis was performed to identify factors associated with PP placement, type of PP utilized, and factors associated with revisions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1,763,260 men were diagnosed with ED, 3% (53,180) of whom underwent PP insertion. The utilization of PP for ED decreased from 4.6% in 2002 to 2.3% in 2010 (P&#x2009;&lt;&#x2009;0.01). This temporal decline in utilization was significant across all demographic factors including age, ethnicity, and geographic location. Men aged 65-74, from the U.S. South and West, and those with Charlson comorbidity scores &gt;1 were more likely to have a PP inserted for ED (P&#x2009;&lt;&#x2009;0.01). African American men were more likely to have a semirigid PP placed compared with a multicomponent inflatable PP, and were more likely to undergo a revision or removal of the PP compared with Caucasian men (P&#x2009;&lt;&#x2009;0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The surgical management of ED with PP changed significantly between 2001 and 2010. The overall utilization of PP decreased, but its use in patients with significant medical comorbidities increased. Age &gt;65, ethnicity, and geography influenced the likelihood of PP placement, prosthesis type, as well as the likelihood of prosthesis removal or revision.</AbstractText><CopyrightInformation>&#xa9; 2015 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najari</LastName><ForeName>Bobby B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davison</LastName><ForeName>Wesley L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Hussein Al Awamlh</LastName><ForeName>Bashir</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Fujun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paduch</LastName><ForeName>Darius A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulhall</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chughtai</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Richard K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32HS00066</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Sex Med. 2015 Oct;12(10):2084</RefSource><PMID Version="1">26307218</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26096365</ArticleId><ArticleId IdType="doi">10.1111/jsm.12921</ArticleId><ArticleId IdType="pii">S1743-6095(15)34145-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26078844</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2005-6745</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Korean journal of urology</Title><ISOAbbreviation>Korean J Urol</ISOAbbreviation></Journal><ArticleTitle>Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction.</ArticleTitle><Pagination><StartPage>461</StartPage><EndPage>465</EndPage><MedlinePgn>461-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4111/kju.2015.56.6.461</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We investigated the long-term survival and patient satisfaction with an inflatable penile prosthesis as a treatment for refractory erectile dysfunction (ED).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Between July 1997 and September 2014, a total of 74 patients underwent implantation of an inflatable penile prosthesis. The present mechanical status of the prosthesis was ascertained by telephone interview and review of medical records, and related clinical factors were analyzed by using Cox proportional hazard regression model. To investigate current status and satisfaction with the devices, novel questionnaires consisting of eight items were administered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (&#xb1;standard deviation) age and follow-up period were 57.0&#xb1;12.2 years and 105.5&#xb1;64.0 months, respectively. Sixteen patients (21.6%) experienced a mechanical failure and 4 patients (5.4%) experienced a nonmechanical failure at a median follow-up of 98.0 months. Mechanical and overall survival rates of the inflatable penile prosthesis at 5, 10, and 15 years were 93.3%, 76.5%, and 64.8% and 89.1%, 71.4%, and 60.5%, respectively, without a statistically significant correlation with host factors including age, cause of ED, and presence of obesity, hypertension, and diabetes mellitus. Overall, 53 patients (71.6%) completed the questionnaires. The overall patient satisfaction rate was 86.8%, and 83.0% of the patients replied that they intended to repeat the same procedure. Among the 8 items asked, satisfaction with the rigidity of the device received the highest score (90.6%). In contrast, only 60.4% of subjects experienced orgasm.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of our study suggest that excellent long-term reliability and high patient satisfaction rates make the implantation of an inflatable penile prosthesis a recommendable surgical treatment for refractory ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Yoon Seob</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Young Hwii</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Phil Hyun</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Ki Hak</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Urol</MedlineTA><NlmUniqueID>101499376</NlmUniqueID><ISSNLinking>2005-6737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009948" MajorTopicYN="N">Orgasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="N">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Patient satisfaction</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement><b>CONFLICTS OF INTEREST:</b> The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26078844</ArticleId><ArticleId IdType="pmc">PMC4462637</ArticleId><ArticleId IdType="doi">10.4111/kju.2015.56.6.461</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Consensus development conference statement. National Institutes of Health. Impotence. December 7-9, 1992. Int J Impot Res. 1993;5:181&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8173631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Montague DK, Moncada I, Carson C, Minhas S, Faria G, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7(1 Pt 2):501&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence: use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Malloy TR, Wein AJ, Carpiniello VL. Improved mechanical survival with revised model inflatable penile prosthesis using rear-tip extenders. J Urol. 1982;128:489&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">7120553</ArticleId></ArticleIdList></Reference><Reference><Citation>Malloy TR, Wein AJ, Carpiniello VL. Reliability of AMS M700 inflatable penile prosthesis. Urology. 1986;28:385&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">3787898</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch JA, Angermeier KW, Lakin MM, Ingleright BJ, Montague DK. Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: comparison of CX/CXM and Ultrex cylinders. J Urol. 1997;158:1400&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4(4 Pt 1):1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DS, Yang KM, Chung HJ, Choi HM, Choi YD, Choi HK. AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term follow-up. J Sex Med. 2010;7:2602&#x2013;2607.</Citation><ArticleIdList><ArticleId IdType="pubmed">20384938</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000;37:50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Howard GE, Hoang A, Yuan JH, Lin HC, Dai YT. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl. 2009;11:411&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735309</ArticleId><ArticleId IdType="pubmed">19525974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar NB, Angermeier KW, Montague DK. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol. 2006;176(6 Pt 1):2599&#x2013;2601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson KH, Cespedes RD. Prospective long-term results and quality-of-life assessment after Dura-II penile prosthesis placement. Urology. 2003;61:437&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12597963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003;170:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796670</ArticleId></ArticleIdList></Reference><Reference><Citation>Candela JV, Hellstrom WJ. Three-piece inflatable penile prosthesis implantation: a comparison of the penoscrotal and infrapubic surgical approaches. J La State Med Soc. 1996;148:296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitarelli A, Divenuto L, Fortunato F, Falco A, Pagliarulo V, Antonini G, et al. Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl. 2013;85:133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">24085235</ArticleId></ArticleIdList></Reference><Reference><Citation>Natali A, Olianas R, Fisch M. Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med. 2008;5:1503&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">18410306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26049734</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-7980</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.</ArticleTitle><Pagination><StartPage>635</StartPage><EndPage>640</EndPage><MedlinePgn>635-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuro.2015.04.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-4806(15)00158-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Phosphodiesterase-5 inhibitors (PDE5i) are the first choice for treating erectile dysfunction (ED) but are not always effective. The aim of this study was to present our experience in treating patients with ED, refractory to treatment with PDE5i, using intraurethral alprostadil (MUSE).</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">We conducted a review of 82 patients with ED and no response to PDE5i, from March 2013 to October 2014. Forty-seven patients (57%) had hypertension (AHT), 24 (29%) had diabetes (DM) and 20 (24%) had AHT and DM. Additionally, 19 (23%) had undergone radical prostatic (RP) surgery. The patients were evaluated after the treatment was applied and at 4 weeks using the following validated questionnaires: International Index of Erectile Function (IIEF-5/SHIM), Global Assessment Questionnaire (GAQ), Sexual Encounter Profile (SEP) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean patient age was 60.5 years (40-80), and the mean follow-up was 11.3 months (1-20). Sixty-eight percent of the treated patients responded to MUSE(&#xae;) (74% in the AHT group, 65% in the AHT+DM group, 62.5% in the DM group and 58% in the RP group). The mean IIEF-5 score was 11.7&#xb1;4.7, which increased to 18.6&#xb1;4.9 after MUSE was administered (P=.027). The mean EDITS score at 4 weeks was 61.6 (6-81.9). The most common adverse effect was urethral burning, which occurred in 24 patients (29%). There were no cases of urinary tract infection, syncope or priapism.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intraurethral alprostadil is an effective treatment and has a broad safety profile for treating patients with erectile dysfunction refractory to oral treatment with PDE5i.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 AEU. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garrido Abad</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital del Henares, Coslada, Madrid, Espa&#xf1;a. Electronic address: pgabad@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinu&#xe9;s Ojas</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital del Henares, Coslada, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Bl&#xe1;zquez</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital del Henares, Coslada, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde Caturla</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital del Henares, Coslada, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez Arjona</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital del Henares, Coslada, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp</MedlineTA><NlmUniqueID>7704993</NlmUniqueID><ISSNLinking>0210-4806</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alprostadil</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Intraurethral</Keyword><Keyword MajorTopicYN="N">Intrauretral</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26049734</ArticleId><ArticleId IdType="doi">10.1016/j.acuro.2015.04.007</ArticleId><ArticleId IdType="pii">S0210-4806(15)00158-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26047655</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8726</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>World journal of urology</Title><ISOAbbreviation>World J Urol</ISOAbbreviation></Journal><ArticleTitle>Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>382</EndPage><MedlinePgn>377-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-015-1608-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Bulbomembranous stenosis is a significant complication of radiotherapy for prostate cancer. Our purpose is to report outcomes of urethroplasty for radiation-induced bulbomembranous urethral stenoses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-five patients underwent urethroplasty for refractory radiation-induced bulbomembranous stenoses from January 2004 to November 2013. Patients had a minimum follow-up of 12 months with routine cystoscopy at 6 and 12 months. Primary outcome was urethral patency, and secondary outcomes were 90-day complications, de novo incontinence, de novo erectile dysfunction and bothersome LUTS. Outcomes were compared using Fisher's exact test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 35 patients, 20 and 15 had stenosis related to external beam radiation therapy and brachytherapy, respectively. Mean stricture length was 3.5 cm. Reconstruction was performed using anastomotic urethroplasty in 23 patients (65.7 %), while 12 required tissue transfer as a buccal mucosa graft (20.0 %) or penile island flap (14.3 %). With 50.5 months of follow-up, thirty patients (85.7 %) achieved cystoscopic patency with no significant difference between techniques (p = 0.32). A 90-day complication rate of 31.4 % was observed (all Clavien 1-2) with no difference between techniques (p = 1.00). Adverse change in continence occurred in 25.7 % of patients (13.3 % in those without previous TURP). Postoperatively, persisting storage LUTS occurred in 40.0 and 30.4 % described adverse change in erectile function (exclusively in the anastomotic urethroplasty group).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reconstruction of radiation-induced bulbomembranous stenosis yields satisfying patency rates. However, radiation-induced urethral stenosis is not an isolated problem as many patients suffer from storage symptoms, erectile dysfunction or incontinence as a consequence of treatment either before or after urethroplasty.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rourke</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Urology, University of Alberta, Suite 400 Hys Centre, 11010-101 Street, Edmonton, AB, T5H 4B9, Canada. krourke@ualberta.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinnaird</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Urology, University of Alberta, Suite 400 Hys Centre, 11010-101 Street, Edmonton, AB, T5H 4B9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorn</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Urology, University of Alberta, Suite 400 Hys Centre, 11010-101 Street, Edmonton, AB, T5H 4B9, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>World J Urol</MedlineTA><NlmUniqueID>8307716</NlmUniqueID><ISSNLinking>0724-4983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003558" MajorTopicYN="N">Cystoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009061" MajorTopicYN="N">Mouth Mucosa</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013524" MajorTopicYN="Y">Surgical Flaps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014525" MajorTopicYN="N">Urethral Stricture</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="N">Urologic Surgical Procedures, Male</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">Surgical</Keyword><Keyword MajorTopicYN="N">Urethral stenosis</Keyword><Keyword MajorTopicYN="N">Urethral stricture</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26047655</ArticleId><ArticleId IdType="doi">10.1007/s00345-015-1608-2</ArticleId><ArticleId IdType="pii">10.1007/s00345-015-1608-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brachytherapy. 2013 Jan-Feb;12(1):50-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22561217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2007 Aug;178(2):529-34; discussion 534</Citation><ArticleIdList><ArticleId IdType="pubmed">17570425</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2014 Jun;83(6):1350-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24704325</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2011 Jun;107(11):1762-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21083643</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 Mar 1;28(7):1117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20124165</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):461-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11872293</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12243818</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Oncol. 1988 Jun;11(3):220-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3289359</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):915-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10863060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2008 Mar 18;148(6):435-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18252677</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2012 Jan;61(1):112-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22001105</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2006 Dec;176(6 Pt 1):2508-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17085144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2006 Apr;175(4):1376-80; discussion 1381</Citation><ArticleIdList><ArticleId IdType="pubmed">16516001</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2015 Dec;116(6):853-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25684118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1997 Jan;15(1):223-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8996146</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2012 Jun;79(6):1402-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22521189</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1257-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7713787</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2014 Mar;83(3 Suppl):S1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24210733</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Urol Assoc J. 2014 May;8(5-6):E296-300</Citation><ArticleIdList><ArticleId IdType="pubmed">24940453</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 1997 Feb;42(2):99-106</Citation><ArticleIdList><ArticleId IdType="pubmed">9106919</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2009 May;91(2):232-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19097660</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2015 Mar;193(3):902-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25261802</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Urol. 2015 Feb;22(1):7648-55</Citation><ArticleIdList><ArticleId IdType="pubmed">25694014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2011 Jul 06;(7):CD008871</Citation><ArticleIdList><ArticleId IdType="pubmed">21735436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2014 May;191(5):1307-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24333513</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2012 Aug;110(3):304-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22340079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2011 May;185(5):1761-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21420123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25898548</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Application of the vacuum erectile device in penile rehabilitation for erectile dysfunction after radical prostatectomy].</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>199</EndPage><MedlinePgn>195-9</MedlinePgn></Pagination><Abstract><AbstractText>The vacuum erectile device (VED) uses negative pressure to increase blood inflow into the corpora cavernosum, with a ring at the base of the penis to maintain erection for intercourse or without a ring for penile rehabilitation. Owing to the limitation of phosphodiesterase 5 inhibitors (PDE5I) shown in the treatment of refractory erectile dysfunction (ED), the use of VED has resurged and is becoming the first line therapy in the treatment of ED following radical prostatectomy (RP). Currently, the combination therapy of VED with PDE5I and that of VED with intracavernous injection are advocated for post-RP ED. Hereby, we review the role of VED in penile rehabilitation, its underlying mechanisms, and the combination therapies for it.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Haocheng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Run</ForeName><Initials>R</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014618" MajorTopicYN="N">Vacuum</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25898548</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25844161</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2046-1402</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>Case Report: Persistent erectile dysfunction in a man with prolactinoma.</ArticleTitle><Pagination><StartPage>13</StartPage><MedlinePgn>13</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.5743.1</ELocationID><Abstract><AbstractText>Erectile dysfunction has been explored as a condition secondary to elevated prolactin; however, the mechanisms by which elevated prolactin levels cause erectile dysfunction have not yet been clearly established. We here present a patient with a history of prolactinoma who suffered from persistent erectile dysfunction despite testosterone supplementation and pharmacological and surgical treatment for the prolactinoma. &#xa0;Patients who have had both prolactinemia and erectile dysfunction have been reported in the literature, but we find no report of a patient with persistent erectile dysfunction in the setting of testosterone supplementation and persistent hyperprolactinemia refractory to treatment. This case provides evidence supporting the idea that suppression of erectile function occurs in both the central and peripheral nervous systems independent of the hypothalamic-pituitary-gonadal axis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badal</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Ranjith</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakky</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandrashekar</LastName><ForeName>Aravind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipshultz</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 HD073917</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">prolactin</Keyword><Keyword MajorTopicYN="N">sexual dysfunction</Keyword></KeywordList><CoiStatement><b>Competing interests: </b>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25844161</ArticleId><ArticleId IdType="pmc">PMC4367515</ArticleId><ArticleId IdType="doi">10.12688/f1000research.5743.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kumar V, Abbas AK, Fausto N, et al. :Robbins &amp; Cotran Pathologic Basis of Disease, 8th Edition. Philadelphia: Saunders.2009;1103&#x2013;4.Reference Source</Citation></Reference><Reference><Citation>Rogers A, Karavitaki N, Wass JA: Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014;349:g5390. 10.1136/bmj.g5390</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5390</ArticleId><ArticleId IdType="pubmed">25208537</ArticleId></ArticleIdList></Reference><Reference><Citation>Almalki MH, Buhary B, Alzahrani S, et al. : Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases. Pituitary. 2014. 10.1007/s11102-014-0588-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-014-0588-3</ArticleId><ArticleId IdType="pubmed">25062894</ArticleId></ArticleIdList></Reference><Reference><Citation>Romijn JA: Chapter 13 - Hyperprolactinemia and prolactinoma. In: Eric Fliers MK and JAR, editor. Handbook Clin Neurol.Elsevier.2014;124:185&#x2013;95. 10.1016/B978-0-444-59602-4.00013-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-59602-4.00013-7</ArticleId><ArticleId IdType="pubmed">25248588</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand KS, Dhikav V: Hyperprolactinemia: an unusual cause of erectile dysfunction. Arch Sex Behav. 2013;42(3):341. 10.1007/s10508-012-0050-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10508-012-0050-4</ArticleId><ArticleId IdType="pubmed">23297150</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter JN, Tyson JE, Tolis G, et al. : Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med. 1978;299(16):847&#x2013;52. 10.1056/NEJM197810192991602</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197810192991602</ArticleId><ArticleId IdType="pubmed">211411</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa M, Zarrilli S, Vitale G, et al. : Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab. 2004;89(2):621&#x2013;5. 10.1210/jc.2003-030852</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-030852</ArticleId><ArticleId IdType="pubmed">14764772</ArticleId></ArticleIdList></Reference><Reference><Citation>Walia R, Bhansali A, Dutta P, et al. : Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. Indian J Med Res. 2011;134(3):314&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193712</ArticleId><ArticleId IdType="pubmed">21985814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25796680</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Molecular biological studies of erectile dysfunction: an update].</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>106</EndPage><MedlinePgn>99-106</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED), as a common male disease, seriously affects the patients' sexual life quality. Most ED patients benefit from phosphodiesterase type 5 (PDE5) inhibitors, but some refractory ED sufferers fail to respond to them. With the rapid development of molecular biology, the relevant molecular signaling pathways of penile erection and molecular pathogenesis of ED have been gradually clarified, and attempts have been made at a better management or a complete cure of ED with advanced molecular biological methods such as the gene therapy. This article presents an overview on the research progress in the molecular signaling pathways, molecular pathogenesis, and gene therapy of ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ji-hong</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Luan</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25796680</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25763121</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2005-6745</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Korean journal of urology</Title><ISOAbbreviation>Korean J Urol</ISOAbbreviation></Journal><ArticleTitle>Evolution of penile prosthetic devices.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>186</EndPage><MedlinePgn>179-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4111/kju.2015.56.3.179</ELocationID><Abstract><AbstractText>Penile implant usage dates to the 16th century yet penile implants to treat erectile dysfunction did not occur until nearly four centuries later. The modern era of penile implants has progressed rapidly over the past 50 years as physicians' knowledge of effective materials for penile prostheses and surgical techniques has improved. Herein, we describe the history of penile prosthetics and the constant quest to improve the technology. Elements of the design from the first inflatable penile prosthesis by Scott and colleagues and the Small-Carrion malleable penile prosthesis are still found in present iterations of these devices. While there have been significant improvements in penile prosthesis design, the promise of an ideal prosthetic device remains elusive. As other erectile dysfunction therapies emerge, penile prostheses will have to continue to demonstrate a competitive advantage. A particular strength of penile prostheses is their efficacy regardless of etiology, thus allowing treatment of even the most refractory cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, Meriter-Unity Point Health, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Urol</MedlineTA><NlmUniqueID>101499376</NlmUniqueID><ISSNLinking>2005-6737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020811" MajorTopicYN="N">Biomedical Technology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">History</Keyword><Keyword MajorTopicYN="N">Penile prosthesis</Keyword></KeywordList><CoiStatement>The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25763121</ArticleId><ArticleId IdType="pmc">PMC4355428</ArticleId><ArticleId IdType="doi">10.4111/kju.2015.56.3.179</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Impotence. NIH Consens Statement. 1992;10:1&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307265</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">23040455</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakky TS, Wang R, Henry GD. The evolution of the inflatable penile prosthetic device and surgical innovations with anatomical considerations. Curr Urol Rep. 2014;15:410.</Citation><ArticleIdList><ArticleId IdType="pubmed">24756452</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss D, Gabouev AI, Jonas U. Nikolaj A. Bogoraz (1874-1952): pioneer of phalloplasty and penile implant surgery. J Sex Med. 2005;2:139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee WF. A history of surgical treatment of impotence. Urology. 1975;05:401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">1091068</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Penile prostheses: state of the art. In: Kirby RS, O'Leary MP, editors. Recent advances in urology. Edinburgh: Churchill Livingstone; 1998. pp. 61&#x2013;72.</Citation></Reference><Reference><Citation>Nelson RP. Pathophysiology, evalution, and treatment of erectile dysfunction. In: Rous SN, editor. Urology annual. Norwalk, CT: Appleton and Lange; 1987. pp. 139&#x2013;169.</Citation></Reference><Reference><Citation>Jonas U. The history of erectile dysfunction management. Int J Impot Res. 2001;13(Suppl 3):S3&#x2013;S7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Delk JR., 2nd Historical advances in penile prostheses. Int J Impot Res. 2000;12(Suppl 4):S101&#x2013;S107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035395</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973;2:80&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">4766860</ArticleId></ArticleIdList></Reference><Reference><Citation>Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis. New implant for management of impotence. Urology. 1975;5:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">1093303</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas U. Alloplastics in the treatment of erectile dysfunction. In: Jonas U, editor. Erectile dysfunction. New York: Springer-Verlag; 1991. pp. 291&#x2013;309.</Citation></Reference><Reference><Citation>Henry GD. Historical review of penile prosthesis design and surgical techniques: part 1 of a three-part review series on penile prosthetic surgery. J Sex Med. 2009;6:675&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">19207278</ArticleId></ArticleIdList></Reference><Reference><Citation>Krane R. Penile prostheses in urology. In: White RW, Palmer JM, editors. New techniques in urology. Mount Kisco, NY: Futura Pub Co.; 1987.</Citation></Reference><Reference><Citation>Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med. 2007;4:296&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17367425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Montague DK, Moncada I, Carson C, Minhas S, Faria G, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7(1 Pt 2):501&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettocchi C, Palumbo F, Spilotros M, Palazzo S, Saracino GA, Martino P, et al. Penile prostheses. Ther Adv Urol. 2010;2:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126066</ArticleId><ArticleId IdType="pubmed">21789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC., 3rd Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol. 2004;171:1611&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pubmed">15017233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter CE, Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med. 2004;1:221&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16429621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooreville M, Adrian S, Delk JR, 2nd, Wilson SK. Implantation of inflatable penile prosthesis in patients with severe corporeal fibrosis: introduction of a new penile cavernotome. J Urol. 1999;162:2054&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569568</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine LA, Hoeh MP. Review of penile prosthetic reservoir: complications and presentation of a modified reservoir placement technique. J Sex Med. 2012;9:2759&#x2013;2769.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672516</ArticleId></ArticleIdList></Reference><Reference><Citation>Tausch TJ, Mauck R, Zhao LC, Morey AF. Penile prosthesis insertion for acute priapism. Urol Clin North Am. 2013;40:421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23905940</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC. Penile prosthesis implantation in the treatment of Peyronie's disease. Int J Impot Res. 1998;10:125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedigh O, Rolle L, Negro CL, Ceruti C, Timpano M, Galletto E, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011;23:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendirci M, Gur S, Sikka SC. Gene therapy for erectile dysfunction. Front Biosci. 2005;10:2758&#x2013;2769.</Citation><ArticleIdList><ArticleId IdType="pubmed">15970531</ArticleId></ArticleIdList></Reference><Reference><Citation>Albersen M, Fandel TM, Lin G, Wang G, Banie L, Lin CS, et al. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med. 2010;7:3331&#x2013;3340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885341</ArticleId><ArticleId IdType="pubmed">20561166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz PJ. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction. Methods Mol Biol. 2004;279:173&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">15199245</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL. Erectile dysfunction management for the future. J Androl. 2009;30:391&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CS, Xin Z, Dai J, Huang YC, Lue TF. Stem-cell therapy for erectile dysfunction. Expert Opin Biol Ther. 2013;13:1585&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">24090162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajfer J, Magee T, Gonzalez-Cadavid N. Future strategies for treating erectile dysfunction. Rev Urol. 2002;4(Suppl 3):S48&#x2013;S53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1476023</ArticleId><ArticleId IdType="pubmed">16986014</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration, Center for Devices and Radiological Health. FDA update on the safety of silicone gelfilled breast implants. Silver Spring, MD: U.S. Food and Drug Administration; 2011.</Citation></Reference><Reference><Citation>Darouiche RO, Bella AJ, Boone TB, Brock G, Broderick GA, Burnett AL, et al. North American consensus document on infection of penile prostheses. Urology. 2013;82:937&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">23958508</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman IJ, Scott FB, Light JK. Experience with inflatable penile prosthesis. Urology. 1984;23(5 Spec No):86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">6719687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25657584</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1176-6328</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Neuropsychiatric disease and treatment</Title><ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation></Journal><ArticleTitle>Levomilnacipran for the treatment of major depressive disorder: a review.</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>135</EndPage><MedlinePgn>125-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S54710</ELocationID><Abstract><AbstractText>Levomilnacipran (LVM, Fetzima(&#xae;)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine, venlafaxine, and desvenlafaxine, it has greater selectivity for inhibiting norepinephrine reuptake than serotonin reuptake. Our review focuses on the efficacy, safety, and tolerability data for five double-blind, placebo-controlled, short-term studies and two long-term studies. In the short-term studies, LVM was found to be more effective than placebo in reducing depression (Montgomery-&#xc5;sberg Depression Rating Scale) scores as well as improving functional impairment (Sheehan Disability Scale) scores. Long-term studies found LVM to be similarly effective but in the only placebo-controlled long-term study, LVM was not significantly superior to placebo. LVM is fairly well tolerated, with the most common adverse events being nausea, headache, dry mouth, hyperhidrosis, and constipation. Discontinuation rates were mildly increased in those being treated with LVM (9%) versus placebo (3%). Adverse events were not dose-related except for urinary hesitancy and erectile dysfunction. LVM was weight neutral, was not toxic to the liver, and did not cause clinically significant QTc prolongation. Consistent with being a predominant potentiator of norepinephrine, pulse and blood pressure were significantly elevated by LVM but rarely induced tachycardia or hypertension. LVM is a relatively safe alternative antidepressant treatment with minimal drug-drug interactions. It is the only antidepressant that has in its labeling that it is not only effective in improving depression but also effective in improving impaired functioning. Whether this important effect on functioning is unique to LVM must be researched. In addition, whether LVM might be effective in norepinephrine-deficit depression, refractory depression, atypical depression, or seasonal depression is yet to be evaluated. Ultimately, head-to-head studies comparing LVM with other antidepressants will determine the place of LM in antidepressant treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asnis</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, NY, USA ; Anxiety and Depression Clinic, Montefiore Medical Center, Bronx, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Anxiety and Depression Clinic, Montefiore Medical Center, Bronx, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neuropsychiatr Dis Treat</MedlineTA><NlmUniqueID>101240304</NlmUniqueID><ISSNLinking>1176-6328</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antidepressant</Keyword><Keyword MajorTopicYN="N">clinical efficacy</Keyword><Keyword MajorTopicYN="N">functional impairment</Keyword><Keyword MajorTopicYN="N">levomilnacipran</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25657584</ArticleId><ArticleId IdType="pmc">PMC4295915</ArticleId><ArticleId IdType="doi">10.2147/NDT.S54710</ArticleId><ArticleId IdType="pii">ndt-11-125</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association Practice guidelines for the treatment of patients with major depressive disorder (third edition) Am J Psychiatry. 2010;167(Suppl):1&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074942</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16390886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886713</ArticleId><ArticleId IdType="pubmed">19460188</ArticleId></ArticleIdList></Reference><Reference><Citation>Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:242&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">23561229</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656841</ArticleId></ArticleIdList></Reference><Reference><Citation>Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant &#x2013; what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67:1089&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24016209</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair AL, Martel JC, Assi&#xe9; MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499664</ArticleId></ArticleIdList></Reference><Reference><Citation>Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675639</ArticleId></ArticleIdList></Reference><Reference><Citation>Blier P, Saint-Andr&#xe9; E, H&#xe9;bert C, de Montigny C, Lavoie N, Debonnel G. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690005</ArticleId></ArticleIdList></Reference><Reference><Citation>Forest Pharmaceuticals, Inc  Fetzima (levominacipran extended-release capsules). United States Prescribing Information.  [Accessed November 2, 2014].  Revised July 2014. Available from:  http://www.frx.com/pi/fetzima_pi.pdf.</Citation></Reference><Reference><Citation>Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868664</ArticleId><ArticleId IdType="pubmed">24144196</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047313</ArticleId><ArticleId IdType="pubmed">24172209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40&#x2013;120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014;3:10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937636</ArticleId><ArticleId IdType="pubmed">27536449</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Gommoll SA, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 2014;5:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411644</ArticleId><ArticleId IdType="pubmed">24902007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33:761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775192</ArticleId><ArticleId IdType="pubmed">23999912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll C. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40&#x2013;120 mg/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci. 2014;11:10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960779</ArticleId><ArticleId IdType="pubmed">24653937</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy W. ECDEU Assessment Manual for Psychopharmacology Clinical Global Impressions. Rockville, MD, USA: National Institute of Mental Health; 1976. (DHEW Publication No. 76-338).</Citation></Reference><Reference><Citation>Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Exploratory_analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Exploratory Administration in support of new drug applications. J Clin Psychiatry. 2011;72:464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527123</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared to other antidepressants clinically relevant? J Clin Psychopharmacol. 2009;24:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">19357527</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Leon AC, Endicott J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">15526252</ArticleId></ArticleIdList></Reference><Reference><Citation>Spijker J, Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) Acta Psychiatr Scand. 2004;110:208&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">15283741</ArticleId></ArticleIdList></Reference><Reference><Citation>Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131098</ArticleId><ArticleId IdType="pubmed">21750623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambunaris A, Gommoll C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014;29:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047314</ArticleId><ArticleId IdType="pubmed">24667487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2011;26:75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21102344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson JC, Delucchi K, Schneider LSJ. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16:558&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">18591576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964861</ArticleId></ArticleIdList></Reference><Reference><Citation>Young EA, Kornstein SG, Marcus SM. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681489</ArticleId><ArticleId IdType="pubmed">18752809</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakostas GI, Culpepper L, Fayad RS, Musgnung J, Guico-Pabia CJ. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2013;28:312&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23881185</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18823760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thase ME, Greenberg WM, Bose A, Gummoll C, Chen C. Safety and tolerability of levomilnacipran SR in major depressive disorder: analysis of 5 short-term double-blind, placebo-controlled studies; Presented at the 166th Annual American Psychiatric Association Meeting; San Francisco, CA, USA. May 20, 2013.</Citation></Reference><Reference><Citation>Nemeroff CB, Thase ME, EPIC 014 Study Group A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007;41:351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16165158</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyttenaere K, Huygens R, Van Buggenhout R. Tamsulosin as an effective treatment for reboxetine-asociated urinary retention. Int Clin Psychopharmacol. 2001;16:353&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol. 2002;12:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11872327</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Khandelwal A, Jiloha RC. Milnacipran-associated urinary retention: a case report. J Clin Psychopharmacol. 2010;30:641.</Citation><ArticleIdList><ArticleId IdType="pubmed">20841968</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888497</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19142100</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasiak NM, Bostwick JR. A review of the risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014;48:1620&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">25204465</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev A, Bjornsson ES. Drug-induced liver injury: morbidity, mortality, and Hy&#x2019;s law. Gastroenterology. 2014;147:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24880009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520440</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone M, Laughren T, Jones ML. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725270</ArticleId><ArticleId IdType="pubmed">19671933</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014;7:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">24524592</ArticleId></ArticleIdList></Reference><Reference><Citation>Asnis GM, Gommoll CP, Chen C. Treating major depressive disorder with levomilnacipran ER: efficacy and tolerability across the dose range; Presented at the 167th Annual American Psychiatric Association Meeting; New York, NY, USA. May 5, 2014.</Citation></Reference><Reference><Citation>Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">16913164</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(Suppl E1):4&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18494537</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2014;29:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235391</ArticleId><ArticleId IdType="pubmed">24172160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66:96&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964563</ArticleId><ArticleId IdType="pubmed">24672116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, Berglund P, Demler O. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 20038;289:3095&#x2013;3105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12813115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25536880</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism.</ArticleTitle><Pagination><StartPage>824</StartPage><EndPage>826</EndPage><MedlinePgn>824-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12803</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Refractory ischemic priapism (RIP) can be difficult to treat, consuming significant healthcare-related resources. Acute insertion of a malleable penile prosthesis (MPP) has been reported as an effective therapy that treats the priapism and restores sexual function.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We report our 6-year, urban public hospital experience with acute insertion of MPP in patients with RIP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed the records of patients receiving MPPs for RIP from 2007 to 2013. Data analyzed included duration of erection, number of emergency room (ER) visits, hospital admissions, days of hospitalization, and postoperative course. Costs were estimated using standard Medicare reimbursement rates.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Healthcare-related costs of treatment of RIP episodes in men presenting to our institution.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the study period, 14 men underwent MPP placement acutely for refractory priapism. Thirteen presented with RIP, and one had stuttering priapism over a 14-day hospitalization. Etiologies included sickle cell anemia (4/13, 29%), medication-induced (3/14, 21%), and idiopathic (7/14, 50%). Average preoperative duration of RIP was 82 hours with considerable consumption of health-care resources (average US $83,818 estimated cost, 4 ER visits [range 1-27], 2 hospital admissions [range 1-5], 1.5 shunt procedures [range 1-3], 5 irrigation and drainage procedures using phenylephrine injection [range 2-20], and 5 hospital admission days [range 2-14]). All patients were discharged within 24 hours of MPP surgery.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The management of RIP is associated with multiple ER visits, prolonged hospital admissions, and significant resource utilization. MPP insertion is efficacious for the immediate resolution of refractory priapism, with potential cost and resource benefits.</AbstractText><CopyrightInformation>&#xa9; 2014 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tausch</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lee C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Morey</LastName><ForeName>Allen F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Jordan A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Belsante</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Seideman</LastName><ForeName>Casey A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Flemons</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1WS297W6MV</RegistryNumber><NameOfSubstance UI="D010656">Phenylephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 May;193(5):1602-3</RefSource><PMID Version="1">25895787</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 Oct;194(4):1027</RefSource><PMID Version="1">26382791</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010656" MajorTopicYN="N">Phenylephrine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25536880</ArticleId><ArticleId IdType="doi">10.1111/jsm.12803</ArticleId><ArticleId IdType="pii">S1743-6095(15)30975-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25523691</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>193</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Re: Clinical outcomes and patient satisfaction rates among elderly male aged &#x2265; 75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>252</StartPage><EndPage>253</EndPage><MedlinePgn>252-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2014.10.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(14)04645-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Griebling</LastName><ForeName>Tomas L</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>World J Urol. 2014 Feb;32(1):173-7</RefSource><PMID Version="1">23708698</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25523691</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2014.10.026</ArticleId><ArticleId IdType="pii">S0022-5347(14)04645-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25302850</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy.</ArticleTitle><Pagination><StartPage>2903</StartPage><EndPage>2914</EndPage><MedlinePgn>2903-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12705</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients undergoing radical prostatectomy (RP) suffer from erectile dysfunction (ED) refractory to phosphodiesterase 5 inhibitors, which act downstream of cavernous nerve (CN)-mediated release of nitric oxide (NO). Direct delivery of NO to the penis could potentially circumvent this limitation.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study aimed to determine if topically applied NO-releasing nanoparticles (NO-NPs) could elicit erections in a rat model of RP through increased blood flow.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-six Sprague Dawley rats underwent bilateral transection of the CN. One week later, NO-NPs were applied topically to the penile shaft in dimethylsulfoxide (DMSO) gel (10 animals) or coconut oil (6 animals). Control animals were treated with empty NPs. Erectile function was determined through the intracorporal pressure/blood pressure ratio (ICP/BP). The effect of the NO-NPs on blood flow was determined using a hamster dorsal window chamber.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Animals were investigated for spontaneous erections, onset and duration of erectile response, and basal ICP/BP ratio. Microcirculatory blood flow was determined through measurements of arteriolar and venular diameter and red blood cell velocity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight of 10 animals treated with NO-NPs suspended in DMSO gel had significant increases in basal ICP/BP, and 6 out of these 10 animals demonstrated spontaneous erections of approximately 1 minute in duration. Time to onset of spontaneous erections ranged from 5 to 37 minutes, and they occurred for at least 45 minutes. Similar results were observed with NO-NPs applied in coconut oil. No erectile response was observed in control animal models treated with empty NPs. The hamster dorsal window chamber experiment demonstrated that NO-NPs applied as a suspension in coconut oil caused a significant increase in the microcirculatory blood flow, sustained over 90 minutes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Topically applied NO-NPs induced spontaneous erections and increased basal ICP in an animal model of RP. These effects are most likely due to increased microcirculatory blood flow. These characteristics suggest that NO-NPs would be useful in penile rehabilitation of patients following RP.</AbstractText><CopyrightInformation>&#xa9; 2014 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tar</LastName><ForeName>Moses</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Albert Einstein College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrales</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Navati</LastName><ForeName>Mahantesh</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Brandon</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nacharaju</LastName><ForeName>Parimala</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Kelvin P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 HL110900</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK087872</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 DK087872</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK087872</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cavernous Nerve</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Microcirculation</Keyword><Keyword MajorTopicYN="N">Nanoparticle</Keyword><Keyword MajorTopicYN="N">Nitric Oxide</Keyword><Keyword MajorTopicYN="N">Radical Prostatectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25302850</ArticleId><ArticleId IdType="mid">NIHMS625188</ArticleId><ArticleId IdType="pmc">PMC4257846</ArticleId><ArticleId IdType="doi">10.1111/jsm.12705</ArticleId><ArticleId IdType="pii">S1743-6095(15)30641-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McCullough AR. Sexual dysfunction after radical prostatectomy. Rev Urol. 2005;7(Suppl 2):S3&#x2013;S10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1477599</ArticleId><ArticleId IdType="pubmed">16985895</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemozaffar M, et al. Prediction of erectile function following treatment for prostate cancer. Jama. 2011;306(11):1205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831607</ArticleId><ArticleId IdType="pubmed">21934053</ArticleId></ArticleIdList></Reference><Reference><Citation>Canguven O, Burnett A. Cavernous nerve injury using rodent animal models. J Sex Med. 2008;5(8):1776&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18774987</ArticleId></ArticleIdList></Reference><Reference><Citation>User HM, et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003;169(3):1175&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12576876</ArticleId></ArticleIdList></Reference><Reference><Citation>Leungwattanakij S, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24(2):239&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634311</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein LT, et al. Apoptosis in the rat penis after penile denervation. J Urol. 1997;158(2):626&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009;6(2):415&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756287</ArticleId><ArticleId IdType="pubmed">19138364</ArticleId></ArticleIdList></Reference><Reference><Citation>Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009;6(8):415&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19657376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacci M, et al. Changes in sex hormone levels after radical prostatectomy: Results of a longitudinal cohort study. Oncol Lett. 2013;6(2):529&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789060</ArticleId><ArticleId IdType="pubmed">24137361</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med. 2009;6(5):1270&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19210708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fode M, et al. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int. 2013;112(7):998&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">23826962</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158(4):1408&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyland K, Vasdev N, Adshead J. The use of vacuum erection devices in erectile dysfunction after radical prostatectomy. Rev Urol. 2013;15(2):67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784970</ArticleId><ArticleId IdType="pubmed">24082845</ArticleId></ArticleIdList></Reference><Reference><Citation>Calenda G, et al. Reversal of Diabetic Vasculopathy in a Rat Model of Type 1 Diabetes by Opiorphin-Related Peptides. Am J Physiol Heart Circ Physiol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197356</ArticleId><ArticleId IdType="pubmed">21784987</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan DM, et al. The rat as a model for the study of penile erection. J Urol. 1989;141(3):656&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">2918611</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol. 2004;171(1):495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini MG, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68(2):429&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sezen SF, et al. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med. 2001;7(10):1073&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuzuarregui JL, et al. Parameters affecting the results in a program of artificial insemination with donor sperm. A 12-year retrospective review of more than 1800 cycles. J Assist Reprod Genet. 2004;21(4):109&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3455611</ArticleId><ArticleId IdType="pubmed">15270209</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, et al. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med. 2010;7(1 Pt 1):224&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864537</ArticleId><ArticleId IdType="pubmed">19765204</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantuoni A, Bertuglia S, Intaglietta M. Quantitation of rhythmic diameter changes in arterial microcirculation. Am J Physiol. 1984;246:H508&#x2013;H517.</Citation><ArticleIdList><ArticleId IdType="pubmed">6720909</ArticleId></ArticleIdList></Reference><Reference><Citation>Endrich B, et al. Technical report: A new chamber technique for microvascular studies in unanaesthetized hamsters. Res Exp Med. 1980;177:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">7003665</ArticleId></ArticleIdList></Reference><Reference><Citation>Intaglietta M, Tompkins WR. Microvascular measurements by video image shearing and splitting. Microvasc Res. 1973;5(3):309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">4709728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipowsky HH, Zweifach BW. Application of the &#x201c;two-slit&#x201d; photometric technique to the measurement of microvascular volumetric flow rates. Microvasc Res. 1978;15:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">634160</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman AJ, et al. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide-Biology and Chemistry. 2008;19(1):12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457680</ArticleId></ArticleIdList></Reference><Reference><Citation>Menger MD, Laschke MW, Vollmar B. Viewing the microcirculation through the window: some twenty years experience with the hamster dorsal skinfold chamber. Eur Surg Res. 2002;34(1&#x2013;2):83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11867907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernabe J, et al. Intracavernous pressure during erection in rats: an integrative approach based on telemetric recording. Am J Physiol. 1999;276(2 Pt 2):R441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9950923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignozzi L, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3(3):419&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16681467</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol. 2003;170(2 Pt 2):S6&#x2013;13. discussion S13&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12853766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt KJ, et al. Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection. Proc Natl Acad Sci U S A. 2012;109(41):16624&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478647</ArticleId><ArticleId IdType="pubmed">23012472</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt KJ, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci U S A. 2002;99(6):4061&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122648</ArticleId><ArticleId IdType="pubmed">11904450</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, et al. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl. 2002;23(1):92&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11780929</ArticleId></ArticleIdList></Reference><Reference><Citation>Feelisch M, et al. Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems. J Biol Chem. 2008;283(49):33927&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590701</ArticleId><ArticleId IdType="pubmed">18835812</ArticleId></ArticleIdList></Reference><Reference><Citation>Melman A, et al. Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat. Gene Ther. 2008;15(5):364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18200069</ArticleId></ArticleIdList></Reference><Reference><Citation>Melman A, Davies KP. Gene therapy in the management of erectile dysfunction (ED): past, present, and future. ScientificWorldJournal. 2009;9:846&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823098</ArticleId><ArticleId IdType="pubmed">20333343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaffari A, et al. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide. 2006;14(1):21&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16188471</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller R, Finnen MJ. The effects of topical treatment with acidified nitrite on wound healing in normal and diabetic mice. Nitric Oxide. 2006;15(4):395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16731016</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda KM, et al. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem. 2005;48(26):8220&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16366603</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, Friedman AJ, Friedman JM. Nitric oxide releasing nanoparticle synthesis and characterization. Methods Mol Biol. 2011;704:187&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21161638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrales P, et al. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radical Biology and Medicine. 2010;49(4):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903640</ArticleId><ArticleId IdType="pubmed">20460149</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman A, Friedman J. New biomaterials for the sustained release of nitric oxide: past, present and future. Expert Opinion on Drug Delivery. 2009;6(10):1113&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">19663720</ArticleId></ArticleIdList></Reference><Reference><Citation>Schopfer FJ, et al. Fatty acid transduction of nitric oxide signaling. Nitrolinoleic acid is a hydrophobically stabilized nitric oxide donor. J Biol Chem. 2005;280(19):19289&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764811</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker PR, et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem. 2005;280(51):42464&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266087</ArticleId><ArticleId IdType="pubmed">16227625</ArticleId></ArticleIdList></Reference><Reference><Citation>Blecher K, et al. Nitric oxide-releasing nanoparticles accelerate wound healing in NOD-SCID mice. Nanomedicine. 2012;8(8):1364&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406184</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez DA, Nosanchuk J, Friedman A. The purview of nitric oxide nanoparticle therapy in infection and wound healing. Nanomedicine (Lond) 2012;7(7):933&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22642306</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, et al. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. Am J Pathol. 2012;180(4):1465&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25260446</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Pseudo-malfunction of the Coloplast Titan Inflatable Penile Prosthesis One-Touch Release Pump.</ArticleTitle><Pagination><StartPage>857</StartPage><EndPage>859</EndPage><MedlinePgn>857-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2014.06.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(14)00595-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define and describe a type of pseudo-malfunction of the Coloplast Titan Inflatable Penile Prosthesis (IPP) One-Touch Release (OTR) pump (Coloplast Corp, Minneapolis, MN).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We retrospectively reviewed a consecutive series of 550 patients with refractory organic erectile dysfunction who were implanted with a Coloplast Titan IPP with the OTR pump during a period of approximately 4 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients were implanted using standard techniques through an infrapubic or penoscrotal approach. Twenty-nine patients (5.3%) complained that their IPP would not inflate and that the pump bulb felt "hard." Examination revealed that their IPP was working normally; however, the inflate/deflate valve disc had become stuck in the deflate position. Very firm pressure had to be applied to the pump bulb to move the valve disc into the inflate position. Once this was accomplished, the device inflated and deflated normally. Another 14 patients (2.5%) reported this phenomenon to us but were able to apply enough pressure on the pump bulb to rectify it.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The inflate/deflate valve disc in the Coloplast Titan OTR pump can occasionally become stuck in the deflate position (7.8% of patients in our experience). Patients may be unable to inflate the device and return for evaluation. In all cases we have encountered, firm pressure on the pump bulb caused the valve to shift into the inflate position, and the device worked properly thereafter. Patients and implanting urologists should be aware of this issue and of the way in which it can be rectified.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garber</LastName><ForeName>Bruce B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Urology, Hahnemann University Hospital, Drexel University College of Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khurgin</LastName><ForeName>Jacob L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Urology, Einstein Medical Center, Philadelphia, PA. Electronic address: jacobkhurgin@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stember</LastName><ForeName>Doron S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Urology, Mount Sinai Beth Israel, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perito</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Urology, Coral Gables Hospital, Coral Gables, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="Y">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25260446</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2014.06.012</ArticleId><ArticleId IdType="pii">S0090-4295(14)00595-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25193347</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-0829</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Current diabetes reports</Title><ISOAbbreviation>Curr Diab Rep</ISOAbbreviation></Journal><ArticleTitle>How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment.</ArticleTitle><Pagination><StartPage>545</StartPage><MedlinePgn>545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11892-014-0545-6</ELocationID><Abstract><AbstractText>Erectile dysfunction (ED) is highly prevalent affecting at least 50 % of men with diabetes mellitus (DM). DM may cause ED through a number of pathophysiological pathways. These include neuropathy, endothelial dysfunction, cavernosal smooth muscle structural/functional changes, and hormonal changes. Lifestyle changes, diabetes control, and treatment of hypogonadism are important as the first step in ED management since there is no curative treatment for ED. Phosphodiesterase type 5 inhibitors (PDE5i) are the first-line treatment option. Intracavernous administration of vasoactive drugs is commonly used as a second-line medical treatment when PDE5i have failed. Alprostadil is the most widely used drug in this second-line setting. The combination of papaverine, phentolamine, and alprostadil represents the most efficacious intracavernous pharmacologic treatment option that may save non-responders to alprostadil. Penile prosthesis implantation can be considered in treatment refractory cases, with excellent functional and safety results in the properly informed patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatzimouratidis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatzichristou</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Diab Rep</MedlineTA><NlmUniqueID>101093791</NlmUniqueID><ISSNLinking>1534-4827</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016540" MajorTopicYN="N">Smoking Cessation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25193347</ArticleId><ArticleId IdType="doi">10.1007/s11892-014-0545-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Urol. 1996 Mar;155(3):802-15</Citation><ArticleIdList><ArticleId IdType="pubmed">8583582</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2001 Feb;44(2):129-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11270668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Aug;7(8):2842-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20626604</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1998 Jun;81(6):889-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9666777</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Jun 23;291(24):2978-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15213209</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2005 Jan;2(1):96-103</Citation><ArticleIdList><ArticleId IdType="pubmed">16422911</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2006 Jan 23;166(2):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16432091</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010 Mar 09;340:c810</Citation><ArticleIdList><ArticleId IdType="pubmed">20215365</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2007 Mar-Apr;19(2):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">16775612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Jan;9(1):259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22008059</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2001 Oct;44(10):1296-301</Citation><ArticleIdList><ArticleId IdType="pubmed">11692178</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 1991 Dec;8(10):964-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1838050</ArticleId></ArticleIdList></Reference><Reference><Citation>J Androl. 2003 Nov-Dec;24(6 Suppl):S17-37</Citation><ArticleIdList><ArticleId IdType="pubmed">14581492</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2008 Aug 5;102(5):525-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18485038</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2009 Oct;63(10):1435-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19769700</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 Jul;50(1):134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16527391</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2006 Mar;8(2):219-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16491275</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 2008 Feb;25(2):138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18290855</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2001 Mar;87(4):394-401</Citation><ArticleIdList><ArticleId IdType="pubmed">11251538</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2006 Mar-Apr;18(2):190-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16136189</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2004 Nov;47(11):1914-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15599697</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Feb 3;281(5):421-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9952201</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2005 Nov;32(4):503-9, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">16291041</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2003 Sep;52(9):2353-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12941776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2012 Aug;87(8):766-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22862865</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1988 Mar;254(3 Pt 2):H459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">2894778</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2010 May;57(5):804-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20189712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2013 Mar;10(3):738-46</Citation><ArticleIdList><ArticleId IdType="pubmed">23253086</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2006 May;97(5):1047-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16643490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2011 Feb;185(2):614-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21168870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Oct;170(4 Pt 1):1437-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14501785</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2005;65(6):773-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15819590</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15184671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Diabetes Complications. 2004 Jul-Aug;18(4):205-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15207837</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R950-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15205187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Jul;170(1):291-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12796708</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1999 Dec;128(8):1804-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10588937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1990 Nov;144(5):1154-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2231889</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Androl. 2006 Nov;8(6):675-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16892168</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2004 Jul;1(1):6-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16422979</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Jul;4(4 Pt 1):1046-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17627749</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2007 Apr;177(4):1438-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17382749</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2001 Dec;13(6):317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11918246</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2005 Dec 26;96(12B):13M-18M</Citation><ArticleIdList><ArticleId IdType="pubmed">16387560</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 1990 May;33(5):306-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2198188</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12117739</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2011 Jul;60(1):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21316145</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2013 Jan;25(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22914567</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2005 Nov;32(4):397-402, v</Citation><ArticleIdList><ArticleId IdType="pubmed">16291032</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2002 Aug;25(8):1458-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12145250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Urol. 2013 Apr;5(2):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23554844</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 Oct;166(4):1368-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11547076</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2007 Apr;30(4):911-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17392552</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2005;65(12):1621-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16060698</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 1998 Nov;21(11):1973-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9802753</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jul;7(7):2338-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20487239</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2008 Sep-Oct;20(5):437-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18385678</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2012 Jul;164(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22795278</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2005 Jan-Feb;17(1):39-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15215881</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Nutr. 2006 Dec;9(8A):1118-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17378950</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 Sep;3(5):883-891</Citation><ArticleIdList><ArticleId IdType="pubmed">16942532</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2008 Feb;9(2):257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18201148</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 Jan 2;336(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8970933</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2006 Aug;68(2):386-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16904458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2012 Sep;87(9):843-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22857780</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2005 Jul 15;96(2):313-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16018863</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2003 Feb;26(2):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12547849</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Feb;163(2):460-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10647654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 May;165(5):1776-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11342975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Nov;158(5):1966-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9334651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Jul;8(7):2048-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21554549</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2006 Nov;27(22):2632-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16854949</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 1999 Jul;84(1):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10444124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2002 Dec;22(24):8467-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12446767</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 1996 Aug;13(8):700-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8862943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1992 Feb;147(2):386-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1732600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2013 Jul;190(1):15-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23602610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1992 Nov;148(5):1587-91</Citation><ArticleIdList><ArticleId IdType="pubmed">1433573</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2005 May;28(5):1201-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15855589</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2003 Mar;26(3):777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12610037</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1997 Dec;50(6):1016-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9426743</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2007 Nov;34(4):535-47, vi</Citation><ArticleIdList><ArticleId IdType="pubmed">17983893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Mar;163(3):788-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10687978</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Apr;169(4):1429-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12629377</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Feb 10;281(6):537-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10022110</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Aug 23;277(34):30614-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12060659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Res. 2001 Sep;23(6):651-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11547937</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 Mar;49(3):557-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16387413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25056711</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1601-0825</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Oral diseases</Title><ISOAbbreviation>Oral Dis</ISOAbbreviation></Journal><ArticleTitle>Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.</ArticleTitle><Pagination><StartPage>e25</StartPage><EndPage>e50</EndPage><MedlinePgn>e25-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/odi.12275</ELocationID><Abstract><AbstractText>By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. As these intracellular second messengers control many cellular homeostatic processes, dysregulation of their signals and signaling pathways initiate or modulate pathophysiological pathways related to various disease states, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication, chronic obstructive pulmonary disease, and psoriasis. Alterations in expression of PDEs and PDE-gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. PDEs also play important role in formation and function of multimolecular signaling/regulatory complexes, called signalosomes. At specific intracellular locations, individual PDEs, together with pathway-specific signaling molecules, regulators, and effectors, are incorporated into specific signalosomes, where they facilitate and regulate compartmentalization of cyclic nucleotide signaling pathways and specific cellular functions. Currently, only a limited number of PDE inhibitors (PDE3, PDE4, PDE5 inhibitors) are used in clinical practice. Future paths to novel drug discovery include the crystal structure-based design approach, which has resulted in generation of more effective family-selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.</AbstractText><CopyrightInformation>&#xa9; 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Degerman</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Maurice</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Manganiello</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>18390537</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>20378368</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>80242965</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>Z01 HL002540-14</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>16390585</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>23659943</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Oral Dis</MedlineTA><NlmUniqueID>9508565</NlmUniqueID><ISSNLinking>1354-523X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.17</RegistryNumber><NameOfSubstance UI="D015105">3',5'-Cyclic-AMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D015105" MajorTopicYN="N">3',5'-Cyclic-AMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A-kinase anchoring protein (AKAP)</Keyword><Keyword MajorTopicYN="N">cAMP</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">oral and systemic diseases</Keyword><Keyword MajorTopicYN="N">phosphodiesterase (PDE)</Keyword><Keyword MajorTopicYN="N">protein kinase A (PKA)</Keyword><Keyword MajorTopicYN="N">signalosome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25056711</ArticleId><ArticleId IdType="mid">NIHMS617465</ArticleId><ArticleId IdType="pmc">PMC4275405</ArticleId><ArticleId IdType="doi">10.1111/odi.12275</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adamo CM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2010;107(44):19079&#x2013;19083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973894</ArticleId><ArticleId IdType="pubmed">20956307</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghaloo TL, et al. Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMP-protein kinase A signaling. J Periodontol. 2006;77(1):21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16579699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, Degerman E, Manganiello VC. Cyclic nucleotide phosphodiesterase 3 signaling complexes. Horm Metab Res. 2012;44(10):776&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, et al. Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. Biochem J. 2009;424(3):399&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953723</ArticleId><ArticleId IdType="pubmed">19747167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, et al. Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J. 2007;404(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868803</ArticleId><ArticleId IdType="pubmed">17324123</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MQ, Stratakis CA. How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol. 2011;336(1-2):162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049838</ArticleId><ArticleId IdType="pubmed">21111774</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361(19):1864&#x2013;1871.</Citation><ArticleIdList><ArticleId IdType="pubmed">19890129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariga M, et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol. 2004;173(12):7531&#x2013;7538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585880</ArticleId></ArticleIdList></Reference><Reference><Citation>Asirvatham AL, et al. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol. 2004;173(8):4806&#x2013;4814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470020</ArticleId></ArticleIdList></Reference><Reference><Citation>Aye TT, et al. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol. 2012;52(2):511&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">21712045</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouni F, Abu SK. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894&#x2013;2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">21771280</ArticleId></ArticleIdList></Reference><Reference><Citation>Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157(6):892&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737648</ArticleId><ArticleId IdType="pubmed">19508401</ArticleId></ArticleIdList></Reference><Reference><Citation>Barad M, et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A. 1998;95(25):15020&#x2013;15025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24568</ArticleId><ArticleId IdType="pubmed">9844008</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">23360759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauman AL, et al. The mAKAP signalosome and cardiac myocyte hypertrophy. IUBMB Life. 2007;59(3):163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487687</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard MB, et al. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem. 2000;275(14):10349&#x2013;10358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744723</ArticleId></ArticleIdList></Reference><Reference><Citation>Beca S, et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res. 2013;112(2):289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579621</ArticleId><ArticleId IdType="pubmed">23168336</ArticleId></ArticleIdList></Reference><Reference><Citation>Beca S, et al. Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current. Circ Res. 2011;109(9):1024&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138878</ArticleId><ArticleId IdType="pubmed">21903937</ArticleId></ArticleIdList></Reference><Reference><Citation>Begum N, Hockman S, Manganiello VC. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCS) via inhibition of mitogen activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J Biol Chem. 2011;286:26238&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138244</ArticleId><ArticleId IdType="pubmed">21632535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">16968949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessay EP, et al. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front Biosci. 2007;12:1899&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127429</ArticleId></ArticleIdList></Reference><Reference><Citation>Biel M, Michalakis S. Cyclic nucleotide-gated channels. Handb Exp Pharmacol. 2009;(191):111&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">19089328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielekova B, et al. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis. Mult Scler. 2009;15(10):1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085182</ArticleId><ArticleId IdType="pubmed">19776093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11&#x2013;S14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15224129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorgo E, Moltu K, Tasken K. Phosphodiesterases as targets for modulating T-cell responses. Handb Exp Pharmacol. 2011;(204):345&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorgo E, et al. Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol. 2010;30(7):1660&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838077</ArticleId><ArticleId IdType="pubmed">20086095</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokland A, Menniti FS, Prickaerts J. PDE inhibition and cognition enhancement. Expert Opin Ther Pat. 2012;22(4):349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">22475506</ArticleId></ArticleIdList></Reference><Reference><Citation>Boess FG, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47(7):1081&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">15555642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger GB, et al. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J. 2006;398(1):23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525009</ArticleId><ArticleId IdType="pubmed">16689683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger GB, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278(35):33351&#x2013;33363.</Citation><ArticleIdList><ArticleId IdType="pubmed">12810716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollen E, Prickaerts J. Phosphodiesterases in neurodegenerative disorders. IUBMB Life. 2012;64(12):965&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">23129425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006;31(12):680&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084085</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748652</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick KE, et al. Guanosine 3',5'-cyclic monophosphate (cGMP)/cGMP-dependent protein kinase induce interleukin-6 transcription in osteoblasts. Mol Endocrinol. 2007;21(5):1148&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341596</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KM, et al. Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci U S A. 2013;110(16):E1533&#x2013;E1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631629</ArticleId><ArticleId IdType="pubmed">23509299</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgin AB, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010;28(1):63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">20037581</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns ME, Arshavsky VY. Beyond counting photons: trials and trends in vertebrate visual transduction. Neuron. 2005;48(3):387&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269358</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, et al. Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31(3):616&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114343</ArticleId><ArticleId IdType="pubmed">21148428</ArticleId></ArticleIdList></Reference><Reference><Citation>Calzetta L, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1496&#x2013;1504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853988</ArticleId><ArticleId IdType="pubmed">20375217</ArticleId></ArticleIdList></Reference><Reference><Citation>Card GL, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol. 2005;23(2):201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685167</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, et al. Tadalafil -a therapeutic option in the management of BPH-LUTS. Int J Clin Pract. 2014;68(1):94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">24341303</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S, Yan C. PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol. 2011;11(6):720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225597</ArticleId><ArticleId IdType="pubmed">21962439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary LR, Avioli LV. Identification and activation of mitogen-activated protein (MAP) kinase in normal human osteoblastic and bone marrow stromal cells: attenuation of MAP kinase activation by cAMP, parathyroid hormone and forskolin. Mol Cell Biochem. 1998;178(1-2):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellaiah MA, et al. Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem. 2003;278(31):29086&#x2013;29097.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellaiah MA, et al. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem. 2000;275(16):11993&#x2013;12002.</Citation><ArticleIdList><ArticleId IdType="pubmed">10766830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RW, et al. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci Lett. 2007;418(2):165&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">17398001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi YW, et al. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag. 2008;4(6):1197&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663440</ArticleId><ArticleId IdType="pubmed">19337533</ArticleId></ArticleIdList></Reference><Reference><Citation>Chini CC, et al. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem. 1997;272(15):9854&#x2013;9859.</Citation><ArticleIdList><ArticleId IdType="pubmed">9092521</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YH, et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest. 2006;116(12):3240&#x2013;3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1678809</ArticleId><ArticleId IdType="pubmed">17143332</ArticleId></ArticleIdList></Reference><Reference><Citation>Claffey MM, et al. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J Med Chem. 2012;55(21):9055&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pubmed">23025719</ArticleId></ArticleIdList></Reference><Reference><Citation>Clapcote SJ, et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron. 2007;54(3):387&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481393</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DM, et al. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cell Signal. 2008;20(12):2356&#x2013;2369.</Citation><ArticleIdList><ArticleId IdType="pubmed">18845247</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376027</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti M, Mika D, Richter W. Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. J Gen Physiol. 2014;143(1):29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874571</ArticleId><ArticleId IdType="pubmed">24378905</ArticleId></ArticleIdList></Reference><Reference><Citation>Creighton J, et al. Spectrin-anchored phosphodiesterase 4D4 restricts cAMP from disrupting microtubules and inducing endothelial cell gap formation. J Cell Sci. 2008;121(Pt 1):110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cygnar KD, Zhao H. Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons. Nat Neurosci. 2009;12(4):454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712288</ArticleId><ArticleId IdType="pubmed">19305400</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009;21(8):1245&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723940</ArticleId><ArticleId IdType="pubmed">19249350</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RJ, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). Invest Ophthalmol Vis Sci. 2008;49(11):5067&#x2013;5076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715364</ArticleId><ArticleId IdType="pubmed">18658088</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rooij J, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396(6710):474&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">9853756</ArticleId></ArticleIdList></Reference><Reference><Citation>Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997;272(11):6823&#x2013;6826.</Citation><ArticleIdList><ArticleId IdType="pubmed">9102399</ArticleId></ArticleIdList></Reference><Reference><Citation>Degerman E, et al. Role for PDE3B in regulation of lipolysis and insulin secretion. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. 3rd edn Lippincott Raven; Philadelphia: 2004. pp. 373&#x2013;383.</Citation></Reference><Reference><Citation>Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004;64(11):3966&#x2013;3973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173009</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMarch Z, et al. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis. 2008;30(3):375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">18424161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanasekaran DN, et al. Scaffold proteins of MAP-kinase modules. Oncogene. 2007;26(22):3185&#x2013;3202.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496915</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge KL, et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. Embo J. 2001;20:1921&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125429</ArticleId><ArticleId IdType="pubmed">11296225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge-Kafka KL, et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078&#x2013;11086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856983</ArticleId><ArticleId IdType="pubmed">20106966</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge-Kafka KL, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 2005;437(7058):574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636584</ArticleId><ArticleId IdType="pubmed">16177794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, et al. Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells. Springerplus. 2013;2:680&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967736</ArticleId><ArticleId IdType="pubmed">24683528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dov A, et al. Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose. Endocrinology. 2008;149(2):741&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991719</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong LT, Rodan GA. Regulation of osteoclast formation and function. Rev Endocr Metab Disord. 2001;2(1):95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704983</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbatarny HS, Maurice DH. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab. 2005;289(4):E695&#x2013;E702.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886225</ArticleId></ArticleIdList></Reference><Reference><Citation>Elks ML, Manganiello VC. Antilipolytic action of insulin: role of cAMP phosphodiesterase activation. Endocrinology. 1985;116(5):2119&#x2013;2121.</Citation><ArticleIdList><ArticleId IdType="pubmed">2985373</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein P. Bone and the cAMP signaling pathway: Emerging therapeutics. Topic in Bone Biology. In: Bronner F, Farach-Carson MC, Roach T, editors. Bone Metabolic Functions and Modulators. Springer-Verlag; London: 2012. pp. 271&#x2013;287.</Citation></Reference><Reference><Citation>Fabbri LM, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716961</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan GC, et al. Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1. Circ Res. 2006;99(11):1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatemi SH, et al. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res. 2008;101(1-3):36&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394866</ArticleId></ArticleIdList></Reference><Reference><Citation>Faucz FR, et al. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab. 2011;96(1):E135&#x2013;E140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038491</ArticleId><ArticleId IdType="pubmed">20881257</ArticleId></ArticleIdList></Reference><Reference><Citation>Favot L, et al. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 2003;90(2):334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888882</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzGerald O. Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis. Nat Rev Rheumatol. 2014 May 20; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">24846499</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox D, Burgin AB, Gurney ME. Structural basis for the design of selective phosphodiesterase 4B inhibitors. Cell Signal. 2014;26(3):657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057648</ArticleId><ArticleId IdType="pubmed">24361374</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciosi LG, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429275</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, et al. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem. 2002;277(49):47581&#x2013;47587.</Citation><ArticleIdList><ArticleId IdType="pubmed">12359732</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011;91(2):651&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527734</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964902</ArticleId><ArticleId IdType="pubmed">20716671</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, et al. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem. 1994;269(36):22477&#x2013;22480.</Citation><ArticleIdList><ArticleId IdType="pubmed">8077192</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, Corbin JD. PDE5 inhibitors: targeting erectile dysfunction in diabetics. Curr Opin Pharmacol. 2011;11(6):683&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">21924956</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacci M, et al. Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging. 2014;31(6):425&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">24811735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal A, et al. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nat Genet. 1994;7(1):64&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">8075643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghigo A, et al. Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation. 2012;126(17):2073&#x2013;2083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913165</ArticleId><ArticleId IdType="pubmed">23008439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097805</ArticleId><ArticleId IdType="pubmed">16883306</ArticleId></ArticleIdList></Reference><Reference><Citation>Giampa C, et al. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One. 2010;5(10):e13417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955524</ArticleId><ArticleId IdType="pubmed">20976216</ArticleId></ArticleIdList></Reference><Reference><Citation>Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16C:89&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">24810285</ArticleId></ArticleIdList></Reference><Reference><Citation>Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol. 2011;204:415&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695651</ArticleId></ArticleIdList></Reference><Reference><Citation>Giembycz M, Newton R. How PDE4 inhibitors work in patients with COPD of the severe, bronchitic, frequent exacerbator phenotype. Clin Chest Med. 2014;35:203&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">24507847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gretarsdottir S, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35(2):131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross-Langenhoff M, et al. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem. 2006;281(5):2841&#x2013;2846.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330539</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirguis E, et al. A Role for Murine Phosphodiesterase 3B in Acquisition of Brown Fat Characteristics by White Adipose Tissue. Endocrinology. 2013;154(9):3152&#x2013;3167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749478</ArticleId><ArticleId IdType="pubmed">23766131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol. 2011;204:167&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara H, et al. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol. 1996;270(5 Pt 1):C1311&#x2013;C1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">8967430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambleton R, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem. 2005;280(47):39168&#x2013;39174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen G, et al. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A. 2000;97(12):6751&#x2013;6756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18727</ArticleId><ArticleId IdType="pubmed">10841571</ArticleId></ArticleIdList></Reference><Reference><Citation>Harndahl L, et al. Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem. 2002;277(40):37446&#x2013;37455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Sharma RK, Soderling TR. Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1989;264(18):10884&#x2013;10887.</Citation><ArticleIdList><ArticleId IdType="pubmed">2543685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem. 1980;255(11):5113&#x2013;5119.</Citation><ArticleIdList><ArticleId IdType="pubmed">6154700</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikaus CC, Pandit J, Klevit RE. Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. Structure. 2009;17(12):1551&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801740</ArticleId><ArticleId IdType="pubmed">20004158</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikaus CC, et al. Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem. 2008;283(33):22749&#x2013;22759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504876</ArticleId><ArticleId IdType="pubmed">18534985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiramoto K, et al. Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells. Cell Signal. 2014:S0898&#x2013;S6568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174556</ArticleId><ArticleId IdType="pubmed">24705027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho GD, et al. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett. 2012;22(7):2585&#x2013;2589.</Citation><ArticleIdList><ArticleId IdType="pubmed">22377514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodsman AB, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15769903</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, et al. Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline. J Bone Miner Metab. 2004;22(4):329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">15221490</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, et al. Effect of phosphodiesterase inhibitor-4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2. Bone. 2002;30(4):589&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">11934650</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res. 2009;69(13):5301&#x2013;5306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734464</ArticleId><ArticleId IdType="pubmed">19549888</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med. 2008;358(7):750&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272904</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35(2):91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">19864144</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res. 2007;100(7):950&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431197</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257373</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SH, et al. Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Nat Genet. 1995;11(4):468&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">7493036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter RW, Mackintosh C, Hers I. Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem. 2009;284(18):12339&#x2013;12348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673302</ArticleId><ArticleId IdType="pubmed">19261611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutson PH, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-py ran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology. 2011;61(4):665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">21619887</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacques P, Van den Bosch F. Emerging therapies for rheumatoid arthritis. Expert Opin Emerg Drugs. 2013;18(2):231&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">23725568</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon KI, et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A. 2010;107(21):9795&#x2013;9800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906898</ArticleId><ArticleId IdType="pubmed">20448200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, YRichter W, Conti M. Insights into physiological functions of PDE4 from KO mice. PDEs in Health and Disease. PDEs in Health and Disease Eds J A Beavo, S H Francis, and M D Houslay. 2007:323&#x2013;346.</Citation></Reference><Reference><Citation>Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99(11):7628&#x2013;7633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124305</ArticleId><ArticleId IdType="pubmed">12032334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci U S A. 1996;93(1):295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40225</ArticleId><ArticleId IdType="pubmed">8552625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambayashi J, Liu Y. Bench to Bedside: Multiple actions of PDE3 inhibitor cilostazol. In: Beavo J, Francis S, Houslay M, editors. Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press; Boca Raton, FL: 2007. pp. 627&#x2013;648.</Citation></Reference><Reference><Citation>Karami-Tehrani F, et al. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">22960860</ArticleId></ArticleIdList></Reference><Reference><Citation>Katakami N, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010;121(23):2584&#x2013;2591.</Citation><ArticleIdList><ArticleId IdType="pubmed">20516379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke H, Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem. 2007;7(4):391&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">17305581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehler J, Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des. 2011;17(2):137&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">21355834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly MP, Brandon NJ. Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals. Prog Brain Res. 2009;179:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20302819</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des. 2010;16(9):1114&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">20030615</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165(5):1288&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372715</ArticleId><ArticleId IdType="pubmed">22014080</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis TM, Wells JN, Hardman JG. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta. 1980;613(1):116&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">6246952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerfant BG, et al. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101(4):400&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">17615371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita T, et al. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone. 2000;27(6):811&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kita T, et al. Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma. Allergol Int. 2009;58(2):267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritzer MD, et al. AKAPs: The architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol. 2012;52(2):351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168680</ArticleId><ArticleId IdType="pubmed">21600214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukreja RC, et al. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011;16(4):e30&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206106</ArticleId><ArticleId IdType="pubmed">22131856</ArticleId></ArticleIdList></Reference><Reference><Citation>Labuda M, et al. Phosphodiesterase type 4D gene polymorphism: association with the response to short-acting bronchodilators in paediatric asthma patients. Mediators Inflamm. 2011;2011:301695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163044</ArticleId><ArticleId IdType="pubmed">21876611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Exome sequencing identifies PDE4D mutations in acrodysostosis. Am J Hum Genet. 2012;90(4):746&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322224</ArticleId><ArticleId IdType="pubmed">22464252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, et al. Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem. 2007;282(14):10414&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pubmed">17244609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LC, Maurice DH, Baillie GS. Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Med Chem. 2013a;5(4):451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">23495691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WH, et al. Cilostazol for Primary Prevention of Stroke in Peripheral Artery Disease: A Population-based Longitudinal Study in Taiwan. Thromb Res. 2013b;132(2):190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">23433530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefievre L, de Lamirande E, Gagnon C. Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa. Biol Reprod. 2002;67(2):423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnart SE, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123(1):25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901878</ArticleId><ArticleId IdType="pubmed">16213210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J. 2006;393(Pt 1):21&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383661</ArticleId><ArticleId IdType="pubmed">16336197</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy J, et al. Phosphodiesterase 4B in the cardiac L-type Ca(2) channel complex regulates Ca(2) current and protects against ventricular arrhythmias in mice. J Clin Invest. 2011;121(7):2651&#x2013;2661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223827</ArticleId><ArticleId IdType="pubmed">21670503</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I, et al. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11(6):689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727450</ArticleId><ArticleId IdType="pubmed">22047791</ArticleId></ArticleIdList></Reference><Reference><Citation>Libe R, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res. 2008;14(12):4016&#x2013;4024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134879</ArticleId><ArticleId IdType="pubmed">18559625</ArticleId></ArticleIdList></Reference><Reference><Citation>Libe R, et al. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 2011;96(1):E208&#x2013;E214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038483</ArticleId><ArticleId IdType="pubmed">21047926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DC, et al. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A. 2013;110(15):6109&#x2013;6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625360</ArticleId><ArticleId IdType="pubmed">23536305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipina TV, et al. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice. Neuropharmacology. 2012;62(3):1252&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376063</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci U S A. 2008;105(36):13309&#x2013;13314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533186</ArticleId><ArticleId IdType="pubmed">18757755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Shakur Y, Kambayashi J. Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol. 2011;(204):211&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugnier C. PDE inhibitors: a new approach to treat metabolic syndrome? Curr Opin Pharmacol. 2011;11(6):698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">22018840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugnier C, et al. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol. 1986;35(10):1743&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">2423089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112(5):352&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">2407167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lygren B, et al. AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8(11):1061&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247390</ArticleId><ArticleId IdType="pubmed">17901878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch MJ, et al. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem. 2005;280(39):33178&#x2013;33189.</Citation><ArticleIdList><ArticleId IdType="pubmed">16030021</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie KF, et al. Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochem J. 2011;435(3):755&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">21323643</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie SJ, et al. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem. 2000;275(22):16609&#x2013;16617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828059</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamas MS, et al. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem. 2011;54(21):7621&#x2013;7638.</Citation><ArticleIdList><ArticleId IdType="pubmed">21988093</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganiello V, Vaughan M. An effect of insulin on cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in fat cells. J Biol Chem. 1973;248(20):7164&#x2013;7170.</Citation><ArticleIdList><ArticleId IdType="pubmed">4355201</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganiello VC, et al. Regulation of cyclic nucleotide phosphodiesterase 3 (PDE3). In: Tagawa T, Murata T, Shimizu K, editors. Phosphodiesterase and Intracellular Signaling. Mie University Press; 2007. pp. 101&#x2013;125.</Citation></Reference><Reference><Citation>Mangas A, Covenas R, Geffard M. New drug therapies for multiple sclerosis. Curr Opin Neurol. 2010;23(3):287&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">20414110</ArticleId></ArticleIdList></Reference><Reference><Citation>Marko D, et al. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem Biophys. 1998;28(2-3):75&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515161</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez SE, et al. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A. 2002;99(20):13260&#x2013;13265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130621</ArticleId><ArticleId IdType="pubmed">12271124</ArticleId></ArticleIdList></Reference><Reference><Citation>Masciarelli S, et al. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest. 2004;114(2):196&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449752</ArticleId><ArticleId IdType="pubmed">15254586</ArticleId></ArticleIdList></Reference><Reference><Citation>Matte SL, Laue TM, Cote RH. Characterization of conformational changes and protein-protein interactions of rod photoreceptor phosphodiesterase (PDE6). J Biol Chem. 2012;287(24):20111&#x2013;20121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370194</ArticleId><ArticleId IdType="pubmed">22514270</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice DH, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014a;13(4):290&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155750</ArticleId><ArticleId IdType="pubmed">24687066</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice DH, et al. Cyclic nucleotide phosphodiesterases (PDEs): coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals. Biochem Soc Trans. 2014b;42(2):250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">24646226</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina AE. Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A. 2010;107(22):9921&#x2013;9922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890434</ArticleId><ArticleId IdType="pubmed">20495091</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J Med Chem. 2012;55(19):8549&#x2013;8558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3469756</ArticleId><ArticleId IdType="pubmed">22985069</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JK, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol. 2007;584(Pt 2):401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2277141</ArticleId><ArticleId IdType="pubmed">17823207</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CL, et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res. 2009;105(10):956&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803071</ArticleId><ArticleId IdType="pubmed">19797176</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa T, et al. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology. 2002;143(9):3604&#x2013;3610.</Citation><ArticleIdList><ArticleId IdType="pubmed">12193576</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin F, et al. Expression and role of phosphodiesterase 6 in the chicken pineal gland. J Neurochem. 2001;78(1):88&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita H, et al. Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. Oncol Rep. 2013;29(4):1275&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621658</ArticleId><ArticleId IdType="pubmed">23381931</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsesian M, et al. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009;14(4):255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096931</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsesian MA, Kukreja RC. PDE inhibition in heart failure. Handb Exp Pharmacol. 2011;204:237&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695643</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsesian M, Wever-Pinzon O, Vandeput F. PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol. 2011;11(6):707&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593071</ArticleId><ArticleId IdType="pubmed">21962613</ArticleId></ArticleIdList></Reference><Reference><Citation>Muradov KG, Granovsky AE, Artemyev NO. Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit. Biochemistry. 2003;42(11):3305&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">12641462</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T, et al. Characterization of phosphodiesterase 3 in human malignant melanoma cell line. Anticancer Res. 2002;22(6A):3171&#x2013;3174.</Citation><ArticleIdList><ArticleId IdType="pubmed">12530061</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T, et al. Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001;12(1):79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">11272291</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray F, et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L294&#x2013;L303.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980375</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel DJ, et al. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res. 2006;98(6):777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114760</ArticleId><ArticleId IdType="pubmed">16514069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura I, et al. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab. 2007;25(6):337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao Y, et al. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. Bone. 2009;44(5):872&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawrocki AR, et al. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance. Diabetes. 2014;63(1):300&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">24101672</ArticleId></ArticleIdList></Reference><Reference><Citation>News and analysis Deal watch: Intra-Cellular Therapies and Takeda to develop PDE1 inhibitors for schizophrenia. Nat Rev Drug Discov. 2011;10(5):329.</Citation><ArticleIdList><ArticleId IdType="pubmed">21532553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev VO, et al. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res. 2006;99(10):1084&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">17038640</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson R, et al. Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cell Signal. 2006;18(10):1713&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503395</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh AL, et al. Phosphodiesterase 3 and 4 negatively regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by prostaglandin E2. Biol Pharm Bull. 2009;32(11):1844&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">19881295</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris RP, et al. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development. 2009;136(11):1869&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680110</ArticleId><ArticleId IdType="pubmed">19429786</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger S, et al. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. J Immunol. 2005;174(12):8082&#x2013;8089.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944316</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki N, et al. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem. 2000;275(15):10831&#x2013;10837.</Citation><ArticleIdList><ArticleId IdType="pubmed">10753877</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudiz RJ, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">22818063</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">1944425</ArticleId></ArticleIdList></Reference><Reference><Citation>Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;(204):391&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695650</ArticleId></ArticleIdList></Reference><Reference><Citation>Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">22497841</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer D, et al. Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. J Biol Chem. 2007;282(13):9411&#x2013;9419.</Citation><ArticleIdList><ArticleId IdType="pubmed">17255105</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit J, et al. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci U S A. 2009;106(43):18225&#x2013;18230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775329</ArticleId><ArticleId IdType="pubmed">19828435</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Yim M. Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability. Arch Pharm Res. 2007;30(4):486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">17489366</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431801</ArticleId><ArticleId IdType="pubmed">22304913</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrucco E, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell. 2004;118(3):375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294162</ArticleId></ArticleIdList></Reference><Reference><Citation>Penmatsa H, et al. Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell. 2010;21(6):1097&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836961</ArticleId><ArticleId IdType="pubmed">20089840</ArticleId></ArticleIdList></Reference><Reference><Citation>Percival JM, et al. Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy. Handb Exp Pharmacol. 2011;(204):323&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063120</ArticleId><ArticleId IdType="pubmed">21695647</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez P, et al. Salivary epithelial cells: an unassuming target site for gene therapeutics. Int J Biochem Cell Biol. 2010;42(6):773&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862875</ArticleId><ArticleId IdType="pubmed">20219693</ArticleId></ArticleIdList></Reference><Reference><Citation>Perino A, et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell. 2011;42(1):84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265115</ArticleId><ArticleId IdType="pubmed">21474070</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter D, et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol. 2007;178(8):4820&#x2013;4831.</Citation><ArticleIdList><ArticleId IdType="pubmed">17404263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitari GM, et al. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci U S A. 2001;98(14):7846&#x2013;7851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC35430</ArticleId><ArticleId IdType="pubmed">11438734</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullamsetti SS, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32(9):1121&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">22525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Puxeddu E, et al. Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity. Proc Natl Acad Sci U S A. 2009;106(15):6158&#x2013;6163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662965</ArticleId><ArticleId IdType="pubmed">19332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085868</ArticleId><ArticleId IdType="pubmed">21232047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamurthy V, et al. Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. Proc Natl Acad Sci U S A. 2004;101(38):13897&#x2013;13902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC518850</ArticleId><ArticleId IdType="pubmed">15365178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampersad SN, et al. Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J Biol Chem. 2010;285(44):33614&#x2013;33622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962459</ArticleId><ArticleId IdType="pubmed">20732872</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond DR, et al. Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion. Cell Signal. 2007;19(12):2507&#x2013;2518.</Citation><ArticleIdList><ArticleId IdType="pubmed">17884339</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed TM, et al. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci. 2002;22(12):5188&#x2013;5197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757711</ArticleId><ArticleId IdType="pubmed">12077213</ArticleId></ArticleIdList></Reference><Reference><Citation>Reneerkens OA, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202(1-3):419&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704616</ArticleId><ArticleId IdType="pubmed">18709359</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter W, Conti M. Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem. 2002;277(43):40212&#x2013;40221.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177055</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter W, et al. PDE4 as a target for cognition enhancement. Expert Opin Ther Targets. 2013;17(9):1011&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066988</ArticleId><ArticleId IdType="pubmed">23883342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge KD, et al. Phototransduction: crystal clear. Trends Biochem Sci. 2003;28(9):479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678959</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivet-Bastide M, et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest. 1997;99(11):2710&#x2013;2718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508117</ArticleId><ArticleId IdType="pubmed">9169501</ArticleId></ArticleIdList></Reference><Reference><Citation>Robichaud A, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110(7):1045&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151147</ArticleId><ArticleId IdType="pubmed">12370283</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodan GA, Noda M. Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr. 1991;1(2):85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1802105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondinone CM, et al. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem. 2000;275(14):10093&#x2013;10098.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbuhler A, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf) 2012;77(2):195&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360985</ArticleId><ArticleId IdType="pubmed">22335482</ArticleId></ArticleIdList></Reference><Reference><Citation>Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32(1):135&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699296</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavi M, Baeeri M, Abdollahi M. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Drug Discov. 2013;8(6):733&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">23570245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabra C, Johansson EM, Mengod G. Critical role for PDE4 subfamilies in the development of experimental autoimmune encephalomyelitis. J Chem Neuroanat. 2013;47:96&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">23274837</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano H, et al. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem. 2008;105(2):546&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">18088367</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K, Guo MY, Sairenji N. Involvement of phosphodiesterase 4 in beta-adrenoceptor agonist-induced amylase release in parotid acinar cells. J Oral Sci. 2009;51(2):173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19550083</ArticleId></ArticleIdList></Reference><Reference><Citation>Savai R, et al. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs. 2010;19(1):117&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001559</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther. 2005;19(5):357&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382298</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt CJ. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem. 2010;10(2):222&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">20166957</ArticleId></ArticleIdList></Reference><Reference><Citation>Schudt C, et al. Phosphodiesterase inhibitors: history of pharmacology. Handb Exp Pharmacol. 2011;(204):1&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695634</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz JE, et al. The GAF-tandem domain of phosphodiesterase 5 as a potential drug target. Handb Exp Pharmacol. 2011;(204):151&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695639</ArticleId></ArticleIdList></Reference><Reference><Citation>Seybold J, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood. 2005;105(9):3569&#x2013;3576.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shailubhai K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000;60(18):5151&#x2013;5157.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016642</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakur Y, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther. 2002;16(5):417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">12652111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakur Y, et al. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem. 2000;275(49):38749&#x2013;38761.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W, et al. Female infertility in PDE3A(&#x2212;/&#x2212;) mice: polo-like kinase 1 (Plk1) may be a target of protein kinase A (PKA) and involved in meiotic arrest of oocytes from PDE3A(&#x2212;/&#x2212;) mice. Cell Cycle. 2010;9(23):4720&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048038</ArticleId><ArticleId IdType="pubmed">21099356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, et al. Expression of cyclic nucleotide phosphodiesterase 3A in isolated rat submandibular acini. Arch Oral Biol. 2006;51(2):83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102722</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, et al. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Cancer Res. 2004;64(7):2568&#x2013;2571.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, et al. Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Res. 2009;29(4):1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin YY, et al. Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the beta-agonist induced hypertrophic response in cardiac myocytes. J Mol Cell Cardiol. 2011;50:872&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">21334344</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010;11:26&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841147</ArticleId><ArticleId IdType="pubmed">20193079</ArticleId></ArticleIdList></Reference><Reference><Citation>Siuciak JA, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51(2):386&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780899</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith FD, et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol. 2010;12(12):1242&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042953</ArticleId><ArticleId IdType="pubmed">21102438</ArticleId></ArticleIdList></Reference><Reference><Citation>Soda T, et al. DISC1-ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1. Mol Psychiatry. 2013:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730299</ArticleId><ArticleId IdType="pubmed">23587879</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangherlin A, et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res. 2011;108(8):929&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083836</ArticleId><ArticleId IdType="pubmed">21330599</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan E, et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol. 2007;18(1):199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135396</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JW, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">23034699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal. 2007;19(8):1765&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482796</ArticleId></ArticleIdList></Reference><Reference><Citation>Taira M, et al. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem. 1993;268(25):18573&#x2013;18579.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamhane U, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 2009;5(3):384&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19736165</ArticleId></ArticleIdList></Reference><Reference><Citation>Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2011;63(2):325&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069536</ArticleId><ArticleId IdType="pubmed">21279986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenor H, et al. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. Handb Exp Pharmacol. 2011;(204):85&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695636</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrenoire C, et al. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem. 2009;284(14):9140&#x2013;9146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666564</ArticleId><ArticleId IdType="pubmed">19218243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WJ, Appleman MM. Cyclic nucleotide phosphodiesterase and cyclic AMP. Ann N Y Acad Sci. 1971;185:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">4330503</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WJ, et al. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res. 1979;10:69&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">222125</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinsley HN, et al. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 2011;4(8):1275&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151326</ArticleId><ArticleId IdType="pubmed">21505183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari S, et al. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol. 2005;69(3):473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuhara Y, et al. Local delivery of rolipram, a phosphodiesterase-4-specific inhibitor, augments bone morphogenetic protein-induced bone formation. J Bone Miner Metab. 2010;28(1):17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19554392</ArticleId></ArticleIdList></Reference><Reference><Citation>Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157(2):351&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">9476844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709600</ArticleId><ArticleId IdType="pubmed">19306895</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011;11(6):670&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034742</ArticleId><ArticleId IdType="pubmed">21962440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LC, Shimizu-Albergine M, Beavo JA. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol. 2011;79(4):639&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063732</ArticleId><ArticleId IdType="pubmed">21187369</ArticleId></ArticleIdList></Reference><Reference><Citation>Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162649</ArticleId><ArticleId IdType="pubmed">21745238</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzawa K, et al. Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. Cancer Med. 2013;2(1):40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797561</ArticleId><ArticleId IdType="pubmed">24133626</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandeput F, et al. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem. 2007;282(45):32749&#x2013;32757.</Citation><ArticleIdList><ArticleId IdType="pubmed">17726023</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta V, Shimizu-Albergine M, Beavo JA. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci U S A. 2006;103(52):19925&#x2013;19930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1750886</ArticleId><ArticleId IdType="pubmed">17172443</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, et al. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res. 2011;8(2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">21222604</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde I, et al. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem. 2001;276(14):11189&#x2013;11198.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 1983;22(3):267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">6302550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi S, et al. Involvement of phosphodiesterase isozymes in osteoblastic differentiation. J Bone Miner Res. 2002;17(2):249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">11811555</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz HA, et al. Beta-cell PDE3B regulates Ca2+-stimulated exocytosis of insulin. Cell Signal. 2007;19(7):1505&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry. 2008;47(48):12760&#x2013;12768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646200</ArticleId><ArticleId IdType="pubmed">18983167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin. 2014 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">24701971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene. 2001;280(1-2):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738832</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaar RE, Cain MH, Bristol JA. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985;28(5):537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">2985781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wensel TG. Signal transducing membrane complexes of photoreceptor outer segments. Vision Res. 2008;48(20):2052&#x2013;2061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615670</ArticleId><ArticleId IdType="pubmed">18456304</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersma A, et al. Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents. J Clin Invest. 1998;102(3):532&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508914</ArticleId><ArticleId IdType="pubmed">9691090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson LS, et al. A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem. 2011;286(18):16285&#x2013;16296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091235</ArticleId><ArticleId IdType="pubmed">21393242</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson LS, et al. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A. 2008;105(36):13650&#x2013;13655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533244</ArticleId><ArticleId IdType="pubmed">18757735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimalawansa SJ. Nitric oxide: novel therapy for osteoporosis. Expert Opin Pharmacother. 2008;9(17):3025&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pubmed">19006476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb ) 2013;3(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680635</ArticleId><ArticleId IdType="pubmed">23888251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters EF, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):E1720&#x2013;E1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">22723325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu AY, et al. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem. 2004;279(36):37928&#x2013;37938.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Wang P. Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IkappaB proteins. Proc Natl Acad Sci U S A. 2004;101(51):17634&#x2013;17639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539753</ArticleId><ArticleId IdType="pubmed">15596729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagami H, et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. Biochem Pharmacol. 2003;66(5):801&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, et al. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J Biol Chem. 1983;258(23):14173&#x2013;14177.</Citation><ArticleIdList><ArticleId IdType="pubmed">6196360</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano Y, et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 2010;126(2):437&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">19569180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res. 2007;100(4):489&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115784</ArticleId><ArticleId IdType="pubmed">17332439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano M, et al. Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol. 2000;279(4):H1898&#x2013;H1905.</Citation><ArticleIdList><ArticleId IdType="pubmed">11009478</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao W, et al. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact. 2007;7(2):119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, et al. K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model. PLoS One. 2012;7(10):e46432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479105</ArticleId><ArticleId IdType="pubmed">23110051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccolo M, et al. A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol. 2000;2(1):25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GH, Martinez JR. Effects of forksolin, dibutyryl cAMP and H89 on Ca2+ mobilization in submandibular salivary cells of newborn rats. Arch Oral Biol. 1999;44(9):735&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011;129(5):1162&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111850</ArticleId><ArticleId IdType="pubmed">21120911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008a;105(49):19532&#x2013;19537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614795</ArticleId><ArticleId IdType="pubmed">19033455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Maratos-Flier E, Flier JS. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology. 2009;150(7):3076&#x2013;3082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703511</ArticleId><ArticleId IdType="pubmed">19359377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Ke H, Colman RW. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol Pharmacol. 2002;62(3):514&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XJ, et al. Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. J Biol Chem. 2008b;283(44):29699&#x2013;29705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573074</ArticleId><ArticleId IdType="pubmed">18779324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmuda-Trzebiatowska E, et al. Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal. 2006;18(3):382&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24976035</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>13</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Treatment strategies for diabetic patients suffering from erectile dysfunction: an update.</ArticleTitle><Pagination><StartPage>1827</StartPage><EndPage>1836</EndPage><MedlinePgn>1827-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.2014.934809</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erectile dysfunction (ED) is one of the most common complications of diabetes. The complex pathophysiology of this disease makes it difficult to create clinical treatments tailored specifically for diabetic patients.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This article will provide an update of both medical and surgical treatment approaches for diabetic ED, as well as discuss established treatments that are the cornerstone of this field.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Currently, PDE type 5 inhibitors represent the first-line treatment for all patients with ED. In the interim since this article's first publication several new PDE5 inhibitors have come to market. Several others that were previously on the market are now available for daily dosing. Analysis of both testosterone level and hemoglobin A1c is an essential part of treatment. Intracavernosal injections and vacuum constriction devices remain safe, and are highly effective treatment options. The implantable penile prosthesis remains a safe, and definitive treatment modality for those patients with refractory ED. Over the coming years as the understanding of the underlying causes of diabetic ED continues, the development of new, noninvasive, but effective medical treatments will lead to even more options for the treatment of this difficult disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Redrow</LastName><ForeName>Grant P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>University of Texas Medical School , 6431 Fannin Street, Suite 6.018, Houston, TX 77030 , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Chad M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Run</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PDE5 inhibitor</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">review</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24976035</ArticleId><ArticleId IdType="doi">10.1517/14656566.2014.934809</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24840016</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Same-session dorsal vein ligation and testing by intracavernous injection prior to penile prosthesis implantation (DVL-ICI-PPI).</ArticleTitle><Pagination><StartPage>2333</StartPage><EndPage>2337</EndPage><MedlinePgn>2333-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12582</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Complications of penile prosthesis implantation (PPI) are rare, nevertheless can be grave. In cases with veno-occlusive dysfunction (VOD), alternative surgical techniques such as dorsal vein ligation (DVL) are controversial. Some patients may opt for trial at DVL to avoid the possible complications of PPI. However, this may be associated with disappointment if DVL fails and another procedure is required.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim if this study is to evaluate the results of a combined approach involving DVL, same-session testing by intracavernous injection (ICI) of prostaglandin E1 (PGE1), and immediate implantation of a penile prosthesis (PPI) in case of poor response to DVL.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Long-term erectile function in cases with favorable intraoperative response to DVL.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-six patients with refractory VOD were operated upon. Through a peno-pubic incision, DVL was performed, followed by ICI of 20&#x2009;&#xb5;g PGE1 in two divided doses, 10&#x2009;&#xb5;g each, 15 minutes apart. Group 1 exhibited full rigidity in response to the first dose. Group 2 exhibited full rigidity in response to the second dose. PPI was not performed for either. Group 3 exhibited suboptimal response to both doses, and PPI was performed through the same incision. Patients were followed up from 24 to 48 months using International Index of Erectile Function-5 scoring.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For Group 1 (n&#x2009;=&#x2009;8), six patients experienced normal erectile function following DVL throughout the whole follow-up period of 48 months (23.1% of all patients), and two patients relapsed. Group 2 (n&#x2009;=&#x2009;6) (23.1%) reported normal erectile function for an average of 6 months, then relapsed. Group 3 (n&#x2009;=&#x2009;12) had a penile prosthesis implanted in the same setting.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combined DVL-ICI-PPI can spare around 23.1% of young patients with VOD from PPI, at no additional risk. Full response to 10&#x2009;&#xb5;g PGE1 at intraoperative testing carries good prognosis to DVL on the long run. Investigation of a larger number of patients is necessary before reaching a final conclusion.</AbstractText><CopyrightInformation>&#xa9; 2014 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaeer</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Andrology, Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaeer</LastName><ForeName>Kamal</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Penile Implant</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Vascular Surgery</Keyword><Keyword MajorTopicYN="N">Vein Ligation</Keyword><Keyword MajorTopicYN="N">Veno-Occlusive Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Venoligation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24840016</ArticleId><ArticleId IdType="doi">10.1111/jsm.12582</ArticleId><ArticleId IdType="pii">S1743-6095(15)30852-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24809413</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6586</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current opinion in urology</Title><ISOAbbreviation>Curr Opin Urol</ISOAbbreviation></Journal><ArticleTitle>Current management of erectile dysfunction in prostate cancer survivors.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>406</EndPage><MedlinePgn>401-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MOU.0000000000000072</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Although no standard management of erectile dysfunction in prostate cancer (CaP) survivors exists, many treatment options are available. This review summarizes the current understanding of the cause and management of erectile dysfunction in CaP survivors.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Erectile dysfunction after radical therapy for CaP may be more common than previously thought. Genetics and vascular comorbidities may have a significant impact on erectile dysfunction after CaP treatment. Although penile rehabilitation with medical modalities show good efficacy in motivated patients, the return of erectile function is never guaranteed with nonsurgical management. Penile prosthesis placement results in early return to sexual function after CaP treatment with high patient satisfaction rates. Various techniques allow safe placement of a three-piece penile prosthesis in patients with a history of pelvic surgery.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">To optimize recovery of erectile function and prevent loss of penile length, penile rehabilitation should be initiated expeditiously after prostatectomy or radiation. In patients with refractory erectile dysfunction, dexterous and motivated patients remain excellent candidates for first and second-line medical therapies. However, early placement of a penile prosthesis following radical prostatectomy is now a proven and viable option.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sherer</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Urol</MedlineTA><NlmUniqueID>9200621</NlmUniqueID><ISSNLinking>0963-0643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24809413</ArticleId><ArticleId IdType="doi">10.1097/MOU.0000000000000072</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24708140</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie's disease.</ArticleTitle><Pagination><StartPage>1593</StartPage><EndPage>1598</EndPage><MedlinePgn>1593-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12530</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Twenty to thirty percent of patients with Peyronie's disease (PD) have erectile dysfunction (ED) refractory to medical therapy and may benefit from a combined procedure addressing both conditions.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to show the efficacy of inflatable penile prosthesis (IPP) insertion and synchronous penile plication for correcting penile curvature and ED in patients with PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review was performed of all patients who underwent IPP insertion with synchronous penile plication at our tertiary care center between 2010 and 2013. All patients received an intraoperative saline intracorporal injection to induce an artificial erection. After the tunica albuginea was exposed via a standard transverse scrotal incision over the proximal penile shaft, the incision was retracted distally and/or laterally as needed for plication suture placement. Plication sutures were placed in parallel opposite the angle of greatest curvature. The incision was returned proximally to the standard penoscrotal junction for IPP insertion. Demographic and surgical data were collected from the patients' medical records. Patient satisfaction was assessed postoperatively using a nonvalidated questionnaire.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The focus of this study was surgical outcomes, both technical and patient-reported satisfaction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen patients with a mean age of 63 years underwent IPP insertion with synchronous penile plication. Patients presented with dorsal (n&#x2009;=&#x2009;11), lateral (n&#x2009;=&#x2009;2), and biplanar curvature (n&#x2009;=&#x2009;5). Mean preoperative curvature was 39 degrees (range 30-60) and was corrected on average to &lt;5 degrees (range &lt;5-12) using a median of four plication sutures (range 3-6). Among 15 patients completing a postoperative satisfaction survey at a mean of 11 months, all reported improvement in their overall condition and penile curvature; one with biplanar deformity reported minor residual curvature. None reported continued pain or required suture release.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IPP insertion with synchronous penile plication for the correction of ED and PD is effective and results in high patient satisfaction.</AbstractText><CopyrightInformation>&#xa9; 2014 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>J Francis</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Morey</LastName><ForeName>Allen F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 Mar;193(3):906</RefSource><PMID Version="1">25765402</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 May;193(5):1603-4</RefSource><PMID Version="1">25895789</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012611" MajorTopicYN="N">Scrotum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013537" MajorTopicYN="N">Sutures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Penile Graft</Keyword><Keyword MajorTopicYN="N">Penile Plication</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Peyronie's Disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24708140</ArticleId><ArticleId IdType="doi">10.1111/jsm.12530</ArticleId><ArticleId IdType="pii">S1743-6095(15)30783-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24687066</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature reviews. Drug discovery</Title><ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Advances in targeting cyclic nucleotide phosphodiesterases.</ArticleTitle><Pagination><StartPage>290</StartPage><EndPage>314</EndPage><MedlinePgn>290-314</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrd4228</ELocationID><Abstract><AbstractText>Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides, their signalling pathways and, consequently, myriad biological responses in health and disease. Currently, a small number of PDE inhibitors are used clinically for treating the pathophysiological dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease. However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maurice</LastName><ForeName>Donald H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Biomedical and Molecular Sciences, Queen's University, Kingston K7L3N6, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Hengming</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Faiyaz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiovascular and Pulmonary Branch, The National Heart, Lung and Blood Institute, US National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yousheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Technology and Business University, Beijing 100048, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Developmental Biology Center, The National Heart, Lung and Blood Institute, US National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manganiello</LastName><ForeName>Vincent C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Cardiovascular and Pulmonary Branch, The National Heart, Lung and Blood Institute, US National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA HL002540-19</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Drug Discov</MedlineTA><NlmUniqueID>101124171</NlmUniqueID><ISSNLinking>1474-1776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.-</RegistryNumber><NameOfSubstance UI="D010727">Phosphoric Diester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>H2D2X058MU</RegistryNumber><NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010727" MajorTopicYN="N">Phosphoric Diester Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests statement</b>. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24687066</ArticleId><ArticleId IdType="mid">NIHMS622246</ArticleId><ArticleId IdType="pmc">PMC4155750</ArticleId><ArticleId IdType="doi">10.1038/nrd4228</ArticleId><ArticleId IdType="pii">nrd4228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376027</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis S, Blount M, Corbin J. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011;91:651&#x2013;690. This is an excellent, comprehensive and very timely review of PDEs.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527734</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165:1288&#x2013;1305. This is an excellent and concise review of PDEs.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372715</ArticleId><ArticleId IdType="pubmed">22014080</ArticleId></ArticleIdList></Reference><Reference><Citation>Derbyshire E, Marletta M. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">22404633</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011;130:71&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856048</ArticleId><ArticleId IdType="pubmed">21185863</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierre S, Eschenhagen T, Geisslinger G, Scholich K. Capturing adenylyl cyclases as potential drug targets. Nature Rev Drug Disc. 2009;8:321&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">19337273</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamm M, Richards DH, Begh&#xe9; B, Fabbri L. Inhaled corticosteroid and long-acting &#x3b2;2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012;106:S9&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">23273165</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8:219&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">23231438</ArticleId></ArticleIdList></Reference><Reference><Citation>Boden WE, et al. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 2012;35:263&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6652630</ArticleId><ArticleId IdType="pubmed">22528319</ArticleId></ArticleIdList></Reference><Reference><Citation>Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW. The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol. 2012;60:2140&#x2013;2149.</Citation><ArticleIdList><ArticleId IdType="pubmed">23021324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rall T, Sutherland E. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem. 1958;232:1065&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">13549487</ArticleId></ArticleIdList></Reference><Reference><Citation>Rall T, West T. The potentiation of cardiac inotropic responses to norepinephrine by theophylline. J Pharmacol Exp Ther. 1963;139:269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">13990605</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res. 2007;100:950&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS. AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol. 2012;52:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168680</ArticleId><ArticleId IdType="pubmed">21600214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke H, Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem. 2007;7:391&#x2013;403. This report is an extensive summary of the three-dimensional structures of PDE families.</Citation><ArticleIdList><ArticleId IdType="pubmed">17305581</ArticleId></ArticleIdList></Reference><Reference><Citation>Card GGL, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004;12:2233&#x2013;2247.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576036</ArticleId></ArticleIdList></Reference><Reference><Citation>Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005;48:3449&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pubmed">15887951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci USA. 2009;106:18225&#x2013;18230. This article reports the first structure, of near-full-length PDE2A, among the PDE families.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775329</ArticleId><ArticleId IdType="pubmed">19828435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LCY, Maurice DH, Baillie GS. Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Med Chem. 2013;5:451&#x2013;464. This report describes novel concepts and approaches regarding the use of signalosome disruptors to therapeutically target cardiovascular disease.</Citation><ArticleIdList><ArticleId IdType="pubmed">23495691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schudt C, Hatzelmann A, Beume R, Tenor H. Phosphodiesterase inhibitors: history of pharmacology. Handb Exp Pharmacol. 2011;204:1&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695634</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">23360759</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson W, Appleman M. Cyclic nucleotide phosphodiesterase &amp; cyclic AMP. Ann NY Acad Sci. 1971;185:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">4330503</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson W, Terasaki W, Epstein P, Strada S. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cycl Nucleotide Res. 1979;10:69&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">222125</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, Wells J, Hardman J. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta. 1980;613:116&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">6246952</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaar R, Cain M, Bristol J. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985;28:537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">2985781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet J. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol. 1986;35:1743&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">2423089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, et al. Selective inhibition of two cAMP PDEs partially purified from calf liver. Biochem. 1983;258:14173&#x2013;14177.</Citation></Reference><Reference><Citation>Movsesian M, Wever-Pinzon O, Vandeput F. PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol. 2011;11:707&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593071</ArticleId><ArticleId IdType="pubmed">21962613</ArticleId></ArticleIdList></Reference><Reference><Citation>Torphy T. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Resp Crit Care Med. 1998;157:351&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">9476844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085868</ArticleId><ArticleId IdType="pubmed">21232047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenor H, et al. Pharmacology, clinical efficacy, and tolerability of PDE4 inhibitors: impact of human pharmacokinetics. Handb Exp Pharmacol. 2011;204:86&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri LM, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716961</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH, Corbin JD. PDE5 inhibitors: targeting erectile dysfunction in diabetics. Curr Opin Pharmacol. 2011;11:683&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">21924956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Rev Drug Disc. 2006;5:689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097805</ArticleId><ArticleId IdType="pubmed">16883306</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgin AB, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotech. 2010;28:63&#x2013;70. This paper provides evidence that novel allosteric PDE4 inhibitors &#x2014; that is, inhibitors whose affinity for the active site is regulated by their interaction with a helical peptide from the UCR2 of PDE4 &#x2014; may decrease the toxicity of PDE4 inhibition without affecting efficacy.</Citation><ArticleIdList><ArticleId IdType="pubmed">20037581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke H, Wang H, Ye M. Structural insight into the substrate specificity of phosphodiesterases. Handb Exp Pharmacol. 2011;204:121&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695637</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai Q, Colicelli J, Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase hydrolysis. Biochem. 2003;42:15559&#x2013;15564.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J. 2007;408:193&#x2013;201. This paper reveals conformational differences among four PDE4 subfamilies, and this information has been especially useful for the design of PDE4-subfamily-selective inhibitors.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267353</ArticleId><ArticleId IdType="pubmed">17727341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Card G, Suzuki Y, Artis D. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell. 2004;15:279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260978</ArticleId></ArticleIdList></Reference><Reference><Citation>Card GL, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotech. 2010;28:38&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho GD, et al. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett. 2012;22:2585&#x2013;2589. This paper discusses the development of PDE4 inhibitors using co-crystallography and scaffold-based drug design through the synthesis and screening of a relatively small number of compounds.</Citation><ArticleIdList><ArticleId IdType="pubmed">22377514</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamas M, Ni Y, Erdei J. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem. 2011;54:7621&#x2013;7638.</Citation><ArticleIdList><ArticleId IdType="pubmed">21988093</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J Med Chem. 2012;55:8549&#x2013;8558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3469756</ArticleId><ArticleId IdType="pubmed">22985069</ArticleId></ArticleIdList></Reference><Reference><Citation>Claffey MM, et al. Application of structure-based drug design and parallel chemistry to identify selective, brain-penetrant, in vivo active PDE 9A inhibitors. J Med Chem. 2012;55:9055&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pubmed">23025719</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyr azol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52:5188&#x2013;5196.</Citation><ArticleIdList><ArticleId IdType="pubmed">19630403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A, Beavo J. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">16968949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranz M, et al. Identification of PDE4B over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg Med Chem. 2009;17:5336&#x2013;5341.</Citation><ArticleIdList><ArticleId IdType="pubmed">19525117</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai Q, et al. Enantiomer discrimination illustrated by high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006;49:1867&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527038</ArticleId><ArticleId IdType="pubmed">16539372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem. 2006;281:21469&#x2013;21479. This paper reports multiple conformations of the H-loop in the PDE5 catalytic domain, which were induced by the binding of various PDE5 inhibitors.</Citation><ArticleIdList><ArticleId IdType="pubmed">16735511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ye M, Robinson H, Francis S, Ke H. Conformational variations of both PDE5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008;73:104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950070</ArticleId><ArticleId IdType="pubmed">17959709</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunton L, Hayes J, Mayer S. Functional compartmentation of cyclic AMP and protein kinase in heart. Adv Cycl Nucleotide Res. 1981;14:391&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">6269390</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxton I, Brunton L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem. 1983;258:10233&#x2013;10239. This paper shows, for the first time, how cAMP-mediated activation of PKA is compartmentalized and describes an important physiological response associated with this compartmentalization.</Citation><ArticleIdList><ArticleId IdType="pubmed">6309796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bregman D, Bhattacharyya N, Rubin C. High affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II-B. Cloning, characterization, and expression of cDNAs for rat brain P150. J Biol Chem. 1989;264:4648&#x2013;4656. This is the first report regarding the isolation and characterization of an AKAP.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bregman D, Hirsch A, Rubin C. Molecular characterization of bovine brain P75, a high affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II beta. J Biol Chem. 1991;266:7207&#x2013;7213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2016323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by &#x3b2;-adrenergic agonists. Proc Natl Acad Sci USA. 1996;93:295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40225</ArticleId><ArticleId IdType="pubmed">8552625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccolo M, et al. A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nature Cell Biol. 2000;2:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice DH. Subcellular signaling in the endothelium: cyclic nucleotides take their place. Curr Opin Pharmacol. 2011;11:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">22036169</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangherlin A, et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res. 2011;108:929&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083836</ArticleId><ArticleId IdType="pubmed">21330599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongillo M, et al. Compartmentalized phosphodiesterase-2 activity blunts &#x3b2;-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16357307</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangherlin A, Zaccolo M. cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function. Biochem Soc Trans. 2012;40:11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22260658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge-Kafka KL, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 2005;437:574&#x2013;578. This paper effectively brings together the importance of AKAPs in coordinating specific subcellular signalling pathways.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636584</ArticleId><ArticleId IdType="pubmed">16177794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson LS, et al. A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 (EPAC1) and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem. 2011;286:16285&#x2013;16296. This is the first report of a PDE3B-based, EPAC1-containing signalosome and the demonstration that a peptide disruptor leads to constitutive activation of EPAC1 in human cells.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091235</ArticleId><ArticleId IdType="pubmed">21393242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampersad SN, et al. Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J Biol Chem. 2010;285:33614&#x2013;33622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962459</ArticleId><ArticleId IdType="pubmed">20732872</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrin A, et al. PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. J Cell Biol. 2012;198:607&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514031</ArticleId><ArticleId IdType="pubmed">22908311</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KM, et al. Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci USA. 2013;110:E1533&#x2013;E1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631629</ArticleId><ArticleId IdType="pubmed">23509299</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti M. Phosphodiesterases and regulation of female reproductive function. Curr Opin Pharmacol. 2011;11:665&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">22019564</ArticleId></ArticleIdList></Reference><Reference><Citation>Masciarelli S, et al. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest. 2004;114:196&#x2013;205. This study shows that Pde3a&#x2212;/&#x2212; mice are infertile because increased cAMP&#x2013;PKA signalling inhibits oocyte maturation in these mice, as well as their capacity for fertilization.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449752</ArticleId><ArticleId IdType="pubmed">15254586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote RH. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo J, Francis S, Houslay M, editors. CRC Press; 2007. pp. 165&#x2013;194.</Citation></Reference><Reference><Citation>Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamurthy V, Niemi GA, Reh TA, Hurley JB. Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. Proc Natl Acad Sci USA. 2004;101:13897&#x2013;13902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC518850</ArticleId><ArticleId IdType="pubmed">15365178</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RJ, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase6 b allele (Pde6bH620Q) Investig Ophthalmol Vis Sci. 2008;49:5067&#x2013;5076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715364</ArticleId><ArticleId IdType="pubmed">18658088</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8:2894&#x2013;2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">21771280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gretarsdottir S, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nature Genet. 2003;35:131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517540</ArticleId></ArticleIdList></Reference><Reference><Citation>Labuda M, et al. Phosphodiesterase type 4D gene polymorphism: association with the response to short-acting bronchodilators in paediatric asthma patients. Mediators Inflamm. 2011;2011:301695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163044</ArticleId><ArticleId IdType="pubmed">21876611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatemi SH, et al. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res. 2008;101:36&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LL, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011;11:670&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034742</ArticleId><ArticleId IdType="pubmed">21962440</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu-albergine M, Tsai LL, Patrucco E, Beavo JA. cAMP-specific phosphodieterases 8A and 8B, essential regulators of Leydig cell steroidogenesis. Mol Pharmacol. 2012;81:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310417</ArticleId><ArticleId IdType="pubmed">22232524</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase, in adrenal hyperplasia. N Engl J Med. 2008;358:750&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbuhler A, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol. 2012;77:195&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360985</ArticleId><ArticleId IdType="pubmed">22335482</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nature Genet. 2006;38:794&#x2013;800. This paper reports that inactivating mutations in PDE11A increase cAMP levels of affected individuals, leading to aberrant cAMP signalling, which can be associated with the development of adrenocortical hyperplasia.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767104</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11:689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727450</ArticleId><ArticleId IdType="pubmed">22047791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lib&#xe9; R, et al. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 2011;96:E208&#x2013;E214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038483</ArticleId><ArticleId IdType="pubmed">21047926</ArticleId></ArticleIdList></Reference><Reference><Citation>Savai R, et al. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs. 2010;19:117&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011;129:1162&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111850</ArticleId><ArticleId IdType="pubmed">21120911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2008;105:19532&#x2013;19537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614795</ArticleId><ArticleId IdType="pubmed">19033455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D, et al. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci USA. 2013;110:6109&#x2013;6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625360</ArticleId><ArticleId IdType="pubmed">23536305</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullamsetti SS, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32:1121&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">22525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MQ, Stratakis CA. How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol. 2011;336:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049838</ArticleId><ArticleId IdType="pubmed">21111774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka D, et al. Phosphatidylinositol 3-kinase-binding protein, PI3KAP/XB130, is required for cAMP-induced amplification of IGF mitogenic activity in FRTL-5 thyroid cells. Mol Endocrinol. 2012;26:1043&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5416991</ArticleId><ArticleId IdType="pubmed">22496359</ArticleId></ArticleIdList></Reference><Reference><Citation>Black KL, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 2008;1230:290&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632551</ArticleId><ArticleId IdType="pubmed">18674521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachtel H. Potential antidepressant effects of rolipram and other selective PDE inhibitors. Neuropharmacol. 1983;22:267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">6302550</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase-4 as a therapeutic target: preclinical and clinical pharmacology. Drug Discov Today. 2005;10:1503&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly M, Brandon N. Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals. Prog Brain Res. 2009;179:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20302819</ArticleId></ArticleIdList></Reference><Reference><Citation>Clapcote SJ, et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron. 2007;54:387&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481393</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JK, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol. 2007;584:401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2277141</ArticleId><ArticleId IdType="pubmed">17823207</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMarch Z, et al. Beneficial effects of rolipram in the R6/2 mouse model of Huntington&#x2019;s disease. Neurobiol Dis. 2008;30:375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">18424161</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamp&#xe0; C, et al. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington&#x2019;s disease. PloS ONE. 2010;5:e13417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955524</ArticleId><ArticleId IdType="pubmed">20976216</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsesian MA, Kukreja RC. PDE inhibition in heart failure. Handb Exp Pharmacol. 2011;204:237&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695643</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, et al. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">1944425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambayashi J, Shakur Y, Liu Y. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo J, Francis S, Houslay M, editors. CRC Press; 2007. pp. 627&#x2013;648.</Citation></Reference><Reference><Citation>Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med. 2011;12:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21200326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukreja RC, et al. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011;16:e30&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206106</ArticleId><ArticleId IdType="pubmed">22131856</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864&#x2013;1871.</Citation><ArticleIdList><ArticleId IdType="pubmed">19890129</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther. 2005;19:357&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S, Yan C. PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmaco. 2011;11:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225597</ArticleId><ArticleId IdType="pubmed">21962439</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CL, et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res. 2009;105:956&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803071</ArticleId><ArticleId IdType="pubmed">19797176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakur Y, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther. 2002;16:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">12652111</ArticleId></ArticleIdList></Reference><Reference><Citation>Toque HA, et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol. 2008;154:787&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2439847</ArticleId><ArticleId IdType="pubmed">18536732</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z, et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011;71:3029&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078184</ArticleId><ArticleId IdType="pubmed">21402712</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z, Tiwari AK, Patel AS, Fu L, Chen Z. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011;71:3735&#x2013;3738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107342</ArticleId><ArticleId IdType="pubmed">21610107</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem. 2011;286:32899&#x2013;32905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190895</ArticleId><ArticleId IdType="pubmed">21799015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yougbar&#xe9; I, et al. NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF&#x3ba;-B signalling pathways while reducing proinflammatory cytokine production. Can J Physiol Pharmacol. 2013;91:353&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656347</ArticleId></ArticleIdList></Reference><Reference><Citation>Minguet S, et al. Adenosine and cAMP are potent inhibitors of the NF-&#x3ba;B pathway downstream of immunoreceptors. Eur J Immunol. 2005;35:31&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580656</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, et al. Phosphodiesterase inhibitors suppress Lactobacillus casei cell-wall-induced NF-&#x3ba;B and MAPK activations and cell proliferation through protein kinase A-or exchange protein activated by cAMP-dependent signal pathways. Scientific World Journal. 2012;2012:748572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356720</ArticleId><ArticleId IdType="pubmed">22645447</ArticleId></ArticleIdList></Reference><Reference><Citation>To Y, et al. Targeting phosphoinositide-3-kinase-&#x3b4; with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:897&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970861</ArticleId><ArticleId IdType="pubmed">20224070</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas JJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246948</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamhane U, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 2009;5:384&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19736165</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng D, et al. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology. 2012;122:148&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">22832561</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng D, Deng J, Jin D, Wu W, Wang J. Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;220:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">22015232</ArticleId></ArticleIdList></Reference><Reference><Citation>Katakami N, Kim Y, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010;121:2584&#x2013;2591.</Citation><ArticleIdList><ArticleId IdType="pubmed">20516379</ArticleId></ArticleIdList></Reference><Reference><Citation>Begum N, Hockman S, Manganiello VC. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J Biol Chem. 2011;286:26238&#x2013;26249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138244</ArticleId><ArticleId IdType="pubmed">21632535</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, et al. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS ONE. 2012;7:e28899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256138</ArticleId><ArticleId IdType="pubmed">22247763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther. 2013;3:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680635</ArticleId><ArticleId IdType="pubmed">23888251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-&#x3b1; responses. Proc Natl Acad Sci USA. 2002;99:7628&#x2013;7633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124305</ArticleId><ArticleId IdType="pubmed">12032334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariga M, et al. Nonredundant function of Phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol. 2004;173:7531&#x2013;7538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA. 2000;97:6751&#x2013;6756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18727</ArticleId><ArticleId IdType="pubmed">10841571</ArticleId></ArticleIdList></Reference><Reference><Citation>Robichaud A, et al. Deletion of phosphodiesterase 4D in mice shortens &#x3b1;2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:1045&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151147</ArticleId><ArticleId IdType="pubmed">12370283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung JH, Manganiello V, Dyck JRB. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol. 2012;22:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3462230</ArticleId><ArticleId IdType="pubmed">22885100</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421&#x2013;433. This paper demonstrates that the metabolic effects of resveratrol may be mediated by PDE4 inhibition.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431801</ArticleId><ArticleId IdType="pubmed">22304913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Maratos-Flier E, Flier JS. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology. 2009;150:3076&#x2013;3082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703511</ArticleId><ArticleId IdType="pubmed">19359377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters E, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:E1720&#x2013;E1725. This paper demonstrates that the PDE4 inhibitor roflumilast has an antidiabetic effect.</Citation><ArticleIdList><ArticleId IdType="pubmed">22723325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugnier C. PDE inhibitors: a new approach to treat metabolic syndrome? Curr Opin Pharmacol. 2011;11:698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">22018840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167474</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo CM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2010;107:19079&#x2013;19083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973894</ArticleId><ArticleId IdType="pubmed">20956307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass DA. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Curr Heart Fail Rep. 2012;9:192&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408604</ArticleId><ArticleId IdType="pubmed">22798047</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanton R, et al. Protein kinase 1G&#x3b1; inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012;1:e003731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541610</ArticleId><ArticleId IdType="pubmed">23316302</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokland A, Menniti F, Prikaerts J. PDE inhibition and cognition enhancement. Exp Opin Ther Pat. 2012;22:349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">22475506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehler J, Nielsen J. PDE10A Inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des. 2011;17:137&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">21355834</ArticleId></ArticleIdList></Reference><Reference><Citation>Grauer S, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009;331:574&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661377</ArticleId></ArticleIdList></Reference><Reference><Citation>IntraCellular Therapies and Takeda to develop PDE1 inhibitors for schizophrenia. Nature Rev Drug Discov. 2011;10:329. No authors listed.</Citation><ArticleIdList><ArticleId IdType="pubmed">21532553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman R, et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington&#x2019;s disease. J Pharmacol Exp Ther. 2011;336:64&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20923867</ArticleId></ArticleIdList></Reference><Reference><Citation>Loukides S, Bartziokas K, Vestbo JR, Singh D. Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr Drug Targets. 2013;14:235&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">23256720</ArticleId></ArticleIdList></Reference><Reference><Citation>Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective PDE inhibitors and novel combination therapies. Handb Exp Pharmacol. 2011;204:415&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695651</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SJ, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol. 2004;66:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371556</ArticleId></ArticleIdList></Reference><Reference><Citation>Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">22497841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C. Phosphodiesterase inhibitors in airway disease. Eur J Pharmacol. 2006;533:110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458289</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson P, Manganiello V, Degerman E. Re-discovering PDE3 Inhibitors: new opportunities for a long neglected target. Curr Top Med Chem. 2007;7:421&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">17305583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak G, Hanania NA. New bronchodilators. Curr Opin Pharmacol. 2012;12:238&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">22445544</ArticleId></ArticleIdList></Reference><Reference><Citation>Banner K, Press N. Dual PDE3/PDE4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157:892&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737648</ArticleId><ArticleId IdType="pubmed">19508401</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster RW, Rakshi K, Carpenter JR, Small RC. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol. 1992;34:527&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1381455</ArticleId><ArticleId IdType="pubmed">1493085</ArticleId></ArticleIdList></Reference><Reference><Citation>Calzetta L, et al. The effect of the mixed Phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346:414&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Petavy F, Macdonald AJ, Lazaar AL, O&#x2019;Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Resp Res. 2010;11:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841147</ArticleId><ArticleId IdType="pubmed">20193079</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawson CT, Scott JD. Signal integration through blending, bolstering, and bifurcating of intracellular information. Nature Struct Mol Biol. 2010;17:653&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086636</ArticleId><ArticleId IdType="pubmed">20495562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells J, McClendon C. Reaching for high-hanging fruit in drug discovery at protein&#x2013;protein interfaces. Nature. 2007;450:1001&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075579</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian F, et al. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem. 2011;286:9079&#x2013;9096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058960</ArticleId><ArticleId IdType="pubmed">21177871</ArticleId></ArticleIdList></Reference><Reference><Citation>Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDEs) and peptide motifs. Curr Pharm Des. 2010;16:1114&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">20030615</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrels B, et al. A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol. 2010;20:1086&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">20493699</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry S, et al. Targeting of cyclic AMP degradation to &#x3b2;2-adrenergic receptors by &#x3b2;-arrestins. Science. 2002;298:834&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem. 1999;274:14909&#x2013;14917.</Citation><ArticleIdList><ArticleId IdType="pubmed">10329691</ArticleId></ArticleIdList></Reference><Reference><Citation>Craik D, Fairlie D, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81:136&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">23253135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin YY, et al. Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the &#x3b2;-agonist induced hypertrophic response in cardiac myocytes. J Mol Cell Cardiol. 2011;50:872&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">21334344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2010;126:1252&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002752</ArticleId><ArticleId IdType="pubmed">21047676</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Adams DR. Putting the lid on phosphodiesterase 4. Nature Biotech. 2010;28:38&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20062038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Robinson H, Ke H. Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. J Biol Chem. 2010;285:38149&#x2013;38156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992248</ArticleId><ArticleId IdType="pubmed">20861010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz JE, et al. The GAF-tandem domain of PDE5 as a potential drug target. Handb Exp Pharmacol. 2011;204:151&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bers D. Cardiac excitation&#x2013;contraction coupling. Nature. 2002;415:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805843</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy J, Richter W, Mika D. Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice. J Clin Investig. 2011;121:2651&#x2013;2661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223827</ArticleId><ArticleId IdType="pubmed">21670503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnart SE, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123:25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901878</ArticleId><ArticleId IdType="pubmed">16213210</ArticleId></ArticleIdList></Reference><Reference><Citation>Beca S, et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res. 2013;112:289&#x2013;297. This study shows that PDE3A, and not PDE3B, is the primary PDE3 isozyme that modulates basal contractility and calcium content of the sarcoplasmic reticulum by regulating cAMP concentrations in microdomains containing macromolecular complexes (signalosomes) composed of AKAP18, sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2), phospholamban and PDE3A.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579621</ArticleId><ArticleId IdType="pubmed">23168336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerfant B, et al. PI3K&#x3b3; is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101:400&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">17615371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghigo A, et al. Phosphoinositide 3-kinase &#x3b3; protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation. 2012;126:2073&#x2013;2083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913165</ArticleId><ArticleId IdType="pubmed">23008439</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina CE, et al. Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. J Am Coll Cardiol. 2012;59:2182&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pubmed">22676938</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar P, et al. PDE3, but not PDE4, reduces &#x3b2;1- and &#x3b2;2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol. 2013;169:528&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682702</ArticleId><ArticleId IdType="pubmed">23489141</ArticleId></ArticleIdList></Reference><Reference><Citation>Siuciak JA, et al. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology. 2007;53:113&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17559891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cygnar K, Zhao H. Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons. Nature Neurosci. 2009;12:454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712288</ArticleId><ArticleId IdType="pubmed">19305400</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirguis E, et al. A Role for phosphodiesterase 3B in acquisition of brown fat characteristics by white adipose tissue in male mice. Endocrinology. 2013;154:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749478</ArticleId><ArticleId IdType="pubmed">23766131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005;175:1523&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16034090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol. 2003;171:6414&#x2013;6420.</Citation><ArticleIdList><ArticleId IdType="pubmed">14662840</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrucco E, Albergine MS, Santana LF, Beavo JA. Phosphodiesterase 8A (PDE8A) regulates excitation contraction coupling in ventricular myocytes. J Mol Cell Cardiol. 2010;49:330&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885478</ArticleId><ArticleId IdType="pubmed">20353794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LL, et al. Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay. Genes Brain Behav. 2012;11:837&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467314</ArticleId><ArticleId IdType="pubmed">22925203</ArticleId></ArticleIdList></Reference><Reference><Citation>Deninno MP, et al. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett. 2009;19:2537&#x2013;2541.</Citation><ArticleIdList><ArticleId IdType="pubmed">19339180</ArticleId></ArticleIdList></Reference><Reference><Citation>Menniti F, Kleiman R, Schmidt C. PDE9A-mediated regulation of cGMP: Impact on synaptic plasticity. Schizophrenia Research. 2008;102(Suppl 2):38&#x2013;39.</Citation></Reference><Reference><Citation>Seeger TF, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">12967715</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccart E, et al. Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-deficient mice suggest a role for striatal signaling in evaluative salience attribution. Neurobiol Learn Mem. 2011;95:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">21130175</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughney K, Taylor J, Florio VA. 3&#x2032;,5&#x2032;-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res. 2005;17:320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15800651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly MP, et al. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci USA. 2010;107:8457&#x2013;8462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889541</ArticleId><ArticleId IdType="pubmed">20404172</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WB, Katugampola S, Able S, Napier C, Harding SE. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. Life Sci. 2012;90:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">22261303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel DDJ, et al. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circulation. 2006;98:777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114760</ArticleId><ArticleId IdType="pubmed">16514069</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Li J, Paskind M, Epstein PM. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA. 1996;93:11236&#x2013;11241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1074519</ArticleId><ArticleId IdType="pubmed">8855339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisch JD, Behr B, Conti M. Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod. 1998;13:1248&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647555</ArticleId></ArticleIdList></Reference><Reference><Citation>Laddha SS, Bhatnagar SP. A new therapeutic approach in Parkinson&#x2019;s disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Bioorg Med Chem. 2009;17:6796&#x2013;6802.</Citation><ArticleIdList><ArticleId IdType="pubmed">19744861</ArticleId></ArticleIdList></Reference><Reference><Citation>MacFarland RT, Zelus BD, Beavo J. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem. 1991;266:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">1845962</ArticleId></ArticleIdList></Reference><Reference><Citation>Favot L, Keravis T, Holl V, Le Bec A, Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 2003;90:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888882</ArticleId></ArticleIdList></Reference><Reference><Citation>Surapisitchat J, Jeon K, Yan C, Beavo J. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res. 2007;101:811&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704206</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson N, Jang E, Haslam R. cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J. 1997;377:371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218329</ArticleId><ArticleId IdType="pubmed">9163326</ArticleId></ArticleIdList></Reference><Reference><Citation>Reneerkens O, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. 2009;202:419&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704616</ArticleId><ArticleId IdType="pubmed">18709359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambleton R, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem. 2005;280:39168&#x2013;39174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172121</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa M, et al. Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol. 2013;64:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869570</ArticleId><ArticleId IdType="pubmed">23988739</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice D, Haslam R. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990;37:671&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">2160060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao A, Huan J, Gupta S, Pal R, Sahu A. A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nature Neurosci. 2002;5:727&#x2013;728. This report identifies PDE3B as a crucial regulator of feeding behaviour in animals.</Citation><ArticleIdList><ArticleId IdType="pubmed">12101402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, et al. Inhibition of phosphodiesterase-4 reverses memory deficits produced by A&#x3b2;25&#x2013;35 or A&#x3b2;1&#x2013;40 peptide in rats. Psychopharmacology. 2010;212:181&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">20640406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tralau-Stewart C, Williamson R. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011;337:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">21205923</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;umer W, et al. AWD 12&#x2013;281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol. 2003;55:1107&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12956900</ArticleId></ArticleIdList></Reference><Reference><Citation>Marko D, et al. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem Biophys. 1998;28:75&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515161</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid D, Pham N. Roflumilast: a novel treatment for chronic obstructive pulmonary disease. Ann Pharmacother. 2012;46:521&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">22433610</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnette MS, et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther. 1998;284:420&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Mix E, Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 2001;7:387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741679</ArticleId><ArticleId IdType="pubmed">11830756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickston SJ, Snider KR, Kappus MR. Tetomilast: new promise for phosphodiesterase-4 inhibitors? Expert Opin Investig Drugs. 2012;21:1845&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pubmed">23043390</ArticleId></ArticleIdList></Reference><Reference><Citation>Man H, et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-&#x3b1; inhibitor. J Med Chem. 2009;52:1522&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">19256507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang R, et al. Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Bioorg Med Chem Lett. 2012;22:2594&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pubmed">22401864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012;188:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704456</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson K, de Groat W. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism (s) of action. Neurourol Urodyn. 2011;30:292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">21284024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh T, Kang K, Ahn B, Yoo M, Kim W. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharmacol Res. 2000;23:471&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, et al. The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. J Vet Med Sci. 2008;70:1199&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19057138</ArticleId></ArticleIdList></Reference><Reference><Citation>Galie N, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148&#x2013;2157.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadoshima-Yamaoka K, et al. ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-&#x3b3; production by mouse activated T lymphocytes. Immunol Lett. 2009;122:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19195485</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, et al. Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson&#x2019;s disease model. Bioorg Med Chem Lett. 2012;22:6286&#x2013;6291.</Citation><ArticleIdList><ArticleId IdType="pubmed">22944118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Osmanova V, Epstein PM, Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem Biophys Res Commun. 2006;345:713&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">16696947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddie S, Anderson KL, Paz A, Itzhak Y. The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice. J Psychopharmacol. 2012;26:1375&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">22596207</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif. 2012;45:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6496613</ArticleId><ArticleId IdType="pubmed">22469131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunder F, Tersteegen A, Rebmann A. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol. 2005;68:1775&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutson PH, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology. 2011;61:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">21619887</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, et al. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. PLoS ONE. 2011;6:e18136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073929</ArticleId><ArticleId IdType="pubmed">21494592</ArticleId></ArticleIdList></Reference><Reference><Citation>Helal CJ, et al. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. J Med Chem. 2011;54:4536&#x2013;4547.</Citation><ArticleIdList><ArticleId IdType="pubmed">21650160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu E, Ma J, Biorn C. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem. 2012;55:4776&#x2013;4787.</Citation><ArticleIdList><ArticleId IdType="pubmed">22548439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzasa RM, et al. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux. Bioorg Med Chem Lett. 2012;22:7371&#x2013;7375.</Citation><ArticleIdList><ArticleId IdType="pubmed">23149228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer U, et al. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. Bioorg Med Chem Lett. 2012;22:1944&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">22321214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofgen N, et al. Discovery of imidazo[1,5-a] pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. J Med Chem. 2010;53:4399&#x2013;4411.</Citation><ArticleIdList><ArticleId IdType="pubmed">20450197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutshall NS, et al. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. Bioorg Med Chem Lett. 2012;22:5595&#x2013;5599.</Citation><ArticleIdList><ArticleId IdType="pubmed">22841436</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis SH. Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J Impot Res. 2005;17:467&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">16079899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA. 2006;103:15124&#x2013;15129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1581426</ArticleId><ArticleId IdType="pubmed">17008408</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CL, et al. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Bas Res Cardiol. 2011;106:1023&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114346</ArticleId><ArticleId IdType="pubmed">22012077</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, et al. Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31:616&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114343</ArticleId><ArticleId IdType="pubmed">21148428</ArticleId></ArticleIdList></Reference><Reference><Citation>Acin-Perez R, et al. A phosphodiesterase 2A isoform localized to mitochondria regulates respiration. J Biol Chem. 2011;286:30423&#x2013;30432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162402</ArticleId><ArticleId IdType="pubmed">21724846</ArticleId></ArticleIdList></Reference><Reference><Citation>Russwurm C, Zoidl G, Koesling D, Russwurm M. Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem. 2009;284:25782&#x2013;25790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757980</ArticleId><ArticleId IdType="pubmed">19632989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed TMA, et al. Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem. 2011;286:41520&#x2013;41529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308863</ArticleId><ArticleId IdType="pubmed">21965681</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro LRV, Schittl J, Fischmeister R. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res. 2010;107:1232&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847310</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka K, et al. Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel. Arterioscler Thromb Vasc Biol. 2011;31:2278&#x2013;2286.</Citation><ArticleIdList><ArticleId IdType="pubmed">21799177</ArticleId></ArticleIdList></Reference><Reference><Citation>Puxeddu E, et al. Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity. Proc Natl Acad Sci USA. 2009;106:6158&#x2013;6163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662965</ArticleId><ArticleId IdType="pubmed">19332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Penmatsa H, et al. Compartmentalized cAMP at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell. 2010;21:1097&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836961</ArticleId><ArticleId IdType="pubmed">20089840</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozuelo Rubio M, Campbell DG, Morrice NA, Mackintosh C. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J. 2005;392:163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317675</ArticleId><ArticleId IdType="pubmed">16153182</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer D, et al. Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. J Biol Chem. 2007;282:9411&#x2013;9419.</Citation><ArticleIdList><ArticleId IdType="pubmed">17255105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, et al. Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J. 2007;404:257&#x2013;268. This study demonstrates that, in 3T3-L1 adipocytes, insulin-induced phosphorylation and activation of membrane-associated PDE3B is co-ordinated with its incorporation into a signalosome containing components of the insulin signalling pathway.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868803</ArticleId><ArticleId IdType="pubmed">17324123</ArticleId></ArticleIdList></Reference><Reference><Citation>Perino A, et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110&#x3b3;. Mol Cell. 2011;42:84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265115</ArticleId><ArticleId IdType="pubmed">21474070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs BD, et al. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J Cell Biol. 2007;177:1119&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064370</ArticleId><ArticleId IdType="pubmed">17576803</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian F, et al. p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cell Signal. 2010;22:1576&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">20600853</ArticleId></ArticleIdList></Reference><Reference><Citation>Huston E, Gall I, Houslay TM, Houslay MD. Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+ J Cell Sci. 2006;119:3799&#x2013;3810.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajpai M, et al. AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa. Biol Reprod. 2006;74:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352331</ArticleId><ArticleId IdType="pubmed">16177223</ArticleId></ArticleIdList></Reference><Reference><Citation>Asirvatham AL, et al. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol. 2004;173:4806&#x2013;4814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcphee I, et al. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific PDE HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem. 1999;274:11796&#x2013;11810.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger GB, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278:33351&#x2013;33363.</Citation><ArticleIdList><ArticleId IdType="pubmed">12810716</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JK, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw NJ, et al. DISC1, PDE4B, and NDE1 at the centrosome and synapse. Biochem Biophys Res Commun. 2008;377:1091&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">18983980</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YH, et al. Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci USA. 2011;108:10679&#x2013;10684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127890</ArticleId><ArticleId IdType="pubmed">21670265</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillie GS, et al. &#x3b2;-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates &#x3b2;-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA. 2003;100:940&#x2013;945. This is the first demonstration that a direct interaction between PDE4 and &#x3b2;-arrestin controls &#x3b2;-adrenergic receptor-mediated signalling in cells.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298705</ArticleId><ArticleId IdType="pubmed">12552097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HW, et al. Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D. Mol Cell Biol. 2010;30:5406&#x2013;5420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2976372</ArticleId><ArticleId IdType="pubmed">20837708</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde I, et al. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem. 2001;276:11189&#x2013;11198.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134006</ArticleId></ArticleIdList></Reference><Reference><Citation>Beca S, et al. Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current. Circ Res. 2011;109:1024&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138878</ArticleId><ArticleId IdType="pubmed">21903937</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo Z, et al. Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D. Biochem Biophys Res Commun. 2012;427:73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">22975349</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan E, et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol. 2007;18:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135396</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge-Kafka KL, et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078&#x2013;11086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856983</ArticleId><ArticleId IdType="pubmed">20106966</ArticleId></ArticleIdList></Reference><Reference><Citation>Halls ML, Cooper DMF. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, &#x3b2;-arrestin 2, PDE4D3 complex. EMBO J. 2010;29:2772&#x2013;2787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924647</ArticleId><ArticleId IdType="pubmed">20664520</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrenoire C, Houslay MD, Baillie GS, Kass RS. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem. 2009;284:9140&#x2013;9146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666564</ArticleId><ArticleId IdType="pubmed">19218243</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond DR, Carter RL, Ward CA, Maurice DH. Distinct phosphodiesterase-4D variants integrate into protein kinase A-based signaling complexes in cardiac and vascular myocytes. Am J Physiol Heart Circ Physiol. 2009;296:H263&#x2013;H271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19060129</ArticleId></ArticleIdList></Reference><Reference><Citation>Creighton J, Zhu B, Alexeyev M, Stevens T. Spectrin-anchored phosphodiesterase 4D4 restricts cAMP from disrupting microtubules and inducing endothelial cell gap formation. J Cell Sci. 2008;121:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073242</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard MB, O&#x2019;Connell JC, Bolger GB, Houslay MD. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett. 1999;460:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571082</ArticleId></ArticleIdList></Reference><Reference><Citation>De Arcangelis V, Liu R, Soto D, Xiang Y. Differential association of phosphodiesterase 4D isoforms with &#x3b2;2-adrenoceptor in cardiac myocytes. J Biol Chem. 2009;284:33824&#x2013;33832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797152</ArticleId><ArticleId IdType="pubmed">19801680</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter W, et al. Signaling from &#x3b2;1- and &#x3b2;2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 2008;27:384&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196435</ArticleId><ArticleId IdType="pubmed">18188154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, et al. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation. 2012;126:942&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428375</ArticleId><ArticleId IdType="pubmed">22829024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson L, Elbatarny H, Crawley S, Bennett B, Maurice DH. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci USA. 2008;105:13650&#x2013;13655. This is the first report to show that compartmentalization of a PDE &#x2014; PDE5 &#x2014; occurs in a cell type (human platelets) in which PDE5 is the sole cGMP&#x2013;PDE activity present.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533244</ArticleId><ArticleId IdType="pubmed">18757735</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Sonati P, Rubin C, Michaeli T. PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem. 2006;281:15050&#x2013;15057.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Wang P. Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with I&#x3ba;B proteins. Proc Natl Acad Sci USA. 2004;101:17634&#x2013;17639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539753</ArticleId><ArticleId IdType="pubmed">15596729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24628851</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Identification and characterization of the MicroRNA profile in aging rats with erectile dysfunction.</ArticleTitle><Pagination><StartPage>1646</StartPage><EndPage>1656</EndPage><MedlinePgn>1646-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12500</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Aging-related erectile dysfunction (A-ED) is a neurovascular and refractory disorder with complicated pathophysiological mechanisms and a high prevalence. MicroRNAs (miRNAs), which modulate a variety of cell functions, may be involved in the pathophysiological processes of this disorder.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the miRNA profile in the corpus cavernosum (CC) of aging rats with ED, and to analyze the target genes and signaling pathways regulated by the dysregulated miRNAs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">According to the apomorphine test, the experimental animals were divided into three groups: aging rats with ED (group AE), aging rats with normal erectile function (group AN), and young rats as normal controls (group YN). After the erectile functional test, CCs from each group were then collected for histological and molecular measurements.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Intracavernous pressure response to electric stimulation of the cavernous nerve was used to evaluate erectile function. Histological changes within CC were evaluated using immunofluorescent staining. GeneChip array was used to analyze the miRNA expression profiling. The miRNA profilings were further validated by real-time polymerase chain reaction. The TargetScan or DAIAN web platform and DAVID were used for bioinformatic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Accompanied with significantly decreased erectile function, the content of smooth muscle and endothelium within the CC of rats with A-ED was significantly decreased compared with both AN group and YN group. miR-1, miR-200a, miR-203, and miR-206 were found and validated up-regulating with above twofold change in AE group. According to the bioinformatics analysis, the four up-expressing miRNAs could regulate eNOS/NO/PKG and PGE1/PKA pathways through regulating 13 target genes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Four miRNAs were found up-regulated significantly in the CC of rats with A-ED. The four miRNAs might play important roles in the development of A-ED by regulating the eNOS/NO/PKG and PGE1/PKA pathways despite lots of experiments still need to be validated.</AbstractText><CopyrightInformation>&#xa9; 2014 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Andrology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China; Department of Andrology, Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qipeng</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Xuefeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wen</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jiadong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Taowei</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Lianjun</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yutian</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496316">Nos3 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.11</RegistryNumber><NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017868" MajorTopicYN="N">Cyclic AMP-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052250" MajorTopicYN="N">Nitric Oxide Synthase Type III</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Array Analysis</Keyword><Keyword MajorTopicYN="N">Endothelial Nitric Oxide Synthase</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">PKA</Keyword><Keyword MajorTopicYN="N">PKG</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24628851</ArticleId><ArticleId IdType="doi">10.1111/jsm.12500</ArticleId><ArticleId IdType="pii">S1743-6095(15)30809-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24515231</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2014</Volume><PubDate><Year>2014</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Corpus cavernosum abscess after Winter procedure performance.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">bcr2013202089</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2013-202089</ELocationID><Abstract><AbstractText>A 23-year-old male patient with sickle-cell disease reported his third episode of priapism complicated by the presence of a corpus cavernosum abscess after the performance of a Winter procedure 20 days prior to his presentation. While in hospital for 11 days, two penile needle aspirations and three surgical drainages were performed with associated antibiotic therapy. He evolved with erectile dysfunction refractory to drug therapy and his infectious condition improved. An early penile prosthesis implantation followed after the use of a vacuum pump in an attempt to decrease the fibrotic process of the corpora cavernosa. Final results were positive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paladino</LastName><ForeName>Joao Roberto</ForeName><Initials>JR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Urology, ABC Medical School, Santo Andre, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Fabio Jose</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Gromatsky</LastName><ForeName>Celso</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pompeo</LastName><ForeName>Antonio Carlos Lima</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000038" MajorTopicYN="N">Abscess</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000755" MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24515231</ArticleId><ArticleId IdType="pmc">PMC3926446</ArticleId><ArticleId IdType="doi">10.1136/bcr-2013-202089</ArticleId><ArticleId IdType="pii">bcr-2013-202089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morrison BF, Burnett AL. Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep 2012;13:268&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">22648304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheirandish P, Chinegwundoh F, Kulkarni S. Treating stuttering priapism. BJU Int 2011;108:1068&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">21914108</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedrach WL, Lerner RM, Linke CA. Penile abscess involving the corpus cavernosum: a case report. J Urol 1989;141:374&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">2643728</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios A, Mass&#xf3; P, Versos R, et al. Absceso del pene. A prop&#xf3;sito de un caso. Arch Esp Urol 2006;59:809&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">17153501</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar J, Sagar B, Shah DK. Spontaneous penile (cavernosal) abscess: case report with discussion of aetiology, diagnosis, and management with review of literature. ScientificWorldJournal 2005;5:39&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5936512</ArticleId><ArticleId IdType="pubmed">15674448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehara H, Kojima K, Hagiwara N, et al. Abscess of the corpus cavernosum. Int J Infect Dis 2007;11:553&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">17398131</ArticleId></ArticleIdList></Reference><Reference><Citation>Velcek D, Evans JA. Cavernosography. Radiology 1982;144:781&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">7111724</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen T. Unusual presentations of gonorrhea. J Am Acad Dermatol 1982;6:369&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">7068965</ArticleId></ArticleIdList></Reference><Reference><Citation>Orvis BR, Lue TF. New therapy for impotence. Urol Clin North Am 1987;14:569&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">2887053</ArticleId></ArticleIdList></Reference><Reference><Citation>Koksal T, Kadioglu A, Tefekli A, et al. Spontaneous bacterial abscess of bilateral cavernosal bodies. BJU Int 1999;84:1107&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">10571649</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearle MS, Wendel EF. Necrotizing cavernositis secondary to periodontal abscess. J Urol 1993;149:1137&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">8483233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24430278</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Pharmacologically induced erect penile length and stretched penile length are both good predictors of post-inflatable prosthesis penile length.</ArticleTitle><Pagination><StartPage>128</StartPage><EndPage>131</EndPage><MedlinePgn>128-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ijir.2013.50</ELocationID><Abstract><AbstractText>Inflatable penile prosthesis (IPP) remains the gold standard for the surgical treatment of refractory erectile dysfunction; however, current literature to aid surgeons on how best to counsel patients on their postoperative inflated penile length is lacking. The aim of this study was to identify preoperative parameters that could better predict postoperative penile length following insertion of an IPP. Twenty men were enrolled in a prospective study examining penile lengths before and after IPP surgery. Patients with Peyronie's disease were excluded from this analysis. Baseline preoperative characteristics, including body mass index, history of hypertension, diabetes, Sexual Health Inventory for Men scores and/or prior radical prostatectomy were recorded. All patients underwent implantation with a three-piece inflatable Coloplast penile prosthesis. We compared stretched penile length to pharmacologically induced erect lengths. Postoperatively, we measured inflated penile lengths at 6 weeks and assessed patients' perception of penile size at 12 weeks. The median (&#xb1;interquartile range) stretched penile length and pharmacologically induced erect penile length was 15 (&#xb1;3) and 14.25 (&#xb1;2)&#x2009;cm, respectively (P=0.5). Median post-prosthesis penile length (13.5&#xb1;2.13&#x2009;cm) was smaller than preoperative pharmacologically induced length (P=0.02) and preoperative stretched penile length (P=0.01). The majority of patients (70%) had a decrease in penile length (median loss 0.5&#xb1;1.5&#x2009;cm); however, this loss was perceptible by 43% of men. Stretched penile length and pharmacologically induced erect penile length were equally good predictors of postoperative inflated length (Spearman's correlation 0.8 and 0.9, respectively). Pharmacologically induced erect penile length and stretched penile lengths are equal predictors of post-prosthesis penile length. The majority of men will experience some decrease in penile length following prosthesis implantation; however &lt;50% report a subjective loss of penile length.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osterberg</LastName><ForeName>E C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maganty</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Depeartment of Urology, North Shore Long Island Jewish Lenox Hill Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 HD073917</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057234" MajorTopicYN="N">Preoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>CONFLICT OF INTEREST</b>. JFE receives compensation as a consultant for Coloplast Inc. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24430278</ArticleId><ArticleId IdType="mid">NIHMS666024</ArticleId><ArticleId IdType="pmc">PMC4342061</ArticleId><ArticleId IdType="doi">10.1038/ijir.2013.50</ArticleId><ArticleId IdType="pii">ijir201350</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647654</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996&#x2013;3002.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414947</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlow WL, Goldwasser B, Gundian JC. Implantation of model AMS 700 penile prosthesis: long-term results. J Urol. 1988;139:741&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">3352035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629377</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK. Penile prosthesis implantation: size matters. Eur Urol. 2007;51:887&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">17081674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondaini N, Ponchietti R, Gontero P, Muir GH, Natali A, Caldarera E, et al. Penile length is normal in most men seeking penile lengthening procedures. Int J Impot Res. 2002;14:283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152118</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O. Supersizing the penis following penile prosthesis implantation. J Sex Med. 2010;7:2608&#x2013;2616.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233283</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Sousa A, Keating M, Moreira S, Baker M, Carrion R. Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery. J Sex Med. 2007;4:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17727355</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveci S, Martin D, Parker M, Mulhall JP. Penile length alterations following penile prosthesis surgery. Eur Urol. 2007;51:1128&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Howard GE, Hoang A, Yuan JH, Lin HC, Dai YT. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl. 2009;11:411&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735309</ArticleId><ArticleId IdType="pubmed">19525974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe&#xf1;a BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">10637462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf JS, Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">18280509</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF. No-touch technique. J Sex Med. 2011;8:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid JF, Wilson SK, Cleves M, Salem EA. Coated implants and &#x2018;no touch&#x2019; surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46% Urology. 2012;79:1310&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessells H, Lue TF, McAninch JW. Penile length in the flaccid and erect states: guidelines for penile augmentation. J Urol. 1996;156:995&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">8709382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Jahoda A, Aviv N, Valenzuela R, Parker M. The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. BJU Int. 2004;93:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678377</ArticleId></ArticleIdList></Reference><Reference><Citation>Benevides MD, Carson CC. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J Urol. 2000;163:785&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">10687977</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges F, Hakim L, Kline C. Surgical technique to maintain penile length after insertion of an inflatable penile prosthesis via infrapubic approach. J Sex Med. 2006;3:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">16681481</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry G, Houghton L, Culkin D, Otheguy J, Shabsigh R, Ohl DA. Comparison of a new length measurement technique for inflatable penile prosthesis implantation to standard techniques: outcomes and patient satisfaction. J Sex Med. 2011;8:2640&#x2013;2646.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679300</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague DK, Angermeier KW. Increasing size with penile implants. Curr Urol Rep. 2008;9:483&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">18947513</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch JA, Angermeier KW, Lakin MM, Ingleright BJ, Montague DK. Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: comparison of CX/CXM and Ultrex cylinders. J Urol. 1997;158:1400&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SK, Cleves MA, Delk JR., 2nd Ultrex cylinders: problems with uncontrolled lengthening (the S-shaped deformity) J Urol. 1996;155:135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490811</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoie M, Kim SS, Soloway MS. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol. 2003;169:1462&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629384</ArticleId></ArticleIdList></Reference><Reference><Citation>Munding MD, Wessells HB, Dalkin BL. Pilot study of changes in stretched penile length 3 months after radical retropubic prostatectomy. Urology. 2001;58:567&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">11597540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontero P, Galzerano M, Bartoletti R, Magnani C, Tizzani A, Frea B, et al. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. J Urol. 2007;178:602&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570431</ArticleId></ArticleIdList></Reference><Reference><Citation>Briganti A, Fabbri F, Salonia A, Gallina A, Chun FK, Deh&#xf2; F, et al. Preserved post-operative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. Eur Urol. 2007;52:702&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17418936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27784554</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>History, Contemporary Outcomes, and Future of Penile Prostheses: A Review of the Literature.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>163</EndPage><MedlinePgn>150-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/smrj.8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(15)30074-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Since their introduction, penile prostheses have consistently remained a superior treatment option for men with erectile dysfunction (ED) refractory to conservative measures. Ongoing enhancements to prosthetic design, materials, and surgical techniques have resulted in improved outcomes.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review available literature on notable historical advancements and improvements of the penile prosthesis, summarize contemporary outcomes of recent devices, and discuss possible future directions of the penile prosthesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A PubMed search was performed of all articles published from 1960 to present relating to penile prosthesis. Priority was given to series with 12 months of follow-up or greater, larger series, and studies reporting on outcomes of more recent prosthetic models.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Main outcomes included historical review of improvements leading to, and contemporary series reporting on rates of mechanical failures, infections, and satisfaction with penile prostheses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Penile prostheses have undergone numerous enhancements since initial reports of synthetic materials utilized in the 1950s. Among others, recent notable device enhancements include Parylene coating, Bioflex&#xae; material, Inhibizone<sup>TM</sup> antibacterial impregnation, hydrophilic coating, lockout valves, and easy release pump mechanisms, all of which have improved mechanical reliability, reduced infection rates, and/or improved patient satisfaction with penile prostheses. Contemporary series of 3-piece penile prostheses report mechanical survival of 81-94%, 68-89%, and 57-76% at 5, 10, and 15 years, respectively. Infection rates of current devices are 1-2% in first-time, low-risk populations, and 2-3% for higher risk groups, with patient and partner satisfaction at 92-100% and 91-95%, respectively. Two-piece and malleable devices are associated with slightly higher mechanical reliability and decreased patient satisfaction. Minimal data currently exist on the outcomes of selected patient populations, including Peyronie's disease and corporal fibrosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Penile prostheses are associated with excellent, long-term outcomes and remain the gold-standard treatment for men with refractory ED. Additional research with prospective studies utilizing objective measures and standardized questionnaires is required. Trost L and Hellstrom WJG. History, contemporary outcomes, and future of penile prostheses: A review of the literature. Sex Med Rev 2013;1:150-163.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Landon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: whellst@tulane.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">IPP</Keyword><Keyword MajorTopicYN="N">Peyronie's Disease</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27784554</ArticleId><ArticleId IdType="doi">10.1002/smrj.8</ArticleId><ArticleId IdType="pii">S2050-0521(15)30074-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24034543</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction.</ArticleTitle><Pagination><StartPage>2774</StartPage><EndPage>2781</EndPage><MedlinePgn>2774-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12311</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patient and female partner satisfaction after implantation of an inflatable penile prosthesis (IPP) assessed by objective means, and the correlation between the partners, is important for determining postoperative sexual life.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The primary goal was to evaluate patients' erectile function and patients' and their partners' satisfaction after IPP implantation. A secondary aim was to investigate potential determinative factors of satisfaction according to device characteristics, demographics, and cause of erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ninety patients, who underwent IPP implantation as an alternative to refractory or undesirable medical treatment for ED, were evaluated. Patients who could not or refused to participate, or were out of a relationship, were excluded. The 69 remaining patients were evaluated for their pre- and postoperative erectile function and posttreatment satisfaction for themselves and their partners.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Preoperative and postoperative scores on the International Index of Erectile Function Questionnaire-five items (IIEF-5) were compared. The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) was given to males and their female partners. Patient demographics, etiology of ED, and implant characteristics were correlated also with patients' EDITS scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean IIEF-5 scores demonstrated a significant improvement after IPP implantation: from 8.88&#xb1;3.75 to 20.97&#xb1;4.37 (P&lt;0.001). The mean patients' EDITS score was 75.48&#xb1;20.54, whereas mean female partners' score was 70.00&#xb1;22.92, highlighting high posttreatment satisfaction for both. Regression analysis suggested a direct linear correlation of satisfaction between the sexual partners as a degree of satisfaction. There were no statistically significant differences according to level of education or implant characteristics. Concerning the etiology of ED, no conclusions could be made.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overcoming previous limitations in determining post-IPP implantation satisfaction, our study reiterates high rates of patient and partner satisfaction. Of particular note, patient satisfaction appears independent of prosthesis type and cylinder length.</AbstractText><CopyrightInformation>&#xa9; 2013 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vakalopoulos</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>A' Urologic Department, Aristotle University of Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampantais</LastName><ForeName>Spyridon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>Stavros</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Laskaridis</LastName><ForeName>Leonidas</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Toutziaris</LastName><ForeName>Chrysovalantis</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Koptsis</LastName><ForeName>Michail</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Katsikas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2014 Apr;191(4):1078</RefSource><PMID Version="1">24703143</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012747" MajorTopicYN="N">Sexual Partners</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Couples Sexual Function</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Female Partner Satisfaction</Keyword><Keyword MajorTopicYN="N">Inflatable Penile Prosthesis</Keyword><Keyword MajorTopicYN="N">Sexual Satisfaction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24034543</ArticleId><ArticleId IdType="doi">10.1111/jsm.12311</ArticleId><ArticleId IdType="pii">S1743-6095(15)30173-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26558095</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>Treatments for fibrosis of the corpora cavernosa.</ArticleTitle><Pagination><StartPage>294</StartPage><EndPage>298</EndPage><MedlinePgn>294-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aju.2013.05.004</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Corporal fibrosis usually occurs after explantation of an infected penile prosthesis, severe penile trauma, refractory low-flow priapism, Peyronie's disease, or the chronic intracavernous injection of vasoactive drugs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed current treatmentss for penile fibrosis. We searched PubMed using the keywords 'penile corporal fibrosis', 'treatment' and 'penile fibrosis', resulting in 63 matches, of which 19 articles met the inclusion criteria.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">This review covers conservative medical therapy for corporal fibrosis and surgical therapeutic methods. The roles of phosphodiesterase- 5 inhibitors and pentoxifylline are analysed. Surgical therapy includes implantation of a penile prosthesis and corporal reconstruction, and these are reviewed. Corporal fibrosis is a major problem for patients, and is associated with severe erectile dysfunction. Conservative treatment options can be applicable in the early phase, but simultaneous corporal reconstruction procedures with concomitant implantation of a penile prosthesis should be attempted in severe cases of corporal fibrosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Egydio</LastName><ForeName>Paulo H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Center for Peyronie's Disease Reconstruction, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuehhas</LastName><ForeName>Franklin E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Medical University of Vienna, Department of Urology, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Corporal fibrosis</Keyword><Keyword MajorTopicYN="N">ED, erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">ICI, intracavernous injection</Keyword><Keyword MajorTopicYN="N">PD, Peyronie&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">PDE5I, phosphodiesterase 5 inhibitors</Keyword><Keyword MajorTopicYN="N">PGE1, prostaglandin E1</Keyword><Keyword MajorTopicYN="N">Penile fibrosis</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26558095</ArticleId><ArticleId IdType="pmc">PMC4443017</ArticleId><ArticleId IdType="doi">10.1016/j.aju.2013.05.004</ArticleId><ArticleId IdType="pii">S2090-598X(13)00068-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gonzalez-Cadavid N.F. Mechanisms of penile fibrosis. J Sex Med. 2009;6(Suppl. 3):353&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19267860</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono F., Giannella R., Somma P., Manno G., Fusco F., Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005;173:1673&#x2013;1676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15821546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K. Reimplantation of inflatable penile prosthesis into scarred corporeal bodies. Int J Impot Res. 2003;15(Suppl. 5):S125&#x2013;S128.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551589</ArticleId></ArticleIdList></Reference><Reference><Citation>Orvis B.R., McAninch J.W. Penile rupture. Urol Clin North Am. 1989;16:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">2652861</ArticleId></ArticleIdList></Reference><Reference><Citation>Stember D.S., Mulhall J.P. Ischemic priapism and implant surgery with sharp corporal fibrosis excision. J Sex Med. 2010;7:1987&#x2013;1990.</Citation><ArticleIdList><ArticleId IdType="pubmed">20929513</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine L.A., Benson J., Hoover C. Inflatable penile prosthesis placement in men with Peyronie&#x2019;s disease and drug-resistant erectile dysfunction: a single-center study. J Sex Med. 2010;7:3775&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20722782</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry G.D., Laborde E. A review of surgical techniques for impending distal erosion and intraoperative penile implant complications: part 2 of a three-part review series on penile prosthetic surgery. J Sex Med. 2012;9:927&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248013</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen E.H., Gasser T.C., Bruskewitz R.C. Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine. J Urol. 1987;137:292&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">3806824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew K.K., Stuckey B.G., Earle C.M., Dhaliwal S.S., Keogh E.J. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res. 1997;9:225&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">9442421</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sakka A.I., Yassin A.A. Amelioration of penile fibrosis: myth or reality. J Androl. 2010;31:324&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">19926883</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cadavid N.F., Rajfer J. Treatment of Peyronie&#x2019;s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini M.G., Kovanecz I., Sanchez S., Vernet D., Davila H.H., Rajfer J. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76:915&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287493</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 1997;79:958&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202566</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I., Horvath A., Azevedo M., de Alexandre R.B., Stratakis C.A. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11:689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727450</ArticleId><ArticleId IdType="pubmed">22047791</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahran A.R., Daiem H.A., Youssif M. Does pentoxifylline enhance the recovery of erectile function after a T-shunt procedure for prolonged ischaemic priapism? A prospective randomised controlled trial. Arab J Urol. 2012;10:425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442918</ArticleId><ArticleId IdType="pubmed">26558062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.Q., Lesser T.F., Kim D.H., Aboseif S.R. Penile corporeal reconstruction during difficult placement of a penile prosthesis. Adv Urol. 2008:370947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581727</ArticleId><ArticleId IdType="pubmed">19009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansalone S., Garaffa G., Djinovic R., Antonini G., Vespasiani G., Ieria F.P. Simultaneous total corporal reconstruction and implantation of a penile prosthesis in patients with erectile dysfunction and severe fibrosis of the corpora cavernosa. J Sex Med. 2012;9:1937&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom W.J., Montague D.K., Moncada I., Carson C., Minhas S., Faria G. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7:501&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.K., Delk J.R., Mulcahy J.J., Cleves M., Salem E.A. Upsizing of inflatable penile implant cylinders in patients with corporal fibrosis. J Sex Med. 2006;3:736&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839331</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio P.H., Kuehhas F.E., Sansalone S. Penile length and girth restoration in severe Peyronie&#x2019;s disease using circular and longitudinal grafting. BJU Int. 2013;111:E213&#x2013;E219.</Citation><ArticleIdList><ArticleId IdType="pubmed">23107452</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Salamanca J.I., Mueller A., Moncada I., Carballido J., Mulhall J.P. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J Sex Med. 2011;8:1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21492405</ArticleId></ArticleIdList></Reference><Reference><Citation>George V.K., Shah G.S., Mills R., Dhabuwala C.B. The management of extensive penile fibrosis: a new technique of &#x2018;minimal scar-tissue excision&#x2019;. Br J Urol. 1996;77:282&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8800900</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague D.K., Angermeier K.W. Corporeal excavation: new technique for penile prosthesis implantation in men with severe corporeal fibrosis. Urology. 2006;67:1072&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O., Shaeer A. Corporoscopic excavation of the fibrosed corpora cavernosa for penile prosthesis implantation: optical corporotomy and trans-corporeal resection, Shaeer&#x2019;s technique. J Sex Med. 2007;4:218&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">17081216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O. Implantation of penile prosthesis in cases of corporeal fibrosis: modified Shaeer&#x2019;s excavation technique. J Sex Med. 2008;5:2470&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">18624970</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll L.D., Fisher J., Benson R.C., Jr., Bilhartz D.L., Minich P.J., Furlow W.L. Treatment of penile fibrosis with prosthetic implantation and flap advancement with tissue debulking. J Urol. 1996;156:394&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8683687</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin-Olugbade O., Parker M., Guhring P., Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3:743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference><Reference><Citation>Djinovic R. Penile corporoplasty in Peyronie&#x2019;s disease: which technique, which graft? Curr Opin Urol. 2011;21:470&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">21941186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Howard G.E., Hoang A., Yuan J.H., Lin H.C., Dai Y.T. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl. 2009;11:411&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735309</ArticleId><ArticleId IdType="pubmed">19525974</ArticleId></ArticleIdList></Reference><Reference><Citation>Garaffa G., Sansalone S., Ralph D.J. Penile reconstruction. Asian J Androl. 2013;15:16&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739136</ArticleId><ArticleId IdType="pubmed">22426595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue T.F., El-Sakka A.I. Lengthening shortened penis caused by Peyronie&#x2019;s disease using circular venous grafting and daily stretching with a vacuum erection device. J Urol. 1999;161:1141&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">10081856</ArticleId></ArticleIdList></Reference><Reference><Citation>Egydio P., Perovic S.V., Sansalone S. Surgical treatment of severe Peyronie&#x2019;s disease for maximum penile length and girth gain. J Urol. 2008;179(Suppl.):256.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph D.J., Minhas S. The management of Peyronie&#x2019;s disease. BJU Int. 2004;93:208&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph D., Gonzalez-Cadavid N., Mirone V., Perovic S., Sohn M., Usta M. The management of Peyronie&#x2019;s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359&#x2013;2374.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A., Sanli O., Akman T., Ersay A., Guven S., Mammadov F. Graft materials in Peyronie&#x2019;s disease surgery: a comprehensive review. J Sex Med. 2007;4:581&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17419820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26558082</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2090-598X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Arab journal of urology</Title><ISOAbbreviation>Arab J Urol</ISOAbbreviation></Journal><ArticleTitle>Sexual dysfunction in 2013: Advances in epidemiology, diagnosis and treatment.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>202</EndPage><MedlinePgn>194-202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aju.2013.06.002</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To provide a contemporary review of the epidemiology, diagnosis and treatment of premature ejaculation (PE) and erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched for English-language articles published in the past 12&#xa0;months using the PubMed database. Relevant articles on the subjects of sexual dysfunction, ED and PE were selected for review.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Recent studies on male sexual dysfunction have provided new therapeutic possibilities. Tramadol, a well-used analgesic, has a new role in the treatment of PE. Super-selective targeting of dorsal penile nerves by surgery or cryoablative technologies might become a viable treatment option for refractory PE in the future. The role of ED as a harbinger of important comorbidities allows for the early detection and intervention of these conditions, which can optimise therapeutic outcomes. The long-term effect of chronic phosphodiesterase-5 inhibitors on endothelial dysfunction, the angiogenic potential of low-intensity extracorporeal shock wave therapy, and further advances in drug-eluting endovascular stents might in future allow clinicians to treat ED more definitively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>King Chien Joe</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Urology, National University Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahmy</LastName><ForeName>Nader</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Urology, St Joseph's Health Care, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Gerald B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Division of Urology, St Joseph's Health Care, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arab J Urol</MedlineTA><NlmUniqueID>101562480</NlmUniqueID><ISSNLinking>2090-598X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cryoablation</Keyword><Keyword MajorTopicYN="N">Endovascular therapy</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Erectile</Keyword><Keyword MajorTopicYN="N">Premature ejaculation</Keyword><Keyword MajorTopicYN="N">Sexual dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26558082</ArticleId><ArticleId IdType="pmc">PMC4442993</ArticleId><ArticleId IdType="doi">10.1016/j.aju.2013.06.002</ArticleId><ArticleId IdType="pii">S2090-598X(13)00076-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jannini E.A., Maggi M., Lenzi A. Evaluation of premature ejaculation. J Sex Med. 2011;8(Suppl. 4):328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">21554554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen R, Porst H, Montorsi F. The Premature Ejaculation Prevalence and Attitudes (PEPA) Survey: a Multi-National Survey [Abstract]. Proceedings of the 11th World Congress of the International Society of Sexual and Impotence Research 2004, 17&#x2013;21 October 2004.</Citation></Reference><Reference><Citation>Santtila P., Jern P., Westberg L., Walum H., Pedersen C.T., Eriksson E. The dopamine transporter gene (DAT1) polymorphism is associated with premature ejaculation. J Sex Med. 2010;7:1538&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pubmed">20141587</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen P.K., Bakker S.C., R&#xe9;thelyi J., Zwinderman A.H., Touw D.J., Olivier B. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med. 2009;6:276&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">19170855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jern P., Westberg L., Johansson A., Jonsson L., Corander J., Sandnabba N.K. Are single nucleotide polymorphisms in the oxytocin and vasopressin 1A/1B receptor genes likely candidates for variation in ejaculatory function? BJU Int. 2012;110 E1173-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22882465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzimouratidis K., Amar E., Eardley I., Giuliano F., Hatzichristou D., Montorsi F. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189712</ArticleId></ArticleIdList></Reference><Reference><Citation>Arafa M., Shamloul R. Development and evaluation of the arabic index of premature ejaculation (AIPE) J Sex Med. 2007;4:1750&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">17970977</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Giuliano F., Ho K.F., Gagnon D.D., McNulty P., Rothman M. The premature ejaculation profile. Validation of self-reported outcome measures for research and practice. BJU Int. 2009;103:358&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">18793300</ArticleId></ArticleIdList></Reference><Reference><Citation>Symonds T., Perelman M.A., Althof S., Giuliano F., Martin M., May K. Development and validation of a premature ejaculation diagnostic tool. Eur Urol. 2007;52:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275165</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldinger M.D. Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int J Impot Res. 2003;15:309&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14562129</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori A.M., Pozza C., Esposito K., Giugliano D., Morano S., Vignozzi L. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7:1139&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19968774</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof S.E., Abdo C.H., Dean J., Hackett G., McCabe M., McMahon C.G. International society for sexual medicine. International society for sexual medicine&#x2019;s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med. 2010;7:2947&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">21050394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Tang K., Wang B. Clinical value of serum 5-HT level in diagnosis and treatment of premature ejaculation. Urol Int. 2013;90:214&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">23207833</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F., Rowland D.L. Standard operating procedures for neurophysiologic assessment of male sexual dysfunction. J Sex Med. 2013;10:1205&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">23577591</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales A. Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment &#x2013; topical versus systemic. Can Urol Assoc J. 2012;6:380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478341</ArticleId><ArticleId IdType="pubmed">23093633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie M.G., Hellstrom W.J. The link between penile hypersensitivity and premature ejaculation. BJU Int. 2011;107:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">20553259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie M.G., Powell J.A. The role of local anaesthetics in premature ejaculation. BJU Int. 2012;110 E943-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22758648</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinsmore W.W., Wyllie M.G. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5&#xa0;min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103:940&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245438</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson C., Wyllie M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med. 2010;7:3179&#x2013;3189.</Citation><ArticleIdList><ArticleId IdType="pubmed">20584124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or D., Salottolo K.M., Orlando A., Winkler J.V. Tramadol ODT study group. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2&#xa0;min. Eur Urol. 2012;61:736&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889833</ArticleId></ArticleIdList></Reference><Reference><Citation>Frink M.C., Hennies H.H., Englberger W., Haurand M., Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996;46:1029&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955860</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarinejad M.R., Hosseini S.Y. Safety and efficacy of tramadol in the treatment of premature ejaculation a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006;26:27&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415702</ArticleId></ArticleIdList></Reference><Reference><Citation>Eassa B.I., El-Shazly M.A. Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. Asian J Androl. 2013;15:138&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739134</ArticleId><ArticleId IdType="pubmed">23103596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong B.L., Malde S. The use of tramadol &#x2018;on-demand&#x2019; for premature ejaculation: a systematic review. Urology. 2013;81:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23102445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Yue X., Duan X., Luo D., Cheng Y., Tian Y. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology. 2012;80:618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">22840860</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossmann M., Kohnen C., Langford R., McCartney C. Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance. Drugs. 1997;53(Suppl. 2):50&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G.X., Yu L.P., Bai W.J., Wang X.F. Selective resection of dorsal nerves of penis for premature ejaculation. Int J Androl. 2012;35:873&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22882515</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhame E.E., Levey K.A., Gharibo C.G. Successful treatment of refractory pudendal neuralgia with pulsed radiofrequency. Pain Phys. 2009;12:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">19461829</ArticleId></ArticleIdList></Reference><Reference><Citation>David Prologo J., Snyder L.L., Cherullo E., Passalacqua M., Pirasteh A., Corn D. guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. J Vasc Interv Radiol. 2013;24:214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">23182939</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O., Shaeer K. The global online sexuality survey (GOSS.): erectile dysfunction among arabic-speaking internet users in the Middle East. J Sex Med. 2011;9:2152&#x2013;2163.</Citation><ArticleIdList><ArticleId IdType="pubmed">21569214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O., Shaeer K. The global online sexuality survey (GOSS). The United States of America in 2011. Chapter I. Erectile dysfunction among English-speakers. J Sex Med. 2012;9:3018&#x2013;3027.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaeer O. The global online sexuality survey (GOSS). The United States of America in 2011 chapter II. Phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10:532&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088586</ArticleId></ArticleIdList></Reference><Reference><Citation>Glina S., Sharlip I.D., Hellstrom W.J.G. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med. 2013;10:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">22971247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed I., El-Sakka A. Erectile dysfunction in Arab countries. Part I prevalence and correlates. Arab J Urol. 2012;10:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442907</ArticleId><ArticleId IdType="pubmed">26558010</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Liao C., Zou Y., Li F., Li T., Zhou Q. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010;7:2805&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367771</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo A.B., Travison T.G., Ganz P., Chiu G.R., Kupelian V., Rosen R.C. Erectile dysfunction and mortality. J Sex Med. 2009;6:2445&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524836</ArticleId><ArticleId IdType="pubmed">19538544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotaling J.M., Walsh T.J., Macleod L.C., Heckbert S., Pocobelli G., Wessells H. Erectile dysfunction is not independently associated with cardiovascular death. Data from the vitamins and lifestyle (VITAL) study. J Sex Med. 2012;9:2104&#x2013;2110.</Citation><ArticleIdList><ArticleId IdType="pubmed">22759697</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks E., Joshy G., Abhayaratna W.P., Kritharides L., Macdonald P.S., Korda R.J. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. Plos Med. 2013;10:e1001372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558249</ArticleId><ArticleId IdType="pubmed">23382654</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T., Hara K., Umematsu H., Suzuki R., Kadowaki T. Erectile dysfunction and cardiovascular events in diabetic men: a meta-analysis of observational studies. Plos One. 2012;7:e43673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433443</ArticleId><ArticleId IdType="pubmed">22962586</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J.Y., Zhang Y.H., Qin L.Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">21920268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanem H.M., Salonia A., Martin-Morales A.S. Physical examination and laboratory testing for men with erectile dysfunction. J Sex Med. 2013;10:108&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">22524416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., Mishra A. The international index of erectile dysfunction (IIEF), a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D., Rosen R.C., Derogatis L.R., Low W.Y., Meuleman E.J.H., Sadovsky R. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med. 2010;7:337&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">20092443</ArticleId></ArticleIdList></Reference><Reference><Citation>Buvat J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res. 2003;15:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">14562140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikka S.C., Hellstrom W.J.G., Brock G., Morales A.M. Standardization of vascular assessment of erectile dysfunction. J Sex Med. 2013;10:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">22970798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella A.J., Sener A., Foell K., Brock G.B. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: an atypical form of Peyronie&#x2019;s disease. J Sex Med. 2007;4:226&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034410</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sakka A.I., Morsy A.M., Fagih B.I. Severity of erectile dysfunction could predict left ventricular diastolic dysfunction in patients without overt cardiac complaint. J Sex Med. 2011;8:2590&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679302</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C.N., Smith C.J., Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332:589&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1397768</ArticleId><ArticleId IdType="pubmed">16528082</ArticleId></ArticleIdList></Reference><Reference><Citation>Son H., Park K., Kim S.W., Paick J.S. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl. 2004;6:117&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15154085</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C.G. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422874</ArticleId></ArticleIdList></Reference><Reference><Citation>Paduch D.A., Bolyakov A., Polzer P.K., Watts S.D. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int. 2013;111:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">23356749</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel A.D., de la Rosette J., Birt J., Porter V., Zarotsky V., Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67:32&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23082930</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick G.A., Brock G.B., Roehrborn C.G., Watts S.D., Elion-Mboussa A., Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010;75:1452&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">20163842</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrborn C.G., Kaminetsky J.C., Auerbach S.M., Montelongo R.M., Elion-Mboussa A., Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2009;105:502&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">19732051</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M., Giuliano F., Mirone V., Xu L., Cox D., Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297243</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerdie R.B., Auerbach S., Roehrborn C.G., Costa P., Garza M.S., Esler A.L. Tadalafil 2.5 or 5&#xa0;mg administered once daily for 12&#xa0;weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9:271&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">21981682</ArticleId></ArticleIdList></Reference><Reference><Citation>De Young L.X., Domes T., Lim K., Carson J., Brock G.B. Endothelial rehabilitation. The impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol. 2008;54:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342431</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A., Vitale C., Volterrani M., Fabbri A., Spera G., Fini M. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008;25:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.J., Wang F.S., Yang K.D., Weng L.H., Hsu C.C., Huang C.S. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. J Orthop Res. 2003;21:984&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">14554209</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida T., Shimokawa H., Oi K., Tatewaki H., Uwatoku T., Abe K. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110:3055&#x2013;3061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15520304</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P., Guo T., Wang W., Peng Y.Z., Wang Y., Zhou P. Randomized and double-blind controlled clinical trial of extracorporeal cardiac shock wave therapy for coronary heart disease. Heart Vessels. 2013;28:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">22457097</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y., Appel B., Jacob G., Massarwi O., Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451317</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardi Y., Appel B., Kilchevsky A., Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187:1769&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenwald I., Appel B., Kitrey N.D., Vardi Y. Shockwave treatment of erectile dysfunction. Ther Adv Urol. 2013;5:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607492</ArticleId><ArticleId IdType="pubmed">23554844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.H., Rocha-Singh K.J. Endovascular therapy for vasculogenic erectile dysfunction. Curr Treat Options Cardiovasc Med. 2012;14:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">22367595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutcher M.A. The &#x2018;Final Voyage&#x2019; of the endeavor stent. JACC Cardiovasc Interv. 2013;6:513&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">23702014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.H., Karimi H., Kao J., Link D., Javidan J., Yamasaki D.S. Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv. 2010;76:882&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">20928837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.H., Goldstein I., Kandzari D.E., K&#xf6;hler T.S., Stinis C.T., Wagner P.J. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;60:2618&#x2013;2627.</Citation><ArticleIdList><ArticleId IdType="pubmed">23177300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23892191</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism.</ArticleTitle><Pagination><StartPage>164</StartPage><EndPage>168</EndPage><MedlinePgn>164-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2013.07.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(13)04915-X</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The current management of ischemic priapism that is refractory to conventional medical therapy is a form of shunt procedure that diverts blood away from the corpus cavernosum. We assessed the outcome of the T-shunt and intracavernous tunneling for the management of ischemic priapism.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">During a 36-month period 45 patients presented with prolonged ischemic priapism. Patients were divided into subgroups according to the duration of priapism. All patients had an unsuccessful primary treatment, and underwent a T-shunt and intracavernous tunneling with cavernous muscle biopsies. All patients completed an IIEF-5 (International Index of Erectile Function-5) questionnaire preoperatively and 6 months postoperatively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Resolution of the priapism using a T-shunt and snake maneuver occurred in all patients with a priapism duration of less than 24 hours and in only 30% of those with priapism lasting more than 48 hours. After a 6-month median followup the IIEF-5 score was significantly reduced from a mean of 24 (range 23 to 25) preoperatively to 7.7 (range 5 to 24), which was related to the duration of the priapism (p &lt;0.0005). All patients with priapism for more than 48 hours had necrotic cavernous smooth muscle on biopsy and had severe erectile dysfunction requiring the insertion of a penile prosthesis. Those patients with moderate and mild erectile dysfunction were treated with phosphodiesterase type 5 inhibitors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The success of the T-shunt with snake tunneling is dependent on the duration of priapism. When it is less than 24 hours the results are favorable, although erectile dysfunction is still present in 50% of patients. In those with a priapism duration greater than 48 hours the technique usually fails to resolve the priapism and all patients end up with erectile dysfunction due to smooth muscle necrosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zacharakis</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom; 2nd Department of Urology, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raheem</LastName><ForeName>Amr Abdel</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Histopathology Department, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skolarikos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>2nd Department of Urology, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Institute of Urology, University College Hospital London, London, United Kingdom. Electronic address: dralph@andrology.co.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aktuelle Urol. 2014 Jul;45(4):259-60</RefSource><PMID Version="1">25166600</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ED</Keyword><Keyword MajorTopicYN="N">IIEF-5</Keyword><Keyword MajorTopicYN="N">International Index of Erectile Function</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">ischemia</Keyword><Keyword MajorTopicYN="N">priapism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23892191</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2013.07.034</ArticleId><ArticleId IdType="pii">S0022-5347(13)04915-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27784586</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Penile Prosthesis Implantation in Acute and Chronic Priapism.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>82</EndPage><MedlinePgn>76-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/smrj.10</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2050-0521(15)30065-2</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review the current literature regarding penile prosthesis implantation in acute and chronic priapism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A nonstructured Pubmed base search using the terms ischemic priapism, penile prosthesis, and refractory erectile dysfunction has been carried out.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Surgical outcome and patient satisfaction following penile prosthesis implantation are reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Implantation of a penile prosthesis in acute and chronic ischemic priapism is associated with increased complication rates, when compared with virgin implants. Implantation in acute priapism allows the painful priapic episode to settle and to preserve penile length, while implantation in chronic priapism is technically much more challenging and often requires the use of downsized shorter cylinders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Implantation of a penile prosthesis in acute refractory ischemic priapism should be the solution of choice, as the dilatation is easier and allows the preservation of penile length, which is one of the main factors influencing postoperative patient's satisfaction in prosthetic surgery. Garaffa G and Ralph D. Penile prosthesis implantation in acute and chronic priapism. Sex Med Rev 2013;1:76-82.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Broomfield Hospital, Whipps Cross Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>St Peter's Andrology and the Institute of Urology, University College London Hospitals, London, United Kingdom. Electronic address: dralph@andrology.co.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Ischemic Priapism</Keyword><Keyword MajorTopicYN="N">Penile Prosthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27784586</ArticleId><ArticleId IdType="doi">10.1002/smrj.10</ArticleId><ArticleId IdType="pii">S2050-0521(15)30065-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23708698</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8726</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>World journal of urology</Title><ISOAbbreviation>World J Urol</ISOAbbreviation></Journal><ArticleTitle>Clinical outcomes and patient satisfaction rates among elderly male aged &#x2265;75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>177</EndPage><MedlinePgn>173-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-013-1102-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of the study is to assess the clinical outcomes and patient satisfaction rate between men aged under and over 75 years who underwent inflatable penile prosthesis (IPP) implantation.</AbstractText><AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">A retrospective review of clinical database and follow-up independent telephone survey was undertaken in all men who underwent first-time IPP implantation between January 2006 and November 2010. Patient demographics, surgical outcomes, and patient satisfaction rate using Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 216 first-time IPP were implanted. Of these, 30 patients were aged &#x2265;75 years. In men aged &#x2265;75 years, 3 patients had IPP revision surgery for mechanical malfunction (average 18.6 months; 12-24 months). While the 2-year Kaplan-Meier estimates of mechanical survival showed better outcome in men aged &#x2265;75 years than men aged &lt;75 years (95 vs. 92%; p = 0.38), there was no difference in the IPP mechanical survival between the 2 groups at 3 years follow-up. There were no statistically significant differences in the ease of IPP use, and EDITS scores among the two groups. The majority of men were satisfied and would recommend the IPP surgery to other men.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Men aged &#x2265;75 years reported satisfactory outcome with IPP surgery with no statistical significant difference identified across device survival and satisfaction rates compared to men aged &lt;75 years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Urology, St Joseph's Health Care, London, ON, Canada, ericchg@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>DeYoung</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Gerald B</ForeName><Initials>GB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>World J Urol</MedlineTA><NlmUniqueID>8307716</NlmUniqueID><ISSNLinking>0724-4983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 Jan;193(1):252-3</RefSource><PMID Version="1">25523691</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004868" MajorTopicYN="N">Equipment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23708698</ArticleId><ArticleId IdType="doi">10.1007/s00345-013-1102-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Urol. 2004 May;45(5):628-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15082206</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Jul;4(4 Pt 1):1074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Sep;4(5):1247-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17727349</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Urol. 2012;2012:240963</Citation><ArticleIdList><ArticleId IdType="pubmed">22690212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Jan;7(1 Pt 2):501-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20092450</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2007 Apr;51(4):887-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17081674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2009 Mar;6(3):675-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19207278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2005 Jul;174(1):253-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15947649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2012 Jun;9(6):1715-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22568579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 Jul;8(7):1917-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21569212</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1999 Apr;53(4):793-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10197859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2004 Sep;52(9):1502-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15341552</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Aug 23;357(8):762-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17715410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Apr;7(4 Pt 1):1362-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19929914</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2009 Sep;104(6):834-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19338558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 Sep;166(3):932-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11490249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 Jul;3(4):743-748</Citation><ArticleIdList><ArticleId IdType="pubmed">16839332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23700721</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update].</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>198</EndPage><MedlinePgn>195-8</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED) is a common disorder that affects the quality of life of both men and their partners. The phosphodiesterase type 5 inhibitor is the first-line drug for ED. Recent researches found that long-term administration of low-dose phosphodiesterase type 5 inhibitors to be a safe and effective therapy for ED, as well as for couples who may prefer more convenience and spontaneity in their sexual activities. Besides, it provides a new therapeutic option for refractory ED. Its action mechanism mainly involves the improvement of the endothelial function of penile vessels and/or maintenance of the function and number of smooth muscle cells. However, whether this therapy can maintain the improved erection function after drug withdrawal needs further studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, China. jiangrui@126.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23700721</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23668707</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-2422</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of medical devices</Title><ISOAbbreviation>Expert Rev Med Devices</ISOAbbreviation></Journal><ArticleTitle>Long-term outcomes of penile prostheses for the treatment of erectile dysfunction.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>366</EndPage><MedlinePgn>353-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/erd.12.92</ELocationID><Abstract><AbstractText>Since their introduction 60 years ago, penile prostheses have remained the standard therapy for the management of refractory erectile dysfunction, with multiple long-term series reporting outcomes. A PubMed search was performed from 1990 to present, and outcomes of penile prosthetics were reviewed. Studies with &lt;12 months follow-up were excluded. Overall mechanical survival of three-piece prostheses range from 81-94, 68-89 and 57-76% at 5, 10 and 15 years, respectively. Contemporary infection rates following recent device modifications are 1-2% (low risk) to 2-3% (high risk). Patient satisfaction ranges from 75-100% and varies by prosthetic device. Outcomes are further reviewed among specialized populations (revision surgery, Peyronie's disease, priapism, corporal fibrosis and neurologic impairments). Penile prostheses remain a viable surgical treatment option with excellent mechanical reliability, low infection rates and significant patient/partner satisfaction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Landon W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-42, New Orleans, LA 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaslin</LastName><ForeName>Ross</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>Wayne J G</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Med Devices</MedlineTA><NlmUniqueID>101230445</NlmUniqueID><ISSNLinking>1743-4440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23668707</ArticleId><ArticleId IdType="doi">10.1586/erd.12.92</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23561355</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>189</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Re: simultaneous penile lengthening and penile prosthesis implantation in patients with peyronie's disease, refractory erectile dysfunction, and severe penile shortening.</ArticleTitle><Pagination><StartPage>1375</StartPage><EndPage>1376</EndPage><MedlinePgn>1375-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2012.12.044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(12)05872-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morey</LastName><ForeName>Allen F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Sex Med. 2012 Jan;9(1):316-21</RefSource><PMID Version="1">22023552</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23561355</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2012.12.044</ArticleId><ArticleId IdType="pii">S0022-5347(12)05872-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23550146</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2005-6737</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Korean journal of urology</Title><ISOAbbreviation>Korean J Urol</ISOAbbreviation></Journal><ArticleTitle>Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms.</ArticleTitle><Pagination><StartPage>100</StartPage><EndPage>105</EndPage><MedlinePgn>100-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4111/kju.2013.54.2.100</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the relationship of improvement in erectile function (EF) with improvement in lower urinary tract symptoms (LUTS) and to assess the contribution of tamsulosin dose to the improvement of EF apart from the indirect influence of LUTS improvement in men with LUTS and erectile dysfunction (ED).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Fifty patients received tamsulosin 0.2 mg/d for the first 4 weeks and were subsequently divided into two groups by patient-reported outcomes. Nonescalators were maintained starting dose and escalators increased to 0.4 mg for the remaining 8 weeks. International Prostatic Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5), and underwent uroflowmetry were evaluated at baseline, and weeks 4 and 12.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LUTS parameters were significantly improved in both groups but insignificant between the 2 groups. The degree of the improvement in the total IPSS and in the voiding, storage, and quality of life (QoL) subscores were significantly correlated with the degree of the improvement in EF; this was especially prominent in patients successfully treated LUTS. The escalators experienced a significantly greater increase in IIEF-5 scores than did the nonescalators (3.3 vs. 1.5).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dose escalation provided similar LUTS improvement in patients with refractory to starting dose. The improvements of LUTS were correlated with the improvement of EF. The increase in the IIEF-5 score was significantly higher in escalators. These findings imply that tamsulosin may contribute to the improvement in EF through the improvement of LUTS and QoL and direct relaxation of the corpus cavernosum in a dose-dependent fashion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Hyun Wook</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Urology, Eulji University School of Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Dae Seon</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Hyun Taek</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Whang</LastName><ForeName>Ha Wook</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jinsung</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun Tak</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae Kyung</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Seung Hyo</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Urol</MedlineTA><NlmUniqueID>101499376</NlmUniqueID><ISSNLinking>2005-6737</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Prostatic hyperplasia</Keyword><Keyword MajorTopicYN="N">Tamsulosin</Keyword></KeywordList><CoiStatement>The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23550146</ArticleId><ArticleId IdType="pmc">PMC3580298</ArticleId><ArticleId IdType="doi">10.4111/kju.2013.54.2.100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">19167031</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">21284024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) Eur Urol. 2005;47:824&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">15925080</ArticleId></ArticleIdList></Reference><Reference><Citation>Orabi H, Albersen M, Lue TF. Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. Int J Impot Res. 2011;23:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593760</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel JC, Elhilali M, Emberton M, Vallancien G Alf-One Study Group. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int. 2006;97:1242&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686719</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">16526818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int. 2005;95(Suppl 4):12&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15871731</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med. 2009;6:2299&#x2013;2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">19493292</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon DG, Bae YD, Lee SW, Moon KH, Ahn TY, Jeong WS, et al. The efficacy and safety of tamsulosin 0.2mg/day on sexual function in BPH: a multicenter open-label, non-comparative, 3 months observational, phase IV prospective study. Korean J Androl. 2009;27:123&#x2013;129.</Citation></Reference><Reference><Citation>Yokoyama T, Hara R, Fukumoto K, Fujii T, Jo Y, Miyaji Y, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011;18:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">21272091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:1624&#x2013;1633.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510238</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, et al. Combined tadalafil and &#x3b1;-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. J Androl. 2012;33:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">21868753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, et al. Efficacy and safety of combination therapy with mirodenafil and &#x3b1;1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res. 2011;23:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">21814227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">17258855</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden EL, Riedner CE, Fornari A, Fuchs SC, Ribeiro EP. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med. 2008;5:2662&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pubmed">18564152</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol. 2003;44:588&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572759</ArticleId></ArticleIdList></Reference><Reference><Citation>Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med. 2009;6:1103&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CC, Liu CC, Huang SP, Li WM, Wu WJ, Huang CH, et al. The impact of irritative lower urinary tract symptoms on erectile dysfunction in aging Taiwanese males. Aging Male. 2010;13:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">20158390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">10473995</ArticleId></ArticleIdList></Reference><Reference><Citation>van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005;95:603&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705088</ArticleId></ArticleIdList></Reference><Reference><Citation>Permpongkosol S, Krilad-O-Larn S, Ratana-O-Larn K. Treatment with a uroselective &#x3b1;1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms. J Sex Med. 2011;8:2582&#x2013;2589.</Citation><ArticleIdList><ArticleId IdType="pubmed">21699664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138360</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res. 2002;14:50&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896478</ArticleId></ArticleIdList></Reference><Reference><Citation>Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 2003;91:873&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">12780851</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L, et al. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med. 2008;5:935&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. Int J Clin Pract. 2011;65:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">21995695</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97(Suppl 2):34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23469669</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Advances in the studies of refractory erectile dysfunction].</ArticleTitle><Pagination><StartPage>82</StartPage><EndPage>85</EndPage><MedlinePgn>82-5</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED) is a common problem, for which PDE5 inhibitors (PDE5I) represent the first line therapy at present and have a success rate of approximately 80%. Refractory ED, which refers to ED in some patients with chronic diseases such as diabetes mellitus and cardiovascular diseases or in those treated by radical prostatectomy, receives little benefit from PDE5I alone. Apart from the NO-cGMP pathway, the processes of erection and ED involve several signaling pathways, such as RhoA/Rho kinase, H2S, CO, etc. The complicated signaling network contributes to the pathogenesis of refractory ED. PDE5I-based alternative therapy and combined therapy may increase the success rate of its treatment. This article outlines the advances in the studies of refractory ED that fails to respond to PDE5I.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo-Yi</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Urology, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, China. 289173082@qq.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23469669</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23352299</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1166-7087</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie</Title><ISOAbbreviation>Prog Urol</ISOAbbreviation></Journal><ArticleTitle>[Greenlight(&#xae;) photoselective vaporisation for benign prostatic hyperplasia: a systematic review].</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>87</EndPage><MedlinePgn>77-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.purol.2012.10.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1166-7087(12)00625-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Transurethral resection of the prostate (TURP) is the most common surgical procedure in urology and remains the gold standard treatment of complicated benign prostatic hyperplasia or refractory to medical treatment. Routinely used since the 2000s, prostate photoselective vaporization (PVP) with Greenlight(&#xae;) laser has been developed to improve the safety of hemostasis in elderly patients and/or with high surgical risk. The purpose of this study was to review the results of PVP from the international literature.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">[corrected] A systematic review of the literature on the research base Pubmed (http://www.ncbi.nlm.nih.gov/) was performed using the keywords benign prostatic hyperplasia; greenlight; photovaporisation; Laser; IPSS score; endoscopicsurgery; morbidity; complication. Prospective and retrospective studies in English and French were selected from its first use in 1998. Finally, we looked for studies that reported at least one of the following items: surgical technique; operative data; complications; anatomical and functional results and/or direct comparison between PVP and TURP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Regardless the PVP technique used to treat adenoma and identify the limits of the prostatic capsule, some parameters are well defined (sweepspeed, angle and distance of the fiber with the tissue) but others are still debated (number of joules per volume, when do we have to stop the PVP) and are reported in a heterogeneous manner due to the different generators. Versus TURP, PVP would offer the same functional results in the medium term but with a lower risk of per- and postoperative bleeding. The study of the risk of erectile dysfunction (ED) after PVP is made difficult due to the heterogeneity of DE assessment and study populations. However, PVP does not seem associated with an increased risk of ED versus TURP. The lack of histological material should lead to preoperative individual screening of prostate. The economy generated by PVP regarding the decrease in average length of stay has been clearly identified in Australia, Canada, Switzerland and USA. Studies will be published soon on French economic model.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PVP with Greenlight(&#xae;) laser appears to be a safe and effective technique. With the new generator XPS, the PVP technique reaches maturity. Its development will certainly lead to a long-term evaluation with high levels of evidence based.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Misra&#xef;</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinique Pasteur, 40, avenue de Lombez, 31300 Toulouse, France. v.misrai@clinique-pasteur.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roupr&#xea;t</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Guillotreau</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bordier</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bruy&#xe8;re</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><VernacularTitle>Traitement de l'hyperplasie b&#xe9;nigne de prostate par photovaporisation au laser Greenlight(&#xae;)&#xa0;: analyse de la litt&#xe9;rature.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Prog Urol</MedlineTA><NlmUniqueID>9307844</NlmUniqueID><ISSNLinking>1166-7087</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="Y">Laser Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020728" MajorTopicYN="N">Transurethral Resection of Prostate</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23352299</ArticleId><ArticleId IdType="doi">10.1016/j.purol.2012.10.013</ArticleId><ArticleId IdType="pii">S1166-7087(12)00625-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23206787</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2016</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Outcome of penile revascularization for arteriogenic erectile dysfunction after pelvic fracture urethral injuries.</ArticleTitle><Pagination><StartPage>1369</StartPage><EndPage>1373</EndPage><MedlinePgn>1369-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2012.07.059</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-4295(12)00937-5</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review our experience with penile revascularization for patients with bilateral occlusion of the deep internal pudendal arteries after pelvic fracture urethral injury (PFUI).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We identified 17 patients who had undergone penile revascularization with end-to-side anastomosis of the deep inferior epigastric artery to the dorsal penile artery from July 1991 to December 2010. Success was defined as achieving erections sufficient for intercourse with or without pharmacologic assistance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients had had a PFUI causing arterial insufficiency and erectile dysfunction not responsive to pharmacologic intervention. Of the 17 patients, 4 (24%) underwent revascularization before and 13 (76%) after PFUI repair. The mean age at revascularization was 32.7 years (range 17-54). At an average follow-up of 3.1 years, the surgery was successful in 14 of the 17 patients (82%). In patients with erectile dysfunction as an indication for surgery, successful erections were achieved in 11 of 13. For those who underwent revascularization to prevent ischemic stenosis of the urethral repair, 3 of 4 achieved successful erections, and all subsequent urethral surgeries were successful. The penile duplex ultrasound parameters showed clinically and statistically significant improvements after revascularization. No operative complications developed. The average hospital length of stay was 4.7 days. Four patients experienced early postoperative complications, including an abdominal wall hematoma requiring evacuation in one, penile edema in two, and a superficial surgical site infection in one. No late complications occurred.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Penile arterial revascularization in select patients can allow for successful treatment of PFUIs and the refractory erectile dysfunction caused by them.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zuckerman</LastName><ForeName>Jack M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia 23502, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCammon</LastName><ForeName>Kurt A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Tisdale</LastName><ForeName>Britton E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Colen</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Uroskie</LastName><ForeName>Ted</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McAdams</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Gerald H</ForeName><Initials>GH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Urology. 2012 Dec;80(6):1373-4</RefSource><PMID Version="1">23206788</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2013 Sep;190(3):935-6</RefSource><PMID Version="1">23931202</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001157" MajorTopicYN="N">Arterial Occlusive Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019074" MajorTopicYN="N">Epigastric Arteries</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012421" MajorTopicYN="N">Rupture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23206787</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2012.07.059</ArticleId><ArticleId IdType="pii">S0090-4295(12)00937-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23204546</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>266</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Radiology</Title><ISOAbbreviation>Radiology</ISOAbbreviation></Journal><ArticleTitle>Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>677</EndPage><MedlinePgn>668-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.12111601</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the safety, morbidity, and short- and intermediate-term results of prostatic arterial embolization (PAE) for benign prostatic hyperplasia (BPH) after failure of medical treatment.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This prospective study was approved by the institutional review board, and informed consent was obtained from all participants. Men older than 50 years with a diagnosis of BPH and moderate-to-severe lower urinary tract symptoms that were refractory to medical treatment for 6 months were eligible. PAE with nonspherical 80-180-&#x3bc;m (mean, 100-&#x3bc;m) and 180-300-&#x3bc;m (mean, 200-&#x3bc;m) polyvinyl alcohol particles was performed by means of a single femoral approach in most cases. Effectiveness variables of International Prostate Symptom Score (IPSS), quality of life (QOL) score, peak urinary flow, postvoid residual volume, International Index Erectile Function (IIEF) score, prostate volume, and prostate-specific antigen level were assessed for up to 24 months after the procedure. Statistical analysis included the Kaplan-Meier method and random-effects generalized least squares regression with autoregressive disturbance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-nine consecutive patients (mean age, 74.1 years) were included. PAE was technically successful in 86 of the 89 patients (97%). Cumulative rates of clinical improvement in these patients were 78% in the 54 patients evaluated at 6 months and 76% in the 29 patients evaluated at 12 months. At 1-month follow-up, IPSS decreased by 10 points, QOL score decreased by 2 points, peak urinary flow increased by 38%, prostate volume decreased by 20%, postvoid residual volume decreased by 30 mL, and IIEF score increased by 0.5 point (all differences were significant at P &lt; .01). These changes were sustained throughout the observation period. There was one major complication: Intraluminal necrotic tissue attached to the bladder, which was removed with simple surgery and did not necessitate wall reconstruction.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PAE is a safe and effective procedure, with low morbidity, no sexual dysfunction, and good short- and intermediate-term symptomatic control associated with prostate volume reduction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pisco</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Interventional Radiology, Hospital S&#xe3;o Lu&#xed;s, Rua Luz Soriano 182, 1200-249 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos Pinheiro</LastName><ForeName>Lu&#xed;s</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bilhim</LastName><ForeName>Tiago</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rio Tinto</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>L&#xfa;cia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vaz Santos</LastName><ForeName>V&#xed;tor</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Ant&#xf3;nio Gouveia</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Radiology</MedlineTA><NlmUniqueID>0401260</NlmUniqueID><ISSNLinking>0033-8419</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-89-5</RegistryNumber><NameOfSubstance UI="D011142">Polyvinyl Alcohol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Radiology. 2013 Sep;268(3):929</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016018" MajorTopicYN="N">Least-Squares Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011142" MajorTopicYN="N">Polyvinyl Alcohol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23204546</ArticleId><ArticleId IdType="doi">10.1148/radiol.12111601</ArticleId><ArticleId IdType="pii">radiol.12111601</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23169570</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-2353</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical anatomy (New York, N.Y.)</Title><ISOAbbreviation>Clin Anat</ISOAbbreviation></Journal><ArticleTitle>Anatomy and physiology of the clitoris, vestibular bulbs, and labia minora with a review of the female orgasm and the prevention of female sexual dysfunction.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>152</EndPage><MedlinePgn>134-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ca.22177</ELocationID><Abstract><AbstractText>This review, with 21 figures and 1 video, aims to clarify some important aspects of the anatomy and physiology of the female erectile organs (triggers of orgasm), which are important for the prevention of female sexual dysfunction. The clitoris is the homologue of the male's glans and corpora cavernosa, and erection is reached in three phases: latent, turgid, and rigid. The vestibular bulbs cause "vaginal" orgasmic contractions, through the rhythmic contraction of the bulbocavernosus muscles. Because of the engorgement with blood during sexual arousal, the labia minora become turgid, doubling or tripling in thickness. The corpus spongiosum of the female urethra becomes congested during sexual arousal; therefore, male erection equals erection of the female erectile organs. The correct anatomical term to describe the erectile tissues responsible for female orgasm is the female penis. Vaginal orgasm and the G-spot do not exist. These claims are found in numerous articles that have been written by Addiego F, Whipple B, Jannini E, Buisson O, O'Connell H, Brody S, Ostrzenski A, and others, have no scientific basis. Orgasm is an intense sensation of pleasure achieved by stimulation of erogenous zones. Women do not have a refractory period after each orgasm and can, therefore, experience multiple orgasms. Clitoral sexual response and the female orgasm are not affected by aging. Sexologists should define having sex/love making when orgasm occurs for both partners with or without vaginal intercourse.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puppo</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centro Italiano di Sessuologia, Via Regnoli 74, Bologna, Italy. dottvincenzopuppo@yahoo.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Anat</MedlineTA><NlmUniqueID>8809128</NlmUniqueID><ISSNLinking>0897-3806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002987" MajorTopicYN="N">Clitoris</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009948" MajorTopicYN="N">Orgasm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014844" MajorTopicYN="N">Vulva</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23169570</ArticleId><ArticleId IdType="doi">10.1002/ca.22177</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23017514</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>189</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Favorable patient reported outcomes after penile plication for wide array of peyronie disease abnormalities.</ArticleTitle><Pagination><StartPage>1019</StartPage><EndPage>1024</EndPage><MedlinePgn>1019-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2012.09.085</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(12)04978-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We present patient reported outcomes from our 5-year experience using penile plication to correct a wide variety of Peyronie disease malformations.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We reviewed the records of all men who underwent penile plication for Peyronie disease, as performed by one of us (AFM). All patients were treated with tunical plication without penile degloving via a 2 cm longitudinal penile incision regardless of curvature severity or erectile function. A concomitant inflatable penile prosthesis was placed in men with refractory erectile dysfunction. A questionnaire was administered to assess the patient perception of postoperative penile curvature, length, rigidity and adequacy for intercourse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 154 treated patients 78 (51%) and 65 (42%) had simple (less than 60 degrees) and complex (biplanar curvature, or curvature 60 degrees or greater) malformation, respectively, while 11 (7%) underwent plication plus inflatable penile prosthesis placement. A total of 132 patients responded to the questionnaire a mean 14 months after surgery. Overall, 96% of patients reported curvature improvement after penile plication, 93% reported erection adequate for sexual intercourse and 95% considered that the overall condition improved after surgery. Despite a significant difference in the number of plication sutures (mean 10 vs 7) and curvature angle correction (mean 57 vs 30 degrees, each p &lt;0.005), self-reported outcomes of complex cases were equivalent to those of simple cases. While 84% of patients had no measureable decrease in stretched penile length, 103 of 154 (78%) reported a perceived penile length reduction after surgery.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Penile plication without degloving is effective for correcting a wide variety of Peyronie disease malformations. It can be safely combined with inflatable penile prosthesis placement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hudak</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morey</LastName><ForeName>Allen F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Adibi</LastName><ForeName>Mehrad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bagrodia</LastName><ForeName>Aditya</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013536" MajorTopicYN="N">Suture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="N">Urologic Surgical Procedures, Male</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23017514</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2012.09.085</ArticleId><ArticleId IdType="pii">S0022-5347(12)04978-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23011737</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1248-9204</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Hernia : the journal of hernias and abdominal wall surgery</Title><ISOAbbreviation>Hernia</ISOAbbreviation></Journal><ArticleTitle>Incarcerated inguinal hernia and small bowel obstruction as a rare complication of a penile prosthesis.</ArticleTitle><Pagination><StartPage>809</StartPage><EndPage>812</EndPage><MedlinePgn>809-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10029-012-0992-4</ELocationID><Abstract><AbstractText>In this paper, we present a rare case of a small bowel obstruction secondary to an incarcerated inguinal hernia as a short-term complication of a penile prosthesis implantation. The patient underwent prosthesis implantation to treat refractory erectile dysfunction after a robotic-assisted laparoscopic radical prostatectomy. He presented 2 weeks later with the incarcerated hernia to our emergency department and surgical service. The hernia was repaired in a tension-free manner, and the bowel was uncompromised. The patient is symptom free at follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serio</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, College of Medicine, Central Michigan University, Saginaw, MI, 48603, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Hernia</MedlineTA><NlmUniqueID>9715168</NlmUniqueID><ISSNLinking>1248-9204</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006552" MajorTopicYN="N">Hernia, Inguinal</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007415" MajorTopicYN="N">Intestinal Obstruction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="Y">Intestine, Small</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="Y">Prosthesis Implantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23011737</ArticleId><ArticleId IdType="doi">10.1007/s10029-012-0992-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdom Imaging. 2009 May-Jun;34(3):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18597140</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2000 Oct;12 Suppl 4:S108-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11035396</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Oct;168(4 Pt 1):1475-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12352421</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Oct 14;302(14):1557-64</Citation><ArticleIdList><ArticleId IdType="pubmed">19826025</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2002 Oct;60(4):569-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12385908</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2010 Jul-Aug;22(4):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20574433</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2001 Jan;57(1):142-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11164160</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2007 Sep;70(3):539-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17686509</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2007 Nov;34(4):535-47, vi</Citation><ArticleIdList><ArticleId IdType="pubmed">17983893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2000 Aug;164(2):376-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2010 Nov;58(5):719-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20728265</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2003 Oct;15 Suppl 5:S134-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Urol. 2011 May;8(5):267-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21467967</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2007 Jul;4(4 Pt 1):1074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17627751</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Int. 1998 Aug;60(4):262-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9701745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Oct 6;358(9288):1124-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11597665</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2007 Dec;70(6):1152-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18158037</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2000 Jan;37(1):50-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10671785</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2011 Jul;128(1):e121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21690112</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2006 Apr;67(4):845.e9-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16566969</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2005 Oct;66(4):814-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16230144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2011 May;8(5):1547-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21385324</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Res. 2005 Mar 29;10(3):121-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15851379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Jun;169(6):2289-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12771773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22784751</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2012</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>188</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Re: Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie's disease, refractory erectile dysfunction, and severe penile shortening.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>552</EndPage><MedlinePgn>551-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2012.04.094</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seftel</LastName><ForeName>Allen D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Sex Med. 2012 Jan;9(1):316-21</RefSource><PMID Version="1">22023552</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22784751</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2012.04.094</ArticleId><ArticleId IdType="pii">S0022-5347(12)03651-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22672747</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-355X</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of radiation oncology, biology, physics</Title><ISOAbbreviation>Int J Radiat Oncol Biol Phys</ISOAbbreviation></Journal><ArticleTitle>Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.</ArticleTitle><Pagination><StartPage>370</StartPage><EndPage>377</EndPage><MedlinePgn>370-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2012.04.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0360-3016(12)00575-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the feasibility of magnetic resonance imaging (MRI)-planned partial salvage permanent prostate implant (psPPI) among patients with biopsy-proven local recurrence after initial PPI without evidence of distant disease.</AbstractText><AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">From 2003-2009, 15 patients underwent MRI/magnetic resonance spectroscopy (MRS) planning for salvage brachytherapy (psPPI, I-125 [n=14; 144 Gy]; Pd-103 [n=1; 125 Gy]) without hormone therapy. Full dose was prescribed to areas of recurrence and underdosage, without entire prostate implantation. Limiting urethral and rectal toxicity was prioritized. Follow-up was from salvage date to prostate-specific antigen (PSA) concentration failure (Phoenix criteria = nadir + 2.0; ASTRO = 3 consecutive rises), recurrence, distant metastases, or last follow-up PSA level. Progression-free survival (PFS) was defined as no PSA failure or biopsy-proven recurrence without all-cause mortality. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At salvage, median age was 68 years, and PSA concentration was 3.5 ng/mL (range, 0.9-5.6 ng/mL). Abnormal MRI/MRS findings were evident in 40% of patients. Biopsy-proven recurrences consisted of a single focus (80%) or 2 foci (20%). At recurrence, Gleason score was 6 (67%) or &#x2265;7 (27%). Median interval between initial and salvage implantation was 69 months (range, 28-132 months). psPPI planning characteristics limited doses to the rectum (mean V100 = 0.5% [0.07 cc]) and urethra (V100 = 12% [0.3 cc]). At median follow-up (23.3 months; range, 8-88 months), treatment failure (n=2) resulted only in localized recurrence; both patients underwent second psPPI with follow-up PSA tests at 12 and 26 months, resulting in 0.6 and 0.7 ng/mL, respectively. American Society for Radiation Oncology PFS rates at 1, 2, and 3 years were 86.7%, 78.4%, and 62.7%, respectively, with 5 patients for whom treatment failed (n=3 with negative transrectal ultrasound-guided biopsy results). Phoenix PFS rates at 1, 2, and 3 years were 100%, 100%, and 71.4%. 73%, respectively; achieved PSA nadir of &lt;0.5 ng/mL; and 47% of patients had a nadir of &lt;0.1 ng/mL. Treatment-related toxicity was minimal, with no operative interventions, fistulas, or other grade &#x2265;3 gastrointestinal (GI)/genitourinary (GU) toxicity. Thirteen percent had grade 1 GI and 33% had grade 2 GU toxicities. Postsalvage, 20% of patients had no erectile dysfunction, 67% of patients had medication-responsive erectile dysfunction, and 13% of patients had erectile dysfunction refractory to medication.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Focal psPPI with MR-planning in highly selected patients is feasible with short-term control comparable to conventional salvage, with less toxicity. Longer follow-up is needed to confirm its impact on quality of life and treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA. hsucc@radonc.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pickett</LastName><ForeName>Barby</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Crehange</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>I-Chow Joe</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Dea</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Gottschalk</LastName><ForeName>Alexander R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Kurhanewicz</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Katsuto</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Roach</LastName><ForeName>Mack</ForeName><Initials>M</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA137207</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA><NlmUniqueID>7603616</NlmUniqueID><ISSNLinking>0360-3016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011868">Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>5TWQ1V240M</RegistryNumber><NameOfSubstance UI="D010165">Palladium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001918" MajorTopicYN="N">Brachytherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058958" MajorTopicYN="N">Organs at Risk</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010165" MajorTopicYN="N">Palladium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011832" MajorTopicYN="N">Radiation Injuries</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011868" MajorTopicYN="N">Radioisotopes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22672747</ArticleId><ArticleId IdType="doi">10.1016/j.ijrobp.2012.04.028</ArticleId><ArticleId IdType="pii">S0360-3016(12)00575-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22562921</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-2501</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of invasive cardiology</Title><ISOAbbreviation>J Invasive Cardiol</ISOAbbreviation></Journal><ArticleTitle>Angiography and endovascular revascularization of pudendal artery atherosclerotic disease in patients with medically refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>236</StartPage><EndPage>240</EndPage><MedlinePgn>236-40</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To report a technique for endovascular treatment of pudendal artery stenoses in medically refractory erectile dysfunction.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="METHODS">Three men with known peripheral arterial disease and erectile dysfunction that was non-responsive to treatment with phosphodiesterase inhibitors underwent angiography and stent placement of the pudendal artery. Stent placement was performed using standard endovascular techniques. All 3 patients reported significant improvement in erectile function following revascularization.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Percutaneous treatment of pudendal artery stenoses with stents is feasible and offered significant benefit to these 3 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babaev</LastName><ForeName>Anvar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiology, NYU Langone Medical Center, NYU School of Medicine, New York, New York, USA. anvar.babaev@nyumc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Rahul R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Invasive Cardiol</MedlineTA><NlmUniqueID>8917477</NlmUniqueID><ISSNLinking>1042-3931</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Invasive Cardiol. 2013 Mar;25(3):A23-4</RefSource><PMID Version="1">23468451</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000800" MajorTopicYN="N">Angioplasty, Balloon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="N">Drug-Eluting Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007083" MajorTopicYN="N">Iliac Artery</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007383" MajorTopicYN="N">Intermittent Claudication</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22562921</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22248110</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2404</StartPage><EndPage>2416</EndPage><MedlinePgn>2404-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02628.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Premature ejaculation (PE) is a highly prevalent and complex syndrome that remains poorly defined and inadequately characterized. Pharmacotherapy represents the current basis of lifelong PE treatment.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The goal of this study was to assess the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of patients with PE without associated erectile dysfunction (ED).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">The posttreatment intravaginal ejaculatory latency time was used as the primary end point of efficacy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of the literature was performed by electronically searching the MedLine database for peer-reviewed articles regarding the mechanism of action and the clinical trials of PDE5 in the management of PE. A meta-analysis of these clinical studies was performed to pool the efficacy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-nine articles that examined the supposed mechanisms of action and 14 articles that reported data from clinical studies were reviewed. The PDE5 may exert their influence by increasing the levels of nitric oxide both centrally (reducing sympathetic drive) and peripherally (leading to smooth-muscle dilatation of the seminal tract). These drugs may also induce peripheral analgesia to prolong the duration of the erection, increase confidence, improve the perception of ejaculatory control and overall sexual satisfaction, and decrease the postorgasmic refractory time for achieving a second erection after ejaculation. Concerning the efficacy, the meta-analysis shows an overall positive effect for the use of PDE5 as monotherapy or as components of a combination regimen in the treatment of PE. The major limitations of the published literature included poor study design, the absence of solid methodology, which was characterized by the lack of a unique PE definition, and the lack of appropriate endpoints for outcome evaluation of a placebo control arm and of Institutional Review Board approval.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is inadequate, partial basic, and clinical evidence to support the use of PDE5 for the treatment of PE.</AbstractText><CopyrightInformation>&#xa9; 2012 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asimakopoulos</LastName><ForeName>Anastasios D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>UOC of Urology, Department of Surgery, University of Tor Vergata, Policlinico Casilino, Rome, Italy. tasospao2003@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miano</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Finazzi Agr&#xf2;</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vespasiani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061686" MajorTopicYN="N">Premature Ejaculation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22248110</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02628.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)34110-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22237486</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0399</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Urologia internationalis</Title><ISOAbbreviation>Urol Int</ISOAbbreviation></Journal><ArticleTitle>Risk of erectile dysfunction and retrograde ejaculation associated with thulium laser vaporesection of the prostate for bladder outflow obstruction: a retrospective study.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>169</EndPage><MedlinePgn>165-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000333046</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to determine the incidence of erectile dysfunction and retrograde ejaculation following thulium:yttrium-aluminium-garnet (Tm:YAG) laser prostate vaporesection (ThuVaRP).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between January 2009 and June 2010, 113 consecutive patients underwent ThuVaRP for bladder outflow obstruction. Of these, 54 (48%) were included in the study as they were able to maintain an erection for sexual intercourse prior to undergoing ThuVaRP. All patients had benign pathology and had not undergone previous bladder neck surgery. The incidence of erectile dysfunction and retrograde ejaculation was reported at a mean follow-up period of 12 months post-operatively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean patient age was 71 years (range 46-90). The mean follow-up period was 12 months (range 4-21). 11 (20%) patients experienced worsening erectile function with 3 (6%) noticing an improvement. A total of 30 patients (56%) experienced some degree of retrograde ejaculation. 4 patients (7%) noticed an improvement in their ejaculation. Retrograde ejaculation was more common in patients with an indwelling catheter in situ for refractory urinary retention (43 vs. 17%, p = 0.04) and in diabetic patients (27 vs. 4%, p = 0.03). There was an increased trend of erectile dysfunction in men aged &#x2265;70 years, with hypertension and with hypercholesterolaemia, but this was not significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our retrospective study has demonstrated that the overall risk of erectile dysfunction and retrograde ejaculation associated with ThuVaRP is 20 and 56%, respectively.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Carol Ling Sze</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Urology, University Hospitals of Leicester, Leicester General Hospital, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Raj P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Batchelder</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Masood A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Urol Int</MedlineTA><NlmUniqueID>0417373</NlmUniqueID><ISSNLinking>0042-1138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="Y">Ejaculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="N">Laser Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053844" MajorTopicYN="N">Lasers, Solid-State</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013932" MajorTopicYN="N">Thulium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001748" MajorTopicYN="N">Urinary Bladder Neck Obstruction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22237486</ArticleId><ArticleId IdType="doi">10.1159/000333046</ArticleId><ArticleId IdType="pii">000333046</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22082149</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: a multicenter study.</ArticleTitle><Pagination><StartPage>309</StartPage><EndPage>315</EndPage><MedlinePgn>309-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02524.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prosthesis (IPP) implantation is a well-established treatment for medically refractory erectile dysfunction, with long-term reliability. Overall survival is 96% at 5 years and 60% at 15 years for primary (virgin) implantation.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to explore factors associated with success and complications of IPP revision surgery in a multicenter study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Reasons for revision including mechanical issues, patient dissatisfaction, corporal deformity, and supersonic transport (SST) deformity were recorded.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">At four institutions, 214 clinically uninfected IPP revisions were performed between November 2000 and November 2007. Data were incomplete for 28 cases (14%). Failure-free survival was estimated using Kaplan-Meier's Meier product limit method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The majority of revisions were secondary to mechanical failure (N = 109; 65%) and combined erosion or infection (N = 17 + 15 = 32; 19%). Sixteen percent (N = 26) were carried out on functional uninfected prostheses secondary to patient dissatisfaction (N = 9), SST deformity (N = 10), scrotal hematoma (N = 2), or upsize revision because of corporal fibrosis (N = 5). Average age at revision was 66 years. Mean follow-up time was 55.7 months. In this study, 12 individuals required a secondary revision procedure or suffered a complication. Despite prior reports of high infection rates with revision surgery, only 5.7% of clinically uninfected and noneroded prostheses were complicated by infection or impending extrusion/erosion, following a revision washout protocol. Overall, 93% of cases were successfully revised, providing functioning IPPs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For this study population, component exchange followed by revision washout showed a low incidence of infection and subsequent mechanical failure.</AbstractText><CopyrightInformation>&#xa9; 2011 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Regional Urology, Shreveport, LA 71106, USA. GDHenry@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donatucci</LastName><ForeName>Craig F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Conners</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Culley C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Steven K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Delk</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lentz</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Cleves</LastName><ForeName>Mario A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Jennermann</LastName><ForeName>Caroline J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2012 Aug;188(2):546</RefSource><PMID Version="1">22784746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="N">Prosthesis Failure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22082149</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02524.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33701-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22023552</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie's disease, refractory erectile dysfunction, and severe penile shortening.</ArticleTitle><Pagination><StartPage>316</StartPage><EndPage>321</EndPage><MedlinePgn>316-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02509.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Due to loss of length, patients who had penile prosthesis implantation for Peyronie's disease (PD) show a statistically significant reduction in their levels of satisfaction when compared with the general implant population.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study is to report our experience of penile lengthening with circumferential graft during penile prosthesis implantation in patients with PD and severe penile shortening.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between March 2006 and February 2008, 23 patients with PD, refractory erectile dysfunction, and severe penile shortening underwent penile lengthening with circumferential graft and concomitant implantation of an inflatable penile prosthesis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Surgical outcome and complications have been recorded during postoperative follow-up. Patients' satisfaction has been assessed 6 months postoperatively with the administration of the modified Erectile Dysfunction Index of Treatment Satisfaction (EDITS) questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After an average follow-up of 22 months (range 6-36), 20 patients attended all the postoperative follow-up visits and returned the EDITS questionnaire. An average length gain of 2.8 cm (range 2.2-4.5) was recorded, and all patients were able to cycle the device and engage in penetrative sexual intercourse. Patient recorded complications included diminished glans sensitivity in four (20%) and persistent dorsal curvature of less than 15&#xb0; in three (15%). Overall, 18 patients (90%) were satisfied with the cosmetic and functional result of surgery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Penile lengthening with circumferential graft during penile prosthesis implantation in patients with PD represents a safe and reproducible technique that yields higher satisfaction rates than penile prosthesis implantation alone in patients with severe penile shortening.</AbstractText><CopyrightInformation>&#xa9; 2011 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sansalone</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, School of Medicine Tor Vergata University of Rome, Rome, Italy. salvatore.sansalone@yahoo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Djinovic</LastName><ForeName>Rados</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Egydio</LastName><ForeName>Paulo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Vespasiani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Miano</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Loreto</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2012 Aug;188(2):551-2</RefSource><PMID Version="1">22784751</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2013 Apr;189(4):1375-6</RefSource><PMID Version="1">23561355</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019737" MajorTopicYN="N">Transplants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22023552</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02509.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33752-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22018158</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1195-9479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Canadian journal of urology</Title><ISOAbbreviation>Can J Urol</ISOAbbreviation></Journal><ArticleTitle>GreenLight 180W XPS photovaporization of the prostate: how I do it.</ArticleTitle><Pagination><StartPage>5918</StartPage><EndPage>5926</EndPage><MedlinePgn>5918-26</MedlinePgn></Pagination><Abstract><AbstractText>Transurethral resection of the prostate (TURP) is the most common surgical intervention for benign prostatic hyperplasia (BPH), largely due to lower urinary tract symptoms refractory to medical therapy. TURP remains the gold standard for men with prostates sized 30g-80g, while open prostatectomy has been the preferred option for men with glands larger than 80g-100 g and those with other lower urinary tract anomalies such as large bladder stones or bladder diverticula. Unfortunately, these procedures have complications including bleeding (often requiring transfusion in 7%-13% of cases), electrolyte abnormalities (2% TURP syndrome), erectile dysfunction (6%-10%), and retrograde ejaculation (50%-75%). The overall incidence of a second intervention (repeat TURP, urethrotomy and bladder neck incision) has been reported in 12% and 15% of men at 5 and 10 years following TURP. Alternative therapies have been developed with the aim of reducing the level of complications while maintaining efficacy. These include microwave therapy, transurethral needle ablation, and a range of laser procedures (Holmium, Diode, Thulium and 532nm-Greenlight). Photoselective vaporization of the prostate (PVP), initially launched as a 60W prototype, was ultimately introduced to the urology community as a 80W system (American Medical Systems, Minnetonka, Minnesota, USA), has been the predominant device used in clinical trials. This 1st generation used an Nd:YAG laser beam passed through a potassium-titanyl-phosphate (KTP) crystal, halving the wavelength (to 532nm), doubling the laser's frequency, and resulting in a green light. Outcomes have demonstrated a reduced frequency and severity of clinical complications, however it was limited to smaller prostate sizes. In 2006, the 120W lithium triborate laser (LBO), also known as the GreenLight HPS (High Performance System) laser was introduced. This laser utilizes a diode pumped Nd:YAG laser light that is emitted through an LBO instead of a KTP crystal, resulting in a higher-powered 532 nm wavelength green light laser while still using the same 70-degree deflecting, side firing, silica fiber delivery system. The HPS offered an 88% more collimated beam and smaller spot size, resulting in much higher irradiance or power density in its 2 predecessors (60W and 80W) with a beam divergence of 8 versus 15 degrees. The primary aim for this upgrade was to reduce lasing time and improve clinical outcomes while demonstrating the same degree of safety for patients. Limitations of the 120W system included treatment of large prostates greater than 80g-100g and increased cost related to fiber devitrification and fracture. In 2011, the 180W-Greenlight XPS system was introduced, not only with increased power setting to vaporize tissue quicker but significant fiber-design changes. Internal cooling, metal-tip cap protection and FiberLife (temperature sensing feedback), better preserve the integrity of the fiber generally producing a 1-fiber per case expectation. Initial personal experience with XPS has provided comparable outcomes related to morbidity, but with the opportunity to perform a more complete and rapid procedure. Published clinical data with the XPS is unfortunately lacking. The objective of this report is to detail our approach and technique for GreenLight XPS drawing on personal experience with both enucleation and vaporization techniques with various laser technologies along with having performed over 500 GreenLight HPS and 100 XPS procedures. In this regard, recommendations for training are also made, which relate to existing users of the 80W and 120W GreenLight laser as well as to new laser users.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zorn</LastName><ForeName>Kevin C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Montreal Hospital Center, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liberman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Urol</MedlineTA><NlmUniqueID>9515842</NlmUniqueID><ISSNLinking>1195-9479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="N">Laser Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053844" MajorTopicYN="N">Lasers, Solid-State</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020728" MajorTopicYN="N">Transurethral Resection of Prostate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014835" MajorTopicYN="N">Volatilization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22018158</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21951711</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2012</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Adrenomedullin mediates adipose tissue-derived stem cell-induced restoration of erectile function in diabetic rats.</ArticleTitle><Pagination><StartPage>482</StartPage><EndPage>493</EndPage><MedlinePgn>482-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02469.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erectile dysfunction (ED) is a major health problem. It is known that diabetic patients are more refractory to common treatments for ED.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To explore the better treatment for ED, we examined the effects of adipose-derived stem cells (ASC) on ED using a diabetic rat model. We also analyzed the cytokines produced by ASC and implicated in ASC-induced restoration of erectile function.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Male Wistar rats were injected with streptozotocin (STZ) to induce diabetes. ASC or adenoviruses were injected into the penis 6 weeks after STZ administration. Erectile function, penile histology and protein expression were analyzed 4 weeks after the injection of ASC or adenoviruses.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Intracavernous pressure and mean arterial pressure were measured to evaluate erectile function. The morphology of the penis was analyzed by Elastica van Gieson stain and immunohistochemistry. The expression of proteins specific for vascular endothelial cells (VEC) was assessed by Western blot analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ASC restored erectile function especially when they were cultured in medium containing growth factors for VEC. This restoration was associated with improvement in the histology of the cavernous body, and increased expression of VEC markers such as VE-cadherin and endothelial nitric oxide synthase (eNOS). When the expression of adrenomedullin (AM), a vasoactive peptide originally isolated from human pheochromocytoma tissue, was knocked down, the effect of ASC on ED was significantly diminished. Knockdown of AM was associated with decreased expressions of VE-cadherin and eNOS. Furthermore, overexpression of AM induced by adenovirus infection significantly improved erectile function in these diabetic rats. Overexpression of AM was associated with increased expressions of VE-cadherin and eNOS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggested that ASC have the potentials to restore erectile function and that AM produced by ASC plays a major role in the restoration of erectile function.</AbstractText><CopyrightInformation>&#xa9; 2011 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishimatsu</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Department of Urology, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Etsu</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kumano</LastName><ForeName>Shintaro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nomiya</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Miao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kume</LastName><ForeName>Haruki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Homma</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>148498-78-6</RegistryNumber><NameOfSubstance UI="D053607">Adrenomedullin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053607" MajorTopicYN="N">Adrenomedullin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21951711</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02469.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33868-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21934623</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2011</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6586</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current opinion in urology</Title><ISOAbbreviation>Curr Opin Urol</ISOAbbreviation></Journal><ArticleTitle>Complications after radical prostatectomy: anastomotic stricture and rectourethral fistula.</ArticleTitle><Pagination><StartPage>461</StartPage><EndPage>464</EndPage><MedlinePgn>461-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MOU.0b013e32834b7e1b</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">With the discovery of prostate-specific antigen and routine prostate cancer screening, came a renewed interest in the radical prostatectomy. As a result of early detection, the majority of prostate cancer is of low risk placing more emphasis on the social consequences of the surgery such as urinary incontinence, anastomotic contracture, erectile dysfunction and rectourethral fistula (RUF) formation. This review is specifically focused on the current approaches to anastomotic stricture and RUF following radical prostatectomy.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">A subset of anastomotic contractures following radical prostatectomy are recurrent and refractory to standard endoscopic therapy. Previous enthusiasm for permanent urethral stents has been dissipated by long-term results showing high revision and complication rates. In an attempt to avoid permanent urethral stents, new adjunctive agents are being used in combination with urethrotomy to achieve a stable, bladder neck anastomosis. There has been a major shift in the cause of RUF from primarily surgical to approximately 50% resulting from radiation/ablation therapy. Surgically induced RUF typically are small, located in bladder neck/trigonal region and can be primarily closed. Radiation/ablation induced fistula are large (&gt;2&#x200a;cm), involve the prostatic urethra and are fibrotic often requiring a combination of onlay grafting and interposition muscle flap for closure. The anterior, perineal sphincter-sparing approach is the optimal approach for closure of all RUF (simple or complex).</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Recent advancements in these two challenging patient populations have allowed reconstructive urologists to remain committed to rehabilitating the lower urinary tract avoiding palliative maneuvers and often-unnecessary urinary and fecal diversion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Jill C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Urology, Trauma and Reconstructive Surgery, Lahey Clinic Medical Center, Burlington, Massachusetts, USA. jill.c.buckley@lahey.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Urol</MedlineTA><NlmUniqueID>9200621</NlmUniqueID><ISSNLinking>0963-0643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="N">Rectal Fistula</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="N">Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014522" MajorTopicYN="N">Urethral Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014525" MajorTopicYN="N">Urethral Stricture</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014548" MajorTopicYN="N">Urinary Fistula</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21934623</ArticleId><ArticleId IdType="doi">10.1097/MOU.0b013e32834b7e1b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21924956</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4973</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current opinion in pharmacology</Title><ISOAbbreviation>Curr Opin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>PDE5 inhibitors: targeting erectile dysfunction in diabetics.</ArticleTitle><Pagination><StartPage>683</StartPage><EndPage>688</EndPage><MedlinePgn>683-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coph.2011.08.004</ELocationID><Abstract><AbstractText>Erectile dysfunction (ED) is strongly linked to cardiovascular disease (CVD), especially in diabetics. ED is associated with deleterious changes in the overall vasculature and is recognized as an indicator of higher risk for adverse cardiovascular events. Endothelial dysfunction, vascular smooth muscle changes and increased fibrosis are indicated as major players in both ED and CVD. ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Use of PDE5 inhibitors in pre-diabetic and diabetic men may protect cardiovascular health, including vascular function in penile tissues.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Sharron H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, United States. Sharron.francis@vanderbilt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbin</LastName><ForeName>Jackie D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Pharmacol</MedlineTA><NlmUniqueID>100966133</NlmUniqueID><ISSNLinking>1471-4892</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>H2D2X058MU</RegistryNumber><NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21924956</ArticleId><ArticleId IdType="doi">10.1016/j.coph.2011.08.004</ArticleId><ArticleId IdType="pii">S1471-4892(11)00148-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21919947</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0272</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Andrologia</Title><ISOAbbreviation>Andrologia</ISOAbbreviation></Journal><ArticleTitle>Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.</ArticleTitle><Pagination><StartPage>293</StartPage><EndPage>296</EndPage><MedlinePgn>293-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1439-0272.2009.00991.x</ELocationID><Abstract><AbstractText>At least 30-35% of men with erectile dysfunction (ED) fail to respond to treatment with phosphodiesterase type 5 (PDE-5) inhibitors. Testosterone (T) has effects not only on sexual desire, but also on the anatomical and physiological substrate of erection. This study analysed the effects of T administration to men unsuccessfully treated for ED with PDE-5 inhibitors only. Twenty-nine men aged 36-75&#x2003;years (mean 59&#x2003;years) with ED were studied. They suffered from ED for a mean of 2.7&#x2003;years and had subnormal plasma T levels (total T &lt;3.5&#x2003;ng&#x2003;ml(-1) ). They received parenteral testosterone undecanoate for 102&#x2003;weeks. Changes of the domains of the International Index of Erectile Function (IIEF) were assessed. After 6&#x2003;weeks of T treatment, the sexual desire domain of IIEF had improved (from 4.1&#x2003;&#xb1;&#x2003;1.4 to 7.2&#x2003;&#xb1;&#x2003;1.7) and erectile function as measured by IIEF started to improve, reaching a plateau after 30&#x2003;weeks (from 9.1&#x2003;&#xb1;&#x2003;2.1 to 26.5&#x2003;&#xb1;&#x2003;2.3). Features of the metabolic syndrome also improved. There were no adverse effects of T administration. Addition of T to treatment of hypogonadal men unsuccessfully treated with PDE-5 inhibitors only, appeared useful and acceptably safe.</AbstractText><CopyrightInformation>&#xa9; 2011 Blackwell Verlag GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department Urology, Instituto Docente de Urolog&#xed;a, Valencia, Venezuela. joseantoniogarcia10@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Fraile</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Escovar</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Andrologia</MedlineTA><NlmUniqueID>0423506</NlmUniqueID><ISSNLinking>0303-4569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>H16A5VCT9C</RegistryNumber><NameOfSubstance UI="C010792">testosterone undecanoate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21919947</ArticleId><ArticleId IdType="doi">10.1111/j.1439-0272.2009.00991.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21771234</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2011</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1464-410X</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>A helping hand in refractory erectile dysfunction.</ArticleTitle><Pagination><StartPage>E150</StartPage><EndPage>E151</EndPage><MedlinePgn>E150-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1464-410X.2011.10180.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wyllie</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Pharma Consulting Ltd, c/o SAS, 940 Cornforth Drive, Sittingbourne Research Centre, Kent, ME9 8PX, UK.. m.wyllie@globalpharma.co.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21771234</ArticleId><ArticleId IdType="doi">10.1111/j.1464-410X.2011.10180.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21735659</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2011</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Oxytocin and male sexual function].</ArticleTitle><Pagination><StartPage>558</StartPage><EndPage>561</EndPage><MedlinePgn>558-61</MedlinePgn></Pagination><Abstract><AbstractText>Oxytocin (OT) is a female hormone with the main function of facilitating uterine contraction and milk ejection. Recent studies show that OT is involved in multiple signaling pathways in the central and peripheral nerve system and mainly regulates the physiology and activity of reproduction, including male reproduction and sexual behavior. The roles of OT in penile erection are bio-phasic with proerectile effect in the central nerve system while peripherally inhibiting erection. OT also mediates ejaculation, post-ejaculatory detumescence and the post-orgasm refractory period. OT and OT-receptor in the central nerve system will be a new target in the drug development for the treatment of erectile dysfunction, while OT intracavernous injection promises to be an effective therapy for priapism. This review focuses on the effects of OT on male sexual activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Ruo-Bing</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Institute of Urology and Nephrology, Guangxi Medical University, Nanning, Guangxi 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin-Hua</ForeName><Initials>XH</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>50-56-6</RegistryNumber><NameOfSubstance UI="D010121">Oxytocin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010121" MajorTopicYN="N">Oxytocin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="Y">Sexual Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21735659</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21502702</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2011</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1576-8260</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archivos espanoles de urologia</Title><ISOAbbreviation>Arch Esp Urol</ISOAbbreviation></Journal><ArticleTitle>[Simultaneous double prosthesis implant more artificial urinary sphincter via transscrotal: surgical technique].</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>319</EndPage><MedlinePgn>311-9</MedlinePgn></Pagination><Abstract><AbstractText>Moderate-severe urinary incontinence and refractory-to-treatment erectile dysfunction after radical prostatectomy are two entities causing an important loss of quality of life to patients. The double implant of penile prosthesis and artificial urinary sphincter is a safe and effective option in these cases. This article describes preoperative considerations and the most important technical steps to do it satisfactorily.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Salamanca</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Servicio y C&#xe1;tedra de Urolog&#xed;a, &#xc1;rea de Medicina Sexual, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Espa&#xf1;a. jims09@me.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moncada</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>del Portillo</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sola</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Ballesteros</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carballido</LastName><ForeName>Joaqu&#xed;n</ForeName><Initials>J</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Implante doble simult&#xe1;neo de pr&#xf3;tesis de pene mas esf&#xed;nter urinario artificial por via transescrotal: t&#xe9;cnica quir&#xfa;rgica.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Esp Urol</MedlineTA><NlmUniqueID>0064757</NlmUniqueID><ISSNLinking>0004-0614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012611" MajorTopicYN="N">Scrotum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016741" MajorTopicYN="Y">Urinary Sphincter, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013520" MajorTopicYN="N">Urologic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21502702</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21492409</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2011</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study.</ArticleTitle><Pagination><StartPage>2112</StartPage><EndPage>2117</EndPage><MedlinePgn>2112-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02285.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Loss of penile length after penile prosthesis implantation is one of the most common complaints. There is no recognized reliable technique to gain length once the device is placed.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This noncontrolled pilot study was designed to evaluate the efficacy and safety of external penile traction therapy in men with a shortened penis used before inflatable prosthesis implantation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ten men with drug refractory erectile dysfunction and a complaint of a shorter penis as a result of radical prostatectomy in four, prior prosthesis explantation in four, and Peyronie's disease in two were entered into this trial. External penile traction was applied for 2-4 hours daily for 2-4 months prior to prosthesis surgery.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Baseline stretched penile length (SPL) was compared with post-traction SPL and postimplant inflated erect length. A non-validated questionnaire assessed patient satisfaction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All men completed the protocol. Daily average device use was 2-4 hours and for up to 4 months. No man had measured or perceived length loss after inflatable penile prosthesis placement. Seventy percent had measured erect length gain compared with baseline pre-traction SPL up to 1.5 cm. There were no adverse events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">External traction therapy appears to result in a preservation of penile length, as no man had measured or perceived length loss following prosthesis placement, but in fact, a small length gain was noted in 70% of the subjects with no adverse events. The protocol is tedious and requires compliance to be effective. External traction therapy prior to inflatable penile prosthesis placement appears to preserve and possibly result in increased post-prosthesis implant erect length.</AbstractText><CopyrightInformation>&#xa9; 2011 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Urology, Rush University Medical Center, Chicago, IL, USA. drlevine@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybak</LastName><ForeName>James</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001837" MajorTopicYN="N">Body Weights and Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010409" MajorTopicYN="N">Penile Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014143" MajorTopicYN="Y">Traction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21492409</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02285.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33590-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21423198</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Combination therapy for erectile dysfunction: an update review.</ArticleTitle><Pagination><StartPage>382</StartPage><EndPage>390</EndPage><MedlinePgn>382-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/aja.2011.2</ELocationID><Abstract><AbstractText>The introduction of oral phosphodiesterase-5 inhibitors (PDE5Is) in the late 1990s and early 2000s revolutionized the field of sexual medicine and PDE5Is are currently first-line monotherapy for erectile dysfunction (ED). However, a significant proportion of patients with complex ED will be therapeutic non-responders to PDE5I monotherapy. Combination therapy has recently been adopted for more refractory cases of ED, but a critical evaluation of current combination therapies is lacking. A thorough PubMed and Cochrane Library search was conducted focusing on the effectiveness of combination therapies for ED in therapeutic non-responders to PDE5I therapy. Journal articles spanning the time period between January 1990 and December 2010 were reviewed. Criteria included all pertinent review articles, randomized controlled trials, cohort studies and retrospective analyses. References from retrieved articles were also manually scanned for additional relevant publications. Published combination therapies include PDE5I plus vacuum erectile device (VED), intraurethral medication, intracavernosal injection (ICI), androgen supplement, &#x3b1;-blocker or miscellaneous combinations. Based on this review, some of these combination treatments appeared to be quite effective in preliminary testing. Caution must be advised, however, as the majority of combination therapy articles in the last decade have numerous limitations including study biases and small subject size. Regardless of limitations, present combination therapy research provides a solid foundation for future studies in complex ED management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhir</LastName><ForeName>Rohit R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hao-Cheng</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Canfield</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Run</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>17298-37-2</RegistryNumber><NameOfSubstance UI="C003223">propionylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014618" MajorTopicYN="N">Vacuum</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21423198</ArticleId><ArticleId IdType="pmc">PMC3739353</ArticleId><ArticleId IdType="doi">10.1038/aja.2011.2</ArticleId><ArticleId IdType="pii">aja20112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lue T, Broderick G.Evaluation and nonsurgical management of erectile dysfunction and premature ejaculationIn: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology, 9th ed., Chapter 22 Philadelphia, PA; WB Saunders; 2006750&#x2013;87.</Citation></Reference><Reference><Citation>McKinlay JB. The worldwide prevalence and epidemiology of respective PDEs, could achieve greater enhance- erectile dysfunction. Int J Impot Res. 2000;2 Suppl 4:S6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer F, Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging. 2004;21:555&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Hoang AN, Romero CA, Lin H, Dai Y, et al. Vacuum therapy in erectile dysfunction&#x2014;science and clinical evidence. Int J Impot Res. 2010;22:211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Westney OL, Wang R. Design and application of a new rat specific vacuum erectile device for penile rehabilitation research. J Sex Med. 2009;6:3247&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">19758281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Lin H, Li P, Zhang R, Luo A, et al. Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study. Eur Urol. 2010;58:773&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20674151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Sofer M, Kaver I, Matzkin H, Greenstein A. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol. 2004;171:292&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665897</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Agarwal A, Allamaneni SS, Lakin MM, Zippe CD. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology. 2005;65:360&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708053</ArticleId></ArticleIdList></Reference><Reference><Citation>Canguven O, Bailen J, Fredriksson W, Bock D, Burnett AL. Combination of vacuum erectile device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6:2561&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19627462</ArticleId></ArticleIdList></Reference><Reference><Citation>Levels of Evidence and Grades of Recommendation. Centre for Evidence-Based Medicine. .http://www.cebm.net/?o=1025(accessed 12 December 2010).</Citation></Reference><Reference><Citation>Kim NN, Huang Y, Moreland RB, Kwak SS, Goldstein I, et al. Cross-regulation of intracellular cAMP and cGMP in cultured human corpus cavernosum smooth muscle cells. Mol Cell Biol Res Commun. 2000;4:10&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydlo JH, Volpe MA, MacChia RJ. Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int. 2000;86:469&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Blute ML, Barrett DM. Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002;4 Suppl 1:S38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850734</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Nandipati KC, Agarwal A, Mansour D, Kaelber DC, et al. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl. 2005;26:757&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291971</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006;8:675&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892168</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999;162:1992&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18:446&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482200</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Park JS, Jeon SB, Cui WS, Kim SZ, et al. Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction. BJU Int. 2008;102:993&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18476965</ArticleId></ArticleIdList></Reference><Reference><Citation>Penson DF, Ng C, Cai L, Rajfer J, Gonz&#xe1;lez-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod. 1996;55:567&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8862773</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilatation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699447</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247755</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed. Urology. 2005;173:530&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">15643239</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology. 2006;67:571&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16527581</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006;38:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16529577</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol. 2003;44:637&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">14644114</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JM, DeSouza R, Wang R. Common approach to managing lower urinary tract symptoms and erectile dysfunction. Asian J Androl. 2008;10:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087643</ArticleId></ArticleIdList></Reference><Reference><Citation>Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 2003;91:873&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">12780851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NN, Goldstein I, Moreland RB, Traish AM. Alpha-adrenergic receptor blockade by phentolamine increases the efficacy of vasodilators in penile corpus cavernosum. Int J Impot Res. 2000;2 Suppl 1:S26&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845762</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med. 2009;6:836&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19143907</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res. 2002;14:50&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17258855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Jahoda A, Aviv N, Valenzuela R, Parker M. The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. . BJU Int. 2004;93:97&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460342</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori G, Trombetta C, de Giorgi G, Pomara G, Maio G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138360</ArticleId></ArticleIdList></Reference><Reference><Citation>Blonde L, Korenman SG, Siegal RL, Orazem J. Sildenafil citrate for treatment of erectile dysfunction is similarly effective in men with type 1 or type 2 diabetes mellitus. Diabetes. 2000;49 Suppl 1:354 (A88)..</Citation></Reference><Reference><Citation>Koppiker N, Boolell M, Price D. Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. Endocr Pract. 2003;9:52&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-&#x2113;-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004;20:1377&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-&#x2113;-carnitine plus propionyl-&#x2113;-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology. 2005;66:1080&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286128</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann HC, Levine LA, Macaluso J, Jr, Walsh M, Bradbury D, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490024</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadiack AM, Herbert GW, Silvester KR, Padron JM.Elucidating the mechanism of the erectogenic effects of PT-141, a synthetic melanocortin agonistSociety for Neuroscience: New Orleans, LA, 2003. Abstract Book: Program No. 399.4.</Citation></Reference><Reference><Citation>Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65:755&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15833522</ArticleId></ArticleIdList></Reference><Reference><Citation>Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. J Sex Med. 2007;4:1136&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdal OL, Ozden C, Gokkaya S, Urgancioglu G, Aktas BK, et al. The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction. Int Urol Nephrol. 2008;40:133&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17764032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondoh N, Higuchi Y, Maruyama T, Nojima M, Yamamoto S, et al. Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: preliminary report. Aging Male. 2008;11:167&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19172547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebret T, Herv&#xe9; JM, Gorny P, Worcel M, Botto H. Efficacy and safety of a novel combination of l-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. 2002;41:608&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen HS, Hsieh CH, Hsu GL, Kao YC, Ling PY, et al. The synergism of penile venous surgery and oral sildenafil in treating patients with erectile dysfunction. Int J Androl. 2005;28:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">16128990</ArticleId></ArticleIdList></Reference><Reference><Citation>Perimenis P, Konstantinopoulos A, Karkoulias K, Markou S, Perimeni P, et al. Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea. Int Urol Nephrol. 2007;39:547&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17310311</ArticleId></ArticleIdList></Reference><Reference><Citation>Banner LL, Anderson RU. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med. 2007;4:1117&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627724</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubin S, Heiman JR, Berger RE, Murallo AV, Yung-Wen L. Comparing Sildenafil alone vs. Sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. J Sex Marital Ther. 2009;35:122&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19266381</ArticleId></ArticleIdList></Reference><Reference><Citation>John H, Lehmann K, Hauri D. Intraurethral prostaglandin improves quality of vacuum erection therapy. Eur Urol. 1996;29:224&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8647152</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmar JL, DeBenedictis TJ, Praiss DE. The use of a vacuum constrictor device to augment a partial erection following an intracavernous injection. J Urol. 1988;140:975&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3172371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Godschalk MF, Katz PG, Mulligan T. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol. 1995;153:1476&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714970</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. 2000;164:376&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893589</ArticleId></ArticleIdList></Reference><Reference><Citation>Benevides MD, Carson CC. Intraurethral application of alprostadil in patients with failed inflatable prosthesis. J Urol. 2000;163:785&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10687977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew KK, Stuckey BG. Use of transurethral alprostadil (MUSE) for glans tumescence in a patient with a penile prosthesis. Int J Impot Res. 2000;12:195&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11045915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, Jahoda A, Aviv N, Valenzuela R, Parker M. The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. . BJU Int. 2004;93:97&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mireku-Boateng AO, Dennery M, Littlejohn J. Use of sildenafil in penile implant patients. Urol Int. 2001;66:149&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11316977</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderdahl DW, Petroski RA, Mode D, Schwartz BF, Thrasher JB. The use of an external vacuum device to augment a penile prosthesis. Tech Urol. 1997;3:100&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9297771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21421100</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-1883</ISSN><JournalIssue CitedMedium="Internet"><Volume>201</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>American journal of surgery</Title><ISOAbbreviation>Am J Surg</ISOAbbreviation></Journal><ArticleTitle>Priapism in the United States: the changing role of sickle cell disease.</ArticleTitle><Pagination><StartPage>468</StartPage><EndPage>474</EndPage><MedlinePgn>468-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjsurg.2010.03.017</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few patients with priapism require inpatient management unless they are refractory to intracavernosal therapy. Their risk factors and outcomes are poorly characterized.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective analysis of the Nationwide Inpatient Sample (1998-2006). Priapism patients were identified and analyzed over time by age, race, sickle-cell disease diagnosis, drug abuse, and penile operations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 4,237 hospitalizations for priapism were identified (30% white, 61.1% black, and 6.3% Hispanics). There was an increasing incidence of priapism over time, concentrated in the middle-age group. There were 1,776 patients (41.9%) with diagnoses of sickle-cell disease, with decreasing proportions over time. Drug abuse was reported in 7.9%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Inpatient diagnoses of priapism are increasing over time with relatively constant numbers of sickle-cell disease patients, suggesting rising nonhematologic causes of priapism. One theory is that increasing use of aggressive therapies for erectile dysfunction might play a role, especially when combined with drug abuse.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chrouser</LastName><ForeName>Kristin L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. chrouser@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajiboye</LastName><ForeName>Onaopemipo B</ForeName><Initials>OB</Initials></Author><Author ValidYN="Y"><LastName>Oyetunji</LastName><ForeName>Tolulope A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Surg</MedlineTA><NlmUniqueID>0370473</NlmUniqueID><ISSNLinking>0002-9610</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000755" MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21421100</ArticleId><ArticleId IdType="doi">10.1016/j.amjsurg.2010.03.017</ArticleId><ArticleId IdType="pii">S0002-9610(10)00469-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21385324</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2011</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Intra-abdominal reservoir placement during penile prosthesis surgery in post-robotically assisted laparoscopic radical prostatectomy patients: a case report and practical considerations.</ArticleTitle><Pagination><StartPage>1547</StartPage><EndPage>1550</EndPage><MedlinePgn>1547-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2011.02229.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Robotically assisted laparoscopic radical prostatectomy (RALP) provides decreased surgical morbidity and faster recovery for patients, but has not significantly changed the incidence of erectile dysfunction and many post RALP patients may require penile prosthesis surgery.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To make physicians aware of the anatomical changes after RALP in comparison to traditional retropubic radical prostatectomy and to make suggestions for safer reservoir placement.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Reservoir location after RALP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 68 year-old patient with severe vasculogenic ED refractory to pharmacologic management following RALP underwent a 3-piece penile prosthesis insertion surgery and laparoscopic right lower abdominal hernia repair. Laparoscopy revealed an intraperitoneal reservoir that was overlying the sigmoid colon with multiple diverticula. The reservoir was laparoscopically repositioned in the dependent pelvis away from the diverticula and the pelvic vessels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient's postoperative course was uneventful without any postoperative complications (2 year follow up).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The altered anatomy of the space of Retzius following RALP will likely result in significantly more cases of inadvertent intraperitoneal reservoir placement. Surgeons performing inflatable penile prosthesis surgery should be aware of these anatomical changes and prepared to consider ectopic reservoir placement when necessary.</AbstractText><CopyrightInformation>&#xa9; 2011 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadeghi-Nejad</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Urology, UMDNJ New Jersey Medical School, Newark, New Jersey, USA. hossein.sadeghi-nejad@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munarriz</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Neel</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2011 Dec;186(6):2300-1</RefSource><PMID Version="1">22078602</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012371" MajorTopicYN="N">Robotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21385324</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2011.02229.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33530-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21143418</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2011</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Isolated infection of a decommissioned penile prosthesis reservoir with Actinomyces neuii.</ArticleTitle><Pagination><StartPage>923</StartPage><EndPage>926</EndPage><MedlinePgn>923-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2010.02144.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflatable penile prostheses (IPPs) are a well-established and reliable treatment for medication refractory erectile dysfunction. The most serious complication with IPPs is infection, with the reported incidence after primary placement 1% to 3% and after revision surgery 8% to 18%.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this report is to describe an infected decommissioned IPP reservoir with Actinomyces neuii with successful preservation of a functioning implant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">After 9 years of successful use with an IPP (AMS 700 CX) for Peyronie's disease and organic erectile dysfunction, a 79-year-old man underwent replacement with an AMS 700 LGX. The decommissioned reservoir was kept in the right prevesical space, and the new reservoir was placed in the left prevesical space. Three months later, he presented with right inguinal pain and swelling.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">He was found to have an infected right reservoir with A. neuii, sparing his new IPP. After removal of the right reservoir, he had an uneventful recovery and has shown no evidence of infection in the new device.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Revision surgery for IPPs carries a higher risk for implant infection. This is the first report of a genitourinary implant infection with A.&#x2003;neuii. Aggressive surgical and medical treatment may allow preservation of the functioning implant, despite gross infection of the decommissioned reservoir.</AbstractText><CopyrightInformation>&#xa9; 2010 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsi</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotaling</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Elysia S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Bollyky</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000190" MajorTopicYN="Y">Actinomyces</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000196" MajorTopicYN="N">Actinomycosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016459" MajorTopicYN="N">Prosthesis-Related Infections</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21143418</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02144.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33441-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21054791</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy.</ArticleTitle><Pagination><StartPage>1182</StartPage><EndPage>1189</EndPage><MedlinePgn>1182-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2010.01881.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Vacuum erection devices (VEDs) are becoming first-line therapies for the treatment of erectile dysfunction and preservation (rehabilitation) of erectile function following treatment for prostate cancer. Currently, there is limited efficacy of the use of phosphodiesterase type 5 inhibitors in elderly patients, or patients with moderate to severe diabetes, hypertension, and coronary artery disease.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The article aims to study the role of VED in patients following prostate cancer therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Alternative therapies such as VED have emerged as one of the primary options for patients refractory to oral therapy. VED has also been successfully used in combination treatment with oral therapy and penile injections. More recently, there has been interest in the use of VED in early intervention protocols to encourage corporeal rehabilitation and prevention of postradical prostatectomy veno-occlusive dysfunction. This is evident by the preservation of penile length and girth that is seen with early use of the VED following radical prostatectomy. There are ongoing studies to help preserve penile length and girth with early use of VED following prostate brachytherapy and external beam radiation for prostate cancer. Recently, there has also been interest in the use of VED to help maintain penile length following surgical correction of Peyronie's disease and to increase penile size prior to implantation of the penile prosthesis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">VEDs can be one of the options for penile rehabilitation after prostate cancer therapy.</AbstractText><CopyrightInformation>&#xa9; 2010 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pahlajani</LastName><ForeName>Geetu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Regional Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raina</LastName><ForeName>Rupesh</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zippe</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001918" MajorTopicYN="N">Brachytherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061345" MajorTopicYN="N">Early Medical Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014618" MajorTopicYN="N">Vacuum</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21054791</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01881.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33959-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20955315</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2011</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Trans-corporal incision of Peyronie's plaques.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>593</EndPage><MedlinePgn>589-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2010.02078.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients presenting with Peyronie's disease (PD) curvature and erectile dysfunction (ED) can achieve straightening and rigidity through penile prosthesis implantation and manual modeling and, if necessary, a relaxing tunical incision with or without grafting. Unfortunately, this maneuver will not correct PD-induced shortening. In addition, incision and grafting after the prosthesis has already been implanted adds to operative time and risk, and may indicate mobilization of the neurovascular bundle and, possibly, a secondary skin incision.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This work describes trans-corporal incision (TCI), a minimally invasive endoscopic approach for plaque incision from within the corpora cavernosa, restoring straightness and length to the penis, before calibration of the corpora cavernosa, allowing implantation of a longer prosthesis in a straight penis, with neither mobilizing the neurovascular bundle nor a secondary incision.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixteen patients with PD deformity and refractory ED were operated upon. Intra-operative artificial erection demonstrated the deformity. Through a penoscrotal incision, the corpora were dilated. TCI was performed to incise Peyronie's plaques at the point of maximum deformity. Artificial erection was re-induced and correction of curvature evaluated. Length was measured before and after TCI. Implantation proceeded as usual.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Penile straightness and length.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Following implantation, the penis was straight in all cases. Pre-TCI length of the corpora was unequal on either side. Post-TCI, both corpora were of equal length with an average increase of 2.5 cm (11.9%) on the right side and 1.9 (9.1%) on the left.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TCI; corporoscopic incision of Peyronie's plaques upon implantation of penile prosthesis is a minimally invasive approach that restores both straightness and length to patients with PD and ED, with neither mobilization of the neurovascular bundle nor plaque incision and grafting.</AbstractText><CopyrightInformation>&#xa9; 2010 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaeer</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. Dr.osama@alrijal.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004724" MajorTopicYN="N">Endoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20955315</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2010.02078.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)33399-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20845293</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2010</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1735-546X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Urology journal</Title><ISOAbbreviation>Urol J</ISOAbbreviation></Journal><ArticleTitle>Erectile function and dysfunction following low flow priapism: a comparison of distal and proximal shunts.</ArticleTitle><Pagination><StartPage>174</StartPage><EndPage>177</EndPage><MedlinePgn>174-7</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare erectile function following low flow priapism in patients undergoing distal and proximal shunts.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">From January 1995 to December 2005, we retrospectively studied 16 patients who presented to our medical center with refractory priapism. Of 16 patients, 5 underwent Winter shunt, while El-Ghorab procedure was performed for 7 patients and the remaining 4 underwent Grayhack shunt. Erectile function was assessed in a minimum follow-up of 2 years (range, 2 to 10 years) using erectile dysfunction (ED) intensity scale [Total score: 5 to 10 (severe ED); 11 to 15 (moderate ED); 16 to 20 (mild ED); and 21 to 25 (no ED)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean patient's age was 40.62 &#xb1; 15.27 years. Mean duration of priapism was 51.12 &#xb1; 37.99 hours. Of 4 patients (25%) who underwent proximal shunt (Grayhack procedure), 2 (50%) were impotent, 1 had potency, and the other one achieved some penile erection with administration of oral sildenafil. Of 5 patients (31.25%) who underwent Winter procedure, 1 died because of metastatic bladder cancer and of 4 remainders, 2 (50%) had normal erectile function, but 1 patient suffered from recurrent priapism. Of 7 patients (43.75%) who underwent El-Ghorab procedure, 1 was lost for follow-up and of remaining 6 patients, 2 (33.3%) had normal erectile function and 4 (66.6%) were impotent. No surgical complication was seen. Median lag time from priapism till surgery for patients with and without ED was 48 and 26 hours, respectively (P = .22).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Grayhack shunt is a safe surgical procedure without any major complications and with lower ED rate. Grayhack shunt might be considered as treatment of choice for refractory low flow priapism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tabibi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University, MC, Tehran, Iran. tabibiali@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdi</LastName><ForeName>Hamidreza</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mahmoudnejad</LastName><ForeName>Nastaran</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Urol J</MedlineTA><NlmUniqueID>101286676</NlmUniqueID><ISSNLinking>1735-1308</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="N">Urologic Surgical Procedures, Male</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20845293</ArticleId><ArticleId IdType="pii">760/499</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20722782</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Inflatable penile prosthesis placement in men with Peyronie's disease and drug-resistant erectile dysfunction: A single-center study.</ArticleTitle><Pagination><StartPage>3775</StartPage><EndPage>3783</EndPage><MedlinePgn>3775-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2010.01971.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erectile dysfunction (ED) frequently accompanies Peyronie's disease (PD) and changes the therapeutic approach.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate a single-center experience with inflatable penile prostheses (IPP) in men with medication refractory ED and PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ninety men underwent placement of an IPP with straightening maneuvers as necessary to address their deformity and ED.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Preoperative assessment included International Index of Erectile Function-erectile function domain (IIEF-EF) and duplex ultrasound to confirm ED and measure erect deformity. Postoperative assessment included a modified Erectile Dysfunction Index of Treatment Satisfaction (EDITS) questionnaire, as well as office visits at 1, 6, and every 12 months thereafter.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Complete chart review was performed with mean follow-up of 49 months. Mean preoperative IIEF-EF score was 11. Full rigidity was not obtained in any patient during duplex ultrasound. Mean curvature at maximum erection was 53&#xb0;. There were seven mechanical failures requiring device replacement, two revision surgeries for pump or reservoir malposition, one infected device, and two corporoplasties for distal tunica erosion. Postoperative office assessment revealed a functionally straight (i.e., &lt;20&#xb0;) erect penis and a properly positioned as well as operational device in all patients. The modified EDITS questionnaire was returned by 56 (62%). Overall, 84% of patients were satisfied with their outcome, yet only 73% were satisfied with their straightness. Patient perceived postoperative curvature correction stabilized quickly and was complete by 3 months in 84% of patients. Satisfaction with ease of inflation, deflation, and concealability was 84%, 71%, and 91%, respectively. Coital activity was reported by 91% of men in this group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In men with PD and ED, IPP placement allowed reliable and satisfactory coitus for the great majority of men. Mechanical failure was 7%. Men with PD undergoing IPP placement should be counseled regarding potential penile length loss and residual curvature, neither of which appeared to interfere with coitus but may reduce satisfaction.</AbstractText><CopyrightInformation>&#xa9; 2010 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Laurence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Urology, Rush University Medical Center, Chicago, IL, USA. drlevine@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Jonas</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hoover</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="Y">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="N">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20722782</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01971.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)32752-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20584123</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Vascularized cadaveric fibula flap for treatment of erectile dysfunction following failure of penile implants.</ArticleTitle><Pagination><StartPage>3504</StartPage><EndPage>3509</EndPage><MedlinePgn>3504-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2010.01914.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Postpriapism erectile dysfunction in patients with sickle cell disease is a particularly devastating condition. Where penile implants have failed, there is no good surgical alternative at present. Free tissue transfer is fraught with risks in patients with sickle cell disease and are not the best option for treatment.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To describe a new surgical technique involving prefabrication of a bone flap for treatment of erectile dysfunction in a patient with sickle cell disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The descending branch of the lateral circumflex femoral artery was isolated and implanted within a cadaveric bone segment. The prefabricated flap was then transferred 2 months later as a neophallus for penile autoaugmentation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bone scan showed viability of the bone flap after transfer. The patient was able to have vaginal intercourse and successfully achieve orgasm 2 months after the second stage surgery.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prefabrication of a cadaveric bone flap and subsequent transfer is a novel and effective technique for treatment of erectile dysfunction refractory to medical management. This technique may be particularly useful for "implant cripples," who have no other surgical option.</AbstractText><CopyrightInformation>&#xa9; 2010 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salgado</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Plastic Surgery, Department of Surgery Holtz Children's Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. salgado_plastics@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chim</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bodner</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000755" MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005360" MajorTopicYN="N">Fibula</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013524" MajorTopicYN="N">Surgical Flaps</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20584123</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2010.01914.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)32727-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22541906</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1166-7087</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie</Title><ISOAbbreviation>Prog Urol</ISOAbbreviation></Journal><ArticleTitle>[Asynchronous implantation of a penile prosthesis (AMS 700) in patients with an artificial urinary sphincter (AMS 800): what functional outcomes can we expect from the AMS 1500?].</ArticleTitle><Pagination><StartPage>354</StartPage><EndPage>359</EndPage><MedlinePgn>354-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.purol.2011.12.002</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report the functional results and morbidity after metachronous implantation of an AMS 800 artificial urinary sphincter (AUS) and an AMS 700 inflatable penile prosthesis (IPP).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">From the 250 patients treated in our department between 2000 and 2011 for the insertion of an AUS, we retrospectively selected patients who also underwent implantation of an IPP. The following data were recorded: age, aetiology of urinary incontinence (UI) and erectile dysfunction (ED), treatment history of UI/ED, date of insertion of the AUS and the IPP and time gap between the two implants. We evaluated both the pad-test and the number of protective pads used per day, before and after AUS insertion. We also analysed the IIEF5 score before and after IPP. Patients were reviewed at 3, 6 and 12 months and annually thereafter.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, five patients were included. The median age was 69 years. The median follow-up after IPP was 22.6 months and the time gap between the two implants was 50 months. The aetiology of UI and ED was prostate surgery in four cases. Complete continence without leakage was observed in three patients and the IIEF5 score increased from 6.6 preoperatively to 22.2 for four patients. One patient developed a urethral erosion of the AUS cuff 6 months after implantation of the IPP. The AUS cuff has been explanted but the patient remains continent with the IPP cylinders semi-inflated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">From our small study, it appears that the combined use of an AMS 800 AUS and an AMS 700 IPP was a feasible and efficacious option in patients with concomitant refractory UI and ED.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alechinsky</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service d'urologie, l'h&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, facult&#xe9; de m&#xe9;decine Pierre-et-Marie-Curie, universit&#xe9; Paris VI, Assistance publique-H&#xf4;pitaux de Paris, 47-83, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ph&#xe9;</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Bourgade</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Parra</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chartier-Kastler</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bitker</LastName><ForeName>M-O</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Roupr&#xea;t</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Implantation asynchrone d'une proth&#xe8;se p&#xe9;nienne (AMS 700) chez des patients avec un sphincter urinaire artificiel (AMS 800)&#xa0;: quels sont les r&#xe9;sultats fonctionnels de l'AMS 1500&#xa0;?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Prog Urol</MedlineTA><NlmUniqueID>9307844</NlmUniqueID><ISSNLinking>1166-7087</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Prog Urol. 2010 May;22(6):365-6</RefSource><PMID Version="1">22541909</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019919" MajorTopicYN="N">Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016741" MajorTopicYN="N">Urinary Sphincter, Artificial</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22541906</ArticleId><ArticleId IdType="doi">10.1016/j.purol.2011.12.002</ArticleId><ArticleId IdType="pii">S1166-7087(11)00407-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20420554</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-2422</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of medical devices</Title><ISOAbbreviation>Expert Rev Med Devices</ISOAbbreviation></Journal><ArticleTitle>AMS 700 inflatable penile prosthesis with InhibiZone.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>317</EndPage><MedlinePgn>311-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/erd.10.6</ELocationID><Abstract><AbstractText>Inflatable penile prostheses are the definitive therapy for erectile dysfunction refractory to medical therapy. For years mechanical malfunction was the most common cause of device failure, but recent advances in design have largely eliminated this, and now infection is the most significant problem with these implants. Antibiotic-coated medical devices, such as central venous and bladder catheters, have proven effective in reducing bacterial colonization and biofilm formation, leading to decreased rates of infection. In 2001, American Medical Systems (AMS) released its AMS 700 series penile prosthesis impregnated with a proprietary combination of the antibiotics rifampin and minocycline, called InhibiZone. Multiple studies have found that this device significantly reduces infection rates in men receiving penile prostheses. In July 2009, the US FDA approved the AMS 700 with InhibiZone as the only inflatable penile prosthesis with clinical evidence showing significant reduction in the rate of revision surgery due to infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKim</LastName><ForeName>Stephen E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>University of North Carolina, Division of Urology, Chapel Hill, NC 27599-7235, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Culley C</ForeName><Initials>CC</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Med Devices</MedlineTA><NlmUniqueID>101230445</NlmUniqueID><ISSNLinking>1743-4440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>FYY3R43WGO</RegistryNumber><NameOfSubstance UI="D008911">Minocycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018441" MajorTopicYN="N">Biofilms</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008911" MajorTopicYN="N">Minocycline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20420554</ArticleId><ArticleId IdType="doi">10.1586/erd.10.6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20299080</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Clinical features and treatment options for Chinese patients with severe primary erectile dysfunction.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>390</EndPage><MedlinePgn>387-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2009.12.008</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate clinical features of Chinese patients with severe primary erectile dysfunction (S-PED) and to identify the ideal treatment options for this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with PED were screened for enrollment in our study. Sexual history, marital status, and erectile function were evaluated by inquiry including International Index of Erectile Function-5. Individuals with severe PED (defined as refractory to management with phosphodiesterase type 5 inhibitor [PDE5i]) underwent serum hormone analysis, penile color duplex Doppler ultrasound, neuroelectromyogram, and cavernosography as appropriate. Long-term treatment results were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 220 PED patients, 72 (32.7%) suffered from severe PED (PDE5i nonresponse). Mean age was 31.5 +/- 4.5 years and mean duration of attempts at sexual activity was 2.4 +/- 3.2 years, Sixty-eight men (94.5%) had organic etiologies for erectile dysfunction, including arteriogenic (n = 13), venogenic (n = 35), endocrinologic (n = 6), neurologic (n = 9), and cavernosal fibrosis (n = 5). Sixteen men (22.2%) had been divorced. Mean erectile function and quality-of-life were significantly improved (P &lt;.001) in the 25 men (34.7%) who were treated by penile prosthesis implantation, at a mean follow-up of 5.6 years. Satisfaction with penile prosthesis for patients and partner was 93.4% and 92.3%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Severe PED has a major impact on young couple's life quality. Venous leak is the most common cause of severe PED. Penile prosthesis implantation is safe and effective for severe PED.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Andrology Center, Urology Institution of Peking University, Peking University First Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing-Liang</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Guang</ForeName><Initials>YG</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yi-Ming</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Wen-Qing</ForeName><Initials>WQ</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Wan-Shou</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Zhe</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Zhong-Cheng</ForeName><Initials>ZC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20299080</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2009.12.008</ArticleId><ArticleId IdType="pii">S0090-4295(09)03062-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20230544</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4733</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>623</EndPage><MedlinePgn>613-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1524-4733.2010.00702.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A conceptual framework for patient-reported outcomes (PROs) is a structured representation of outcome concepts and issues. Our aim was to develop a conceptual framework of PROs for hormone-refractory prostate cancer (HRPC) to support measurement clarity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relevant outcome issues were identified from review of recent clinical trials. This provided content for an interview with 15 metastatic HRPC patients and a survey of 10 practitioners. All participants were asked about the relevance and importance of 26 outcomes and were allowed to nominate new outcomes. Practitioners were also asked to determine which outcomes endorsed by patients were attributable to the disease (symptoms) versus treatment (side effects). Analyses of archived clinical trial data were used to verify and augment the interview and survey results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients endorsed 11 concerns as relevant and important to HRPC including general pain, bone pain, urinary problems, fatigue, appetite loss, constipation, erectile dysfunction, peripheral neuropathy, diarrhea, PSA anxiety, and changes in self image. Practitioner judgments helped classify each concern into one of four categories, disease symptom, treatment side effect, both symptom and side effect, or psychological concern. Additionally, patients endorsed (and practitioners confirmed) the relevance and importance of several general domains of quality of life. Analyses of archived data confirmed the importance of these issues and suggested two additional concerns.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Findings were used to propose a conceptual framework of PROs for metastatic HRPC. Such frameworks can be used to help specify targets for assessment in clinical studies such as treatment trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eton</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Division of Health Care Policy &amp; Research, Mayo Clinic, Rochester, MN, USA. eton.david@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shevrin</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Beaumont</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Victorson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>BZ114NVM5P</RegistryNumber><NameOfSubstance UI="D008942">Mitoxantrone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="N">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008942" MajorTopicYN="N">Mitoxantrone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20230544</ArticleId><ArticleId IdType="doi">10.1111/j.1524-4733.2010.00702.x</ArticleId><ArticleId IdType="pii">S1098-3015(10)60103-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20218319</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Vardenafil for refractory erectile dysfunction: the latest advances].</ArticleTitle><Pagination><StartPage>1035</StartPage><EndPage>1038</EndPage><MedlinePgn>1035-8</MedlinePgn></Pagination><Abstract><AbstractText>In recent years, more and more attention has been drawn to the role of phosphodiesterase 5 (PDE5) in penile erection. The cyclic nucleotide (cGMP) signaling pathway mediates the smooth-muscle relaxing effect of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathological pivot of many forms of erectile dysfunction (ED) and leads to the development of some chronic diseases. Therapeutic outcomes have shown that vardenafil is effective and safe in the treatment of ED associated with dyslipidemia, hypertension, depression, diabetes, radical retropubic prostatectomy, spinal cord injury, sildenafil failure, renal transplantation, chronic prostatitis and that accompanied by premature ejaculation. Vardenafil provides a reasonable therapeutic alternative for these refractory ED patients. In addition, vardenafil can prolong erectile duration of ED patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao-Yang</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Reproduction and Genetics, PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-Feng</ForeName><Initials>YF</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>29</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20218319</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20104670</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1 Pt 1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>98</EndPage><MedlinePgn>89-98</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erectile dysfunction (ED) is a major complication of type 2 diabetes, and many diabetic men with ED are refractory to common ED therapies.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine whether autologous adipose tissue-derived stem cells (ADSCs) injected into the penis of impotent type 2 diabetic rats improve erectile function.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Blood glucose levels, intracavernous pressure (ICP) increase upon cavernous nerve (CN) electrostimulation, and immunohistochemistry.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-two male Zucker diabetic fatty (ZDF) rats were used. At 22 weeks of age, all the animals underwent unilateral CN electrostimulation and ICP measurement to confirm impotence. Paragonadal adipose tissue was harvested to procure ADSCs. The impotent animals were randomized to ADSC treatment and sham control groups. At 23 weeks of age, the treatment group animals underwent a penile injection of 1 million ADSCs; the control group animals received vehicle only. Erectile function studies were repeated at 26 weeks of age, followed by tissue harvest.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rats developed diabetes within the first 10 weeks of age. At 22 weeks of age, 20 out of the 22 rats presented with ED. The post-treatment ICP increase during CN stimulation and ICP increase/mean arterial pressure were significantly higher in the treatment group compared with controls. Three weeks after injection into the corpus cavernosum, only a small number of BrdU-labeled ADSCs was detectable within corporal tissue of the treatment group. There was a significant increase in neuronal nitric oxide synthase (nNOS) in the penile dorsal nerve and in the number of endothelial cells in the corpora cavernosa of the rats in the treatment group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Autologous ADSCs injected into the penis were effective to improve erectile function and to alter the microarchitecture of the corpus cavernosum. Since the number of ADSCs retained in the corpus cavernosum is very small, we postulate that their paracrine function, not trans-differentiation to smooth muscle or endothelial cells, is responsible for the improvement in penile function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Maurice M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California School of Medicine-Knuppe Molecular Urology Laboratory, San Francisco, CA 94143-0738, USA. mgarcia@urology.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fandel</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guiting</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Shindel</LastName><ForeName>Alan W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Banie</LastName><ForeName>Lia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ching-Shwun</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Tom F</ForeName><Initials>TF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK045370</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DK045370</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DK045370-13</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2011 Jan;59(1):168-9</RefSource><PMID Version="1">21414869</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011924" MajorTopicYN="N">Rats, Zucker</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20104670</ArticleId><ArticleId IdType="mid">NIHMS213723</ArticleId><ArticleId IdType="pmc">PMC2904063</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01541.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)32835-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dey J, Shepherd MD. Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc. 2002;77:276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888032</ArticleId></ArticleIdList></Reference><Reference><Citation>Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol. 2003;170:S24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12853769</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Arjonilla M, Schwarcz M, Swerdloff RS, et al. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18843273</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. Jama. 2007;298:2028.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986696</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexanderson E, Rodriguez-Valero M, Martinez A, et al. Endothelial Dysfunction in Recently Diagnosed Type 2 Diabetic Patients Evaluated by PET. Mol Imaging Biol. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18769972</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57:505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17229978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90:2636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Arver S, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract. 2008;62:791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2327081</ArticleId><ArticleId IdType="pubmed">18266714</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N. National Diabetes Statistics. National Diabetes Information Clearinghouse (NDIC); 2007.  ( http://diabetes.niddk.nih.gov/index.htm.</Citation></Reference><Reference><Citation>Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab. 2005;7:307.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G, Garcia M, Ning H, et al. Defining stem and progenitor cells within adipose tissue. Stem Cells Dev. 2008;17:1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865901</ArticleId><ArticleId IdType="pubmed">18597617</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies. Stem Cells. 2007;25:818.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee RH, Kim B, Choi I, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem. 2004;14:311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319535</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc Med. 2004;14:318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596109</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rocco G, Iachininoto MG, Tritarelli A, et al. Myogenic potential of adipose-tissue-derived cells. J Cell Sci. 2006;119:2945.</Citation><ArticleIdList><ArticleId IdType="pubmed">16825428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Park BS, Sung JH, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48:15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17643966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning H, Lin G, Lue TF, et al. Neuron-like differentiation of adipose tissue-derived stromal cells and vascular smooth muscle cells. Differentiation. 2006;74:510.</Citation><ArticleIdList><ArticleId IdType="pubmed">17177848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigotti G, Marchi A, Galie M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007;119:1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">17415234</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair. 2008;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584012</ArticleId><ArticleId IdType="pubmed">19014650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh PS. The effect of vascular endothelial growth factor and brain-derived neurotrophic factor on cavernosal nerve regeneration in a nerve-crush rat model. British Journal of Urology. 2003;92:470.</Citation><ArticleIdList><ArticleId IdType="pubmed">12930443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes. 2003;52:2353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SW, Seo SW, Choi CY, et al. Porous poly(lactic-co-glycolic acid) microsphere as cell culture substrate and cell transplantation vehicle for adipose tissue engineering. Tissue Eng Part C Methods. 2008;14:25.</Citation><ArticleIdList><ArticleId IdType="pubmed">18454643</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon MH, Kim SY, Kim YJ, et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem. 2006;17:279.</Citation><ArticleIdList><ArticleId IdType="pubmed">16791003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosova I, Dao M, Capoccia B, et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008;26:2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017477</ArticleId><ArticleId IdType="pubmed">18511601</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Yang H, Lu L, et al. Comparison of the labeling efficiency of BrdU, DiI and FISH labeling techniques in bone marrow stromal cells. Brain Res. 2008;1215:11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18468584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannello F, Tonti GA. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells. 2007;25:1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17395775</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells. 2007;25:197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008421</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahdadfar A, Fronsdal K, Haug T, et al. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells. 2005;23:1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16081661</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration, C. f. B. E. a. R. C. Investigational New Drug (IND) Guidances. 2008.  ( http://www.fda.gov/Cber/ind/indpubs.htm)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19956198</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-4820</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature reviews. Urology</Title><ISOAbbreviation>Nat Rev Urol</ISOAbbreviation></Journal><ArticleTitle>Treatment of a patient with post-TURP hemorrhage using bilateral SAPE.</ArticleTitle><Pagination><StartPage>680</StartPage><EndPage>685</EndPage><MedlinePgn>680-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrurol.2009.215</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A 74-year-old man developed severe, life-threatening bleeding refractory to endoscopic fulguration from a prostatic capsular perforation while undergoing transurethral resection of prostate (TURP) for complicated benign prostatic hyperplasia. At the time of the procedure the patient had several comorbidities, including hypertension and associated nephropathy, and erectile dysfunction.</AbstractText><AbstractText Label="INVESTIGATIONS" NlmCategory="METHODS">CT angiography and pelvic arteriography.</AbstractText><AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Post-TURP arterial hemorrhage refractory to conventional methods of hemostasis, complicated by TURP syndrome and disseminated intravascular coagulopathy.</AbstractText><AbstractText Label="MANAGEMENT" NlmCategory="RESULTS">Bilateral selective arterial prostatic embolization, after endoscopic hemostasis and continuous catheter balloon traction failed to stop the hemorrhage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Lincoln</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. fencer_77@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Sudhakar K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Consigliere</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Heng</LastName><ForeName>Chin Tiong</ForeName><Initials>CT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Urol</MedlineTA><NlmUniqueID>101500082</NlmUniqueID><ISSNLinking>1759-4812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="Y">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020728" MajorTopicYN="N">Transurethral Resection of Prostate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19956198</ArticleId><ArticleId IdType="doi">10.1038/nrurol.2009.215</ArticleId><ArticleId IdType="pii">nrurol.2009.215</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Coll Surg. 2002 Feb;194(2):142-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11848631</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1990 Sep;65(3):337-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2121204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Jan;169(1):276-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12478158</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 1981 Aug;140(2):331-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7196055</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S10-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11251026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Dec;168(6):2550-1</Citation><ArticleIdList><ArticleId IdType="pubmed">12441972</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2003 Aug;92(3):245-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12887476</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2008 Feb;71(2):181-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18308078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):411-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11181877</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2006 Nov;50(5):969-79; discussion 980</Citation><ArticleIdList><ArticleId IdType="pubmed">16469429</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2006 Jan;96(1):8-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 1964 Apr;55:516-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14138015</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1997 Feb;84(2):438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9024044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2008 Jul;180(1):246-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18499179</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endourol. 2008 Dec;22(12):2687-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19025392</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 2000 Oct;128(4):678-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11015102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vasc Interv Radiol. 2000 May;11(5):573-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10834487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 1985 Mar;28(3):183-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3971826</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2009 Apr;145(1):24-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19222477</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 1999 Nov;42(11):1475-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10566538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19876857</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1556-9039</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of medical toxicology : official journal of the American College of Medical Toxicology</Title><ISOAbbreviation>J Med Toxicol</ISOAbbreviation></Journal><ArticleTitle>Refractory priapism associated with ingestion of yohimbe extract.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>225</EndPage><MedlinePgn>223-5</MedlinePgn></Pagination><Abstract><AbstractText>Extracts of the bark of the central African tree Pausinystalia yohimbe contain yohimbine, an indole alkaloid, which is used to treat erectile dysfunction. The reported side effects of over-the-counter preparations of yohimbine include gastrointestinal upset, anxiety, increased blood pressure, headache, agitation, rash, tachycardia, and frequent urination. In this report, we describe a severe case of intractable priapism associated with the ingestion of yohimbe extract. Management required insertion of a proximal cavernosal spongiosum shunt (Quackles shunt) in the operating room.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrueto</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Toxicol</MedlineTA><NlmUniqueID>101284598</NlmUniqueID><ISSNLinking>1556-9039</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004366">Nonprescription Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004366" MajorTopicYN="N">Nonprescription Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032068" MajorTopicYN="N">Pausinystalia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024301" MajorTopicYN="N">Plant Bark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="N">Urologic Surgical Procedures, Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19876857</ArticleId><ArticleId IdType="pmc">PMC3550410</ArticleId><ArticleId IdType="doi">10.1007/BF03178272</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guay AT, Spark RF, Jacobson J, et al. Yohimbe treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res. 2002;14:25&#x2013;31. doi: 10.1038/sj.ijir.3900803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900803</ArticleId><ArticleId IdType="pubmed">11896474</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales A. Yohimbe in erectile dysfunction: the facts. Int J Impot Res. 2000;12(suppl 1):S70&#x2013;S74. doi: 10.1038/sj.ijir.3900508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijir.3900508</ArticleId><ArticleId IdType="pubmed">10845767</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev. 2004;9:4&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15005641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst E, Pittler MH. Yohimbe for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433&#x2013;436. doi: 10.1016/S0022-5347(01)63942-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(01)63942-9</ArticleId><ArticleId IdType="pubmed">9649257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int. 2001;88(suppl 3):11&#x2013;17. doi: 10.1046/j.1464-4096.2001.123.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-4096.2001.123.x</ArticleId><ArticleId IdType="pubmed">11578273</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeniyi AA, Brindley GS, Pryor JP, et al. Yohimbe in the treatment of orgasmic dysfunction. Asian J Androl. 2007;9:403&#x2013;407. doi: 10.1111/j.1745-7262.2007.00276.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7262.2007.00276.x</ArticleId><ArticleId IdType="pubmed">17486282</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam SW, Worcel m, Michael W. Yohimbine: a clinical review. Pharmacol Ther. 2001;91:215&#x2013;243. doi: 10.1016/S0163-7258(01)00156-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-7258(01)00156-5</ArticleId><ArticleId IdType="pubmed">11744068</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19817976</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>A case of mechanical failure with proximal perforation at the time of revision surgery.</ArticleTitle><Pagination><StartPage>2629</StartPage><EndPage>2633</EndPage><MedlinePgn>2629-32; quiz 2633</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2009.01475.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Implantation of inflatable penile prosthesis (IPP) is a well-established treatment for medically refractory erectile dysfunction with proven long-term reliability. However, if an IPP fails, the subsequent surgery to fix the IPP can be more difficult with higher risks of complications than the primary implantation. Aims. To review and evaluate a case of a difficult IPP replacement surgery for ways to improve surgical techniques and outcomes.</AbstractText><AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">Perform a case report of a difficult IPP replacement surgery in which the patient had proximal perforation of the tunica albuginea with a review of the pertinent literature. Results. The rear tip sling is a successful way to repair proximal perforation of the tunica albuginea. Recent publications show new surgical techniques to lower infection rates in IPP revision surgery.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The rear tip sling appears to have better outcomes than a synthetic windsock for repairs of proximal perforation of the tunica albuginea. Recent publications have shown that the revision washout decreases penile prosthesis infection rates in revision surgeries.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While revision surgery for IPPs have higher risks than primary implantation, newer surgical techniques are helping to reduce these risks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zanoni</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Vita-Salute University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="N">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19817976</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2009.01475.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)32264-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19474796</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>227</EndPage><MedlinePgn>221-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ijir.2009.21</ELocationID><Abstract><AbstractText>Premature ejaculation (PE) is thought to be the most common male sexual dysfunction; however, the prevalence of lifelong (LL)-PE is relatively low. The aim of this study was to investigate the effects of on-demand vardenafil (10 mg) to modify the intravaginal ejaculatory latency time (IELT) in men with LL-PE without erectile dysfunction. Forty-two men (18-35 years) were enrolled in a 16-week, double-blind, placebo-controlled, cross-over study. Primary end point was the modification from baseline of IELT assessed by stopwatch technique; secondary end points were post-ejaculatory refractory time (PERT) and variations of scores at the Index of Premature Ejaculation questionnaire. The changes in geometric mean IELT were superior after taking vardenafil (0.6+/-0.3 vs 4.5+/-1.1 min, P&lt;0.01), compared with placebo (0.7+/-0.3 vs 0.9+/-1.0 min, ns). PERT dropped significantly after vardenafil (16.7+/-2.0 vs 4.3+/-0.9 min, P&lt;0.001), compared with placebo (15.3+/-2.2 vs 15.8+/-2.3 min). Patients who took vardenafil (vs placebo) reported significantly (P&lt;0.01) increased ejaculatory control (6+/-2 vs 16+/-2), improved overall sexual satisfaction (7+/-2 vs 15+/-1) and distress (4+/-1 vs 8+/-1) scores, respectively. Multiple regression analysis (r(2)=0.86) for IELT by the number of attempts at sexual intercourse showed significant differences between the slopes of lines for placebo and vardenafil (P&lt;0.0001). The most common adverse events for vardenafil (vs placebo) were headache (10 vs 3%), flushing (12 vs 0%) and dyspepsia (10 vs 0%), which tended to disappear over the time. In conclusion, in our study, vardenafil increased IELT and reduced PERT in men with LL-PE. Besides, improvements in confidence, perception of ejaculatory control and overall sexual satisfaction were reported.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aversa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chair of Internal Medicine, DFM, Sapienza University of Rome, Italy. antonio.aversa@uniroma1.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pili</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Francomano</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bruzziches</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>La Pera</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19474796</ArticleId><ArticleId IdType="doi">10.1038/ijir.2009.21</ArticleId><ArticleId IdType="pii">ijir200921</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19220270</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-410X</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>Have phosphodiesterase-5 inhibitors changed the indications for penile implants?</ArticleTitle><Pagination><StartPage>1518</StartPage><EndPage>1521</EndPage><MedlinePgn>1518-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1464-410X.2009.08356.x</ELocationID><Abstract><AbstractText>OBJECTIVE To evaluate the indications for penile prosthesis implantation in the treatment of erectile dysfunction (ED) before and after the introduction of sildenafil. PATIENTS AND METHODS Penile prosthesis implantation was indicated in 144 men with ED at our institution between 1992 and 2007; 83 (55.6%) accepted the procedure, 55 (38.2%) refused it and six (4.2%) accepted but eventually had no surgery. Sixty-seven patients were operated primarily, and the remainder were referred cases with complications after or dissatisfaction with primary operations done elsewhere. Thirty-two were operated before the introduction of sildenafil (BS) and 35 after (AS). RESULTS In the BS group the most frequent aetiology was vascular disease, with 11(34%) vs two (6%) in the AS group. The most frequent aetiology in the AS group was previous radical pelvic surgery (radical prostatectomy, sigmoidectomy, etc.) with 17 (49%) vs none in the BS group. There were no significant differences in complication rates in both groups. Satisfaction rates in patients with malleable and inflatable devices were 36 (86%) and 17 (85%), respectively. CONCLUSIONS After the introduction of oral therapy for ED there were some changes in the aetiology of refractory ED; ED after radical prostatectomy is gaining acceptance as the main reason for a penile implant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cort&#xe9;s-Gonz&#xe1;lez</LastName><ForeName>Jeff R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Instituto H. Ellis, Sao Paulo, Brazil. jrcor77@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glina</LastName><ForeName>Sidney</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19220270</ArticleId><ArticleId IdType="doi">10.1111/j.1464-410X.2009.08356.x</ArticleId><ArticleId IdType="pii">BJU8356</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19183233</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1442-2042</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of urology : official journal of the Japanese Urological Association</Title><ISOAbbreviation>Int J Urol</ISOAbbreviation></Journal><ArticleTitle>Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>150</EndPage><MedlinePgn>143-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1442-2042.2008.02207.x</ELocationID><Abstract><AbstractText>Adenosine 5'-triphosphate (ATP) mediates a variety of biological functions and has been shown to play a physiological role in almost every system in the body. In the genito-urinary system, extracellular ATP has been shown to play a functional role in several different capacities, ranging from nociception in the ureter and bladder, to erectile dysfunction via its action on different 'purinergic receptors'. Discovery of the trophic effects of ATP has led to a surge in interest in this signalling system in various malignancies. To date five P2 receptor subtypes have been implicated in the growth inhibition of cancer cells, namely P2X5, P2X7, P2Y1, P2Y2 and P2Y11. Limited data are available on urological malignancies. ATP induces its anti-neoplastic effect primarily via purinergic receptor-mediated apoptosis via calcium-independent pathways, and this has been confirmed in vitro and in vivo. Studies have highlighted functional roles for the P2X5 and/or P2Y11 receptors in both hormone refractory prostate cancer and high-grade bladder cancer, although the contributory effect of pro-apoptotic P2X7 receptors remains unclear. Clinical trials have shown intravenous ATP successfully attenuates a range of systemic symptoms associated with advanced malignancies. This raises the possibility that selective targeting of specific aberrant pathways may allow for treatment of advanced primary malignancies and their systemic effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shabbir</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, St. George's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnstock</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Urol</MedlineTA><NlmUniqueID>9440237</NlmUniqueID><ISSNLinking>0919-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058913">Purinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011983">Receptors, Purinergic</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048708" MajorTopicYN="N">Cell Growth Processes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058913" MajorTopicYN="N">Purinergic Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011983" MajorTopicYN="N">Receptors, Purinergic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>68</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19183233</ArticleId><ArticleId IdType="doi">10.1111/j.1442-2042.2008.02207.x</ArticleId><ArticleId IdType="pii">IJU2207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18947517</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6285</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current urology reports</Title><ISOAbbreviation>Curr Urol Rep</ISOAbbreviation></Journal><ArticleTitle>Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.</ArticleTitle><Pagination><StartPage>506</StartPage><EndPage>513</EndPage><MedlinePgn>506-13</MedlinePgn></Pagination><Abstract><AbstractText>Vacuum erection devices (VED) are becoming first-line therapies for erectile dysfunction and preservation (rehabilitation) of erectile function following treatment for prostate cancer. Currently, phosphodiesterase-5 inhibitors have limited efficacy in elderly patients or patients with moderate to severe diabetes, hypertension, and coronary artery disease. Alternative therapies, such as VED, have emerged as a primary option for patients refractory to oral therapy. VED has also been successfully used in combination treatment with oral therapy and penile injections. More recently, there has been interest in the use of VED in early intervention protocols to encourage corporeal rehabilitation and prevention of post-radical prostatectomy venoocclusive dysfunction. This is evident by the preservation of penile length and girth seen with the early use of the VED following radical prostatectomy. There are ongoing studies to help preserve penile length and girth with early use of VED following prostate brachytherapy and external beam radiation for prostate cancer. Recently, there has also been interest in VED to help maintain penile length following surgical correction of Peyronie's disease and to increase penile size before implantation of the penile prosthesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zippe</LastName><ForeName>Craig D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Glickman Urological and Kidney Institute at Marymount, The Cleveland Clinic, Garfield Heights, OH 44125, USA. zippec@ccf.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahlajani</LastName><ForeName>Geetu</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Urol Rep</MedlineTA><NlmUniqueID>100900943</NlmUniqueID><ISSNLinking>1527-2737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012046" MajorTopicYN="N">Rehabilitation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014618" MajorTopicYN="N">Vacuum</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18947517</ArticleId><ArticleId IdType="doi">10.1007/s11934-008-0086-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urology. 1997 Jun;49(6):932-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9187703</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Marital Ther. 2003 May-Jun;29(3):227-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12851127</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2005 Sep-Oct;17(5):431-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15889124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Board Fam Pract. 2002 Nov-Dec;15(6):501-2</Citation><ArticleIdList><ArticleId IdType="pubmed">12463298</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostate Cancer Prostatic Dis. 2004;7(3):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15249931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Nov;140(5):975-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3172371</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Feb 22;326(7386):424-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12595382</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatr Nephrol Urol. 1998;8(1):15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9650043</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 Apr;169(4):1462-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12629384</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Apr 15;320(7241):1062-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10764371</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2006 Jan-Feb;18(1):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15988545</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Urol Nephrol. 1996;28(2):235-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8836796</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Feb 20;318(7182):518-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10024264</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1995 Jun;75(6):786-91</Citation><ArticleIdList><ArticleId IdType="pubmed">7613837</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1998 Feb 28;316(7132):678-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9522795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Marital Ther. 1991 Summer;17(2):81-93</Citation><ArticleIdList><ArticleId IdType="pubmed">1920472</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2001 May;28(2):335-41, ix-x</Citation><ArticleIdList><ArticleId IdType="pubmed">11402585</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Esp Urol. 2000 Nov;53(9):819-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11196388</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2007 Oct;100(4):858-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17822466</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 2000 Oct;93(10):962-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11147477</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1990 Jul;144(1):79-82</Citation><ArticleIdList><ArticleId IdType="pubmed">2359184</ArticleId></ArticleIdList></Reference><Reference><Citation>Tech Urol. 1997 Summer;3(2):100-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9297771</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1995 Dec;76(6):757-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8535721</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2007 Nov;34(4):601-18, viii</Citation><ArticleIdList><ArticleId IdType="pubmed">17983900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Jan;171(1):292-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14665897</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2001 Oct;58(4):567-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11597540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ned Tijdschr Geneeskd. 1993 Feb 20;137(8):412-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8446200</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Urol. 1997;15(1):78-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9066099</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2005;65(12):1621-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16060698</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1989 Sep;142(3):729-31</Citation><ArticleIdList><ArticleId IdType="pubmed">2769849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tech Urol. 1997 Fall;3(3):129-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9422443</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1992 Jun;39(6):526-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1615600</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1992 Dec;70(6):652-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1486393</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2000 Jan;85(1):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10619955</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2006;23(2):101-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16536634</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Urol. 2005 Dec 14;5:18</Citation><ArticleIdList><ArticleId IdType="pubmed">16354303</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Int. 2003;70(2):141-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12592043</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2000 Nov 6;173(9):492-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11149308</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1994 Jul;74(1):102-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8044504</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrologia. 1999;31 Suppl 1:89-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10643525</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz. 2003 Jun;28(4):314-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12825147</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2000 Apr;55(4):477-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10736486</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 2001 Aug;28(3):613-27</Citation><ArticleIdList><ArticleId IdType="pubmed">11590817</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 1999 Oct;11(5):287-99</Citation><ArticleIdList><ArticleId IdType="pubmed">10553808</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Urol Belg. 1992;60(1):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1414725</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2003 Feb;91(3):176-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12580997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2000 Jan;17(1):77-107</Citation><ArticleIdList><ArticleId IdType="pubmed">10747767</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2006 Mar;3(2):361-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16490033</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2001 Nov;166(5):1779-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11586223</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2005 Feb;65(2):360-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15708053</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cornerstone. 2005;7(1):57-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16156424</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Braz J Urol. 2005 Jul-Aug;31(4):375-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16137408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Apr;161(4):1141-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10081856</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1986 Feb;27(2):126-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3946035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18930579</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>The immediate insertion of a penile prosthesis for acute ischaemic priapism.</ArticleTitle><Pagination><StartPage>1033</StartPage><EndPage>1038</EndPage><MedlinePgn>1033-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2008.09.044</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ischaemic priapism (IP), which is refractory to conventional medical and surgical intervention, results in necrosis of the corpus cavernosum smooth muscle. These patients eventually develop a variable degree of corporal smooth muscle fibrosis that presents as erectile dysfunction and penile shortening.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the long-term outcome of patients who have undergone the immediate insertion of a penile prosthesis as a treatment for an acute episode of IP refractory to medical therapy or shunt surgery.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A total of 50 patients presented with prolonged IP that was unresponsive to conventional treatment. Unsuccessful shunt surgery had been performed in 13 patients. All patients had evidence of cavernosal smooth muscle necrosis and, therefore, underwent an immediate insertion of a penile prosthesis in the acute setting.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Mean age, duration of priapism in hours, intraoperative and postoperative complications, the surgical outcome, and patients' satisfaction were recorded.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">A malleable penile prosthesis was inserted in 43 patients and a three-piece inflatable implant in was inserted in 7 patients; a subsequent elective exchange of a malleable to an inflatable device was performed in 6 patients. After a median follow-up of 15.7 mo (4-60 mo), 42 patients had already resumed successful sexual intercourse. Prosthesis infection occurred in three patients (6%), which was managed by explantation and delayed reinsertion. A further six patients needed revision surgery. No patient complained of penile shortening, and the overall satisfaction rate was 96%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The immediate insertion of a penile prosthesis for acute refractory ischaemic priapism is a simple and successful procedure that treats the acute episode as well as the inevitable erectile dysfunction that will occur with preservation of penile length.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>St. Peter's Hospitals and The Institute of Urology, London, United Kingdom. dralph@andrology.co.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaffa</LastName><ForeName>Giulio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Muneer</LastName><ForeName>Asif</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Rowland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Sukbinder</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18930579</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2008.09.044</ArticleId><ArticleId IdType="pii">S0302-2838(08)01167-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18581678</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-0614</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archivos espanoles de urologia</Title><ISOAbbreviation>Arch Esp Urol</ISOAbbreviation></Journal><ArticleTitle>[Neurogenic etiology in patients with erectile dysfunction].</ArticleTitle><Pagination><StartPage>403</StartPage><EndPage>411</EndPage><MedlinePgn>403-11</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Erectile dysfunction (ED) is a disorder with a high prevalence that increases with age. It is estimated that 18.9% of men's between 25 and 70 years suffer it in Spain. Most cases have a multifactorial origin and it is admitted the influence on its pathogenesis of systemic diseases, different kind of drugs, psychogenic factors, cardiovascular, endocrinological and neurological diseases. Neurologic cause erectile dysfunction may have its origin in the central or peripheral nervous system. Among possible process of neurogenic erectile dysfunction of central origin would be tumors, cerebral vascular accidents, encephalitis, Parkinson disease, multiple sclerosis and other demyelinization diseases, dementias, olivopontocerebellar degeneration and epilepsy. Myelopathies of any etiology may be, depending on their localization and extension, cause of erectile dysfunction. At the peripheral level, disorders of the sensitive tracts constituting the afferent limb of the erection spinal reflex, and the efferent vegetative or somatic tracts mediating arterial vasodilatation, cavernous smooth muscle relaxation or pelvic floor striated muscle contraction. The aim of this work is to review in detail the most relevant causes of neurogenic erectile dysfunction, their etiopathogenic mechanisms and therapeutic approaches currently considered more adequate for each particular case.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The correct diagnostic approach to patients with erectile dysfunction passes through identification, if possible, of the etiopathogenic factors implied. Regarding this, detection and identification of a possible neurogenic risk factor will contribute to a better understanding of the physiopathologic mechanisms, and more adequate diagnostic, prognostic and therapeutic approaches, mainly in those patients refractory to first line therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valles Antu&#xf1;a</LastName><ForeName>Consuelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Neurofisiolog&#xed;a, Cl&#xed;nica del Hospital Universitario Central de Asturias, Oviedo, Espa&#xf1;a. consuvall@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez G&#xf3;mez</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Escaf</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Gonz&#xe1;lez</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Etiolog&#xed;a neur&#xf3;gena en pacientes con disfunci&#xf3;n er&#xe9;ctil.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Esp Urol</MedlineTA><NlmUniqueID>0064757</NlmUniqueID><ISSNLinking>0004-0614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015653" MajorTopicYN="N">Cystectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011115" MajorTopicYN="N">Polyneuropathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18581678</ArticleId><ArticleId IdType="doi">10.4321/s0004-06142008000300007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18498327</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2008</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>12</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Penile prosthesis pump tubing erosion into urethra appearing as inability to catheterize: a case report.</ArticleTitle><Pagination><StartPage>2960</StartPage><EndPage>2962</EndPage><MedlinePgn>2960-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2008.00868.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erosion of penile prosthesis tubing represents a late complication of penile prosthesis surgery. To our knowledge, this is the first report of isolated erosion of penile implant pump tubing into the urethra in an otherwise asymptomatic patient. The patient had no signs of infection or erosion and no voiding complaints. His only problem was that his urinary catheter was not able to be placed during his vascular surgery procedure.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patient with a 5-year history of erectile dysfunction refractory to therapy with PDE5 inhibitors, injection therapy, and vacuum erection device therapy underwent placement of an Alpha-1 Mentor inflatable penile prosthesis. The patient underwent femoral-popliteal bypass at month 21, and during the procedure, the vascular service was unable to place a urinary catheter. Erosion of the tubing from his penile prosthesis was then noted at approximately the junction between the membranous and bulbar urethra.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patient was without signs of infection and had no voiding complaints. These findings were discovered because of the inability to place a urinary catheter for his femoral-popliteal bypass. Diagnosis was made by flexible cystoscopy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">No evidence of infection was noted on examination, and the patient was otherwise asymptomatic. Diagnosis can be made by flexible cystoscopy. Subsequent removal of the penile implant was curative.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Division of Urology, West Virginia University, Morgantown, WV 26506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Zaslau</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003558" MajorTopicYN="N">Cystoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005263" MajorTopicYN="N">Femoral Artery</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011150" MajorTopicYN="N">Popliteal Artery</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="Y">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014546" MajorTopicYN="Y">Urinary Catheterization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18498327</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2008.00868.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31908-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18221960</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>179</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Erectile dysfunction and sleep related disorders.</ArticleTitle><Pagination><StartPage>837</StartPage><EndPage>841</EndPage><MedlinePgn>837-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2007.10.024</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There are reported links between erectile dysfunction and sleep disorders. We reviewed the physiology of penile erection during sleep and the possible links between the pathophysiology of erectile dysfunction and the most commonly diagnosed sleep disorders.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A MEDLINE search using the identifiers erectile dysfunction, sleep, sleep disorders, sleep apnea, insomnia and narcolepsy was performed to identify the current literature pertaining to erectile dysfunction and sleep disorders. The peer reviewed literature and relevant surveys from 1985 to 2006 were subsequently reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An association between erectile dysfunction and sleep disorders appears to exist in survey studies relying on self-report and in small case series. Hormonal, neural and endothelial mechanisms have been implicated in linking sleep disorders with erectile dysfunction. Treatment of sleep disorders, specifically sleep apnea with continuous positive airway pressure, has been shown to improve patient erectile function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinicians should consider concomitant sleep disorders when evaluating patients with erectile dysfunction, especially in those refractory to routine therapy. Further studies are necessary to clearly define the causative link between sleep disorders and erectile dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jankowski</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Urology and Division of Pulmonary, Critical Care and Sleep Medicine, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio 44106, USA. jtjanko@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seftel</LastName><ForeName>Allen D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Strohl</LastName><ForeName>Kingman P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>32</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18221960</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2007.10.024</ArticleId><ArticleId IdType="pii">S0022-5347(07)02754-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18062399</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0026-4075</ISSN><JournalIssue CitedMedium="Print"><Volume>172</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Military medicine</Title><ISOAbbreviation>Mil Med</ISOAbbreviation></Journal><ArticleTitle>Immediate insertion of a semirigid penile prosthesis for refractory ischemic priapism.</ArticleTitle><Pagination><StartPage>1211</StartPage><EndPage>1212</EndPage><MedlinePgn>1211-2</MedlinePgn></Pagination><Abstract><AbstractText>The insertion of a penile prosthesis for reduction of ischemic priapism has previously been described for cases of sickle cell disease, delayed presentation, or failure of previous shunt surgery. We report the first case of immediate insertion of a malleable prosthesis as primary surgical therapy for refractory ischemic priapism in a patient with known preexisting erectile dysfunction. We propose a novel management algorithm incorporating the acute insertion of a penile prosthesis as an effective option in the management of refractory ischemic priapism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tausch</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Urology Service, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>L Andrew</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Morey</LastName><ForeName>Allen F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mil Med</MedlineTA><NlmUniqueID>2984771R</NlmUniqueID><ISSNLinking>0026-4075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008887" MajorTopicYN="N">Military Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008889" MajorTopicYN="N">Military Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18062399</ArticleId><ArticleId IdType="doi">10.7205/milmed.172.11.1211</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17936150</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>16</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure.</ArticleTitle><Pagination><StartPage>1523</StartPage><EndPage>1531</EndPage><MedlinePgn>1523-31</MedlinePgn></Pagination><Abstract><AbstractText>Between 25,000 and 75,000 new cases of angina refractory to maximal medical therapy and standard coronary revascularization procedures are diagnosed each year. In addition, heart failure also places an enormous burden on the U.S. health care system, with an estimated economic impact ranging from $20 billion to more than $50 billion per year. The technique of counterpulsation, studied for almost one-half century now, is considered a safe, highly beneficial, low-cost, noninvasive treatment for these angina patients, and now for heart failure patients as well. Recent evidence suggests that enhanced external counterpulsation (EECP) therapy may improve symptoms and decrease long-term morbidity via more than 1 mechanism, including improvement in endothelial function, promotion of collateralization, enhancement of ventricular function, improvement in oxygen consumption (VO2), regression of atherosclerosis, and peripheral training effects similar to exercise. Numerous clinical trials in the last 2 decades have shown EECP therapy to be safe and effective for patients with refractory angina with a clinical response rate averaging 70% to 80%, which is sustained up to 5 years. It is not only safe in patients with coexisting heart failure, but also is shown to improve quality of life and exercise capacity and to improve left ventricular function long-term. Interestingly, EECP therapy has been studied for various potential uses other than heart disease, such as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on. This review summarizes the current evidence for its use in stable angina and heart failure and its future directions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manchanda</LastName><ForeName>Aarush</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, The George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soran</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Am Coll Cardiol. 2007 Dec 18;50(25):2441</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000787" MajorTopicYN="N">Angina Pectoris</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003326" MajorTopicYN="N">Coronary Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17936150</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2007.07.024</ArticleId><ArticleId IdType="pii">S0735-1097(07)02392-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17934566</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-6161</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Reviews in urology</Title><ISOAbbreviation>Rev Urol</ISOAbbreviation></Journal><ArticleTitle>Oral and non-oral combination therapy for erectile dysfunction.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>105</EndPage><MedlinePgn>99-105</MedlinePgn></Pagination><Abstract><AbstractText>An estimated 30 million men in the United States suffer from varying degrees of erectile dysfunction. Increasing age and comorbidities are likely to increase the number of men who are initially refractory or become refractory to phosphodiesterase (PDE)-5 inhibitors, the most popular oral therapy. Combination therapy, a concept well proved in other areas of medicine, is therefore of increasing importance. Combination oral and non-oral (intracavernosal injection and intraurethral application) therapies have been shown to salvage monotherapy. The early introduction of combination therapy has been shown to expedite both the return of natural function and PDE-5 inhibitor responsiveness in post-prostatectomy patients with no reports of serious adverse events. Larger controlled studies are needed to corroborate those encouraging findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nehra</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic College of Medicine Rochester, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Rev Urol</MedlineTA><NlmUniqueID>100889067</NlmUniqueID><ISSNLinking>1523-6161</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alprostadil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Intracavernosal injection</Keyword><Keyword MajorTopicYN="N">Intraurethral application</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17934566</ArticleId><ArticleId IdType="pmc">PMC2002499</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman HA, Goldstein I, Hatzichristou DG. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay JB, Digruttolo L, Glasser D. International differences in the epidemiology of male erectile dysfunction. Int J Clin Pract Suppl. 1999;102:35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10665122</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12(4 suppl):S6&#x2013;S11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035380</ArticleId></ArticleIdList></Reference><Reference><Citation>Leriche R. Aorto-iliac resection with bilateral lumbar sympathectomy for aortic thrombosis: the syndrome of aortic and terminal arterial obliteration. La Presse M&#xe9;dicale. 1940;48:601&#x2013;607.</Citation></Reference><Reference><Citation>Watts GF, Chew KK, Stuckey BG. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med. 2007;4:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">17457350</ArticleId></ArticleIdList></Reference><Reference><Citation>Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med. 2007;74(3 suppl):S30&#x2013;S37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17549823</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuckey BG, Walsh JP, Ching HL. Erectile dysfunction predicts generalised cardiovascular disease: evidence from a case-control study. Atherosclerosis. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16989839</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi P, Ravagnani PM, Galli S. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27:2632&#x2013;2639.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854949</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi P, Ravagnani PM, Galli S. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol. 2006;50:721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">16901623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162(3 Pt 1):722&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10458352</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Padma-Nathan H, McCullough A. Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, doubleblind, placebo-controlled trial. J Urol. 2004;172:1036&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhall JP, McLaughlin TP, Harnett JP. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med. 2005;2:848&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422809</ArticleId></ArticleIdList></Reference><Reference><Citation>Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. 1982;2:938.</Citation><ArticleIdList><ArticleId IdType="pubmed">6126784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmueli J, Israilov S, Segenreich E. Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents. Int J Impot Res. 1999;11:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098948</ArticleId></ArticleIdList></Reference><Reference><Citation>Baniel J, Israilov S, Engelstein D. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urology. 2000;56:647&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">11018623</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulgham PF, Cochran JS, Denman JL. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol. 1998;160(6 Pt 1):2041&#x2013;2046.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom WJ, Bennett AH, Gesundheit N. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology. 1996;48:851&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">8973666</ArticleId></ArticleIdList></Reference><Reference><Citation>Guay AT, Perez JB, Velasquez E. Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol. 2000;38:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11111182</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidyanathan S, Soni BM, Krishnan KR. Special precautions to be observed while using alprostadil in patients with spinal cord injury. Spinal Cord. 1997;35:402&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">9194266</ArticleId></ArticleIdList></Reference><Reference><Citation>Purvis K, Brekke I, Christiansen E. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure. Int J Impot Res. 1996;8:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">8735188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, Rajasekaran M, Champion HC. The influence of castration on pharmacologically induced penile erection in the cat. J Androl. 1998;19:551&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalacqua TJ, Champion HC, Rajasekaran M. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4) J Urol. 1999;162:1848&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pubmed">10524946</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty PC, Bivalacqua TJ, Champion HC. Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats. J Urol. 2001;165:1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162(3 Pt 1):722&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10458352</ArticleId></ArticleIdList></Reference><Reference><Citation>Montorsi F, Nathan HP, McCullough A. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004;172:1036&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311032</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock G, Nehra A, Lipshultz LI. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003;170(4 Pt 1):1278&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501741</ArticleId></ArticleIdList></Reference><Reference><Citation>Costabile RA, Spevak M, Fishman IJ. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol. 1998;160:1325&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol. 2000;38:30&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10859438</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Nandipati KC, Agarwal A. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl. 2005;26:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002;14(1 suppl):S38&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850734</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999;162:1992&#x2013;1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase- 5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int. 2005;95:843&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15794795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandipati KC, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18:446&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res. 2005;17:354&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int. 1999;83:812&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10368203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydlo JH, Volpe MA, MacChia RJ. Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int. 2000;86:469&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971274</ArticleId></ArticleIdList></Reference><Reference><Citation>Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig. 1994;72:139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">8186662</ArticleId></ArticleIdList></Reference><Reference><Citation>Padma-Nathan H, Hellstrom WJ, Kaiser FE. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970933</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R, Agarwal A, Nandipati KC. Interim analysis of the early use of MUSE following radical prostatectomy (RP) to facilitate early sexual activity and return of spontaneous sexual activity (abstract 737) J Urol. 2005;173(4 suppl):200&#x2013;201.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17712492</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-682X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Asian journal of andrology</Title><ISOAbbreviation>Asian J Androl</ISOAbbreviation></Journal><ArticleTitle>Outcome of implanting penile prosthesis for treating erectile dysfunction: experience with 42 cases.</ArticleTitle><Pagination><StartPage>716</StartPage><EndPage>719</EndPage><MedlinePgn>716-9</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To report a short-time result of three-piece inflatable penile prosthesis (IPP) implantation on treating patients with organic erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three-piece IPPs were implanted in 42 Chinese patients with ED refractory to systemic treatment between May 2002 and May 2004. The etiologies of ED were neurogenic (28 with paraplegia and seven with traumatic nervi-erigentes injury); congenital venous leakage (5 cases), fibrosis of corpus cavernosum (1case) and Klinefelter's syndrome (1 case). The follow-up period ranged from 24 to 57 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Implantation procedures were successfully performed upon all 42 patients. The length of implanted prosthesis was from 13 cm to 18 cm, and the diameter was 1 cm. The implanted prosthesis was made by the Medical Instrumentation Company of Muping (Muping, Shandong, China). Localized infection occurred in only one patient and mechanical complications occurred in five patients. Coitus could be performed in 41 cases (97.6%). Three patients with congenital venous leakage made their spouses pregnant after implantation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Implantation of three-piece IPP is an effective and safe modality for treating patients with ED. It can be well accepted by Chinese patients because of its efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xuan</LastName><ForeName>Xu-Jun</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Division of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dao-Hu</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Asian J Androl</MedlineTA><NlmUniqueID>100942132</NlmUniqueID><ISSNLinking>1008-682X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010264" MajorTopicYN="N">Paraplegia</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17712492</ArticleId><ArticleId IdType="doi">10.1111/j.1745-7262.2007.00269.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17634052</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Enhanced external counterpulsation in patients with coronary artery disease-associated erectile dysfunction. Part II: impact of disease duration and treatment courses.</ArticleTitle><Pagination><StartPage>1448</StartPage><EndPage>1453</EndPage><MedlinePgn>1448-53</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Enhanced external counterpulsation (EECP) is a noninvasive outpatient treatment used for patients with intractable angina refractory to aggressive surgical and medical treatment. Recent results have demonstrated a positive impact of EECP on patients with ischemic heart disease (IHD)-associated erectile dysfunction (ED).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the effect of IHD duration and number of EECP courses on efficacy and satisfaction rate of EECP on patients with IHD-associated ED.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">We compared pre- and post-EECP responses to erectile function (EF) domain, Q3 and Q4 of the International Index of Erectile Function score in patients who received one or two courses of EECP and those who had &lt;5- or &gt;or=5-years duration of IHD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As mentioned in part I a total of 44 male patients with intractable angina caused by coronary insufficiency were enrolled in this study. Treatment course of EECP consists of 35 1-hour sessions over 7 weeks. Another 35 1-hour sessions over another 7 weeks were offered to patients who received one course and required a second course because of no or minimal improvement from class IV to class III angina after the first course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients who received only one course (N = 34) had significantly higher EF domain, Q3 and Q4, in pre- and post-EECP results than patients who received two courses (N = 10) after they completed the first course. Patients who had &lt;5-years duration of IHD had significantly higher pre- and post EECP than patients who had &gt;or=5 years regarding EF domain, Q3 and Q4. Considering the global efficacy question, overall satisfaction, and angina, there were significant improvements of post EECP in patients with &lt;5 years than in patients with &gt;or=5-years duration of IHD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The efficacy and satisfaction rate of EECP in patients with IHD-associated ED were negatively influenced by longer duration of IHD and requirement of a second course of EECP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Sakka</LastName><ForeName>Ahmed I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Urology, Suez Canal University, Ismailia, Egypt. aielsakka@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morsy</LastName><ForeName>Ayman M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Fagih</LastName><ForeName>Bassam I</ForeName><Initials>BI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17634052</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00550.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31656-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17627728</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>4 Pt 2</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Reservoir repositioning and successful thrombectomy for deep venous thrombosis secondary to compression of pelvic veins by an inflatable penile prosthesis reservoir.</ArticleTitle><Pagination><StartPage>1185</StartPage><EndPage>1187</EndPage><MedlinePgn>1185-7</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We describe a 51-year-old man with a history of radiation therapy and large bowel diversion for rectal cancer who underwent an uneventful penile implant surgery for erectile dysfunction that was refractory to conservative therapy. The patient presented with acute left lower extremity swelling and pain a few days after surgery. Workup revealed compression of the pelvic veins by the prosthesis reservoir.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To highlight an avoidable, adverse event related to penile prosthesis reservoirs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective review of a clinical case.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient underwent repositioning of the reservoir followed by venous thrombectomy and Greenfield filter placement.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To the best of our knowledge, this is the first report of an early diagnosis and successful thrombectomy of the external iliac and common femoral vein thrombosis secondary to reservoir compression. Awareness of this possible adverse event and the management strategy are helpful to surgeons who perform penile prosthesis surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brison</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>UMDNJ New Jersey Medical School, Department of Surgery, Division of Urology, Newark, NJ 07103-2714, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilbeigi</LastName><ForeName>Pedram</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sadeghi-Nejad</LastName><ForeName>Hossein</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005268" MajorTopicYN="N">Femoral Vein</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007084" MajorTopicYN="N">Iliac Vein</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="N">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="N">Thrombectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17627728</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00266.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31636-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17493089</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1368-5031</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of clinical practice</Title><ISOAbbreviation>Int J Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Effect of enhanced external counterpulsation on medically refractory angina patients with erectile dysfunction.</ArticleTitle><Pagination><StartPage>757</StartPage><EndPage>762</EndPage><MedlinePgn>757-62</MedlinePgn></Pagination><Abstract><AbstractText>Patients with refractory angina often suffer from erectile dysfunction. Enhanced external counterpulsation (EECP) decreases symptoms of angina, and increases nitric oxide release. This study evaluated the effect of EECP on sexual function in men with severe angina. The International Index of Erectile Function (IIEF) was used to assess erectile function of severe angina patients enroled in the International EECP Patient Registry. Their symptom status, medication use, adverse clinical events and quality of life were also recorded before and after completing a course of EECP. A cohort of 120 men (mean age 65.0+/-9.7) was enroled. The men had severe coronary disease with 69% having a prior myocardial infarction, 90% prior coronary artery bypass graft or percutaneous coronary intervention, 49% with three vessel coronary artery disease, 86% were not candidates for further revascularisation, 71% hypertensive, 83% dyslipidaemia, 42% diabetes mellitus, 75% smoking and 68% using nitrates. Functional status was low with a mean Duke Activity Status Inventory score of 16.6+/-14.8. After 35 h of EECP anginal status improved in 89%, and functional status in 63%. A comparison of the IIEF scores pre- and post-EECP therapy demonstrated a significant improvement in erectile function from 10.0+/-1.0 to 11.8+/-1.0 (p=0.003), intercourse satisfaction (4.2+/-0.5 to 5.0+/-0.5, p=0.009) and overall satisfaction (4.7+/-0.3 to 5.3+/-0.3, p=0.001). However, there were no significant changes in orgasmic function (4.2+/-0.4 to 4.6+/-0.4, p=0.19) or sexual desire (5.3+/-0.2 to 5.5+/-0.2). The findings suggest that EECP therapy is associated with improvement in erectile function in men with refractory angina.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lawson</LastName><ForeName>W E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA. william.lawson@stonybrook.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>J C K</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Kennard</LastName><ForeName>E D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Soran</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Kelsey</LastName><ForeName>S F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><CollectiveName>IEPR Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Int J Clin Pract</MedlineTA><NlmUniqueID>9712381</NlmUniqueID><ISSNLinking>1368-5031</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Clin Pract. 2007 May;61(5):716-8</RefSource><PMID Version="1">17493083</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000787" MajorTopicYN="N">Angina Pectoris</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17493089</ArticleId><ArticleId IdType="doi">10.1111/j.1742-1241.2007.01328.x</ArticleId><ArticleId IdType="pii">IJCP1328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17484406</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1124-3562</ISSN><JournalIssue CitedMedium="Print"><Volume>79</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</Title><ISOAbbreviation>Arch Ital Urol Androl</ISOAbbreviation></Journal><ArticleTitle>Long-term delayed extrusion of a penile prosthesis.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>42</EndPage><MedlinePgn>41-2</MedlinePgn></Pagination><Abstract><AbstractText>An 84-year-old patient presented with partial extrusion of a semirigid penile prosthesis, implanted 20 years earlier following a diagnosis of erectile dysfunction refractory to oral and injection therapy. Four years previously, the patient was diagnosed with bilateral obliterans arteriopathy limited to the iliac arteries and, two years later, with chronic renal failure. At presentation, the patient complained of lower urinary tract symptoms, and his body temperature was 39 degres C. Physical Examination, Urine Culture, and Blood Tests were performed; a spontaneous partial extrusion of the left rod of the penile prosthesis through a urethral erosion was observed. A manual removal of the eroded cylinder under local anaesthesia was achieved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gacci</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Florence, Italy. maurogacci@yahoo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vittori</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Giubilei</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nelli</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rossetti</LastName><ForeName>Mario Alberto</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Serni</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lapini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Carini</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Natali</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Arch Ital Urol Androl</MedlineTA><NlmUniqueID>9308247</NlmUniqueID><ISSNLinking>1124-3562</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020878" MajorTopicYN="N">Device Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011475" MajorTopicYN="Y">Prosthesis Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17484406</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17433083</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Enhanced external counterpulsation in patients with coronary artery disease-associated erectile dysfunction. Part I: effects of risk factors.</ArticleTitle><Pagination><StartPage>771</StartPage><EndPage>779</EndPage><MedlinePgn>771-779</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2007.00458.x</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(15)31588-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Recently it has been demonstrated that enhanced external counterpulsation (EECP) could improve erectile dysfunction (ED) in patients with refractory ischemic heart disease (IHD).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the effect of risk factors on the efficacy and the satisfaction rate of EECP in patients with coronary artery disease (CAD)-associated ED.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">To assess the effect of risk factors on EECP efficacy and satisfaction rate, we compared the pre- and post-EECP responses to erectile function domain, Q3, and Q4 in patients with and without risk factors. Overall satisfaction and global efficacy question (GEQ) were also assessed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 44 male consecutive patients with intractable angina caused by coronary insufficiency which cannot be controlled by conventional therapy were enrolled in this study. Patients were screened and followed up for ED using erectile function domain of the International Index for Erectile Function. A thorough sexual, medical, and psychosocial history was taken from all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients had severe diffuse triple vessels disease. They all had class III or IV angina. They were receiving the maximal antianginal pharmacotherapy. The mean age +/- SD was 57.1 +/- 5.6 years. Of the patients, 63.9% were below 60 years, and 86.4% were current or ex-smokers. There were significant differences between pre- and post-EECP regarding erectile function domain, Q3, and Q4. The sociodemographic variables were not significantly different among the studies groups and had not affected the GEQ or overall satisfaction. Overall satisfaction and GEQ were negatively influenced by smoking and presence of more than two risk factors. However, diabetes, hypertension, dyslipidemia, myocardial infraction, and obesity have not had such effects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The efficacy and satisfaction rate of EECP in patients with CAD-associated ED were negatively influenced by presence of risk factors; however, the global efficacy and the overall patients' satisfaction were encouraging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Sakka</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, Suez Canal University, Ismailia, Egypt;. Electronic address: aielsakka@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morsy</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoracic Surgery, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagih</LastName><ForeName>Bassam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Al-Noor Specialist Hospital, Makkah, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="Y">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17433083</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2007.00458.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31588-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17201714</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-9580</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Sexual dysfunctions and blood hormonal profile in men with focal epilepsy.</ArticleTitle><Pagination><StartPage>2135</StartPage><EndPage>2140</EndPage><MedlinePgn>2135-40</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the incidence of sexual dysfunction in men with focal epilepsy and to establish their hormonal profiles.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We prospectively analyzed sexual functions and hormone blood levels in 40 male patients (age ranged from 18 to 44 years, with an average age of 27.6+/-5.6 years) with refractory focal epilepsy. We used the Czech version of the structured questionnaire entitled International Inventory of Erectile Function (IIEF) to assess the patients' sexual functions. The subscales of this questionnaire separately evaluate erectile function (IIEF I), orgasmic function (IIEF II), sexual desire (IIEF III), intercourse satisfaction (IIEF IV), and overall satisfaction with sex life (IIEF V). In all of the patients, the following blood tests were performed: quantitative assessment of blood levels of prolactin (PRL), total testosterone (total-T), free androgen index (FAI), sexual hormone-binding globulin (SHBG), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), progesterone (PRG), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). All these quantitative laboratory data were correlated with other clinical variables and with the results of the IIEF. chi2 and Wilcoxon tests were used for the statistical analysis. A p-value&lt;0.05 was considered to be statistically significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At least one of the types of sexual dysfunction, as defined by IIEF (IIEF I, II, and III), was found in 22 (55%) of the 40 patients (55%). Erectile dysfunction (IIEF I) was found in six (15%) of 40 patients, orgasmic dysfunction (IIEF II) in six (15%) of 40 patients, and loss of sexual desire (IIEF III) in 16 (40%) of 40 patients. According to other subscales of IIEF, 22 (55%) of 40 patients were not satisfied with sexual intercourse (IIEF IV), and 20 (50%) of 40 patients were not satisfied with their sex livee (IIEF V). None of the subscales of IIEF was significantly correlated with the age of the patients or with the duration of epilepsy. In patients with at least one of the sexual dysfunctions (IIEF I, II, and III), we found a statistically significant increase of FSH and SHBG, and a decrease of DHEAS and FAI in comparison with those in the patients with normal sexual functions. In patients with erectile dysfunction, we found the same changes and a significant increase of E2. In patients with orgasmic dysfunction, we found a statistically significant decrease of DHEAS. In patients with dysfunction of sexual desire, we noticed a significant increase of SHBG and a decrease of DHEAS and FAI. All patients with orgasmic dysfunction were being treated with carbamazepine (CBZ) in monotherapy or combination therapy. In patients with at least one type of sexual dysfunction (IIEF I, II, and III), we found a higher proportion of valproate treatment in monotherapy or combination therapy in comparison with CBZ.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study showed a relatively high incidence of sexual dysfunction and dissatisfaction with sexual intercourse and sex life, as defined by the IIEF I-V questionnaire, in men with refractory focal epilepsy. The most frequent dysfunction in these patients is the impairment of sexual desire. However, our study indicates some specific hormonal changes related to various types of sexual dysfunction that are not related to antiepileptic drug treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuba</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Masaryk University, St. Anne's Hospital, Brno, Czech Republic. robert.kuba@fnusa.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohanka</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Z&#xe1;kopcan</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Novotn&#xe1;</LastName><ForeName>Irena</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rektor</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012738">Sex Hormone-Binding Globulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>459AG36T1B</RegistryNumber><NameOfSubstance UI="D003687">Dehydroepiandrosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4G7DS2Q64Y</RegistryNumber><NameOfSubstance UI="D011374">Progesterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-62-4</RegistryNumber><NameOfSubstance UI="D011388">Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-67-9</RegistryNumber><NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-68-0</RegistryNumber><NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2008 Jan-Feb;8(1):6-8</RefSource><PMID Version="1">18265878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003687" MajorTopicYN="N">Dehydroepiandrosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004828" MajorTopicYN="N">Epilepsies, Partial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009948" MajorTopicYN="N">Orgasm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012738" MajorTopicYN="N">Sex Hormone-Binding Globulin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020018" MajorTopicYN="N">Sexual Dysfunctions, Psychological</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17201714</ArticleId><ArticleId IdType="doi">10.1111/j.1528-1167.2006.00851.x</ArticleId><ArticleId IdType="pii">EPI851</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">16985943</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-6161</ISSN><JournalIssue CitedMedium="Print"><Volume>5 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>Reviews in urology</Title><ISOAbbreviation>Rev Urol</ISOAbbreviation></Journal><ArticleTitle>Case scenarios in androgen deficiency.</ArticleTitle><Pagination><StartPage>S41</StartPage><EndPage>S48</EndPage><MedlinePgn>S41-8</MedlinePgn></Pagination><Abstract><AbstractText>Deciding whether to choose androgen replacement for a particular patient is one of the many tasks facing the urologist. Factors including androgen levels, medical history, symptom profile, current medications, and prostate cancer risk all need to be considered when making this decision. However, the role each of these factors plays in arguing for or against androgen replacement remains controversial and more research is needed in many of these areas before the outstanding issues can be resolved. This article presents three cases involving patients who may require androgen supplementation. The cases describe (1) partial androgen deficiency syndrome, (2) testosterone deficiency in an anorchic man after bilateral orchiectomy for seminoma, and (3) a patient with sildenafil-refractory erectile dysfunction following treatment of localized prostate cancer with radiation therapy and androgen ablation. These cases illustrate some of the dilemmas and controversies surrounding androgen replacement that face the practicing urologist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Rev Urol</MedlineTA><NlmUniqueID>100889067</NlmUniqueID><ISSNLinking>1523-6161</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16985943</ArticleId><ArticleId IdType="pmc">PMC1502325</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lund BC, Bever-Stille KA, Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy. 1999;19:951&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">10453966</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract. 2002;19:95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11818357</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachter M. Erectile dysfunction and lipid disorders. Curr Med Res Opin. 2000;16(suppl 1):S9&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329828</ArticleId></ArticleIdList></Reference><Reference><Citation>Buajordet I, Madsen S, Olsen H. Statins&#x2014;the pattern of adverse effects with emphasis on mental reactions. Data from a national and an international database. Tidsskr Nor Laegeforen. 1997;117:3210&#x2013;3213.</Citation><ArticleIdList><ArticleId IdType="pubmed">9411859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8809645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49:1234&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobs AS, Miller S, Neri G, et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism. 2000;49:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647074</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Zhu JC, Dou JT, et al. Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male. 2002;5:47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040975</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670&#x2013;2677.</Citation><ArticleIdList><ArticleId IdType="pubmed">10946864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong JH, Ahn TY. Oral testosterone replacement in Korean patients with PADAM. Aging Male. 2002;5:52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040976</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg G, Schreier L, Geloso G, et al. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men. Horm Metab Res. 2002;34:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11972293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57:M460&#x2013;M465.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084809</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales A. Androgen replacement therapy and prostate safety. Eur Urol. 2002;41:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932266</ArticleId></ArticleIdList></Reference><Reference><Citation>Svetec DA, Canby ED, Thompson IM, Sabanegh ES., Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol. 1997;158:1775&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001;54:437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">11318778</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas TH, Connelly RR, McLeod DG, et al. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol. 1995;59:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543173</ArticleId></ArticleIdList></Reference><Reference><Citation>Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract. 2000;6:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11421528</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995;27:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">7541528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304729</ArticleId></ArticleIdList></Reference><Reference><Citation>Steers WD. 5 alpha-reductase activity in the prostate. Urology. 2001;58(6) Suppl 1:17&#x2013;24. discussion 24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750244</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller J, Sionit L. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. J Cell Biochem Suppl. 1992;16H:109&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">1283893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone levels and sexual activity in the aging male. BJU Int. 2002;89:526&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11942957</ArticleId></ArticleIdList></Reference><Reference><Citation>Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitouras PD, Martin CE, Harman SM. Relationship of serum testosterone to sexual activity in healthy elderly men. J Gerontol. 1982;37:288&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069152</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">11158037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">1719016</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middleaged men. Biol Psychiatry. 2001;50:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11543741</ArticleId></ArticleIdList></Reference><Reference><Citation>Fossa SD, Opjordsmoen S, Haug E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer. 1999;35:1220&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">10615233</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell SJ, Radford JA, Adams JE, et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 2001;55:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11589674</ArticleId></ArticleIdList></Reference><Reference><Citation>Copinschi G, Van Cauter E. Effects of ageing on modulation of hormonal secretions by sleep and circadian rhythmicity. Horm Res. 1995;43:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721257</ArticleId></ArticleIdList></Reference><Reference><Citation>Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47:727&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">9497881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167:1952&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956415</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000;133:951&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119396</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla S, Melton LJ, 3rd, Riggs BL. Estrogens and bone health in men. Calcif Tissue Int. 2001;69:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11730247</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla S, Melton LJ, 3rd, Atkinson EJ, O&#x2019;Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555&#x2013;3561.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502778</ArticleId></ArticleIdList></Reference><Reference><Citation>Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging. 2000;17:431&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">11200304</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles T, Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol. 2002;167:2448&#x2013;2452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11992055</ArticleId></ArticleIdList></Reference><Reference><Citation>Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11743286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara I, Miyake H, Yamada Y, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol. 2002;9:322&#x2013;328. discussion 28.</Citation><ArticleIdList><ArticleId IdType="pubmed">12269247</ArticleId></ArticleIdList></Reference><Reference><Citation>Debruyne FM, Witjes WP. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol Urol. 2000;4:251&#x2013;256. discussion 57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062381</ArticleId></ArticleIdList></Reference><Reference><Citation>Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology. 1999;54:694&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">10510930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig G. PADAM from the urologic viewpoint [in German] Urologe A. 2000;39:407&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">11045038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16979814</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0302-2838</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.</ArticleTitle><Pagination><StartPage>940</StartPage><EndPage>947</EndPage><MedlinePgn>940-7</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Erectile dysfunction (ED) and decline of testosterone levels are frequently observed with age and also in illnesses with a common basis of endothelial damage.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To review molecular mechanisms underlying androgen action upon its receptor and phosphodiesterase type 5 (PDE5) expression and regulation by testosterone in cavernous tissue and their clinical implication in the treatment of ED refractory to PDE5 inhibitors (PDE5-Is).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From January 2003 to May 2006 [corrected] we performed an extensive, unsystematic MEDLINE literature search reviewing relevant data on basic and clinical studies regarding the efficacy of combination therapies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most trials using testosterone alone for treatment of ED in hypogonadal men suffer from methodologic problems and report inconsistent results, but overall the trials suggest that testosterone is superior to placebo. Orally effective PDE5-Is, such as sildenafil, tadalafil, or vardenafil, may be ineffective depending on the demonstration of testosterone regulation of PDE5 expression in human corpus cavernous, and their efficacy may be enhanced by testosterone adjunction whenever necessary.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Screening for hypogonadism in all men with ED is necessary to identify men with severe hypogonadism and some cases of mild to moderate hypogonadism, who may benefit from testosterone treatment. Identification of threshold values for testosterone supplementation to appropriately benefit from PDE5-Is failure may improve clinical management of unresponsive patients with minimization of unwanted effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Emanuela A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medical Pathophysiology, University of Rome La Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aversa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517381">PDE5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur Urol. 2007 Mar;51(3):872</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2006 Nov;50(5):898-900</RefSource><PMID Version="1">16893603</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>53</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16979814</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2006.06.049</ArticleId><ArticleId IdType="pii">S0302-2838(06)00811-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16952676</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5347</ISSN><JournalIssue CitedMedium="Print"><Volume>176</Volume><Issue>4 Pt 1</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training.</ArticleTitle><Pagination><StartPage>1534</StartPage><EndPage>1539</EndPage><MedlinePgn>1534-8; discussion 1538-9</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The impact of chronic pelvic pain syndrome on sexual function in men is underestimated. We quantified sexual dysfunction (ejaculatory pain, decreased libido, erectile dysfunction and ejaculatory difficulties) in men with chronic pelvic pain syndrome and assessed the effects of pelvic muscle trigger point release concomitant with paradoxical relaxation training.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We treated 146 men with a mean age of 42 years who had had refractory chronic pelvic pain syndrome for at least 1 month with trigger point release/paradoxical relaxation training to release trigger points in the pelvic floor musculature. The Pelvic Pain Symptom Survey and National Institutes of Health-Chronic Prostatitis Symptom Index were used to document the severity/frequency of pain, urinary and sexual symptoms. A global response assessment was done to record patient perceptions of overall therapeutic effects at an average 5-month followup.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline 133 men (92%) had sexual dysfunction, including ejaculatory pain in 56%, decreased libido in 66%, and erectile and ejaculatory dysfunction in 31%. After trigger point release/paradoxical relaxation training specific Pelvic Pain Symptom Survey sexual symptoms improved an average of 77% to 87% in responders, that is greater than 50% improvement. Overall a global response assessment of markedly or moderately improved, indicating clinical success, was reported by 70% of patients who had a significant decrease of 9 (35%) and 7 points (26%) on the National Institutes of Health-Chronic Prostatitis Symptom Index (p &lt; 0.001). Pelvic Pain Symptom Survey sexual scores improved 43% with a markedly improved global response assessment (p &lt; 0.001) but only 10% with moderate improvement (p = 0.96).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sexual dysfunction is common in men with refractory chronic pelvic pain syndrome but it is unexpected in the mid fifth decade of life. Application of the trigger point release/paradoxical relaxation training protocol was associated with significant improvement in pelvic pain, urinary symptoms, libido, ejaculatory pain, and erectile and ejaculatory dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Rodney U</ForeName><Initials>RU</Initials><AffiliationInfo><Affiliation>Department of Urology, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Christine A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017699" MajorTopicYN="N">Pelvic Pain</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026741" MajorTopicYN="Y">Physical Therapy Modalities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011472" MajorTopicYN="N">Prostatitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012064" MajorTopicYN="Y">Relaxation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16952676</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2006.06.010</ArticleId><ArticleId IdType="pii">S0022-5347(06)01377-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16904460</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>401</EndPage><MedlinePgn>397-401</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To prospectively investigate whether vardenafil can effectively treat patients for whom sildenafil (100 mg) has failed. The introduction of two new oral phosphodiesterase type 5 inhibitors (tadalafil and vardenafil) raises the question of whether the new agents will permit us to treat sildenafil nonresponders with another oral agent.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were seen at one institution during a 5-year period. A total of 327 patients complaining of sildenafil-refractory erectile dysfunction underwent intracavernous pharmacologic injection and color duplex Doppler ultrasonography. Subsequently 59 of these men tried vardenafil home dosing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 327 men in whom sildenafil failed, 16% were younger than 50, 21% were 51 to 60, 34% were 61 to 70, and 28% were older than 70 years. The Doppler diagnoses were arterial insufficiency in 154 (47%), mixed vascular insufficiency in 73 (22%), and cavernous venous occlusive disease in 57 (17%). Forty-three men (13%) had normal erectile responses to prostaglandin E1 (10 to 20 microg). Of the 59 men who tried vardenafil, 19% were younger than 50, 17% were 51 to 60, 40% were 61 to 70, and 23% were older than 70 years. The Doppler diagnoses were arterial insufficiency in 28 (42%), mixed vascular insufficiency in 10 (19%), and cavernous venous occlusive disease in 15 (29%). Six men (8%) had normal erectile responses to prostaglandin E1. Only 7 (12%) of the 59 men reported that home vardenafil dosing resulted in successful intercourse.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An appropriate diagnostic evaluation and subsequent treatment algorithm have yet to be established for those for whom phosphodiesterase type 5 inhibitors fail. We found that most sildenafil nonresponders had severe arterial insufficiency and were older, with 62% older than 60 years. Our preliminary experience suggests that only a small percentage (12%) of sildenafil nonresponders can be salvaged with vardenafil.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brisson</LastName><ForeName>Theodore E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broderick</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Thiel</LastName><ForeName>David D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Pinkstaff</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16904460</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2006.03.005</ArticleId><ArticleId IdType="pii">S0090-4295(06)00347-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16700206</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-4806</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp</ISOAbbreviation></Journal><ArticleTitle>[Penile prosthesis for the treatment of erectile dysfunction].</ArticleTitle><Pagination><StartPage>159</StartPage><EndPage>169</EndPage><MedlinePgn>159-69</MedlinePgn></Pagination><Abstract><AbstractText>The erectile dysfunction is a pathology that, with different degrees of intensity, affects nearly the 20% of the spanish adult men. The treatment is usually performed in stages, reserving the penile prosthesis for when other previous treatments have failed. The aim of this work is to evaluate, according to the state of present knowledge, the effectiveness and security of the penile prosthesis for the treatment of the erectile dysfunction. With this purpose 52 articles were selected, observing a 5 years prosthesis survival of 78-91% and a 3-8% of surgical complications. Mechanical failures and infection percentages were smaller in the semi-rigid prosthesis that in the inflatable ones, with high levels of postoperative satisfaction in patients as well as in their couples, even greater than in other treatments available at the present time. The penile prosthesis implantation must be reserved for the organic erectile dysfunction when previous treatments have failed, evaluating the risk-benefit relation and informing the patient of the results that are hoped to be obtained and of the possible complications that can arise. In view of the great concern of our society with the erectile function and the availability of effective drugs, an increase in the demand of penile prosthesis implantation is predictable in those patients highly motivated, but refractory to the less invasive treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atienza Merino</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Axencia de Avaliaci&#xf3;n de Tecnolox&#xed;as Sanitarias de Galicia (avalia-t) Conseller&#xed;a de Sanidade, Edif. Administrativo de San L&#xe1;zaro, Santiago de Compostela. gerardo.atienza.merino@sergas.es</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La pr&#xf3;tesis de pene en el tratamiento de la disfunci&#xf3;n er&#xe9;ctil.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp</MedlineTA><NlmUniqueID>7704993</NlmUniqueID><ISSNLinking>0210-4806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>57</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16700206</ArticleId><ArticleId IdType="doi">10.1016/s0210-4806(06)73418-0</ArticleId><ArticleId IdType="pii">S0210-4806(06)73418-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16681467</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat.</ArticleTitle><Pagination><StartPage>419</StartPage><EndPage>431</EndPage><MedlinePgn>419-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Numerous men develop postprostatectomy erectile dysfunction (PPED), due to surgery-related nervous damage. PPED is often refractory to phosphodiesterase type 5 (PDE5) inhibitors therapy.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To verify whether chronic tadalafil (CT) preserves bilateral cavernous neurotomy (BCN)-induced penile damage and hypo-oxygenation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a rat model of BCN we evaluated in vitro and ex vivo effect of CT treatment (2 mg/kg, daily for 3 months).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bilateral cavernous neurotomy induced massive hypoxia and decreased muscle/fiber ratio, completely restored by CT. Hypersensitivity of hypoxic tissues to the relaxant effect of the endothelin type B receptor (ETB) agonist IRL-1620 was observed, along with ETB mRNA and protein overexpression. CT restored sensitivity to IRL-1620, and normalized ETB expression. Hypoxic penis showed increased sensitivity to the relaxant effect of the nitric oxide donor sodium nitroprusside (SNP), while acute tadalafil (100 nM) did not amplify the SNP effect. Accordingly, PDE5 mRNA and protein were reduced in BCN penile tissues. By restoring PDE5, CT decreased SNP-induced relaxation and rescued sensitivity to acute tadalafil. However, in hypoxic penis, CT normalizes neither acetylcholine hyporesponsiveness nor neuronal nitric oxide synthase-endothelial nitric oxide synthase expression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Chronic tadalafil restores some of the investigated BCN-induced alterations, including PDE5 and tadalafil efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vignozzi</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Andrology Unit, Department of Clinical Physiopathology, Center of Research, Transfer and High Education, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ambrosini</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Luconi</LastName><ForeName>Michaela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vannelli</LastName><ForeName>Gabriella Barbara</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Donati</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Crescioli</LastName><ForeName>Clara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin-Hua</ForeName><Initials>XH</Initials></Author><Author ValidYN="Y"><LastName>Mirone</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Forti</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016232">Endothelins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020030">Nitric Oxide Donors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>11X778QIZS</RegistryNumber><NameOfSubstance UI="C074308">sovateltide</NameOfSubstance></Chemical><Chemical><RegistryNumber>169D1260KM</RegistryNumber><NameOfSubstance UI="D009599">Nitroprusside</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016232" MajorTopicYN="N">Endothelins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020030" MajorTopicYN="N">Nitric Oxide Donors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009599" MajorTopicYN="N">Nitroprusside</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000294" MajorTopicYN="Y">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16681467</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00208.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31353-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16573707</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0105-6263</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of andrology</Title><ISOAbbreviation>Int J Androl</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>509</EndPage><MedlinePgn>503-09</MedlinePgn></Pagination><Abstract><AbstractText>To date, there is no FDA-approved therapy for premature ejaculation (PE). Recently, phosphodiesterase 5 inhibitors (PDE5-Is) have been demonstrated to have encouraging results in the treatment of PE by a few studies. The aim of this review was to assess the updated manuscripts and thereafter present the practical recommendations and possible mechanisms concerning PDE5-Is for treating PE. Using MEDLINE, we searched and assessed the peer manuscripts published from 1 January 1996 to 1 September 2005 about PDE5-Is for treating PE. The results show that the number of patients in all the reports is very few and most of the studies do not employ double-blinded and placebo-controlled tests, though they are prospective and randomized. Therefore, the results and conclusions might be biased. PDE5-Is are suggested to be used in PE with old age or associated with erectile dysfunction (ED), or to be employed alone or in combination with selective-serotonin reuptake inhibitors (SSRIs) when SSRIs fail to treat PE; behavioural therapy is proposed to be used for preventing the recurrence of PE following withdrawal of PDE5-Is. In addition, for the PE patient with a definite aetiological cause, the aetiology should be cured first, if PE still exists, followed by PDE-Is prescription. Possible mechanisms that are involved include relaxing the smooth muscles of vas deferens, seminal vesicle, prostate and urethra; decreasing the central sympathetic output; inducing peripheral analgesia; prolonging the duration of erection; and increasing confidence, the perception of ejaculatory control, overall sexual satisfaction, and decreasing the post-orgasmic refractory time to achieve a second erection after ejaculation. Well-designed multicentre studies are urgently warranted to further elucidate the efficacies and safety as well as mechanisms of PDE5-Is in the treatment of PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>W F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Department of Urology, Hainan Provincial People's Hospital, Haikou, Hainan Province, China. weifuwang9999@yahoo.com.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Androl</MedlineTA><NlmUniqueID>8000141</NlmUniqueID><ISSNLinking>0105-6263</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517381">PDE5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="Y">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="N">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16573707</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2605.2006.00689.x</ArticleId><ArticleId IdType="pii">IJA689</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16529577</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4569</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Andrologia</Title><ISOAbbreviation>Andrologia</ISOAbbreviation></Journal><ArticleTitle>Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study.</ArticleTitle><Pagination><StartPage>61</StartPage><EndPage>68</EndPage><MedlinePgn>61-8</MedlinePgn></Pagination><Abstract><AbstractText>The study was aimed at investigating the efficacy of tadalafil (Cialis) in combination with transdermal testosterone (Testogel) for the treatment of tadalafil-refractory erectile dysfunction in hypogonadal patients. In an open-label, retrospective trial, 69 hypogonadal nonresponders to tadalafil monotherapy (mean age: 59 years, total testosterone &lt; or =3.4 ng ml(-1)) were randomly divided into two homogeneous groups. Group I (n = 35) received Testogel (5 g containing 50 mg testosterone, daily) for 4 weeks, followed by concurrent therapy with tadalafil (20 mg, twice a week). Group II (n = 34) was assigned to treatment with Testogel (5 g containing 50 mg testosterone, daily) for a duration of 10 weeks before adjunctive therapy with tadalafil was initiated. Total testosterone levels were measured at baseline, week 4 and week 10. Sexual function was assessed employing the International Index of Erectile Function (IIEF). As an additional measure of efficacy, a questionnaire completed by the patients' partner was used. Mean testosterone levels were observed to increase from baseline to study end. Following 4 weeks of therapy, an improvement in Erectile Function (EF) from baseline was observed, which was greater in group I than in group II. The assessment after week 10 showed that EF had further increased and was quite similar now in both groups. Partners found that erectile capacity had greatly improved from baseline to study end. No adverse effects have been observed. These data suggest that combination therapy with testosterone and tadalafil is an effective means in a subset of hypogonadal patients who did not respond to tadalafil alone. We assume that testosterone-induced remodelling of penile tissue structure is one underlying reason for the observed improvement of erectile function. The results imply that this process may require a longer period of testosterone administration than 4 weeks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yassin</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Clinic of Urology and Andrology, Segeberger Kliniken, Norderstedt, Hamburg, Germany. yassin@t-online.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Diede</LastName><ForeName>H E</ForeName><Initials>HE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Andrologia</MedlineTA><NlmUniqueID>0423506</NlmUniqueID><ISSNLinking>0303-4569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16529577</ArticleId><ArticleId IdType="doi">10.1111/j.1439-0272.2006.00712.x</ArticleId><ArticleId IdType="pii">AND712</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16469026</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1464-4096</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.</ArticleTitle><Pagination><StartPage>559</StartPage><EndPage>566</EndPage><MedlinePgn>559-66</MedlinePgn></Pagination><Abstract><AbstractText>The prevalence of benign prostatic hypertrophy (BPH) and erectile dysfunction (ED) both increase with age, and increasing evidence suggests a common cause rather than independent age-related changes. Arterial hypertension often accompanies these urological disorders, suggesting the possibility that increased alpha-adrenoceptor activity may be causal in all three conditions. As evidence for this model, alpha-adrenoceptor antagonists such as doxazosin produce therapeutically beneficial effects in lowering blood pressure, reducing prostate growth and BPH symptoms, and relieving ED. At postjunctional alpha(1)-receptors in the corpus cavernosa, noradrenaline causes vascular smooth muscle cell contraction, restricting blood flow, resulting in penile detumescence. Just as alpha-adrenoceptor antagonism results in systemic vasorelaxation to lower blood pressure, the same mechanism in the penis modulates the effects of noradrenaline to favour vasodilatation, resulting in improved erectile function. Increasing clinical evidence attests to the effectiveness of doxazosin in relieving ED, even in patients refractory to ED-specific treatment, as well as in reducing BPH symptoms and elevated blood pressure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA. kaplans@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DE Rose</LastName><ForeName>Aldo F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>O'leary</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>McVary</LastName><ForeName>Kevin T</ForeName><Initials>KT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>NW1291F1W8</RegistryNumber><NameOfSubstance UI="D017292">Doxazosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017292" MajorTopicYN="N">Doxazosin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007989" MajorTopicYN="N">Libido</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16469026</ArticleId><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05959.x</ArticleId><ArticleId IdType="pii">BJU5959</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16422868</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation.</ArticleTitle><Pagination><StartPage>368</StartPage><EndPage>375</EndPage><MedlinePgn>368-75</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Premature ejaculation (PE) is the most common ejaculatory dysfunction. We assessed the efficacy of sildenafil to increase the time to ejaculation, improve ejaculatory control, and decrease the postejaculatory erectile refractory time in men with PE.</AbstractText><AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">The main study was an 8-week, double-blind, placebo-controlled, parallel group study in men between 18 and 65 years of age with diagnosed PE. A substudy was also conducted using a subset of patients (two-way crossover, one center) before entry to the main study. The primary study measured intravaginal ejaculatory latency (IELT) and responses to the Index of Premature Ejaculation (IPE) questionnaire. The substudy measured vibrotactile stimulation ejaculatory latency time (VTS-ELT) and postejaculatory erectile refractory time. Differences between treatment groups were determined by ancova at the 5% level of significance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The change in IELT (1.6 +/- 6.08 vs. 0.6 +/- 2.07 minutes) and VTS-ELT (2.9 +/- 0.4 vs. 2.4 +/- 0.4 minutes) were higher after taking sildenafil, compared with placebo, but did not reach statistical significance. However, patients who took sildenafil (vs. placebo) reported significantly (P &lt; 0.05) increased ejaculatory control (1.8 +/- 0.3 vs. 1.5 +/- 0.3), increased ejaculatory confidence (2.2 +/- 0.2 vs. 1.9 +/- 0.2), and improved overall sexual satisfaction scores (3.1 +/- 0.2 vs. 2.8 +/- 02) on the IPE, and had a decreased postejaculatory erectile refractory time (3.2 +/- 0.7 vs. 6.4 +/- 0.7 minutes). The most common adverse events for sildenafil (vs. placebo) were headache (15% vs. 1%), flushing (15% vs. 0%), dyspepsia (5% vs. 1%), abnormal vision (5% vs. 0%), and rhinitis (5% vs. 0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although IELT and VTS-ELT were not significantly improved, sildenafil increased confidence, the perception of ejaculatory control, and overall sexual satisfaction, and decreased the refractory time to achieve a second erection after ejaculation in men with PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Chris G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Australian Centre for Sexual Health, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuckey</LastName><ForeName>Bronwyn G A</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Morten</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Purvis</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Koppiker</LastName><ForeName>Nandan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Haughie</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boolell</LastName><ForeName>Mitra</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16422868</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2005.20351.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31180-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16304209</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2006</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0196-3635</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of andrology</Title><ISOAbbreviation>J Androl</ISOAbbreviation></Journal><ArticleTitle>Erection- and ejaculation-preserving cystectomy with orthotopic urinary diversion: is it feasible?</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>267</EndPage><MedlinePgn>263-7</MedlinePgn></Pagination><Abstract><AbstractText>Nerve-sparing techniques to preserve sexual function in men undergoing cystoprostatectomy have been documented by different centers. We evaluated the results of the first 4 erection- and ejaculation-preserving cystectomies performed in our department. The ages of patients ranged between 36 and 43 years. In all cases, patients wished to maintain sexual function. Of the cases, 3 patients had pT1 G3 transitional cell carcinoma (TCC) refractory to treatment and one had pT2a adenocarcinoma of the bladder. Extirpation of the bladder and anterior proximal prostate en bloc with preservation of the vasa deferentia, seminal vesicles, posterior prostate, and neurovascular bundles was performed after pelvic lymphadenectomy. W-ileal neobladder was performed by using 40 cm of ileum. All patients had erections at the third month. Of the cases, 2 patients had antegrade ejaculation. The ejaculate volumes were 0.8 and 1.2 mL in patients with antegrade ejaculation. Patients in the other cases had retrograde ejaculation. All patients were continent day and night. We started clean intermittent catheterization in 1 case because of residual urine. There were no local recurrences. One patient with TCC died because of systemic disease in the postoperative 32nd month. The most important drawback of potent cases in cystectomy decision is erectile dysfunction after radical cystectomy. This drawback causes delay of the operation and sometimes mortality. As was the case in other reports, our limited number of cases in this study demonstrated that erection and ejaculation could be preserved in selected groups of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girgin</LastName><ForeName>Cengiz</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology Clinic, Ataturk Research and Training Hospital, Izmir, Turkey. girgincengiz@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oder</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sahin</LastName><ForeName>M Oguz</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Sezer</LastName><ForeName>Akif</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Berkmen</LastName><ForeName>Serdar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Rusen</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dincel</LastName><ForeName>Cetin</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Androl</MedlineTA><NlmUniqueID>8106453</NlmUniqueID><ISSNLinking>0196-3635</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015653" MajorTopicYN="N">Cystectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005298" MajorTopicYN="N">Fertility</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014547" MajorTopicYN="N">Urinary Diversion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16304209</ArticleId><ArticleId IdType="doi">10.2164/jandrol.05074</ArticleId><ArticleId IdType="pii">jandrol.05074</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16238920</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1527-2737</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current urology reports</Title><ISOAbbreviation>Curr Urol Rep</ISOAbbreviation></Journal><ArticleTitle>Conservative management options for Peyronie's disease.</ArticleTitle><Pagination><StartPage>454</StartPage><EndPage>460</EndPage><MedlinePgn>454-60</MedlinePgn></Pagination><Abstract><AbstractText>Peyronie's disease is an acquired condition that presents clinically with a palpable induration, a distinct plaque, or a curvature of the erect penis. At times, the erections are painful. Erectile dysfunction (ED) often is associated with Peyronie's disease. The current era of phosphodiesterase therapy for the treatment of ED seems to have increased the number of patients presenting for treatment of Peyronie's disease. During the past decade, significant advances have been made in understanding the pathophysiology of the disease, resulting in numerous nonsurgical therapies proposed for the treatment of Peyronie's disease. These medical treatments can be administered systemically, locally, or intralesionally. Unfortunately, there are few randomized, placebo-controlled trials to evaluate most of these proposed therapies. In evaluating therapies for Peyronie's disease, it must be remembered that the natural disease history includes spontaneous resolution of pain and even a small improvement in penile curvature in some men. This article reviews the natural history, scientific understanding, and nonsurgical treatment options for the mild to moderate Peyronie's deformities. Surgical therapy remains the mainstay of treatment for severe and refractory cases of Peyronie's disease that result in a physical or psychologic dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Urology, County of Los Angeles Harbor, UCLA Medical Center, 1000 West Carson Street, Torrence, CA 90509, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Cadavid</LastName><ForeName>Nestor</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rajfer</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Urol Rep</MedlineTA><NlmUniqueID>100900943</NlmUniqueID><ISSNLinking>1527-2737</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>43</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16238920</ArticleId><ArticleId IdType="doi">10.1007/s11934-005-0041-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Clin Pathol. 1969 Oct;52(4):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">5820969</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2001 Jul;88(1):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11446848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1975 Dec;114(6):898-900</Citation><ArticleIdList><ArticleId IdType="pubmed">1195471</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Oct;158(4):1388-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9302127</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1982 Dec;54(6):748-50</Citation><ArticleIdList><ArticleId IdType="pubmed">7150935</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Int. 1980;35(6):407-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7222302</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Urol Nephrol. 1976;10(1):12-20</Citation><ArticleIdList><ArticleId IdType="pubmed">1273527</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1994 Aug;44(2):291-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8048212</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2000 Dec;12(6):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11416833</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 1948 Feb;41(2):173-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18898262</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1998 Apr;51(4):620-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9586617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Oct;158(4):1391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9302128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1957 Feb;77(2):251-66</Citation><ArticleIdList><ArticleId IdType="pubmed">13406874</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2003 May;169(5):1775-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12686831</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1993 Jan;149(1):56-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8417217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2004 Jun;16(3):238-43</Citation><ArticleIdList><ArticleId IdType="pubmed">14973528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Androl. 2000 Jan-Feb;21(1):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10670523</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2000 Dec;38(6):663-9;discussion 670</Citation><ArticleIdList><ArticleId IdType="pubmed">11111181</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2005 Oct;48(4):656-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15982798</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Feb;171(2 Pt 1):740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14713800</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1991 Oct;146(4):1007-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1895413</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1997 Nov;50(5):764-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9372889</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Aug;168(2):621-5; discussion 625-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12131321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2004 Apr;171(4):1605-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15017231</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2002 Jun;89(9):895-900</Citation><ArticleIdList><ArticleId IdType="pubmed">12010235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1990 Dec;144(6):1376-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2231932</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitric Oxide. 2002 May;6(3):283-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12009846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1993 Jan;149(1):53-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8267684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Androl. 1999 Jul-Aug;20(4):444-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10452584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1999 Dec;162(6):2003-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10569556</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2002 Nov;60(5):795-9; discussion 799-800</Citation><ArticleIdList><ArticleId IdType="pubmed">12429298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tech Urol. 1997 Fall;3(3):135-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9422444</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1992 Dec;70(6):648-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1486392</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2005 Apr;47(4):530-5; discussion 535-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15774254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Dec;168(6):2483-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12441945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1994 Jul;152(1):105-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8201639</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Urol Belg. 1988;56(2):317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3400537</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hyperthermia. 2005 Jun;21(4):367-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16019862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1997 Jan;157(1):325-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8976290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16042713</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1464-4096</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase type 5 inhibitors for erectile dysfunction.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>280</EndPage><MedlinePgn>257-80</MedlinePgn></Pagination><Abstract><AbstractText>The cyclic nucleotide signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical prostatectomy). Conversely, selective inhibition of the enzyme that catalyses the degradation of cGMP (phosphodiesterase type 5, PDE-5) promotes erectile responses to sexual stimulation. The successful launch and commercialization of the selective PDE5 inhibitor (PDE5I) sildenafil transformed the treatment of ED, not only by providing an effective, well tolerated oral ED therapy, but also by fostering greater candour about the problem among men. Sildenafil is highly effective in promoting erectile responses across a wide spectrum of severity and causes of ED, including patients with ED that is often refractory to treatment. The recent advent of vardenafil, which has the highest in vitro potency of all available PDE5Is, and tadalafil, which has a prolonged half-life that may enable couples to have sexual activity with less planning, represent further advances. Other PDE5Is offering further potential improvements are under active investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Culley C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Carson@med.unc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Tom F</ForeName><Initials>TF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.-</RegistryNumber><NameOfSubstance UI="D010727">Phosphoric Diester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517381">PDE5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010727" MajorTopicYN="Y">Phosphoric Diester Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>114</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16042713</ArticleId><ArticleId IdType="doi">10.1111/j.1464-410X.2005.05614.x</ArticleId><ArticleId IdType="pii">BJU5614</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15882732</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability.</ArticleTitle><Pagination><StartPage>964</StartPage><EndPage>967</EndPage><MedlinePgn>964-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the outcomes of a select cohort of patients with severe voiding dysfunction, refractory to medical management, and a concomitant diagnosis of prostate cancer, who were treated with radical prostatectomy and augmentation enterocystoplasty.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four men with biopsy-proven prostatic adenocarcinoma, as well as a diagnosis of severe overactive bladder, underwent combined radical retropubic prostatectomy and augmentation enterocystoplasty. All patients underwent fluorourodynamic testing confirming nonobstructive detrusor instability or hyperreflexia. Three patients underwent nerve-sparing radical retropubic prostatectomy with a clamshell ileocystoplasty, and one with neurogenic hyperreflexia underwent sigmoid cystoplasty with a continent catheterizable stoma at radical retropubic prostatectomy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean follow-up was 21.5 months (range 8 to 48). All patients had an undetectable prostate-specific antigen level postoperatively. The average hospitalization was 8 days. Perioperative complications occurred in 2 patients, including a prolonged urine leak managed with catheter drainage and postoperative hematuria requiring cystoscopic clot evacuation. Erectile function was preserved in 2 patients with good preoperative erections. At last follow-up, the 3 patients who voided per urethra had minimal postvoid residual urine volumes and maintained good continence, with only 1 patient describing occasional mild stress incontinence. At last follow-up, the patient with the sigmoid cystoplasty catheterized every 4 hours with volumes of about 300 mL and complete stomal continence. No patient required anticholinergic medications postoperatively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The concomitant diagnosis of prostate cancer and severe detrusor instability may be difficult to treat. The results of our study have shown that for those desiring surgical management for their prostate cancer, a combined bladder augmentation and radical prostatectomy may be performed with minimal added morbidity and significantly improved voiding function in the properly selected individual.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quek</LastName><ForeName>Marcus L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, California 90089, USA. quekm@hsc.usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Piers</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Lieskovsky</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="Y">Prostatectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001743" MajorTopicYN="N">Urinary Bladder</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001745" MajorTopicYN="N">Urinary Bladder Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014555" MajorTopicYN="N">Urination Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15882732</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2004.11.011</ArticleId><ArticleId IdType="pii">S0090-4295(04)01356-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15648556</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0391-4097</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of endocrinological investigation</Title><ISOAbbreviation>J Endocrinol Invest</ISOAbbreviation></Journal><ArticleTitle>Might erectile dysfunction be due to the thermolabile variant of methylenetetrahydrofolate reductase?</ArticleTitle><Pagination><StartPage>883</StartPage><EndPage>885</EndPage><MedlinePgn>883-5</MedlinePgn></Pagination><Abstract><AbstractText>Hyperhomocysteinemia is considered one of the most important cardiovascular risk factors increasing considerably the risk of stroke and myocardial infarction. With respect to endothelial function, direct effects of hyperhomocysteinemia on vascular endothelial cells have been demonstrated through the reduction of endothelial nitric oxide production. In this paper, we report the case of a young man with homozygote genotype mutated with 5-methylenetetrahydrofolate reductase (MTHFR) thermolabile variant who, in the absence of relational stress, developed an erectile dysfunction (ED) refractory to the vasoactive type-V phosphodiesterase (PDE5) inhibitor therapy. After one month of treatment with 5 mg/day folic acid and 1000 microg/day cyanocobalamin, the patient restarted the assumption of 50 mg sildenafil, obtaining satisfying erections during sexual intercourse. We suggest that hyperhomocysteinemia may interfere with penile blood supply and, thus, be responsible for ED. If this relationship is confirmed, plasma levels and urinary homocysteine (HCy) should be evaluated in selected young patients with vascular ED. Furthermore, careful attention should be given to the risk of ED when dealing with this metabolic disturbance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Seminology and Immunology of Reproduction, Department of Medical Physiopathology, University of Rome La Sapienza, Rome, Italy. francesco.lombardo@uniroma1.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgr&#xf2;</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gandini</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dondero</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jannini</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>J Endocrinol Invest</MedlineTA><NlmUniqueID>7806594</NlmUniqueID><ISSNLinking>0391-4097</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006397">Hematinics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>935E97BOY8</RegistryNumber><NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.1.20</RegistryNumber><NameOfSubstance UI="D042965">Methylenetetrahydrofolate Reductase (NADPH2)</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6YC3EG204</RegistryNumber><NameOfSubstance UI="D014805">Vitamin B 12</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006397" MajorTopicYN="N">Hematinics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042965" MajorTopicYN="N">Methylenetetrahydrofolate Reductase (NADPH2)</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014805" MajorTopicYN="N">Vitamin B 12</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15648556</ArticleId><ArticleId IdType="doi">10.1007/BF03346286</ArticleId><ArticleId IdType="pii">5199</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Circulation. 1999 Mar 9;99(9):1230-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10069792</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Apr;14(2):93-9; discussion 100</Citation><ArticleIdList><ArticleId IdType="pubmed">11979323</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2002 Jan;33(1):51-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11779888</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2003 Sep;44(3):366-70; discussion 370-1</Citation><ArticleIdList><ArticleId IdType="pubmed">12932938</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherosclerosis. 2002 Mar;161(1):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11882329</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2001 Aug;39(8):758-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11592447</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 May;10(1):111-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7647779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Pract (1995). 1997 Jun 15;32(6):81-2, 85, 88-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9194803</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2000 Feb 8;101(5):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10662744</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1997 Jun;49(6):822-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1997 Mar 4;95(5):1119-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9054838</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1993 Jan;57(1):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8416664</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1992 Aug 19;268(7):877-81</Citation><ArticleIdList><ArticleId IdType="pubmed">1640615</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 1998 Aug;11(8 Pt 1):1019-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9715796</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15383186</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-7995</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes.</ArticleTitle><Pagination><StartPage>1377</StartPage><EndPage>1384</EndPage><MedlinePgn>1377-84</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the efficacy and tolerability of oral propionyl-L-carnitine (PLC) plus sildenafil in men with erectile dysfunction (ED) and diabetes unresponsive to sildenafil monotherapy.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Patients with medically documented ED of organic or mixed aetiology and diabetes (type 1 and 2) were randomised to receive oral PLC (2 g/day) plus sildenafil (50 mg twice weekly) (20 patients, Group 1) or sildenafil alone (20 patients, Group 2), in a double-blind, fixed-dose study. All patients had been previously treated unsuccessfully with a minimum of eight administrations of sildenafil. Efficacy was evaluated using the International Index of Erectile Function (IIEF) questionnaire: total score, subscores for questions 3 (Q3; achieving an erection) and 4 (Q4; maintaining an erection) and global efficacy question (GEQ: 'Has treatment improved your erections?'). Patients Event Logs were also used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After 24 weeks of treatment, mean scores for IIEF Q3 and Q4 had improved significantly in patients of Group 1 (4.25 +/- 0.63 and 3.95 +/- 1.0) compared with Group 2 (2.9 +/- 0.71 and 2.7 +/- 0.96) (p &lt; 0.01). Moreover, the percentage of patients with improved erections (GEQ 68% vs. 23%) and successful intercourse attempts (76% vs. 34%) was significantly increased in Group 1 compared with Group 2 (p &lt; 0.01). Fourteen (70%) patients in Group 1 and four (20%) in Group 2 reported an increase in mean IIEF EF domain score of &gt; or = 4 (p &lt; 0.01). Treatments were well tolerated and no patient discontinued study medication. Two patients in Group 1 reported mild gastric pain.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Salvage therapy with PLC plus sildenafil was more effective than sildenafil in the treatment of ED in patients with diabetes refractory to sildenafil monotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Urology U Bracci, University La Sapienza, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicini</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Prigiotti</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Koverech</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Di Silverio</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>17298-37-2</RegistryNumber><NameOfSubstance UI="C003223">propionylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="Y">Diabetes Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15383186</ArticleId><ArticleId IdType="doi">10.1185/030079904X2394</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15134987</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Use of intraurethral alprostadil in patients not responding to sildenafil citrate.</ArticleTitle><Pagination><StartPage>951</StartPage><EndPage>954</EndPage><MedlinePgn>951-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether intraurethral alprostadil would be an effective alternative for men with erectile dysfunction who did not respond adequately to sildenafil citrate but desired minimally invasive treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 44 male patients aged 41 to 74 years with erectile dysfunction refractory to treatment with sildenafil citrate were enrolled in this study. Of the 44 patients, 10 had undergone prior radical retropubic prostatectomy. The patients were evaluated for subjective improvement in an office setting and completed the Sexual Health Inventory for Men questionnaire as an objective assessment of improved erectile ability. Success was defined as subjective improvement in erectile function, as well as an improved Sexual Health Inventory for Men score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 44 men, 13 (29.5%) responded successfully to intraurethral alprostadil, with a follow-up ranging from 2 to 15 months. The remaining 31 men had no response (n = 28, 90%), refused escalating doses (n = 2, 7%), or were lost to follow-up (n = 1, 3%). In the subgroup of 10 men with prior radical retropubic prostatectomy, 5 (50%) reported success with intraurethral alprostadil (500 microg in 2 patients and 1000 microg in 3 patients).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although sildenafil citrate remains the most common initial therapy in men with erectile dysfunction, intraurethral alprostadil may be a reasonable treatment option for sildenafil nonresponders. This may be especially true in men having undergone prior radical retropubic prostatectomy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaffe</LastName><ForeName>Jamison S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Urology, Department of Surgery, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antell</LastName><ForeName>Mara R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Greenstein</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Phillip C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Mydlo</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Harkaway</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="N">Urethra</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15134987</ArticleId><ArticleId IdType="doi">10.1016/j.urology.2003.11.039</ArticleId><ArticleId IdType="pii">S0090429503013372</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14673246</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1540-9740</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Skinmed</Title><ISOAbbreviation>Skinmed</ISOAbbreviation></Journal><ArticleTitle>Erectile dysfunctions.</ArticleTitle><Pagination><StartPage>350</StartPage><EndPage>356</EndPage><MedlinePgn>350-6</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction is one of the prime challenges confronting the treating physician. Its prevalence is directly proportional to aging. It is imperative to comprehend the intricate mechanism of erection in order to individualize the approach to management. Thus, it is appropriate to evaluate the etiology of erectile dysfunction. Normal aging, as well as psychogenic, vascular, neurogenic, and endocrinologic causes and/or those due to structural abnormalities of the penis should be considered when evaluating details to determine its probable cause. An increasing use of drugs, a legacy of civilization, has considerably compounded the problem. Therapy for erectile dysfunction, apart from psychosexual counseling, includes medical treatment by alpha adrenoceptor antagonists, dopamine agonists, phosphodiesterase type 5 inhibitors, sublingual apomorphine hydrochloride, or hormone therapy. Transdermal or transurethral corporeal drug delivery are other possible treatment modalities. Vacuum devices and surgical approaches are considered relevant only in refractory cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sehgal</LastName><ForeName>Virendra N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>The Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, India. drsehgal@ndf.vsnl.net.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Govind</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Skinmed</MedlineTA><NlmUniqueID>101168327</NlmUniqueID><ISSNLinking>1540-9740</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14673246</ArticleId><ArticleId IdType="doi">10.1111/j.1540-9740.2003.01950.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14582685</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1594-0667</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Aging clinical and experimental research</Title><ISOAbbreviation>Aging Clin Exp Res</ISOAbbreviation></Journal><ArticleTitle>New achievements and pharmacotherapeutic approaches to impotence in the elderly.</ArticleTitle><Pagination><StartPage>222</StartPage><EndPage>233</EndPage><MedlinePgn>222-33</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED) has a negative impact on the quality of life of elderly men, but impotence is not an absolute concomitant of aging. Aging changes influencing sexual function in men consist of a decreased capacity to reach arousal by imagination or view, fragility of erection, and an increase in the refractory period. These events may be part of the andropause syndrome, which includes a decrease in intellectual activity, fatigue, depression, decreases in body hair, lean body mass and bone mineral density, accompanied by an increase in weight. As a consequence, the overlap of aging processes, concurrent diseases and social situations to which elderly men are subject, results in the great variability reported in epidemiological studies. In the same way, the complex physiology of erection depends on the social, environmental, or physical context in which it occurs. New achievements in research on intracellular mechanisms of erection and on the neuroendocrinology of aging contribute to better understanding the pathophysiology of ED in the elderly. For example, testosterone declines with age with great interindividual variability, since other hormonal changes are also involved. What currently can be easily identified is the alteration of LH-testosterone feedback alterations, although hormone levels fall in the normal range. Nevertheless, the extent to which age-dependent decline in hormones leads to health problems that may affect the quality of life remains to be clarified. Several concepts on aging-related processes have been challenged, and conditions that were once accepted as physiologically age-related are now thought to lead to medical problems, but until now erectile dysfunction remains underreported, underdiagnosed, and undertreated, especially in the elderly. Nowadays, we are witnessing a rapid growth in available pharmacotherapies, from intracavernous injections of vasoactive drugs, to powerful new oral agents, with differing pharmacological dynamic and kinetic properties. New options for treatment are therefore possible, taking into account both the possibility of changing ineffective drugs and augmenting efficacy by means of synergistic associations. This rich generation of progress is certainly contributing to a better medical approach to sexuality in aging people.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frajese</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Roma Tor Vergata University, Roma, Italy. gfraj@flashnet.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Aging Clin Exp Res</MedlineTA><NlmUniqueID>101132995</NlmUniqueID><ISSNLinking>1594-0667</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>117</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14582685</ArticleId><ArticleId IdType="doi">10.1007/BF03324503</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14562136</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-9930</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>354</EndPage><MedlinePgn>347-54</MedlinePgn></Pagination><Abstract><AbstractText>Phosphodiesterase (PDE) inhibitors represent an important advance in the treatment of erectile dysfunction (ED). In spite of widespread use and generally good efficacy, as a class they remain ineffective in 15-57% of men. Specific cohorts of patients with severe vascular or neurogenic basis to their ED, such as diabetic men or those who have undergone radical pelvic surgery, demonstrate lower response rates with PDE inhibition treatment. We believe that circulating levels of nitric oxide (NO) may be enhanced through delivery of adequate concentrations of free oxygen radical scavenger molecules such as vitamin E. Higher levels of NO, theoretically, should produce increased penile blood flow with the potential for a synergistic effect when combined with a PDE5 inhibitor. With this hypothesis in mind, 20 adult male Sprague-Dawley streptozotocin-induced (60 mg/kg i.p.) diabetic rats were divided into four therapeutic groups (n=5). Group I--control animals received peanut oil, group II--vitamin E 20 IU/day, group III--sildenafil 5 mg/kg/day and group IV--vitamin E 20 IU/day plus sildenafil 5 mg/kg/day, by oral gavage daily for 3 weeks. Erectile function was assessed as a rise in intracavernous pressure following cavernous nerve electrostimulation. Penile tissue was harvested to determine the changes in tissue morphology including neuronal nitric oxide synthase, smooth muscle alpha-actin and endothelial cell integrity. PDE5 protein content and activity were measured. Significant increases in intracavernous pressure were measured in the animals receiving combined vitamin E plus sildenafil treatment. Immunohistochemical staining showed increases of neuronal nitric oxide synthase, endothelial cell and smooth muscle cell staining. Western blot analysis did not show significant differences of PDE5 protein between the groups. However, higher PDE5 activity was measured in the sildenafil group and lower activity of PDE5 was recorded in the cohort receiving vitamin E with sildenafil. Vitamin E enhanced the therapeutic effect of the PDE5 inhibitor in a meaningful way in this animal model of diabetes. This study indicates a potential means of salvaging erectile function among patients who are refractory to sildenafil.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Young</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, St Joseph's Health Care, Lawson Health Research Institute, The University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>G B</ForeName><Initials>GB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517384">Pde5a protein, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14562136</ArticleId><ArticleId IdType="doi">10.1038/sj.ijir.3901026</ArticleId><ArticleId IdType="pii">3901026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14513643</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Treatment of the paraplegic patient with erectile dysfunction by implantation of China-made three-piece inflatable penile prosthesis].</ArticleTitle><Pagination><StartPage>352</StartPage><EndPage>354</EndPage><MedlinePgn>352-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of the treatment on paraplegic patients with erectile dysfunction (ED) by implantation of China-made three-piece inflatable penile prosthesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighteen paraplegic patients with ED refractory to non-operative treatment were implanted with three-piece inflatable penile prosthesis through an incision at the border of penis and scrotum. The rate of maintained coitus and the satisfactory coitus of spouse were obtained by inquiring and letter visiting.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Operations were successfully performed upon all 18 patients. Follow-ups after operations ranged from 3 months to 36 months, mean follow-up being 18 months. Fluid exudation from penile prosthesis and localized infection occurred in one patient and mechanic complication occurred in two. Maintained coitus rate was 17/18. Ejaculation reflection occurred in three patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment of paraplegic patient with ED refractory to non-operative treatment by implantation of China-made three-piece inflatable penile prosthesis has good concealment and rehabilitative effect, with similar mechanical troubles to imported products. With excellent covertness, implantation of three-piece inflatable penile prosthesis is well accepted by ED patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xuan</LastName><ForeName>Xu-Jun</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhi-Shun</ForeName><Initials>ZS</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010264" MajorTopicYN="N">Paraplegia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14513643</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12913722</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5347</ISSN><JournalIssue CitedMedium="Print"><Volume>170</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of shunt surgery for refractory low flow priapism: a report on the incidence of failed detumescence and erectile dysfunction.</ArticleTitle><Pagination><StartPage>883</StartPage><EndPage>886</EndPage><MedlinePgn>883-6</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The reported success rate for surgical cavernosa-to-spongiosum shunts in patients with refractory low flow priapism is variable and yet it is reported to be as high as 100% in terms of achieving detumescence. The long-term potency rate after the introduction of the shunt procedure is also as high as 50%. We reviewed the efficacy of various shunts in terms of achieving detumescence and we clarified the rate of erectile dysfunction at long-term followup.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Patients were included in the analysis if they had painful low flow priapism more than 4 hours in duration that was refractory to conservative management, ultimately requiring a surgical shunt. Data, including etiology, duration and initial treatment measures, were retrospectively compiled in the last 12 years and the type of surgical shunts performed were recorded. Followup erectile function was assessed by clinical notes and a telephone survey using the International Index of Erectile Function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 28 consecutive patients included in the study 13 (46.4%) required more than 1 operation for failed detumesence, of whom 12 (92.3%) initially underwent a Winter shunt. Only 2 of the 20 men (10%) with available followup reported preservation of pre-morbid erectile function. Three men (15%) achieved partial erection without the assistance of oral or injectable agents.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In contrast to previously reported success rates, approximately 50% of our patients required reoperation for failed detumescence following a cavernosa-to-spongiosum shunt. In our experience the Winter shunt was the least successful operation, whereas reoperation was uncommonly required following an Al-Ghorab or Quackels shunt. As many as 90% of our patients had erectile dysfunction at followup.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Randy G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Urologic Surgery, Vanderbilt University School of Medicine, Medical Center North, Nashville, TN 37232, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Milam</LastName><ForeName>Douglas F</ForeName><Initials>DF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013521" MajorTopicYN="Y">Urologic Surgical Procedures, Male</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12913722</ArticleId><ArticleId IdType="doi">10.1097/01.ju.0000081291.37860.a5</ArticleId><ArticleId IdType="pii">S0022-5347(05)63255-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12904810</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-9930</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time.</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>228</EndPage><MedlinePgn>225-8</MedlinePgn></Pagination><Abstract><AbstractText>Sildenafil is one of two oral drugs approved for first-line treatment of erectile dysfunction (ED). Anecdotally, some young healthy men who wish to enhance their sexual performance are requesting or abusing sildenafil. In this randomized double-blind, placebo-controlled clinical study, we investigated the effect of sildenafil in young men without ED. A total of 60 young healthy men age 20-40 y with no reported ED were enrolled for this single-dose home-use study. Subjects had used no medication in the 6 months prior to the study. All had been engaged in a stable relationship for at least 3 months. After completing the IIEF-5 questionnaire, patients were randomized in a double-blind fashion to receive either one 25 mg tablet of sildenafil (group 1) taken prior to intercourse, or an identical placebo tablet (group 2). All subjects completed a questionnaire relating to their erectile quality. There were no differences between the two groups in the reported improvement of erection quality, 12/30 sildenafil vs 10/30 placebo (Fisher's test, P=0.79). Sildenafil caused a significant reduction of the postejaculatory refractory time (12/30 vs 4/30) (chi(2) test, P=0.04). Sildenafil does not improve erections in young healthy men. Sildenafil should not be given to young healthy men to improve their erections and patients should be advised against recreational abuse of the drug. In this limited single-dose home study, sildenafil appears to reduce the postorgasmic refractory time. Although controlled studies are needed to evaluate the efficacy of erection-enhancing drugs in premature ejaculation, it is possible that sildenafil might be useful for this indication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mondaini</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Florence, Italy. mondatre@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponchietti</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>G H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Montorsi</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Di Loro</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009948" MajorTopicYN="Y">Orgasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12904810</ArticleId><ArticleId IdType="doi">10.1038/sj.ijir.3901005</ArticleId><ArticleId IdType="pii">3901005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12887744</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Treatment of erectile dysfunction by implantation of domestic made three-piece inflatable penile prosthesis, a retrospective study of 29 cases].</ArticleTitle><Pagination><StartPage>561</StartPage><EndPage>563</EndPage><MedlinePgn>561-3</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of implantation of domestic made three-piece inflatable penile prosthesis on erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Domestic made three-piece inflatable penile prosthesis were implanted through an incision at the border of penis and scrotum on 29 patients with ED refractory to non-operative treatment, among which 23 being with neurogenic ED, including 18 paraplegia cases and 5 cases of traumatic injury of nervi erigentes; 4 cases with ED caused by arteriovenous fistula; I case with ED caused by fibrosis of corpus cavernosum, and 1 case with ED caused by Klinefelter's syndrome. Follow-up was conducted for 3 - 36 months to survey the clinical effect.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Operation was successfully performed upon all 29 patients. Follow-up after operation lasted 3 - 36 months, 18 months on average. Fluid exudation of penile prosthesis and localized infection occurred in 1 patient and mechanic complication occurred in 2 patients. Maintained sexual intercourse rate was 28/29. 3 ED patients with primary arteriovenous fistula made their spouses pregnant after treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">With excellent covertness and at low cost, implantation of domestic made three-piece inflatable penile prosthesis is effective and well accepted by ED patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xuan</LastName><ForeName>Xu-jun</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guan-xiang</ForeName><Initials>GX</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Yong-qiang</ForeName><Initials>YQ</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="N">Penile Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12887744</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12749129</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1009-3591</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Zhonghua nan ke xue = National journal of andrology</Title><ISOAbbreviation>Zhonghua Nan Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Three-piece inflatable penile prosthesis implantation for the treatment of penile erectile dysfunction].</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>114</EndPage><MedlinePgn>109-10, 114</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To introduce the method and experience of three-piece inflatable penile prosthesis for treatment of erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Both AMS700CX/CXM and MENTOR ALPHA I three-piece inflatable prosthesis were used for 48 cases of ED.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no rejection, mechanical problems, urethral injury and penile skin necrosis after surgery. All patients had satisfaction of sexual life. Only one case had trauma of tunica albuginea (2.08%) and the implantation had to be cancelled. There were 2 cases of post-operative infection (4.17%), 10 cases of prepuce edema(20.8%), 8 cases of penile pain(16.67%). The effective rate was 97.9% and satisfaction rate was almost 100%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Three-piece inflatable penile prosthesis was more compatible to human physiology. It is natural, easy to hide and use, and it caused little trauma in surgery with high rate of successful implantation and patient satisfaction. It was indicated for all kinds of ED, especially suitable for refractory and drug incurable ED patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Zhen-Nong</ForeName><Initials>ZN</Initials><AffiliationInfo><Affiliation>Department of Urology, Second Affiliated Hospital of Guang Zhou Medical College, Guangzhou, Guangdong 510260, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhi-Guang</ForeName><Initials>ZG</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nan Ke Xue</MedlineTA><NlmUniqueID>101093592</NlmUniqueID><ISSNLinking>1009-3591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019935" MajorTopicYN="Y">Penile Implantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12749129</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12494291</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-9930</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction.</ArticleTitle><Pagination><StartPage>533</StartPage><EndPage>538</EndPage><MedlinePgn>533-8</MedlinePgn></Pagination><Abstract><AbstractText>The objectives of this study were to evaluate the efficacy and tolerability of high dose sildenafil as a salvage therapy for patients refractory to the maximum recommended dose of sildenafil. Fifty four fully evaluated patients with chronic erectile failure (ED) who had previously failed to respond to a home trial of sildenafil (100 mg) with erections suitable for sexual intercourse were studied. Each man was treated at home with sildenafil at escalating doses of up to 200 mg until either maximal response or intolerable adverse effects occurred. Erectile function was quantified using the erectile function domain of the International Index of Erectile Function (IIEF) before treatment, with sildenafil 100 mg and with maximal dose of sildenafil and a global efficacy question after 4 weeks of treatment. The mean age of the study group was 59.6+/-11.2 y. 13/54 (24%) had arteriogenic ED, 16/54 (30%) had mixed vasculogenic ED, 9/54 (17%) had cavernosal veno-occlusive dysfunction, 11/54 (20%) had post radical retropubic prostatectomy ED and 5/54 (9%) had psychogenic ED. 13/54 (24.1%) responded to sildenafil at a median maximal dose of 200 mg, 4/13 required 150 mg and 9/13 required 200 mg. 41/54 (76%) failed to respond to sildenafil. Mean IIEF question 3 and 4 scores were 1.5 and 1.4 at baseline, 2.2 and 1.9 with sildenafil 100 mg, 2.8 and 2.5 with sildenafil 150 mg and 3.0 and 2.9 with sildenafil 200 mg, respectively. After 4 weeks, treatment was regarded as having improved their erections by 37%, 46.3% and 68% of patients with sildenafil 100 mg, 150 mg and 200 mg, respectively. 34/54 (63%) reported adverse effects with maximal dose sildenafil comprising headache (19), facial flushing (32), dyspepsia (14), nasal congestion (11), dizziness (5) and visual disturbances (5). 4/13 (31%) responders refused to continue treatment due to adverse effects.In conclusion, sildenafil at doses of up to 200 mg is an effective salvage therapy for 24.1% of previous sildenafil non-responders but is limited by a significantly higher incidence of adverse effects and a 31% treatment discontinuation rate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Australian Centre for Sexual Health, St Luke's Hospital Complex, Sydney, Australia. cmcmahon@mail.usyd.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2003 Aug;170(2 Pt 1):684</RefSource><PMID Version="1">14601583</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="Y">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>21</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>21</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12494291</ArticleId><ArticleId IdType="doi">10.1038/sj.ijir.3900936</ArticleId><ArticleId IdType="pii">3900936</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12494278</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-9930</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP.</ArticleTitle><Pagination><StartPage>462</StartPage><EndPage>465</EndPage><MedlinePgn>462-5</MedlinePgn></Pagination><Abstract><AbstractText>Sildenafil is frequently the first-line treatment for post-radical retropubic prostatectomy (RRP) erectile dysfunction (ED) with maximum treatment satisfaction rates of 43%-80%. The etiology of erectile dysfunction after RRP has been attributed to psychogenic, vascular, veno- occlusive or nerve injury causes. The purpose of this study was to gain insight into the penile duplex Doppler arterial parameters in men with ED after RRP who failed sildenafil. The purpose was to assess whether sildenafil failure after RRP is associated with underlying corporal arterial disease. A total of 174 consecutive men presenting with sildenafil refractory ED after nerve-sparing RRP underwent color duplex penile Doppler evaluation with vasoactive injection. Mean age was 59.6 y and mean time from surgery was 11.6 months. Some 81% (141/174) of the men had no pre-operative ED (PED). Significant differences in penile duplex Doppler parameters for arterial disease were seen between men with and without PED. In men without PED, 19% (27/141) manifested arterial insufficiency. However, in men with PED, 50% (16/33) demonstrated arterial disease. Nerve sparing status did not affect the presence of arterial disease. Sildenafil refractory erectile dysfunction after RRP in men without PED is not predominantly associated with penile Doppler parameters consistent with arterial insufficiency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Urology, New York University School of Medicine, New York 10016, USA. andy.mccullough@msnyuhealth.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Telegrafi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lepor</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018616" MajorTopicYN="N">Ultrasonography, Doppler, Duplex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2002</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>21</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>21</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12494278</ArticleId><ArticleId IdType="doi">10.1038/sj.ijir.3900909</ArticleId><ArticleId IdType="pii">3900909</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12414334</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>2 Suppl 2</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression.</ArticleTitle><Pagination><StartPage>58</StartPage><EndPage>66</EndPage><MedlinePgn>58-66</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED) and depression are highly prevalent conditions and frequently occur concomitantly in predisposed individuals. Men with ED and depression are also likely to have other comorbid conditions, including diabetes, hypertension, and heart disease. Because ED is also a common adverse effect of some medications for these conditions, patients are frequently noncompliant with treatment. Sildenafil citrate (Viagra) is effective in treating ED of a broad range of etiologies, suggesting that it may be equally beneficial in patients with ED that is associated with depressive symptoms and in those with ED resulting from serotonergic reuptake inhibitor (SRI) antidepressant treatment. We review the results of 3 randomized, placebo-controlled trials and a retrospective analysis of data pooled from 10 clinical trials that examine the efficacy of sildenafil in treating ED associated with depression and as an adverse effect of SRI treatment. The results suggest that sildenafil is efficacious as a first-line treatment for ED in men with untreated minor depression, in men with ED that is refractory to successful SRI treatment of depression, and in those whose depression was successfully treated but who developed ED as a consequence of SRI treatment. Given the complex interrelations among ED, depression, and other comorbid conditions, the key to proper management is a comprehensive evaluation, including sexual function, and an accurate differential diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nurnberg</LastName><ForeName>H George</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Health Sciences Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131-5286, USA. geon@unm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seidman</LastName><ForeName>Stuart N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Gelenberg</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shabsigh</LastName><ForeName>Ridwan</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12414334</ArticleId><ArticleId IdType="doi">10.1016/s0090-4295(02)01691-6</ArticleId><ArticleId IdType="pii">S0090429502016916</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11993245</PMID><DateCompleted><Year>2002</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1053-816X</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Urologic nursing</Title><ISOAbbreviation>Urol Nurs</ISOAbbreviation></Journal><ArticleTitle>Penile prosthesis: patient teaching and perioperative care.</ArticleTitle><Pagination><StartPage>81</StartPage><EndPage>92</EndPage><MedlinePgn>81-90, 92</MedlinePgn></Pagination><Abstract><AbstractText>As more options become available for treating erectile dysfunction (ED), more men are seeking treatment. Despite excellent efficacy of available medical management, a percentage of these patients will be refractory to the less invasive options for treatment, leaving the surgical implantation of a penile prosthesis as their remaining option for definitive treatment of ED. The patient seeking penile prosthesis surgery faces many challenges as he proceeds through the perioperative processes. A thorough understanding of indications, preoperative assessment and teaching, intraoperative procedure, and postoperative care and teaching for the patient receiving a penile prosthesis will enable him to achieve the best possible outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quallich</LastName><ForeName>Susanne A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Section of Urology, Ann Arbor Veterans' Affairs Health System, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohl</LastName><ForeName>Dana A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urol Nurs</MedlineTA><NlmUniqueID>8812256</NlmUniqueID><ISSNLinking>1053-816X</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000075202" MajorTopicYN="N">Contraindications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="Y">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>12</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11993245</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11896478</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-9930</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>53</EndPage><MedlinePgn>50-3</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil. We enrolled 28 patients with non-organic erectile dysfunction, for whom 3 months of sildenafil monotherapy had failed. They were divided in two random and homogeneous groups: 14 were treated with doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse); the other 14 patients received sildenafil and placebo. The results were assessed by means of the IIEF questionnaire before the beginning of the study, after 30 days of therapy and after 60 days. Of the 14 patients treated with doxazosin and sildenafil, 11 (78.6%) showed a statistically significant increase of IIEF; in the placebo group, only one patient (7.1%) recorded a significant IIEF increase. The differences observed in the two groups were statistically very significant (P=0.0016). Blood pressure did not show significant alterations. Side effects were minimal and even present during sildenafil monotherapy. The combination therapy with sildenafil and doxazosin resulted in the safe and effective treatment of men with non-organic erectile dysfunction for whom sildenafil alone had failed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Rose</LastName><ForeName>A F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Urology, S. Martino Hospital, University of Genoa, Italy. aldoderose@smartino.ge.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giglio</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Traverso</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lantieri</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Carmignani</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>NW1291F1W8</RegistryNumber><NameOfSubstance UI="D017292">Doxazosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017292" MajorTopicYN="N">Doxazosin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2001</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11896478</ArticleId><ArticleId IdType="doi">10.1038/sj.ijir.3900815</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22151777</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1094-7159</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neuromodulation : journal of the International Neuromodulation Society</Title><ISOAbbreviation>Neuromodulation</ISOAbbreviation></Journal><ArticleTitle>Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>24</EndPage><MedlinePgn>16-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1046/j.1525-1403.2002._2004.x</ELocationID><Abstract><AbstractText>We began this study to determine the efficacy and safety of intrathecal baclofen (ITB) delivered by a programmable pump for the treatment of severe spasticity of spinal cord origin. One hundred fifty two patients with severe spasticity of spinal origin, refractory to oral baclofen, or who experienced intolerable side-effects were given a test dose of ITB. Only those who had a satisfactory response were considered to be appropriate for pump implantation. All but one of the 152 patients had a satisfactory response, and the pump was implanted in 131 patients. Pre- and postoperative spasticity scores were compared and analyzed. The mean Ashworth score for rigidity decreased from 4.2 preoperatively to 1.3 (p &lt; 0.0005) on ITB. The spasm score decreased from a mean of 3.4 to 0.6 (p &lt; 0.0005). Reduction of spasticity resulted in improved levels of physical activity, decreased pain, and augmentation of sleep. Drug-related complications included constipation, muscular hypotonia, urinary retention, erectile dysfunction, nausea, dizziness, drowsiness, hypotension and bradycardia as well as tolerance to baclofen. Some patients experienced post-spinal puncture headaches. Catheter-related problems included occlusions, breaks, punctures, and dislodgments. Superficial pump pocket infection, pocket erosion, cerebrospinal fluid (CSF) leak, post-spinal puncture headache, and meningitis were some of the procedure-related complications. Two pumps flipped and another pump valve was stuck. We conclude that long-term intrathecal baclofen by an implanted programmable pump is a safe and effective method of treating severe intractable spinal spasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ordia</LastName><ForeName>Joe I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Boston Medical Center, and Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Adamski</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chagnon</LastName><ForeName>Kimberly G</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Spatz</LastName><ForeName>Edward L</ForeName><Initials>EL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuromodulation</MedlineTA><NlmUniqueID>9804159</NlmUniqueID><ISSNLinking>1094-7159</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22151777</ArticleId><ArticleId IdType="doi">10.1046/j.1525-1403.2002._2004.x</ArticleId><ArticleId IdType="pii">S1094-7159(21)00493-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11149308</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0025-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>173</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Erectile dysfunction.</ArticleTitle><Pagination><StartPage>492</StartPage><EndPage>497</EndPage><MedlinePgn>492-7</MedlinePgn></Pagination><Abstract><AbstractText>Erectile dysfunction (ED) is a common condition and can usually be managed pharmacologically, with drugs delivered by intracavernosal injection (ICI), transurethrally or orally. The cardiovascular status of the patient and his overall fitness for renewed sexual activity must be assessed before treatment for ED is initiated. The efficacy of sildenafil is related to the extent and severity of ED, and is significantly reduced in patients with severe vasculogenic ED, ED associated with diabetes and after radical prostatectomy. Alprostadil (prostaglandin E1) is the drug of first choice in patients treated with ICI; it is effective in 72.6% of men with ED and is associated with a low risk of priapism and cavernosal fibrosis. Transurethral alprostadil is significantly less effective than alprostadil ICI, producing improved erections in 30%-40%, but rigid erections in only 10%, of men with ED. There is Level II evidence that: alprostadil ICI is an effective treatment for ED papaverine ICI is associated with a high risk of cavernosal fibrosis and priapism papaverine ICI should be restricted to informed patients refractory to treatment with alprostadil ICI transurethral alprostadil is less effective than alprostadil ICI sildenafil is an effective treatment for ED.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>North Shore Private Hospital, Sydney, NSW. cmcmahon@mail.usyd.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>DAA13NKG2Q</RegistryNumber><NameOfSubstance UI="D010208">Papaverine</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010208" MajorTopicYN="N">Papaverine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11149308</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.2000.tb139304.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10992364</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5347</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction.</ArticleTitle><Pagination><StartPage>1192</StartPage><EndPage>1196</EndPage><MedlinePgn>1192-6</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We assessed the efficacy and safety of sildenafil citrate as treatment for erectile dysfunction.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A total of 433 completely evaluated men with chronic erectile dysfunction were treated with sildenafil citrate. Response was assessed prospectively by baseline and followup physician interviews, and by a patient self-administered 15-item questionnaire on the domains of patient treatment response and satisfaction, partner treatment satisfaction, comparative previous treatment satisfaction, adverse effects, and patient and partner quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 304 men (70.2%) who completed the questionnaire 278 received sildenafil, including 186 who previously had undergone treatment for erectile dysfunction, principally involving intracavernous injection therapy. A response was elicited by a median dose of 100 mg. in 188 patients (67.6%) who achieved erection suitable for sexual intercourse. Those with psychogenic erectile dysfunction responded significantly better than those with organic dysfunction (p &lt;0.001). Erection suitable for intercourse was attained by 30.8% of patients with erectile dysfunction after radical prostatectomy and 80% with cavernous veno-occlusive dysfunction. Of previous intracavernous injection responders 29.9% were refractory to sildenafil, while 33. 3% of previous intracavernous injection nonresponders responded to sildenafil. The sildenafil response was considered inferior to the intracavernous injection response by 43.6% of the men who previously responded to intracavernous injection, of whom 51.5% continued to receive intracavernous injection as the only treatment (19.5%) or as an alternative to sildenafil (32%). Adverse effects in 53.6% of cases were assessed as mild in 56.4%, moderate in 38.3% and severe in 5.3%. Multiple adverse effects were reported by 62.4% of patients, while 17 (6.1%) discontinued sildenafil as a direct result of intolerable adverse effects. The most common adverse effects were facial flushing in 33.5% of cases, headaches in 23.4%, nasal congestion in 12.6%, dyspepsia in 10.1% and dizziness in 10.8%. Baseline patient and partner quality of life scores significantly improved after sildenafil treatment (p &lt;0.001), while significantly improved quality of life was noticed by 51.5% and 43.1%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sildenafil citrate is effective oral first line treatment for erectile dysfunction. Although more than 50% of men reported adverse effects, most were considered mild and rarely resulted in treatment cessation. There was a trend in those on intracavernous injection who responded to sildenafil to continue intracavernous injection as the only therapy or as an alternative to sildenafil. Also, we noted that some cases refractory to sildenafil responded to intracavernous injection. These findings imply that intracavernous injection remains an effective erectile dysfunction treatment option.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Australian Centre for Sexual Health, St. Luke's Hospital Complex, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samali</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10992364</ArticleId><ArticleId IdType="pii">S0022-5347(05)67139-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10611201</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0268-1161</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Human reproduction (Oxford, England)</Title><ISOAbbreviation>Hum Reprod</ISOAbbreviation></Journal><ArticleTitle>Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>134</EndPage><MedlinePgn>131-4</MedlinePgn></Pagination><Abstract><AbstractText>Sildenafil is a specific inhibitor of phosphodiesterase (PDE) type 5 and represents a powerful therapy for male erectile dysfunction (ED) of different aetiology. Recently, sildenafil has been shown to restore erections in temporary ED related to the need of semen collection for assisted reproductive techniques. In this study, we investigated whether sildenafil administration modifies seminal parameters and/or erectile function in normal healthy volunteers. In a double-blind, randomized, placebo-controlled, cross-over two period investigation we enrolled 20 healthy male volunteers (mean +/- SE age 32 +/- 0.5 years). Subjects were not using any medication for the 3 month period prior to the study and were engaged in a stable relationship with proven fertility. The effects of sildenafil (100 mg) on seminal parameters and erectile function after audiovisual sexual stimulation were evaluated by semen analysis and by colour-Duplex ultrasound (the Resistive Index) respectively. In all subjects, sildenafil caused no changes in seminal and erection parameters when compared to placebo. Interestingly, sildenafil administration led to a marked reduction of the post-ejaculatory refractory time (10.8 +/- 0.9 min versus 2.6 +/- 0.7 min for placebo and sildenafil respectively; P &lt; 0.0001). These results indicate that in normal subjects acute sildenafil treatment does not modify semen characteristics and has a positive influence over the resumption of erections following ejaculation in the presence of a continuous erotic stimulus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aversa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cattedra di Andrologia, Dipartimento di Fisiopatologia Medica, University of Rome La Sapienza, Italy and Department of Endocrinology, St. Bartholomew's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzilli</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Delfino</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Isidori</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Fabbri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Reprod</MedlineTA><NlmUniqueID>8701199</NlmUniqueID><ISSNLinking>0268-1161</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004542" MajorTopicYN="N">Ejaculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012661" MajorTopicYN="N">Semen</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013076" MajorTopicYN="N">Sperm Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013081" MajorTopicYN="N">Sperm Motility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10611201</ArticleId><ArticleId IdType="doi">10.1093/humrep/15.1.131</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10417850</PMID><DateCompleted><Year>1999</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4401</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Annales d'urologie</Title><ISOAbbreviation>Ann Urol (Paris)</ISOAbbreviation></Journal><ArticleTitle>Arterial embolization in the treatment of post-traumatic priapism.</ArticleTitle><Pagination><StartPage>210</StartPage><EndPage>218</EndPage><MedlinePgn>210-8</MedlinePgn></Pagination><Abstract><AbstractText>Priapism is a prolonged penile erection not associated with sexual arousal. Two types of priapism have been described: the more common one is the "veno-occlusive" priapism and can be frequently observed as the consequence of an intracavernosal injection of vaso-active drugs for the treatment of erectile dysfunction. The less common type of priapism is known as "high flow" priapism and usually follows perineal or direct penile trauma. The clinical presentation in case of high flow priapism is quite typical: hystory of recent penile or perineal trauma followed, by the onset of a painless, incomplete and constant erection of the penis. A color-flow Doppler sonogram should be performed as first diagnostic step: this examination allows to identify the presence of patent cavernous arteries and prominent venous drainage with focal area of high flow turbulence along the pathway of one or both the cavernous arteries. An arterial blood sample taken from the corpora will confirm the diagnosis. At first, conservative therapeutical attempts can be suggested, with mechanical external compression of the perineum, the use of ice packs, corporeal aspiration and irrigation with saline. Besides, intracorporeal administration of alpha-agonists and methylene blue should be performed. Unfortunately, these conservative measures often result unsuccessful, and more invasive approaches must be considered. The radiological superselective transcatheter embolization of the proximal artery supplying arterial-lacunar fistula should be the present treatment of choice in these cases of high-flow priapism refractory to conservative and medical treatments. The first successful management of high flow priapism by selective arterial embolization was reported by Wear and coworkers in 1977. Autologous clots and gelatine sponge have been extensively used and become very popular as the embolic agent. More recently, platinum microcoils have been proposed with the aim to achieve more precise and selective embolization. In our single-case-experience on the treatment of high flow priapism by arterial embolization, we used the recently introduced tungsten microcoils. At the time of the follow-up, 2 months later, patient reported satisfactory intercourse with an approximately 75% of penile rigidity. By comparison with microsurgical ligature of the damaged vessel, selective embolization is, at least theoretically, a less invasive procedure, particularly with reference to the trauma caused to the erectile tissue. High-flow priapism is a fairly rare urological pathology which does not require immediate and emergency treatment (as is the case, instead, with venous-occlusive priapism), since the risk of post-ischaemic fibrosis is excluded thanks to the fact that oxygen is supplied to the cavernous tissue. Once the diagnosis has been established with certainty, therefore, the specialist has the necessary time at disposal to arrange for the most appropriate therapeutic steps. When, as is frequently the case, conservative measures prove ineffective, the current treatment of choice for cases of fistula of the cavernous artery would appear to be superselective embolization of the artery, provided same can be performed at specialized centres and by experienced personnel.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Urology, Ospedale Maggiore I.R.C.C.S., Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovaria</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Saccheri</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pozzoni</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Montanaris</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Urol (Paris)</MedlineTA><NlmUniqueID>0212342</NlmUniqueID><ISSNLinking>0003-4401</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000792" MajorTopicYN="N">Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018615" MajorTopicYN="Y">Ultrasonography, Doppler, Color</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016157" MajorTopicYN="N">Vascular Fistula</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10417850</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10368209</PMID><DateCompleted><Year>1999</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1464-4096</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>1999</Year><Month>May</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>A KATP-channel opener as a potential treatment modality for erectile dysfunction.</ArticleTitle><Pagination><StartPage>837</StartPage><EndPage>841</EndPage><MedlinePgn>837-41</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of pinacidil (a KATP-channel opener) for the treatment of penile erectile dysfunction and to examine the role of the K+-channel in cavernosal smooth muscle contractility.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Using a feline model, the magnitude of penile erection caused by pinacidil was compared with that caused by erectogenic drugs, e.g. acetylcholine, prostaglandin E1 (PGE1) and L-arginine. The effects of K+-channel blockers (4-aminopyridine, glibenclamide and tetraethylammonium) and pinacidil on penile erections induced by the drugs were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The intra-arterial injection of pinacidil caused a dose-dependent increase in intracavernosal pressure (ICP) and the increase in ICP induced by pinacidil with acetylcholine, PGE1 or L-arginine was more pronounced than with the compounds alone. Furthermore, pinacidil (1 mmol/L) effectively reversed the inhibitory effects of the K+-channel blockers on the cavernosal relaxation induced by acetylcholine, PGE1 or L-arginine (P&lt;0.01). Notably, pinacidil induced cavernosal relaxation after injecting the drugs even in cases refractory to higher concentrations (0.1 mol/L) of the drugs (n=11, P&lt;0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that pinacidil is effective in relaxing feline erectile tissue in vivo, probably via increased K+ permeability and subsequent hyperpolarization. Further comparative studies with erectogenic compounds on human erectile tissue and clinical testing are required to determine whether K+-channel openers can be used in the diagnosis and treatment of erectile dysfunction. However, pinacidil seems promising as an intracavernosal agent combined with PGE1 to produce synergistic effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Urology, Korea University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byun</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7B0ZZH8P2W</RegistryNumber><NameOfSubstance UI="D020110">Pinacidil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020110" MajorTopicYN="N">Pinacidil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>6</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>6</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10368209</ArticleId><ArticleId IdType="doi">10.1046/j.1464-410x.1999.00029.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9886582</PMID><DateCompleted><Year>1999</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0090-4295</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Treatment of erectile dysfunction with sildenafil.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>24</EndPage><MedlinePgn>19-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the efficacy of sildenafil for the treatment of erectile dysfunction (ED) in a clinical practice setting; to evaluate the correlation between patient and partner perceptions of treatment outcomes; and to assess the relation between the severity of ED and response to treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Among the first 100 men to receive sildenafil in a urology practice setting, 74 (mean + SD age 64+/-11 years) completed a validated sexual function questionnaire (International Index of Erectile Function [IIEF]) before and after a 4 to 6-week treatment period. A modified version of the same questionnaire was independently completed by partners. ED was categorized into a severity class of I to IV.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sildenafil treatment improved erections by 71% to 95%, according to responses in key IIEF questions 3 and 4. Overall, 57 (77%) of 74 patients desired to continue treatment after the test period. Patient score on the IIEF was correlated with partner score on the modified questionnaire before and after treatment (r = 0.67 to 0.81, P &lt;0.01). IIEF scores were reflected in a simple severity classification system. Men with the best preservation of erections (severity class I) exhibited the best responses to sildenafil, whereas men with no erections (severity class IV) were much less likely to respond to the drug and desire continuation of treatment (P &lt;0.01). Patients with a radical prostatectomy were relatively refractory to sildenafil, except for 2 of 5 who had undergone a nerve-sparing operation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In clinical practice, sildenafil is an effective treatment of ED, according to partner-validated questionnaire responses; and the results of treatment are predictable with an ED severity classification system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>L S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Urology, University of California Los Angeles, School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dorey</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Macairan</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>P B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Urology. 1999 May;53(5):1070-1</RefSource><PMID Version="1">10223508</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9886582</ArticleId><ArticleId IdType="doi">10.1016/s0090-4295(98)00525-1</ArticleId><ArticleId IdType="pii">S0090-4295(98)00525-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9599636</PMID><DateCompleted><Year>1998</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4401</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Annales d'urologie</Title><ISOAbbreviation>Ann Urol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Treatment for impotence].</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>79</EndPage><MedlinePgn>77-9</MedlinePgn></Pagination><Abstract><AbstractText>For the treatment of erectile dysfunction, the authors recommend that prostheses be reserved for cases refractory to all other treatments. Local treatments by injection of erectogenic substances consist of paraverine and prostaglandin E1. A new oral treatment is also available, not with yohimbine or apomorphine, but with sildenafil (viagra).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giuliano</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service d'Urologie, CHU de Bic&#xea;tre, Le Kremlin-Bic&#xea;tre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jardin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les traitements de l'impuissance.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Urol (Paris)</MedlineTA><NlmUniqueID>0212342</NlmUniqueID><ISSNLinking>0003-4401</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>DAA13NKG2Q</RegistryNumber><NameOfSubstance UI="D010208">Papaverine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010208" MajorTopicYN="N">Papaverine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015917" MajorTopicYN="N">Penile Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>0</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9599636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8658990</PMID><DateCompleted><Year>1996</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-6193</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>1994</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Ulster medical journal</Title><ISOAbbreviation>Ulster Med J</ISOAbbreviation></Journal><ArticleTitle>Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.</ArticleTitle><Pagination><StartPage>18</StartPage><EndPage>22</EndPage><MedlinePgn>18-22</MedlinePgn></Pagination><Abstract><AbstractText>Fifty consecutive patients with erectile failure who had previously proved refractory to papaverine and phentolamine intracavernosal therapy or were inappropriate candidates for such treatment were treated with intracavernosal prostaglandin E1. Forty patients (80%) achieved an erection sufficient for sexual intercourse and after a mean follow-up period of 5.9 months, 32 patients were continuing to use treatment successfully. The average dose was 14 micrograms (range 2.5 to 30 micrograms). There were no cases of priapism or cavernosal fibrosis and no systemic side effects. A low incidence (8%) of local discomfort was reported. We conclude that prostaglandin is a safe and effective vasoactive agent for the treatment of erectile failure in a genito-urinary outpatient clinic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>D K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Genito-Urinary Medicine Clinic, Royal Victoria Hospital, Belfast.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Convery</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dinsmore</LastName><ForeName>W W</ForeName><Initials>WW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Northern Ireland</Country><MedlineTA>Ulster Med J</MedlineTA><NlmUniqueID>0417367</NlmUniqueID><ISSNLinking>0041-6193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009660" MajorTopicYN="N" Type="Geographic">Northern Ireland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8658990</ArticleId><ArticleId IdType="pmc">PMC2449095</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Urol. 1989 Jan;141(1):54-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2908954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Dec;140(6):1415-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3193506</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1990 Jan;65(1):68-71</Citation><ArticleIdList><ArticleId IdType="pubmed">2310934</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1991 Jun;37(6):516-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2038782</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1992 Mar;147(3):623-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1538443</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Urol. 1992 Apr;69(4):404-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1581812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1975 Dec;56(6):1404-10</Citation><ArticleIdList><ArticleId IdType="pubmed">1202078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1982 Oct 23;2(8304):938</Citation><ArticleIdList><ArticleId IdType="pubmed">6126784</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1983 Oct;143:332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6626852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1985 Jan;133(1):39-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2578067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Feb;137(2):292-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3806824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1987 Aug;138(2):404-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2439714</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Jul;140(1):66-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3379700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Sep;140(3):525-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3045341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1988 Sep;140(3):615-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3411687</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1989 Feb;141(2):323-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2913354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8212440</PMID><DateCompleted><Year>1993</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0090-4295</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Urology</Title><ISOAbbreviation>Urology</ISOAbbreviation></Journal><ArticleTitle>Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage.</ArticleTitle><Pagination><StartPage>409</StartPage><EndPage>411</EndPage><MedlinePgn>409-11</MedlinePgn></Pagination><Abstract><AbstractText>Recent experimental work has demonstrated that nitric oxide (NO) is the neurotransmitter responsible for cavernous smooth muscle relaxation. We studied the effect of a direct NO-donor, linsidomine chlorhydrate (SIN-1), in 30 patients with venous leakage confirmed by dynamic pharmacocavernosography and pharmacocavernosometry that was refractory to prostaglandin E1 (PGE1) under the assumption that the more physiologic approach might give better results. In all 30 patients, response to SIN-1 was no better, and in 22 cases it was less than the response to PGE1. No systemic or local side effects of SIN-1 were observed. SIN-1 is not superior to PGE1 in the treatment of erectile dysfunction caused by venous leakage, and failure of NO-mediated smooth muscle relaxation does not play a part in the entity, "venous leakage."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wegner</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Urology, Universit&#xe4;tsklinikum Steglitz, Freie Universit&#xe4;t Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knispel</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Urology</MedlineTA><NlmUniqueID>0366151</NlmUniqueID><ISSNLinking>0090-4295</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O5U71P6VQ</RegistryNumber><NameOfSubstance UI="C002385">linsidomine</NameOfSubstance></Chemical><Chemical><RegistryNumber>D46583G77X</RegistryNumber><NameOfSubstance UI="D008981">Molsidomine</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008981" MajorTopicYN="N">Molsidomine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014680" MajorTopicYN="N">Veins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8212440</ArticleId><ArticleId IdType="doi">10.1016/0090-4295(93)90371-g</ArticleId><ArticleId IdType="pii">0090-4295(93)90371-G</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
